<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for prodromal stage of psychosis - Bosnjak Kuharic, D - 2019 | Cochrane Library</title> <meta content="Interventions for prodromal stage of psychosis - Bosnjak Kuharic, D - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012236.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for prodromal stage of psychosis - Bosnjak Kuharic, D - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012236.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012236.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for prodromal stage of psychosis" name="citation_title"/> <meta content="Dina Bosnjak Kuharic" name="citation_author"/> <meta content="University Psychiatric Hospital Vrapče" name="citation_author_institution"/> <meta content="dina.bosnjak@gmail.com" name="citation_author_email"/> <meta content="Ivana Kekin" name="citation_author"/> <meta content="Clinical Hospital Centre Zagreb" name="citation_author_institution"/> <meta content="Joanne Hew" name="citation_author"/> <meta content="South London and Maudsley NHS Foundation Trust" name="citation_author_institution"/> <meta content="Martina Rojnic Kuzman" name="citation_author"/> <meta content="Clinical Hospital Centre Zagreb" name="citation_author_institution"/> <meta content="Livia Puljak" name="citation_author"/> <meta content="Catholic University of Croatia" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD012236.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/11/01" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012236.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012236.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012236.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Cognitive Behavioral Therapy; Antipsychotic Agents [*therapeutic use]; Fatty Acids, Omega‐3 [*therapeutic use]; Prodromal Symptoms; Psychotic Disorders [diagnosis, *prevention &amp; control]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012236.pub2&amp;doi=10.1002/14651858.CD012236.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012236.pub2&amp;doi=10.1002/14651858.CD012236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012236.pub2&amp;doi=10.1002/14651858.CD012236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012236.pub2&amp;doi=10.1002/14651858.CD012236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012236.pub2&amp;doi=10.1002/14651858.CD012236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012236.pub2&amp;doi=10.1002/14651858.CD012236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012236.pub2&amp;doi=10.1002/14651858.CD012236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012236.pub2&amp;doi=10.1002/14651858.CD012236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012236.pub2&amp;doi=10.1002/14651858.CD012236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012236.pub2&amp;doi=10.1002/14651858.CD012236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012236.pub2&amp;doi=10.1002/14651858.CD012236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012236.pub2&amp;doi=10.1002/14651858.CD012236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012236.pub2&amp;doi=10.1002/14651858.CD012236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012236.pub2&amp;doi=10.1002/14651858.CD012236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012236.pub2&amp;doi=10.1002/14651858.CD012236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012236.pub2&amp;doi=10.1002/14651858.CD012236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012236.pub2&amp;doi=10.1002/14651858.CD012236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012236.pub2&amp;doi=10.1002/14651858.CD012236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012236.pub2&amp;doi=10.1002/14651858.CD012236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012236.pub2&amp;doi=10.1002/14651858.CD012236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012236.pub2&amp;doi=10.1002/14651858.CD012236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012236.pub2&amp;doi=10.1002/14651858.CD012236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012236.pub2&amp;doi=10.1002/14651858.CD012236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="PrHmaMrX";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012236\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012236\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012236\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012236\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","ja","fa","fr","pl","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012236.pub2",title:"Interventions for prodromal stage of psychosis",firstPublishedDate:"Nov 1, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012236.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012236.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012236.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012236.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012236.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012236.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012236.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012236.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012236.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012236.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>10791 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012236.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-sec-0520"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-sec-0038"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-sec-0039"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-sec-0116"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-sec-0425"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/appendices#CD012236-sec-0530"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/table_n/CD012236StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/table_n/CD012236StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for prodromal stage of psychosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/information#CD012236-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Dina Bosnjak Kuharic</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/information#CD012236-cr-0003">Ivana Kekin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/information#CD012236-cr-0004">Joanne Hew</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/information#CD012236-cr-0005">Martina Rojnic Kuzman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012236.pub2/information#CD012236-cr-0006">Livia Puljak</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/information/en#CD012236-sec-0533">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 01 November 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012236.pub2">https://doi.org/10.1002/14651858.CD012236.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012236-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012236-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012236-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012236-abs-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012236-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012236-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012236-abs-0001" lang="en"> <section id="CD012236-sec-0001"> <h3 class="title" id="CD012236-sec-0001">Background</h3> <p>Psychosis is a serious mental condition characterised by a loss of contact with reality. There may be a prodromal period or stage of psychosis, where early signs of symptoms indicating onset of first episode psychosis (FEP) occur. A number of services, incorporating multimodal treatment approaches (pharmacotherapy, psychotherapy and psychosocial interventions), developed worldwide, now focus on this prodromal period with the aim of preventing psychosis in people at risk of developing FEP. </p> </section> <section id="CD012236-sec-0002"> <h3 class="title" id="CD012236-sec-0002">Objectives</h3> <p>The primary objective is to assess the safety and efficacy of early interventions for people in the prodromal stage of psychosis. </p> <p>The secondary objective is, if possible, to compare the effectiveness of the various different interventions. </p> </section> <section id="CD012236-sec-0003"> <h3 class="title" id="CD012236-sec-0003">Search methods</h3> <p>We searched Cochrane Schizophrenia's study‐based Register of studies (including trials registers) on 8 June 2016 and 4 August 2017. </p> </section> <section id="CD012236-sec-0004"> <h3 class="title" id="CD012236-sec-0004">Selection criteria</h3> <p>All randomised controlled trials (RCTs) evaluating interventions for participants older than 12 years, who had developed a prodromal stage of psychosis. </p> </section> <section id="CD012236-sec-0005"> <h3 class="title" id="CD012236-sec-0005">Data collection and analysis</h3> <p>Review authors independently inspected citations, selected studies, extracted data, and assessed study quality. </p> </section> <section id="CD012236-sec-0006"> <h3 class="title" id="CD012236-sec-0006">Main results</h3> <p>We included 20 studies with 2151 participants. The studies analysed 13 different comparisons. Group A comparisons explored the absolute effects of the experimental intervention. Group B were comparisons within which we could not be clear whether differential interactive effects were also ongoing. Group C comparisons explored differential effects between clearly distinct treatments. </p> <p>A key outcome for this review was ‘transition to psychosis’. For details of other main outcomes please see 'Summary of findings' tables. </p> <p>In Group A (comparisons of absolute effects) we found no clear difference between amino acids and placebo (risk ratio (RR) 0.48 95% confidence interval (CI) 0.08 to 2.98; 2 RCTs, 52 participants; very low‐quality evidence). When omega‐3 fatty acids were compared to placebo, fewer participants given the omega‐3 (10%) transitioned to psychosis compared to the placebo group (33%) during long‐term follow‐up of seven years (RR 0.24 95% CI 0.09 to 0.67; 1 RCT, 81 participants; low‐quality evidence). </p> <p>In Group B (comparisons where complex interactions are probable) and in the subgroup focusing on antipsychotic drugs added to specific care packages, the amisulpiride + needs‐focused intervention (NFI) compared to NFI comparison (no reporting of transition to psychosis; 1 RCT, 102 participants; very low‐quality evidence) and the olanzapine + supportive intervention compared to supportive intervention alone comparison (RR 0.58 95% CI 0.28 to 1.18; 1 RCT, 60 participants; very low‐quality evidence) showed no clear differences between groups. </p> <p>In the second Group B subgroup (cognitive behavioural therapies (CBT)), when CBT + supportive therapy was compared with supportive therapy alone around 8% of participants allocated to the combination of CBT and supportive therapy group transitioned to psychosis during follow‐up by 18 months, compared with double that percentage in the supportive therapy alone group (RR 0.45 95% CI 0.23 to 0.89; 2 RCTs, 252 participants; very low‐quality evidence). The CBT + risperidone versus CBT + placebo comparison identified no clear difference between treatments (RR 1.02 95% CI 0.39 to 2.67; 1 RCT, 87 participants; very low‐quality evidence) and this also applies to the CBT + needs‐based intervention (NBI) + risperidone versus NBI comparison (RR 0.75 95% CI 0.39 to 1.46; 1 RCT, 59 participants; very low‐quality evidence). </p> <p>Group C (differential effects) also involved six comparisons. The first compared CBT with supportive therapy. No clear difference was found for the ‘transition to psychosis’ outcome (RR 0.74 95% CI 0.28 to 1.98; 1 RCT, 72 participants; very low‐quality evidence). The second subgroup compared CBT + supportive intervention was compared with a NBI + supportive intervention, again, data were equivocal, few and of very low quality (RR 6.32 95% CI 0.34 to 117.09; 1 RCT, 57 participants). In the CBT + risperidone versus supportive therapy comparison, again there was no clear difference between groups (RR 0.76 95% CI 0.28 to 2.03; 1 RCT, 71 participants; very low‐quality evidence). </p> <p>The three other comparisons in Group C demonstrated no clear differences between treatment groups. When cognitive training was compared to active control (tablet games) (no reporting of transition to psychosis; 1 RCT, 62 participants; very low quality data), family treatment compared with enhanced care comparison (RR 0.54 95% CI 0.18 to 1.59; 2 RCTs, 229 participants; very low‐quality evidence) and integrated treatment compared to standard treatment comparison (RR 0.57 95% CI 0.28 to 1.15; 1 RCT, 79 participants; very low‐quality evidence) no effects of any of these approaches was evident. </p> </section> <section id="CD012236-sec-0007"> <h3 class="title" id="CD012236-sec-0007">Authors' conclusions</h3> <p>There has been considerable research effort in this area and several interventions have been trialled. The evidence available suggests that omega‐3 fatty acids may prevent transition to psychosis but this evidence is low quality and more research is needed to confirm this finding. Other comparisons did not show any clear differences in effect for preventing transition to psychosis but again, the quality of this evidence is very low or low and not strong enough to make firm conclusions. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012236-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012236-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012236-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012236-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012236-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012236-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012236-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012236-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012236-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012236-abs-0014">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012236-abs-0005" lang="en"> <h3>Early interventions for people at risk of developing psychosis</h3> <p><b>Review question</b> </p> <p>Is there high‐quality evidence indicating that interventions for people at risk of developing psychosis are effective? </p> <p><b>Background</b> </p> <p>Psychoses are serious mental conditions characterised by a loss of contact with reality. The first clear episode of psychosis can be preceded by a 'prodromal' period of at least six months, where a person experiences gradual non‐specific changes in thoughts, perceptions, behaviours and functioning. Although an individual is experiencing changes, they have not yet started to experience the more obvious psychotic symptoms such as delusions (fixed false beliefs) or hallucinations (perceptions without a cause). A number of services with treatment approaches that combine pharmacotherapy, psychotherapy and psychosocial treatments, developed worldwide, are now focusing on prevention of psychosis in people at risk by giving treatments during this prodromal period. This review assesses the evidence available concerning the effects of different treatment approaches for people not yet diagnosed with a non affective psychosis but who are in the prodromal stage of psychosis. </p> <p><b>Searching for evidence</b> </p> <p>On 8 June 2016 and 4 August 2017 we ran electronic searches of the Cochrane Schizophrenia's specialised register of studies in order to find clinical studies that randomly allocated individuals at risk of developing psychosis to receive various treatments for preventing development of psychosis. </p> <p><b>Evidence found</b> </p> <p>We were able to include 20 studies with 2151 participants. These studies analysed a wide range of treatments. All the review findings are of, at very best, low quality. There is some suggestion from one small study that people at risk of psychosis may benefit from taking omega‐3 fatty acids in terms of reduced transition to psychosis. Other studies found adding antipsychotic drugs to supportive‐care packages did not seem to make much difference in terms of transition to full illness. When cognitive behavioural therapy (CBT) + supportive therapy was compared with supportive therapy alone around 8% of participants treated allocated to the combination of CBT and supportive therapy transitioned to psychosis during follow‐up by 18 months, compared with double that percentage in people who just received supportive therapy. This could be important but these data are of very low quality. All other testing of CBT and other packages of care found no clear difference between treatments for transition to psychosis. </p> <p><b>Conclusions</b> </p> <p>There has been considerable effort and expense invested testing treatment approaches for prevention of the first episode of schizophrenia. Currently, there is some low‐quality evidence suggesting that omega‐3 fatty acids may be effective, but there is no high‐quality evidence to suggest that any type of treatment is effective, and no firm conclusions can be made. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012236-sec-0520" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012236-sec-0520">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012236-sec-0724">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012236-sec-0520"></div> <h3 class="title" id="CD012236-sec-0521">Implications for practice</h3> <section id="CD012236-sec-0521"> <section id="CD012236-sec-0522"> <h5 class="title">1. For participants in prodromal stage of psychosis</h5> <p>There is no convincing, unbiased, high‐quality evidence to suggest that any type of intervention for preventing the development of illness in at‐risk individuals in the prodromal stage of psychosis is superior to the comparators. There is a lot of very low‐quality evidence but nothing that supports, or refutes the use of any or no treatment approach. The low‐quality evidence regarding some benefit from taking omega‐3 fatty acids in terms of reduced transitions to psychosis could be used to support longer‐term use of this as omega‐3 did not seem to do any harm. Even this evidence was not very convincing and serves to 'medialise' the issue for many young people. However, the latter may be less of a danger than suggesting therapy is helpful when it is not clearly the case. </p> </section> <section id="CD012236-sec-0523"> <h5 class="title">2. For physicians</h5> <p>Various interventions have been tested for treatment of individuals with prodromal symptoms of psychosis, with no or very little difference among them. There is limited evidence that several interventions may be beneficial but those data are based on low, or very low‐quality evidence that require unbiased replication. Olanzapine is probably ill‐advised because of the early weight gain. The current level of evidence is insufficient to recommend routine use of any of the interventions ‐ all must be seen as experimental. </p> </section> <section id="CD012236-sec-0524"> <h5 class="title">3. For policymakers</h5> <p>Those who make policy have little to guide them from studies. Any policy, therefore, will be founded on opinion and evidence from potentially less rigorous evaluations. </p> </section> </section> <h3 class="title" id="CD012236-sec-0525">Implications for research</h3> <section id="CD012236-sec-0525"> <section id="CD012236-sec-0526"> <h5 class="title">1. Current reporting</h5> <p>If all studies had complied with good reporting standards (<a href="http://www.consort-statement.org/" target="_blank">CONSORT</a>), or, even better, made all data available, as is encouraged by the <a href="http://www.alltrials.net/" target="_blank">AllTrials</a> initiative, we would know more from already existing data. Selective and poor reporting of data resulted in loss of information which would never have been what people entering the study would have agreed to. This represents waste of opportunity, resource, evidence and trust (<a href="./references#CD012236-bbs2-0126" title="GlasziouP , ChalmersI . Research waste is still a scandal ‐ an essay by Paul Glasziou and Iain Chalmers. BMJ (Clinical Research Ed.)2018;363:k4645. [PUBMED: 30420358] ">Glasziou 2018</a>). </p> </section> <section id="CD012236-sec-0527"> <h5 class="title">2. Future studies</h5> <p>This is an area of research where new, large, methodologically rigorous studies are necessary, that will yield high‐quality evidence about the benefits and harms of interventions used for treatment of individuals at risk of developing psychosis. The majority of currently available studies were small, with fewer than 50 participants per arm, and they suffered from a number of methodological shortcomings, and selective reporting. These problems can be avoided with adequate study design planning, and inclusion of larger numbers of participants. Available studies have analysed a limited number of clinically relevant outcomes, which should be rectified in future studies. The major obstacle in analysing the results of this review is the difficulty in interpreting results on key outcomes in a pragmatic way, as described in the section Applicability (<a href="#CD012236-sec-0511">Overall completeness and applicability of evidence</a>). Thus, in future studies focusing on comparing the efficacy and effectiveness of different psychosocial approaches, especially in combination with pharmacotherapy, a clearer delineation of intervention and control treatment is necessary. Study design should incorporate measurements that could objectify as much as possible the effect of each intervention specifically. Control conditions should be kept as neutral as possible. The inclusion of interventions as part of standard treatment (such as medication or counselling or psychoeducation etc.) imports a bias from the beginning of the study, as the intervention is not compared to a neutral (non‐treatment condition or placebo) control, but to an active control, which in many case may already be quite effective for the treatment of the prodromes. </p> <p>It is particularly important to conduct long‐term studies for proper assessment of those interventions. </p> <p>As can be seen from this review, many things have been tested for people with prodromal illnesses. We do realise that it takes great time and effort to draw up a protocol for a new study, but we have given this some thought and seen and thought about all existing studies. Considering the fact that there is no gold standard for the treatment of prodromal psychosis, and that all available treatments are actually new and unproven, it is difficult to suggest what a new intervention should be compared against. On the other hand, comparison to a placebo group or people on a waiting list for treatment over a period of adequate study duration (for example six months) is not feasible as it requires denying any treatment to people at risk. Moreover, considering that people at risk do not hold 'firm' psychiatric diagnosis, the principle of 'first do no harm' is even more important. Thus, we suggest a two‐stage research approach: first, to compare low‐dose, antipsychotics versus any psychosocial programme available in the setting (defined as treatment as usual). In the second step, different components of the psychosocial programme should be compared against each other, but should follow similar rules in the duration, frequency and number of sessions. We sketch an outline for such a study in <a href="#CD012236-tbl-0015">Table 2</a>, emphasising the relevance of choosing adequate interventions and comparators, as well as the need for longer follow‐up of participants. </p> <div class="table" id="CD012236-tbl-0015"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Suggested design for new study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised</p> <p>Blinding: double‐blind (participants and study team, treatment provider, investigator, outcomes assessor) </p> <p>Duration: &gt; 6 months of intervention period + &gt; 12 months' follow‐up period</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: ultra high risk sample</p> <p>N = 300*</p> <p>Sex: men and women</p> <p>Age: 14‐30 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stage 1</p> <p>1. Low‐dose antipsychotic + treatment as usual</p> <p>2. Treatment as usual: psychosocial programme available in the setting</p> <p>Stage 2</p> <p>Comparison of different components of the psychosocial programme (compared components should follow similar rules in the duration, frequency and number of sessions) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prodromal symptoms: transition to psychosis</p> <p>Global state: clinically important change in global state</p> <p>Mental state: clinically important change in mental state</p> <p>Functioning: clinically important change in functioning</p> <p>Adverse effects: at least one serious adverse event</p> <p>Quality of life: important change in quality of life</p> <p>Satisfaction with treatment: leaving the study early</p> <p>Economics: cost of care</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*Sample size suggested because at around 300 participants power to detect a difference in groups of 15% becomes realistic. </p> </td> </tr> </tbody> </table> </div> <p>It is clear that greater collaboration in the conduct of studies in this area would greatly enhance the existing evidence‐base. There are now many examples of collaboration between trialists, clinicians and patients on deciding what to measure as outcomes, and how and when to measure these outcomes (<a href="http://www.comet-initiative.org/" target="_blank">COMET</a>). We see no reason why this subgroup of subspecialists should be exempt from working together to get compromise and larger sets of high‐quality data. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012236-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012236-sec-0029"></div> <div class="table" id="CD012236-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Group A: amino acids compared to placebo for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Amino acids compared to placebo for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> amino acids<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with amino acids</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Prodromal symptoms: transition to psychosis</b> </p> <p>Endpoint data (events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.48<br/> (0.08 to 2.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>52<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>107 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>51 per 1000<br/> (9 to 319) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global state: clinically important change in global state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: psychosis risk symptoms</b> </p> <p>Average total score (SOPS total score; higher score = worse, scale from: 0‐114)</p> <p>Short‐term<br/> Follow‐up: 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychosis risk symptoms was 42.0 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 10 points lower<br/> (22.38 lower to 2.38 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for our predefined outcome of interest 'Clinically important change in mental state' were not reported by the studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: suicidal thoughts</b> </p> <p>Short‐term (events)<br/> Follow‐up: by 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.57<br/> (0.15 to 83.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>44<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life: clinically important change in quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>Endpoint data (events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/> (0.55 to 1.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>52<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>464 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>446 per 1000<br/> (255 to 785) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SOPS:</b> Scale of Psychotic Symptoms </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, high attrition, blinding of outcome assessors not described, unclear risk of selective reporting bias.<br/> <sup>2</sup>Imprecision: rated 'very serious'; evidence from two small studies.<br/> <sup>3</sup>Risk of bias: rated 'very serious'; 1 randomisation method not described, allocation concealment method not described, blinding of outcome assessors not described, unclear risk of selective reporting bias.<br/> <sup>4</sup>Imprecision: rated 'very serious'; evidence from one small study.<br/> <sup>5</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, high attrition. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012236-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Group A: omega‐3 fatty acids compared to placebo for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Omega‐3 fatty acids compared to placebo for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> omega‐3 fatty acids<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with omega‐3 fatty acids</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Prodromal symptoms: transition to psychosis</b> </p> <p>Long‐term (events)<br/> Follow‐up: 7 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.24<br/> (0.09 to 0.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>81<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>96 per 1000<br/> (36 to 268) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Global state: antipsychotic prescription</b> </p> <p>Long‐term (events)<br/> Follow‐up: 7 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.54<br/> (0.30 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>69<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>543 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>293 per 1000<br/> (163 to 537) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: psychotic symptoms</b> </p> <p>Average total score (PANSS, higher score = worse, scale from 30‐210)</p> <p>Long‐term (up to 7 years)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychotic symptoms was 57.4 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 11.40 points lower<br/> (20.55 lower to 2.25 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for our predefined outcome of interest 'Clinically important change in mental state' were not reported by the studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: neurological, extrapyramidal</b> </p> <p>UKU (events)</p> <p>Medium‐term<br/> Follow‐up: by 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.57<br/> (0.94 to 7.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>304<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000<br/> (31 to 232) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life: clinically important change in quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>Long‐term (events)<br/> Follow‐up: 7 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.46<br/> (0.45 to 4.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>81<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>146 per 1000<br/> (45 to 480) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>PANSS:</b> Positive and Negative Syndrome Scale; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>UKU:</b> Udvalg for Kliniske Undersøgelser Adverse Effects Scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Imprecision: rated 'very serious'; evidence from one small study. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012236-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Group B antipsychotic drugs: amisulpiride + needs‐focused intervention compared to needs‐focused intervention for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Amisulpiride + needs‐focused intervention compared to needs‐focused intervention for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> amisulpiride + needs‐focused intervention (NFI)<br/> <b>Comparison:</b> needs‐focused intervention (NFI) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with NFI</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with amisulpiride + NFI</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Prodromal symptoms: transition to psychosis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global state: clinically important change in global state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mental state: clinically important change in mental state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: suicidal thoughts</b> </p> <p>(events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.25<br/> (0.01 to 6.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>102<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/> (0 to 127) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life: clinically important change in quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>Endpoint data (events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.59<br/> (0.38 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>124<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>492 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>290 per 1000<br/> (187 to 462) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>NFI:</b> needs‐focused intervention; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, participants not blinded, outcome assessors not blinded, high attrition, unclear risk of selective reporting bias.<br/> <sup>2</sup>Imprecision: rated 'very serious'; evidence from one small study. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012236-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Group B antipsychotic drugs: olanzapine + supportive intervention compared to placebo + supportive intervention for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Olanzapine + supportive intervention compared to placebo + supportive intervention for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> olanzapine + supportive intervention<br/> <b>Comparison:</b> placebo + supportive intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo + supportive intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with olanzapine + supportive intervention</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Prodromal symptoms: transition to psychosis</b> </p> <p>Endpoint data, (events)</p> <p>Medium‐term<br/> Follow‐up: by 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.58<br/> (0.28 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>448 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>260 per 1000<br/> (126 to 529) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: global illness severity</b> </p> <p>Average total score, CGI (higher score = worse, scale from: 2‐14)</p> <p>Medium‐term<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean global state: global illness severity was 3.86 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.23 points lower<br/> (0.82 lower to 0.36 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: psychosis risk symptoms</b> </p> <p>SOPS total (higher score = worse, scale from: 0‐114)<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychosis risk symptoms was 36.56 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychosis risk symptoms was 33.8</p> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for this outcome were skewed, and therefore we did not present summary estimates</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: average weight gain change</b> </p> <p>kg gained (higher scores = worse)</p> <p>Medium‐term<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean adverse effects: average weight gain change was 0.32 kg</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 8.49 kg higher<br/> (4.90 higher to 12.08 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life: clinically important change in quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>Endpoint data (events)<br/> Medium‐term </p> <p>Follow‐up: by 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.59<br/> (0.88 to 2.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>345 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>548 per 1000<br/> (303 to 993) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CGI:</b> Clinical Global Impression‐Severity of Illness Scale; <b>CI:</b> Confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio; <b>SOPS:</b> Scale of Prodromal Symptoms </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, high attrition, unclear risk of selective reporting bias.<br/> <sup>2</sup>Imprecision: rated 'very serious'; evidence from one small study. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012236-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Group B cognitive behavioural therapy: cognitive behavioural therapy + supportive therapy compared to supportive therapy for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cognitive behavioural therapy + supportive therapy compared to supportive therapy for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> cognitive behavioural therapy (CBT) + supportive therapy<br/> <b>Comparison:</b> supportive therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with supportive therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CBT + supportive therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Prodromal symptoms: transition to psychosis</b> </p> <p>Long‐term (events)<br/> Follow‐up: by 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.45<br/> (0.23 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>252<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>195 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88 per 1000<br/> (45 to 174) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global state: clinically important change in global state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state</b> </p> <p>PANSS total (higher score = worse, scale from: 30‐210)<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state was 39.1 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state was 39.4 points</p> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for this outcome were skewed, and therefore we did not present summary estimates</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects: at least one serious adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p>Average total score, MANSA (higher score = better, scale from: 16‐112)</p> <p>Long‐term<br/> Follow‐up: 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life was 55.5 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.50 points higher<br/> (2.93 lower to 5.93 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for clinically important change in quality of life not available.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>Endpoint data (events)</p> <p>Additional follow‐up: by between &gt; 2 years to 4 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/> (0.74 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>261<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>2,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>468 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>450 per 1000<br/> (347 to 581) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CBT:</b> cognitive behavioural therapy; <b>CI:</b> confidence interval; <b>MANSA:</b> Montgomery–Asberg Depression Rating Scale; <b>MD:</b> mean difference; <b>PANSS:</b> Positive and Negative Syndrome Scale; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SOPS:</b> Scale of Prodromal Symptoms </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated 'very serious'; allocation concealment not described, participants not blinded, high attrition, unclear risk of selective reporting bias.<br/> <sup>2</sup>Imprecision: rated 'very serious'; evidence from two small studies.<br/> <sup>3</sup>Risk of bias: rated 'very serious'; allocation concealment not described, participants not blinded, outcome assessors not blinded, high attrition.<br/> <sup>4</sup>Imprecision: rated 'very serious'; evidence from one small study.<br/> <sup>5</sup>Risk of bias: rated 'very serious; allocation concealment not described, participants not blinded, unclear risk of selective reporting bias.<br/> <sup>6</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, participants not blinded, outcome assessors not blinded, high attrition. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012236-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Group B cognitive behavioural therapy: cognitive behavioural therapy + risperidone compared to cognitive behavioural therapy + placebo for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cognitive behavioural therapy + risperidone compared to cognitive behavioural therapy + placebo for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> cognitive behavioural therapy (CBT) + risperidone<br/> <b>Comparison:</b> cognitive behavioural therapy (CBT) + placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CBT + placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CBT + risperidone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Prodromal symptoms: transition to psychosis</b> </p> <p>Endpoint data (events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.02<br/> (0.39 to 2.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>87<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>159 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>162 per 1000<br/> (62 to 425) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global state: clinically important change in global state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: psychopathology</b> </p> <p>Total endpoint data, BPRS (higher score = worse, scale from 0‐126)<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychopathology was 16.5 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychopathology was 14 points</p> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for this outcome were skewed, and therefore we did not present summary estimates</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: specific ‐ doctors' assessment of adverse effects</b> </p> <p>UKU (events)<br/> Medium‐term </p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (0.55 to 1.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>379 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>391 per 1000<br/> (209 to 724) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p>Average endpoint score, QLS (higher score = better, scale from: 0‐126)</p> <p>Medium‐term<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life was 0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 5.70 higher<br/> (7.86 lower to 19.26 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for clinically important change in quality of life were not available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>Endpoint data (events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.09<br/> (0.62 to 1.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>87<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>341 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>372 per 1000<br/> (211 to 655) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>BPRS:</b> Brief Psychiatric Rating Scale; <b>CBT:</b> cognitive behavioural therapy; <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>QLS:</b> Quality of Life Scale; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>UKU:</b> Udvalg for Kliniske Undersøgelser Adverse Effects Scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, high attrition.<br/> <sup>2</sup>Imprecision: rated 'very serious'; evidence from one small study. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012236-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Group B cognitive behavioural therapy: cognitive behavioural therapy (specific preventive intervention) + needs‐based intervention + risperidone compared to needs‐based intervention for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cognitive behavioural therapy (specific preventive intervention) + needs‐based intervention + risperidone compared to needs‐based intervention for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> cognitive behavioural therapy (specific preventive intervention) (CBT(SPI)) + needs‐based intervention (NBI) + risperidone<br/> <b>Comparison:</b> needs‐based intervention (NBI) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with NBI</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CBT(SPI) + NBI + risperidone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Prodromal symptoms: transition to psychosis</b> </p> <p>Endpoint data (events)</p> <p>Long‐term<br/> Follow‐up: up to 4 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.75<br/> (0.39 to 1.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>59<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>429 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>321 per 1000<br/> (167 to 626) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global state: clinically important change in global state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: psychopathology</b> </p> <p>Total endpoint data, BPRS (higher score = worse, scale from: 0‐126)<br/> Follow‐up: 4 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychopathology was 22.47</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychopathology was 26.33</p> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for this outcome were skewed, and therefore we did not present summary estimates</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects: at least one serious adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p>Average endpoint score, QLS (higher score = better, scale from: 0‐126)</p> <p>Long‐term<br/> Follow‐up: up to 4 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life was 80.53 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.03 points lower<br/> (16.90 lower to 12.84 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for clinically important change in quality of life were not available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>(events)</p> <p>Long‐term<br/> Follow‐up: up to 4 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.57<br/> (0.26 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>59<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>393 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>224 per 1000<br/> (102 to 503) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>BPRS:</b> Brief Psychiatric Rating Scale; <b>CBT(SPI):</b> cognitive behavioural therapy (specific preventive intervention); <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>QLS:</b> Quality of Life Scale; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment not described, participants not blinded, outcome assessors not blinded.<br/> <sup>2</sup>Imprecision: rated 'very serious'; evidence from one small study. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012236-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Group C cognitive behavioural therapy: cognitive behavioural therapy + placebo compared to supportive therapy + placebo for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cognitive behavioural therapy + placebo compared to supportive therapy + placebo for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> cognitive behavioural therapy (CBT) + placebo<br/> <b>Comparison:</b> supportive therapy + placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with supportive therapy + placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CBT + placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Prodromal symptoms: transition to psychosis</b> </p> <p>Endpoint data (events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.74<br/> (0.28 to 1.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>72<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>214 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>159 per 1000<br/> (60 to 424) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global state: clinically important change in global state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: psychopathology</b> </p> <p>Total endpoint data, BPRS (higher score = worse, scale from 0‐126)<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychopathology: was 15.3 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychopathology: was 16.5 points</p> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for this outcome were skewed, and therefore we did not present summary estimates</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported data we could use for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: specific ‐ doctors' assessment of adverse effects</b> </p> <p>UKU (events)</p> <p>Medium‐term<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.39<br/> (0.61 to 3.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>51<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>273 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>379 per 1000<br/> (166 to 867) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p>Average endpoint scores, QLS (higher score = better, scale from 0‐126)</p> <p>Medium‐term<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life was 84.4 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 3.30 points lower<br/> (18.76 lower to 12.16 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for clinically important change in quality of life were not available.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>Endpoint data (events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.06<br/> (0.54 to 2.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>72<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>321 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>341 per 1000<br/> (174 to 672) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>BPRS:</b> Brief Psychiatric Rating Scale; <b>CBT:</b> cognitive behavioural therapy; <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>QLS:</b> Quality of Life Scale; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>UKU:</b> Udvalg for Kliniske Undersøgelser Adverse Effects Scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated 'serious'; randomisation process unclear, method of allocation concealment unclear, large attrition of participants.<br/> <sup>2</sup>Imprecision: rated ' very serious'; evidence from one small study. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012236-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Group C cognitive behavioural therapy: cognitive behavioural therapy + supportive intervention compared to non‐directive reflective listening + supportive intervention for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cognitive behavioural therapy + supportive intervention compared to non‐directive reflective listening + supportive intervention for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> cognitive behavioural therapy (CBT) + supportive intervention<br/> <b>Comparison:</b> non‐directive reflective listening (NDRL) + supportive intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with NDRL + supportive intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CBT + supportive intervention</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Prodromal symptoms: transition to psychosis</b> </p> <p>Endpoint data (events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 6.32<br/> (0.34 to 117.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global state: clinically important change in global state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mental state: clinically important change in mental state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects: at least one serious adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life: clinically important change in quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>Endpoint data (events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.35<br/> (0.81 to 2.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>444 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>600 per 1000<br/> (360 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CBT:</b> cognitive behavioural therapy; <b>CI:</b> confidence interval; <b>NDRL:</b> non‐directive reflective listening; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated 'very serious'; allocation concealment method unclear; participants not blinded; high attrition.<br/> <sup>2</sup>Imprecision: rated 'very serious'; evidence from one small study. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012236-tbl-0010"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Group C cognitive behavioural therapy: cognitive behavioural therapy + risperidone compared to supportive therapy + placebo for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cognitive behavioural therapy + risperidone compared to supportive therapy + placebo for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> cognitive behavioural therapy (CBT) + risperidone<br/> <b>Comparison:</b> supportive therapy + placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with supportive therapy + placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CBT + risperidone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Prodromal symptoms: transition to psychosis</b> </p> <p>Endpoint data (events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.76<br/> (0.28 to 2.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>71<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>214 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>163 per 1000<br/> (60 to 435) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global state: clinically important change in global state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: psychopathology</b> </p> <p>Total endpoint data, BPRS (higher score = worse, scale from: 0‐126)<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychopathology was 15.3 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychopathology was 14 points</p> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for this outcome were skewed, and therefore we did not present summary estimates</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: doctors' assessment of adverse effects</b> </p> <p>UKU (events)</p> <p>Medium‐term<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.43<br/> (0.64 to 3.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>58<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>273 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>390 per 1000<br/> (175 to 862) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p>Average endpoint scores, QLS (higher score = better, scale from: 0‐126)</p> <p>Medium‐term<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life was 84.4 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.40 points higher<br/> (9.91 lower to 14.71 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for clinically important change in quality of life were not available.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>Endpoint data (events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.16<br/> (0.60 to 2.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>71<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>321 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>373 per 1000<br/> (193 to 723) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>BPRS:</b> Brief Psychiatric Rating Scale; <b>CI:</b> confidence interval; <b>QLS:</b> Quality of Life Scale; <b>RR:</b> risk ratio; <b>UKU:</b> Udvalg for Kliniske Undersøgelser Adverse Effects Scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, high attrition </p> <p><sup>2</sup> Imprecision: rated 'very serious'; evidence from one small study </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012236-tbl-0011"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Group C other: cognitive training compared to active control (tablet games) for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cognitive training compared to active control (tablet games) for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> cognitive training<br/> <b>Comparison:</b> active control (tablet games) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with active control (tablet games)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with cognitive training</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Prodromal symptoms: transition to psychosis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global state: clinically important change in global state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: psychosis risk symptoms</b> </p> <p>SOPS total (higher score = worse, scale from: 0‐114)<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychosis risk symptoms was 25.49 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychosis risk symptoms was 33.9 points</p> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for this outcome were skewed, and therefore we did not present summary estimates</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects: at least one serious adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life: clinically important change in quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>Endpoint data (events)</p> <p>Long‐term<br/> Follow‐up: by 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.78<br/> (0.48 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>83<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>485 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>378 per 1000<br/> (233 to 625) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SOPS:</b> Scale of Prodromal Symptoms </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, high attrition.<br/> <sup>2</sup>Imprecision: rated 'very serious'; evidence from one small study. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012236-tbl-0012"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 12.</span> <span class="table-title">Group C other: family treatment compared to enhanced care for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Family treatment compared to enhanced care for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> family treatment<br/> <b>Comparison:</b> enhanced care </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with enhanced care</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with family treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Prodromal symptoms: transition to psychosis</b> </p> <p>FACT</p> <p>Long‐term<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.71<br/> (0.35 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>199 per 1000<br/> (98 to 406) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Global state: antipsychotic prescriptions</b> </p> <p>(events)<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.18<br/> (0.69 to 2.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>129<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>270 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>318 per 1000<br/> (186 to 545) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: specific ‐ psychosis risk, positive symptoms</b> </p> <p>Average total score, SOPS positive (higher score = worse, scale from 0‐30)</p> <p>Short‐term<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: specific ‐ psychosis risk, positive symptoms was 9.84 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.01 points lower<br/> (3.87 lower to 0.15 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for our predefined outcome of interest 'Clinically important change in mental state' were not reported by the studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: suicide</b> </p> <p>(events)</p> <p>Long‐term (by 24 months)<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.00<br/> (0.06 to 15.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/> (1 to 311) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life: clinically important change in quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>FACT</p> <p>Long‐term<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/> (0.52 to 1.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>320 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>301 per 1000<br/> (166 to 538) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>FACT:</b> Family‐aided Assertive Community Treatment; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SOPS:</b> Scale for Prodromal Symptoms </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, participants not blinded, high attrition, unclear risk of selective reporting bias.<br/> <sup>2</sup>Imprecision: rated 'very serious'; evidence from one small study.<br/> <sup>3</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, participants not blinded, outcome assessors not blinded, unclear risk of selective reporting bias. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012236-tbl-0013"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 13.</span> <span class="table-title">Group C other: integrated treatment compared to standard treatment for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Integrated treatment compared to standard treatment for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> integrated treatment<br/> <b>Comparison:</b> standard treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with standard treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with integrated treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Prodromal symptoms: transition to psychosis</b> </p> <p>Endpoint data (events)</p> <p>Long‐term<br/> Follow‐up: by 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.57<br/> (0.28 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>79<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>378 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>216 per 1000<br/> (106 to 435) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global state: clinically important change in global state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state</b> </p> <p>SANS total (higher score = worse, scale from 0‐130)<br/> Follow‐up: 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state was 1.7 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state was 1.34 points</p> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for this outcome were skewed, and therefore we did not present summary estimates</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects: at least one serious adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life: clinically important change in quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>Endpoint data (events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.66<br/> (0.25 to 1.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>79<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>216 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000<br/> (54 to 374) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio; <b>SANS:</b> Scale for Assessment of Negative Symptoms </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated 'very serious'; allocation concealment method not described, participants not blinded, outcome assessors not blinded, moderate attrition, unclear risk of selective reporting bias.<br/> <sup>2</sup>Imprecision: rated 'very serious'; evidence from one small study. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012236-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012236-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012236-sec-0543">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD012236-sec-0030"></div> <section id="CD012236-sec-0031"> <h3 class="title" id="CD012236-sec-0031">Description of the condition</h3> <p>Schizophrenia is a chronic, recurrent illness that usually starts with a prodromal phase, eventually followed by the first acute phase. It continues with periods of remission and acute psychosis. With each episode of psychosis, mental state will usually deteriorate, finally reaching a state of chronicity. People with schizophrenia usually have more than three psychotic episodes, with only partial remission from each episode over the course of their illness (<a href="./references#CD012236-bbs2-0189" title="WiersmaD , NienhuisFJ , SlooffCJ , GielR . Natural course of schizophrenic disorders: a 15‐year followup of a Dutch incidence cohort. Schizophrenia Bulletin1998;24(1):75–85. ">Wiersma 1998</a>), and decline in functional status is linked to the progression of neurobiological damage over time (<a href="./references#CD012236-bbs2-0084" title="AndreasenNC , LiuD , ZiebellS , VoraA , HoBC . Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. American Journal of Psychiatry2013;170(6):609‐15. ">Andreasen 2013</a>). </p> <p>Schizophrenia has a prevalence of 1% worldwide, affecting a substantial number of people each year (<a href="./references#CD012236-bbs2-0191" title="WittchenHU , JacobiF , RehmJ , GustavssonA , SvenssonM , JönssonB , et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. European Neuropsychopharmacology2011;21(9):655–79. ">Wittchen 2011</a>). Treatment of schizophrenia is complex, costly, and offers only partial, limited improvement in two‐thirds of sufferers. Treatment response is best for first‐episode psychoses, but unfortunately, due to treatment non‐adherence, the majority of patients relapse within a few years. With every new relapse, treatment resistance increases (<a href="./references#CD012236-bbs2-0121" title="EmsleyR , ChilizaB , AsmalR , HarveyBH . The nature of relapse in schizophrenia. BMC Psychiatry2013;13:50. ">Emsley 2013</a>). Over its course, schizophrenia still remains a disorder with low functional recovery rates (<a href="./references#CD012236-bbs2-0145" title="JaaskelainenE , JuolaP , HirvonenN , McGrathJJ , SahaS , IsohanniM , et al. A systematic review and meta‐analysis of recovery in schizophrenia. Schizophrenia Bulletin2013;39(6):1296–306. ">Jaaskelainen 2013</a>; <a href="./references#CD012236-bbs2-0192" title="WunderinkL , NieboerRM , WiersmaD , SytemaS , NienhuisFJ . Recovery in remitted first‐episode psychosis at 7 years of follow‐up of an early dose reduction/discontinuation or maintenance treatment strategy long‐term follow‐up of a 2‐year randomised clinical trial. JAMA Psychiatry2013;70(9):913‐20. [DOI: 10.1001/jamapsychiatry.2013.19] ">Wunderink 2013</a>), and remains among the leading causes of disability (<a href="./references#CD012236-bbs2-0191" title="WittchenHU , JacobiF , RehmJ , GustavssonA , SvenssonM , JönssonB , et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. European Neuropsychopharmacology2011;21(9):655–79. ">Wittchen 2011</a>). </p> <p>A number of early intervention services, developed over the last 20 years worldwide, have shifted attention to the treatment of the early course of schizophrenia, including the prevention of schizophrenia in people at risk. Specialised teams have established a set of clinical criteria for identifying people at risk of developing schizophrenia, this includes the clinical high risk (CHR) criteria (comprising the 'at‐risk mental state' (ARMS) or prodromal syndrome); the ultra high risk (UHR) criteria (comprising the attenuated psychotic syndrome (APS)); the 'Brief Limited Intermittent Psychotic Syndrome' (BLIPS); and genetic risk combined with functional decline (<a href="./references#CD012236-bbs2-0104" title="CornblattB , LenczT , ObuchowskiM . The schizophrenia prodrome: treatment and high‐risk perspectives. Schizophrenia Research2002;54(1‐2):177‐86. ">Cornblatt 2002</a>; <a href="./references#CD012236-bbs2-0161" title="MillerTJ , McGlashanTH , RosenJL , CadenheadK , CannonT , VenturaJ , et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophrenia Bulletin2003;29(4):703‐15. ">Miller 2003</a>; <a href="./references#CD012236-bbs2-0197" title="YungAR , PhillipsLJ , YuenHP , McGorryPD . Risk factors for psychosis in an ultra high‐risk group: psychopathology and clinical features. Schizophrenia Research2004;67(2‐3):131‐42. ">Yung 2004</a>; <a href="./references#CD012236-bbs2-0099" title="BroomeMR , WoolleyJB , JohnsLC , ValmaggiaLR , TabrahamP , GafoorR , et al. Outreach and support in south London (OASIS): implementation of a clinical service for prodromal psychosis and the at risk mental state. European Psychiatry2005;20(5‐6):372‐8. ">Broome 2005</a>; <a href="./references#CD012236-bbs2-0198" title="YungAR , YuenHP , McGorryPD , PhillipsLJ , KellyD , Dell’OlioM , et al. Mapping the onset of psychosis: the Comprehensive Assessment of At‐Risk Mental States. Australian &amp; New Zealand Journal of Psychiatry2005;39(11‐12):964‐71. ">Yung 2005</a>; <a href="./references#CD012236-bbs2-0101" title="CannonTD , CadenheadK , CornblattB , WoodsSW , AddingtonJ , WalkerE , et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Archives of General Psychiatry2008;65(1):28‐37. ">Cannon 2008</a>). Another approach has been researched ‐ the Basic Symptom approach. This includes the cognitive‐perceptive (COPER) basic symptoms; and Cognitive Disturbances (COGDIS; <a href="./references#CD012236-bbs2-0174" title="Schultze‐LutterF . Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. Schizophrenia Bulletin2009;35(1):5‐8. ">Schultze‐Lutter 2009</a>). The use of psychometric prognostic interviews for CHR have been reviewed by Fusar‐Poli, and their use as clinical tools for high risk services worldwide has been supported (<a href="./references#CD012236-bbs2-0125" title="Fusar‐PoliP , Schultze‐LutterF , CappucciatiM , RutiglianoG , BonoldiI , StahlD , et al. The dark side of the moon: meta‐analytical impact of recruitment strategies on risk enrichment in the clinical high risk state for psychosis. Schizophrenia Bulletin2016;42(3):732‐43. ">Fusar‐Poli 2016</a>). </p> <p>People with CHR criteria have been found to have neurocognitive impairments, and corresponding neurotransmitter and structural changes have been identified. These include hyperdopaminergia in the striatum and hippocampal glutamate alterations (<a href="./references#CD012236-bbs2-0181" title="StoneJM , HowesOD , EgertonA , KambeitzJ , AllenP , LythgoeDJ , et al. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biological Psychiatry2010;68(7):599–602. [DOI: 10.1016/j.biopsych.2010.05.034] ">Stone 2010</a>; <a href="./references#CD012236-bbs2-0078" title="AllenP , ChaddockCA , HowesOD , EgertonA , SealML , Fusar‐PoliP , et al. Abnormal relationship between medial temporal lobe and subcortical dopamine function in people with an ultra high risk for psychosis. Schizophrenia Bulletin2012;38(5):1040–9. [DOI: 10.1093/schbul/sbr017] ">Allen 2012</a>; <a href="./references#CD012236-bbs2-0143" title="HowesOD , Fusar‐PoliP , BloomfieldM , SelvarajS , McGuireP . From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairments. Current Pharmaceutical Design2012;18(4):459‐65. ">Howes 2012</a>), thalamic disconnectivity (<a href="./references#CD012236-bbs2-0086" title="AnticevicA , HautK , MurrayJD , RepovsG , YangGJ , DiehlC , et al. Association of thalamic dysconnectivity and conversion to psychosis in youth and young adults at elevated clinical risk. JAMA Psychiatry2015;72(9):882‐91. [DOI: 10.1001/jamapsychiatry.2015.0566] ">Anticevic 2015</a>), as well as reductions in grey matter in the left parahippocampal and fusiform gyri (<a href="./references#CD012236-bbs2-0147" title="JobDE , WhalleyHC , McIntoshAM , JohnstoneEC , LawrieSM . Grey matter changes can improve the prediction of schizophrenia in subjects at high risk. BMC Psychiatry2006;4:29. ">Job 2006</a>), and temporal lobe volume reduction (<a href="./references#CD012236-bbs2-0103" title="ChungY , JacobsonA , HeG , VanErpTG , McEwenS , AddingtonJ , et al. Prodromal symptom severity predicts accelerated gray matter reduction and third ventricle expansion among clinically high risk youth developing psychotic disorders. Molecular Neuropsychiatry2015;1(1):13‐22. ">Chung 2015</a>). </p> </section> <section id="CD012236-sec-0032"> <h3 class="title" id="CD012236-sec-0032">Description of the intervention</h3> <p>There are a number of early intervention services that focus on treating early phases or prodromal stage of schizophrenia and preventing development of psychoses in CHR/UHR groups. </p> <section id="CD012236-sec-0033"> <h4 class="title">1. Pharmacotherapy treatment</h4> <p>Pharmacotherpay includes antipsychotics, mood stabilisers and antidepressant treatment.</p> <p>Antipsychotic treatment is a well‐established treatment for first episode psychosis. However, due to a number of potential side effects as well as the lack of firm evidence that it is effective for prevention of psychosis, antipsychotic treatment is currently suggested in the prodromal phase of the illness only for more complex cases and only with a few atypical antipsychotics (<a href="./references#CD012236-bbs2-0172" title="SchmidtSJ , Schultze‐LutterF , SchimmelmannBG , MaricNP , SalokangasRK , Riecher‐RösslerA , et al. EPA guidance on the early intervention in clinical high risk states of psychoses. European Psychiatry2015;30(3):388‐404. [DOI: 10.1016/j.eurpsy.2015.01.013] ">Schmidt 2015</a>). Treatment with antidepressants is not suggested for the treatment of acute‐episode psychosis, as evidence suggests that antidepressants may be associated with the risk of worsening psychosis. However, it has been suggested that treating prodromal depressive syndromes may actually delay the onset of psychosis (<a href="./references#CD012236-bbs2-0105" title="CornblattBA , LenczT , SmithCW , OlsenR , AutherAM , NakayamaE , et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. Journal of Clinical Psychiatry2007;68(4):546‐57. ">Cornblatt 2007a</a>; <a href="./references#CD012236-bbs2-0124" title="Fusar‐PoliP , ValmaggiaL , McGuireP . Can antidepressants prevent psychosis?. Lancet2007;370(9601):1746‐8. ">Fusar‐Poli 2007</a>). Mood stabilisers are used as first‐ or second‐line treatment for bipolar disorders, which sometimes present as affective psychoses. Their use in the prodromal stage may potentially be useful (<a href="./references#CD012236-bbs2-0092" title="BergerGE , WoodSJ , RossM , HamerCA , WellardRM , PellG , et al. Neuroprotective effects of low‐dose lithium in individuals at ultra‐high risk for psychosis. A longitudinal MRI/MRS study. Current Pharmaceutical Design2012;18(4):570‐5. ">Berger 2012</a>). Anxiolitics are used for the short‐term reduction of anxiety in first‐episode psychosis. It has been suggested that reducing anxiety in the prodromal phase of the illness may postpone psychosis (<a href="./references#CD012236-bbs2-0159" title="McAuslandL , BuchyL , CadenheadKS , CannonTD , CornblattBA , HeinssenR , et al. Anxiety in youth at clinical high risk for psychosis. Early Intervention in Psychiatry2017; Vol. 11, issue 6:480‐487. [DOI: 10.1111/eip.12274] ">McAusland 2015</a>). </p> </section> <section id="CD012236-sec-0034"> <h4 class="title">2. The use of nutritives/supplements and alternative medication</h4> <p>This category includes omega‐3, glycine, D‐serine, B vitamins, folic acid, and immune response modulators. </p> <p>Based on the hypothesis of the alteration of metabolism of lipids, homocysteine levels and neuroinflammation in schizophrenia, a number of studies examined the influence of different supplements aimed at restoring lipid metabolism or low levels of vitamins in UHR people (<a href="./references#CD012236-bbs2-0080" title="AmmingerGP , SchaferMR , PapageorgiouK , KlierCM , CottonSM , HarriganSM , et al. Long‐chain omega‐3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo‐controlled trial. Archives of General Psychiatry2010;67(2):146‐54. ">Amminger 2010</a>; <a href="./references#CD012236-bbs2-0019" title="NCT00291226 . Glycine vs Placebo for the Schizophrenia Prodrome. www.ClinicalTrials.gov/ct/show/2006. [CSzG: 14759] WoodsS , WalshB , HawkinsK , MillerT , SaksaJ , D'SouzaD , et al. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. Early Intervention in Psychiatry2012;6:29. [CSzG: 24987] WoodsSW , KantrowitzJT , JavittDC . NMDAR‐based treatments for patients at clinical high risk for psychosis. Biological Psychiatry2014;1:11S. [CSzG: 29041] WoodsSW , WalshBC , HawkinsKA , MillerTJ , SaksaJR , D'SouzaDC , et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. European Neuropsychopharmacology2013;23(8):931‐40. [CSzG: 28750] ">Woods‐1‐USA</a>; <a href="./references#CD012236-bbs2-0177" title="SommerIE , VanWestrhenenR , BegemannMJ , deWitteLD , LeuchtS , KahnRS . Efficacy of anti‐inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophrenia Bulletin2014;40(1):181‐91. [DOI: 10.1093/schbul/sbt139] ">Sommer 2014</a>; <a href="./references#CD012236-bbs2-0148" title="KantrowitzJT , WoodsSW , PetkovaE , CornblattB , CorcoranCM , ChenH , et al. D‐serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double‐blind, placebo‐controlled, randomised parallel group mechanistic proof‐of‐concept trial. Lancet Psychiatry2015;2(5):403‐12. [DOI: 10.1016/S2215‐0366(15)00098‐X] ">Kantrowitz 2015</a>; <a href="./references#CD012236-bbs2-0194" title="XuXJ , JiangGS . Niacin‐respondent subset of schizophrenia – a therapeutic review. European Review for Medical and Pharmacological Sciences2015;19(6):988‐97. ">Xu 2015</a>). </p> </section> <section id="CD012236-sec-0035"> <h4 class="title">3. Psychotherapy or psychosocial interventions</h4> <p>Psychotherapy and psychosocial interventions include psychoeducation, social skills training, metacognitive training, cognitive remediation, family therapy, individual psychotherapy, and combined multiple approaches. </p> <p>Most early intervention services focus on psychosocial methods, offered for a variable duration of time, and suggested psychosocial interventions as the first‐line treatment for the prodromal stage. Studies showed variable and generally modest effectiveness of a variety of psychosocial methods for people with schizophrenia, especially over a longer assessment period (<a href="./references#CD012236-bbs2-0122" title="FalloonIR , BoydJL , McGillCW , WilliamsonM , RazaniJ , MossHB , et al. Family management in the prevention of morbidity of schizophrenia. Clinical outcome of a two‐year longitudinal study. Archives of General Psychiatry1985;42(9):887–96. ">Falloon 1985</a>; <a href="./references#CD012236-bbs2-0142" title="HogartyGE , AndersonCM , ReissDJ , KornblithSJ , GreenwaldDP , UrlichRF , et al. Family psychoeducation, social skills training, and maintenance chemotherapy in the after­care treatment of schizophrenia. II. Two‐year effects of a controlled study on relapse and adjustment. Archives of General Psychiatry1991;48(4):340–7. ">Hogarty 1991</a>; <a href="./references#CD012236-bbs2-0116" title="DolderCR , LacroJP , LeckbandS , JesteDV . Interventions to improve antipsychotic medication adherence: review of recent literature. Journal of Clinical Psychopharmacology2003;23(4):389–99. ">Dolder 2003</a>; <a href="./references#CD012236-bbs2-0118" title="DurhamRC , ChambersJA , PowerKG , SharpDM , MacdonaldRR , MajorKA , et al. Long‐term outcome of cognitive behaviour therapy clinical trials in central Scotland. Health Technology Assessment2005;9(42):1‐174. ">Durham 2005</a>; <a href="./references#CD012236-bbs2-0185" title="VelliganDI , DiamondPM , MaplesNJ , MintzJ , LiX , GlahnDC , et al. Comparing the efficacy of interventions that use environmental supports to improve outcomes in patients with schizophrenia. Schizophrenia Research2008;102(1‐3):312–9. ">Velligan 2008</a>; <a href="./references#CD012236-bbs2-0146" title="JauharS , McKennaPJ , RaduaJ , FungE , SalvadorR , LawsKR . Cognitive–behavioural therapy for the symptoms of schizophrenia: systematic review and meta‐analysis with examination of potential bias. British Journal of Psychiatry2014;204(1):20‐9. [DOI: 10.1192/bjp.bp.112.116285] ">Jauhar 2014</a>; <a href="./references#CD012236-bbs2-0081" title="AndersonK , LaxhmanN , PriebeS . Can mental health interventions change social networks? A systematic review. BMC Psychiatry2015;15:297. [DOI: 10.1186/s12888‐015‐0684‐6] ">Anderson 2015</a>; <a href="./references#CD012236-bbs2-0100" title="CaiY , ZhuY , ZhangW , WangY , ZhangC . Comprehensive family therapy: an effective approach for cognitive rehabilitation in schizophrenia. Neuropsychiatric Disease and Treatment2015;11:1247–53. ">Cai 2015</a>; <a href="./references#CD012236-bbs2-0171" title="RuggeriM , BonettoC , LasalviaA , FiorittiA , deGirolamoG , SantonastasoP , et al. Feasibility and effectiveness of a multi‐element psychosocial intervention for first‐ episode psychosis: results from the cluster‐randomised controlled GET UP PIANO trial in a catchment area of 10 million inhabitants. Schizophrenia Bulletin2015;41(5):1192–203. ">Ruggeri 2015</a>). </p> </section> </section> <section id="CD012236-sec-0036"> <h3 class="title" id="CD012236-sec-0036">How the intervention might work</h3> <p>There are a variety of treatment options, and each of them may work differently:</p> <p>Pharmacotherapy based on antipsychotics has documented efficacy for psychotic symptoms, based on their blockade/agonism of multireceptor sites. In particular, cortical dopamine transmission via D1 receptors may play a role in impaired working memory and negative symptoms, whereas striatal dopamine activity via D2 receptors may modulate response inhibition, temporal organisation, and motor performance (<a href="./references#CD012236-bbs2-0074" title="Abi‐DarghamA . Do we still believe in the dopamine hypothesis? New data bring new evidence. International Journal of Neuropsychopharmacology2004;7(Suppl 1):S1‐5. ">Abi‐Dargham 2004</a>). </p> <p>Mood stabilisers may act as modulators of glutamate neurotransmission, counteracting the effect of the excessive glutamate transmission. Anxiolytics may increase GABA neurotransmission, subsequently decreasing excessive glutamate transmission. Both of these support the glutamate hypothesis of schizophrenia. Antidepressants may increase serotoninergic, noradrenergic or dopaminergic neurotransmission in the prefrontal cortex, subsequently affecting cognitive and depressive symptoms in the prodromal stage. </p> <p>Nutritives/supplements and alternative medication (omega‐3, glycine, D‐serine, B vitamins, folic acid) act as glutamatergic modulators (glycine, D‐serine), suppressing the increased immune response (acetylsalicylate and others) or counteracting the altered phospholipid metabolism observed in some people with schizophrenia (<a href="./references#CD012236-bbs2-0080" title="AmmingerGP , SchaferMR , PapageorgiouK , KlierCM , CottonSM , HarriganSM , et al. Long‐chain omega‐3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo‐controlled trial. Archives of General Psychiatry2010;67(2):146‐54. ">Amminger 2010</a>; <a href="./references#CD012236-bbs2-0019" title="NCT00291226 . Glycine vs Placebo for the Schizophrenia Prodrome. www.ClinicalTrials.gov/ct/show/2006. [CSzG: 14759] WoodsS , WalshB , HawkinsK , MillerT , SaksaJ , D'SouzaD , et al. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. Early Intervention in Psychiatry2012;6:29. [CSzG: 24987] WoodsSW , KantrowitzJT , JavittDC . NMDAR‐based treatments for patients at clinical high risk for psychosis. Biological Psychiatry2014;1:11S. [CSzG: 29041] WoodsSW , WalshBC , HawkinsKA , MillerTJ , SaksaJR , D'SouzaDC , et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. European Neuropsychopharmacology2013;23(8):931‐40. [CSzG: 28750] ">Woods‐1‐USA</a>; <a href="./references#CD012236-bbs2-0177" title="SommerIE , VanWestrhenenR , BegemannMJ , deWitteLD , LeuchtS , KahnRS . Efficacy of anti‐inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophrenia Bulletin2014;40(1):181‐91. [DOI: 10.1093/schbul/sbt139] ">Sommer 2014</a>; <a href="./references#CD012236-bbs2-0148" title="KantrowitzJT , WoodsSW , PetkovaE , CornblattB , CorcoranCM , ChenH , et al. D‐serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double‐blind, placebo‐controlled, randomised parallel group mechanistic proof‐of‐concept trial. Lancet Psychiatry2015;2(5):403‐12. [DOI: 10.1016/S2215‐0366(15)00098‐X] ">Kantrowitz 2015</a>; <a href="./references#CD012236-bbs2-0194" title="XuXJ , JiangGS . Niacin‐respondent subset of schizophrenia – a therapeutic review. European Review for Medical and Pharmacological Sciences2015;19(6):988‐97. ">Xu 2015</a>). </p> <p>Psychosocial interventions may enhance self‐confidence and self‐esteem, cognitive abilities, social skills, social network and support, all contributing to increased coping mechanisms and decreased anxiety and vulnerability to stressors, and subsequently to psychosis. </p> </section> <section id="CD012236-sec-0037"> <h3 class="title" id="CD012236-sec-0037">Why it is important to do this review</h3> <p>Psychosis has a large impact on an individual's life, causing long‐term health, economic and social problems. Identifying and treating people in the prodromal stage of psychosis may prevent full transition to schizophrenia and in turn negate some of the ill effects brought about by psychosis. Since firm evidence of the efficacy and safety of different treatment approaches in this vulnerable group is lacking, a systematic review can help inform decisions of healthcare workers, researchers, politicians and other public health decision makers. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012236-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012236-sec-0038">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012236-sec-0551">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012236-sec-0038"></div> <p>The primary objective is to assess the safety and efficacy of early interventions for people in the prodromal stage of psychosis. </p> <p>The secondary objective is, if possible, to compare the effectiveness of the various different interventions. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012236-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012236-sec-0039">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012236-sec-0552">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012236-sec-0039"></div> <section id="CD012236-sec-0040"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012236-sec-0041"> <h4 class="title">Types of studies</h4> <p>All relevant randomised controlled studies. If a study had been described as 'double‐blind' but implied randomisation, we would have included such studies in a sensitivity analysis (see <a href="#CD012236-sec-0110">Sensitivity analysis</a>). We excluded quasi‐randomised studies, such as those allocating by alternate days of the week. </p> </section> <section id="CD012236-sec-0042"> <h4 class="title">Types of participants</h4> <p>We included participants older than 12 years, who had developed a prodromal stage of psychosis, including people that met at least one of the following criteria: </p> <p> <ol id="CD012236-list-0001"> <li> <p>positive psychiatric heredity (relatives that suffer from schizophrenia spectrum disorders and non‐organic psychosis) combined with functional decline over the last 12 months; </p> </li> <li> <p>experienced Brief Limited Intermittent Psychotic Symptoms combined with functional decline over the last 12 months; </p> </li> <li> <p>experienced Attenuated Psychosis Syndrome combined with functional decline over the last 12 months. </p> </li> </ol> </p> <p>Exclusion criteria were mental illness in childhood that can present with psychosis (such as autism); organic conditions that can present with psychosis; neurological disorders; mental retardation; comorbid alcoholism or abuse of opiates and other substance disorders (excluding marijuana); pregnancy and lactation; and the use of medications that can produce psychotic reactions. </p> <p>Studies had to use internationally recognised criteria for diagnosis (such as Diagnostic and Statistical Manual of Mental Disorders V (DSM‐5) or previous editions of DSM (<a href="./references#CD012236-bbs2-0088" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. 5th Edition. Arlington: American Psychiatric Association, 2013. ">APA 2013</a>); and the International Classification of Diseases 10 (ICD‐10) or previous editions of ICD (<a href="./references#CD012236-bbs2-0188" title="WHO . International Statistical Classification of Diseases and Related Health Problems, 10th revision. Geneva: World Health Organization, 2010. ">WHO 2010</a>)). For studies that included only a subset of relevant participants, we only included the study if data for the population of interest were reported separately. </p> </section> <section id="CD012236-sec-0043"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD012236-list-0002"> <li> <p>Pharmacotherapy: any oral antipsychotics</p> </li> <li> <p>Alternative medication (e.g. omega‐3, B12 vitamins, folic acid, B6 vitamins)</p> </li> <li> <p>Psychotherapies: including psychodynamically oriented individual psychotherapy, cognitive behavioural psychotherapy, group therapy (psychodynamically oriented), systemic therapy, interpersonal therapy, integrative therapy, family therapy </p> </li> <li> <p>Pyschosocial interventions: including psychoeducation (individual, group and family), metacognitive training (individual and group), cognitive remediation training, social skills training </p> </li> <li> <p>Combined pharmacotherapy and psychotherapy or psychosocial interventions, or psychosocial interventions including a combination of at least two approaches, one of which is pharmacotherapy and one psychotherapy or psychosocial intervention </p> </li> <li> <p>Placebo</p> </li> <li> <p>No therapy or treatment, or treatment as usual (TAU) (e.g. brief outpatients’ consultations less than once every three months). </p> </li> </ol> </p> </section> <section id="CD012236-sec-0044"> <h4 class="title">Types of outcome measures</h4> <p>We divided all outcomes into short‐term (less than six months), medium‐term (7 to 12 months) and long‐term (over one year) outcomes. </p> <section id="CD012236-sec-0045"> <h5 class="title">Primary outcomes</h5> <section id="CD012236-sec-0046"> <h6 class="title">1. Prodromal symptoms</h6> <p>1.1. Transition to psychosis during follow‐up period<br/> 1.2. Clinically important change of severity of prodromal symptoms<br/> 1.3. Any change in prodromal symptoms<br/> 1.4. Remission of prodromal symptoms </p> </section> <section id="CD012236-sec-0047"> <h6 class="title">2. Global state</h6> <p>2.1. Clinically important change in global state</p> </section> <section id="CD012236-sec-0048"> <h6 class="title">3. Adverse effects</h6> <p>3.1. Clinically important general adverse effects</p> </section> </section> <section id="CD012236-sec-0049"> <h5 class="title">Secondary outcomes</h5> <section id="CD012236-sec-0050"> <h6 class="title">1. General overall functioning (social functioning, relationship status, employment status, academic status) </h6> <p>1.1. Clinically important change in overall functioning, as defined by each of the studies<br/> 1.2. Average endpoint/change score in overall functioning scales<br/> 1.3 Clinically important change in social functioning, as defined by each of the studies<br/> 1.4. Average endpoint/change score in social functioning scales<br/> 1.5. Change in the relationship status, as defined by each of the studies<br/> 1.6. Change in the employment status, as defined by each of the studies<br/> 1.7. Change in the academic status, as defined by each of the studies </p> </section> <section id="CD012236-sec-0051"> <h6 class="title">2. Global state</h6> <p>2.1. Any change in global state<br/> 2.2. Average endpoint/change score in global state scales </p> </section> <section id="CD012236-sec-0052"> <h6 class="title">3. Mental state: general symptoms; specific psychotic symptoms (positive symptoms (delusions, hallucinations, disordered thinking); negative symptoms (avolition, poor self‐care, blunted affect)); mood; psychomotor; cognitive </h6> <p>3.1. Clinically important change in mental state, as defined by each of the studies<br/> 3.2. Average endpoint/change score in mental state scales<br/> 3.3. Clinically important change in positive symptoms, as defined by each of the studies<br/> 3.4. Average endpoint/change score in positive symptoms scales<br/> 3.5. Clinically important change in negative symptoms, as defined by each of the studies<br/> 3.6. Average endpoint/change score in negative symptoms scales<br/> 3.7. Clinically important change in affective/mood symptoms, as defined by each of the studies<br/> 3.8. Average endpoint/change score in affective/mood symptoms scales<br/> 3.9. Clinically important change in psychomotor symptoms, as defined by each of the studies<br/> 3.10. Average endpoint/change score in psychomotor symptoms scales<br/> 3.11. Clinically important change in cognitive symptoms, as defined by each of the studies<br/> 3.12. Average endpoint/change score in cognitive symptoms scales </p> </section> <section id="CD012236-sec-0053"> <h6 class="title">4. Behaviour: general behaviour, specific behaviours (for example, aggressive or violent behaviour); occurrence of violent incidents (to self, others or property) </h6> <p>4.1. Clinically important change in overall behaviour, as defined by each of the studies<br/> 4.2. Average endpoint/change score in overall behaviour scales<br/> 4.3. Clinically important change in specific behaviour, as defined by each of the studies<br/> 4.4. Average endpoint/change score in specific behaviour scales<br/> 4.5. Occurrence of violent incidents </p> </section> <section id="CD012236-sec-0054"> <h6 class="title">5. Adverse effects</h6> <p>5.1. Average endpoint/change score in general adverse effect scores<br/> 5.2. Clinically important specific adverse effects<br/> 5.3. Average endpoint/change score in specific adverse effect scores<br/> 5.4. Various adverse effects: specific movement disorders (extrapyramidal side effects, specifically tardive dyskinesia and neuroleptic malignant syndrome); sedation; dry mouth; weight gain; sleepiness; dizziness; palpitations; muscle rigidity; hypersalivation; blurred vision; dysuria; nausea; nocturnal enuresis; thirst; polyuria; prolactinaemia side‐effects (swollen nipples, galactorrhoea, loss of sexual pleasure, erectile dysfunction) </p> </section> <section id="CD012236-sec-0055"> <h6 class="title">6. Death by suicide or by natural causes</h6> </section> <section id="CD012236-sec-0056"> <h6 class="title">7. Quality of life</h6> <p>7.1. Any change in quality of life, as defined by each of the studies<br/> 7.2. Average endpoint/change score in quality‐of‐life scales </p> </section> <section id="CD012236-sec-0057"> <h6 class="title">8. Satisfaction with treatment (participant/carer)</h6> <p>8.1. Leaving the study early<br/> 8.2. Participant/carer not satisfied with treatment<br/> 8.3. Participant/carer average satisfaction score<br/> 8.4. Participant/carer change in the satisfaction scores </p> </section> <section id="CD012236-sec-0058"> <h6 class="title">9. Service outcomes</h6> <p>9.1. Hospital admission<br/> 9.2. Duration of hospital stay </p> </section> <section id="CD012236-sec-0059"> <h6 class="title">10. Economic outcomes</h6> <p>10.1. Cost of care</p> </section> <section id="CD012236-sec-0060"> <h6 class="title">'Summary of findings' table</h6> <p>We used the GRADE approach to interpret findings (<a href="./references#CD012236-bbs2-0175" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al. on behalf of the Cochrane Applicability and Recommendations Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Schünemann 2017</a>); and <a href="./references#CD012236-bbs2-0130" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version 19 September 2019. Hamilton (ON): McMaster University (developed by Evidence Prime). ">GRADEpro GDT</a> to import data from Review Manager 5 (RevMan 5) to create 'Summary of findings' tables (<a href="./references#CD012236-bbs2-0169" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). These tables provide outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient care and decision making. We selected the following main outcomes for inclusion in the 'Summary of findings' table: </p> <p> <ol id="CD012236-list-0003"> <li> <p>Prodromal symptoms: transition to psychosis</p> </li> <li> <p>Global state: clinically important change in global state</p> </li> <li> <p>Mental state: clinically important change in mental state</p> </li> <li> <p>Behaviour: clinically important change in behaviour</p> </li> <li> <p>Adverse effects: at least one serious adverse event</p> </li> <li> <p>Quality of life: clinically important change in quality of life</p> </li> <li> <p>Satisfaction with treatment: leaving the study early</p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD012236-sec-0061"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012236-sec-0062"> <h4 class="title">Electronic searches</h4> <section id="CD012236-sec-0063"> <h5 class="title">Cochrane Schizophrenia’s Register of studies</h5> <p>On 8 June 2016 and 4 August 2017, the Information Specialist searched Cochrane Schizophrenia’s study‐based Register of studies using the following search strategy, which has been developed based on literature review and consulting with the authors of the review: </p> <p>(*At Risk* OR *At‐Risk* OR *Attenuat* Psycho* Syndrome* OR *Brief Limited Intermittent Psycho* Symptom* OR *Brief Limited Intermittent Psycho* Syndrome* OR *Brief Self Limited Psycho* Syndrome* OR *Brief Self‐Limited Psycho* Syndrome* OR *Cognit* Disturbance* OR *Cognit* Percept* Basic Symptom* OR *Cognitive‐Percept* Basic Symptom* OR *Conver* OR *Elevated Clinical Risk* OR *Family History* OR *Genetic* Risk* OR *Heredity* OR *High Clinical Risk* OR *High Genetic Risk* OR *High Risk* OR *High‐Risk* OR *Inherit* OR *Onset* OR *Pre Delusion* OR *Pre Psycho* OR *Predelusion* OR *Pre‐Delusion* OR *Prepsycho* OR *Pre‐Psycho* OR *Prodrom* OR *Relative* OR *Risk* Syndrome* OR *Sub Psycho* OR *Subpsycho* OR *Sub‐Psycho* OR *Transition* OR *Vulnerable*) in Title OR Abstract of REFERENCE OR (*At Risk of Psychosis* OR *Prodromal Illness* OR *Family History of Psychosis* OR *Early Onset*) in Healthcare Condition of STUDY </p> <p>In study‐based registers, searching the major concept retrieves all the synonym keywords and relevant studies because all the studies have already been organised based on their interventions and linked to the relevant topics. </p> <p>Cochrane Schizophrenia’s Register of studies is compiled by systematic searches of major resources (including AMED, BIOSIS CINAHL, EMBASE, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, handsearches, grey literature, and conference proceedings (see <a href="https://schizophrenia.cochrane.org/register-trials" target="_blank">Cochrane Schizophrenia Register of trials</a>). There are no language, date, document type, or publication status limitations for inclusion of records into the register. </p> </section> </section> <section id="CD012236-sec-0064"> <h4 class="title">Searching other resources</h4> <section id="CD012236-sec-0065"> <h5 class="title">1. Reference searching</h5> <p>We inspected references of all included studies for further relevant studies.</p> </section> <section id="CD012236-sec-0066"> <h5 class="title">2. Personal contact</h5> <p>We contacted the first author of each included study for information regarding unpublished studies. We noted the outcome of this contact in the sections '<a href="./references#CD012236-sec-0539" title="">Characteristics of included studies</a>' or '<a href="./references#CD012236-sec-0541" title="">Characteristics of studies awaiting classification</a>'. </p> </section> </section> </section> <section id="CD012236-sec-0067"> <h3 class="title" id="CD012236-sec-0067">Data collection and analysis</h3> <section id="CD012236-sec-0068"> <h4 class="title">Selection of studies</h4> <p>DB and IK independently inspected citations from the searches and identified relevant abstracts. JH re‐inspected a random 20% sample to ensure reliability. In the case of disputes, we acquired the full report for more detailed scrutiny. We obtained full reports of the abstracts meeting the review criteria and DB and IK inspected these. Again, JH re‐inspected a random 20% of the full reports in order to ensure reliable selection. Where it was not possible to resolve disagreement by discussion, we attempted to contact the authors of the study for clarification. </p> </section> <section id="CD012236-sec-0069"> <h4 class="title">Data extraction and management</h4> <section id="CD012236-sec-0070"> <h5 class="title">1. Extraction</h5> <p>Review authors DB and IK extracted data from all included studies. In addition, to ensure reliability, JH independently extracted data from a random sample of these studies, comprising 10% of the total. Again, we discussed any disagreement, documented decisions and, if necessary, contacted authors of studies for clarification. With remaining problems MRK helped to clarify issues and we documented these final decisions. We extracted data presented only in graphs and figures whenever possible, but only included them if two review authors independently had the same result. We attempted to contact study authors through an open‐ended request in order to obtain missing information or for clarification whenever necessary. If studies were multicentre, where possible we extracted data relevant to each component centre separately. </p> </section> <section id="CD012236-sec-0071"> <h5 class="title">2. Management</h5> <section id="CD012236-sec-0072"> <h6 class="title">2.1 Forms</h6> <p>We extracted data onto standard, simple forms.</p> </section> <section id="CD012236-sec-0073"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We included continuous data from rating scales only if:<br/> <br/> a) the psychometric properties of the measuring instrument had been described in a peer‐reviewed journal (<a href="./references#CD012236-bbs2-0156" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>); and<br/> b) the measuring instrument had not been written or modified by one of the trialists for that particular study.<br/> <br/> Ideally the measuring instrument should either be i. a self‐report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly; in '<a href="#CD012236-sec-0117">Description of studies</a>' we noted if this is the case or not. </p> </section> <section id="CD012236-sec-0074"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>There are advantages of both endpoint and change data. Change data can remove a component of between‐person variability from the analysis. On the other hand calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult‐to‐measure conditions such as schizophrenia. We decided to primarily use endpoint data, and only use change data if the former are not available and used mean differences (MD) rather than standardised mean differences throughout (<a href="./references#CD012236-bbs2-0110" title="DeeksJJ , HigginsJP , Altman DG(editors) , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). </p> </section> <section id="CD012236-sec-0075"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we applied the following standards to all data before inclusion. </p> <section id="CD012236-sec-0076"> <p><b>Endpoint data (more than 200 participants)</b></p> <p>We entered data from studies of at least 200 participants in analyses, irrespective of the following rules, because skewed data pose less of a problem in large studies. </p> </section> <section id="CD012236-sec-0077"> <p><b>Change data</b></p> <p>We also entered change data as when continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not. We presented and entered change data into statistical analyses where possible. </p> </section> <section id="CD012236-sec-0078"> <p><b>Endpoint data (fewer than 200 participants)</b></p> <p>a) when a scale starts from the finite number zero, we subtracted the lowest possible value from the mean, and divided this by the standard deviation. If this value was lower than 1, it strongly suggests a skew and we excluded these data. If this ratio was higher than 1 but below 2, there is suggestion of skew. We entered these data and tested whether their inclusion or exclusion would change the results substantially. Finally, if the ratio was larger than 2 we included such data because skew is less likely (<a href="./references#CD012236-bbs2-0079" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313(7066):1200. ">Altman 1996</a>; <a href="./references#CD012236-bbs2-0110" title="DeeksJJ , HigginsJP , Altman DG(editors) , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). </p> <p>b) if a scale starts from a positive value (such as the Positive and Negative Syndrome Scale (PANSS, <a href="https://archie.cochrane.org/sections/documents/view?version=z1605101530218030650632632125744%26format=REVMAN#REF-Kay-1986" target="_blank">Kay 1986</a>), which can have values from 30 to 210), we modified the calculation described to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S − S min), where S is the mean score and 'S min' is the minimum score. </p> </section> </section> <section id="CD012236-sec-0079"> <h6 class="title">2.5 Common measure</h6> <p>To facilitate comparison between studies, we converted variables that could be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD012236-sec-0080"> <h6 class="title">2.6 Conversion of continuous to binary</h6> <p>Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS, <a href="./references#CD012236-bbs2-0165" title="OverallJE , GorhamDR . The Brief Psychiatric Rating Scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>), or the PANSS (<a href="./references#CD012236-bbs2-0149" title="KaySR , OplerLA . The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin1987;13(2):261‐76. [PUBMED: 3616518] ">Kay 1987</a>), this could be considered as a clinically significant response (<a href="./references#CD012236-bbs2-0152" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of Brief Psychiatric Rating Scale scores. British Journal of Psychiatry2005;187:366‐71. [PUBMED: 16199797] ">Leucht 2005a</a>; <a href="./references#CD012236-bbs2-0153" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelRR . What does the PANSS mean?. Schizophrenia Research2005;79(2‐3):231‐8. [PUBMED: 15982856] ">Leucht 2005b</a>). If data based on these thresholds were not available, we used the primary cut‐off presented by the original study authors. </p> </section> <section id="CD012236-sec-0081"> <h6 class="title">2.7 Direction of graphs</h6> <p>Where possible, we entered data in such a way that the area to the left of the line of no effect indicates a favourable outcome for early intervention. Where keeping to this made it impossible to avoid outcome titles with clumsy double‐negatives (e.g. 'Not un‐improved') we reported data where the left of the line indicated an unfavourable outcome and made a note in the relevant graphs. </p> </section> </section> </section> <section id="CD012236-sec-0082"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Review authors DB and LP worked independently to assess risk of bias by using criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012236-bbs2-0141" title="HigginsJP , AltmanDG , Sterne JA(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. </p> <p>For attrition bias, we used the following assessment criteria: we judged as low risk of bias studies where attrition was under 30%, unclear risk of bias if attrition was between 30% and 50%, and high risk of bias if total attrition rate, or attrition in any of the groups, was higher than 50%. If attrition was under 30%, but reasons for attrition were unclear, we judged the study as unclear risk of attrition bias. </p> <p>If the raters disagreed, we made the final rating by consensus. Where inadequate details of randomisation and other characteristics of studies were provided, we contacted authors of the studies in order to obtain further information. We have noted the level of risk of bias in both the text of the review and in <a href="#CD012236-fig-0001">Figure 1</a>; <a href="#CD012236-fig-0002">Figure 2</a> </p> <div class="figure" id="CD012236-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies" data-id="CD012236-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD012236-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD012236-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> </div> </section> <section id="CD012236-sec-0083"> <h4 class="title">Measures of treatment effect</h4> <section id="CD012236-sec-0084"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive than odds ratios (<a href="./references#CD012236-bbs2-0098" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie1999;54(4):405‐11. [PUBMED: 10667106] ">Boissel 1999</a>); and that odds ratios tend to be interpreted as RR by clinicians (<a href="./references#CD012236-bbs2-0109" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000. ">Deeks 2000</a>). </p> </section> <section id="CD012236-sec-0085"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes we aimed to estimate mean difference (MD) between groups. We preferred not to calculate effect size measures (standardised mean difference (SMD)). However, if scales of very considerable similarity were used, we presumed there was a small difference in measurement, and calculated effect size and transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD012236-sec-0086"> <h4 class="title">Unit of analysis issues</h4> <section id="CD012236-sec-0087"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra‐class correlation in clustered trials, leading to a 'unit of analysis' error whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated (<a href="./references#CD012236-bbs2-0115" title="DivineGW , BrownJT , FrazierLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7(6):623‐9. ">Divine 1992</a>). This causes type I errors (<a href="./references#CD012236-bbs2-0097" title="BlandJM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600. ">Bland 1997</a>; <a href="./references#CD012236-bbs2-0131" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149(9):876‐3. ">Gulliford 1999</a>). </p> <p>Where clustering is not accounted for in primary studies, we presented data in a table, with a (*) symbol to indicate the presence of a probable unit‐of‐analysis error. We aimed to contact first authors of studies to obtain intra‐class correlation coefficients for their clustered data and to adjust for this by using accepted methods (<a href="./references#CD012236-bbs2-0131" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149(9):876‐3. ">Gulliford 1999</a>). Where primary studies incorporated clustering into their analysis, we presented these data as if from a non‐cluster randomised trial, but adjusted for the clustering effect. </p> <p>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intra‐class correlation coefficient (ICC): [Design effect = 1 + (m − 1) * ICC] (<a href="./references#CD012236-bbs2-0117" title="DonnerA , KlarN . Issues in the meta‐analysis of cluster randomised trials. Statistics in Medicine2002;21(19):2971‐80. ">Donner 2002</a>). If the ICC was not reported we assumed it was 0.1 (<a href="./references#CD012236-bbs2-0183" title="UkoumunneOC , GullifordMC , ChinnS , SterneJA , BurneyPG . Methods for evaluating area‐wide and organisation‐based intervention in health and health care: a systematic review. Health Technology Assessment1999;3(5):iii‐92. ">Ukoumunne 1999</a>). </p> <p>If cluster trials have been appropriately analysed taking into account intra‐class correlation coefficients and relevant data documented in the report, synthesis with other studies is possible using the generic inverse variance technique. </p> </section> <section id="CD012236-sec-0088"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase the participants can differ systematically from their initial state despite a wash‐out phase. For the same reason cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD012236-bbs2-0120" title="ElbourneDR , AltmanDG , HigginsJP , CurtinaF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). As both effects are very likely in severe mental illness, we only used data of the first phase of cross‐over trials. </p> </section> <section id="CD012236-sec-0089"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>Where a study involved more than two treatment arms we, if relevant, presented the additional treatment arms in comparisons. If data were binary we simply added these and combined within the two‐by‐two table. If data were continuous we combined data following the formula in section 7.7.3.8  (Combining groups) of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012236-bbs2-0139" title="HigginsJP , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). Where the additional treatment arms were not relevant, we did not reproduce these data. </p> </section> </section> <section id="CD012236-sec-0090"> <h4 class="title">Dealing with missing data</h4> <section id="CD012236-sec-0091"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD012236-bbs2-0193" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). We chose that, for any particular outcome, when more than 50% of data was unaccounted for, we did not reproduce these data or used them within analyses. If, however, more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we addressed this within the 'Summary of findings' tables by downgrading quality. Finally, we also downgraded quality within the 'Summary of findings' tables when loss was 25% to 50% in total. </p> </section> <section id="CD012236-sec-0092"> <h5 class="title">2. Binary</h5> <p>In the case where attrition for a binary outcome was between 0% and 50% and where these data were not clearly described, we presented data on a 'once‐randomised‐always‐analyse' basis (an intention‐to‐treat analysis). Those leaving the study early were all assumed to have the same rates of negative outcome as those who completed, with the exception of the outcome of death and adverse effects. For these outcomes we used the rate of those who stayed in the study ‐ in that particular arm of the study ‐ for those who did not. We undertook a sensitivity analysis testing how prone the primary outcomes were to change when data only from people who completed the study to that point were compared to the intention‐to‐treat analysis using the above assumptions. </p> </section> <section id="CD012236-sec-0093"> <h5 class="title">3. Continuous</h5> <section id="CD012236-sec-0094"> <h6 class="title">3.1 Attrition</h6> <p>In the case where attrition for a continuous outcome was between 0% and 50%, and data only from people who completed the study to that point were reported, we reproduced these. </p> </section> <section id="CD012236-sec-0095"> <h6 class="title">3.2 Standard deviations</h6> <p>If standard deviations (SDs) were not reported, we first tried to obtain the missing values from the study authors. If not available, where there were missing measures of variance for continuous data, but an exact standard error and confidence intervals available for group means, and either P value or T value available for differences in mean, we calculated them according to the rules described in the <i>Cochrane Handbook for Systemic Reviews of Interventions</i>. When studies only reported the standard error (SE), we calculated SDs by the formula SD = SE * √(n). Chapters 7.7.3 (<a href="./references#CD012236-bbs2-0139" title="HigginsJP , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>), and 16.1.3 (<a href="./references#CD012236-bbs2-0140" title="HigginsJP , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>), of the <i>Cochrane Handbook for Systemic Reviews of Interventions</i> present detailed formulae for estimating SDs from P values, T or F values, confidence intervals, ranges or other statistics. If these formulae did not apply, we calculated the SDs according to a validated imputation method that is based on the SDs of the other included studies (<a href="./references#CD012236-bbs2-0123" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(7):7‐10. ">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study’s outcome and thus to lose information. We nevertheless examined the validity of the imputations in a sensitivity analysis excluding imputed values. </p> </section> <section id="CD012236-sec-0096"> <h6 class="title">3.3 Assumptions about participants who left the studies early or were lost to follow‐up</h6> <p>Various methods were available to account for participants who left the studies early or were lost to follow‐up. Some studies just presented the results of study completers, others used the method of last observation carried forward (LOCF), while more recently, methods such as multiple imputation or mixed‐effects models for repeated measurements (MMRM) have become more of a standard. While the latter methods seem somewhat better than LOCF (<a href="./references#CD012236-bbs2-0151" title="LeonAC , MallinckrodtCH , Chuang‐SteinC , ArchibaldDG , ArcherGE , ChartierK . Attrition in randomised controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry2006;59(11):1001‐5. [PUBMED: 16905632] ">Leon 2006</a>), we feel that the high percentage of participants leaving the studies early and differences in the reasons for leaving the studies early between groups is often the core problem in randomised schizophrenia studies. We therefore did not exclude studies based on the statistical approach used. However, we preferably used the more sophisticated approaches. For example, we preferred to use MMRM or multiple‐imputation to LOCF and completer analyses only if some kind of ITT data were not available at all. Moreover, we addressed this issue in the item 'incomplete outcome data' of the 'Risk of bias' tool. </p> </section> </section> </section> <section id="CD012236-sec-0097"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD012236-sec-0098"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations that we had not predicted would arise and if such situations or participant groups arose, we fully discussed them. </p> </section> <section id="CD012236-sec-0099"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods that we had not predicted would arise and if such situations or participant groups arose, we fully discussed them. </p> </section> <section id="CD012236-sec-0100"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD012236-sec-0101"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD012236-sec-0102"> <h6 class="title">3.2 Employing the I² statistic</h6> <p>We investigated heterogeneity between studies by considering the I² method alongside the Chi² P value. The I² statistic provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD012236-bbs2-0138" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). The importance of the observed value of the I² statistic depends on i) the magnitude and direction of effects and ii) strength of evidence for heterogeneity (e.g. P value from Chi²  test, or a confidence interval for I² statistic). We interpreted an I² statistic estimate greater than 50% accompanied by a statistically significant Chi² statistic as evidence of substantial levels of heterogeneity (<a href="./references#CD012236-bbs2-0110" title="DeeksJJ , HigginsJP , Altman DG(editors) , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). When we found substantial levels of heterogeneity in the primary outcome, we explored reasons for heterogeneity (<a href="#CD012236-sec-0105">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD012236-sec-0103"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD012236-bbs2-0119" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315:629‐34. ">Egger 1997</a>). These are described in Section 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012236-bbs2-0180" title="SterneJA , EggerM , MoherD , BoutronI (editors) . Chapter 10: Addressing reporting biases. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Sterne 2017</a>). We were aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We did not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar size. In cases where funnel plots were possible, we looked for statistical advice in their interpretation. </p> </section> <section id="CD012236-sec-0104"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random‐effects model: it puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect these studies can either inflate or deflate the effect size. We chose to use random‐effects or fixed‐effect models for all analyses after the selection of studies. </p> </section> <section id="CD012236-sec-0105"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD012236-sec-0106"> <h5 class="title">1. Subgroup analyses</h5> <section id="CD012236-sec-0107"> <h6 class="title">1.1 Primary outcomes</h6> <p>If data were available, then for primary outcomes we investigated whether continuous treatment over a longer period (&gt; 6 months) was more effective than structured short‐duration treatments of any kind. </p> </section> <section id="CD012236-sec-0108"> <h6 class="title">1.2 Clinical state, stage or problem</h6> <p>We proposed to undertake this review and provide an overview of the various interventions available for people in the prodromal stage of psychosis. In addition, however, we reported any available data on subgroups of people in the same clinical state, stage and with similar problems. </p> </section> </section> <section id="CD012236-sec-0109"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>We reported if inconsistency was high. First we investigated whether data had been entered correctly. Second, if data were correct, we visually inspected the graph and successively removed studies from the analysis to see if homogeneity was restored. For this review we decided that when this occurred with data contributing to the summary finding of no more than 10% of the total weighting, we would present the data. If not, we did not pool data, but discussed these issues. We know of no supporting research for this 10% cut‐off but are investigating use of prediction intervals as an alternative to this unsatisfactory state. </p> <p>When unanticipated clinical or methodological heterogeneity were obvious we simply stated hypotheses regarding these for future reviews or versions of this review. We did not undertake analyses relating to these. </p> </section> </section> <section id="CD012236-sec-0110"> <h4 class="title">Sensitivity analysis</h4> <section id="CD012236-sec-0111"> <h5 class="title">1. Implication of randomisation</h5> <p>We aimed to include studies in a sensitivity analysis if they were described in some way as to imply randomisation. We included these studies for the primary outcomes, and if their inclusion did not result in a substantive difference, they remained in the analyses. If their inclusion did result in significant differences, we did not add the data from these lower‐quality studies to the results of the better studies, but presented such data within a subcategory. </p> </section> <section id="CD012236-sec-0112"> <h5 class="title">2. Assumptions for lost binary data</h5> <p>Where assumptions had to be made regarding people lost to follow‐up (see <a href="#CD012236-sec-0090">Dealing with missing data</a>), we compared the findings of the primary outcomes when we used our assumption compared with completer data only. If there was a substantial difference, we reported results and discussed them but continued to employ our assumption. </p> <p>Where assumptions had to be made regarding missing SD data (see <a href="#CD012236-sec-0090">Dealing with missing data</a>), we compared the findings on primary outcomes when we used our assumption compared with completer data only. We undertook a sensitivity analysis testing how prone results were to change when 'completer' data only were compared to the imputed data using the above assumption. If there was a substantial difference, we reported results and discussed them but continued to employ our assumption. </p> </section> <section id="CD012236-sec-0113"> <h5 class="title">3. Risk of bias</h5> <p>For primary outcomes, we analysed the effects of excluding studies that we judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available, allocation concealment, blinding and outcome reporting). If the exclusion of studies at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, then we included relevant data from these studies in the analysis. </p> </section> <section id="CD012236-sec-0114"> <h5 class="title">4. Imputed values</h5> <p>We also undertook a sensitivity analysis to assess the effects of including data from studies where we used imputed values for ICC in calculating the design effect in cluster‐randomised studies. </p> <p>If we noted substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we did not pool data from the excluded studies with the other studies contributing to the outcome, but presented them separately. </p> </section> <section id="CD012236-sec-0115"> <h5 class="title">5. Fixed and random effects</h5> <p>If we synthesised data using a fixed‐effect model, we also synthesised data for the primary outcome using a random‐effects model to evaluate whether this alters the significance of the results. If we synthesised data using a random‐effects model we also synthesised data for the primary outcome using a fixed‐effect model to evaluate whether this alters the significance of the results. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012236-sec-0116" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012236-sec-0116"></div> <section id="CD012236-sec-0117"> <h3 class="title">Description of studies</h3> <p>For substantive descriptions of studies, please see <a href="./references#CD012236-sec-0539" title="">Characteristics of included studies</a>; <a href="./references#CD012236-sec-0540" title="">Characteristics of excluded studies</a>; <a href="./references#CD012236-sec-0542" title="">Characteristics of ongoing studies</a>. </p> <section id="CD012236-sec-0118"> <h4 class="title">Results of the search</h4> <p>The original search (8 June 2016) identified 4852 abstracts to be screened. In addition, after screening the references of the studies, we identified three additional potentially eligible studies. After screening, we identified 70 potentially eligible unique studies, which were reported in 337 manuscripts (<a href="#CD012236-fig-0003">Figure 3</a>). Out of these 70, 19 were finished studies that met our inclusion criteria. <a href="./references#CD012236-bbs2-0045" title="CornblattB . Risperidone vs sertraline for prodromal schizophrenia. Stanley Foundation Research Programs2009. NCT00169988 . Sertraline alone vs in combination with risperidone in the treatment of attenuated positive and negative symptoms. www.ClinicalTrials.gov/ct/show/2005. ">RAP‐USA</a> and <a href="./references#CD012236-bbs2-0039" title="McGorryP , AmmingerP . A comparison study of quetiapine medication and psychological therapy versus placebo tablets and psychological therapy in patients who are deemed at risk of developing a psychotic disorder. Australian New Zealand Clinical Trials Registry2010. ">NEURAPRO‐Q‐Australia</a> also met the inclusion criteria, but these studies terminated early in the recruitment phase so we excluded them from the analysis. Overall, we excluded 51 studies from the analysis (25 that did not meet the inclusion criteria, two that met the inclusion criteria but were terminated early, 16 that we classified as ongoing studies and eight that we classified as awaiting assessment due to insufficient data). </p> <div class="figure" id="CD012236-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD012236-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> <p>The update search (4 August 2017), found a further 84 new references. Among them, there were 37 potentially eligible manuscripts; some of which described studies that we had already found in the initial search. Out of these, we identified three potentially eligible unique studies; of those three studies, we were able to include one additional study (<a href="./references#CD012236-bbs2-0016" title="NCT01619319 . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. ClinicalTrials.gov/show/NCT016193192012. [CSzG: 24387] PiskulicD , BarbatoM , AddingtonJ . Cognitive remediation in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:89. [CSzG: 24973] PiskulicD , BarbatoM , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2012;136:S245‐6. [CSzG: 29632] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2014;153(Suppl. 1):S218. [CSzG: 28827] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation therapy on cognition in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2014;8:86. [CSzG: 29633] ">Piskulic‐Canada</a>). Two other studies met the inclusion criteria but we did not include them as one was terminated (<a href="./references#CD012236-bbs2-0030" title="NCT00276263 . Sarcosine (n‐methylglycine) trial for individuals at risk for developing schizophrenia and related disorders. www.ClinicalTrials.gov/ct/show/2006. ">Heresco‐Levy‐Israel</a>), and one was ongoing (<a href="./references#CD012236-bbs2-0062" title="NCT02047539 . Randomised controlled trial of aspirin vs placebo in the treatment of pre‐psychosis [Randomised controlled trial of aspirin vs placebo in the treatment of patients with the clinical risk syndrome for psychosis]. Clinicaltrials.gov/show/NCT02047539. USA, 2014. ">NCT02047539</a>). One study, that we had previously categorised as awaiting assessment, we excluded after publication of the results. </p> <p>Therefore, in total, we analysed 73 unique studies (reported in 374 manuscripts), of which we included 20 studies; we excluded 29 studies because they did not meet the inclusion criteria or were terminated early, 17 were still ongoing and seven are currently awaiting classification (three of which published data that are not usable for analysis and four of which require further clarification). </p> <p>For substantive descriptions of studies, please see the <a href="./references#CD012236-sec-0539" title="">Characteristics of included studies</a>, <a href="./references#CD012236-sec-0542" title="">Characteristics of ongoing studies</a>, <a href="./references#CD012236-sec-0541" title="">Characteristics of studies awaiting classification</a> and <a href="./references#CD012236-sec-0540" title="">Characteristics of excluded studies</a>. </p> </section> <section id="CD012236-sec-0119"> <h4 class="title">Included studies</h4> <p>We included 20 studies with 2016 participants (<a href="./references#CD012236-bbs2-0001" title="AddingtonJ , EpsteinI , LiuL , FrenchP , BoydellKM , ZipurskyRB . A randomised controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research2011;125(1):54‐61. [CSzG: Ref21945] AddingtonJ , ZipurskyR , EpsteinI . ADAPT (Access, Detection and Psychological Treatments). Schizophrenia Research2006;86(Suppl 1):S6. [CSzG: Ref13364] NCT00260273 . Access, detection and psychological treatments. www.ClinicalTrials.gov/ct/show/2005. [CSzG: Ref14638] ">ADAPT‐Canada</a>; <a href="./references#CD012236-bbs2-0002" title="AmmingerG . Ethyl eicosapentanoic acid for prodromal psychosis. Stanley Foundation Research Programs2009. [CSzG: Ref17423] AmmingerG , SchaferM , PapageorgiouK , CottonS , HarriganS , MackinnonA , et al. Indicated prevention with long‐chain omega‐3 fatty acids in adolescents at ultra‐high‐risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2008;2(Suppl 1):A29. [CSzG: Ref19107] AmmingerGP , ChanenAM , OhmannS , KlierCM , MossahebN , BechdolfA , et al. Omega‐3 fatty acid supplementation in adolescents with borderline personality disorder and ultra‐high risk criteria for psychosis: a post hoc subgroup analysis of a double‐blind, randomised controlled trial. Canadian Journal of Psychiatry2013;58(7):402‐8. [CSzG: Ref28534] AmmingerGP , HarrisMS , McGorryPD , HenryLP . Omega‐3 fatty acids for indicated prevention: treatment results and pathomechanisms. European Archives of Psychiatry and Clinical Neuroscience2013;263(Suppl. 1):S44‐5. [CSzG: Ref28434] AmmingerGP , LeicesterS , YungAR , YuenHP , McGorryPD . Age predicts transition to psychosis in an ultra‐high risk sample. Proceedings of the 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:61. AmmingerGP , McGorryPD . Update on omega‐3 polyunsaturated fatty acids in early ‐stage psychotic disorders. Neuropsychopharmacology2012;37(1):309‐10. [CSzG: Ref23726] AmmingerGP , MechelliA , RiceS , KimSW , KlierCM , McNamaraRK , et al. Predictors of treatment response in young people at ultra‐high risk for psychosis who received long‐chain omega‐3 fatty acids. Translational Psychiatry2015;5:e495. [CSzG: Ref29299] AmmingerGP , SchaferMR . Indicated prevention with omega‐3 fatty acids in adolescents at ultra‐high risk for psychosis ‐ rationale, methods, and 3‐months outcome. Schizophrenia Research2006;86(Suppl 1):S97‐8. [CSzG: Ref13367] AmmingerGP , SchaferMR . Is it feasible to conduct a RCT in ultra‐high risk individuals at a child and adolescent psychiatric service?. Schizophrenia Research2006;86(Suppl 1):S98. [CSzG: Ref13368] AmmingerGP , SchaferMR , KlierCM , PapageorgiouK , SlavikJ , HolzerI , et al. Indicated prevention with long‐chain omega‐3 fatty acids in young people at ultra‐high risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2010;4(Suppl 1):7. [CSzG: Ref23467] AmmingerGP , SchaferMR , SchlogelhoferM , KlierCM , McGorryPD . Longer‐term outcome in the prevention of psychotic disorders by the Vienna omega‐3 study. Nature Communications2015;6:7934. [CSzG: Ref33023] AmmingerGP , SchlogelhoferM , KlierC , McGorryP , SchaferM . Longer‐term follow‐up in the Vienna omega‐3 psychosis prevention trial. Early Intervention in Psychiatry2014;8:41. [CSzG: Ref29378] AmmingerGP , SchäferMR , PapageorgiouK , KlierCM , CottonSM , HarriganSM , et al. Long‐chain omega‐3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo‐controlled trial. Archives of General Psychiatry2010;67(2):146‐54. [CSzG: Ref20680; DOI: 10.1001/archgenpsychiatry.2009.192.] AmmingerP , MossahebN , SchlgelhoferM , SchaferM . Fatty acid metabolism and the onset of psychotic disorder. European Psychiatry2011;26(Suppl 1):2089. [CSzG: Ref22967] Anonymous . Fish oil may help ward off psychosis. Journal of Psychosocial Nursing and Mental Health Services2010;48(5):55. [CSzG: Ref20739] BergerG , AmmingerP , McGorryP . Stage dependant effect of omega‐3 fatty acids in emerging psychosis. European Psychiatry2011;26(Suppl 1):1347. [CSzG: Ref22966] BergerGE , ProffittTM , McConchieM , YuenH , WoodSJ , AmmingerGP , et al. Ethyl‐eicosapentaenoic acid in first‐episode psychosis: a randomised, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(12):1867‐75. [CSzG: Ref15561; ISSN: 1555‐2101] EhrlichA . Evidence‐based medicine. Omega‐3 supplementation delays transition to psychotic disorder in ultra‐high‐risk adolescents and young adults. Clinical Advisor for Nurse Practitioners2010;13(5):79‐80. [CSzG: Ref21562] FöckingM , DickerP , LopezLM , CannonM , SchäferMR , McGorryPD , et al. Differential expression of the inflammation marker IL12p40 in the at‐risk mental state for psychosis: a predictor of transition to psychotic disorder?. BMC Psychiatry2016;16(1):326. [DOI: 10.1186/s12888‐016‐1039‐7] KlierC , HollmannM , SchlögelhoferM , MossahebN , FriedrichM , AmmingerPG . Indicated prevention with omega‐3 fatty acids (EPA/DHA) in adolescents with &quot;at‐risk‐mental‐state“ for psychosis. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. [CSzG: Ref12438] LavoieS , BenningerF , FeuchtM , KlierCM , SchaeferMR , AmmingerGP . Correlates of EEG resting states with erythrocyte membrane omega‐3 fatty acid levels and psychopathological symptoms in individuals at ultra‐high risk for psychosis. Early Intervention in Psychiatry2014;8:137. [CSzG: Ref29516] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultra‐high risk individuals who transitioned to psychosis. Schizophrenia Research2012;138(2‐3):206‐11. [CSzG: Ref24256] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultrahigh risk individuals who transitioned to psychosis. Early Intervention in Psychiatry2012;6:38. [CSzG: Ref24960] MossahebN , PapageorgiouK , SchaferMR , BeckerJ , SchloegelhoferM , AmmingerGP . Changes in triglyceride levels in ultra‐high risk for psychosis individuals treated with omega‐3 fatty acids. Early Intervention in Psychiatry2018; Vol. 12, issue 1:30‐36. [DOI: 10.1111/eip.12275] MossahebN , SchaferMR , SchlogelhoferM , KlierCM , CottonSM , McGorryPD , et al. Effect of omega‐3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?. Schizophrenia Research2013;148(1‐3):163‐7. [CSzG: Ref28649] NCT00396643 . Indicated prevention with omega‐3 fatty acids in adolescents with ‘at‐risk‐mental‐state’ for psychosis: a randomised, double blind, placebo‐controlled treatment trial. www.ClinicalTrials.gov/ct/show/2006. [CSzG: Ref14873] PapageorgiouK , SchaferMR , SchlogelhoferM , MossahebN , AmmingerGP . Indicated prevention with omega‐3 fatty acids in young people with 'at‐risk‐mental‐state' for psychosis: design of a 5‐year follow‐up. European Archives of Psychiatry and Clinical Neuroscience2011;261:S55. [CSzG: Ref23749] SchaferMR , KlierCM , PapageorgiouK , FriedrichMH , AmmingerGP . Early detection of psychotic disorders. Neuropsychiatrie2007;21(1):37‐44. [CSzG: Ref15290] SmesnyS , MilleitB , HiplerUC , MilleitC , SchaferMR , KlierCM , et al. Omega‐3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra‐high risk for psychosis. Molecular Psychiatry2013;19(3):317‐24. [CSzG: Ref28243] SmesnyS , MilleitB , SchaeferMR , HesseJ , SchlögelhoferM , LangbeinK , et al. Effects of omega‐3 PUFA on immune markers in adolescent individuals at ultra‐high risk for psychosis ‐ results of the randomised controlled Vienna omega‐3 study. Schizophrenia Research2017;S0920‐9964(17):30039‐7. [DOI: 10.1016/j.schres.2017.01.026] ">Amminger‐Austria</a>; <a href="./references#CD012236-bbs2-0003" title="ChoiJ , CorcoranC , DixonL , FiszdonJ , JavittD . Processing speed training and social functioning in young adults at clinical high risk for psychosis: a pilot study. Early Intervention in Psychiatry2014;8:109. [CSzG: Ref29417] ChoiJ , CorcoranC , DixonL , JavittDC . Processing speed training and social functioning in teenagers and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2015;41:S41. [CSzG: Ref29418] ChoiJ , CorcoranCM , FiszdonJM , StevensM , JavittDC , DeasyM , et al. Pupillometer‐based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis. Psychiatric Rehabilitation Journal2017;40(1):33‐42. [CSzG: Ref35317] ">Choi‐USA</a>; <a href="./references#CD012236-bbs2-0004" title="CrittendenK , FlemingJ , StartupM , CarrV , BakerA , SchallU , et al. Recruitment and engagement of youth in an ultra high risk treatment study. Early Intervention in Psychiatry2008;2(Suppl 1):A127. [CSzG: Ref19115] StainH , BucciS , HalperinS , EmsleyR , ShallU , LewinT , et al. DEPTh: randomised controlled trial of cognitive behavioral therapy for young people at ultra high risk for psychosis. Early Intervention in Psychiatry2014;8:15. [CSzG: Ref29673] StainHJ , BucciS , BakerA , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of CBT for young people at risk for psychosis: the Detection and Evaluation of Psychological Therapy (DEPTh) trial. European Archives of Psychiatry and Clinical Neuroscience2015;1:S8‐9. [CSzG: Ref33810] StainHJ , BucciS , BakerAL , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of cognitive behaviour therapy versus non‐directive reflective listening for young people at ultra high risk of developing psychosis: the detection and evaluation of psychological therapy (DEPTh) trial. Schizophrenia Research2016;176(2‐3):212‐9. [CSzG: Ref35298] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. Rural and urban youth at ultra high risk for psychosis: baseline characteristics from the DEPTh randomised controlled trial of cognitive behavior therapy. Schizophrenia Bulletin2011;37:322. [CSzG: Ref22815] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy for youth at ultra high risk for psychosis: baseline characteristics for rural and urban youth. Australian and New Zealand Journal of Psychiatry2010:25‐6. [CSzG: Ref21845] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy targeting ultra high risk for psychosis: baseline comparisons for rural and urban youth. Early Intervention in Psychiatry2010;4(Suppl 1):113. [CSzG: Ref23498] StainHJ , StartupM , CarrV , BakerA , SchallU . The DEPTh project: a multisite RCT for youths at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S51‐2. [CSzG: Ref13401] StartupM . The DEPTh project: detection, evaluation, and psychological therapy for health. Australian New Zealand Clinical Trials Registry2006. [CszG: Ref18442] ">DEPTh‐Australia</a>; <a href="./references#CD012236-bbs2-0005" title="ByrneRE , MorrisonAP . Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. Psychology and Psychotherapy2014;87(3):357‐71. [CSzG: Ref29312] FlachC , FrenchP , DunnG , FowlerD , GumleyAI , BirchwoodM , et al. Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE‐2 trial. British Journal of Psychiatry2015;207(2):123‐9. [CSzG: Ref33109] MorrisonA . Early detection and intervention evaluation for individuals at high risk of psychosis 2. http://www.controlled‐trials.com2008. [CSzG: Ref18285] MorrisonA . Early detection and intervention evaluation for people at risk of psychosis (edie‐2): A multisite randomised controlled trial of cognitive therapy for at‐risk mental states. Early Intervention in Psychiatry2012;6:11. [CSzG: Ref24968] MorrisonA , FrenchP , BentallR , LewisS , BirchwoodM , FowlerD , et al. Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. Early Intervention in Psychiatry2008;2(Suppl 1):A15. [CSzG: Ref19128] MorrisonAP . EDIE‐2: early detection and psychological intervention for individuals at high risk of psychosis (2). www.controlled‐trials.com2007. [CSzG: Ref15381] MorrisonAP , BirchwoodM , PyleM , FlachC , StewartSL , ByrneR , et al. Impact of cognitive therapy on internalised stigma in people with at‐risk mental states. British Journal of Psychiatry2013;203(2):140‐5. [CSzG: Ref28630] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ2012;344(7852):e2233. [CSzG: Ref24208] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at‐risk of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29554] MorrisonAP , PyleM , StewartSL , FrenchP , ByrneR , FlachC , et al. Internalised stigma in young people at high risk of developing psychosis: findings from a cognitive therapy trial. Schizophrenia Research2014;153:S42. [CSzG: Ref29555] MorrisonAP , StewartSL , FrenchP , BentallRP , BirchwoodM , ByrneR , et al. Early detection and intervention evaluation for people at high‐risk of psychosis‐2 (EDIE‐2): trial rationale, design and baseline characteristics. Early Intervention in Psychiatry2011;5(1):24‐32. [CSzG: Ref22695] MorrisonT . Early detection and psychological intervention for individuals at high risk of psychosis. EDIE‐2. Data on File2006. [CSzG: Ref13874] PelosiAJ . Rational policy making for early psychosis might yet become possible. BMJ2012;344(7856):e3137. [CSzG: Ref24326] PyleM , StewartSL , FrenchP , ByrneR , PattersonP , GumleyA , et al. Internalised stigma, emotional dysfunction and unusual experiences in young people at risk of psychosis. Early Intervention in Psychiatry2015;9(2):133‐40. [CSzG: Ref29813] ">EDIE‐2‐UK</a>; <a href="./references#CD012236-bbs2-0006" title="DragtS , Van derGaagM . Prevention of psychosis with a cognitive behavioural intervention in help‐seeking young people with an at risk mental state for developing psychosis. www.trialregister.nl/trialreg/index.asp2007. [CSzG: Ref19655] IsingHK , KraanTC , RietdijkJ , DragtS , KlaassenRM , BoonstraN , et al. Four‐year follow‐up of cognitive behavioral therapy in persons at ultra‐high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2016;42(5):1243‐52. [CSzG: Ref35214] IsingHK , LokkerbolJ , RietdijkJ , DragtS , KlaassenRM , KraanT , et al. Four‐year cost‐effectiveness of cognitive behavior therapy for preventing first‐episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2017;43(2):365‐74. [CSzG: Ref35824] IsingHK , SmitF , VelingW , RietdijkJ , DragtS , KlaassenRM , et al. Cost‐effectiveness of preventing first‐episode psychosis in ultra‐high‐risk subjects: multi‐centre randomised controlled trial. Psychological Medicine2015;45(7):1435‐46. [CSzG: Ref27798] KraanTC , IsingHK , FokkemaM , VelthorstE , Van denBergDP , KerkhovenM , et al. The effect of childhood adversity on 4‐year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE‐NL) Trial. Psychiatry Research2017;247:55‐62. [CSzG: Ref35559] NiemanDH , RuhrmannS , RietdijkJ , DragtS , IsingH , KlaassenR , et al. Preventive psychotherapy. Schizophrenia Research2014;153:S42‐3. [CSzG: Ref29601] RietdijkJ , DragtS , KlaassenR , IsingH , NiemanD , WunderinkL , et al. A single blind randomised controlled trial of cognitive behavioural therapy in a help‐seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE‐NL) trial. Trials2010;11:30. [CSzG: Ref20654] Van DerGaagM . The effects of CBT in personswith ultra high risk: the Dutch EDIE trial. European Archives of Psychiatry and Clinical Neuroscience2011;261:S18. [CSzG: Ref23756] Van DerGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first‐episode of psychosis. Early Intervention in Psychiatry2012;6:12. [CSzG: Ref24985] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomised controlled clinical trial. Schizophrenia Bulletin2012;38(6):1180‐8. [CSzG: Ref24935] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. The effects of cognitive behavioural therapy for subjects at ultra‐high risk for developing psychosis. Schizophrenia Bulletin2013;39:S356. [CSzG: Ref28121] Van derGaagM . The prevention of psychosis in at risk mental state. www.controlled‐trials.com2008. [CSzG: Ref17488] Van derGaagM , NiemanD , Van denBergD . CBT for those at risk of a first episode psychosis: Evidence‐based psychotherapy for people with an 'at risk mental state'. 1st Edition. Hove, UK: Routledge, 2013. Van derGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first episode of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29692] ">EDIE‐NL</a>; <a href="./references#CD012236-bbs2-0007" title="FrenchP , ShryaneN , BentallRP , LewisSW , MorrisonAP . Effects of cognitive therapy on the longitudinal development of psychotic experiences in people at high risk of developing psychosis. British Journal of Psychiatry. Supplements2007;191(Suppl 51):s82‐7. [CSzG: Ref16121] LewisS . EDIE ‐ Early detection and intervention for psychosis. National Research Register2001; Vol. 3. [CSzG: Ref13023] LewisS . EDIE ‐ early detection and intervention for psychosis (in primary care). National Research Register2002; Vol. 1. [CszG: Ref9342] MorrisonA . Early detection and intervention for psychosis in primary care. National Research Register2003. [CSzG: Ref15485] MorrisonA . Findings from a randomised controlled trial and clinical service delivering cognitive therapy to people at ultra‐high risk of developing psychosis. Schizophrenia Research2004;70(1):43‐4. [CSzG: Ref11526] MorrisonA . Follow‐up of prodromal symptoms. National Research Register2004; Vol. 3. [CSzG: Ref13036] MorrisonA , BentallR , FrenchP , Kilcommons A, LewisSW . Very early intervention in prodromal psychosis: a randomised trial. Schizophrenia Research2002;53(3 Suppl 1):42. [CSzG: Ref8096] MorrisonA , FrenchP , WalfordL , LewisS , Kilcommons A, GreenJ , et al. A randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;67(1):7. [CSzG: Ref11324] MorrisonA , FrenchP , WatfordL , LewisS , Kilcommons A, GreenJ , et al. Randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;70(1):63. [CSzG: Ref11527] MorrisonAP . Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: results of a randomised controlled trial. Schizophrenia Research2006;86(Suppl 1):S59. [CSzG: Ref13388] MorrisonAP , BentallRP , FrenchP , Kilcommons A, GreenJ , WalfordL , et al. Cognitive therapy in ultra high risk individuals for psychosis: randomised controlled trial. Schizophrenia Research2003;60:326. [CSzG: Ref9726] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, KnightA , et al. Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high‐risk individuals. Study design and interim analysis of transition rate and psychological risk factors. British Journal of Psychiatry. Supplements2002;181(43):s78‐84. [CSzG: Ref8737] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, LewisS . Early detection and intervention for psychosis in primary care. 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002. [CSzG: Ref8932] MorrisonAP , FrenchP , ParkerS , RobertsM , StevensH , BentallRP , et al. Three‐year follow‐up of a randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophrenia Bulletin2007;33(3):682‐7. [CSzG: Ref15288] MorrisonAP , FrenchP , WalfordL , LewisSW , Kilcommons A, GreenJ , et al. Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: randomised controlled trial. British Journal of Psychiatry2004;185:291‐7. [CSzG: Ref11450] MorrisonT . Early detection and intervention for psychosis in primary care. National Research Register2001; Vol. 1. [CSzG: Ref13037] MorrisonT , BentallR , FrenchP , Kilcommons A, GreenJ , LewisS . Early detection and intervention for psychosis in primary care. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:44. [CSzG: Ref8932] RentonJ , MorrisonA . Effectiveness of cognitive therapy for psychosis and implications for early intervention. Schizophrenia Research2004;70(1):142. [CSzG: Ref11536] ">EDIE‐UK</a>; <a href="./references#CD012236-bbs2-0008" title="McFarlaneWR , CookWL , WoodberryKA . A randomised clinical trial of familyaided assertive community treatment for young persons at high risk for onset of an initial psychosis. Schizophrenia Bulletin2011;37:314. [CSzG: Ref22796] NCT01597141 . Psychosis: early detection, intervention and prevention. ClinicalTrials.gov/show/NCT015971412012. [CSzG: Ref24315] ">EDIP‐USA</a>; <a href="./references#CD012236-bbs2-0009" title="BechdolfA . Preventing progression to first‐episode psychosis in people in the early initial prodromal state. Early Intervention in Psychiatry2012;6:11. [CSzG: 24944] BechdolfA , BuhlerB , BerningJ , WagnerM , StammE , StreitM . Cognitive behavioural therapy in the early initial prodromal state of psychosis: first results. Schizophrenia Research2004;67(1):202. [CSzG: Ref11285] BechdolfA , KlosterkotterJ . Cognitive‐behavioural treatment (CBT) in the early initial prodromal state of psychosis: concept and practical approach. Schizophrenia Research2004;70(1):52. [CSzG: Ref11506] BechdolfA , RuhrmannS , JanssenB , BottlenderR , WagnerM , MaurerK , et al. Early recognition and intervention for people at risk of schizophrenia [Fruherkennung und intervention bei personen mit erhohtem psychoserisiko]. Psychoneuroendocrinology2004;30(11):606‐14. [CSzG: Ref11376] BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: Ref12511] BechdolfA , VeithV , BerningJ , StammE , DeckerP , JanssenB , et al. Cognitive behavioral therapy (CBT) in the early initial prodromal state of psychosis: first results of a randomised trial. Schizophrenia Research2004;70(1):62‐3. [CSzG: Ref11507] BechdolfA , WagnerM , RuhrmannS , HarriganS , PutzfeldV , PukropR , et al. Preventing progression to first‐episode psychosis in early initial prodromal states. British Journal of Psychiatry2012;200(1):22‐9. [CSzG: Ref24206] BechdolfA , WagnerM , RuhrmannS , HarriganS , VeithV , PukropR , et al. CBT for prevention of first episode psychosis in people in an putative early initial prodromal state. Early Intervention in Psychiatry2008;2(Suppl 1):A16. [CSzG: 19109] BechdolfA , WagnerM , VeithV , PukropR , BerningJ , StammE , et al. A randomised controlled trial of cognitive‐behavioral therapy in the early initial prodromal state of psychosis. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:22‐3. [CSzG: 20193] BechdolfA , WagnerM , VeithV , RuhrmannR , JanssenB , BottlenderR , et al. A randomised controlled multicenter trial of cognitive behaviour therapy in the early initial prodromal state of psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13369] BechdolfA , WagnerM , VeithV , RuhrmannS , PukropR , Brockhaus‐DumkeA , et al. Randomised controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Intervention in Psychiatry2007;1(1):71‐8. [CSzG: 16450] BechdolfA , WesselsH , WagnerM , KuhrK , BerningJ , PutzfeldV , et al. Predictors of treatment response to psychosocial interventions in people at risk. European Archives of Psychiatry and Clinical Neuroscience2015;1:S9. [CSzG: 33601] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] KommescherM , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. Early Intervention in Psychiatry2016;10(1):17‐27. [CSzG: 32187] NCT00204087 . Psychological intervention for persons at risk of psychosis in the early initial prodromal state. www.ClinicalTrials.gov/ct/show/2005. [CSzG: 14890] WesselsH , WagnerM , FrommannI , BerningJ , PutzfeldV , JanssenB , et al. Neuropsychological functioning as a predictor of treatment response to psychoeducational, cognitive behavioral therapy in people at clinical high risk of first episode psychosis. Psychiatrische Praxis2015;42(6):313‐9. [CSzG: 33130] ZarafonitisS , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Psychoeducation for persons at risk of psychosis. Psychotherapeut2012;57(4):326‐34. [CSzG: 24807] ">EIPS‐Germany</a>; <a href="./references#CD012236-bbs2-0010" title="KantrowitzJT , WoodsSW , PetkovaE , CornblattB , CorcoranCM , ChenH , et al. D‐serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double‐blind, placebo‐controlled, randomised parallel group mechanistic proof‐of‐concept trial. Lancet Psychiatry2015;2(5):403‐12. [CSzG: 29487] NCT00826202 . D‐serine for the schizophrenia prodrome. www.ClinicalTrials.gov/ct/show/2009. [CSzG: 17391] ">Kantrowitz‐USA</a>; <a href="./references#CD012236-bbs2-0011" title="BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: 12511] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] RuhrmannS , BechdolfA , KuhnKU , WagnerM , Schultze‐LutterF Janssen B , et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry. Supplements2007;51:s88‐95. [CSzG: 16127] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Acute symptomatic treatment effects in persons clinically at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13397] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Intervention in the late initial prodromal state (LIPS) of psychosis. Schizophrenia Research2006;86(Suppl 1):S96. [CSzG: 13398] ">LIPS‐Germany</a>; <a href="./references#CD012236-bbs2-0012" title="MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Family‐focused therapy for individuals at clinical high risk for psychosis: treatment fidelity within a multisite randomised trial. Early Intervention in Psychiatry2016;10(2):137‐43. [CSzG: 29018] MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Treatment fidelity and differentiation in a randomised controlled trial of family‐focused therapy for youth at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:95. [CSzG: 24965] MiklowitzDJ , O'BrienMP , SchlosserDA , AddingtonJ , CandanKA , MarshallC , et al. Family‐focused treatment for adolescents and young adults at high risk for psychosis: results of a randomised trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(8):848‐58. [CSzG: 29019] NCT01907282 . Prevention trial of family focused treatment in youth at risk for psychosis. Clinicaltrials.gov/show/NCT019072822010. [CSzG: 27965] O'BrienMP , MiklowitzDJ , CandanKA , MarshallC , DominguesI , WalshBC , et al. A randomised trial of family focused therapy with populations at clinical high risk for psychosis: effects on interactional behavior. Journal of Consulting and Clinical Psychology2013;82(1):90‐101. [CSzG: 28565] O'BrienMP , MiklowitzDJ , CannonTD . Decreases in perceived maternal criticism predict improvement in subthreshold psychotic symptoms in a randomised trial of family‐focused therapy for individuals at clinical high risk for psychosis. Journal of Family Psychology2015;29(6):945–951.. [CSzG: 32212] SchlosserDA , MiklowitzDJ , O'BrienMP , DeSilvaSD , ZinbergJL , CannonTD . A randomised trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Intervention in Psychiatry2012;6(3):283‐91. [CSzG: 24491] ">Miklowitz‐USA</a>; <a href="./references#CD012236-bbs2-0013" title="ACTRN12608000475347 . A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder. Australian New Zealand Clinical Trials Registry2009. [CSzG: 18420] HKCTR‐1438 . The NEURAPRO‐E (North America, EURope, Australia PROdrome) Study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for symptomatic patients at ultra‐high risk for early progression to schizophrenia and other psychotic disorders. www.hkClinicaltrials.com/trial_details.aspx?trialID=d09bd177‐b9fd‐4162‐b04f‐3ebfed49baa32011. [CSzG: 29270] McGorryP , MarkulevC , NelsonB , YuenHP , SchaeferM , YungAR , et al. The NEURAPRO‐E study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Schizophrenia Bulletin2015;41:S322‐3. [CSzG: 29546] McGorryPD , NelsonB , MarkulevC , YuenHP , SchaferMR , MossahebN , et al. Effect of omega‐3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomised clinical trial. JAMA psychiatry2017;74(1):19‐27. [CSzG: 35590] NelsonB , AmmingerG , MarkulevC , YuenHP , LavoieS , SchaeferM , et al. NEURAPOR: a multi‐center RCT of omega‐3 polyunsaturated fatty acids versus placebo in young people at ultra‐high risk of psychotic disorders: medium‐term outcome. Schizophrenia Bulletin2017;43:S107. [CSzG: 36016] ">NEURAPRO‐AAE</a>; <a href="./references#CD012236-bbs2-0014" title="NordentoftM , JeppesenP , PetersenL , ThorupA , OhlenschlaegerJ , ChristensenT , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. European Psychiatry2007;22:S129‐S. [CSzG: 20471] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the OPUS trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;83(1):29‐40. [CSzG: 13197] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;86(Suppl 1):S44. [CSzG: 13393] ">Nordentoft‐Denmark</a>; <a href="./references#CD012236-bbs2-0015" title="McGorryP . Can the onset of schizophrenia be delayed or prevented?. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S26. [CSzG: 8351] McGorryP , AdlardS , YungA , McDonaldA , PhillipsL , HearnN . Detection and intervention in pre‐psychotic schizophrenia. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4836] McGorryP , YungA , FranceyS , PhillipsL , NelsonB . A blinded, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and befriending in young people at risk of psychotic disorder: baseline characteristics of the sample. Acta Neuropsychiatrica2006;18(6):261. [CSzG: 35157] McGorryPD , HearnN , GermanoD , BravinJ , PhillipsLJ , YungAR , et al. Prepsychotic intervention in schizophrenia: a stitch in time?. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington DC, USA. 1999. [CSzG: 3584] McGorryPD , PhillipsLJ , NelsonB , LeicesterS , BakerK , KrstevH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and befriending in young people with subthreshold symptoms at incipient risk of psychotic disorder: six month outcome data. Schizophrenia Bulletin2007;33(2):446. [CSzG: 15203] McGorryPD , PhillipsLJ , YungAR , FranceyS , GermanoD , BravinJ , et al. A randomised controlled trial of interventions in the pre psychotic phase of psychotic disorders. Schizophrenia Research2000;41(1):9. [CSzG: 5149] McGorryPD , YungAR , PhillipsL , AdlardS , HallgrenM , PattonG , et al. Pre‐psychotic intervention in schizophrenia: a stitch in time?. Schizophrenia Research1998;29(1‐2):160. [CSzG: 3585] McGorryPD , YungAR , PhillipsLJ , YuenHP , FranceyS , CosgraveEM , et al. Randomised controlled trial of interventions designed to reduce the risk of progression to first‐episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry2002;59(10):921‐8. [CSzG: 8576] PhilippsLJ , McGorryP , YungA , FranceyD , GermanoF , BravinJ , et al. The development of preventive interventions for early psychosis: early findings and directions for the future. 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001; Vol. 2, issue Suppl 1. [CSzG: 7614] PhillipsL , CottonS , YuenHP , MihalopoulosC , ShihS , KellyD , et al. Cost effectiveness of a preventive intervention for young people at ultra high risk of developing psychosis. Schizophrenia Bulletin2007;33(2):488‐9. [CSzG: 15227] PhillipsLJ , CottonS , MihalopoulosC , ShihS , YungAR , CarterR , et al. Cost implications of specific and non‐specific treatment for young persons at ultra high risk of developing a first episode of psychosis. Early Intervention in Psychiatry2009;3(1):28‐34. [CSzG: 18308] PhillipsLJ , LeicesterSB , O'DwyerLE , FranceySM , KoutsogiannisJ , Abdel‐BakiA , et al. The PACE clinic: identification and management of young people at &quot;ultra&quot; high risk of psychosis. Journal of Psychiatric Practice2002;8(5):255‐69. [CSzG: 18235] PhillipsLJ , McGorryPD , YuenHP , WardJ , DonovanK , KellyD , et al. Medium term follow‐up of a randomised controlled trial of interventions for young people at ultra high risk of psychosis. Schizophrenia Research2007;96(1‐3):25‐33. [CSzG: 15544] PhillipsLJ , YungAR , YuenHP , PantelisC , McGorryPD . Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. American Journal of Medical Genetics2002;114(8):929‐37. [CSzG: 18236] ">PACE‐Australia</a>; <a href="./references#CD012236-bbs2-0016" title="NCT01619319 . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. ClinicalTrials.gov/show/NCT016193192012. [CSzG: 24387] PiskulicD , BarbatoM , AddingtonJ . Cognitive remediation in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:89. [CSzG: 24973] PiskulicD , BarbatoM , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2012;136:S245‐6. [CSzG: 29632] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2014;153(Suppl. 1):S218. [CSzG: 28827] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation therapy on cognition in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2014;8:86. [CSzG: 29633] ">Piskulic‐Canada</a>; <a href="./references#CD012236-bbs2-0017" title='BlockJJ , McGlashonTH . Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790‐9. American Journal of Psychiatry2006; Vol. 163, issue 10:1838. [CSzG: 13960] BreierAF , ZipurskyRB , PerkinsDO , AddingtonJM , TohenMF , DavidSR , et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951] HawkinsKA , AddingtonJ , KeefeR , ChristensenB , WoodsS , ZipurskyR , et al. Neuropsychological functioning in the first episode prodrome and early psychosis. Schizophrenia Research2004;70(1):101. [CSzG: 11515] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , MillerTJ , et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research2004;67(1):205. [CSzG: Ref11301] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , ZipurskyRB , et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. [CSzG: 16470] HawkinsKA , KeefeRS , ChristensenBK , AddingtonJ , WoodsSW , CallahanJ , et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. Schizophrenia Research2008;105(1‐3):1‐9. [CSzG: 16983] HoffmanRE , WoodsS , PredaA , TohenM , BreierA , GlistJ , et al. Excessive top‐down perceptual processing and reduced real‐world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. Schizophrenia Research2006;86(Suppl 1):S46. [CSzG: 13377] HoffmanRE , WoodsSW , HawkinsKA , PittmanB , TohenM , PredaA , et al. Extracting spurious messages from noise and risk of schizophrenia‐spectrum disorders in prodromal population. British Journal of Psychiatry2007;191(2):355‐6. [CSzG: 16068] McGlashanT , ZipurskyR , PerkinsD , AddingtonJ . Olanzapine for treatment of the schizophrenia prodrome: 2‐year results of a randomised placebo‐controlled study. Schizophrenia Research2004;67(1):164. [CSzG: 11320] McGlashanTH . Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. [CSzG: 10191] McGlashanTH . Treatment intervention in the New Haven PRIME clinic prodromal sample. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4835] McGlashanTH , MillerTJ , WoodsSW . Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research2002;53(3 Suppl 1):15. [CSzG: 8093] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005] McGlashanTH , MillerTJ , ZipurskyRB , WoodsSW , PerkinsDO , HawkinsKA , et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9803] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerT , WoodsSW , et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry2006;163(5):790‐9. [CSzG: 12654] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerTJ , WoodsSW , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research2003;61(1):7‐18. [CSzG: 9828] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJ , WoodsSW , MillerTJ , et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research2003;60:295. [CSzG: 9722] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJM , WoodsSW , LindborgS , et al. Olanzapine versus pbo for the schizophrenic prodrome: one‐year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9804] McGlashlanTH , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTH , WoodsSW , et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:42. [CSzG: 8934] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , MillerT , WoodsS , et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. Schizophrenia Research2004;70(1):6. [CSzG: 11524] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , WoodsS , MillerT , et al. Olanzapine vs. placebo for prodromal schizophrenia. Schizophrenia Research2004;67(1):6. [CSzG: 11321] MillerTJ , ZipurskyRB , PerkinsD , AddingtonJ , WoodsSW , HawkinsKA , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research2003;61(1):19‐30. [CSzG: 9829] RosenJL , WoodsSW , MillerTJ , McGlashanTH . Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease2002;190:133‐41. [CSzG: 8274] TaylorHE , ParkerS , MansellW , MorrisonAP . Effects of appraisals of anomalous experience on distress in people at risk of psychosis. Behavioural and Cognitive Psychotherapy2012;41(1):24‐33. [CSzG: 24374] WoodsS , ZipurskyR , PerkinsD , AddingtonJ , MarquezE , BreierA , et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:43. [CSzG: 8933] WoodsSW . Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):497. [CSzG: 19829] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research. 2003. [CSzG: 9978] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research2003;60:306‐7. [CSzG: 9752] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):453‐64. [CSzG: 9994] WoodsSW , McGlashanTH . Sample size planning for prodromal intervention trials. Schizophrenia Research2002;53(3 Suppl 1):40. [CSzG: 8116] WoodsSW , ZipurskyRB , PerkinsDO , AddingtonJM , MillerTJ , BreierAF , et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053] '>PRIME‐USA</a>; <a href="./references#CD012236-bbs2-0018" title="LoewyR , FisherM , MathalonDH , VinogradovS . Interim analyses of a randomised controlled trial of computerised cognitive training in clinical high risk for psychosis. Schizophrenia Bulletin2013;39:S238‐9. [CSzG: 28151] LoewyR , FisherM , SchlosserDA , BiagiantiB , StuartB , MathalonDH , et al. Intensive auditory cognitive training improves verbal memory in adolescents and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2016;42(Suppl 1):S118‐26. [CSzG: 35221] VinogradovS , LoewyR , FisherM , LeeA , NiendamT , RaglandJD , et al. Neuroplasticity‐based cognitive training in ultra‐high risk adolescents and recent onset patients with schizophrenia. Schizophrenia Research2012;136:S30. [CSzG: 29703] ">Vinogradov‐USA</a>; <a href="./references#CD012236-bbs2-0019" title="NCT00291226 . Glycine vs Placebo for the Schizophrenia Prodrome. www.ClinicalTrials.gov/ct/show/2006. [CSzG: 14759] WoodsS , WalshB , HawkinsK , MillerT , SaksaJ , D'SouzaD , et al. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. Early Intervention in Psychiatry2012;6:29. [CSzG: 24987] WoodsSW , KantrowitzJT , JavittDC . NMDAR‐based treatments for patients at clinical high risk for psychosis. Biological Psychiatry2014;1:11S. [CSzG: 29041] WoodsSW , WalshBC , HawkinsKA , MillerTJ , SaksaJR , D'SouzaDC , et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. European Neuropsychopharmacology2013;23(8):931‐40. [CSzG: 28750] ">Woods‐1‐USA</a>; <a href="./references#CD012236-bbs2-0020" title="McGorryP . Second generation intervention research in the pre‐psychotic phase of illness in schizophrenia and related psychoses. Australian New Zealand Clinical Trials Registry2000. [CSzG: 18439] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceyS , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: 12‐month outcome. Schizophrenia Research2012;136:S17‐8. [CSzG: 29547] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceySM , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: twelve‐month outcome. Journal of Clinical Psychiatry2013;74(4):349‐56. [CSzG: 28737] NelsonB , PhillipsLJ , YungAR , FranceySM , LeicesterS , BakerK , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and supportive therapy in young people with subthreshold symptoms at incipient risk of psychotic disorder: baseline characteristics of the sample. Schizophrenia Bulletin2007;33(2):450. [CSzG: 15212] PhillipsLJ , NelsonB , YuenHP , FranceySM , SimmonsM , StanfordC , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: study design and baseline characteristics. Australian and New Zealand Journal of Psychiatry2009;;43(9):818–29. YungA , AmmingerP , BergerG , ThompsomA , PhillipsL , NelsonB , et al. Randomised controlled trial of antipsychotic and cognitive therapy in young people at ultra‐high risk of psychosis. Early Intervention in Psychiatry2012;6:11. [CSzG: 24989] YungA , NelsonB , PhillipsL , FranceyS , LeicesterS , YuenH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and supportive therapy in young people at ultra high risk of psychotic disorder: 12 month outcome data. Early Intervention in Psychiatry2008;2(Suppl 1):A12. [CSzG: 19138] YungAR , PhillipsLJ , NelsonB , FranceySM , YuenHP , SimmonsMB , et al. Randomised controlled trial of interventions for young people at ultra high risk for psychosis: 6‐month analysis. Journal of Clinical Psychiatry2011;72(4):430‐40. [CSzG: 22929] ">Yung‐Australia</a>). </p> <section id="CD012236-sec-0120"> <h5 class="title">1. Methods</h5> <p>All the included studies stated that they were randomised. For further description of study methods, please see <a href="./references#CD012236-sec-0539" title="">Characteristics of included studies</a> and <a href="#CD012236-sec-0154">Risk of bias in included studies</a>. </p> </section> <section id="CD012236-sec-0121"> <h5 class="title">2. Participants and setting</h5> <section id="CD012236-sec-0122"> <h6 class="title">2.1 Within the cognitive behavioural therapy (CBT) and supportive therapy versus supportive therapy alone comparison </h6> <p>There are five included studies (<a href="./references#CD012236-bbs2-0001" title="AddingtonJ , EpsteinI , LiuL , FrenchP , BoydellKM , ZipurskyRB . A randomised controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research2011;125(1):54‐61. [CSzG: Ref21945] AddingtonJ , ZipurskyR , EpsteinI . ADAPT (Access, Detection and Psychological Treatments). Schizophrenia Research2006;86(Suppl 1):S6. [CSzG: Ref13364] NCT00260273 . Access, detection and psychological treatments. www.ClinicalTrials.gov/ct/show/2005. [CSzG: Ref14638] ">ADAPT‐Canada</a>; <a href="./references#CD012236-bbs2-0007" title="FrenchP , ShryaneN , BentallRP , LewisSW , MorrisonAP . Effects of cognitive therapy on the longitudinal development of psychotic experiences in people at high risk of developing psychosis. British Journal of Psychiatry. Supplements2007;191(Suppl 51):s82‐7. [CSzG: Ref16121] LewisS . EDIE ‐ Early detection and intervention for psychosis. National Research Register2001; Vol. 3. [CSzG: Ref13023] LewisS . EDIE ‐ early detection and intervention for psychosis (in primary care). National Research Register2002; Vol. 1. [CszG: Ref9342] MorrisonA . Early detection and intervention for psychosis in primary care. National Research Register2003. [CSzG: Ref15485] MorrisonA . Findings from a randomised controlled trial and clinical service delivering cognitive therapy to people at ultra‐high risk of developing psychosis. Schizophrenia Research2004;70(1):43‐4. [CSzG: Ref11526] MorrisonA . Follow‐up of prodromal symptoms. National Research Register2004; Vol. 3. [CSzG: Ref13036] MorrisonA , BentallR , FrenchP , Kilcommons A, LewisSW . Very early intervention in prodromal psychosis: a randomised trial. Schizophrenia Research2002;53(3 Suppl 1):42. [CSzG: Ref8096] MorrisonA , FrenchP , WalfordL , LewisS , Kilcommons A, GreenJ , et al. A randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;67(1):7. [CSzG: Ref11324] MorrisonA , FrenchP , WatfordL , LewisS , Kilcommons A, GreenJ , et al. Randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;70(1):63. [CSzG: Ref11527] MorrisonAP . Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: results of a randomised controlled trial. Schizophrenia Research2006;86(Suppl 1):S59. [CSzG: Ref13388] MorrisonAP , BentallRP , FrenchP , Kilcommons A, GreenJ , WalfordL , et al. Cognitive therapy in ultra high risk individuals for psychosis: randomised controlled trial. Schizophrenia Research2003;60:326. [CSzG: Ref9726] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, KnightA , et al. Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high‐risk individuals. Study design and interim analysis of transition rate and psychological risk factors. British Journal of Psychiatry. Supplements2002;181(43):s78‐84. [CSzG: Ref8737] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, LewisS . Early detection and intervention for psychosis in primary care. 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002. [CSzG: Ref8932] MorrisonAP , FrenchP , ParkerS , RobertsM , StevensH , BentallRP , et al. Three‐year follow‐up of a randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophrenia Bulletin2007;33(3):682‐7. [CSzG: Ref15288] MorrisonAP , FrenchP , WalfordL , LewisSW , Kilcommons A, GreenJ , et al. Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: randomised controlled trial. British Journal of Psychiatry2004;185:291‐7. [CSzG: Ref11450] MorrisonT . Early detection and intervention for psychosis in primary care. National Research Register2001; Vol. 1. [CSzG: Ref13037] MorrisonT , BentallR , FrenchP , Kilcommons A, GreenJ , LewisS . Early detection and intervention for psychosis in primary care. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:44. [CSzG: Ref8932] RentonJ , MorrisonA . Effectiveness of cognitive therapy for psychosis and implications for early intervention. Schizophrenia Research2004;70(1):142. [CSzG: Ref11536] ">EDIE‐UK</a>; <a href="./references#CD012236-bbs2-0005" title="ByrneRE , MorrisonAP . Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. Psychology and Psychotherapy2014;87(3):357‐71. [CSzG: Ref29312] FlachC , FrenchP , DunnG , FowlerD , GumleyAI , BirchwoodM , et al. Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE‐2 trial. British Journal of Psychiatry2015;207(2):123‐9. [CSzG: Ref33109] MorrisonA . Early detection and intervention evaluation for individuals at high risk of psychosis 2. http://www.controlled‐trials.com2008. [CSzG: Ref18285] MorrisonA . Early detection and intervention evaluation for people at risk of psychosis (edie‐2): A multisite randomised controlled trial of cognitive therapy for at‐risk mental states. Early Intervention in Psychiatry2012;6:11. [CSzG: Ref24968] MorrisonA , FrenchP , BentallR , LewisS , BirchwoodM , FowlerD , et al. Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. Early Intervention in Psychiatry2008;2(Suppl 1):A15. [CSzG: Ref19128] MorrisonAP . EDIE‐2: early detection and psychological intervention for individuals at high risk of psychosis (2). www.controlled‐trials.com2007. [CSzG: Ref15381] MorrisonAP , BirchwoodM , PyleM , FlachC , StewartSL , ByrneR , et al. Impact of cognitive therapy on internalised stigma in people with at‐risk mental states. British Journal of Psychiatry2013;203(2):140‐5. [CSzG: Ref28630] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ2012;344(7852):e2233. [CSzG: Ref24208] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at‐risk of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29554] MorrisonAP , PyleM , StewartSL , FrenchP , ByrneR , FlachC , et al. Internalised stigma in young people at high risk of developing psychosis: findings from a cognitive therapy trial. Schizophrenia Research2014;153:S42. [CSzG: Ref29555] MorrisonAP , StewartSL , FrenchP , BentallRP , BirchwoodM , ByrneR , et al. Early detection and intervention evaluation for people at high‐risk of psychosis‐2 (EDIE‐2): trial rationale, design and baseline characteristics. Early Intervention in Psychiatry2011;5(1):24‐32. [CSzG: Ref22695] MorrisonT . Early detection and psychological intervention for individuals at high risk of psychosis. EDIE‐2. Data on File2006. [CSzG: Ref13874] PelosiAJ . Rational policy making for early psychosis might yet become possible. BMJ2012;344(7856):e3137. [CSzG: Ref24326] PyleM , StewartSL , FrenchP , ByrneR , PattersonP , GumleyA , et al. Internalised stigma, emotional dysfunction and unusual experiences in young people at risk of psychosis. Early Intervention in Psychiatry2015;9(2):133‐40. [CSzG: Ref29813] ">EDIE‐2‐UK</a>; <a href="./references#CD012236-bbs2-0006" title="DragtS , Van derGaagM . Prevention of psychosis with a cognitive behavioural intervention in help‐seeking young people with an at risk mental state for developing psychosis. www.trialregister.nl/trialreg/index.asp2007. [CSzG: Ref19655] IsingHK , KraanTC , RietdijkJ , DragtS , KlaassenRM , BoonstraN , et al. Four‐year follow‐up of cognitive behavioral therapy in persons at ultra‐high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2016;42(5):1243‐52. [CSzG: Ref35214] IsingHK , LokkerbolJ , RietdijkJ , DragtS , KlaassenRM , KraanT , et al. Four‐year cost‐effectiveness of cognitive behavior therapy for preventing first‐episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2017;43(2):365‐74. [CSzG: Ref35824] IsingHK , SmitF , VelingW , RietdijkJ , DragtS , KlaassenRM , et al. Cost‐effectiveness of preventing first‐episode psychosis in ultra‐high‐risk subjects: multi‐centre randomised controlled trial. Psychological Medicine2015;45(7):1435‐46. [CSzG: Ref27798] KraanTC , IsingHK , FokkemaM , VelthorstE , Van denBergDP , KerkhovenM , et al. The effect of childhood adversity on 4‐year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE‐NL) Trial. Psychiatry Research2017;247:55‐62. [CSzG: Ref35559] NiemanDH , RuhrmannS , RietdijkJ , DragtS , IsingH , KlaassenR , et al. Preventive psychotherapy. Schizophrenia Research2014;153:S42‐3. [CSzG: Ref29601] RietdijkJ , DragtS , KlaassenR , IsingH , NiemanD , WunderinkL , et al. A single blind randomised controlled trial of cognitive behavioural therapy in a help‐seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE‐NL) trial. Trials2010;11:30. [CSzG: Ref20654] Van DerGaagM . The effects of CBT in personswith ultra high risk: the Dutch EDIE trial. European Archives of Psychiatry and Clinical Neuroscience2011;261:S18. [CSzG: Ref23756] Van DerGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first‐episode of psychosis. Early Intervention in Psychiatry2012;6:12. [CSzG: Ref24985] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomised controlled clinical trial. Schizophrenia Bulletin2012;38(6):1180‐8. [CSzG: Ref24935] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. The effects of cognitive behavioural therapy for subjects at ultra‐high risk for developing psychosis. Schizophrenia Bulletin2013;39:S356. [CSzG: Ref28121] Van derGaagM . The prevention of psychosis in at risk mental state. www.controlled‐trials.com2008. [CSzG: Ref17488] Van derGaagM , NiemanD , Van denBergD . CBT for those at risk of a first episode psychosis: Evidence‐based psychotherapy for people with an 'at risk mental state'. 1st Edition. Hove, UK: Routledge, 2013. Van derGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first episode of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29692] ">EDIE‐NL</a>; <a href="./references#CD012236-bbs2-0009" title="BechdolfA . Preventing progression to first‐episode psychosis in people in the early initial prodromal state. Early Intervention in Psychiatry2012;6:11. [CSzG: 24944] BechdolfA , BuhlerB , BerningJ , WagnerM , StammE , StreitM . Cognitive behavioural therapy in the early initial prodromal state of psychosis: first results. Schizophrenia Research2004;67(1):202. [CSzG: Ref11285] BechdolfA , KlosterkotterJ . Cognitive‐behavioural treatment (CBT) in the early initial prodromal state of psychosis: concept and practical approach. Schizophrenia Research2004;70(1):52. [CSzG: Ref11506] BechdolfA , RuhrmannS , JanssenB , BottlenderR , WagnerM , MaurerK , et al. Early recognition and intervention for people at risk of schizophrenia [Fruherkennung und intervention bei personen mit erhohtem psychoserisiko]. Psychoneuroendocrinology2004;30(11):606‐14. [CSzG: Ref11376] BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: Ref12511] BechdolfA , VeithV , BerningJ , StammE , DeckerP , JanssenB , et al. Cognitive behavioral therapy (CBT) in the early initial prodromal state of psychosis: first results of a randomised trial. Schizophrenia Research2004;70(1):62‐3. [CSzG: Ref11507] BechdolfA , WagnerM , RuhrmannS , HarriganS , PutzfeldV , PukropR , et al. Preventing progression to first‐episode psychosis in early initial prodromal states. British Journal of Psychiatry2012;200(1):22‐9. [CSzG: Ref24206] BechdolfA , WagnerM , RuhrmannS , HarriganS , VeithV , PukropR , et al. CBT for prevention of first episode psychosis in people in an putative early initial prodromal state. Early Intervention in Psychiatry2008;2(Suppl 1):A16. [CSzG: 19109] BechdolfA , WagnerM , VeithV , PukropR , BerningJ , StammE , et al. A randomised controlled trial of cognitive‐behavioral therapy in the early initial prodromal state of psychosis. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:22‐3. [CSzG: 20193] BechdolfA , WagnerM , VeithV , RuhrmannR , JanssenB , BottlenderR , et al. A randomised controlled multicenter trial of cognitive behaviour therapy in the early initial prodromal state of psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13369] BechdolfA , WagnerM , VeithV , RuhrmannS , PukropR , Brockhaus‐DumkeA , et al. Randomised controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Intervention in Psychiatry2007;1(1):71‐8. [CSzG: 16450] BechdolfA , WesselsH , WagnerM , KuhrK , BerningJ , PutzfeldV , et al. Predictors of treatment response to psychosocial interventions in people at risk. European Archives of Psychiatry and Clinical Neuroscience2015;1:S9. [CSzG: 33601] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] KommescherM , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. Early Intervention in Psychiatry2016;10(1):17‐27. [CSzG: 32187] NCT00204087 . Psychological intervention for persons at risk of psychosis in the early initial prodromal state. www.ClinicalTrials.gov/ct/show/2005. [CSzG: 14890] WesselsH , WagnerM , FrommannI , BerningJ , PutzfeldV , JanssenB , et al. Neuropsychological functioning as a predictor of treatment response to psychoeducational, cognitive behavioral therapy in people at clinical high risk of first episode psychosis. Psychiatrische Praxis2015;42(6):313‐9. [CSzG: 33130] ZarafonitisS , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Psychoeducation for persons at risk of psychosis. Psychotherapeut2012;57(4):326‐34. [CSzG: 24807] ">EIPS‐Germany</a>). These studies included participants between the ages of 14 and 36 years old (mean ages ranged from 20.6 to 26). The studies were conducted in different locations around the world: <a href="./references#CD012236-bbs2-0001" title="AddingtonJ , EpsteinI , LiuL , FrenchP , BoydellKM , ZipurskyRB . A randomised controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research2011;125(1):54‐61. [CSzG: Ref21945] AddingtonJ , ZipurskyR , EpsteinI . ADAPT (Access, Detection and Psychological Treatments). Schizophrenia Research2006;86(Suppl 1):S6. [CSzG: Ref13364] NCT00260273 . Access, detection and psychological treatments. www.ClinicalTrials.gov/ct/show/2005. [CSzG: Ref14638] ">ADAPT‐Canada</a> was conducted in Toronto, Canada; <a href="./references#CD012236-bbs2-0007" title="FrenchP , ShryaneN , BentallRP , LewisSW , MorrisonAP . Effects of cognitive therapy on the longitudinal development of psychotic experiences in people at high risk of developing psychosis. British Journal of Psychiatry. Supplements2007;191(Suppl 51):s82‐7. [CSzG: Ref16121] LewisS . EDIE ‐ Early detection and intervention for psychosis. National Research Register2001; Vol. 3. [CSzG: Ref13023] LewisS . EDIE ‐ early detection and intervention for psychosis (in primary care). National Research Register2002; Vol. 1. [CszG: Ref9342] MorrisonA . Early detection and intervention for psychosis in primary care. National Research Register2003. [CSzG: Ref15485] MorrisonA . Findings from a randomised controlled trial and clinical service delivering cognitive therapy to people at ultra‐high risk of developing psychosis. Schizophrenia Research2004;70(1):43‐4. [CSzG: Ref11526] MorrisonA . Follow‐up of prodromal symptoms. National Research Register2004; Vol. 3. [CSzG: Ref13036] MorrisonA , BentallR , FrenchP , Kilcommons A, LewisSW . Very early intervention in prodromal psychosis: a randomised trial. Schizophrenia Research2002;53(3 Suppl 1):42. [CSzG: Ref8096] MorrisonA , FrenchP , WalfordL , LewisS , Kilcommons A, GreenJ , et al. A randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;67(1):7. [CSzG: Ref11324] MorrisonA , FrenchP , WatfordL , LewisS , Kilcommons A, GreenJ , et al. Randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;70(1):63. [CSzG: Ref11527] MorrisonAP . Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: results of a randomised controlled trial. Schizophrenia Research2006;86(Suppl 1):S59. [CSzG: Ref13388] MorrisonAP , BentallRP , FrenchP , Kilcommons A, GreenJ , WalfordL , et al. Cognitive therapy in ultra high risk individuals for psychosis: randomised controlled trial. Schizophrenia Research2003;60:326. [CSzG: Ref9726] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, KnightA , et al. Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high‐risk individuals. Study design and interim analysis of transition rate and psychological risk factors. British Journal of Psychiatry. Supplements2002;181(43):s78‐84. [CSzG: Ref8737] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, LewisS . Early detection and intervention for psychosis in primary care. 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002. [CSzG: Ref8932] MorrisonAP , FrenchP , ParkerS , RobertsM , StevensH , BentallRP , et al. Three‐year follow‐up of a randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophrenia Bulletin2007;33(3):682‐7. [CSzG: Ref15288] MorrisonAP , FrenchP , WalfordL , LewisSW , Kilcommons A, GreenJ , et al. Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: randomised controlled trial. British Journal of Psychiatry2004;185:291‐7. [CSzG: Ref11450] MorrisonT . Early detection and intervention for psychosis in primary care. National Research Register2001; Vol. 1. [CSzG: Ref13037] MorrisonT , BentallR , FrenchP , Kilcommons A, GreenJ , LewisS . Early detection and intervention for psychosis in primary care. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:44. [CSzG: Ref8932] RentonJ , MorrisonA . Effectiveness of cognitive therapy for psychosis and implications for early intervention. Schizophrenia Research2004;70(1):142. [CSzG: Ref11536] ">EDIE‐UK</a> and <a href="./references#CD012236-bbs2-0005" title="ByrneRE , MorrisonAP . Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. Psychology and Psychotherapy2014;87(3):357‐71. [CSzG: Ref29312] FlachC , FrenchP , DunnG , FowlerD , GumleyAI , BirchwoodM , et al. Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE‐2 trial. British Journal of Psychiatry2015;207(2):123‐9. [CSzG: Ref33109] MorrisonA . Early detection and intervention evaluation for individuals at high risk of psychosis 2. http://www.controlled‐trials.com2008. [CSzG: Ref18285] MorrisonA . Early detection and intervention evaluation for people at risk of psychosis (edie‐2): A multisite randomised controlled trial of cognitive therapy for at‐risk mental states. Early Intervention in Psychiatry2012;6:11. [CSzG: Ref24968] MorrisonA , FrenchP , BentallR , LewisS , BirchwoodM , FowlerD , et al. Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. Early Intervention in Psychiatry2008;2(Suppl 1):A15. [CSzG: Ref19128] MorrisonAP . EDIE‐2: early detection and psychological intervention for individuals at high risk of psychosis (2). www.controlled‐trials.com2007. [CSzG: Ref15381] MorrisonAP , BirchwoodM , PyleM , FlachC , StewartSL , ByrneR , et al. Impact of cognitive therapy on internalised stigma in people with at‐risk mental states. British Journal of Psychiatry2013;203(2):140‐5. [CSzG: Ref28630] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ2012;344(7852):e2233. [CSzG: Ref24208] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at‐risk of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29554] MorrisonAP , PyleM , StewartSL , FrenchP , ByrneR , FlachC , et al. Internalised stigma in young people at high risk of developing psychosis: findings from a cognitive therapy trial. Schizophrenia Research2014;153:S42. [CSzG: Ref29555] MorrisonAP , StewartSL , FrenchP , BentallRP , BirchwoodM , ByrneR , et al. Early detection and intervention evaluation for people at high‐risk of psychosis‐2 (EDIE‐2): trial rationale, design and baseline characteristics. Early Intervention in Psychiatry2011;5(1):24‐32. [CSzG: Ref22695] MorrisonT . Early detection and psychological intervention for individuals at high risk of psychosis. EDIE‐2. Data on File2006. [CSzG: Ref13874] PelosiAJ . Rational policy making for early psychosis might yet become possible. BMJ2012;344(7856):e3137. [CSzG: Ref24326] PyleM , StewartSL , FrenchP , ByrneR , PattersonP , GumleyA , et al. Internalised stigma, emotional dysfunction and unusual experiences in young people at risk of psychosis. Early Intervention in Psychiatry2015;9(2):133‐40. [CSzG: Ref29813] ">EDIE‐2‐UK</a> were conducted in multiple locations in the UK; <a href="./references#CD012236-bbs2-0006" title="DragtS , Van derGaagM . Prevention of psychosis with a cognitive behavioural intervention in help‐seeking young people with an at risk mental state for developing psychosis. www.trialregister.nl/trialreg/index.asp2007. [CSzG: Ref19655] IsingHK , KraanTC , RietdijkJ , DragtS , KlaassenRM , BoonstraN , et al. Four‐year follow‐up of cognitive behavioral therapy in persons at ultra‐high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2016;42(5):1243‐52. [CSzG: Ref35214] IsingHK , LokkerbolJ , RietdijkJ , DragtS , KlaassenRM , KraanT , et al. Four‐year cost‐effectiveness of cognitive behavior therapy for preventing first‐episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2017;43(2):365‐74. [CSzG: Ref35824] IsingHK , SmitF , VelingW , RietdijkJ , DragtS , KlaassenRM , et al. Cost‐effectiveness of preventing first‐episode psychosis in ultra‐high‐risk subjects: multi‐centre randomised controlled trial. Psychological Medicine2015;45(7):1435‐46. [CSzG: Ref27798] KraanTC , IsingHK , FokkemaM , VelthorstE , Van denBergDP , KerkhovenM , et al. The effect of childhood adversity on 4‐year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE‐NL) Trial. Psychiatry Research2017;247:55‐62. [CSzG: Ref35559] NiemanDH , RuhrmannS , RietdijkJ , DragtS , IsingH , KlaassenR , et al. Preventive psychotherapy. Schizophrenia Research2014;153:S42‐3. [CSzG: Ref29601] RietdijkJ , DragtS , KlaassenR , IsingH , NiemanD , WunderinkL , et al. A single blind randomised controlled trial of cognitive behavioural therapy in a help‐seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE‐NL) trial. Trials2010;11:30. [CSzG: Ref20654] Van DerGaagM . The effects of CBT in personswith ultra high risk: the Dutch EDIE trial. European Archives of Psychiatry and Clinical Neuroscience2011;261:S18. [CSzG: Ref23756] Van DerGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first‐episode of psychosis. Early Intervention in Psychiatry2012;6:12. [CSzG: Ref24985] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomised controlled clinical trial. Schizophrenia Bulletin2012;38(6):1180‐8. [CSzG: Ref24935] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. The effects of cognitive behavioural therapy for subjects at ultra‐high risk for developing psychosis. Schizophrenia Bulletin2013;39:S356. [CSzG: Ref28121] Van derGaagM . The prevention of psychosis in at risk mental state. www.controlled‐trials.com2008. [CSzG: Ref17488] Van derGaagM , NiemanD , Van denBergD . CBT for those at risk of a first episode psychosis: Evidence‐based psychotherapy for people with an 'at risk mental state'. 1st Edition. Hove, UK: Routledge, 2013. Van derGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first episode of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29692] ">EDIE‐NL</a> in The Hague, Rivierduinen and Friesland, Netherlands; and lastly, <a href="./references#CD012236-bbs2-0009" title="BechdolfA . Preventing progression to first‐episode psychosis in people in the early initial prodromal state. Early Intervention in Psychiatry2012;6:11. [CSzG: 24944] BechdolfA , BuhlerB , BerningJ , WagnerM , StammE , StreitM . Cognitive behavioural therapy in the early initial prodromal state of psychosis: first results. Schizophrenia Research2004;67(1):202. [CSzG: Ref11285] BechdolfA , KlosterkotterJ . Cognitive‐behavioural treatment (CBT) in the early initial prodromal state of psychosis: concept and practical approach. Schizophrenia Research2004;70(1):52. [CSzG: Ref11506] BechdolfA , RuhrmannS , JanssenB , BottlenderR , WagnerM , MaurerK , et al. Early recognition and intervention for people at risk of schizophrenia [Fruherkennung und intervention bei personen mit erhohtem psychoserisiko]. Psychoneuroendocrinology2004;30(11):606‐14. [CSzG: Ref11376] BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: Ref12511] BechdolfA , VeithV , BerningJ , StammE , DeckerP , JanssenB , et al. Cognitive behavioral therapy (CBT) in the early initial prodromal state of psychosis: first results of a randomised trial. Schizophrenia Research2004;70(1):62‐3. [CSzG: Ref11507] BechdolfA , WagnerM , RuhrmannS , HarriganS , PutzfeldV , PukropR , et al. Preventing progression to first‐episode psychosis in early initial prodromal states. British Journal of Psychiatry2012;200(1):22‐9. [CSzG: Ref24206] BechdolfA , WagnerM , RuhrmannS , HarriganS , VeithV , PukropR , et al. CBT for prevention of first episode psychosis in people in an putative early initial prodromal state. Early Intervention in Psychiatry2008;2(Suppl 1):A16. [CSzG: 19109] BechdolfA , WagnerM , VeithV , PukropR , BerningJ , StammE , et al. A randomised controlled trial of cognitive‐behavioral therapy in the early initial prodromal state of psychosis. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:22‐3. [CSzG: 20193] BechdolfA , WagnerM , VeithV , RuhrmannR , JanssenB , BottlenderR , et al. A randomised controlled multicenter trial of cognitive behaviour therapy in the early initial prodromal state of psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13369] BechdolfA , WagnerM , VeithV , RuhrmannS , PukropR , Brockhaus‐DumkeA , et al. Randomised controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Intervention in Psychiatry2007;1(1):71‐8. [CSzG: 16450] BechdolfA , WesselsH , WagnerM , KuhrK , BerningJ , PutzfeldV , et al. Predictors of treatment response to psychosocial interventions in people at risk. European Archives of Psychiatry and Clinical Neuroscience2015;1:S9. [CSzG: 33601] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] KommescherM , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. Early Intervention in Psychiatry2016;10(1):17‐27. [CSzG: 32187] NCT00204087 . Psychological intervention for persons at risk of psychosis in the early initial prodromal state. www.ClinicalTrials.gov/ct/show/2005. [CSzG: 14890] WesselsH , WagnerM , FrommannI , BerningJ , PutzfeldV , JanssenB , et al. Neuropsychological functioning as a predictor of treatment response to psychoeducational, cognitive behavioral therapy in people at clinical high risk of first episode psychosis. Psychiatrische Praxis2015;42(6):313‐9. [CSzG: 33130] ZarafonitisS , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Psychoeducation for persons at risk of psychosis. Psychotherapeut2012;57(4):326‐34. [CSzG: 24807] ">EIPS‐Germany</a> in Cologne, Bonn, Dusseldorf, and Munich. The method of recruitment varied. <a href="./references#CD012236-bbs2-0001" title="AddingtonJ , EpsteinI , LiuL , FrenchP , BoydellKM , ZipurskyRB . A randomised controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research2011;125(1):54‐61. [CSzG: Ref21945] AddingtonJ , ZipurskyR , EpsteinI . ADAPT (Access, Detection and Psychological Treatments). Schizophrenia Research2006;86(Suppl 1):S6. [CSzG: Ref13364] NCT00260273 . Access, detection and psychological treatments. www.ClinicalTrials.gov/ct/show/2005. [CSzG: Ref14638] ">ADAPT‐Canada</a> recruited participants via advertisement on radio, public transit and local newspaper. <a href="./references#CD012236-bbs2-0007" title="FrenchP , ShryaneN , BentallRP , LewisSW , MorrisonAP . Effects of cognitive therapy on the longitudinal development of psychotic experiences in people at high risk of developing psychosis. British Journal of Psychiatry. Supplements2007;191(Suppl 51):s82‐7. [CSzG: Ref16121] LewisS . EDIE ‐ Early detection and intervention for psychosis. National Research Register2001; Vol. 3. [CSzG: Ref13023] LewisS . EDIE ‐ early detection and intervention for psychosis (in primary care). National Research Register2002; Vol. 1. [CszG: Ref9342] MorrisonA . Early detection and intervention for psychosis in primary care. National Research Register2003. [CSzG: Ref15485] MorrisonA . Findings from a randomised controlled trial and clinical service delivering cognitive therapy to people at ultra‐high risk of developing psychosis. Schizophrenia Research2004;70(1):43‐4. [CSzG: Ref11526] MorrisonA . Follow‐up of prodromal symptoms. National Research Register2004; Vol. 3. [CSzG: Ref13036] MorrisonA , BentallR , FrenchP , Kilcommons A, LewisSW . Very early intervention in prodromal psychosis: a randomised trial. Schizophrenia Research2002;53(3 Suppl 1):42. [CSzG: Ref8096] MorrisonA , FrenchP , WalfordL , LewisS , Kilcommons A, GreenJ , et al. A randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;67(1):7. [CSzG: Ref11324] MorrisonA , FrenchP , WatfordL , LewisS , Kilcommons A, GreenJ , et al. Randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;70(1):63. [CSzG: Ref11527] MorrisonAP . Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: results of a randomised controlled trial. Schizophrenia Research2006;86(Suppl 1):S59. [CSzG: Ref13388] MorrisonAP , BentallRP , FrenchP , Kilcommons A, GreenJ , WalfordL , et al. Cognitive therapy in ultra high risk individuals for psychosis: randomised controlled trial. Schizophrenia Research2003;60:326. [CSzG: Ref9726] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, KnightA , et al. Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high‐risk individuals. Study design and interim analysis of transition rate and psychological risk factors. British Journal of Psychiatry. Supplements2002;181(43):s78‐84. [CSzG: Ref8737] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, LewisS . Early detection and intervention for psychosis in primary care. 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002. [CSzG: Ref8932] MorrisonAP , FrenchP , ParkerS , RobertsM , StevensH , BentallRP , et al. Three‐year follow‐up of a randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophrenia Bulletin2007;33(3):682‐7. [CSzG: Ref15288] MorrisonAP , FrenchP , WalfordL , LewisSW , Kilcommons A, GreenJ , et al. Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: randomised controlled trial. British Journal of Psychiatry2004;185:291‐7. [CSzG: Ref11450] MorrisonT . Early detection and intervention for psychosis in primary care. National Research Register2001; Vol. 1. [CSzG: Ref13037] MorrisonT , BentallR , FrenchP , Kilcommons A, GreenJ , LewisS . Early detection and intervention for psychosis in primary care. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:44. [CSzG: Ref8932] RentonJ , MorrisonA . Effectiveness of cognitive therapy for psychosis and implications for early intervention. Schizophrenia Research2004;70(1):142. [CSzG: Ref11536] ">EDIE‐UK</a> recruited participants from community settings. The participants from <a href="./references#CD012236-bbs2-0009" title="BechdolfA . Preventing progression to first‐episode psychosis in people in the early initial prodromal state. Early Intervention in Psychiatry2012;6:11. [CSzG: 24944] BechdolfA , BuhlerB , BerningJ , WagnerM , StammE , StreitM . Cognitive behavioural therapy in the early initial prodromal state of psychosis: first results. Schizophrenia Research2004;67(1):202. [CSzG: Ref11285] BechdolfA , KlosterkotterJ . Cognitive‐behavioural treatment (CBT) in the early initial prodromal state of psychosis: concept and practical approach. Schizophrenia Research2004;70(1):52. [CSzG: Ref11506] BechdolfA , RuhrmannS , JanssenB , BottlenderR , WagnerM , MaurerK , et al. Early recognition and intervention for people at risk of schizophrenia [Fruherkennung und intervention bei personen mit erhohtem psychoserisiko]. Psychoneuroendocrinology2004;30(11):606‐14. [CSzG: Ref11376] BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: Ref12511] BechdolfA , VeithV , BerningJ , StammE , DeckerP , JanssenB , et al. Cognitive behavioral therapy (CBT) in the early initial prodromal state of psychosis: first results of a randomised trial. Schizophrenia Research2004;70(1):62‐3. [CSzG: Ref11507] BechdolfA , WagnerM , RuhrmannS , HarriganS , PutzfeldV , PukropR , et al. Preventing progression to first‐episode psychosis in early initial prodromal states. British Journal of Psychiatry2012;200(1):22‐9. [CSzG: Ref24206] BechdolfA , WagnerM , RuhrmannS , HarriganS , VeithV , PukropR , et al. CBT for prevention of first episode psychosis in people in an putative early initial prodromal state. Early Intervention in Psychiatry2008;2(Suppl 1):A16. [CSzG: 19109] BechdolfA , WagnerM , VeithV , PukropR , BerningJ , StammE , et al. A randomised controlled trial of cognitive‐behavioral therapy in the early initial prodromal state of psychosis. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:22‐3. [CSzG: 20193] BechdolfA , WagnerM , VeithV , RuhrmannR , JanssenB , BottlenderR , et al. A randomised controlled multicenter trial of cognitive behaviour therapy in the early initial prodromal state of psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13369] BechdolfA , WagnerM , VeithV , RuhrmannS , PukropR , Brockhaus‐DumkeA , et al. Randomised controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Intervention in Psychiatry2007;1(1):71‐8. [CSzG: 16450] BechdolfA , WesselsH , WagnerM , KuhrK , BerningJ , PutzfeldV , et al. Predictors of treatment response to psychosocial interventions in people at risk. European Archives of Psychiatry and Clinical Neuroscience2015;1:S9. [CSzG: 33601] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] KommescherM , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. Early Intervention in Psychiatry2016;10(1):17‐27. [CSzG: 32187] NCT00204087 . Psychological intervention for persons at risk of psychosis in the early initial prodromal state. www.ClinicalTrials.gov/ct/show/2005. [CSzG: 14890] WesselsH , WagnerM , FrommannI , BerningJ , PutzfeldV , JanssenB , et al. Neuropsychological functioning as a predictor of treatment response to psychoeducational, cognitive behavioral therapy in people at clinical high risk of first episode psychosis. Psychiatrische Praxis2015;42(6):313‐9. [CSzG: 33130] ZarafonitisS , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Psychoeducation for persons at risk of psychosis. Psychotherapeut2012;57(4):326‐34. [CSzG: 24807] ">EIPS‐Germany</a> and <a href="./references#CD012236-bbs2-0005" title="ByrneRE , MorrisonAP . Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. Psychology and Psychotherapy2014;87(3):357‐71. [CSzG: Ref29312] FlachC , FrenchP , DunnG , FowlerD , GumleyAI , BirchwoodM , et al. Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE‐2 trial. British Journal of Psychiatry2015;207(2):123‐9. [CSzG: Ref33109] MorrisonA . Early detection and intervention evaluation for individuals at high risk of psychosis 2. http://www.controlled‐trials.com2008. [CSzG: Ref18285] MorrisonA . Early detection and intervention evaluation for people at risk of psychosis (edie‐2): A multisite randomised controlled trial of cognitive therapy for at‐risk mental states. Early Intervention in Psychiatry2012;6:11. [CSzG: Ref24968] MorrisonA , FrenchP , BentallR , LewisS , BirchwoodM , FowlerD , et al. Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. Early Intervention in Psychiatry2008;2(Suppl 1):A15. [CSzG: Ref19128] MorrisonAP . EDIE‐2: early detection and psychological intervention for individuals at high risk of psychosis (2). www.controlled‐trials.com2007. [CSzG: Ref15381] MorrisonAP , BirchwoodM , PyleM , FlachC , StewartSL , ByrneR , et al. Impact of cognitive therapy on internalised stigma in people with at‐risk mental states. British Journal of Psychiatry2013;203(2):140‐5. [CSzG: Ref28630] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ2012;344(7852):e2233. [CSzG: Ref24208] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at‐risk of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29554] MorrisonAP , PyleM , StewartSL , FrenchP , ByrneR , FlachC , et al. Internalised stigma in young people at high risk of developing psychosis: findings from a cognitive therapy trial. Schizophrenia Research2014;153:S42. [CSzG: Ref29555] MorrisonAP , StewartSL , FrenchP , BentallRP , BirchwoodM , ByrneR , et al. Early detection and intervention evaluation for people at high‐risk of psychosis‐2 (EDIE‐2): trial rationale, design and baseline characteristics. Early Intervention in Psychiatry2011;5(1):24‐32. [CSzG: Ref22695] MorrisonT . Early detection and psychological intervention for individuals at high risk of psychosis. EDIE‐2. Data on File2006. [CSzG: Ref13874] PelosiAJ . Rational policy making for early psychosis might yet become possible. BMJ2012;344(7856):e3137. [CSzG: Ref24326] PyleM , StewartSL , FrenchP , ByrneR , PattersonP , GumleyA , et al. Internalised stigma, emotional dysfunction and unusual experiences in young people at risk of psychosis. Early Intervention in Psychiatry2015;9(2):133‐40. [CSzG: Ref29813] ">EDIE‐2‐UK</a> were help‐seeking. Different assessment criteria were used, ranging from Criteria of Prodromal States (COPS) in <a href="./references#CD012236-bbs2-0001" title="AddingtonJ , EpsteinI , LiuL , FrenchP , BoydellKM , ZipurskyRB . A randomised controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research2011;125(1):54‐61. [CSzG: Ref21945] AddingtonJ , ZipurskyR , EpsteinI . ADAPT (Access, Detection and Psychological Treatments). Schizophrenia Research2006;86(Suppl 1):S6. [CSzG: Ref13364] NCT00260273 . Access, detection and psychological treatments. www.ClinicalTrials.gov/ct/show/2005. [CSzG: Ref14638] ">ADAPT‐Canada</a>, CAARMS criteria (<a href="./references#CD012236-bbs2-0198" title="YungAR , YuenHP , McGorryPD , PhillipsLJ , KellyD , Dell’OlioM , et al. Mapping the onset of psychosis: the Comprehensive Assessment of At‐Risk Mental States. Australian &amp; New Zealand Journal of Psychiatry2005;39(11‐12):964‐71. ">Yung 2005</a>), in <a href="./references#CD012236-bbs2-0005" title="ByrneRE , MorrisonAP . Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. Psychology and Psychotherapy2014;87(3):357‐71. [CSzG: Ref29312] FlachC , FrenchP , DunnG , FowlerD , GumleyAI , BirchwoodM , et al. Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE‐2 trial. British Journal of Psychiatry2015;207(2):123‐9. [CSzG: Ref33109] MorrisonA . Early detection and intervention evaluation for individuals at high risk of psychosis 2. http://www.controlled‐trials.com2008. [CSzG: Ref18285] MorrisonA . Early detection and intervention evaluation for people at risk of psychosis (edie‐2): A multisite randomised controlled trial of cognitive therapy for at‐risk mental states. Early Intervention in Psychiatry2012;6:11. [CSzG: Ref24968] MorrisonA , FrenchP , BentallR , LewisS , BirchwoodM , FowlerD , et al. Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. Early Intervention in Psychiatry2008;2(Suppl 1):A15. [CSzG: Ref19128] MorrisonAP . EDIE‐2: early detection and psychological intervention for individuals at high risk of psychosis (2). www.controlled‐trials.com2007. [CSzG: Ref15381] MorrisonAP , BirchwoodM , PyleM , FlachC , StewartSL , ByrneR , et al. Impact of cognitive therapy on internalised stigma in people with at‐risk mental states. British Journal of Psychiatry2013;203(2):140‐5. [CSzG: Ref28630] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ2012;344(7852):e2233. [CSzG: Ref24208] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at‐risk of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29554] MorrisonAP , PyleM , StewartSL , FrenchP , ByrneR , FlachC , et al. Internalised stigma in young people at high risk of developing psychosis: findings from a cognitive therapy trial. Schizophrenia Research2014;153:S42. [CSzG: Ref29555] MorrisonAP , StewartSL , FrenchP , BentallRP , BirchwoodM , ByrneR , et al. Early detection and intervention evaluation for people at high‐risk of psychosis‐2 (EDIE‐2): trial rationale, design and baseline characteristics. Early Intervention in Psychiatry2011;5(1):24‐32. [CSzG: Ref22695] MorrisonT . Early detection and psychological intervention for individuals at high risk of psychosis. EDIE‐2. Data on File2006. [CSzG: Ref13874] PelosiAJ . Rational policy making for early psychosis might yet become possible. BMJ2012;344(7856):e3137. [CSzG: Ref24326] PyleM , StewartSL , FrenchP , ByrneR , PattersonP , GumleyA , et al. Internalised stigma, emotional dysfunction and unusual experiences in young people at risk of psychosis. Early Intervention in Psychiatry2015;9(2):133‐40. [CSzG: Ref29813] ">EDIE‐2‐UK</a> and <a href="./references#CD012236-bbs2-0006" title="DragtS , Van derGaagM . Prevention of psychosis with a cognitive behavioural intervention in help‐seeking young people with an at risk mental state for developing psychosis. www.trialregister.nl/trialreg/index.asp2007. [CSzG: Ref19655] IsingHK , KraanTC , RietdijkJ , DragtS , KlaassenRM , BoonstraN , et al. Four‐year follow‐up of cognitive behavioral therapy in persons at ultra‐high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2016;42(5):1243‐52. [CSzG: Ref35214] IsingHK , LokkerbolJ , RietdijkJ , DragtS , KlaassenRM , KraanT , et al. Four‐year cost‐effectiveness of cognitive behavior therapy for preventing first‐episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2017;43(2):365‐74. [CSzG: Ref35824] IsingHK , SmitF , VelingW , RietdijkJ , DragtS , KlaassenRM , et al. Cost‐effectiveness of preventing first‐episode psychosis in ultra‐high‐risk subjects: multi‐centre randomised controlled trial. Psychological Medicine2015;45(7):1435‐46. [CSzG: Ref27798] KraanTC , IsingHK , FokkemaM , VelthorstE , Van denBergDP , KerkhovenM , et al. The effect of childhood adversity on 4‐year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE‐NL) Trial. Psychiatry Research2017;247:55‐62. [CSzG: Ref35559] NiemanDH , RuhrmannS , RietdijkJ , DragtS , IsingH , KlaassenR , et al. Preventive psychotherapy. Schizophrenia Research2014;153:S42‐3. [CSzG: Ref29601] RietdijkJ , DragtS , KlaassenR , IsingH , NiemanD , WunderinkL , et al. A single blind randomised controlled trial of cognitive behavioural therapy in a help‐seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE‐NL) trial. Trials2010;11:30. [CSzG: Ref20654] Van DerGaagM . The effects of CBT in personswith ultra high risk: the Dutch EDIE trial. European Archives of Psychiatry and Clinical Neuroscience2011;261:S18. [CSzG: Ref23756] Van DerGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first‐episode of psychosis. Early Intervention in Psychiatry2012;6:12. [CSzG: Ref24985] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomised controlled clinical trial. Schizophrenia Bulletin2012;38(6):1180‐8. [CSzG: Ref24935] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. The effects of cognitive behavioural therapy for subjects at ultra‐high risk for developing psychosis. Schizophrenia Bulletin2013;39:S356. [CSzG: Ref28121] Van derGaagM . The prevention of psychosis in at risk mental state. www.controlled‐trials.com2008. [CSzG: Ref17488] Van derGaagM , NiemanD , Van denBergD . CBT for those at risk of a first episode psychosis: Evidence‐based psychotherapy for people with an 'at risk mental state'. 1st Edition. Hove, UK: Routledge, 2013. Van derGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first episode of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29692] ">EDIE‐NL</a>, adapted criteria (<a href="./references#CD012236-bbs2-0196" title="YungAR , PhillipsLJ , McGorryPD , McFarlaneCA , FranceyS , HarriganS , et al. Prediction of psychosis: a step towards indicated prevention of schizophrenia. British Journal of Psychiatry1998;172 (Suppl. 33):14–20. ">Yung 1998</a>), in <a href="./references#CD012236-bbs2-0007" title="FrenchP , ShryaneN , BentallRP , LewisSW , MorrisonAP . Effects of cognitive therapy on the longitudinal development of psychotic experiences in people at high risk of developing psychosis. British Journal of Psychiatry. Supplements2007;191(Suppl 51):s82‐7. [CSzG: Ref16121] LewisS . EDIE ‐ Early detection and intervention for psychosis. National Research Register2001; Vol. 3. [CSzG: Ref13023] LewisS . EDIE ‐ early detection and intervention for psychosis (in primary care). National Research Register2002; Vol. 1. [CszG: Ref9342] MorrisonA . Early detection and intervention for psychosis in primary care. National Research Register2003. [CSzG: Ref15485] MorrisonA . Findings from a randomised controlled trial and clinical service delivering cognitive therapy to people at ultra‐high risk of developing psychosis. Schizophrenia Research2004;70(1):43‐4. [CSzG: Ref11526] MorrisonA . Follow‐up of prodromal symptoms. National Research Register2004; Vol. 3. [CSzG: Ref13036] MorrisonA , BentallR , FrenchP , Kilcommons A, LewisSW . Very early intervention in prodromal psychosis: a randomised trial. Schizophrenia Research2002;53(3 Suppl 1):42. [CSzG: Ref8096] MorrisonA , FrenchP , WalfordL , LewisS , Kilcommons A, GreenJ , et al. A randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;67(1):7. [CSzG: Ref11324] MorrisonA , FrenchP , WatfordL , LewisS , Kilcommons A, GreenJ , et al. Randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;70(1):63. [CSzG: Ref11527] MorrisonAP . Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: results of a randomised controlled trial. Schizophrenia Research2006;86(Suppl 1):S59. [CSzG: Ref13388] MorrisonAP , BentallRP , FrenchP , Kilcommons A, GreenJ , WalfordL , et al. Cognitive therapy in ultra high risk individuals for psychosis: randomised controlled trial. Schizophrenia Research2003;60:326. [CSzG: Ref9726] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, KnightA , et al. Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high‐risk individuals. Study design and interim analysis of transition rate and psychological risk factors. British Journal of Psychiatry. Supplements2002;181(43):s78‐84. [CSzG: Ref8737] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, LewisS . Early detection and intervention for psychosis in primary care. 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002. [CSzG: Ref8932] MorrisonAP , FrenchP , ParkerS , RobertsM , StevensH , BentallRP , et al. Three‐year follow‐up of a randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophrenia Bulletin2007;33(3):682‐7. [CSzG: Ref15288] MorrisonAP , FrenchP , WalfordL , LewisSW , Kilcommons A, GreenJ , et al. Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: randomised controlled trial. British Journal of Psychiatry2004;185:291‐7. [CSzG: Ref11450] MorrisonT . Early detection and intervention for psychosis in primary care. National Research Register2001; Vol. 1. [CSzG: Ref13037] MorrisonT , BentallR , FrenchP , Kilcommons A, GreenJ , LewisS . Early detection and intervention for psychosis in primary care. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:44. [CSzG: Ref8932] RentonJ , MorrisonA . Effectiveness of cognitive therapy for psychosis and implications for early intervention. Schizophrenia Research2004;70(1):142. [CSzG: Ref11536] ">EDIE‐UK</a> and criteria for the Early Initial Prodrome State in <a href="./references#CD012236-bbs2-0009" title="BechdolfA . Preventing progression to first‐episode psychosis in people in the early initial prodromal state. Early Intervention in Psychiatry2012;6:11. [CSzG: 24944] BechdolfA , BuhlerB , BerningJ , WagnerM , StammE , StreitM . Cognitive behavioural therapy in the early initial prodromal state of psychosis: first results. Schizophrenia Research2004;67(1):202. [CSzG: Ref11285] BechdolfA , KlosterkotterJ . Cognitive‐behavioural treatment (CBT) in the early initial prodromal state of psychosis: concept and practical approach. Schizophrenia Research2004;70(1):52. [CSzG: Ref11506] BechdolfA , RuhrmannS , JanssenB , BottlenderR , WagnerM , MaurerK , et al. Early recognition and intervention for people at risk of schizophrenia [Fruherkennung und intervention bei personen mit erhohtem psychoserisiko]. Psychoneuroendocrinology2004;30(11):606‐14. [CSzG: Ref11376] BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: Ref12511] BechdolfA , VeithV , BerningJ , StammE , DeckerP , JanssenB , et al. Cognitive behavioral therapy (CBT) in the early initial prodromal state of psychosis: first results of a randomised trial. Schizophrenia Research2004;70(1):62‐3. [CSzG: Ref11507] BechdolfA , WagnerM , RuhrmannS , HarriganS , PutzfeldV , PukropR , et al. Preventing progression to first‐episode psychosis in early initial prodromal states. British Journal of Psychiatry2012;200(1):22‐9. [CSzG: Ref24206] BechdolfA , WagnerM , RuhrmannS , HarriganS , VeithV , PukropR , et al. CBT for prevention of first episode psychosis in people in an putative early initial prodromal state. Early Intervention in Psychiatry2008;2(Suppl 1):A16. [CSzG: 19109] BechdolfA , WagnerM , VeithV , PukropR , BerningJ , StammE , et al. A randomised controlled trial of cognitive‐behavioral therapy in the early initial prodromal state of psychosis. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:22‐3. [CSzG: 20193] BechdolfA , WagnerM , VeithV , RuhrmannR , JanssenB , BottlenderR , et al. A randomised controlled multicenter trial of cognitive behaviour therapy in the early initial prodromal state of psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13369] BechdolfA , WagnerM , VeithV , RuhrmannS , PukropR , Brockhaus‐DumkeA , et al. Randomised controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Intervention in Psychiatry2007;1(1):71‐8. [CSzG: 16450] BechdolfA , WesselsH , WagnerM , KuhrK , BerningJ , PutzfeldV , et al. Predictors of treatment response to psychosocial interventions in people at risk. European Archives of Psychiatry and Clinical Neuroscience2015;1:S9. [CSzG: 33601] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] KommescherM , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. Early Intervention in Psychiatry2016;10(1):17‐27. [CSzG: 32187] NCT00204087 . Psychological intervention for persons at risk of psychosis in the early initial prodromal state. www.ClinicalTrials.gov/ct/show/2005. [CSzG: 14890] WesselsH , WagnerM , FrommannI , BerningJ , PutzfeldV , JanssenB , et al. Neuropsychological functioning as a predictor of treatment response to psychoeducational, cognitive behavioral therapy in people at clinical high risk of first episode psychosis. Psychiatrische Praxis2015;42(6):313‐9. [CSzG: 33130] ZarafonitisS , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Psychoeducation for persons at risk of psychosis. Psychotherapeut2012;57(4):326‐34. [CSzG: 24807] ">EIPS‐Germany</a>. </p> </section> <section id="CD012236-sec-0123"> <h6 class="title">2.2 Within the CBT versus different pharmacological or other interventions comparison</h6> <p>There are three included studies (<a href="./references#CD012236-bbs2-0004" title="CrittendenK , FlemingJ , StartupM , CarrV , BakerA , SchallU , et al. Recruitment and engagement of youth in an ultra high risk treatment study. Early Intervention in Psychiatry2008;2(Suppl 1):A127. [CSzG: Ref19115] StainH , BucciS , HalperinS , EmsleyR , ShallU , LewinT , et al. DEPTh: randomised controlled trial of cognitive behavioral therapy for young people at ultra high risk for psychosis. Early Intervention in Psychiatry2014;8:15. [CSzG: Ref29673] StainHJ , BucciS , BakerA , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of CBT for young people at risk for psychosis: the Detection and Evaluation of Psychological Therapy (DEPTh) trial. European Archives of Psychiatry and Clinical Neuroscience2015;1:S8‐9. [CSzG: Ref33810] StainHJ , BucciS , BakerAL , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of cognitive behaviour therapy versus non‐directive reflective listening for young people at ultra high risk of developing psychosis: the detection and evaluation of psychological therapy (DEPTh) trial. Schizophrenia Research2016;176(2‐3):212‐9. [CSzG: Ref35298] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. Rural and urban youth at ultra high risk for psychosis: baseline characteristics from the DEPTh randomised controlled trial of cognitive behavior therapy. Schizophrenia Bulletin2011;37:322. [CSzG: Ref22815] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy for youth at ultra high risk for psychosis: baseline characteristics for rural and urban youth. Australian and New Zealand Journal of Psychiatry2010:25‐6. [CSzG: Ref21845] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy targeting ultra high risk for psychosis: baseline comparisons for rural and urban youth. Early Intervention in Psychiatry2010;4(Suppl 1):113. [CSzG: Ref23498] StainHJ , StartupM , CarrV , BakerA , SchallU . The DEPTh project: a multisite RCT for youths at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S51‐2. [CSzG: Ref13401] StartupM . The DEPTh project: detection, evaluation, and psychological therapy for health. Australian New Zealand Clinical Trials Registry2006. [CszG: Ref18442] ">DEPTh‐Australia</a>; <a href="./references#CD012236-bbs2-0015" title="McGorryP . Can the onset of schizophrenia be delayed or prevented?. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S26. [CSzG: 8351] McGorryP , AdlardS , YungA , McDonaldA , PhillipsL , HearnN . Detection and intervention in pre‐psychotic schizophrenia. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4836] McGorryP , YungA , FranceyS , PhillipsL , NelsonB . A blinded, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and befriending in young people at risk of psychotic disorder: baseline characteristics of the sample. Acta Neuropsychiatrica2006;18(6):261. [CSzG: 35157] McGorryPD , HearnN , GermanoD , BravinJ , PhillipsLJ , YungAR , et al. Prepsychotic intervention in schizophrenia: a stitch in time?. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington DC, USA. 1999. [CSzG: 3584] McGorryPD , PhillipsLJ , NelsonB , LeicesterS , BakerK , KrstevH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and befriending in young people with subthreshold symptoms at incipient risk of psychotic disorder: six month outcome data. Schizophrenia Bulletin2007;33(2):446. [CSzG: 15203] McGorryPD , PhillipsLJ , YungAR , FranceyS , GermanoD , BravinJ , et al. A randomised controlled trial of interventions in the pre psychotic phase of psychotic disorders. Schizophrenia Research2000;41(1):9. [CSzG: 5149] McGorryPD , YungAR , PhillipsL , AdlardS , HallgrenM , PattonG , et al. Pre‐psychotic intervention in schizophrenia: a stitch in time?. Schizophrenia Research1998;29(1‐2):160. [CSzG: 3585] McGorryPD , YungAR , PhillipsLJ , YuenHP , FranceyS , CosgraveEM , et al. Randomised controlled trial of interventions designed to reduce the risk of progression to first‐episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry2002;59(10):921‐8. [CSzG: 8576] PhilippsLJ , McGorryP , YungA , FranceyD , GermanoF , BravinJ , et al. The development of preventive interventions for early psychosis: early findings and directions for the future. 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001; Vol. 2, issue Suppl 1. [CSzG: 7614] PhillipsL , CottonS , YuenHP , MihalopoulosC , ShihS , KellyD , et al. Cost effectiveness of a preventive intervention for young people at ultra high risk of developing psychosis. Schizophrenia Bulletin2007;33(2):488‐9. [CSzG: 15227] PhillipsLJ , CottonS , MihalopoulosC , ShihS , YungAR , CarterR , et al. Cost implications of specific and non‐specific treatment for young persons at ultra high risk of developing a first episode of psychosis. Early Intervention in Psychiatry2009;3(1):28‐34. [CSzG: 18308] PhillipsLJ , LeicesterSB , O'DwyerLE , FranceySM , KoutsogiannisJ , Abdel‐BakiA , et al. The PACE clinic: identification and management of young people at &quot;ultra&quot; high risk of psychosis. Journal of Psychiatric Practice2002;8(5):255‐69. [CSzG: 18235] PhillipsLJ , McGorryPD , YuenHP , WardJ , DonovanK , KellyD , et al. Medium term follow‐up of a randomised controlled trial of interventions for young people at ultra high risk of psychosis. Schizophrenia Research2007;96(1‐3):25‐33. [CSzG: 15544] PhillipsLJ , YungAR , YuenHP , PantelisC , McGorryPD . Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. American Journal of Medical Genetics2002;114(8):929‐37. [CSzG: 18236] ">PACE‐Australia</a>; <a href="./references#CD012236-bbs2-0020" title="McGorryP . Second generation intervention research in the pre‐psychotic phase of illness in schizophrenia and related psychoses. Australian New Zealand Clinical Trials Registry2000. [CSzG: 18439] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceyS , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: 12‐month outcome. Schizophrenia Research2012;136:S17‐8. [CSzG: 29547] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceySM , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: twelve‐month outcome. Journal of Clinical Psychiatry2013;74(4):349‐56. [CSzG: 28737] NelsonB , PhillipsLJ , YungAR , FranceySM , LeicesterS , BakerK , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and supportive therapy in young people with subthreshold symptoms at incipient risk of psychotic disorder: baseline characteristics of the sample. Schizophrenia Bulletin2007;33(2):450. [CSzG: 15212] PhillipsLJ , NelsonB , YuenHP , FranceySM , SimmonsM , StanfordC , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: study design and baseline characteristics. Australian and New Zealand Journal of Psychiatry2009;;43(9):818–29. YungA , AmmingerP , BergerG , ThompsomA , PhillipsL , NelsonB , et al. Randomised controlled trial of antipsychotic and cognitive therapy in young people at ultra‐high risk of psychosis. Early Intervention in Psychiatry2012;6:11. [CSzG: 24989] YungA , NelsonB , PhillipsL , FranceyS , LeicesterS , YuenH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and supportive therapy in young people at ultra high risk of psychotic disorder: 12 month outcome data. Early Intervention in Psychiatry2008;2(Suppl 1):A12. [CSzG: 19138] YungAR , PhillipsLJ , NelsonB , FranceySM , YuenHP , SimmonsMB , et al. Randomised controlled trial of interventions for young people at ultra high risk for psychosis: 6‐month analysis. Journal of Clinical Psychiatry2011;72(4):430‐40. [CSzG: 22929] ">Yung‐Australia</a>). These studies were conducted in Australia, apart from <a href="./references#CD012236-bbs2-0004" title="CrittendenK , FlemingJ , StartupM , CarrV , BakerA , SchallU , et al. Recruitment and engagement of youth in an ultra high risk treatment study. Early Intervention in Psychiatry2008;2(Suppl 1):A127. [CSzG: Ref19115] StainH , BucciS , HalperinS , EmsleyR , ShallU , LewinT , et al. DEPTh: randomised controlled trial of cognitive behavioral therapy for young people at ultra high risk for psychosis. Early Intervention in Psychiatry2014;8:15. [CSzG: Ref29673] StainHJ , BucciS , BakerA , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of CBT for young people at risk for psychosis: the Detection and Evaluation of Psychological Therapy (DEPTh) trial. European Archives of Psychiatry and Clinical Neuroscience2015;1:S8‐9. [CSzG: Ref33810] StainHJ , BucciS , BakerAL , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of cognitive behaviour therapy versus non‐directive reflective listening for young people at ultra high risk of developing psychosis: the detection and evaluation of psychological therapy (DEPTh) trial. Schizophrenia Research2016;176(2‐3):212‐9. [CSzG: Ref35298] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. Rural and urban youth at ultra high risk for psychosis: baseline characteristics from the DEPTh randomised controlled trial of cognitive behavior therapy. Schizophrenia Bulletin2011;37:322. [CSzG: Ref22815] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy for youth at ultra high risk for psychosis: baseline characteristics for rural and urban youth. Australian and New Zealand Journal of Psychiatry2010:25‐6. [CSzG: Ref21845] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy targeting ultra high risk for psychosis: baseline comparisons for rural and urban youth. Early Intervention in Psychiatry2010;4(Suppl 1):113. [CSzG: Ref23498] StainHJ , StartupM , CarrV , BakerA , SchallU . The DEPTh project: a multisite RCT for youths at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S51‐2. [CSzG: Ref13401] StartupM . The DEPTh project: detection, evaluation, and psychological therapy for health. Australian New Zealand Clinical Trials Registry2006. [CszG: Ref18442] ">DEPTh‐Australia</a>, which also included participants from Newcastle, UK. The age of participants was between 14 to 30 years, and they were recruited from clinical settings. All of these studies defined UHR using CAARMS criteria (<a href="./references#CD012236-bbs2-0198" title="YungAR , YuenHP , McGorryPD , PhillipsLJ , KellyD , Dell’OlioM , et al. Mapping the onset of psychosis: the Comprehensive Assessment of At‐Risk Mental States. Australian &amp; New Zealand Journal of Psychiatry2005;39(11‐12):964‐71. ">Yung 2005</a>). </p> </section> <section id="CD012236-sec-0124"> <h6 class="title">2.3 Within the cognitive training versus active control group comparison</h6> <p>There are three included studies (<a href="./references#CD012236-bbs2-0003" title="ChoiJ , CorcoranC , DixonL , FiszdonJ , JavittD . Processing speed training and social functioning in young adults at clinical high risk for psychosis: a pilot study. Early Intervention in Psychiatry2014;8:109. [CSzG: Ref29417] ChoiJ , CorcoranC , DixonL , JavittDC . Processing speed training and social functioning in teenagers and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2015;41:S41. [CSzG: Ref29418] ChoiJ , CorcoranCM , FiszdonJM , StevensM , JavittDC , DeasyM , et al. Pupillometer‐based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis. Psychiatric Rehabilitation Journal2017;40(1):33‐42. [CSzG: Ref35317] ">Choi‐USA</a>; <a href="./references#CD012236-bbs2-0016" title="NCT01619319 . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. ClinicalTrials.gov/show/NCT016193192012. [CSzG: 24387] PiskulicD , BarbatoM , AddingtonJ . Cognitive remediation in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:89. [CSzG: 24973] PiskulicD , BarbatoM , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2012;136:S245‐6. [CSzG: 29632] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2014;153(Suppl. 1):S218. [CSzG: 28827] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation therapy on cognition in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2014;8:86. [CSzG: 29633] ">Piskulic‐Canada</a>; <a href="./references#CD012236-bbs2-0018" title="LoewyR , FisherM , MathalonDH , VinogradovS . Interim analyses of a randomised controlled trial of computerised cognitive training in clinical high risk for psychosis. Schizophrenia Bulletin2013;39:S238‐9. [CSzG: 28151] LoewyR , FisherM , SchlosserDA , BiagiantiB , StuartB , MathalonDH , et al. Intensive auditory cognitive training improves verbal memory in adolescents and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2016;42(Suppl 1):S118‐26. [CSzG: 35221] VinogradovS , LoewyR , FisherM , LeeA , NiendamT , RaglandJD , et al. Neuroplasticity‐based cognitive training in ultra‐high risk adolescents and recent onset patients with schizophrenia. Schizophrenia Research2012;136:S30. [CSzG: 29703] ">Vinogradov‐USA</a>). Ages of participants from these studies ranged between 12 to 35 years, and were recruited from North America (USA or Canada). All three studies made diagnosis using SIPS criteria. <a href="./references#CD012236-bbs2-0003" title="ChoiJ , CorcoranC , DixonL , FiszdonJ , JavittD . Processing speed training and social functioning in young adults at clinical high risk for psychosis: a pilot study. Early Intervention in Psychiatry2014;8:109. [CSzG: Ref29417] ChoiJ , CorcoranC , DixonL , JavittDC . Processing speed training and social functioning in teenagers and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2015;41:S41. [CSzG: Ref29418] ChoiJ , CorcoranCM , FiszdonJM , StevensM , JavittDC , DeasyM , et al. Pupillometer‐based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis. Psychiatric Rehabilitation Journal2017;40(1):33‐42. [CSzG: Ref35317] ">Choi‐USA</a> and <a href="./references#CD012236-bbs2-0016" title="NCT01619319 . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. ClinicalTrials.gov/show/NCT016193192012. [CSzG: 24387] PiskulicD , BarbatoM , AddingtonJ . Cognitive remediation in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:89. [CSzG: 24973] PiskulicD , BarbatoM , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2012;136:S245‐6. [CSzG: 29632] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2014;153(Suppl. 1):S218. [CSzG: 28827] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation therapy on cognition in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2014;8:86. [CSzG: 29633] ">Piskulic‐Canada</a> recruited participants who had been enrolled in other related research and <a href="./references#CD012236-bbs2-0018" title="LoewyR , FisherM , MathalonDH , VinogradovS . Interim analyses of a randomised controlled trial of computerised cognitive training in clinical high risk for psychosis. Schizophrenia Bulletin2013;39:S238‐9. [CSzG: 28151] LoewyR , FisherM , SchlosserDA , BiagiantiB , StuartB , MathalonDH , et al. Intensive auditory cognitive training improves verbal memory in adolescents and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2016;42(Suppl 1):S118‐26. [CSzG: 35221] VinogradovS , LoewyR , FisherM , LeeA , NiendamT , RaglandJD , et al. Neuroplasticity‐based cognitive training in ultra‐high risk adolescents and recent onset patients with schizophrenia. Schizophrenia Research2012;136:S30. [CSzG: 29703] ">Vinogradov‐USA</a> recruited participants from community settings. </p> </section> <section id="CD012236-sec-0125"> <h6 class="title">2.4 Within the family treatment versus enhanced treatment comparison</h6> <p>There are two included studies: (<a href="./references#CD012236-bbs2-0008" title="McFarlaneWR , CookWL , WoodberryKA . A randomised clinical trial of familyaided assertive community treatment for young persons at high risk for onset of an initial psychosis. Schizophrenia Bulletin2011;37:314. [CSzG: Ref22796] NCT01597141 . Psychosis: early detection, intervention and prevention. ClinicalTrials.gov/show/NCT015971412012. [CSzG: Ref24315] ">EDIP‐USA</a>; <a href="./references#CD012236-bbs2-0012" title="MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Family‐focused therapy for individuals at clinical high risk for psychosis: treatment fidelity within a multisite randomised trial. Early Intervention in Psychiatry2016;10(2):137‐43. [CSzG: 29018] MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Treatment fidelity and differentiation in a randomised controlled trial of family‐focused therapy for youth at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:95. [CSzG: 24965] MiklowitzDJ , O'BrienMP , SchlosserDA , AddingtonJ , CandanKA , MarshallC , et al. Family‐focused treatment for adolescents and young adults at high risk for psychosis: results of a randomised trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(8):848‐58. [CSzG: 29019] NCT01907282 . Prevention trial of family focused treatment in youth at risk for psychosis. Clinicaltrials.gov/show/NCT019072822010. [CSzG: 27965] O'BrienMP , MiklowitzDJ , CandanKA , MarshallC , DominguesI , WalshBC , et al. A randomised trial of family focused therapy with populations at clinical high risk for psychosis: effects on interactional behavior. Journal of Consulting and Clinical Psychology2013;82(1):90‐101. [CSzG: 28565] O'BrienMP , MiklowitzDJ , CannonTD . Decreases in perceived maternal criticism predict improvement in subthreshold psychotic symptoms in a randomised trial of family‐focused therapy for individuals at clinical high risk for psychosis. Journal of Family Psychology2015;29(6):945–951.. [CSzG: 32212] SchlosserDA , MiklowitzDJ , O'BrienMP , DeSilvaSD , ZinbergJL , CannonTD . A randomised trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Intervention in Psychiatry2012;6(3):283‐91. [CSzG: 24491] ">Miklowitz‐USA</a>). <a href="./references#CD012236-bbs2-0008" title="McFarlaneWR , CookWL , WoodberryKA . A randomised clinical trial of familyaided assertive community treatment for young persons at high risk for onset of an initial psychosis. Schizophrenia Bulletin2011;37:314. [CSzG: Ref22796] NCT01597141 . Psychosis: early detection, intervention and prevention. ClinicalTrials.gov/show/NCT015971412012. [CSzG: Ref24315] ">EDIP‐USA</a> took place in Portland, USA and <a href="./references#CD012236-bbs2-0012" title="MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Family‐focused therapy for individuals at clinical high risk for psychosis: treatment fidelity within a multisite randomised trial. Early Intervention in Psychiatry2016;10(2):137‐43. [CSzG: 29018] MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Treatment fidelity and differentiation in a randomised controlled trial of family‐focused therapy for youth at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:95. [CSzG: 24965] MiklowitzDJ , O'BrienMP , SchlosserDA , AddingtonJ , CandanKA , MarshallC , et al. Family‐focused treatment for adolescents and young adults at high risk for psychosis: results of a randomised trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(8):848‐58. [CSzG: 29019] NCT01907282 . Prevention trial of family focused treatment in youth at risk for psychosis. Clinicaltrials.gov/show/NCT019072822010. [CSzG: 27965] O'BrienMP , MiklowitzDJ , CandanKA , MarshallC , DominguesI , WalshBC , et al. A randomised trial of family focused therapy with populations at clinical high risk for psychosis: effects on interactional behavior. Journal of Consulting and Clinical Psychology2013;82(1):90‐101. [CSzG: 28565] O'BrienMP , MiklowitzDJ , CannonTD . Decreases in perceived maternal criticism predict improvement in subthreshold psychotic symptoms in a randomised trial of family‐focused therapy for individuals at clinical high risk for psychosis. Journal of Family Psychology2015;29(6):945–951.. [CSzG: 32212] SchlosserDA , MiklowitzDJ , O'BrienMP , DeSilvaSD , ZinbergJL , CannonTD . A randomised trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Intervention in Psychiatry2012;6(3):283‐91. [CSzG: 24491] ">Miklowitz‐USA</a> undertook research in multiple states in the USA and Canada. Participants were aged between 12 to 35 years, and SIPS criteria was used to define CHR. Both studies recruited participants who had been enrolled in previous related studies. </p> </section> <section id="CD012236-sec-0126"> <h6 class="title">2.5 Within the integrated treatment versus standard treatment comparison</h6> <p>There is one study included in this comparison. <a href="./references#CD012236-bbs2-0014" title="NordentoftM , JeppesenP , PetersenL , ThorupA , OhlenschlaegerJ , ChristensenT , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. European Psychiatry2007;22:S129‐S. [CSzG: 20471] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the OPUS trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;83(1):29‐40. [CSzG: 13197] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;86(Suppl 1):S44. [CSzG: 13393] ">Nordentoft‐Denmark</a> was conducted in inpatient and outpatient mental health services in Copenhagen and Aarhus County, Denmark. Participants met criteria for schizotypal disorder (ICD‐10) and had a mean age of 24.9 years. </p> </section> <section id="CD012236-sec-0127"> <h6 class="title">2.6 Within the antipsychotic drugs comparison</h6> <p>There are two included studies (<a href="./references#CD012236-bbs2-0011" title="BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: 12511] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] RuhrmannS , BechdolfA , KuhnKU , WagnerM , Schultze‐LutterF Janssen B , et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry. Supplements2007;51:s88‐95. [CSzG: 16127] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Acute symptomatic treatment effects in persons clinically at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13397] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Intervention in the late initial prodromal state (LIPS) of psychosis. Schizophrenia Research2006;86(Suppl 1):S96. [CSzG: 13398] ">LIPS‐Germany</a>; <a href="./references#CD012236-bbs2-0017" title='BlockJJ , McGlashonTH . Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790‐9. American Journal of Psychiatry2006; Vol. 163, issue 10:1838. [CSzG: 13960] BreierAF , ZipurskyRB , PerkinsDO , AddingtonJM , TohenMF , DavidSR , et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951] HawkinsKA , AddingtonJ , KeefeR , ChristensenB , WoodsS , ZipurskyR , et al. Neuropsychological functioning in the first episode prodrome and early psychosis. Schizophrenia Research2004;70(1):101. [CSzG: 11515] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , MillerTJ , et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research2004;67(1):205. [CSzG: Ref11301] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , ZipurskyRB , et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. [CSzG: 16470] HawkinsKA , KeefeRS , ChristensenBK , AddingtonJ , WoodsSW , CallahanJ , et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. Schizophrenia Research2008;105(1‐3):1‐9. [CSzG: 16983] HoffmanRE , WoodsS , PredaA , TohenM , BreierA , GlistJ , et al. Excessive top‐down perceptual processing and reduced real‐world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. Schizophrenia Research2006;86(Suppl 1):S46. [CSzG: 13377] HoffmanRE , WoodsSW , HawkinsKA , PittmanB , TohenM , PredaA , et al. Extracting spurious messages from noise and risk of schizophrenia‐spectrum disorders in prodromal population. British Journal of Psychiatry2007;191(2):355‐6. [CSzG: 16068] McGlashanT , ZipurskyR , PerkinsD , AddingtonJ . Olanzapine for treatment of the schizophrenia prodrome: 2‐year results of a randomised placebo‐controlled study. Schizophrenia Research2004;67(1):164. [CSzG: 11320] McGlashanTH . Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. [CSzG: 10191] McGlashanTH . Treatment intervention in the New Haven PRIME clinic prodromal sample. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4835] McGlashanTH , MillerTJ , WoodsSW . Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research2002;53(3 Suppl 1):15. [CSzG: 8093] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005] McGlashanTH , MillerTJ , ZipurskyRB , WoodsSW , PerkinsDO , HawkinsKA , et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9803] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerT , WoodsSW , et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry2006;163(5):790‐9. [CSzG: 12654] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerTJ , WoodsSW , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research2003;61(1):7‐18. [CSzG: 9828] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJ , WoodsSW , MillerTJ , et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research2003;60:295. [CSzG: 9722] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJM , WoodsSW , LindborgS , et al. Olanzapine versus pbo for the schizophrenic prodrome: one‐year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9804] McGlashlanTH , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTH , WoodsSW , et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:42. [CSzG: 8934] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , MillerT , WoodsS , et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. Schizophrenia Research2004;70(1):6. [CSzG: 11524] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , WoodsS , MillerT , et al. Olanzapine vs. placebo for prodromal schizophrenia. Schizophrenia Research2004;67(1):6. [CSzG: 11321] MillerTJ , ZipurskyRB , PerkinsD , AddingtonJ , WoodsSW , HawkinsKA , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research2003;61(1):19‐30. [CSzG: 9829] RosenJL , WoodsSW , MillerTJ , McGlashanTH . Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease2002;190:133‐41. [CSzG: 8274] TaylorHE , ParkerS , MansellW , MorrisonAP . Effects of appraisals of anomalous experience on distress in people at risk of psychosis. Behavioural and Cognitive Psychotherapy2012;41(1):24‐33. [CSzG: 24374] WoodsS , ZipurskyR , PerkinsD , AddingtonJ , MarquezE , BreierA , et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:43. [CSzG: 8933] WoodsSW . Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):497. [CSzG: 19829] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research. 2003. [CSzG: 9978] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research2003;60:306‐7. [CSzG: 9752] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):453‐64. [CSzG: 9994] WoodsSW , McGlashanTH . Sample size planning for prodromal intervention trials. Schizophrenia Research2002;53(3 Suppl 1):40. [CSzG: 8116] WoodsSW , ZipurskyRB , PerkinsDO , AddingtonJM , MillerTJ , BreierAF , et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053] '>PRIME‐USA</a>). <a href="./references#CD012236-bbs2-0011" title="BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: 12511] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] RuhrmannS , BechdolfA , KuhnKU , WagnerM , Schultze‐LutterF Janssen B , et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry. Supplements2007;51:s88‐95. [CSzG: 16127] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Acute symptomatic treatment effects in persons clinically at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13397] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Intervention in the late initial prodromal state (LIPS) of psychosis. Schizophrenia Research2006;86(Suppl 1):S96. [CSzG: 13398] ">LIPS‐Germany</a> recruited participants in community settings in Cologne, Bonn, Dusseldorf and Munich, whilst <a href="./references#CD012236-bbs2-0017" title='BlockJJ , McGlashonTH . Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790‐9. American Journal of Psychiatry2006; Vol. 163, issue 10:1838. [CSzG: 13960] BreierAF , ZipurskyRB , PerkinsDO , AddingtonJM , TohenMF , DavidSR , et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951] HawkinsKA , AddingtonJ , KeefeR , ChristensenB , WoodsS , ZipurskyR , et al. Neuropsychological functioning in the first episode prodrome and early psychosis. Schizophrenia Research2004;70(1):101. [CSzG: 11515] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , MillerTJ , et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research2004;67(1):205. [CSzG: Ref11301] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , ZipurskyRB , et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. [CSzG: 16470] HawkinsKA , KeefeRS , ChristensenBK , AddingtonJ , WoodsSW , CallahanJ , et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. Schizophrenia Research2008;105(1‐3):1‐9. [CSzG: 16983] HoffmanRE , WoodsS , PredaA , TohenM , BreierA , GlistJ , et al. Excessive top‐down perceptual processing and reduced real‐world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. Schizophrenia Research2006;86(Suppl 1):S46. [CSzG: 13377] HoffmanRE , WoodsSW , HawkinsKA , PittmanB , TohenM , PredaA , et al. Extracting spurious messages from noise and risk of schizophrenia‐spectrum disorders in prodromal population. British Journal of Psychiatry2007;191(2):355‐6. [CSzG: 16068] McGlashanT , ZipurskyR , PerkinsD , AddingtonJ . Olanzapine for treatment of the schizophrenia prodrome: 2‐year results of a randomised placebo‐controlled study. Schizophrenia Research2004;67(1):164. [CSzG: 11320] McGlashanTH . Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. [CSzG: 10191] McGlashanTH . Treatment intervention in the New Haven PRIME clinic prodromal sample. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4835] McGlashanTH , MillerTJ , WoodsSW . Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research2002;53(3 Suppl 1):15. [CSzG: 8093] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005] McGlashanTH , MillerTJ , ZipurskyRB , WoodsSW , PerkinsDO , HawkinsKA , et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9803] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerT , WoodsSW , et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry2006;163(5):790‐9. [CSzG: 12654] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerTJ , WoodsSW , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research2003;61(1):7‐18. [CSzG: 9828] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJ , WoodsSW , MillerTJ , et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research2003;60:295. [CSzG: 9722] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJM , WoodsSW , LindborgS , et al. Olanzapine versus pbo for the schizophrenic prodrome: one‐year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9804] McGlashlanTH , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTH , WoodsSW , et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:42. [CSzG: 8934] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , MillerT , WoodsS , et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. Schizophrenia Research2004;70(1):6. [CSzG: 11524] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , WoodsS , MillerT , et al. Olanzapine vs. placebo for prodromal schizophrenia. Schizophrenia Research2004;67(1):6. [CSzG: 11321] MillerTJ , ZipurskyRB , PerkinsD , AddingtonJ , WoodsSW , HawkinsKA , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research2003;61(1):19‐30. [CSzG: 9829] RosenJL , WoodsSW , MillerTJ , McGlashanTH . Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease2002;190:133‐41. [CSzG: 8274] TaylorHE , ParkerS , MansellW , MorrisonAP . Effects of appraisals of anomalous experience on distress in people at risk of psychosis. Behavioural and Cognitive Psychotherapy2012;41(1):24‐33. [CSzG: 24374] WoodsS , ZipurskyR , PerkinsD , AddingtonJ , MarquezE , BreierA , et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:43. [CSzG: 8933] WoodsSW . Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):497. [CSzG: 19829] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research. 2003. [CSzG: 9978] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research2003;60:306‐7. [CSzG: 9752] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):453‐64. [CSzG: 9994] WoodsSW , McGlashanTH . Sample size planning for prodromal intervention trials. Schizophrenia Research2002;53(3 Suppl 1):40. [CSzG: 8116] WoodsSW , ZipurskyRB , PerkinsDO , AddingtonJM , MillerTJ , BreierAF , et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053] '>PRIME‐USA</a> recruited treatment‐seeking patients in an outpatient setting in New Haven and North Carolina (USA) and Calgary and Toronto (Canada). The age range of participants was 18 to 36 years for <a href="./references#CD012236-bbs2-0011" title="BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: 12511] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] RuhrmannS , BechdolfA , KuhnKU , WagnerM , Schultze‐LutterF Janssen B , et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry. Supplements2007;51:s88‐95. [CSzG: 16127] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Acute symptomatic treatment effects in persons clinically at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13397] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Intervention in the late initial prodromal state (LIPS) of psychosis. Schizophrenia Research2006;86(Suppl 1):S96. [CSzG: 13398] ">LIPS‐Germany</a> and 12 to 45 years for <a href="./references#CD012236-bbs2-0017" title='BlockJJ , McGlashonTH . Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790‐9. American Journal of Psychiatry2006; Vol. 163, issue 10:1838. [CSzG: 13960] BreierAF , ZipurskyRB , PerkinsDO , AddingtonJM , TohenMF , DavidSR , et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951] HawkinsKA , AddingtonJ , KeefeR , ChristensenB , WoodsS , ZipurskyR , et al. Neuropsychological functioning in the first episode prodrome and early psychosis. Schizophrenia Research2004;70(1):101. [CSzG: 11515] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , MillerTJ , et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research2004;67(1):205. [CSzG: Ref11301] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , ZipurskyRB , et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. [CSzG: 16470] HawkinsKA , KeefeRS , ChristensenBK , AddingtonJ , WoodsSW , CallahanJ , et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. Schizophrenia Research2008;105(1‐3):1‐9. [CSzG: 16983] HoffmanRE , WoodsS , PredaA , TohenM , BreierA , GlistJ , et al. Excessive top‐down perceptual processing and reduced real‐world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. Schizophrenia Research2006;86(Suppl 1):S46. [CSzG: 13377] HoffmanRE , WoodsSW , HawkinsKA , PittmanB , TohenM , PredaA , et al. Extracting spurious messages from noise and risk of schizophrenia‐spectrum disorders in prodromal population. British Journal of Psychiatry2007;191(2):355‐6. [CSzG: 16068] McGlashanT , ZipurskyR , PerkinsD , AddingtonJ . Olanzapine for treatment of the schizophrenia prodrome: 2‐year results of a randomised placebo‐controlled study. Schizophrenia Research2004;67(1):164. [CSzG: 11320] McGlashanTH . Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. [CSzG: 10191] McGlashanTH . Treatment intervention in the New Haven PRIME clinic prodromal sample. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4835] McGlashanTH , MillerTJ , WoodsSW . Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research2002;53(3 Suppl 1):15. [CSzG: 8093] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005] McGlashanTH , MillerTJ , ZipurskyRB , WoodsSW , PerkinsDO , HawkinsKA , et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9803] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerT , WoodsSW , et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry2006;163(5):790‐9. [CSzG: 12654] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerTJ , WoodsSW , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research2003;61(1):7‐18. [CSzG: 9828] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJ , WoodsSW , MillerTJ , et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research2003;60:295. [CSzG: 9722] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJM , WoodsSW , LindborgS , et al. Olanzapine versus pbo for the schizophrenic prodrome: one‐year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9804] McGlashlanTH , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTH , WoodsSW , et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:42. [CSzG: 8934] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , MillerT , WoodsS , et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. Schizophrenia Research2004;70(1):6. [CSzG: 11524] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , WoodsS , MillerT , et al. Olanzapine vs. placebo for prodromal schizophrenia. Schizophrenia Research2004;67(1):6. [CSzG: 11321] MillerTJ , ZipurskyRB , PerkinsD , AddingtonJ , WoodsSW , HawkinsKA , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research2003;61(1):19‐30. [CSzG: 9829] RosenJL , WoodsSW , MillerTJ , McGlashanTH . Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease2002;190:133‐41. [CSzG: 8274] TaylorHE , ParkerS , MansellW , MorrisonAP . Effects of appraisals of anomalous experience on distress in people at risk of psychosis. Behavioural and Cognitive Psychotherapy2012;41(1):24‐33. [CSzG: 24374] WoodsS , ZipurskyR , PerkinsD , AddingtonJ , MarquezE , BreierA , et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:43. [CSzG: 8933] WoodsSW . Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):497. [CSzG: 19829] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research. 2003. [CSzG: 9978] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research2003;60:306‐7. [CSzG: 9752] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):453‐64. [CSzG: 9994] WoodsSW , McGlashanTH . Sample size planning for prodromal intervention trials. Schizophrenia Research2002;53(3 Suppl 1):40. [CSzG: 8116] WoodsSW , ZipurskyRB , PerkinsDO , AddingtonJM , MillerTJ , BreierAF , et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053] '>PRIME‐USA</a>. The participants for <a href="./references#CD012236-bbs2-0011" title="BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: 12511] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] RuhrmannS , BechdolfA , KuhnKU , WagnerM , Schultze‐LutterF Janssen B , et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry. Supplements2007;51:s88‐95. [CSzG: 16127] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Acute symptomatic treatment effects in persons clinically at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13397] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Intervention in the late initial prodromal state (LIPS) of psychosis. Schizophrenia Research2006;86(Suppl 1):S96. [CSzG: 13398] ">LIPS‐Germany</a> fulfilled the Basic Symptom criteria for either the Early Initial Prodrome State or Late Initial Prodrome State. The participants for <a href="./references#CD012236-bbs2-0017" title='BlockJJ , McGlashonTH . Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790‐9. American Journal of Psychiatry2006; Vol. 163, issue 10:1838. [CSzG: 13960] BreierAF , ZipurskyRB , PerkinsDO , AddingtonJM , TohenMF , DavidSR , et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951] HawkinsKA , AddingtonJ , KeefeR , ChristensenB , WoodsS , ZipurskyR , et al. Neuropsychological functioning in the first episode prodrome and early psychosis. Schizophrenia Research2004;70(1):101. [CSzG: 11515] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , MillerTJ , et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research2004;67(1):205. [CSzG: Ref11301] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , ZipurskyRB , et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. [CSzG: 16470] HawkinsKA , KeefeRS , ChristensenBK , AddingtonJ , WoodsSW , CallahanJ , et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. Schizophrenia Research2008;105(1‐3):1‐9. [CSzG: 16983] HoffmanRE , WoodsS , PredaA , TohenM , BreierA , GlistJ , et al. Excessive top‐down perceptual processing and reduced real‐world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. Schizophrenia Research2006;86(Suppl 1):S46. [CSzG: 13377] HoffmanRE , WoodsSW , HawkinsKA , PittmanB , TohenM , PredaA , et al. Extracting spurious messages from noise and risk of schizophrenia‐spectrum disorders in prodromal population. British Journal of Psychiatry2007;191(2):355‐6. [CSzG: 16068] McGlashanT , ZipurskyR , PerkinsD , AddingtonJ . Olanzapine for treatment of the schizophrenia prodrome: 2‐year results of a randomised placebo‐controlled study. Schizophrenia Research2004;67(1):164. [CSzG: 11320] McGlashanTH . Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. [CSzG: 10191] McGlashanTH . Treatment intervention in the New Haven PRIME clinic prodromal sample. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4835] McGlashanTH , MillerTJ , WoodsSW . Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research2002;53(3 Suppl 1):15. [CSzG: 8093] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005] McGlashanTH , MillerTJ , ZipurskyRB , WoodsSW , PerkinsDO , HawkinsKA , et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9803] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerT , WoodsSW , et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry2006;163(5):790‐9. [CSzG: 12654] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerTJ , WoodsSW , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research2003;61(1):7‐18. [CSzG: 9828] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJ , WoodsSW , MillerTJ , et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research2003;60:295. [CSzG: 9722] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJM , WoodsSW , LindborgS , et al. Olanzapine versus pbo for the schizophrenic prodrome: one‐year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9804] McGlashlanTH , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTH , WoodsSW , et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:42. [CSzG: 8934] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , MillerT , WoodsS , et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. Schizophrenia Research2004;70(1):6. [CSzG: 11524] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , WoodsS , MillerT , et al. Olanzapine vs. placebo for prodromal schizophrenia. Schizophrenia Research2004;67(1):6. [CSzG: 11321] MillerTJ , ZipurskyRB , PerkinsD , AddingtonJ , WoodsSW , HawkinsKA , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research2003;61(1):19‐30. [CSzG: 9829] RosenJL , WoodsSW , MillerTJ , McGlashanTH . Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease2002;190:133‐41. [CSzG: 8274] TaylorHE , ParkerS , MansellW , MorrisonAP . Effects of appraisals of anomalous experience on distress in people at risk of psychosis. Behavioural and Cognitive Psychotherapy2012;41(1):24‐33. [CSzG: 24374] WoodsS , ZipurskyR , PerkinsD , AddingtonJ , MarquezE , BreierA , et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:43. [CSzG: 8933] WoodsSW . Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):497. [CSzG: 19829] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research. 2003. [CSzG: 9978] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research2003;60:306‐7. [CSzG: 9752] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):453‐64. [CSzG: 9994] WoodsSW , McGlashanTH . Sample size planning for prodromal intervention trials. Schizophrenia Research2002;53(3 Suppl 1):40. [CSzG: 8116] WoodsSW , ZipurskyRB , PerkinsDO , AddingtonJM , MillerTJ , BreierAF , et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053] '>PRIME‐USA</a> fulfilled SIPS criteria. </p> </section> <section id="CD012236-sec-0128"> <h6 class="title">2.7 Within the different nutritives/supplements versus alternative medication comparison</h6> <p>There are four included studies (<a href="./references#CD012236-bbs2-0002" title="AmmingerG . Ethyl eicosapentanoic acid for prodromal psychosis. Stanley Foundation Research Programs2009. [CSzG: Ref17423] AmmingerG , SchaferM , PapageorgiouK , CottonS , HarriganS , MackinnonA , et al. Indicated prevention with long‐chain omega‐3 fatty acids in adolescents at ultra‐high‐risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2008;2(Suppl 1):A29. [CSzG: Ref19107] AmmingerGP , ChanenAM , OhmannS , KlierCM , MossahebN , BechdolfA , et al. Omega‐3 fatty acid supplementation in adolescents with borderline personality disorder and ultra‐high risk criteria for psychosis: a post hoc subgroup analysis of a double‐blind, randomised controlled trial. Canadian Journal of Psychiatry2013;58(7):402‐8. [CSzG: Ref28534] AmmingerGP , HarrisMS , McGorryPD , HenryLP . Omega‐3 fatty acids for indicated prevention: treatment results and pathomechanisms. European Archives of Psychiatry and Clinical Neuroscience2013;263(Suppl. 1):S44‐5. [CSzG: Ref28434] AmmingerGP , LeicesterS , YungAR , YuenHP , McGorryPD . Age predicts transition to psychosis in an ultra‐high risk sample. Proceedings of the 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:61. AmmingerGP , McGorryPD . Update on omega‐3 polyunsaturated fatty acids in early ‐stage psychotic disorders. Neuropsychopharmacology2012;37(1):309‐10. [CSzG: Ref23726] AmmingerGP , MechelliA , RiceS , KimSW , KlierCM , McNamaraRK , et al. Predictors of treatment response in young people at ultra‐high risk for psychosis who received long‐chain omega‐3 fatty acids. Translational Psychiatry2015;5:e495. [CSzG: Ref29299] AmmingerGP , SchaferMR . Indicated prevention with omega‐3 fatty acids in adolescents at ultra‐high risk for psychosis ‐ rationale, methods, and 3‐months outcome. Schizophrenia Research2006;86(Suppl 1):S97‐8. [CSzG: Ref13367] AmmingerGP , SchaferMR . Is it feasible to conduct a RCT in ultra‐high risk individuals at a child and adolescent psychiatric service?. Schizophrenia Research2006;86(Suppl 1):S98. [CSzG: Ref13368] AmmingerGP , SchaferMR , KlierCM , PapageorgiouK , SlavikJ , HolzerI , et al. Indicated prevention with long‐chain omega‐3 fatty acids in young people at ultra‐high risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2010;4(Suppl 1):7. [CSzG: Ref23467] AmmingerGP , SchaferMR , SchlogelhoferM , KlierCM , McGorryPD . Longer‐term outcome in the prevention of psychotic disorders by the Vienna omega‐3 study. Nature Communications2015;6:7934. [CSzG: Ref33023] AmmingerGP , SchlogelhoferM , KlierC , McGorryP , SchaferM . Longer‐term follow‐up in the Vienna omega‐3 psychosis prevention trial. Early Intervention in Psychiatry2014;8:41. [CSzG: Ref29378] AmmingerGP , SchäferMR , PapageorgiouK , KlierCM , CottonSM , HarriganSM , et al. Long‐chain omega‐3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo‐controlled trial. Archives of General Psychiatry2010;67(2):146‐54. [CSzG: Ref20680; DOI: 10.1001/archgenpsychiatry.2009.192.] AmmingerP , MossahebN , SchlgelhoferM , SchaferM . Fatty acid metabolism and the onset of psychotic disorder. European Psychiatry2011;26(Suppl 1):2089. [CSzG: Ref22967] Anonymous . Fish oil may help ward off psychosis. Journal of Psychosocial Nursing and Mental Health Services2010;48(5):55. [CSzG: Ref20739] BergerG , AmmingerP , McGorryP . Stage dependant effect of omega‐3 fatty acids in emerging psychosis. European Psychiatry2011;26(Suppl 1):1347. [CSzG: Ref22966] BergerGE , ProffittTM , McConchieM , YuenH , WoodSJ , AmmingerGP , et al. Ethyl‐eicosapentaenoic acid in first‐episode psychosis: a randomised, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(12):1867‐75. [CSzG: Ref15561; ISSN: 1555‐2101] EhrlichA . Evidence‐based medicine. Omega‐3 supplementation delays transition to psychotic disorder in ultra‐high‐risk adolescents and young adults. Clinical Advisor for Nurse Practitioners2010;13(5):79‐80. [CSzG: Ref21562] FöckingM , DickerP , LopezLM , CannonM , SchäferMR , McGorryPD , et al. Differential expression of the inflammation marker IL12p40 in the at‐risk mental state for psychosis: a predictor of transition to psychotic disorder?. BMC Psychiatry2016;16(1):326. [DOI: 10.1186/s12888‐016‐1039‐7] KlierC , HollmannM , SchlögelhoferM , MossahebN , FriedrichM , AmmingerPG . Indicated prevention with omega‐3 fatty acids (EPA/DHA) in adolescents with &quot;at‐risk‐mental‐state“ for psychosis. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. [CSzG: Ref12438] LavoieS , BenningerF , FeuchtM , KlierCM , SchaeferMR , AmmingerGP . Correlates of EEG resting states with erythrocyte membrane omega‐3 fatty acid levels and psychopathological symptoms in individuals at ultra‐high risk for psychosis. Early Intervention in Psychiatry2014;8:137. [CSzG: Ref29516] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultra‐high risk individuals who transitioned to psychosis. Schizophrenia Research2012;138(2‐3):206‐11. [CSzG: Ref24256] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultrahigh risk individuals who transitioned to psychosis. Early Intervention in Psychiatry2012;6:38. [CSzG: Ref24960] MossahebN , PapageorgiouK , SchaferMR , BeckerJ , SchloegelhoferM , AmmingerGP . Changes in triglyceride levels in ultra‐high risk for psychosis individuals treated with omega‐3 fatty acids. Early Intervention in Psychiatry2018; Vol. 12, issue 1:30‐36. [DOI: 10.1111/eip.12275] MossahebN , SchaferMR , SchlogelhoferM , KlierCM , CottonSM , McGorryPD , et al. Effect of omega‐3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?. Schizophrenia Research2013;148(1‐3):163‐7. [CSzG: Ref28649] NCT00396643 . Indicated prevention with omega‐3 fatty acids in adolescents with ‘at‐risk‐mental‐state’ for psychosis: a randomised, double blind, placebo‐controlled treatment trial. www.ClinicalTrials.gov/ct/show/2006. [CSzG: Ref14873] PapageorgiouK , SchaferMR , SchlogelhoferM , MossahebN , AmmingerGP . Indicated prevention with omega‐3 fatty acids in young people with 'at‐risk‐mental‐state' for psychosis: design of a 5‐year follow‐up. European Archives of Psychiatry and Clinical Neuroscience2011;261:S55. [CSzG: Ref23749] SchaferMR , KlierCM , PapageorgiouK , FriedrichMH , AmmingerGP . Early detection of psychotic disorders. Neuropsychiatrie2007;21(1):37‐44. [CSzG: Ref15290] SmesnyS , MilleitB , HiplerUC , MilleitC , SchaferMR , KlierCM , et al. Omega‐3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra‐high risk for psychosis. Molecular Psychiatry2013;19(3):317‐24. [CSzG: Ref28243] SmesnyS , MilleitB , SchaeferMR , HesseJ , SchlögelhoferM , LangbeinK , et al. Effects of omega‐3 PUFA on immune markers in adolescent individuals at ultra‐high risk for psychosis ‐ results of the randomised controlled Vienna omega‐3 study. Schizophrenia Research2017;S0920‐9964(17):30039‐7. [DOI: 10.1016/j.schres.2017.01.026] ">Amminger‐Austria</a>; <a href="./references#CD012236-bbs2-0010" title="KantrowitzJT , WoodsSW , PetkovaE , CornblattB , CorcoranCM , ChenH , et al. D‐serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double‐blind, placebo‐controlled, randomised parallel group mechanistic proof‐of‐concept trial. Lancet Psychiatry2015;2(5):403‐12. [CSzG: 29487] NCT00826202 . D‐serine for the schizophrenia prodrome. www.ClinicalTrials.gov/ct/show/2009. [CSzG: 17391] ">Kantrowitz‐USA</a>; <a href="./references#CD012236-bbs2-0013" title="ACTRN12608000475347 . A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder. Australian New Zealand Clinical Trials Registry2009. [CSzG: 18420] HKCTR‐1438 . The NEURAPRO‐E (North America, EURope, Australia PROdrome) Study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for symptomatic patients at ultra‐high risk for early progression to schizophrenia and other psychotic disorders. www.hkClinicaltrials.com/trial_details.aspx?trialID=d09bd177‐b9fd‐4162‐b04f‐3ebfed49baa32011. [CSzG: 29270] McGorryP , MarkulevC , NelsonB , YuenHP , SchaeferM , YungAR , et al. The NEURAPRO‐E study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Schizophrenia Bulletin2015;41:S322‐3. [CSzG: 29546] McGorryPD , NelsonB , MarkulevC , YuenHP , SchaferMR , MossahebN , et al. Effect of omega‐3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomised clinical trial. JAMA psychiatry2017;74(1):19‐27. [CSzG: 35590] NelsonB , AmmingerG , MarkulevC , YuenHP , LavoieS , SchaeferM , et al. NEURAPOR: a multi‐center RCT of omega‐3 polyunsaturated fatty acids versus placebo in young people at ultra‐high risk of psychotic disorders: medium‐term outcome. Schizophrenia Bulletin2017;43:S107. [CSzG: 36016] ">NEURAPRO‐AAE</a>; <a href="./references#CD012236-bbs2-0019" title="NCT00291226 . Glycine vs Placebo for the Schizophrenia Prodrome. www.ClinicalTrials.gov/ct/show/2006. [CSzG: 14759] WoodsS , WalshB , HawkinsK , MillerT , SaksaJ , D'SouzaD , et al. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. Early Intervention in Psychiatry2012;6:29. [CSzG: 24987] WoodsSW , KantrowitzJT , JavittDC . NMDAR‐based treatments for patients at clinical high risk for psychosis. Biological Psychiatry2014;1:11S. [CSzG: 29041] WoodsSW , WalshBC , HawkinsKA , MillerTJ , SaksaJR , D'SouzaDC , et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. European Neuropsychopharmacology2013;23(8):931‐40. [CSzG: 28750] ">Woods‐1‐USA</a>). <a href="./references#CD012236-bbs2-0002" title="AmmingerG . Ethyl eicosapentanoic acid for prodromal psychosis. Stanley Foundation Research Programs2009. [CSzG: Ref17423] AmmingerG , SchaferM , PapageorgiouK , CottonS , HarriganS , MackinnonA , et al. Indicated prevention with long‐chain omega‐3 fatty acids in adolescents at ultra‐high‐risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2008;2(Suppl 1):A29. [CSzG: Ref19107] AmmingerGP , ChanenAM , OhmannS , KlierCM , MossahebN , BechdolfA , et al. Omega‐3 fatty acid supplementation in adolescents with borderline personality disorder and ultra‐high risk criteria for psychosis: a post hoc subgroup analysis of a double‐blind, randomised controlled trial. Canadian Journal of Psychiatry2013;58(7):402‐8. [CSzG: Ref28534] AmmingerGP , HarrisMS , McGorryPD , HenryLP . Omega‐3 fatty acids for indicated prevention: treatment results and pathomechanisms. European Archives of Psychiatry and Clinical Neuroscience2013;263(Suppl. 1):S44‐5. [CSzG: Ref28434] AmmingerGP , LeicesterS , YungAR , YuenHP , McGorryPD . Age predicts transition to psychosis in an ultra‐high risk sample. Proceedings of the 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:61. AmmingerGP , McGorryPD . Update on omega‐3 polyunsaturated fatty acids in early ‐stage psychotic disorders. Neuropsychopharmacology2012;37(1):309‐10. [CSzG: Ref23726] AmmingerGP , MechelliA , RiceS , KimSW , KlierCM , McNamaraRK , et al. Predictors of treatment response in young people at ultra‐high risk for psychosis who received long‐chain omega‐3 fatty acids. Translational Psychiatry2015;5:e495. [CSzG: Ref29299] AmmingerGP , SchaferMR . Indicated prevention with omega‐3 fatty acids in adolescents at ultra‐high risk for psychosis ‐ rationale, methods, and 3‐months outcome. Schizophrenia Research2006;86(Suppl 1):S97‐8. [CSzG: Ref13367] AmmingerGP , SchaferMR . Is it feasible to conduct a RCT in ultra‐high risk individuals at a child and adolescent psychiatric service?. Schizophrenia Research2006;86(Suppl 1):S98. [CSzG: Ref13368] AmmingerGP , SchaferMR , KlierCM , PapageorgiouK , SlavikJ , HolzerI , et al. Indicated prevention with long‐chain omega‐3 fatty acids in young people at ultra‐high risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2010;4(Suppl 1):7. [CSzG: Ref23467] AmmingerGP , SchaferMR , SchlogelhoferM , KlierCM , McGorryPD . Longer‐term outcome in the prevention of psychotic disorders by the Vienna omega‐3 study. Nature Communications2015;6:7934. [CSzG: Ref33023] AmmingerGP , SchlogelhoferM , KlierC , McGorryP , SchaferM . Longer‐term follow‐up in the Vienna omega‐3 psychosis prevention trial. Early Intervention in Psychiatry2014;8:41. [CSzG: Ref29378] AmmingerGP , SchäferMR , PapageorgiouK , KlierCM , CottonSM , HarriganSM , et al. Long‐chain omega‐3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo‐controlled trial. Archives of General Psychiatry2010;67(2):146‐54. [CSzG: Ref20680; DOI: 10.1001/archgenpsychiatry.2009.192.] AmmingerP , MossahebN , SchlgelhoferM , SchaferM . Fatty acid metabolism and the onset of psychotic disorder. European Psychiatry2011;26(Suppl 1):2089. [CSzG: Ref22967] Anonymous . Fish oil may help ward off psychosis. Journal of Psychosocial Nursing and Mental Health Services2010;48(5):55. [CSzG: Ref20739] BergerG , AmmingerP , McGorryP . Stage dependant effect of omega‐3 fatty acids in emerging psychosis. European Psychiatry2011;26(Suppl 1):1347. [CSzG: Ref22966] BergerGE , ProffittTM , McConchieM , YuenH , WoodSJ , AmmingerGP , et al. Ethyl‐eicosapentaenoic acid in first‐episode psychosis: a randomised, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(12):1867‐75. [CSzG: Ref15561; ISSN: 1555‐2101] EhrlichA . Evidence‐based medicine. Omega‐3 supplementation delays transition to psychotic disorder in ultra‐high‐risk adolescents and young adults. Clinical Advisor for Nurse Practitioners2010;13(5):79‐80. [CSzG: Ref21562] FöckingM , DickerP , LopezLM , CannonM , SchäferMR , McGorryPD , et al. Differential expression of the inflammation marker IL12p40 in the at‐risk mental state for psychosis: a predictor of transition to psychotic disorder?. BMC Psychiatry2016;16(1):326. [DOI: 10.1186/s12888‐016‐1039‐7] KlierC , HollmannM , SchlögelhoferM , MossahebN , FriedrichM , AmmingerPG . Indicated prevention with omega‐3 fatty acids (EPA/DHA) in adolescents with &quot;at‐risk‐mental‐state“ for psychosis. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. [CSzG: Ref12438] LavoieS , BenningerF , FeuchtM , KlierCM , SchaeferMR , AmmingerGP . Correlates of EEG resting states with erythrocyte membrane omega‐3 fatty acid levels and psychopathological symptoms in individuals at ultra‐high risk for psychosis. Early Intervention in Psychiatry2014;8:137. [CSzG: Ref29516] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultra‐high risk individuals who transitioned to psychosis. Schizophrenia Research2012;138(2‐3):206‐11. [CSzG: Ref24256] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultrahigh risk individuals who transitioned to psychosis. Early Intervention in Psychiatry2012;6:38. [CSzG: Ref24960] MossahebN , PapageorgiouK , SchaferMR , BeckerJ , SchloegelhoferM , AmmingerGP . Changes in triglyceride levels in ultra‐high risk for psychosis individuals treated with omega‐3 fatty acids. Early Intervention in Psychiatry2018; Vol. 12, issue 1:30‐36. [DOI: 10.1111/eip.12275] MossahebN , SchaferMR , SchlogelhoferM , KlierCM , CottonSM , McGorryPD , et al. Effect of omega‐3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?. Schizophrenia Research2013;148(1‐3):163‐7. [CSzG: Ref28649] NCT00396643 . Indicated prevention with omega‐3 fatty acids in adolescents with ‘at‐risk‐mental‐state’ for psychosis: a randomised, double blind, placebo‐controlled treatment trial. www.ClinicalTrials.gov/ct/show/2006. [CSzG: Ref14873] PapageorgiouK , SchaferMR , SchlogelhoferM , MossahebN , AmmingerGP . Indicated prevention with omega‐3 fatty acids in young people with 'at‐risk‐mental‐state' for psychosis: design of a 5‐year follow‐up. European Archives of Psychiatry and Clinical Neuroscience2011;261:S55. [CSzG: Ref23749] SchaferMR , KlierCM , PapageorgiouK , FriedrichMH , AmmingerGP . Early detection of psychotic disorders. Neuropsychiatrie2007;21(1):37‐44. [CSzG: Ref15290] SmesnyS , MilleitB , HiplerUC , MilleitC , SchaferMR , KlierCM , et al. Omega‐3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra‐high risk for psychosis. Molecular Psychiatry2013;19(3):317‐24. [CSzG: Ref28243] SmesnyS , MilleitB , SchaeferMR , HesseJ , SchlögelhoferM , LangbeinK , et al. Effects of omega‐3 PUFA on immune markers in adolescent individuals at ultra‐high risk for psychosis ‐ results of the randomised controlled Vienna omega‐3 study. Schizophrenia Research2017;S0920‐9964(17):30039‐7. [DOI: 10.1016/j.schres.2017.01.026] ">Amminger‐Austria</a> took place in Vienna, Austria; <a href="./references#CD012236-bbs2-0010" title="KantrowitzJT , WoodsSW , PetkovaE , CornblattB , CorcoranCM , ChenH , et al. D‐serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double‐blind, placebo‐controlled, randomised parallel group mechanistic proof‐of‐concept trial. Lancet Psychiatry2015;2(5):403‐12. [CSzG: 29487] NCT00826202 . D‐serine for the schizophrenia prodrome. www.ClinicalTrials.gov/ct/show/2009. [CSzG: 17391] ">Kantrowitz‐USA</a> and <a href="./references#CD012236-bbs2-0019" title="NCT00291226 . Glycine vs Placebo for the Schizophrenia Prodrome. www.ClinicalTrials.gov/ct/show/2006. [CSzG: 14759] WoodsS , WalshB , HawkinsK , MillerT , SaksaJ , D'SouzaD , et al. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. Early Intervention in Psychiatry2012;6:29. [CSzG: 24987] WoodsSW , KantrowitzJT , JavittDC . NMDAR‐based treatments for patients at clinical high risk for psychosis. Biological Psychiatry2014;1:11S. [CSzG: 29041] WoodsSW , WalshBC , HawkinsKA , MillerTJ , SaksaJR , D'SouzaDC , et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. European Neuropsychopharmacology2013;23(8):931‐40. [CSzG: 28750] ">Woods‐1‐USA</a> took place in the USA; and <a href="./references#CD012236-bbs2-0013" title="ACTRN12608000475347 . A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder. Australian New Zealand Clinical Trials Registry2009. [CSzG: 18420] HKCTR‐1438 . The NEURAPRO‐E (North America, EURope, Australia PROdrome) Study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for symptomatic patients at ultra‐high risk for early progression to schizophrenia and other psychotic disorders. www.hkClinicaltrials.com/trial_details.aspx?trialID=d09bd177‐b9fd‐4162‐b04f‐3ebfed49baa32011. [CSzG: 29270] McGorryP , MarkulevC , NelsonB , YuenHP , SchaeferM , YungAR , et al. The NEURAPRO‐E study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Schizophrenia Bulletin2015;41:S322‐3. [CSzG: 29546] McGorryPD , NelsonB , MarkulevC , YuenHP , SchaferMR , MossahebN , et al. Effect of omega‐3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomised clinical trial. JAMA psychiatry2017;74(1):19‐27. [CSzG: 35590] NelsonB , AmmingerG , MarkulevC , YuenHP , LavoieS , SchaeferM , et al. NEURAPOR: a multi‐center RCT of omega‐3 polyunsaturated fatty acids versus placebo in young people at ultra‐high risk of psychotic disorders: medium‐term outcome. Schizophrenia Bulletin2017;43:S107. [CSzG: 36016] ">NEURAPRO‐AAE</a> is a multicentre study that took place in Australia, Switzerland, Denmark, Austria, Hong Kong, Singapore, Germany and the Netherlands. Participants were aged between 13 to 40 years. <a href="./references#CD012236-bbs2-0002" title="AmmingerG . Ethyl eicosapentanoic acid for prodromal psychosis. Stanley Foundation Research Programs2009. [CSzG: Ref17423] AmmingerG , SchaferM , PapageorgiouK , CottonS , HarriganS , MackinnonA , et al. Indicated prevention with long‐chain omega‐3 fatty acids in adolescents at ultra‐high‐risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2008;2(Suppl 1):A29. [CSzG: Ref19107] AmmingerGP , ChanenAM , OhmannS , KlierCM , MossahebN , BechdolfA , et al. Omega‐3 fatty acid supplementation in adolescents with borderline personality disorder and ultra‐high risk criteria for psychosis: a post hoc subgroup analysis of a double‐blind, randomised controlled trial. Canadian Journal of Psychiatry2013;58(7):402‐8. [CSzG: Ref28534] AmmingerGP , HarrisMS , McGorryPD , HenryLP . Omega‐3 fatty acids for indicated prevention: treatment results and pathomechanisms. European Archives of Psychiatry and Clinical Neuroscience2013;263(Suppl. 1):S44‐5. [CSzG: Ref28434] AmmingerGP , LeicesterS , YungAR , YuenHP , McGorryPD . Age predicts transition to psychosis in an ultra‐high risk sample. Proceedings of the 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:61. AmmingerGP , McGorryPD . Update on omega‐3 polyunsaturated fatty acids in early ‐stage psychotic disorders. Neuropsychopharmacology2012;37(1):309‐10. [CSzG: Ref23726] AmmingerGP , MechelliA , RiceS , KimSW , KlierCM , McNamaraRK , et al. Predictors of treatment response in young people at ultra‐high risk for psychosis who received long‐chain omega‐3 fatty acids. Translational Psychiatry2015;5:e495. [CSzG: Ref29299] AmmingerGP , SchaferMR . Indicated prevention with omega‐3 fatty acids in adolescents at ultra‐high risk for psychosis ‐ rationale, methods, and 3‐months outcome. Schizophrenia Research2006;86(Suppl 1):S97‐8. [CSzG: Ref13367] AmmingerGP , SchaferMR . Is it feasible to conduct a RCT in ultra‐high risk individuals at a child and adolescent psychiatric service?. Schizophrenia Research2006;86(Suppl 1):S98. [CSzG: Ref13368] AmmingerGP , SchaferMR , KlierCM , PapageorgiouK , SlavikJ , HolzerI , et al. Indicated prevention with long‐chain omega‐3 fatty acids in young people at ultra‐high risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2010;4(Suppl 1):7. [CSzG: Ref23467] AmmingerGP , SchaferMR , SchlogelhoferM , KlierCM , McGorryPD . Longer‐term outcome in the prevention of psychotic disorders by the Vienna omega‐3 study. Nature Communications2015;6:7934. [CSzG: Ref33023] AmmingerGP , SchlogelhoferM , KlierC , McGorryP , SchaferM . Longer‐term follow‐up in the Vienna omega‐3 psychosis prevention trial. Early Intervention in Psychiatry2014;8:41. [CSzG: Ref29378] AmmingerGP , SchäferMR , PapageorgiouK , KlierCM , CottonSM , HarriganSM , et al. Long‐chain omega‐3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo‐controlled trial. Archives of General Psychiatry2010;67(2):146‐54. [CSzG: Ref20680; DOI: 10.1001/archgenpsychiatry.2009.192.] AmmingerP , MossahebN , SchlgelhoferM , SchaferM . Fatty acid metabolism and the onset of psychotic disorder. European Psychiatry2011;26(Suppl 1):2089. [CSzG: Ref22967] Anonymous . Fish oil may help ward off psychosis. Journal of Psychosocial Nursing and Mental Health Services2010;48(5):55. [CSzG: Ref20739] BergerG , AmmingerP , McGorryP . Stage dependant effect of omega‐3 fatty acids in emerging psychosis. European Psychiatry2011;26(Suppl 1):1347. [CSzG: Ref22966] BergerGE , ProffittTM , McConchieM , YuenH , WoodSJ , AmmingerGP , et al. Ethyl‐eicosapentaenoic acid in first‐episode psychosis: a randomised, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(12):1867‐75. [CSzG: Ref15561; ISSN: 1555‐2101] EhrlichA . Evidence‐based medicine. Omega‐3 supplementation delays transition to psychotic disorder in ultra‐high‐risk adolescents and young adults. Clinical Advisor for Nurse Practitioners2010;13(5):79‐80. [CSzG: Ref21562] FöckingM , DickerP , LopezLM , CannonM , SchäferMR , McGorryPD , et al. Differential expression of the inflammation marker IL12p40 in the at‐risk mental state for psychosis: a predictor of transition to psychotic disorder?. BMC Psychiatry2016;16(1):326. [DOI: 10.1186/s12888‐016‐1039‐7] KlierC , HollmannM , SchlögelhoferM , MossahebN , FriedrichM , AmmingerPG . Indicated prevention with omega‐3 fatty acids (EPA/DHA) in adolescents with &quot;at‐risk‐mental‐state“ for psychosis. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. [CSzG: Ref12438] LavoieS , BenningerF , FeuchtM , KlierCM , SchaeferMR , AmmingerGP . Correlates of EEG resting states with erythrocyte membrane omega‐3 fatty acid levels and psychopathological symptoms in individuals at ultra‐high risk for psychosis. Early Intervention in Psychiatry2014;8:137. [CSzG: Ref29516] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultra‐high risk individuals who transitioned to psychosis. Schizophrenia Research2012;138(2‐3):206‐11. [CSzG: Ref24256] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultrahigh risk individuals who transitioned to psychosis. Early Intervention in Psychiatry2012;6:38. [CSzG: Ref24960] MossahebN , PapageorgiouK , SchaferMR , BeckerJ , SchloegelhoferM , AmmingerGP . Changes in triglyceride levels in ultra‐high risk for psychosis individuals treated with omega‐3 fatty acids. Early Intervention in Psychiatry2018; Vol. 12, issue 1:30‐36. [DOI: 10.1111/eip.12275] MossahebN , SchaferMR , SchlogelhoferM , KlierCM , CottonSM , McGorryPD , et al. Effect of omega‐3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?. Schizophrenia Research2013;148(1‐3):163‐7. [CSzG: Ref28649] NCT00396643 . Indicated prevention with omega‐3 fatty acids in adolescents with ‘at‐risk‐mental‐state’ for psychosis: a randomised, double blind, placebo‐controlled treatment trial. www.ClinicalTrials.gov/ct/show/2006. [CSzG: Ref14873] PapageorgiouK , SchaferMR , SchlogelhoferM , MossahebN , AmmingerGP . Indicated prevention with omega‐3 fatty acids in young people with 'at‐risk‐mental‐state' for psychosis: design of a 5‐year follow‐up. European Archives of Psychiatry and Clinical Neuroscience2011;261:S55. [CSzG: Ref23749] SchaferMR , KlierCM , PapageorgiouK , FriedrichMH , AmmingerGP . Early detection of psychotic disorders. Neuropsychiatrie2007;21(1):37‐44. [CSzG: Ref15290] SmesnyS , MilleitB , HiplerUC , MilleitC , SchaferMR , KlierCM , et al. Omega‐3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra‐high risk for psychosis. Molecular Psychiatry2013;19(3):317‐24. [CSzG: Ref28243] SmesnyS , MilleitB , SchaeferMR , HesseJ , SchlögelhoferM , LangbeinK , et al. Effects of omega‐3 PUFA on immune markers in adolescent individuals at ultra‐high risk for psychosis ‐ results of the randomised controlled Vienna omega‐3 study. Schizophrenia Research2017;S0920‐9964(17):30039‐7. [DOI: 10.1016/j.schres.2017.01.026] ">Amminger‐Austria</a> used Yung's criteria for the 'ultra high risk' mental state. <a href="./references#CD012236-bbs2-0010" title="KantrowitzJT , WoodsSW , PetkovaE , CornblattB , CorcoranCM , ChenH , et al. D‐serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double‐blind, placebo‐controlled, randomised parallel group mechanistic proof‐of‐concept trial. Lancet Psychiatry2015;2(5):403‐12. [CSzG: 29487] NCT00826202 . D‐serine for the schizophrenia prodrome. www.ClinicalTrials.gov/ct/show/2009. [CSzG: 17391] ">Kantrowitz‐USA</a> and <a href="./references#CD012236-bbs2-0019" title="NCT00291226 . Glycine vs Placebo for the Schizophrenia Prodrome. www.ClinicalTrials.gov/ct/show/2006. [CSzG: 14759] WoodsS , WalshB , HawkinsK , MillerT , SaksaJ , D'SouzaD , et al. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. Early Intervention in Psychiatry2012;6:29. [CSzG: 24987] WoodsSW , KantrowitzJT , JavittDC . NMDAR‐based treatments for patients at clinical high risk for psychosis. Biological Psychiatry2014;1:11S. [CSzG: 29041] WoodsSW , WalshBC , HawkinsKA , MillerTJ , SaksaJR , D'SouzaDC , et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. European Neuropsychopharmacology2013;23(8):931‐40. [CSzG: 28750] ">Woods‐1‐USA</a> used the SOPS criteria, whilst <a href="./references#CD012236-bbs2-0013" title="ACTRN12608000475347 . A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder. Australian New Zealand Clinical Trials Registry2009. [CSzG: 18420] HKCTR‐1438 . The NEURAPRO‐E (North America, EURope, Australia PROdrome) Study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for symptomatic patients at ultra‐high risk for early progression to schizophrenia and other psychotic disorders. www.hkClinicaltrials.com/trial_details.aspx?trialID=d09bd177‐b9fd‐4162‐b04f‐3ebfed49baa32011. [CSzG: 29270] McGorryP , MarkulevC , NelsonB , YuenHP , SchaeferM , YungAR , et al. The NEURAPRO‐E study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Schizophrenia Bulletin2015;41:S322‐3. [CSzG: 29546] McGorryPD , NelsonB , MarkulevC , YuenHP , SchaferMR , MossahebN , et al. Effect of omega‐3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomised clinical trial. JAMA psychiatry2017;74(1):19‐27. [CSzG: 35590] NelsonB , AmmingerG , MarkulevC , YuenHP , LavoieS , SchaeferM , et al. NEURAPOR: a multi‐center RCT of omega‐3 polyunsaturated fatty acids versus placebo in young people at ultra‐high risk of psychotic disorders: medium‐term outcome. Schizophrenia Bulletin2017;43:S107. [CSzG: 36016] ">NEURAPRO‐AAE</a> included participants who met the criteria for “at risk” groups, as measured by Trait and State Risk Factor, Attenuated Psychotic Symptoms (APS) or Brief Limited Intermittent Psychotic Symptoms (BLIPS). </p> </section> </section> <section id="CD012236-sec-0129"> <h5 class="title">3. Study size</h5> <p>The size of studies ranged from eight participants to 304 participants.</p> <p> <div class="table" id="CD012236-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0013" title="ACTRN12608000475347 . A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder. Australian New Zealand Clinical Trials Registry2009. [CSzG: 18420] HKCTR‐1438 . The NEURAPRO‐E (North America, EURope, Australia PROdrome) Study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for symptomatic patients at ultra‐high risk for early progression to schizophrenia and other psychotic disorders. www.hkClinicaltrials.com/trial_details.aspx?trialID=d09bd177‐b9fd‐4162‐b04f‐3ebfed49baa32011. [CSzG: 29270] McGorryP , MarkulevC , NelsonB , YuenHP , SchaeferM , YungAR , et al. The NEURAPRO‐E study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Schizophrenia Bulletin2015;41:S322‐3. [CSzG: 29546] McGorryPD , NelsonB , MarkulevC , YuenHP , SchaferMR , MossahebN , et al. Effect of omega‐3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomised clinical trial. JAMA psychiatry2017;74(1):19‐27. [CSzG: 35590] NelsonB , AmmingerG , MarkulevC , YuenHP , LavoieS , SchaeferM , et al. NEURAPOR: a multi‐center RCT of omega‐3 polyunsaturated fatty acids versus placebo in young people at ultra‐high risk of psychotic disorders: medium‐term outcome. Schizophrenia Bulletin2017;43:S107. [CSzG: 36016] ">NEURAPRO‐AAE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>304</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0005" title="ByrneRE , MorrisonAP . Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. Psychology and Psychotherapy2014;87(3):357‐71. [CSzG: Ref29312] FlachC , FrenchP , DunnG , FowlerD , GumleyAI , BirchwoodM , et al. Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE‐2 trial. British Journal of Psychiatry2015;207(2):123‐9. [CSzG: Ref33109] MorrisonA . Early detection and intervention evaluation for individuals at high risk of psychosis 2. http://www.controlled‐trials.com2008. [CSzG: Ref18285] MorrisonA . Early detection and intervention evaluation for people at risk of psychosis (edie‐2): A multisite randomised controlled trial of cognitive therapy for at‐risk mental states. Early Intervention in Psychiatry2012;6:11. [CSzG: Ref24968] MorrisonA , FrenchP , BentallR , LewisS , BirchwoodM , FowlerD , et al. Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. Early Intervention in Psychiatry2008;2(Suppl 1):A15. [CSzG: Ref19128] MorrisonAP . EDIE‐2: early detection and psychological intervention for individuals at high risk of psychosis (2). www.controlled‐trials.com2007. [CSzG: Ref15381] MorrisonAP , BirchwoodM , PyleM , FlachC , StewartSL , ByrneR , et al. Impact of cognitive therapy on internalised stigma in people with at‐risk mental states. British Journal of Psychiatry2013;203(2):140‐5. [CSzG: Ref28630] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ2012;344(7852):e2233. [CSzG: Ref24208] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at‐risk of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29554] MorrisonAP , PyleM , StewartSL , FrenchP , ByrneR , FlachC , et al. Internalised stigma in young people at high risk of developing psychosis: findings from a cognitive therapy trial. Schizophrenia Research2014;153:S42. [CSzG: Ref29555] MorrisonAP , StewartSL , FrenchP , BentallRP , BirchwoodM , ByrneR , et al. Early detection and intervention evaluation for people at high‐risk of psychosis‐2 (EDIE‐2): trial rationale, design and baseline characteristics. Early Intervention in Psychiatry2011;5(1):24‐32. [CSzG: Ref22695] MorrisonT . Early detection and psychological intervention for individuals at high risk of psychosis. EDIE‐2. Data on File2006. [CSzG: Ref13874] PelosiAJ . Rational policy making for early psychosis might yet become possible. BMJ2012;344(7856):e3137. [CSzG: Ref24326] PyleM , StewartSL , FrenchP , ByrneR , PattersonP , GumleyA , et al. Internalised stigma, emotional dysfunction and unusual experiences in young people at risk of psychosis. Early Intervention in Psychiatry2015;9(2):133‐40. [CSzG: Ref29813] ">EDIE‐2‐UK</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0006" title="DragtS , Van derGaagM . Prevention of psychosis with a cognitive behavioural intervention in help‐seeking young people with an at risk mental state for developing psychosis. www.trialregister.nl/trialreg/index.asp2007. [CSzG: Ref19655] IsingHK , KraanTC , RietdijkJ , DragtS , KlaassenRM , BoonstraN , et al. Four‐year follow‐up of cognitive behavioral therapy in persons at ultra‐high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2016;42(5):1243‐52. [CSzG: Ref35214] IsingHK , LokkerbolJ , RietdijkJ , DragtS , KlaassenRM , KraanT , et al. Four‐year cost‐effectiveness of cognitive behavior therapy for preventing first‐episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2017;43(2):365‐74. [CSzG: Ref35824] IsingHK , SmitF , VelingW , RietdijkJ , DragtS , KlaassenRM , et al. Cost‐effectiveness of preventing first‐episode psychosis in ultra‐high‐risk subjects: multi‐centre randomised controlled trial. Psychological Medicine2015;45(7):1435‐46. [CSzG: Ref27798] KraanTC , IsingHK , FokkemaM , VelthorstE , Van denBergDP , KerkhovenM , et al. The effect of childhood adversity on 4‐year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE‐NL) Trial. Psychiatry Research2017;247:55‐62. [CSzG: Ref35559] NiemanDH , RuhrmannS , RietdijkJ , DragtS , IsingH , KlaassenR , et al. Preventive psychotherapy. Schizophrenia Research2014;153:S42‐3. [CSzG: Ref29601] RietdijkJ , DragtS , KlaassenR , IsingH , NiemanD , WunderinkL , et al. A single blind randomised controlled trial of cognitive behavioural therapy in a help‐seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE‐NL) trial. Trials2010;11:30. [CSzG: Ref20654] Van DerGaagM . The effects of CBT in personswith ultra high risk: the Dutch EDIE trial. European Archives of Psychiatry and Clinical Neuroscience2011;261:S18. [CSzG: Ref23756] Van DerGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first‐episode of psychosis. Early Intervention in Psychiatry2012;6:12. [CSzG: Ref24985] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomised controlled clinical trial. Schizophrenia Bulletin2012;38(6):1180‐8. [CSzG: Ref24935] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. The effects of cognitive behavioural therapy for subjects at ultra‐high risk for developing psychosis. Schizophrenia Bulletin2013;39:S356. [CSzG: Ref28121] Van derGaagM . The prevention of psychosis in at risk mental state. www.controlled‐trials.com2008. [CSzG: Ref17488] Van derGaagM , NiemanD , Van denBergD . CBT for those at risk of a first episode psychosis: Evidence‐based psychotherapy for people with an 'at risk mental state'. 1st Edition. Hove, UK: Routledge, 2013. Van derGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first episode of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29692] ">EDIE‐NL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0020" title="McGorryP . Second generation intervention research in the pre‐psychotic phase of illness in schizophrenia and related psychoses. Australian New Zealand Clinical Trials Registry2000. [CSzG: 18439] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceyS , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: 12‐month outcome. Schizophrenia Research2012;136:S17‐8. [CSzG: 29547] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceySM , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: twelve‐month outcome. Journal of Clinical Psychiatry2013;74(4):349‐56. [CSzG: 28737] NelsonB , PhillipsLJ , YungAR , FranceySM , LeicesterS , BakerK , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and supportive therapy in young people with subthreshold symptoms at incipient risk of psychotic disorder: baseline characteristics of the sample. Schizophrenia Bulletin2007;33(2):450. [CSzG: 15212] PhillipsLJ , NelsonB , YuenHP , FranceySM , SimmonsM , StanfordC , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: study design and baseline characteristics. Australian and New Zealand Journal of Psychiatry2009;;43(9):818–29. YungA , AmmingerP , BergerG , ThompsomA , PhillipsL , NelsonB , et al. Randomised controlled trial of antipsychotic and cognitive therapy in young people at ultra‐high risk of psychosis. Early Intervention in Psychiatry2012;6:11. [CSzG: 24989] YungA , NelsonB , PhillipsL , FranceyS , LeicesterS , YuenH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and supportive therapy in young people at ultra high risk of psychotic disorder: 12 month outcome data. Early Intervention in Psychiatry2008;2(Suppl 1):A12. [CSzG: 19138] YungAR , PhillipsLJ , NelsonB , FranceySM , YuenHP , SimmonsMB , et al. Randomised controlled trial of interventions for young people at ultra high risk for psychosis: 6‐month analysis. Journal of Clinical Psychiatry2011;72(4):430‐40. [CSzG: 22929] ">Yung‐Australia</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0009" title="BechdolfA . Preventing progression to first‐episode psychosis in people in the early initial prodromal state. Early Intervention in Psychiatry2012;6:11. [CSzG: 24944] BechdolfA , BuhlerB , BerningJ , WagnerM , StammE , StreitM . Cognitive behavioural therapy in the early initial prodromal state of psychosis: first results. Schizophrenia Research2004;67(1):202. [CSzG: Ref11285] BechdolfA , KlosterkotterJ . Cognitive‐behavioural treatment (CBT) in the early initial prodromal state of psychosis: concept and practical approach. Schizophrenia Research2004;70(1):52. [CSzG: Ref11506] BechdolfA , RuhrmannS , JanssenB , BottlenderR , WagnerM , MaurerK , et al. Early recognition and intervention for people at risk of schizophrenia [Fruherkennung und intervention bei personen mit erhohtem psychoserisiko]. Psychoneuroendocrinology2004;30(11):606‐14. [CSzG: Ref11376] BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: Ref12511] BechdolfA , VeithV , BerningJ , StammE , DeckerP , JanssenB , et al. Cognitive behavioral therapy (CBT) in the early initial prodromal state of psychosis: first results of a randomised trial. Schizophrenia Research2004;70(1):62‐3. [CSzG: Ref11507] BechdolfA , WagnerM , RuhrmannS , HarriganS , PutzfeldV , PukropR , et al. Preventing progression to first‐episode psychosis in early initial prodromal states. British Journal of Psychiatry2012;200(1):22‐9. [CSzG: Ref24206] BechdolfA , WagnerM , RuhrmannS , HarriganS , VeithV , PukropR , et al. CBT for prevention of first episode psychosis in people in an putative early initial prodromal state. Early Intervention in Psychiatry2008;2(Suppl 1):A16. [CSzG: 19109] BechdolfA , WagnerM , VeithV , PukropR , BerningJ , StammE , et al. A randomised controlled trial of cognitive‐behavioral therapy in the early initial prodromal state of psychosis. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:22‐3. [CSzG: 20193] BechdolfA , WagnerM , VeithV , RuhrmannR , JanssenB , BottlenderR , et al. A randomised controlled multicenter trial of cognitive behaviour therapy in the early initial prodromal state of psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13369] BechdolfA , WagnerM , VeithV , RuhrmannS , PukropR , Brockhaus‐DumkeA , et al. Randomised controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Intervention in Psychiatry2007;1(1):71‐8. [CSzG: 16450] BechdolfA , WesselsH , WagnerM , KuhrK , BerningJ , PutzfeldV , et al. Predictors of treatment response to psychosocial interventions in people at risk. European Archives of Psychiatry and Clinical Neuroscience2015;1:S9. [CSzG: 33601] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] KommescherM , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. Early Intervention in Psychiatry2016;10(1):17‐27. [CSzG: 32187] NCT00204087 . Psychological intervention for persons at risk of psychosis in the early initial prodromal state. www.ClinicalTrials.gov/ct/show/2005. [CSzG: 14890] WesselsH , WagnerM , FrommannI , BerningJ , PutzfeldV , JanssenB , et al. Neuropsychological functioning as a predictor of treatment response to psychoeducational, cognitive behavioral therapy in people at clinical high risk of first episode psychosis. Psychiatrische Praxis2015;42(6):313‐9. [CSzG: 33130] ZarafonitisS , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Psychoeducation for persons at risk of psychosis. Psychotherapeut2012;57(4):326‐34. [CSzG: 24807] ">EIPS‐Germany</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0012" title="MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Family‐focused therapy for individuals at clinical high risk for psychosis: treatment fidelity within a multisite randomised trial. Early Intervention in Psychiatry2016;10(2):137‐43. [CSzG: 29018] MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Treatment fidelity and differentiation in a randomised controlled trial of family‐focused therapy for youth at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:95. [CSzG: 24965] MiklowitzDJ , O'BrienMP , SchlosserDA , AddingtonJ , CandanKA , MarshallC , et al. Family‐focused treatment for adolescents and young adults at high risk for psychosis: results of a randomised trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(8):848‐58. [CSzG: 29019] NCT01907282 . Prevention trial of family focused treatment in youth at risk for psychosis. Clinicaltrials.gov/show/NCT019072822010. [CSzG: 27965] O'BrienMP , MiklowitzDJ , CandanKA , MarshallC , DominguesI , WalshBC , et al. A randomised trial of family focused therapy with populations at clinical high risk for psychosis: effects on interactional behavior. Journal of Consulting and Clinical Psychology2013;82(1):90‐101. [CSzG: 28565] O'BrienMP , MiklowitzDJ , CannonTD . Decreases in perceived maternal criticism predict improvement in subthreshold psychotic symptoms in a randomised trial of family‐focused therapy for individuals at clinical high risk for psychosis. Journal of Family Psychology2015;29(6):945–951.. [CSzG: 32212] SchlosserDA , MiklowitzDJ , O'BrienMP , DeSilvaSD , ZinbergJL , CannonTD . A randomised trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Intervention in Psychiatry2012;6(3):283‐91. [CSzG: 24491] ">Miklowitz‐USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0011" title="BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: 12511] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] RuhrmannS , BechdolfA , KuhnKU , WagnerM , Schultze‐LutterF Janssen B , et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry. Supplements2007;51:s88‐95. [CSzG: 16127] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Acute symptomatic treatment effects in persons clinically at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13397] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Intervention in the late initial prodromal state (LIPS) of psychosis. Schizophrenia Research2006;86(Suppl 1):S96. [CSzG: 13398] ">LIPS‐Germany</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0008" title="McFarlaneWR , CookWL , WoodberryKA . A randomised clinical trial of familyaided assertive community treatment for young persons at high risk for onset of an initial psychosis. Schizophrenia Bulletin2011;37:314. [CSzG: Ref22796] NCT01597141 . Psychosis: early detection, intervention and prevention. ClinicalTrials.gov/show/NCT015971412012. [CSzG: Ref24315] ">EDIP‐USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0018" title="LoewyR , FisherM , MathalonDH , VinogradovS . Interim analyses of a randomised controlled trial of computerised cognitive training in clinical high risk for psychosis. Schizophrenia Bulletin2013;39:S238‐9. [CSzG: 28151] LoewyR , FisherM , SchlosserDA , BiagiantiB , StuartB , MathalonDH , et al. Intensive auditory cognitive training improves verbal memory in adolescents and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2016;42(Suppl 1):S118‐26. [CSzG: 35221] VinogradovS , LoewyR , FisherM , LeeA , NiendamT , RaglandJD , et al. Neuroplasticity‐based cognitive training in ultra‐high risk adolescents and recent onset patients with schizophrenia. Schizophrenia Research2012;136:S30. [CSzG: 29703] ">Vinogradov‐USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0002" title="AmmingerG . Ethyl eicosapentanoic acid for prodromal psychosis. Stanley Foundation Research Programs2009. [CSzG: Ref17423] AmmingerG , SchaferM , PapageorgiouK , CottonS , HarriganS , MackinnonA , et al. Indicated prevention with long‐chain omega‐3 fatty acids in adolescents at ultra‐high‐risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2008;2(Suppl 1):A29. [CSzG: Ref19107] AmmingerGP , ChanenAM , OhmannS , KlierCM , MossahebN , BechdolfA , et al. Omega‐3 fatty acid supplementation in adolescents with borderline personality disorder and ultra‐high risk criteria for psychosis: a post hoc subgroup analysis of a double‐blind, randomised controlled trial. Canadian Journal of Psychiatry2013;58(7):402‐8. [CSzG: Ref28534] AmmingerGP , HarrisMS , McGorryPD , HenryLP . Omega‐3 fatty acids for indicated prevention: treatment results and pathomechanisms. European Archives of Psychiatry and Clinical Neuroscience2013;263(Suppl. 1):S44‐5. [CSzG: Ref28434] AmmingerGP , LeicesterS , YungAR , YuenHP , McGorryPD . Age predicts transition to psychosis in an ultra‐high risk sample. Proceedings of the 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:61. AmmingerGP , McGorryPD . Update on omega‐3 polyunsaturated fatty acids in early ‐stage psychotic disorders. Neuropsychopharmacology2012;37(1):309‐10. [CSzG: Ref23726] AmmingerGP , MechelliA , RiceS , KimSW , KlierCM , McNamaraRK , et al. Predictors of treatment response in young people at ultra‐high risk for psychosis who received long‐chain omega‐3 fatty acids. Translational Psychiatry2015;5:e495. [CSzG: Ref29299] AmmingerGP , SchaferMR . Indicated prevention with omega‐3 fatty acids in adolescents at ultra‐high risk for psychosis ‐ rationale, methods, and 3‐months outcome. Schizophrenia Research2006;86(Suppl 1):S97‐8. [CSzG: Ref13367] AmmingerGP , SchaferMR . Is it feasible to conduct a RCT in ultra‐high risk individuals at a child and adolescent psychiatric service?. Schizophrenia Research2006;86(Suppl 1):S98. [CSzG: Ref13368] AmmingerGP , SchaferMR , KlierCM , PapageorgiouK , SlavikJ , HolzerI , et al. Indicated prevention with long‐chain omega‐3 fatty acids in young people at ultra‐high risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2010;4(Suppl 1):7. [CSzG: Ref23467] AmmingerGP , SchaferMR , SchlogelhoferM , KlierCM , McGorryPD . Longer‐term outcome in the prevention of psychotic disorders by the Vienna omega‐3 study. Nature Communications2015;6:7934. [CSzG: Ref33023] AmmingerGP , SchlogelhoferM , KlierC , McGorryP , SchaferM . Longer‐term follow‐up in the Vienna omega‐3 psychosis prevention trial. Early Intervention in Psychiatry2014;8:41. [CSzG: Ref29378] AmmingerGP , SchäferMR , PapageorgiouK , KlierCM , CottonSM , HarriganSM , et al. Long‐chain omega‐3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo‐controlled trial. Archives of General Psychiatry2010;67(2):146‐54. [CSzG: Ref20680; DOI: 10.1001/archgenpsychiatry.2009.192.] AmmingerP , MossahebN , SchlgelhoferM , SchaferM . Fatty acid metabolism and the onset of psychotic disorder. European Psychiatry2011;26(Suppl 1):2089. [CSzG: Ref22967] Anonymous . Fish oil may help ward off psychosis. Journal of Psychosocial Nursing and Mental Health Services2010;48(5):55. [CSzG: Ref20739] BergerG , AmmingerP , McGorryP . Stage dependant effect of omega‐3 fatty acids in emerging psychosis. European Psychiatry2011;26(Suppl 1):1347. [CSzG: Ref22966] BergerGE , ProffittTM , McConchieM , YuenH , WoodSJ , AmmingerGP , et al. Ethyl‐eicosapentaenoic acid in first‐episode psychosis: a randomised, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(12):1867‐75. [CSzG: Ref15561; ISSN: 1555‐2101] EhrlichA . Evidence‐based medicine. Omega‐3 supplementation delays transition to psychotic disorder in ultra‐high‐risk adolescents and young adults. Clinical Advisor for Nurse Practitioners2010;13(5):79‐80. [CSzG: Ref21562] FöckingM , DickerP , LopezLM , CannonM , SchäferMR , McGorryPD , et al. Differential expression of the inflammation marker IL12p40 in the at‐risk mental state for psychosis: a predictor of transition to psychotic disorder?. BMC Psychiatry2016;16(1):326. [DOI: 10.1186/s12888‐016‐1039‐7] KlierC , HollmannM , SchlögelhoferM , MossahebN , FriedrichM , AmmingerPG . Indicated prevention with omega‐3 fatty acids (EPA/DHA) in adolescents with &quot;at‐risk‐mental‐state“ for psychosis. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. [CSzG: Ref12438] LavoieS , BenningerF , FeuchtM , KlierCM , SchaeferMR , AmmingerGP . Correlates of EEG resting states with erythrocyte membrane omega‐3 fatty acid levels and psychopathological symptoms in individuals at ultra‐high risk for psychosis. Early Intervention in Psychiatry2014;8:137. [CSzG: Ref29516] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultra‐high risk individuals who transitioned to psychosis. Schizophrenia Research2012;138(2‐3):206‐11. [CSzG: Ref24256] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultrahigh risk individuals who transitioned to psychosis. Early Intervention in Psychiatry2012;6:38. [CSzG: Ref24960] MossahebN , PapageorgiouK , SchaferMR , BeckerJ , SchloegelhoferM , AmmingerGP . Changes in triglyceride levels in ultra‐high risk for psychosis individuals treated with omega‐3 fatty acids. Early Intervention in Psychiatry2018; Vol. 12, issue 1:30‐36. [DOI: 10.1111/eip.12275] MossahebN , SchaferMR , SchlogelhoferM , KlierCM , CottonSM , McGorryPD , et al. Effect of omega‐3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?. Schizophrenia Research2013;148(1‐3):163‐7. [CSzG: Ref28649] NCT00396643 . Indicated prevention with omega‐3 fatty acids in adolescents with ‘at‐risk‐mental‐state’ for psychosis: a randomised, double blind, placebo‐controlled treatment trial. www.ClinicalTrials.gov/ct/show/2006. [CSzG: Ref14873] PapageorgiouK , SchaferMR , SchlogelhoferM , MossahebN , AmmingerGP . Indicated prevention with omega‐3 fatty acids in young people with 'at‐risk‐mental‐state' for psychosis: design of a 5‐year follow‐up. European Archives of Psychiatry and Clinical Neuroscience2011;261:S55. [CSzG: Ref23749] SchaferMR , KlierCM , PapageorgiouK , FriedrichMH , AmmingerGP . Early detection of psychotic disorders. Neuropsychiatrie2007;21(1):37‐44. [CSzG: Ref15290] SmesnyS , MilleitB , HiplerUC , MilleitC , SchaferMR , KlierCM , et al. Omega‐3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra‐high risk for psychosis. Molecular Psychiatry2013;19(3):317‐24. [CSzG: Ref28243] SmesnyS , MilleitB , SchaeferMR , HesseJ , SchlögelhoferM , LangbeinK , et al. Effects of omega‐3 PUFA on immune markers in adolescent individuals at ultra‐high risk for psychosis ‐ results of the randomised controlled Vienna omega‐3 study. Schizophrenia Research2017;S0920‐9964(17):30039‐7. [DOI: 10.1016/j.schres.2017.01.026] ">Amminger‐Austria</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0014" title="NordentoftM , JeppesenP , PetersenL , ThorupA , OhlenschlaegerJ , ChristensenT , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. European Psychiatry2007;22:S129‐S. [CSzG: 20471] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the OPUS trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;83(1):29‐40. [CSzG: 13197] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;86(Suppl 1):S44. [CSzG: 13393] ">Nordentoft‐Denmark</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0003" title="ChoiJ , CorcoranC , DixonL , FiszdonJ , JavittD . Processing speed training and social functioning in young adults at clinical high risk for psychosis: a pilot study. Early Intervention in Psychiatry2014;8:109. [CSzG: Ref29417] ChoiJ , CorcoranC , DixonL , JavittDC . Processing speed training and social functioning in teenagers and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2015;41:S41. [CSzG: Ref29418] ChoiJ , CorcoranCM , FiszdonJM , StevensM , JavittDC , DeasyM , et al. Pupillometer‐based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis. Psychiatric Rehabilitation Journal2017;40(1):33‐42. [CSzG: Ref35317] ">Choi‐USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0015" title="McGorryP . Can the onset of schizophrenia be delayed or prevented?. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S26. [CSzG: 8351] McGorryP , AdlardS , YungA , McDonaldA , PhillipsL , HearnN . Detection and intervention in pre‐psychotic schizophrenia. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4836] McGorryP , YungA , FranceyS , PhillipsL , NelsonB . A blinded, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and befriending in young people at risk of psychotic disorder: baseline characteristics of the sample. Acta Neuropsychiatrica2006;18(6):261. [CSzG: 35157] McGorryPD , HearnN , GermanoD , BravinJ , PhillipsLJ , YungAR , et al. Prepsychotic intervention in schizophrenia: a stitch in time?. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington DC, USA. 1999. [CSzG: 3584] McGorryPD , PhillipsLJ , NelsonB , LeicesterS , BakerK , KrstevH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and befriending in young people with subthreshold symptoms at incipient risk of psychotic disorder: six month outcome data. Schizophrenia Bulletin2007;33(2):446. [CSzG: 15203] McGorryPD , PhillipsLJ , YungAR , FranceyS , GermanoD , BravinJ , et al. A randomised controlled trial of interventions in the pre psychotic phase of psychotic disorders. Schizophrenia Research2000;41(1):9. [CSzG: 5149] McGorryPD , YungAR , PhillipsL , AdlardS , HallgrenM , PattonG , et al. Pre‐psychotic intervention in schizophrenia: a stitch in time?. Schizophrenia Research1998;29(1‐2):160. [CSzG: 3585] McGorryPD , YungAR , PhillipsLJ , YuenHP , FranceyS , CosgraveEM , et al. Randomised controlled trial of interventions designed to reduce the risk of progression to first‐episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry2002;59(10):921‐8. [CSzG: 8576] PhilippsLJ , McGorryP , YungA , FranceyD , GermanoF , BravinJ , et al. The development of preventive interventions for early psychosis: early findings and directions for the future. 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001; Vol. 2, issue Suppl 1. [CSzG: 7614] PhillipsL , CottonS , YuenHP , MihalopoulosC , ShihS , KellyD , et al. Cost effectiveness of a preventive intervention for young people at ultra high risk of developing psychosis. Schizophrenia Bulletin2007;33(2):488‐9. [CSzG: 15227] PhillipsLJ , CottonS , MihalopoulosC , ShihS , YungAR , CarterR , et al. Cost implications of specific and non‐specific treatment for young persons at ultra high risk of developing a first episode of psychosis. Early Intervention in Psychiatry2009;3(1):28‐34. [CSzG: 18308] PhillipsLJ , LeicesterSB , O'DwyerLE , FranceySM , KoutsogiannisJ , Abdel‐BakiA , et al. The PACE clinic: identification and management of young people at &quot;ultra&quot; high risk of psychosis. Journal of Psychiatric Practice2002;8(5):255‐69. [CSzG: 18235] PhillipsLJ , McGorryPD , YuenHP , WardJ , DonovanK , KellyD , et al. Medium term follow‐up of a randomised controlled trial of interventions for young people at ultra high risk of psychosis. Schizophrenia Research2007;96(1‐3):25‐33. [CSzG: 15544] PhillipsLJ , YungAR , YuenHP , PantelisC , McGorryPD . Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. American Journal of Medical Genetics2002;114(8):929‐37. [CSzG: 18236] ">PACE‐Australia</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0007" title="FrenchP , ShryaneN , BentallRP , LewisSW , MorrisonAP . Effects of cognitive therapy on the longitudinal development of psychotic experiences in people at high risk of developing psychosis. British Journal of Psychiatry. Supplements2007;191(Suppl 51):s82‐7. [CSzG: Ref16121] LewisS . EDIE ‐ Early detection and intervention for psychosis. National Research Register2001; Vol. 3. [CSzG: Ref13023] LewisS . EDIE ‐ early detection and intervention for psychosis (in primary care). National Research Register2002; Vol. 1. [CszG: Ref9342] MorrisonA . Early detection and intervention for psychosis in primary care. National Research Register2003. [CSzG: Ref15485] MorrisonA . Findings from a randomised controlled trial and clinical service delivering cognitive therapy to people at ultra‐high risk of developing psychosis. Schizophrenia Research2004;70(1):43‐4. [CSzG: Ref11526] MorrisonA . Follow‐up of prodromal symptoms. National Research Register2004; Vol. 3. [CSzG: Ref13036] MorrisonA , BentallR , FrenchP , Kilcommons A, LewisSW . Very early intervention in prodromal psychosis: a randomised trial. Schizophrenia Research2002;53(3 Suppl 1):42. [CSzG: Ref8096] MorrisonA , FrenchP , WalfordL , LewisS , Kilcommons A, GreenJ , et al. A randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;67(1):7. [CSzG: Ref11324] MorrisonA , FrenchP , WatfordL , LewisS , Kilcommons A, GreenJ , et al. Randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;70(1):63. [CSzG: Ref11527] MorrisonAP . Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: results of a randomised controlled trial. Schizophrenia Research2006;86(Suppl 1):S59. [CSzG: Ref13388] MorrisonAP , BentallRP , FrenchP , Kilcommons A, GreenJ , WalfordL , et al. Cognitive therapy in ultra high risk individuals for psychosis: randomised controlled trial. Schizophrenia Research2003;60:326. [CSzG: Ref9726] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, KnightA , et al. Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high‐risk individuals. Study design and interim analysis of transition rate and psychological risk factors. British Journal of Psychiatry. Supplements2002;181(43):s78‐84. [CSzG: Ref8737] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, LewisS . Early detection and intervention for psychosis in primary care. 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002. [CSzG: Ref8932] MorrisonAP , FrenchP , ParkerS , RobertsM , StevensH , BentallRP , et al. Three‐year follow‐up of a randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophrenia Bulletin2007;33(3):682‐7. [CSzG: Ref15288] MorrisonAP , FrenchP , WalfordL , LewisSW , Kilcommons A, GreenJ , et al. Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: randomised controlled trial. British Journal of Psychiatry2004;185:291‐7. [CSzG: Ref11450] MorrisonT . Early detection and intervention for psychosis in primary care. National Research Register2001; Vol. 1. [CSzG: Ref13037] MorrisonT , BentallR , FrenchP , Kilcommons A, GreenJ , LewisS . Early detection and intervention for psychosis in primary care. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:44. [CSzG: Ref8932] RentonJ , MorrisonA . Effectiveness of cognitive therapy for psychosis and implications for early intervention. Schizophrenia Research2004;70(1):142. [CSzG: Ref11536] ">EDIE‐UK</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0017" title='BlockJJ , McGlashonTH . Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790‐9. American Journal of Psychiatry2006; Vol. 163, issue 10:1838. [CSzG: 13960] BreierAF , ZipurskyRB , PerkinsDO , AddingtonJM , TohenMF , DavidSR , et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951] HawkinsKA , AddingtonJ , KeefeR , ChristensenB , WoodsS , ZipurskyR , et al. Neuropsychological functioning in the first episode prodrome and early psychosis. Schizophrenia Research2004;70(1):101. [CSzG: 11515] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , MillerTJ , et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research2004;67(1):205. [CSzG: Ref11301] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , ZipurskyRB , et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. [CSzG: 16470] HawkinsKA , KeefeRS , ChristensenBK , AddingtonJ , WoodsSW , CallahanJ , et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. Schizophrenia Research2008;105(1‐3):1‐9. [CSzG: 16983] HoffmanRE , WoodsS , PredaA , TohenM , BreierA , GlistJ , et al. Excessive top‐down perceptual processing and reduced real‐world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. Schizophrenia Research2006;86(Suppl 1):S46. [CSzG: 13377] HoffmanRE , WoodsSW , HawkinsKA , PittmanB , TohenM , PredaA , et al. Extracting spurious messages from noise and risk of schizophrenia‐spectrum disorders in prodromal population. British Journal of Psychiatry2007;191(2):355‐6. [CSzG: 16068] McGlashanT , ZipurskyR , PerkinsD , AddingtonJ . Olanzapine for treatment of the schizophrenia prodrome: 2‐year results of a randomised placebo‐controlled study. Schizophrenia Research2004;67(1):164. [CSzG: 11320] McGlashanTH . Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. [CSzG: 10191] McGlashanTH . Treatment intervention in the New Haven PRIME clinic prodromal sample. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4835] McGlashanTH , MillerTJ , WoodsSW . Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research2002;53(3 Suppl 1):15. [CSzG: 8093] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005] McGlashanTH , MillerTJ , ZipurskyRB , WoodsSW , PerkinsDO , HawkinsKA , et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9803] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerT , WoodsSW , et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry2006;163(5):790‐9. [CSzG: 12654] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerTJ , WoodsSW , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research2003;61(1):7‐18. [CSzG: 9828] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJ , WoodsSW , MillerTJ , et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research2003;60:295. [CSzG: 9722] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJM , WoodsSW , LindborgS , et al. Olanzapine versus pbo for the schizophrenic prodrome: one‐year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9804] McGlashlanTH , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTH , WoodsSW , et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:42. [CSzG: 8934] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , MillerT , WoodsS , et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. Schizophrenia Research2004;70(1):6. [CSzG: 11524] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , WoodsS , MillerT , et al. Olanzapine vs. placebo for prodromal schizophrenia. Schizophrenia Research2004;67(1):6. [CSzG: 11321] MillerTJ , ZipurskyRB , PerkinsD , AddingtonJ , WoodsSW , HawkinsKA , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research2003;61(1):19‐30. [CSzG: 9829] RosenJL , WoodsSW , MillerTJ , McGlashanTH . Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease2002;190:133‐41. [CSzG: 8274] TaylorHE , ParkerS , MansellW , MorrisonAP . Effects of appraisals of anomalous experience on distress in people at risk of psychosis. Behavioural and Cognitive Psychotherapy2012;41(1):24‐33. [CSzG: 24374] WoodsS , ZipurskyR , PerkinsD , AddingtonJ , MarquezE , BreierA , et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:43. [CSzG: 8933] WoodsSW . Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):497. [CSzG: 19829] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research. 2003. [CSzG: 9978] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research2003;60:306‐7. [CSzG: 9752] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):453‐64. [CSzG: 9994] WoodsSW , McGlashanTH . Sample size planning for prodromal intervention trials. Schizophrenia Research2002;53(3 Suppl 1):40. [CSzG: 8116] WoodsSW , ZipurskyRB , PerkinsDO , AddingtonJM , MillerTJ , BreierAF , et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053] '>PRIME‐USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0004" title="CrittendenK , FlemingJ , StartupM , CarrV , BakerA , SchallU , et al. Recruitment and engagement of youth in an ultra high risk treatment study. Early Intervention in Psychiatry2008;2(Suppl 1):A127. [CSzG: Ref19115] StainH , BucciS , HalperinS , EmsleyR , ShallU , LewinT , et al. DEPTh: randomised controlled trial of cognitive behavioral therapy for young people at ultra high risk for psychosis. Early Intervention in Psychiatry2014;8:15. [CSzG: Ref29673] StainHJ , BucciS , BakerA , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of CBT for young people at risk for psychosis: the Detection and Evaluation of Psychological Therapy (DEPTh) trial. European Archives of Psychiatry and Clinical Neuroscience2015;1:S8‐9. [CSzG: Ref33810] StainHJ , BucciS , BakerAL , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of cognitive behaviour therapy versus non‐directive reflective listening for young people at ultra high risk of developing psychosis: the detection and evaluation of psychological therapy (DEPTh) trial. Schizophrenia Research2016;176(2‐3):212‐9. [CSzG: Ref35298] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. Rural and urban youth at ultra high risk for psychosis: baseline characteristics from the DEPTh randomised controlled trial of cognitive behavior therapy. Schizophrenia Bulletin2011;37:322. [CSzG: Ref22815] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy for youth at ultra high risk for psychosis: baseline characteristics for rural and urban youth. Australian and New Zealand Journal of Psychiatry2010:25‐6. [CSzG: Ref21845] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy targeting ultra high risk for psychosis: baseline comparisons for rural and urban youth. Early Intervention in Psychiatry2010;4(Suppl 1):113. [CSzG: Ref23498] StainHJ , StartupM , CarrV , BakerA , SchallU . The DEPTh project: a multisite RCT for youths at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S51‐2. [CSzG: Ref13401] StartupM . The DEPTh project: detection, evaluation, and psychological therapy for health. Australian New Zealand Clinical Trials Registry2006. [CszG: Ref18442] ">DEPTh‐Australia</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0001" title="AddingtonJ , EpsteinI , LiuL , FrenchP , BoydellKM , ZipurskyRB . A randomised controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research2011;125(1):54‐61. [CSzG: Ref21945] AddingtonJ , ZipurskyR , EpsteinI . ADAPT (Access, Detection and Psychological Treatments). Schizophrenia Research2006;86(Suppl 1):S6. [CSzG: Ref13364] NCT00260273 . Access, detection and psychological treatments. www.ClinicalTrials.gov/ct/show/2005. [CSzG: Ref14638] ">ADAPT‐Canada</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0010" title="KantrowitzJT , WoodsSW , PetkovaE , CornblattB , CorcoranCM , ChenH , et al. D‐serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double‐blind, placebo‐controlled, randomised parallel group mechanistic proof‐of‐concept trial. Lancet Psychiatry2015;2(5):403‐12. [CSzG: 29487] NCT00826202 . D‐serine for the schizophrenia prodrome. www.ClinicalTrials.gov/ct/show/2009. [CSzG: 17391] ">Kantrowitz‐USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0016" title="NCT01619319 . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. ClinicalTrials.gov/show/NCT016193192012. [CSzG: 24387] PiskulicD , BarbatoM , AddingtonJ . Cognitive remediation in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:89. [CSzG: 24973] PiskulicD , BarbatoM , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2012;136:S245‐6. [CSzG: 29632] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2014;153(Suppl. 1):S218. [CSzG: 28827] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation therapy on cognition in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2014;8:86. [CSzG: 29633] ">Piskulic‐Canada</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0019" title="NCT00291226 . Glycine vs Placebo for the Schizophrenia Prodrome. www.ClinicalTrials.gov/ct/show/2006. [CSzG: 14759] WoodsS , WalshB , HawkinsK , MillerT , SaksaJ , D'SouzaD , et al. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. Early Intervention in Psychiatry2012;6:29. [CSzG: 24987] WoodsSW , KantrowitzJT , JavittDC . NMDAR‐based treatments for patients at clinical high risk for psychosis. Biological Psychiatry2014;1:11S. [CSzG: 29041] WoodsSW , WalshBC , HawkinsKA , MillerTJ , SaksaJR , D'SouzaDC , et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. European Neuropsychopharmacology2013;23(8):931‐40. [CSzG: 28750] ">Woods‐1‐USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> </tbody> </table> </div> </p> </section> <section id="CD012236-sec-0130"> <h5 class="title">4. Length of studies</h5> <p>The length of intervention ranged from eight weeks to 24 months. The overall length of the studies (including intervention and follow‐up) ranged from three months to 84 months. Three studies were specific as they had additional follow‐up longer than it was planned in their protocols. These were <a href="./references#CD012236-bbs2-0002" title="AmmingerG . Ethyl eicosapentanoic acid for prodromal psychosis. Stanley Foundation Research Programs2009. [CSzG: Ref17423] AmmingerG , SchaferM , PapageorgiouK , CottonS , HarriganS , MackinnonA , et al. Indicated prevention with long‐chain omega‐3 fatty acids in adolescents at ultra‐high‐risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2008;2(Suppl 1):A29. [CSzG: Ref19107] AmmingerGP , ChanenAM , OhmannS , KlierCM , MossahebN , BechdolfA , et al. Omega‐3 fatty acid supplementation in adolescents with borderline personality disorder and ultra‐high risk criteria for psychosis: a post hoc subgroup analysis of a double‐blind, randomised controlled trial. Canadian Journal of Psychiatry2013;58(7):402‐8. [CSzG: Ref28534] AmmingerGP , HarrisMS , McGorryPD , HenryLP . Omega‐3 fatty acids for indicated prevention: treatment results and pathomechanisms. European Archives of Psychiatry and Clinical Neuroscience2013;263(Suppl. 1):S44‐5. [CSzG: Ref28434] AmmingerGP , LeicesterS , YungAR , YuenHP , McGorryPD . Age predicts transition to psychosis in an ultra‐high risk sample. Proceedings of the 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:61. AmmingerGP , McGorryPD . Update on omega‐3 polyunsaturated fatty acids in early ‐stage psychotic disorders. Neuropsychopharmacology2012;37(1):309‐10. [CSzG: Ref23726] AmmingerGP , MechelliA , RiceS , KimSW , KlierCM , McNamaraRK , et al. Predictors of treatment response in young people at ultra‐high risk for psychosis who received long‐chain omega‐3 fatty acids. Translational Psychiatry2015;5:e495. [CSzG: Ref29299] AmmingerGP , SchaferMR . Indicated prevention with omega‐3 fatty acids in adolescents at ultra‐high risk for psychosis ‐ rationale, methods, and 3‐months outcome. Schizophrenia Research2006;86(Suppl 1):S97‐8. [CSzG: Ref13367] AmmingerGP , SchaferMR . Is it feasible to conduct a RCT in ultra‐high risk individuals at a child and adolescent psychiatric service?. Schizophrenia Research2006;86(Suppl 1):S98. [CSzG: Ref13368] AmmingerGP , SchaferMR , KlierCM , PapageorgiouK , SlavikJ , HolzerI , et al. Indicated prevention with long‐chain omega‐3 fatty acids in young people at ultra‐high risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2010;4(Suppl 1):7. [CSzG: Ref23467] AmmingerGP , SchaferMR , SchlogelhoferM , KlierCM , McGorryPD . Longer‐term outcome in the prevention of psychotic disorders by the Vienna omega‐3 study. Nature Communications2015;6:7934. [CSzG: Ref33023] AmmingerGP , SchlogelhoferM , KlierC , McGorryP , SchaferM . Longer‐term follow‐up in the Vienna omega‐3 psychosis prevention trial. Early Intervention in Psychiatry2014;8:41. [CSzG: Ref29378] AmmingerGP , SchäferMR , PapageorgiouK , KlierCM , CottonSM , HarriganSM , et al. Long‐chain omega‐3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo‐controlled trial. Archives of General Psychiatry2010;67(2):146‐54. [CSzG: Ref20680; DOI: 10.1001/archgenpsychiatry.2009.192.] AmmingerP , MossahebN , SchlgelhoferM , SchaferM . Fatty acid metabolism and the onset of psychotic disorder. European Psychiatry2011;26(Suppl 1):2089. [CSzG: Ref22967] Anonymous . Fish oil may help ward off psychosis. Journal of Psychosocial Nursing and Mental Health Services2010;48(5):55. [CSzG: Ref20739] BergerG , AmmingerP , McGorryP . Stage dependant effect of omega‐3 fatty acids in emerging psychosis. European Psychiatry2011;26(Suppl 1):1347. [CSzG: Ref22966] BergerGE , ProffittTM , McConchieM , YuenH , WoodSJ , AmmingerGP , et al. Ethyl‐eicosapentaenoic acid in first‐episode psychosis: a randomised, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(12):1867‐75. [CSzG: Ref15561; ISSN: 1555‐2101] EhrlichA . Evidence‐based medicine. Omega‐3 supplementation delays transition to psychotic disorder in ultra‐high‐risk adolescents and young adults. Clinical Advisor for Nurse Practitioners2010;13(5):79‐80. [CSzG: Ref21562] FöckingM , DickerP , LopezLM , CannonM , SchäferMR , McGorryPD , et al. Differential expression of the inflammation marker IL12p40 in the at‐risk mental state for psychosis: a predictor of transition to psychotic disorder?. BMC Psychiatry2016;16(1):326. [DOI: 10.1186/s12888‐016‐1039‐7] KlierC , HollmannM , SchlögelhoferM , MossahebN , FriedrichM , AmmingerPG . Indicated prevention with omega‐3 fatty acids (EPA/DHA) in adolescents with &quot;at‐risk‐mental‐state“ for psychosis. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. [CSzG: Ref12438] LavoieS , BenningerF , FeuchtM , KlierCM , SchaeferMR , AmmingerGP . Correlates of EEG resting states with erythrocyte membrane omega‐3 fatty acid levels and psychopathological symptoms in individuals at ultra‐high risk for psychosis. Early Intervention in Psychiatry2014;8:137. [CSzG: Ref29516] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultra‐high risk individuals who transitioned to psychosis. Schizophrenia Research2012;138(2‐3):206‐11. [CSzG: Ref24256] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultrahigh risk individuals who transitioned to psychosis. Early Intervention in Psychiatry2012;6:38. [CSzG: Ref24960] MossahebN , PapageorgiouK , SchaferMR , BeckerJ , SchloegelhoferM , AmmingerGP . Changes in triglyceride levels in ultra‐high risk for psychosis individuals treated with omega‐3 fatty acids. Early Intervention in Psychiatry2018; Vol. 12, issue 1:30‐36. [DOI: 10.1111/eip.12275] MossahebN , SchaferMR , SchlogelhoferM , KlierCM , CottonSM , McGorryPD , et al. Effect of omega‐3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?. Schizophrenia Research2013;148(1‐3):163‐7. [CSzG: Ref28649] NCT00396643 . Indicated prevention with omega‐3 fatty acids in adolescents with ‘at‐risk‐mental‐state’ for psychosis: a randomised, double blind, placebo‐controlled treatment trial. www.ClinicalTrials.gov/ct/show/2006. [CSzG: Ref14873] PapageorgiouK , SchaferMR , SchlogelhoferM , MossahebN , AmmingerGP . Indicated prevention with omega‐3 fatty acids in young people with 'at‐risk‐mental‐state' for psychosis: design of a 5‐year follow‐up. European Archives of Psychiatry and Clinical Neuroscience2011;261:S55. [CSzG: Ref23749] SchaferMR , KlierCM , PapageorgiouK , FriedrichMH , AmmingerGP . Early detection of psychotic disorders. Neuropsychiatrie2007;21(1):37‐44. [CSzG: Ref15290] SmesnyS , MilleitB , HiplerUC , MilleitC , SchaferMR , KlierCM , et al. Omega‐3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra‐high risk for psychosis. Molecular Psychiatry2013;19(3):317‐24. [CSzG: Ref28243] SmesnyS , MilleitB , SchaeferMR , HesseJ , SchlögelhoferM , LangbeinK , et al. Effects of omega‐3 PUFA on immune markers in adolescent individuals at ultra‐high risk for psychosis ‐ results of the randomised controlled Vienna omega‐3 study. Schizophrenia Research2017;S0920‐9964(17):30039‐7. [DOI: 10.1016/j.schres.2017.01.026] ">Amminger‐Austria</a>(1 year according to the protocol, but 7 years with the additional follow‐up), <a href="./references#CD012236-bbs2-0006" title="DragtS , Van derGaagM . Prevention of psychosis with a cognitive behavioural intervention in help‐seeking young people with an at risk mental state for developing psychosis. www.trialregister.nl/trialreg/index.asp2007. [CSzG: Ref19655] IsingHK , KraanTC , RietdijkJ , DragtS , KlaassenRM , BoonstraN , et al. Four‐year follow‐up of cognitive behavioral therapy in persons at ultra‐high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2016;42(5):1243‐52. [CSzG: Ref35214] IsingHK , LokkerbolJ , RietdijkJ , DragtS , KlaassenRM , KraanT , et al. Four‐year cost‐effectiveness of cognitive behavior therapy for preventing first‐episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2017;43(2):365‐74. [CSzG: Ref35824] IsingHK , SmitF , VelingW , RietdijkJ , DragtS , KlaassenRM , et al. Cost‐effectiveness of preventing first‐episode psychosis in ultra‐high‐risk subjects: multi‐centre randomised controlled trial. Psychological Medicine2015;45(7):1435‐46. [CSzG: Ref27798] KraanTC , IsingHK , FokkemaM , VelthorstE , Van denBergDP , KerkhovenM , et al. The effect of childhood adversity on 4‐year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE‐NL) Trial. Psychiatry Research2017;247:55‐62. [CSzG: Ref35559] NiemanDH , RuhrmannS , RietdijkJ , DragtS , IsingH , KlaassenR , et al. Preventive psychotherapy. Schizophrenia Research2014;153:S42‐3. [CSzG: Ref29601] RietdijkJ , DragtS , KlaassenR , IsingH , NiemanD , WunderinkL , et al. A single blind randomised controlled trial of cognitive behavioural therapy in a help‐seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE‐NL) trial. Trials2010;11:30. [CSzG: Ref20654] Van DerGaagM . The effects of CBT in personswith ultra high risk: the Dutch EDIE trial. European Archives of Psychiatry and Clinical Neuroscience2011;261:S18. [CSzG: Ref23756] Van DerGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first‐episode of psychosis. Early Intervention in Psychiatry2012;6:12. [CSzG: Ref24985] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomised controlled clinical trial. Schizophrenia Bulletin2012;38(6):1180‐8. [CSzG: Ref24935] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. The effects of cognitive behavioural therapy for subjects at ultra‐high risk for developing psychosis. Schizophrenia Bulletin2013;39:S356. [CSzG: Ref28121] Van derGaagM . The prevention of psychosis in at risk mental state. www.controlled‐trials.com2008. [CSzG: Ref17488] Van derGaagM , NiemanD , Van denBergD . CBT for those at risk of a first episode psychosis: Evidence‐based psychotherapy for people with an 'at risk mental state'. 1st Edition. Hove, UK: Routledge, 2013. Van derGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first episode of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29692] ">EDIE‐NL</a> (1.5 years planned, but 4 years with the additional follow‐up) and <a href="./references#CD012236-bbs2-0015" title="McGorryP . Can the onset of schizophrenia be delayed or prevented?. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S26. [CSzG: 8351] McGorryP , AdlardS , YungA , McDonaldA , PhillipsL , HearnN . Detection and intervention in pre‐psychotic schizophrenia. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4836] McGorryP , YungA , FranceyS , PhillipsL , NelsonB . A blinded, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and befriending in young people at risk of psychotic disorder: baseline characteristics of the sample. Acta Neuropsychiatrica2006;18(6):261. [CSzG: 35157] McGorryPD , HearnN , GermanoD , BravinJ , PhillipsLJ , YungAR , et al. Prepsychotic intervention in schizophrenia: a stitch in time?. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington DC, USA. 1999. [CSzG: 3584] McGorryPD , PhillipsLJ , NelsonB , LeicesterS , BakerK , KrstevH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and befriending in young people with subthreshold symptoms at incipient risk of psychotic disorder: six month outcome data. Schizophrenia Bulletin2007;33(2):446. [CSzG: 15203] McGorryPD , PhillipsLJ , YungAR , FranceyS , GermanoD , BravinJ , et al. A randomised controlled trial of interventions in the pre psychotic phase of psychotic disorders. Schizophrenia Research2000;41(1):9. [CSzG: 5149] McGorryPD , YungAR , PhillipsL , AdlardS , HallgrenM , PattonG , et al. Pre‐psychotic intervention in schizophrenia: a stitch in time?. Schizophrenia Research1998;29(1‐2):160. [CSzG: 3585] McGorryPD , YungAR , PhillipsLJ , YuenHP , FranceyS , CosgraveEM , et al. Randomised controlled trial of interventions designed to reduce the risk of progression to first‐episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry2002;59(10):921‐8. [CSzG: 8576] PhilippsLJ , McGorryP , YungA , FranceyD , GermanoF , BravinJ , et al. The development of preventive interventions for early psychosis: early findings and directions for the future. 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001; Vol. 2, issue Suppl 1. [CSzG: 7614] PhillipsL , CottonS , YuenHP , MihalopoulosC , ShihS , KellyD , et al. Cost effectiveness of a preventive intervention for young people at ultra high risk of developing psychosis. Schizophrenia Bulletin2007;33(2):488‐9. [CSzG: 15227] PhillipsLJ , CottonS , MihalopoulosC , ShihS , YungAR , CarterR , et al. Cost implications of specific and non‐specific treatment for young persons at ultra high risk of developing a first episode of psychosis. Early Intervention in Psychiatry2009;3(1):28‐34. [CSzG: 18308] PhillipsLJ , LeicesterSB , O'DwyerLE , FranceySM , KoutsogiannisJ , Abdel‐BakiA , et al. The PACE clinic: identification and management of young people at &quot;ultra&quot; high risk of psychosis. Journal of Psychiatric Practice2002;8(5):255‐69. [CSzG: 18235] PhillipsLJ , McGorryPD , YuenHP , WardJ , DonovanK , KellyD , et al. Medium term follow‐up of a randomised controlled trial of interventions for young people at ultra high risk of psychosis. Schizophrenia Research2007;96(1‐3):25‐33. [CSzG: 15544] PhillipsLJ , YungAR , YuenHP , PantelisC , McGorryPD . Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. American Journal of Medical Genetics2002;114(8):929‐37. [CSzG: 18236] ">PACE‐Australia</a> (1 year planned, but 4 years with additional follow‐up). </p> <p> <div class="table" id="CD012236-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0011" title="BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: 12511] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] RuhrmannS , BechdolfA , KuhnKU , WagnerM , Schultze‐LutterF Janssen B , et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry. Supplements2007;51:s88‐95. [CSzG: 16127] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Acute symptomatic treatment effects in persons clinically at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13397] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Intervention in the late initial prodromal state (LIPS) of psychosis. Schizophrenia Research2006;86(Suppl 1):S96. [CSzG: 13398] ">LIPS‐Germany</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0010" title="KantrowitzJT , WoodsSW , PetkovaE , CornblattB , CorcoranCM , ChenH , et al. D‐serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double‐blind, placebo‐controlled, randomised parallel group mechanistic proof‐of‐concept trial. Lancet Psychiatry2015;2(5):403‐12. [CSzG: 29487] NCT00826202 . D‐serine for the schizophrenia prodrome. www.ClinicalTrials.gov/ct/show/2009. [CSzG: 17391] ">Kantrowitz‐USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0003" title="ChoiJ , CorcoranC , DixonL , FiszdonJ , JavittD . Processing speed training and social functioning in young adults at clinical high risk for psychosis: a pilot study. Early Intervention in Psychiatry2014;8:109. [CSzG: Ref29417] ChoiJ , CorcoranC , DixonL , JavittDC . Processing speed training and social functioning in teenagers and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2015;41:S41. [CSzG: Ref29418] ChoiJ , CorcoranCM , FiszdonJM , StevensM , JavittDC , DeasyM , et al. Pupillometer‐based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis. Psychiatric Rehabilitation Journal2017;40(1):33‐42. [CSzG: Ref35317] ">Choi‐USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0019" title="NCT00291226 . Glycine vs Placebo for the Schizophrenia Prodrome. www.ClinicalTrials.gov/ct/show/2006. [CSzG: 14759] WoodsS , WalshB , HawkinsK , MillerT , SaksaJ , D'SouzaD , et al. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. Early Intervention in Psychiatry2012;6:29. [CSzG: 24987] WoodsSW , KantrowitzJT , JavittDC . NMDAR‐based treatments for patients at clinical high risk for psychosis. Biological Psychiatry2014;1:11S. [CSzG: 29041] WoodsSW , WalshBC , HawkinsKA , MillerTJ , SaksaJR , D'SouzaDC , et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. European Neuropsychopharmacology2013;23(8):931‐40. [CSzG: 28750] ">Woods‐1‐USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0016" title="NCT01619319 . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. ClinicalTrials.gov/show/NCT016193192012. [CSzG: 24387] PiskulicD , BarbatoM , AddingtonJ . Cognitive remediation in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:89. [CSzG: 24973] PiskulicD , BarbatoM , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2012;136:S245‐6. [CSzG: 29632] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2014;153(Suppl. 1):S218. [CSzG: 28827] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation therapy on cognition in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2014;8:86. [CSzG: 29633] ">Piskulic‐Canada</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Years</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0001" title="AddingtonJ , EpsteinI , LiuL , FrenchP , BoydellKM , ZipurskyRB . A randomised controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research2011;125(1):54‐61. [CSzG: Ref21945] AddingtonJ , ZipurskyR , EpsteinI . ADAPT (Access, Detection and Psychological Treatments). Schizophrenia Research2006;86(Suppl 1):S6. [CSzG: Ref13364] NCT00260273 . Access, detection and psychological treatments. www.ClinicalTrials.gov/ct/show/2005. [CSzG: Ref14638] ">ADAPT‐Canada</a>; <a href="./references#CD012236-bbs2-0004" title="CrittendenK , FlemingJ , StartupM , CarrV , BakerA , SchallU , et al. Recruitment and engagement of youth in an ultra high risk treatment study. Early Intervention in Psychiatry2008;2(Suppl 1):A127. [CSzG: Ref19115] StainH , BucciS , HalperinS , EmsleyR , ShallU , LewinT , et al. DEPTh: randomised controlled trial of cognitive behavioral therapy for young people at ultra high risk for psychosis. Early Intervention in Psychiatry2014;8:15. [CSzG: Ref29673] StainHJ , BucciS , BakerA , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of CBT for young people at risk for psychosis: the Detection and Evaluation of Psychological Therapy (DEPTh) trial. European Archives of Psychiatry and Clinical Neuroscience2015;1:S8‐9. [CSzG: Ref33810] StainHJ , BucciS , BakerAL , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of cognitive behaviour therapy versus non‐directive reflective listening for young people at ultra high risk of developing psychosis: the detection and evaluation of psychological therapy (DEPTh) trial. Schizophrenia Research2016;176(2‐3):212‐9. [CSzG: Ref35298] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. Rural and urban youth at ultra high risk for psychosis: baseline characteristics from the DEPTh randomised controlled trial of cognitive behavior therapy. Schizophrenia Bulletin2011;37:322. [CSzG: Ref22815] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy for youth at ultra high risk for psychosis: baseline characteristics for rural and urban youth. Australian and New Zealand Journal of Psychiatry2010:25‐6. [CSzG: Ref21845] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy targeting ultra high risk for psychosis: baseline comparisons for rural and urban youth. Early Intervention in Psychiatry2010;4(Suppl 1):113. [CSzG: Ref23498] StainHJ , StartupM , CarrV , BakerA , SchallU . The DEPTh project: a multisite RCT for youths at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S51‐2. [CSzG: Ref13401] StartupM . The DEPTh project: detection, evaluation, and psychological therapy for health. Australian New Zealand Clinical Trials Registry2006. [CszG: Ref18442] ">DEPTh‐Australia</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0005" title="ByrneRE , MorrisonAP . Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. Psychology and Psychotherapy2014;87(3):357‐71. [CSzG: Ref29312] FlachC , FrenchP , DunnG , FowlerD , GumleyAI , BirchwoodM , et al. Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE‐2 trial. British Journal of Psychiatry2015;207(2):123‐9. [CSzG: Ref33109] MorrisonA . Early detection and intervention evaluation for individuals at high risk of psychosis 2. http://www.controlled‐trials.com2008. [CSzG: Ref18285] MorrisonA . Early detection and intervention evaluation for people at risk of psychosis (edie‐2): A multisite randomised controlled trial of cognitive therapy for at‐risk mental states. Early Intervention in Psychiatry2012;6:11. [CSzG: Ref24968] MorrisonA , FrenchP , BentallR , LewisS , BirchwoodM , FowlerD , et al. Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. Early Intervention in Psychiatry2008;2(Suppl 1):A15. [CSzG: Ref19128] MorrisonAP . EDIE‐2: early detection and psychological intervention for individuals at high risk of psychosis (2). www.controlled‐trials.com2007. [CSzG: Ref15381] MorrisonAP , BirchwoodM , PyleM , FlachC , StewartSL , ByrneR , et al. Impact of cognitive therapy on internalised stigma in people with at‐risk mental states. British Journal of Psychiatry2013;203(2):140‐5. [CSzG: Ref28630] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ2012;344(7852):e2233. [CSzG: Ref24208] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at‐risk of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29554] MorrisonAP , PyleM , StewartSL , FrenchP , ByrneR , FlachC , et al. Internalised stigma in young people at high risk of developing psychosis: findings from a cognitive therapy trial. Schizophrenia Research2014;153:S42. [CSzG: Ref29555] MorrisonAP , StewartSL , FrenchP , BentallRP , BirchwoodM , ByrneR , et al. Early detection and intervention evaluation for people at high‐risk of psychosis‐2 (EDIE‐2): trial rationale, design and baseline characteristics. Early Intervention in Psychiatry2011;5(1):24‐32. [CSzG: Ref22695] MorrisonT . Early detection and psychological intervention for individuals at high risk of psychosis. EDIE‐2. Data on File2006. [CSzG: Ref13874] PelosiAJ . Rational policy making for early psychosis might yet become possible. BMJ2012;344(7856):e3137. [CSzG: Ref24326] PyleM , StewartSL , FrenchP , ByrneR , PattersonP , GumleyA , et al. Internalised stigma, emotional dysfunction and unusual experiences in young people at risk of psychosis. Early Intervention in Psychiatry2015;9(2):133‐40. [CSzG: Ref29813] ">EDIE‐2‐UK</a>; <a href="./references#CD012236-bbs2-0008" title="McFarlaneWR , CookWL , WoodberryKA . A randomised clinical trial of familyaided assertive community treatment for young persons at high risk for onset of an initial psychosis. Schizophrenia Bulletin2011;37:314. [CSzG: Ref22796] NCT01597141 . Psychosis: early detection, intervention and prevention. ClinicalTrials.gov/show/NCT015971412012. [CSzG: Ref24315] ">EDIP‐USA</a>; <a href="./references#CD012236-bbs2-0012" title="MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Family‐focused therapy for individuals at clinical high risk for psychosis: treatment fidelity within a multisite randomised trial. Early Intervention in Psychiatry2016;10(2):137‐43. [CSzG: 29018] MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Treatment fidelity and differentiation in a randomised controlled trial of family‐focused therapy for youth at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:95. [CSzG: 24965] MiklowitzDJ , O'BrienMP , SchlosserDA , AddingtonJ , CandanKA , MarshallC , et al. Family‐focused treatment for adolescents and young adults at high risk for psychosis: results of a randomised trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(8):848‐58. [CSzG: 29019] NCT01907282 . Prevention trial of family focused treatment in youth at risk for psychosis. Clinicaltrials.gov/show/NCT019072822010. [CSzG: 27965] O'BrienMP , MiklowitzDJ , CandanKA , MarshallC , DominguesI , WalshBC , et al. A randomised trial of family focused therapy with populations at clinical high risk for psychosis: effects on interactional behavior. Journal of Consulting and Clinical Psychology2013;82(1):90‐101. [CSzG: 28565] O'BrienMP , MiklowitzDJ , CannonTD . Decreases in perceived maternal criticism predict improvement in subthreshold psychotic symptoms in a randomised trial of family‐focused therapy for individuals at clinical high risk for psychosis. Journal of Family Psychology2015;29(6):945–951.. [CSzG: 32212] SchlosserDA , MiklowitzDJ , O'BrienMP , DeSilvaSD , ZinbergJL , CannonTD . A randomised trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Intervention in Psychiatry2012;6(3):283‐91. [CSzG: 24491] ">Miklowitz‐USA</a>; <a href="./references#CD012236-bbs2-0013" title="ACTRN12608000475347 . A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder. Australian New Zealand Clinical Trials Registry2009. [CSzG: 18420] HKCTR‐1438 . The NEURAPRO‐E (North America, EURope, Australia PROdrome) Study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for symptomatic patients at ultra‐high risk for early progression to schizophrenia and other psychotic disorders. www.hkClinicaltrials.com/trial_details.aspx?trialID=d09bd177‐b9fd‐4162‐b04f‐3ebfed49baa32011. [CSzG: 29270] McGorryP , MarkulevC , NelsonB , YuenHP , SchaeferM , YungAR , et al. The NEURAPRO‐E study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Schizophrenia Bulletin2015;41:S322‐3. [CSzG: 29546] McGorryPD , NelsonB , MarkulevC , YuenHP , SchaferMR , MossahebN , et al. Effect of omega‐3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomised clinical trial. JAMA psychiatry2017;74(1):19‐27. [CSzG: 35590] NelsonB , AmmingerG , MarkulevC , YuenHP , LavoieS , SchaeferM , et al. NEURAPOR: a multi‐center RCT of omega‐3 polyunsaturated fatty acids versus placebo in young people at ultra‐high risk of psychotic disorders: medium‐term outcome. Schizophrenia Bulletin2017;43:S107. [CSzG: 36016] ">NEURAPRO‐AAE</a>; <a href="./references#CD012236-bbs2-0014" title="NordentoftM , JeppesenP , PetersenL , ThorupA , OhlenschlaegerJ , ChristensenT , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. European Psychiatry2007;22:S129‐S. [CSzG: 20471] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the OPUS trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;83(1):29‐40. [CSzG: 13197] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;86(Suppl 1):S44. [CSzG: 13393] ">Nordentoft‐Denmark</a>; <a href="./references#CD012236-bbs2-0017" title='BlockJJ , McGlashonTH . Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790‐9. American Journal of Psychiatry2006; Vol. 163, issue 10:1838. [CSzG: 13960] BreierAF , ZipurskyRB , PerkinsDO , AddingtonJM , TohenMF , DavidSR , et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951] HawkinsKA , AddingtonJ , KeefeR , ChristensenB , WoodsS , ZipurskyR , et al. Neuropsychological functioning in the first episode prodrome and early psychosis. Schizophrenia Research2004;70(1):101. [CSzG: 11515] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , MillerTJ , et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research2004;67(1):205. [CSzG: Ref11301] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , ZipurskyRB , et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. [CSzG: 16470] HawkinsKA , KeefeRS , ChristensenBK , AddingtonJ , WoodsSW , CallahanJ , et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. Schizophrenia Research2008;105(1‐3):1‐9. [CSzG: 16983] HoffmanRE , WoodsS , PredaA , TohenM , BreierA , GlistJ , et al. Excessive top‐down perceptual processing and reduced real‐world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. Schizophrenia Research2006;86(Suppl 1):S46. [CSzG: 13377] HoffmanRE , WoodsSW , HawkinsKA , PittmanB , TohenM , PredaA , et al. Extracting spurious messages from noise and risk of schizophrenia‐spectrum disorders in prodromal population. British Journal of Psychiatry2007;191(2):355‐6. [CSzG: 16068] McGlashanT , ZipurskyR , PerkinsD , AddingtonJ . Olanzapine for treatment of the schizophrenia prodrome: 2‐year results of a randomised placebo‐controlled study. Schizophrenia Research2004;67(1):164. [CSzG: 11320] McGlashanTH . Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. [CSzG: 10191] McGlashanTH . Treatment intervention in the New Haven PRIME clinic prodromal sample. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4835] McGlashanTH , MillerTJ , WoodsSW . Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research2002;53(3 Suppl 1):15. [CSzG: 8093] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005] McGlashanTH , MillerTJ , ZipurskyRB , WoodsSW , PerkinsDO , HawkinsKA , et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9803] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerT , WoodsSW , et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry2006;163(5):790‐9. [CSzG: 12654] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerTJ , WoodsSW , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research2003;61(1):7‐18. [CSzG: 9828] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJ , WoodsSW , MillerTJ , et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research2003;60:295. [CSzG: 9722] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJM , WoodsSW , LindborgS , et al. Olanzapine versus pbo for the schizophrenic prodrome: one‐year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9804] McGlashlanTH , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTH , WoodsSW , et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:42. [CSzG: 8934] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , MillerT , WoodsS , et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. Schizophrenia Research2004;70(1):6. [CSzG: 11524] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , WoodsS , MillerT , et al. Olanzapine vs. placebo for prodromal schizophrenia. Schizophrenia Research2004;67(1):6. [CSzG: 11321] MillerTJ , ZipurskyRB , PerkinsD , AddingtonJ , WoodsSW , HawkinsKA , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research2003;61(1):19‐30. [CSzG: 9829] RosenJL , WoodsSW , MillerTJ , McGlashanTH . Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease2002;190:133‐41. [CSzG: 8274] TaylorHE , ParkerS , MansellW , MorrisonAP . Effects of appraisals of anomalous experience on distress in people at risk of psychosis. Behavioural and Cognitive Psychotherapy2012;41(1):24‐33. [CSzG: 24374] WoodsS , ZipurskyR , PerkinsD , AddingtonJ , MarquezE , BreierA , et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:43. [CSzG: 8933] WoodsSW . Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):497. [CSzG: 19829] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research. 2003. [CSzG: 9978] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research2003;60:306‐7. [CSzG: 9752] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):453‐64. [CSzG: 9994] WoodsSW , McGlashanTH . Sample size planning for prodromal intervention trials. Schizophrenia Research2002;53(3 Suppl 1):40. [CSzG: 8116] WoodsSW , ZipurskyRB , PerkinsDO , AddingtonJM , MillerTJ , BreierAF , et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053] '>PRIME‐USA</a>; <a href="./references#CD012236-bbs2-0018" title="LoewyR , FisherM , MathalonDH , VinogradovS . Interim analyses of a randomised controlled trial of computerised cognitive training in clinical high risk for psychosis. Schizophrenia Bulletin2013;39:S238‐9. [CSzG: 28151] LoewyR , FisherM , SchlosserDA , BiagiantiB , StuartB , MathalonDH , et al. Intensive auditory cognitive training improves verbal memory in adolescents and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2016;42(Suppl 1):S118‐26. [CSzG: 35221] VinogradovS , LoewyR , FisherM , LeeA , NiendamT , RaglandJD , et al. Neuroplasticity‐based cognitive training in ultra‐high risk adolescents and recent onset patients with schizophrenia. Schizophrenia Research2012;136:S30. [CSzG: 29703] ">Vinogradov‐USA</a>; <a href="./references#CD012236-bbs2-0020" title="McGorryP . Second generation intervention research in the pre‐psychotic phase of illness in schizophrenia and related psychoses. Australian New Zealand Clinical Trials Registry2000. [CSzG: 18439] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceyS , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: 12‐month outcome. Schizophrenia Research2012;136:S17‐8. [CSzG: 29547] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceySM , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: twelve‐month outcome. Journal of Clinical Psychiatry2013;74(4):349‐56. [CSzG: 28737] NelsonB , PhillipsLJ , YungAR , FranceySM , LeicesterS , BakerK , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and supportive therapy in young people with subthreshold symptoms at incipient risk of psychotic disorder: baseline characteristics of the sample. Schizophrenia Bulletin2007;33(2):450. [CSzG: 15212] PhillipsLJ , NelsonB , YuenHP , FranceySM , SimmonsM , StanfordC , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: study design and baseline characteristics. Australian and New Zealand Journal of Psychiatry2009;;43(9):818–29. YungA , AmmingerP , BergerG , ThompsomA , PhillipsL , NelsonB , et al. Randomised controlled trial of antipsychotic and cognitive therapy in young people at ultra‐high risk of psychosis. Early Intervention in Psychiatry2012;6:11. [CSzG: 24989] YungA , NelsonB , PhillipsL , FranceyS , LeicesterS , YuenH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and supportive therapy in young people at ultra high risk of psychotic disorder: 12 month outcome data. Early Intervention in Psychiatry2008;2(Suppl 1):A12. [CSzG: 19138] YungAR , PhillipsLJ , NelsonB , FranceySM , YuenHP , SimmonsMB , et al. Randomised controlled trial of interventions for young people at ultra high risk for psychosis: 6‐month analysis. Journal of Clinical Psychiatry2011;72(4):430‐40. [CSzG: 22929] ">Yung‐Australia</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0007" title="FrenchP , ShryaneN , BentallRP , LewisSW , MorrisonAP . Effects of cognitive therapy on the longitudinal development of psychotic experiences in people at high risk of developing psychosis. British Journal of Psychiatry. Supplements2007;191(Suppl 51):s82‐7. [CSzG: Ref16121] LewisS . EDIE ‐ Early detection and intervention for psychosis. National Research Register2001; Vol. 3. [CSzG: Ref13023] LewisS . EDIE ‐ early detection and intervention for psychosis (in primary care). National Research Register2002; Vol. 1. [CszG: Ref9342] MorrisonA . Early detection and intervention for psychosis in primary care. National Research Register2003. [CSzG: Ref15485] MorrisonA . Findings from a randomised controlled trial and clinical service delivering cognitive therapy to people at ultra‐high risk of developing psychosis. Schizophrenia Research2004;70(1):43‐4. [CSzG: Ref11526] MorrisonA . Follow‐up of prodromal symptoms. National Research Register2004; Vol. 3. [CSzG: Ref13036] MorrisonA , BentallR , FrenchP , Kilcommons A, LewisSW . Very early intervention in prodromal psychosis: a randomised trial. Schizophrenia Research2002;53(3 Suppl 1):42. [CSzG: Ref8096] MorrisonA , FrenchP , WalfordL , LewisS , Kilcommons A, GreenJ , et al. A randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;67(1):7. [CSzG: Ref11324] MorrisonA , FrenchP , WatfordL , LewisS , Kilcommons A, GreenJ , et al. Randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;70(1):63. [CSzG: Ref11527] MorrisonAP . Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: results of a randomised controlled trial. Schizophrenia Research2006;86(Suppl 1):S59. [CSzG: Ref13388] MorrisonAP , BentallRP , FrenchP , Kilcommons A, GreenJ , WalfordL , et al. Cognitive therapy in ultra high risk individuals for psychosis: randomised controlled trial. Schizophrenia Research2003;60:326. [CSzG: Ref9726] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, KnightA , et al. Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high‐risk individuals. Study design and interim analysis of transition rate and psychological risk factors. British Journal of Psychiatry. Supplements2002;181(43):s78‐84. [CSzG: Ref8737] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, LewisS . Early detection and intervention for psychosis in primary care. 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002. [CSzG: Ref8932] MorrisonAP , FrenchP , ParkerS , RobertsM , StevensH , BentallRP , et al. Three‐year follow‐up of a randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophrenia Bulletin2007;33(3):682‐7. [CSzG: Ref15288] MorrisonAP , FrenchP , WalfordL , LewisSW , Kilcommons A, GreenJ , et al. Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: randomised controlled trial. British Journal of Psychiatry2004;185:291‐7. [CSzG: Ref11450] MorrisonT . Early detection and intervention for psychosis in primary care. National Research Register2001; Vol. 1. [CSzG: Ref13037] MorrisonT , BentallR , FrenchP , Kilcommons A, GreenJ , LewisS . Early detection and intervention for psychosis in primary care. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:44. [CSzG: Ref8932] RentonJ , MorrisonA . Effectiveness of cognitive therapy for psychosis and implications for early intervention. Schizophrenia Research2004;70(1):142. [CSzG: Ref11536] ">EDIE‐UK</a>; <a href="./references#CD012236-bbs2-0009" title="BechdolfA . Preventing progression to first‐episode psychosis in people in the early initial prodromal state. Early Intervention in Psychiatry2012;6:11. [CSzG: 24944] BechdolfA , BuhlerB , BerningJ , WagnerM , StammE , StreitM . Cognitive behavioural therapy in the early initial prodromal state of psychosis: first results. Schizophrenia Research2004;67(1):202. [CSzG: Ref11285] BechdolfA , KlosterkotterJ . Cognitive‐behavioural treatment (CBT) in the early initial prodromal state of psychosis: concept and practical approach. Schizophrenia Research2004;70(1):52. [CSzG: Ref11506] BechdolfA , RuhrmannS , JanssenB , BottlenderR , WagnerM , MaurerK , et al. Early recognition and intervention for people at risk of schizophrenia [Fruherkennung und intervention bei personen mit erhohtem psychoserisiko]. Psychoneuroendocrinology2004;30(11):606‐14. [CSzG: Ref11376] BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: Ref12511] BechdolfA , VeithV , BerningJ , StammE , DeckerP , JanssenB , et al. Cognitive behavioral therapy (CBT) in the early initial prodromal state of psychosis: first results of a randomised trial. Schizophrenia Research2004;70(1):62‐3. [CSzG: Ref11507] BechdolfA , WagnerM , RuhrmannS , HarriganS , PutzfeldV , PukropR , et al. Preventing progression to first‐episode psychosis in early initial prodromal states. British Journal of Psychiatry2012;200(1):22‐9. [CSzG: Ref24206] BechdolfA , WagnerM , RuhrmannS , HarriganS , VeithV , PukropR , et al. CBT for prevention of first episode psychosis in people in an putative early initial prodromal state. Early Intervention in Psychiatry2008;2(Suppl 1):A16. [CSzG: 19109] BechdolfA , WagnerM , VeithV , PukropR , BerningJ , StammE , et al. A randomised controlled trial of cognitive‐behavioral therapy in the early initial prodromal state of psychosis. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:22‐3. [CSzG: 20193] BechdolfA , WagnerM , VeithV , RuhrmannR , JanssenB , BottlenderR , et al. A randomised controlled multicenter trial of cognitive behaviour therapy in the early initial prodromal state of psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13369] BechdolfA , WagnerM , VeithV , RuhrmannS , PukropR , Brockhaus‐DumkeA , et al. Randomised controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Intervention in Psychiatry2007;1(1):71‐8. [CSzG: 16450] BechdolfA , WesselsH , WagnerM , KuhrK , BerningJ , PutzfeldV , et al. Predictors of treatment response to psychosocial interventions in people at risk. European Archives of Psychiatry and Clinical Neuroscience2015;1:S9. [CSzG: 33601] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] KommescherM , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. Early Intervention in Psychiatry2016;10(1):17‐27. [CSzG: 32187] NCT00204087 . Psychological intervention for persons at risk of psychosis in the early initial prodromal state. www.ClinicalTrials.gov/ct/show/2005. [CSzG: 14890] WesselsH , WagnerM , FrommannI , BerningJ , PutzfeldV , JanssenB , et al. Neuropsychological functioning as a predictor of treatment response to psychoeducational, cognitive behavioral therapy in people at clinical high risk of first episode psychosis. Psychiatrische Praxis2015;42(6):313‐9. [CSzG: 33130] ZarafonitisS , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Psychoeducation for persons at risk of psychosis. Psychotherapeut2012;57(4):326‐34. [CSzG: 24807] ">EIPS‐Germany</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0006" title="DragtS , Van derGaagM . Prevention of psychosis with a cognitive behavioural intervention in help‐seeking young people with an at risk mental state for developing psychosis. www.trialregister.nl/trialreg/index.asp2007. [CSzG: Ref19655] IsingHK , KraanTC , RietdijkJ , DragtS , KlaassenRM , BoonstraN , et al. Four‐year follow‐up of cognitive behavioral therapy in persons at ultra‐high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2016;42(5):1243‐52. [CSzG: Ref35214] IsingHK , LokkerbolJ , RietdijkJ , DragtS , KlaassenRM , KraanT , et al. Four‐year cost‐effectiveness of cognitive behavior therapy for preventing first‐episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2017;43(2):365‐74. [CSzG: Ref35824] IsingHK , SmitF , VelingW , RietdijkJ , DragtS , KlaassenRM , et al. Cost‐effectiveness of preventing first‐episode psychosis in ultra‐high‐risk subjects: multi‐centre randomised controlled trial. Psychological Medicine2015;45(7):1435‐46. [CSzG: Ref27798] KraanTC , IsingHK , FokkemaM , VelthorstE , Van denBergDP , KerkhovenM , et al. The effect of childhood adversity on 4‐year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE‐NL) Trial. Psychiatry Research2017;247:55‐62. [CSzG: Ref35559] NiemanDH , RuhrmannS , RietdijkJ , DragtS , IsingH , KlaassenR , et al. Preventive psychotherapy. Schizophrenia Research2014;153:S42‐3. [CSzG: Ref29601] RietdijkJ , DragtS , KlaassenR , IsingH , NiemanD , WunderinkL , et al. A single blind randomised controlled trial of cognitive behavioural therapy in a help‐seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE‐NL) trial. Trials2010;11:30. [CSzG: Ref20654] Van DerGaagM . The effects of CBT in personswith ultra high risk: the Dutch EDIE trial. European Archives of Psychiatry and Clinical Neuroscience2011;261:S18. [CSzG: Ref23756] Van DerGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first‐episode of psychosis. Early Intervention in Psychiatry2012;6:12. [CSzG: Ref24985] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomised controlled clinical trial. Schizophrenia Bulletin2012;38(6):1180‐8. [CSzG: Ref24935] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. The effects of cognitive behavioural therapy for subjects at ultra‐high risk for developing psychosis. Schizophrenia Bulletin2013;39:S356. [CSzG: Ref28121] Van derGaagM . The prevention of psychosis in at risk mental state. www.controlled‐trials.com2008. [CSzG: Ref17488] Van derGaagM , NiemanD , Van denBergD . CBT for those at risk of a first episode psychosis: Evidence‐based psychotherapy for people with an 'at risk mental state'. 1st Edition. Hove, UK: Routledge, 2013. Van derGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first episode of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29692] ">EDIE‐NL</a>; <a href="./references#CD012236-bbs2-0015" title="McGorryP . Can the onset of schizophrenia be delayed or prevented?. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S26. [CSzG: 8351] McGorryP , AdlardS , YungA , McDonaldA , PhillipsL , HearnN . Detection and intervention in pre‐psychotic schizophrenia. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4836] McGorryP , YungA , FranceyS , PhillipsL , NelsonB . A blinded, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and befriending in young people at risk of psychotic disorder: baseline characteristics of the sample. Acta Neuropsychiatrica2006;18(6):261. [CSzG: 35157] McGorryPD , HearnN , GermanoD , BravinJ , PhillipsLJ , YungAR , et al. Prepsychotic intervention in schizophrenia: a stitch in time?. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington DC, USA. 1999. [CSzG: 3584] McGorryPD , PhillipsLJ , NelsonB , LeicesterS , BakerK , KrstevH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and befriending in young people with subthreshold symptoms at incipient risk of psychotic disorder: six month outcome data. Schizophrenia Bulletin2007;33(2):446. [CSzG: 15203] McGorryPD , PhillipsLJ , YungAR , FranceyS , GermanoD , BravinJ , et al. A randomised controlled trial of interventions in the pre psychotic phase of psychotic disorders. Schizophrenia Research2000;41(1):9. [CSzG: 5149] McGorryPD , YungAR , PhillipsL , AdlardS , HallgrenM , PattonG , et al. Pre‐psychotic intervention in schizophrenia: a stitch in time?. Schizophrenia Research1998;29(1‐2):160. [CSzG: 3585] McGorryPD , YungAR , PhillipsLJ , YuenHP , FranceyS , CosgraveEM , et al. Randomised controlled trial of interventions designed to reduce the risk of progression to first‐episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry2002;59(10):921‐8. [CSzG: 8576] PhilippsLJ , McGorryP , YungA , FranceyD , GermanoF , BravinJ , et al. The development of preventive interventions for early psychosis: early findings and directions for the future. 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001; Vol. 2, issue Suppl 1. [CSzG: 7614] PhillipsL , CottonS , YuenHP , MihalopoulosC , ShihS , KellyD , et al. Cost effectiveness of a preventive intervention for young people at ultra high risk of developing psychosis. Schizophrenia Bulletin2007;33(2):488‐9. [CSzG: 15227] PhillipsLJ , CottonS , MihalopoulosC , ShihS , YungAR , CarterR , et al. Cost implications of specific and non‐specific treatment for young persons at ultra high risk of developing a first episode of psychosis. Early Intervention in Psychiatry2009;3(1):28‐34. [CSzG: 18308] PhillipsLJ , LeicesterSB , O'DwyerLE , FranceySM , KoutsogiannisJ , Abdel‐BakiA , et al. The PACE clinic: identification and management of young people at &quot;ultra&quot; high risk of psychosis. Journal of Psychiatric Practice2002;8(5):255‐69. [CSzG: 18235] PhillipsLJ , McGorryPD , YuenHP , WardJ , DonovanK , KellyD , et al. Medium term follow‐up of a randomised controlled trial of interventions for young people at ultra high risk of psychosis. Schizophrenia Research2007;96(1‐3):25‐33. [CSzG: 15544] PhillipsLJ , YungAR , YuenHP , PantelisC , McGorryPD . Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. American Journal of Medical Genetics2002;114(8):929‐37. [CSzG: 18236] ">PACE‐Australia</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0002" title="AmmingerG . Ethyl eicosapentanoic acid for prodromal psychosis. Stanley Foundation Research Programs2009. [CSzG: Ref17423] AmmingerG , SchaferM , PapageorgiouK , CottonS , HarriganS , MackinnonA , et al. Indicated prevention with long‐chain omega‐3 fatty acids in adolescents at ultra‐high‐risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2008;2(Suppl 1):A29. [CSzG: Ref19107] AmmingerGP , ChanenAM , OhmannS , KlierCM , MossahebN , BechdolfA , et al. Omega‐3 fatty acid supplementation in adolescents with borderline personality disorder and ultra‐high risk criteria for psychosis: a post hoc subgroup analysis of a double‐blind, randomised controlled trial. Canadian Journal of Psychiatry2013;58(7):402‐8. [CSzG: Ref28534] AmmingerGP , HarrisMS , McGorryPD , HenryLP . Omega‐3 fatty acids for indicated prevention: treatment results and pathomechanisms. European Archives of Psychiatry and Clinical Neuroscience2013;263(Suppl. 1):S44‐5. [CSzG: Ref28434] AmmingerGP , LeicesterS , YungAR , YuenHP , McGorryPD . Age predicts transition to psychosis in an ultra‐high risk sample. Proceedings of the 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:61. AmmingerGP , McGorryPD . Update on omega‐3 polyunsaturated fatty acids in early ‐stage psychotic disorders. Neuropsychopharmacology2012;37(1):309‐10. [CSzG: Ref23726] AmmingerGP , MechelliA , RiceS , KimSW , KlierCM , McNamaraRK , et al. Predictors of treatment response in young people at ultra‐high risk for psychosis who received long‐chain omega‐3 fatty acids. Translational Psychiatry2015;5:e495. [CSzG: Ref29299] AmmingerGP , SchaferMR . Indicated prevention with omega‐3 fatty acids in adolescents at ultra‐high risk for psychosis ‐ rationale, methods, and 3‐months outcome. Schizophrenia Research2006;86(Suppl 1):S97‐8. [CSzG: Ref13367] AmmingerGP , SchaferMR . Is it feasible to conduct a RCT in ultra‐high risk individuals at a child and adolescent psychiatric service?. Schizophrenia Research2006;86(Suppl 1):S98. [CSzG: Ref13368] AmmingerGP , SchaferMR , KlierCM , PapageorgiouK , SlavikJ , HolzerI , et al. Indicated prevention with long‐chain omega‐3 fatty acids in young people at ultra‐high risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2010;4(Suppl 1):7. [CSzG: Ref23467] AmmingerGP , SchaferMR , SchlogelhoferM , KlierCM , McGorryPD . Longer‐term outcome in the prevention of psychotic disorders by the Vienna omega‐3 study. Nature Communications2015;6:7934. [CSzG: Ref33023] AmmingerGP , SchlogelhoferM , KlierC , McGorryP , SchaferM . Longer‐term follow‐up in the Vienna omega‐3 psychosis prevention trial. Early Intervention in Psychiatry2014;8:41. [CSzG: Ref29378] AmmingerGP , SchäferMR , PapageorgiouK , KlierCM , CottonSM , HarriganSM , et al. Long‐chain omega‐3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo‐controlled trial. Archives of General Psychiatry2010;67(2):146‐54. [CSzG: Ref20680; DOI: 10.1001/archgenpsychiatry.2009.192.] AmmingerP , MossahebN , SchlgelhoferM , SchaferM . Fatty acid metabolism and the onset of psychotic disorder. European Psychiatry2011;26(Suppl 1):2089. [CSzG: Ref22967] Anonymous . Fish oil may help ward off psychosis. Journal of Psychosocial Nursing and Mental Health Services2010;48(5):55. [CSzG: Ref20739] BergerG , AmmingerP , McGorryP . Stage dependant effect of omega‐3 fatty acids in emerging psychosis. European Psychiatry2011;26(Suppl 1):1347. [CSzG: Ref22966] BergerGE , ProffittTM , McConchieM , YuenH , WoodSJ , AmmingerGP , et al. Ethyl‐eicosapentaenoic acid in first‐episode psychosis: a randomised, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(12):1867‐75. [CSzG: Ref15561; ISSN: 1555‐2101] EhrlichA . Evidence‐based medicine. Omega‐3 supplementation delays transition to psychotic disorder in ultra‐high‐risk adolescents and young adults. Clinical Advisor for Nurse Practitioners2010;13(5):79‐80. [CSzG: Ref21562] FöckingM , DickerP , LopezLM , CannonM , SchäferMR , McGorryPD , et al. Differential expression of the inflammation marker IL12p40 in the at‐risk mental state for psychosis: a predictor of transition to psychotic disorder?. BMC Psychiatry2016;16(1):326. [DOI: 10.1186/s12888‐016‐1039‐7] KlierC , HollmannM , SchlögelhoferM , MossahebN , FriedrichM , AmmingerPG . Indicated prevention with omega‐3 fatty acids (EPA/DHA) in adolescents with &quot;at‐risk‐mental‐state“ for psychosis. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. [CSzG: Ref12438] LavoieS , BenningerF , FeuchtM , KlierCM , SchaeferMR , AmmingerGP . Correlates of EEG resting states with erythrocyte membrane omega‐3 fatty acid levels and psychopathological symptoms in individuals at ultra‐high risk for psychosis. Early Intervention in Psychiatry2014;8:137. [CSzG: Ref29516] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultra‐high risk individuals who transitioned to psychosis. Schizophrenia Research2012;138(2‐3):206‐11. [CSzG: Ref24256] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultrahigh risk individuals who transitioned to psychosis. Early Intervention in Psychiatry2012;6:38. [CSzG: Ref24960] MossahebN , PapageorgiouK , SchaferMR , BeckerJ , SchloegelhoferM , AmmingerGP . Changes in triglyceride levels in ultra‐high risk for psychosis individuals treated with omega‐3 fatty acids. Early Intervention in Psychiatry2018; Vol. 12, issue 1:30‐36. [DOI: 10.1111/eip.12275] MossahebN , SchaferMR , SchlogelhoferM , KlierCM , CottonSM , McGorryPD , et al. Effect of omega‐3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?. Schizophrenia Research2013;148(1‐3):163‐7. [CSzG: Ref28649] NCT00396643 . Indicated prevention with omega‐3 fatty acids in adolescents with ‘at‐risk‐mental‐state’ for psychosis: a randomised, double blind, placebo‐controlled treatment trial. www.ClinicalTrials.gov/ct/show/2006. [CSzG: Ref14873] PapageorgiouK , SchaferMR , SchlogelhoferM , MossahebN , AmmingerGP . Indicated prevention with omega‐3 fatty acids in young people with 'at‐risk‐mental‐state' for psychosis: design of a 5‐year follow‐up. European Archives of Psychiatry and Clinical Neuroscience2011;261:S55. [CSzG: Ref23749] SchaferMR , KlierCM , PapageorgiouK , FriedrichMH , AmmingerGP . Early detection of psychotic disorders. Neuropsychiatrie2007;21(1):37‐44. [CSzG: Ref15290] SmesnyS , MilleitB , HiplerUC , MilleitC , SchaferMR , KlierCM , et al. Omega‐3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra‐high risk for psychosis. Molecular Psychiatry2013;19(3):317‐24. [CSzG: Ref28243] SmesnyS , MilleitB , SchaeferMR , HesseJ , SchlögelhoferM , LangbeinK , et al. Effects of omega‐3 PUFA on immune markers in adolescent individuals at ultra‐high risk for psychosis ‐ results of the randomised controlled Vienna omega‐3 study. Schizophrenia Research2017;S0920‐9964(17):30039‐7. [DOI: 10.1016/j.schres.2017.01.026] ">Amminger‐Austria</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> </tbody> </table> </div> </p> </section> <section id="CD012236-sec-0131"> <h5 class="title">5. Interventions</h5> <p>Within this review, we aim to summarise best evidence of the effects of a series of treatments for people with prodromal illness. In doing so it was always likely that we would identify several treatments that have been used for these people but we did not pre‐state within our protocol groupings for the treatments. In order to make presentation of the results and discussion less of a list and more of a logical categorisation we have grouped treatments into three. </p> <p>The first group (A) is where researchers seem to have been investigating the absolute effects of the experimental intervention, comparing these treatments with – essentially ‐ placebo. The two comparisons in question happened within the context of ongoing standard care but we could see no reason why meaningful interaction with the standard care would occur. </p> <p>The second group (B) is a series of five comparisons where the experimental treatment is either a package of care or is given as an adjunct to a form of care that is not standard and even where the underlying treatment is thought of as a relatively simple approach. Differential interaction could have happened enhancing the effects of, for example, CBT or undermining its effects. Such interaction was not discussed in the papers so does not leave us reassured – hence this second grouping. </p> <p>The final group (C) is a series of six comparisons where differential effects seem to be being explored. These comparisons are comparing two different approaches. </p> <section id="CD012236-sec-0132"> <h6 class="title">5.1 Group A: absolute effects</h6> <section id="CD012236-sec-0133"> <p><b>5.1.1 Different nutrients/supplements versus alternative medication</b></p> <p>Four studies assessed effectiveness of different nutrients/supplements and alternative medication. Two of them involved amino‐acids, D‐serine (<a href="./references#CD012236-bbs2-0010" title="KantrowitzJT , WoodsSW , PetkovaE , CornblattB , CorcoranCM , ChenH , et al. D‐serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double‐blind, placebo‐controlled, randomised parallel group mechanistic proof‐of‐concept trial. Lancet Psychiatry2015;2(5):403‐12. [CSzG: 29487] NCT00826202 . D‐serine for the schizophrenia prodrome. www.ClinicalTrials.gov/ct/show/2009. [CSzG: 17391] ">Kantrowitz‐USA</a>), and glycine (<a href="./references#CD012236-bbs2-0019" title="NCT00291226 . Glycine vs Placebo for the Schizophrenia Prodrome. www.ClinicalTrials.gov/ct/show/2006. [CSzG: 14759] WoodsS , WalshB , HawkinsK , MillerT , SaksaJ , D'SouzaD , et al. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. Early Intervention in Psychiatry2012;6:29. [CSzG: 24987] WoodsSW , KantrowitzJT , JavittDC . NMDAR‐based treatments for patients at clinical high risk for psychosis. Biological Psychiatry2014;1:11S. [CSzG: 29041] WoodsSW , WalshBC , HawkinsKA , MillerTJ , SaksaJR , D'SouzaDC , et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. European Neuropsychopharmacology2013;23(8):931‐40. [CSzG: 28750] ">Woods‐1‐USA</a>), and the other two involved omega‐3 fatty acids (<a href="./references#CD012236-bbs2-0002" title="AmmingerG . Ethyl eicosapentanoic acid for prodromal psychosis. Stanley Foundation Research Programs2009. [CSzG: Ref17423] AmmingerG , SchaferM , PapageorgiouK , CottonS , HarriganS , MackinnonA , et al. Indicated prevention with long‐chain omega‐3 fatty acids in adolescents at ultra‐high‐risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2008;2(Suppl 1):A29. [CSzG: Ref19107] AmmingerGP , ChanenAM , OhmannS , KlierCM , MossahebN , BechdolfA , et al. Omega‐3 fatty acid supplementation in adolescents with borderline personality disorder and ultra‐high risk criteria for psychosis: a post hoc subgroup analysis of a double‐blind, randomised controlled trial. Canadian Journal of Psychiatry2013;58(7):402‐8. [CSzG: Ref28534] AmmingerGP , HarrisMS , McGorryPD , HenryLP . Omega‐3 fatty acids for indicated prevention: treatment results and pathomechanisms. European Archives of Psychiatry and Clinical Neuroscience2013;263(Suppl. 1):S44‐5. [CSzG: Ref28434] AmmingerGP , LeicesterS , YungAR , YuenHP , McGorryPD . Age predicts transition to psychosis in an ultra‐high risk sample. Proceedings of the 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:61. AmmingerGP , McGorryPD . Update on omega‐3 polyunsaturated fatty acids in early ‐stage psychotic disorders. Neuropsychopharmacology2012;37(1):309‐10. [CSzG: Ref23726] AmmingerGP , MechelliA , RiceS , KimSW , KlierCM , McNamaraRK , et al. Predictors of treatment response in young people at ultra‐high risk for psychosis who received long‐chain omega‐3 fatty acids. Translational Psychiatry2015;5:e495. [CSzG: Ref29299] AmmingerGP , SchaferMR . Indicated prevention with omega‐3 fatty acids in adolescents at ultra‐high risk for psychosis ‐ rationale, methods, and 3‐months outcome. Schizophrenia Research2006;86(Suppl 1):S97‐8. [CSzG: Ref13367] AmmingerGP , SchaferMR . Is it feasible to conduct a RCT in ultra‐high risk individuals at a child and adolescent psychiatric service?. Schizophrenia Research2006;86(Suppl 1):S98. [CSzG: Ref13368] AmmingerGP , SchaferMR , KlierCM , PapageorgiouK , SlavikJ , HolzerI , et al. Indicated prevention with long‐chain omega‐3 fatty acids in young people at ultra‐high risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2010;4(Suppl 1):7. [CSzG: Ref23467] AmmingerGP , SchaferMR , SchlogelhoferM , KlierCM , McGorryPD . Longer‐term outcome in the prevention of psychotic disorders by the Vienna omega‐3 study. Nature Communications2015;6:7934. [CSzG: Ref33023] AmmingerGP , SchlogelhoferM , KlierC , McGorryP , SchaferM . Longer‐term follow‐up in the Vienna omega‐3 psychosis prevention trial. Early Intervention in Psychiatry2014;8:41. [CSzG: Ref29378] AmmingerGP , SchäferMR , PapageorgiouK , KlierCM , CottonSM , HarriganSM , et al. Long‐chain omega‐3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo‐controlled trial. Archives of General Psychiatry2010;67(2):146‐54. [CSzG: Ref20680; DOI: 10.1001/archgenpsychiatry.2009.192.] AmmingerP , MossahebN , SchlgelhoferM , SchaferM . Fatty acid metabolism and the onset of psychotic disorder. European Psychiatry2011;26(Suppl 1):2089. [CSzG: Ref22967] Anonymous . Fish oil may help ward off psychosis. Journal of Psychosocial Nursing and Mental Health Services2010;48(5):55. [CSzG: Ref20739] BergerG , AmmingerP , McGorryP . Stage dependant effect of omega‐3 fatty acids in emerging psychosis. European Psychiatry2011;26(Suppl 1):1347. [CSzG: Ref22966] BergerGE , ProffittTM , McConchieM , YuenH , WoodSJ , AmmingerGP , et al. Ethyl‐eicosapentaenoic acid in first‐episode psychosis: a randomised, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(12):1867‐75. [CSzG: Ref15561; ISSN: 1555‐2101] EhrlichA . Evidence‐based medicine. Omega‐3 supplementation delays transition to psychotic disorder in ultra‐high‐risk adolescents and young adults. Clinical Advisor for Nurse Practitioners2010;13(5):79‐80. [CSzG: Ref21562] FöckingM , DickerP , LopezLM , CannonM , SchäferMR , McGorryPD , et al. Differential expression of the inflammation marker IL12p40 in the at‐risk mental state for psychosis: a predictor of transition to psychotic disorder?. BMC Psychiatry2016;16(1):326. [DOI: 10.1186/s12888‐016‐1039‐7] KlierC , HollmannM , SchlögelhoferM , MossahebN , FriedrichM , AmmingerPG . Indicated prevention with omega‐3 fatty acids (EPA/DHA) in adolescents with &quot;at‐risk‐mental‐state“ for psychosis. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. [CSzG: Ref12438] LavoieS , BenningerF , FeuchtM , KlierCM , SchaeferMR , AmmingerGP . Correlates of EEG resting states with erythrocyte membrane omega‐3 fatty acid levels and psychopathological symptoms in individuals at ultra‐high risk for psychosis. Early Intervention in Psychiatry2014;8:137. [CSzG: Ref29516] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultra‐high risk individuals who transitioned to psychosis. Schizophrenia Research2012;138(2‐3):206‐11. [CSzG: Ref24256] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultrahigh risk individuals who transitioned to psychosis. Early Intervention in Psychiatry2012;6:38. [CSzG: Ref24960] MossahebN , PapageorgiouK , SchaferMR , BeckerJ , SchloegelhoferM , AmmingerGP . Changes in triglyceride levels in ultra‐high risk for psychosis individuals treated with omega‐3 fatty acids. Early Intervention in Psychiatry2018; Vol. 12, issue 1:30‐36. [DOI: 10.1111/eip.12275] MossahebN , SchaferMR , SchlogelhoferM , KlierCM , CottonSM , McGorryPD , et al. Effect of omega‐3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?. Schizophrenia Research2013;148(1‐3):163‐7. [CSzG: Ref28649] NCT00396643 . Indicated prevention with omega‐3 fatty acids in adolescents with ‘at‐risk‐mental‐state’ for psychosis: a randomised, double blind, placebo‐controlled treatment trial. www.ClinicalTrials.gov/ct/show/2006. [CSzG: Ref14873] PapageorgiouK , SchaferMR , SchlogelhoferM , MossahebN , AmmingerGP . Indicated prevention with omega‐3 fatty acids in young people with 'at‐risk‐mental‐state' for psychosis: design of a 5‐year follow‐up. European Archives of Psychiatry and Clinical Neuroscience2011;261:S55. [CSzG: Ref23749] SchaferMR , KlierCM , PapageorgiouK , FriedrichMH , AmmingerGP . Early detection of psychotic disorders. Neuropsychiatrie2007;21(1):37‐44. [CSzG: Ref15290] SmesnyS , MilleitB , HiplerUC , MilleitC , SchaferMR , KlierCM , et al. Omega‐3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra‐high risk for psychosis. Molecular Psychiatry2013;19(3):317‐24. [CSzG: Ref28243] SmesnyS , MilleitB , SchaeferMR , HesseJ , SchlögelhoferM , LangbeinK , et al. Effects of omega‐3 PUFA on immune markers in adolescent individuals at ultra‐high risk for psychosis ‐ results of the randomised controlled Vienna omega‐3 study. Schizophrenia Research2017;S0920‐9964(17):30039‐7. [DOI: 10.1016/j.schres.2017.01.026] ">Amminger‐Austria</a>; <a href="./references#CD012236-bbs2-0013" title="ACTRN12608000475347 . A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder. Australian New Zealand Clinical Trials Registry2009. [CSzG: 18420] HKCTR‐1438 . The NEURAPRO‐E (North America, EURope, Australia PROdrome) Study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for symptomatic patients at ultra‐high risk for early progression to schizophrenia and other psychotic disorders. www.hkClinicaltrials.com/trial_details.aspx?trialID=d09bd177‐b9fd‐4162‐b04f‐3ebfed49baa32011. [CSzG: 29270] McGorryP , MarkulevC , NelsonB , YuenHP , SchaeferM , YungAR , et al. The NEURAPRO‐E study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Schizophrenia Bulletin2015;41:S322‐3. [CSzG: 29546] McGorryPD , NelsonB , MarkulevC , YuenHP , SchaferMR , MossahebN , et al. Effect of omega‐3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomised clinical trial. JAMA psychiatry2017;74(1):19‐27. [CSzG: 35590] NelsonB , AmmingerG , MarkulevC , YuenHP , LavoieS , SchaeferM , et al. NEURAPOR: a multi‐center RCT of omega‐3 polyunsaturated fatty acids versus placebo in young people at ultra‐high risk of psychotic disorders: medium‐term outcome. Schizophrenia Bulletin2017;43:S107. [CSzG: 36016] ">NEURAPRO‐AAE</a>). </p> <p>a. Different nutrients/supplements</p> <p><a href="./references#CD012236-bbs2-0010" title="KantrowitzJT , WoodsSW , PetkovaE , CornblattB , CorcoranCM , ChenH , et al. D‐serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double‐blind, placebo‐controlled, randomised parallel group mechanistic proof‐of‐concept trial. Lancet Psychiatry2015;2(5):403‐12. [CSzG: 29487] NCT00826202 . D‐serine for the schizophrenia prodrome. www.ClinicalTrials.gov/ct/show/2009. [CSzG: 17391] ">Kantrowitz‐USA</a> assessed effects of orally administered D‐serine on negative symptoms in participants at high risk for developing psychosis according to SOPS criteria. </p> <p>The intervention arm of <a href="./references#CD012236-bbs2-0019" title="NCT00291226 . Glycine vs Placebo for the Schizophrenia Prodrome. www.ClinicalTrials.gov/ct/show/2006. [CSzG: 14759] WoodsS , WalshB , HawkinsK , MillerT , SaksaJ , D'SouzaD , et al. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. Early Intervention in Psychiatry2012;6:29. [CSzG: 24987] WoodsSW , KantrowitzJT , JavittDC . NMDAR‐based treatments for patients at clinical high risk for psychosis. Biological Psychiatry2014;1:11S. [CSzG: 29041] WoodsSW , WalshBC , HawkinsKA , MillerTJ , SaksaJR , D'SouzaDC , et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. European Neuropsychopharmacology2013;23(8):931‐40. [CSzG: 28750] ">Woods‐1‐USA</a> received glycine. The doses were 0.2 g/kg during the first seven days, followed by 0.4 g/kg until the end of the study. </p> <p>Participants in <a href="./references#CD012236-bbs2-0002" title="AmmingerG . Ethyl eicosapentanoic acid for prodromal psychosis. Stanley Foundation Research Programs2009. [CSzG: Ref17423] AmmingerG , SchaferM , PapageorgiouK , CottonS , HarriganS , MackinnonA , et al. Indicated prevention with long‐chain omega‐3 fatty acids in adolescents at ultra‐high‐risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2008;2(Suppl 1):A29. [CSzG: Ref19107] AmmingerGP , ChanenAM , OhmannS , KlierCM , MossahebN , BechdolfA , et al. Omega‐3 fatty acid supplementation in adolescents with borderline personality disorder and ultra‐high risk criteria for psychosis: a post hoc subgroup analysis of a double‐blind, randomised controlled trial. Canadian Journal of Psychiatry2013;58(7):402‐8. [CSzG: Ref28534] AmmingerGP , HarrisMS , McGorryPD , HenryLP . Omega‐3 fatty acids for indicated prevention: treatment results and pathomechanisms. European Archives of Psychiatry and Clinical Neuroscience2013;263(Suppl. 1):S44‐5. [CSzG: Ref28434] AmmingerGP , LeicesterS , YungAR , YuenHP , McGorryPD . Age predicts transition to psychosis in an ultra‐high risk sample. Proceedings of the 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:61. AmmingerGP , McGorryPD . Update on omega‐3 polyunsaturated fatty acids in early ‐stage psychotic disorders. Neuropsychopharmacology2012;37(1):309‐10. [CSzG: Ref23726] AmmingerGP , MechelliA , RiceS , KimSW , KlierCM , McNamaraRK , et al. Predictors of treatment response in young people at ultra‐high risk for psychosis who received long‐chain omega‐3 fatty acids. Translational Psychiatry2015;5:e495. [CSzG: Ref29299] AmmingerGP , SchaferMR . Indicated prevention with omega‐3 fatty acids in adolescents at ultra‐high risk for psychosis ‐ rationale, methods, and 3‐months outcome. Schizophrenia Research2006;86(Suppl 1):S97‐8. [CSzG: Ref13367] AmmingerGP , SchaferMR . Is it feasible to conduct a RCT in ultra‐high risk individuals at a child and adolescent psychiatric service?. Schizophrenia Research2006;86(Suppl 1):S98. [CSzG: Ref13368] AmmingerGP , SchaferMR , KlierCM , PapageorgiouK , SlavikJ , HolzerI , et al. Indicated prevention with long‐chain omega‐3 fatty acids in young people at ultra‐high risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2010;4(Suppl 1):7. [CSzG: Ref23467] AmmingerGP , SchaferMR , SchlogelhoferM , KlierCM , McGorryPD . Longer‐term outcome in the prevention of psychotic disorders by the Vienna omega‐3 study. Nature Communications2015;6:7934. [CSzG: Ref33023] AmmingerGP , SchlogelhoferM , KlierC , McGorryP , SchaferM . Longer‐term follow‐up in the Vienna omega‐3 psychosis prevention trial. Early Intervention in Psychiatry2014;8:41. [CSzG: Ref29378] AmmingerGP , SchäferMR , PapageorgiouK , KlierCM , CottonSM , HarriganSM , et al. Long‐chain omega‐3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo‐controlled trial. Archives of General Psychiatry2010;67(2):146‐54. [CSzG: Ref20680; DOI: 10.1001/archgenpsychiatry.2009.192.] AmmingerP , MossahebN , SchlgelhoferM , SchaferM . Fatty acid metabolism and the onset of psychotic disorder. European Psychiatry2011;26(Suppl 1):2089. [CSzG: Ref22967] Anonymous . Fish oil may help ward off psychosis. Journal of Psychosocial Nursing and Mental Health Services2010;48(5):55. [CSzG: Ref20739] BergerG , AmmingerP , McGorryP . Stage dependant effect of omega‐3 fatty acids in emerging psychosis. European Psychiatry2011;26(Suppl 1):1347. [CSzG: Ref22966] BergerGE , ProffittTM , McConchieM , YuenH , WoodSJ , AmmingerGP , et al. Ethyl‐eicosapentaenoic acid in first‐episode psychosis: a randomised, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(12):1867‐75. [CSzG: Ref15561; ISSN: 1555‐2101] EhrlichA . Evidence‐based medicine. Omega‐3 supplementation delays transition to psychotic disorder in ultra‐high‐risk adolescents and young adults. Clinical Advisor for Nurse Practitioners2010;13(5):79‐80. [CSzG: Ref21562] FöckingM , DickerP , LopezLM , CannonM , SchäferMR , McGorryPD , et al. Differential expression of the inflammation marker IL12p40 in the at‐risk mental state for psychosis: a predictor of transition to psychotic disorder?. BMC Psychiatry2016;16(1):326. [DOI: 10.1186/s12888‐016‐1039‐7] KlierC , HollmannM , SchlögelhoferM , MossahebN , FriedrichM , AmmingerPG . Indicated prevention with omega‐3 fatty acids (EPA/DHA) in adolescents with &quot;at‐risk‐mental‐state“ for psychosis. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. [CSzG: Ref12438] LavoieS , BenningerF , FeuchtM , KlierCM , SchaeferMR , AmmingerGP . Correlates of EEG resting states with erythrocyte membrane omega‐3 fatty acid levels and psychopathological symptoms in individuals at ultra‐high risk for psychosis. Early Intervention in Psychiatry2014;8:137. [CSzG: Ref29516] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultra‐high risk individuals who transitioned to psychosis. Schizophrenia Research2012;138(2‐3):206‐11. [CSzG: Ref24256] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultrahigh risk individuals who transitioned to psychosis. Early Intervention in Psychiatry2012;6:38. [CSzG: Ref24960] MossahebN , PapageorgiouK , SchaferMR , BeckerJ , SchloegelhoferM , AmmingerGP . Changes in triglyceride levels in ultra‐high risk for psychosis individuals treated with omega‐3 fatty acids. Early Intervention in Psychiatry2018; Vol. 12, issue 1:30‐36. [DOI: 10.1111/eip.12275] MossahebN , SchaferMR , SchlogelhoferM , KlierCM , CottonSM , McGorryPD , et al. Effect of omega‐3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?. Schizophrenia Research2013;148(1‐3):163‐7. [CSzG: Ref28649] NCT00396643 . Indicated prevention with omega‐3 fatty acids in adolescents with ‘at‐risk‐mental‐state’ for psychosis: a randomised, double blind, placebo‐controlled treatment trial. www.ClinicalTrials.gov/ct/show/2006. [CSzG: Ref14873] PapageorgiouK , SchaferMR , SchlogelhoferM , MossahebN , AmmingerGP . Indicated prevention with omega‐3 fatty acids in young people with 'at‐risk‐mental‐state' for psychosis: design of a 5‐year follow‐up. European Archives of Psychiatry and Clinical Neuroscience2011;261:S55. [CSzG: Ref23749] SchaferMR , KlierCM , PapageorgiouK , FriedrichMH , AmmingerGP . Early detection of psychotic disorders. Neuropsychiatrie2007;21(1):37‐44. [CSzG: Ref15290] SmesnyS , MilleitB , HiplerUC , MilleitC , SchaferMR , KlierCM , et al. Omega‐3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra‐high risk for psychosis. Molecular Psychiatry2013;19(3):317‐24. [CSzG: Ref28243] SmesnyS , MilleitB , SchaeferMR , HesseJ , SchlögelhoferM , LangbeinK , et al. Effects of omega‐3 PUFA on immune markers in adolescent individuals at ultra‐high risk for psychosis ‐ results of the randomised controlled Vienna omega‐3 study. Schizophrenia Research2017;S0920‐9964(17):30039‐7. [DOI: 10.1016/j.schres.2017.01.026] ">Amminger‐Austria</a> received omega‐3 fatty acids (daily dose of capsules containing 700 mg of eicosapentaenoic acid and 500 mg of docosahexaenoic acid) as an active intervention. These were offered over a period of three months. </p> <p>The active intervention for <a href="./references#CD012236-bbs2-0013" title="ACTRN12608000475347 . A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder. Australian New Zealand Clinical Trials Registry2009. [CSzG: 18420] HKCTR‐1438 . The NEURAPRO‐E (North America, EURope, Australia PROdrome) Study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for symptomatic patients at ultra‐high risk for early progression to schizophrenia and other psychotic disorders. www.hkClinicaltrials.com/trial_details.aspx?trialID=d09bd177‐b9fd‐4162‐b04f‐3ebfed49baa32011. [CSzG: 29270] McGorryP , MarkulevC , NelsonB , YuenHP , SchaeferM , YungAR , et al. The NEURAPRO‐E study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Schizophrenia Bulletin2015;41:S322‐3. [CSzG: 29546] McGorryPD , NelsonB , MarkulevC , YuenHP , SchaferMR , MossahebN , et al. Effect of omega‐3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomised clinical trial. JAMA psychiatry2017;74(1):19‐27. [CSzG: 35590] NelsonB , AmmingerG , MarkulevC , YuenHP , LavoieS , SchaeferM , et al. NEURAPOR: a multi‐center RCT of omega‐3 polyunsaturated fatty acids versus placebo in young people at ultra‐high risk of psychotic disorders: medium‐term outcome. Schizophrenia Bulletin2017;43:S107. [CSzG: 36016] ">NEURAPRO‐AAE</a> was combined omega‐3 fatty acids (2.8 g of marine fish oil containing approximately 1.4 g eicosapentaenoic acid/docosahexaenoic acid in 4 x 0.700 g capsules daily with cognitive behavioural case management (sessions of 30 to 60 minutes' duration). Omega‐3 fatty acids and up to 20 sessions of cognitive behavioural case management were administered over the first six months. During the follow‐up period, further sessions of case management were available on a needs‐basis for up to 12 months from study entry. </p> <p>b. Alternative medication</p> <p><a href="./references#CD012236-bbs2-0010" title="KantrowitzJT , WoodsSW , PetkovaE , CornblattB , CorcoranCM , ChenH , et al. D‐serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double‐blind, placebo‐controlled, randomised parallel group mechanistic proof‐of‐concept trial. Lancet Psychiatry2015;2(5):403‐12. [CSzG: 29487] NCT00826202 . D‐serine for the schizophrenia prodrome. www.ClinicalTrials.gov/ct/show/2009. [CSzG: 17391] ">Kantrowitz‐USA</a> gave matched placebo to the control group. Some of the participants continued taking medication that had been prescribed to them prior to the study (antidepressants, anxiolytics), but the majority (over 60%) did not receive any other psychotropic medication. </p> <p>The control group in <a href="./references#CD012236-bbs2-0019" title="NCT00291226 . Glycine vs Placebo for the Schizophrenia Prodrome. www.ClinicalTrials.gov/ct/show/2006. [CSzG: 14759] WoodsS , WalshB , HawkinsK , MillerT , SaksaJ , D'SouzaD , et al. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. Early Intervention in Psychiatry2012;6:29. [CSzG: 24987] WoodsSW , KantrowitzJT , JavittDC . NMDAR‐based treatments for patients at clinical high risk for psychosis. Biological Psychiatry2014;1:11S. [CSzG: 29041] WoodsSW , WalshBC , HawkinsKA , MillerTJ , SaksaJR , D'SouzaDC , et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. European Neuropsychopharmacology2013;23(8):931‐40. [CSzG: 28750] ">Woods‐1‐USA</a> received placebo. After 12 weeks, all participants from both groups could chose to use open‐label glycine for another 12 weeks. </p> <p>Control participants in <a href="./references#CD012236-bbs2-0002" title="AmmingerG . Ethyl eicosapentanoic acid for prodromal psychosis. Stanley Foundation Research Programs2009. [CSzG: Ref17423] AmmingerG , SchaferM , PapageorgiouK , CottonS , HarriganS , MackinnonA , et al. Indicated prevention with long‐chain omega‐3 fatty acids in adolescents at ultra‐high‐risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2008;2(Suppl 1):A29. [CSzG: Ref19107] AmmingerGP , ChanenAM , OhmannS , KlierCM , MossahebN , BechdolfA , et al. Omega‐3 fatty acid supplementation in adolescents with borderline personality disorder and ultra‐high risk criteria for psychosis: a post hoc subgroup analysis of a double‐blind, randomised controlled trial. Canadian Journal of Psychiatry2013;58(7):402‐8. [CSzG: Ref28534] AmmingerGP , HarrisMS , McGorryPD , HenryLP . Omega‐3 fatty acids for indicated prevention: treatment results and pathomechanisms. European Archives of Psychiatry and Clinical Neuroscience2013;263(Suppl. 1):S44‐5. [CSzG: Ref28434] AmmingerGP , LeicesterS , YungAR , YuenHP , McGorryPD . Age predicts transition to psychosis in an ultra‐high risk sample. Proceedings of the 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:61. AmmingerGP , McGorryPD . Update on omega‐3 polyunsaturated fatty acids in early ‐stage psychotic disorders. Neuropsychopharmacology2012;37(1):309‐10. [CSzG: Ref23726] AmmingerGP , MechelliA , RiceS , KimSW , KlierCM , McNamaraRK , et al. Predictors of treatment response in young people at ultra‐high risk for psychosis who received long‐chain omega‐3 fatty acids. Translational Psychiatry2015;5:e495. [CSzG: Ref29299] AmmingerGP , SchaferMR . Indicated prevention with omega‐3 fatty acids in adolescents at ultra‐high risk for psychosis ‐ rationale, methods, and 3‐months outcome. Schizophrenia Research2006;86(Suppl 1):S97‐8. [CSzG: Ref13367] AmmingerGP , SchaferMR . Is it feasible to conduct a RCT in ultra‐high risk individuals at a child and adolescent psychiatric service?. Schizophrenia Research2006;86(Suppl 1):S98. [CSzG: Ref13368] AmmingerGP , SchaferMR , KlierCM , PapageorgiouK , SlavikJ , HolzerI , et al. Indicated prevention with long‐chain omega‐3 fatty acids in young people at ultra‐high risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2010;4(Suppl 1):7. [CSzG: Ref23467] AmmingerGP , SchaferMR , SchlogelhoferM , KlierCM , McGorryPD . Longer‐term outcome in the prevention of psychotic disorders by the Vienna omega‐3 study. Nature Communications2015;6:7934. [CSzG: Ref33023] AmmingerGP , SchlogelhoferM , KlierC , McGorryP , SchaferM . Longer‐term follow‐up in the Vienna omega‐3 psychosis prevention trial. Early Intervention in Psychiatry2014;8:41. [CSzG: Ref29378] AmmingerGP , SchäferMR , PapageorgiouK , KlierCM , CottonSM , HarriganSM , et al. Long‐chain omega‐3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo‐controlled trial. Archives of General Psychiatry2010;67(2):146‐54. [CSzG: Ref20680; DOI: 10.1001/archgenpsychiatry.2009.192.] AmmingerP , MossahebN , SchlgelhoferM , SchaferM . Fatty acid metabolism and the onset of psychotic disorder. European Psychiatry2011;26(Suppl 1):2089. [CSzG: Ref22967] Anonymous . Fish oil may help ward off psychosis. Journal of Psychosocial Nursing and Mental Health Services2010;48(5):55. [CSzG: Ref20739] BergerG , AmmingerP , McGorryP . Stage dependant effect of omega‐3 fatty acids in emerging psychosis. European Psychiatry2011;26(Suppl 1):1347. [CSzG: Ref22966] BergerGE , ProffittTM , McConchieM , YuenH , WoodSJ , AmmingerGP , et al. Ethyl‐eicosapentaenoic acid in first‐episode psychosis: a randomised, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(12):1867‐75. [CSzG: Ref15561; ISSN: 1555‐2101] EhrlichA . Evidence‐based medicine. Omega‐3 supplementation delays transition to psychotic disorder in ultra‐high‐risk adolescents and young adults. Clinical Advisor for Nurse Practitioners2010;13(5):79‐80. [CSzG: Ref21562] FöckingM , DickerP , LopezLM , CannonM , SchäferMR , McGorryPD , et al. Differential expression of the inflammation marker IL12p40 in the at‐risk mental state for psychosis: a predictor of transition to psychotic disorder?. BMC Psychiatry2016;16(1):326. [DOI: 10.1186/s12888‐016‐1039‐7] KlierC , HollmannM , SchlögelhoferM , MossahebN , FriedrichM , AmmingerPG . Indicated prevention with omega‐3 fatty acids (EPA/DHA) in adolescents with &quot;at‐risk‐mental‐state“ for psychosis. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. [CSzG: Ref12438] LavoieS , BenningerF , FeuchtM , KlierCM , SchaeferMR , AmmingerGP . Correlates of EEG resting states with erythrocyte membrane omega‐3 fatty acid levels and psychopathological symptoms in individuals at ultra‐high risk for psychosis. Early Intervention in Psychiatry2014;8:137. [CSzG: Ref29516] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultra‐high risk individuals who transitioned to psychosis. Schizophrenia Research2012;138(2‐3):206‐11. [CSzG: Ref24256] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultrahigh risk individuals who transitioned to psychosis. Early Intervention in Psychiatry2012;6:38. [CSzG: Ref24960] MossahebN , PapageorgiouK , SchaferMR , BeckerJ , SchloegelhoferM , AmmingerGP . Changes in triglyceride levels in ultra‐high risk for psychosis individuals treated with omega‐3 fatty acids. Early Intervention in Psychiatry2018; Vol. 12, issue 1:30‐36. [DOI: 10.1111/eip.12275] MossahebN , SchaferMR , SchlogelhoferM , KlierCM , CottonSM , McGorryPD , et al. Effect of omega‐3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?. Schizophrenia Research2013;148(1‐3):163‐7. [CSzG: Ref28649] NCT00396643 . Indicated prevention with omega‐3 fatty acids in adolescents with ‘at‐risk‐mental‐state’ for psychosis: a randomised, double blind, placebo‐controlled treatment trial. www.ClinicalTrials.gov/ct/show/2006. [CSzG: Ref14873] PapageorgiouK , SchaferMR , SchlogelhoferM , MossahebN , AmmingerGP . Indicated prevention with omega‐3 fatty acids in young people with 'at‐risk‐mental‐state' for psychosis: design of a 5‐year follow‐up. European Archives of Psychiatry and Clinical Neuroscience2011;261:S55. [CSzG: Ref23749] SchaferMR , KlierCM , PapageorgiouK , FriedrichMH , AmmingerGP . Early detection of psychotic disorders. Neuropsychiatrie2007;21(1):37‐44. [CSzG: Ref15290] SmesnyS , MilleitB , HiplerUC , MilleitC , SchaferMR , KlierCM , et al. Omega‐3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra‐high risk for psychosis. Molecular Psychiatry2013;19(3):317‐24. [CSzG: Ref28243] SmesnyS , MilleitB , SchaeferMR , HesseJ , SchlögelhoferM , LangbeinK , et al. Effects of omega‐3 PUFA on immune markers in adolescent individuals at ultra‐high risk for psychosis ‐ results of the randomised controlled Vienna omega‐3 study. Schizophrenia Research2017;S0920‐9964(17):30039‐7. [DOI: 10.1016/j.schres.2017.01.026] ">Amminger‐Austria</a> received placebo (coconut oil capsules). Antipsychotic medication and mood stabilisers were not permitted, but participants could receive antidepressants for moderate to severe levels of depression (MADRS score of 21) and benzodiazepines for any one or a combination of anxiety, agitation or insomnia. Also, all participants were offered nine sessions of needs‐based psychological and psychosocial interventions with the research follow‐up interviews. </p> <p><a href="./references#CD012236-bbs2-0013" title="ACTRN12608000475347 . A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder. Australian New Zealand Clinical Trials Registry2009. [CSzG: 18420] HKCTR‐1438 . The NEURAPRO‐E (North America, EURope, Australia PROdrome) Study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for symptomatic patients at ultra‐high risk for early progression to schizophrenia and other psychotic disorders. www.hkClinicaltrials.com/trial_details.aspx?trialID=d09bd177‐b9fd‐4162‐b04f‐3ebfed49baa32011. [CSzG: 29270] McGorryP , MarkulevC , NelsonB , YuenHP , SchaeferM , YungAR , et al. The NEURAPRO‐E study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Schizophrenia Bulletin2015;41:S322‐3. [CSzG: 29546] McGorryPD , NelsonB , MarkulevC , YuenHP , SchaferMR , MossahebN , et al. Effect of omega‐3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomised clinical trial. JAMA psychiatry2017;74(1):19‐27. [CSzG: 35590] NelsonB , AmmingerG , MarkulevC , YuenHP , LavoieS , SchaeferM , et al. NEURAPOR: a multi‐center RCT of omega‐3 polyunsaturated fatty acids versus placebo in young people at ultra‐high risk of psychotic disorders: medium‐term outcome. Schizophrenia Bulletin2017;43:S107. [CSzG: 36016] ">NEURAPRO‐AAE</a> provided control group participants with placebo capsules (paraffin/coconut oil, tocopherols, a small amount of fish oil) with cognitive behavioural case management in the same amount as in the intervention group. During the first 12 months of the study, antidepressants (selective serotonin reuptake inhibitors (SSRI)) were allowed for moderate to severe depression (MADRS score 21 or above for at least two consecutive weeks; <a href="./references#CD012236-bbs2-0162" title="MontgomerySA , AsbergM . A new depression scale designed to be sensitive to change. British Journal of Psychiatry1979;134:382‐9. ">Montgomery 1979</a>) and benzodiazepines for anxiety. Antipsychotics and mood stabilisers were not allowed during the study period (unless the participant was withdrawn). </p> </section> </section> <section id="CD012236-sec-0134"> <h6 class="title">5.2 Group B: comparisons in which interaction is probable</h6> <section id="CD012236-sec-0135"> <p><b>5.2.1 Antipsychotic drugs</b></p> <p>Two included studies assessed efficacy of antipsychotics, alone or in combination with another type of treatment: amisulpiride (<a href="./references#CD012236-bbs2-0011" title="BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: 12511] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] RuhrmannS , BechdolfA , KuhnKU , WagnerM , Schultze‐LutterF Janssen B , et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry. Supplements2007;51:s88‐95. [CSzG: 16127] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Acute symptomatic treatment effects in persons clinically at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13397] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Intervention in the late initial prodromal state (LIPS) of psychosis. Schizophrenia Research2006;86(Suppl 1):S96. [CSzG: 13398] ">LIPS‐Germany</a>), and olanzapine (<a href="./references#CD012236-bbs2-0017" title='BlockJJ , McGlashonTH . Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790‐9. American Journal of Psychiatry2006; Vol. 163, issue 10:1838. [CSzG: 13960] BreierAF , ZipurskyRB , PerkinsDO , AddingtonJM , TohenMF , DavidSR , et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951] HawkinsKA , AddingtonJ , KeefeR , ChristensenB , WoodsS , ZipurskyR , et al. Neuropsychological functioning in the first episode prodrome and early psychosis. Schizophrenia Research2004;70(1):101. [CSzG: 11515] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , MillerTJ , et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research2004;67(1):205. [CSzG: Ref11301] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , ZipurskyRB , et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. [CSzG: 16470] HawkinsKA , KeefeRS , ChristensenBK , AddingtonJ , WoodsSW , CallahanJ , et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. Schizophrenia Research2008;105(1‐3):1‐9. [CSzG: 16983] HoffmanRE , WoodsS , PredaA , TohenM , BreierA , GlistJ , et al. Excessive top‐down perceptual processing and reduced real‐world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. Schizophrenia Research2006;86(Suppl 1):S46. [CSzG: 13377] HoffmanRE , WoodsSW , HawkinsKA , PittmanB , TohenM , PredaA , et al. Extracting spurious messages from noise and risk of schizophrenia‐spectrum disorders in prodromal population. British Journal of Psychiatry2007;191(2):355‐6. [CSzG: 16068] McGlashanT , ZipurskyR , PerkinsD , AddingtonJ . Olanzapine for treatment of the schizophrenia prodrome: 2‐year results of a randomised placebo‐controlled study. Schizophrenia Research2004;67(1):164. [CSzG: 11320] McGlashanTH . Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. [CSzG: 10191] McGlashanTH . Treatment intervention in the New Haven PRIME clinic prodromal sample. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4835] McGlashanTH , MillerTJ , WoodsSW . Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research2002;53(3 Suppl 1):15. [CSzG: 8093] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005] McGlashanTH , MillerTJ , ZipurskyRB , WoodsSW , PerkinsDO , HawkinsKA , et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9803] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerT , WoodsSW , et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry2006;163(5):790‐9. [CSzG: 12654] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerTJ , WoodsSW , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research2003;61(1):7‐18. [CSzG: 9828] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJ , WoodsSW , MillerTJ , et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research2003;60:295. [CSzG: 9722] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJM , WoodsSW , LindborgS , et al. Olanzapine versus pbo for the schizophrenic prodrome: one‐year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9804] McGlashlanTH , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTH , WoodsSW , et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:42. [CSzG: 8934] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , MillerT , WoodsS , et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. Schizophrenia Research2004;70(1):6. [CSzG: 11524] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , WoodsS , MillerT , et al. Olanzapine vs. placebo for prodromal schizophrenia. Schizophrenia Research2004;67(1):6. [CSzG: 11321] MillerTJ , ZipurskyRB , PerkinsD , AddingtonJ , WoodsSW , HawkinsKA , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research2003;61(1):19‐30. [CSzG: 9829] RosenJL , WoodsSW , MillerTJ , McGlashanTH . Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease2002;190:133‐41. [CSzG: 8274] TaylorHE , ParkerS , MansellW , MorrisonAP . Effects of appraisals of anomalous experience on distress in people at risk of psychosis. Behavioural and Cognitive Psychotherapy2012;41(1):24‐33. [CSzG: 24374] WoodsS , ZipurskyR , PerkinsD , AddingtonJ , MarquezE , BreierA , et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:43. [CSzG: 8933] WoodsSW . Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):497. [CSzG: 19829] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research. 2003. [CSzG: 9978] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research2003;60:306‐7. [CSzG: 9752] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):453‐64. [CSzG: 9994] WoodsSW , McGlashanTH . Sample size planning for prodromal intervention trials. Schizophrenia Research2002;53(3 Suppl 1):40. [CSzG: 8116] WoodsSW , ZipurskyRB , PerkinsDO , AddingtonJM , MillerTJ , BreierAF , et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053] '>PRIME‐USA</a>). </p> <p><a href="./references#CD012236-bbs2-0011" title="BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: 12511] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] RuhrmannS , BechdolfA , KuhnKU , WagnerM , Schultze‐LutterF Janssen B , et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry. Supplements2007;51:s88‐95. [CSzG: 16127] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Acute symptomatic treatment effects in persons clinically at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13397] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Intervention in the late initial prodromal state (LIPS) of psychosis. Schizophrenia Research2006;86(Suppl 1):S96. [CSzG: 13398] ">LIPS‐Germany</a> used needs‐focused intervention (NFI) with amisulpiride (mean dose 118 mg/day) in the intervention group and NFI only in the control group for prevention of psychosis in the late initial prodromas state that is defined by the presence of attenuated positive symptoms or brief limited intermittent positive symptoms, or both, within the three months preceding the study using Early Recognition Inventory (ERIraos) questionnaire (<a href="./references#CD012236-bbs2-0158" title="MaurerK , HorrmannF , SchmidtG , TrendlerG , HäfnerH . The early recognition inventory ERIraos: a two‐step procedure for detection of ‘‘at‐risk mental states’’. Schizophrenia Research2004;70 (suppl):s76. ">Maurer 2004</a>). NFI included psychoeducation, crisis intervention, family counselling and assistance with education or work‐related difficulties, according to participants' needs. </p> <p>The Prevention through Risk Identification Management and Education study (<a href="./references#CD012236-bbs2-0017" title='BlockJJ , McGlashonTH . Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790‐9. American Journal of Psychiatry2006; Vol. 163, issue 10:1838. [CSzG: 13960] BreierAF , ZipurskyRB , PerkinsDO , AddingtonJM , TohenMF , DavidSR , et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951] HawkinsKA , AddingtonJ , KeefeR , ChristensenB , WoodsS , ZipurskyR , et al. Neuropsychological functioning in the first episode prodrome and early psychosis. Schizophrenia Research2004;70(1):101. [CSzG: 11515] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , MillerTJ , et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research2004;67(1):205. [CSzG: Ref11301] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , ZipurskyRB , et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. [CSzG: 16470] HawkinsKA , KeefeRS , ChristensenBK , AddingtonJ , WoodsSW , CallahanJ , et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. Schizophrenia Research2008;105(1‐3):1‐9. [CSzG: 16983] HoffmanRE , WoodsS , PredaA , TohenM , BreierA , GlistJ , et al. Excessive top‐down perceptual processing and reduced real‐world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. Schizophrenia Research2006;86(Suppl 1):S46. [CSzG: 13377] HoffmanRE , WoodsSW , HawkinsKA , PittmanB , TohenM , PredaA , et al. Extracting spurious messages from noise and risk of schizophrenia‐spectrum disorders in prodromal population. British Journal of Psychiatry2007;191(2):355‐6. [CSzG: 16068] McGlashanT , ZipurskyR , PerkinsD , AddingtonJ . Olanzapine for treatment of the schizophrenia prodrome: 2‐year results of a randomised placebo‐controlled study. Schizophrenia Research2004;67(1):164. [CSzG: 11320] McGlashanTH . Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. [CSzG: 10191] McGlashanTH . Treatment intervention in the New Haven PRIME clinic prodromal sample. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4835] McGlashanTH , MillerTJ , WoodsSW . Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research2002;53(3 Suppl 1):15. [CSzG: 8093] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005] McGlashanTH , MillerTJ , ZipurskyRB , WoodsSW , PerkinsDO , HawkinsKA , et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9803] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerT , WoodsSW , et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry2006;163(5):790‐9. [CSzG: 12654] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerTJ , WoodsSW , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research2003;61(1):7‐18. [CSzG: 9828] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJ , WoodsSW , MillerTJ , et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research2003;60:295. [CSzG: 9722] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJM , WoodsSW , LindborgS , et al. Olanzapine versus pbo for the schizophrenic prodrome: one‐year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9804] McGlashlanTH , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTH , WoodsSW , et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:42. [CSzG: 8934] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , MillerT , WoodsS , et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. Schizophrenia Research2004;70(1):6. [CSzG: 11524] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , WoodsS , MillerT , et al. Olanzapine vs. placebo for prodromal schizophrenia. Schizophrenia Research2004;67(1):6. [CSzG: 11321] MillerTJ , ZipurskyRB , PerkinsD , AddingtonJ , WoodsSW , HawkinsKA , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research2003;61(1):19‐30. [CSzG: 9829] RosenJL , WoodsSW , MillerTJ , McGlashanTH . Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease2002;190:133‐41. [CSzG: 8274] TaylorHE , ParkerS , MansellW , MorrisonAP . Effects of appraisals of anomalous experience on distress in people at risk of psychosis. Behavioural and Cognitive Psychotherapy2012;41(1):24‐33. [CSzG: 24374] WoodsS , ZipurskyR , PerkinsD , AddingtonJ , MarquezE , BreierA , et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:43. [CSzG: 8933] WoodsSW . Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):497. [CSzG: 19829] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research. 2003. [CSzG: 9978] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research2003;60:306‐7. [CSzG: 9752] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):453‐64. [CSzG: 9994] WoodsSW , McGlashanTH . Sample size planning for prodromal intervention trials. Schizophrenia Research2002;53(3 Suppl 1):40. [CSzG: 8116] WoodsSW , ZipurskyRB , PerkinsDO , AddingtonJM , MillerTJ , BreierAF , et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053] '>PRIME‐USA</a>) compared olanzapine (5 mg/day to 15 mg/day, mean 8 mg/day) with placebo. During the one‐year treatment period, individual and family psychosocial interventions were available for both groups. In case of agitation or insomnia, or both, lorazepam (max 8 mg/day), diazepam (max 40 mg/day) and chloral hydrate (max 100 mg/day) were allowed. Benztropine mesylate or biperiden (max 6 mg/day) were used to treat extrapyramidal symptoms and nizatidine (300 mg/day to 600 mg/day) for weight gain. Antidepressants were allowed at the time of admission (with a tendency to cut them off), but once a patient was randomised, the initiation of antidepressants was not allowed. </p> </section> <section id="CD012236-sec-0136"> <p><b>5.2.2 Cognitive behavioural therapy (CBT)</b></p> <p>a. CBT plus supportive therapy versus supportive therapy alone</p> <p>Five included studies are relevant (<a href="./references#CD012236-bbs2-0001" title="AddingtonJ , EpsteinI , LiuL , FrenchP , BoydellKM , ZipurskyRB . A randomised controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research2011;125(1):54‐61. [CSzG: Ref21945] AddingtonJ , ZipurskyR , EpsteinI . ADAPT (Access, Detection and Psychological Treatments). Schizophrenia Research2006;86(Suppl 1):S6. [CSzG: Ref13364] NCT00260273 . Access, detection and psychological treatments. www.ClinicalTrials.gov/ct/show/2005. [CSzG: Ref14638] ">ADAPT‐Canada</a>; <a href="./references#CD012236-bbs2-0005" title="ByrneRE , MorrisonAP . Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. Psychology and Psychotherapy2014;87(3):357‐71. [CSzG: Ref29312] FlachC , FrenchP , DunnG , FowlerD , GumleyAI , BirchwoodM , et al. Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE‐2 trial. British Journal of Psychiatry2015;207(2):123‐9. [CSzG: Ref33109] MorrisonA . Early detection and intervention evaluation for individuals at high risk of psychosis 2. http://www.controlled‐trials.com2008. [CSzG: Ref18285] MorrisonA . Early detection and intervention evaluation for people at risk of psychosis (edie‐2): A multisite randomised controlled trial of cognitive therapy for at‐risk mental states. Early Intervention in Psychiatry2012;6:11. [CSzG: Ref24968] MorrisonA , FrenchP , BentallR , LewisS , BirchwoodM , FowlerD , et al. Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. Early Intervention in Psychiatry2008;2(Suppl 1):A15. [CSzG: Ref19128] MorrisonAP . EDIE‐2: early detection and psychological intervention for individuals at high risk of psychosis (2). www.controlled‐trials.com2007. [CSzG: Ref15381] MorrisonAP , BirchwoodM , PyleM , FlachC , StewartSL , ByrneR , et al. Impact of cognitive therapy on internalised stigma in people with at‐risk mental states. British Journal of Psychiatry2013;203(2):140‐5. [CSzG: Ref28630] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ2012;344(7852):e2233. [CSzG: Ref24208] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at‐risk of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29554] MorrisonAP , PyleM , StewartSL , FrenchP , ByrneR , FlachC , et al. Internalised stigma in young people at high risk of developing psychosis: findings from a cognitive therapy trial. Schizophrenia Research2014;153:S42. [CSzG: Ref29555] MorrisonAP , StewartSL , FrenchP , BentallRP , BirchwoodM , ByrneR , et al. Early detection and intervention evaluation for people at high‐risk of psychosis‐2 (EDIE‐2): trial rationale, design and baseline characteristics. Early Intervention in Psychiatry2011;5(1):24‐32. [CSzG: Ref22695] MorrisonT . Early detection and psychological intervention for individuals at high risk of psychosis. EDIE‐2. Data on File2006. [CSzG: Ref13874] PelosiAJ . Rational policy making for early psychosis might yet become possible. BMJ2012;344(7856):e3137. [CSzG: Ref24326] PyleM , StewartSL , FrenchP , ByrneR , PattersonP , GumleyA , et al. Internalised stigma, emotional dysfunction and unusual experiences in young people at risk of psychosis. Early Intervention in Psychiatry2015;9(2):133‐40. [CSzG: Ref29813] ">EDIE‐2‐UK</a>; <a href="./references#CD012236-bbs2-0006" title="DragtS , Van derGaagM . Prevention of psychosis with a cognitive behavioural intervention in help‐seeking young people with an at risk mental state for developing psychosis. www.trialregister.nl/trialreg/index.asp2007. [CSzG: Ref19655] IsingHK , KraanTC , RietdijkJ , DragtS , KlaassenRM , BoonstraN , et al. Four‐year follow‐up of cognitive behavioral therapy in persons at ultra‐high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2016;42(5):1243‐52. [CSzG: Ref35214] IsingHK , LokkerbolJ , RietdijkJ , DragtS , KlaassenRM , KraanT , et al. Four‐year cost‐effectiveness of cognitive behavior therapy for preventing first‐episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2017;43(2):365‐74. [CSzG: Ref35824] IsingHK , SmitF , VelingW , RietdijkJ , DragtS , KlaassenRM , et al. Cost‐effectiveness of preventing first‐episode psychosis in ultra‐high‐risk subjects: multi‐centre randomised controlled trial. Psychological Medicine2015;45(7):1435‐46. [CSzG: Ref27798] KraanTC , IsingHK , FokkemaM , VelthorstE , Van denBergDP , KerkhovenM , et al. The effect of childhood adversity on 4‐year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE‐NL) Trial. Psychiatry Research2017;247:55‐62. [CSzG: Ref35559] NiemanDH , RuhrmannS , RietdijkJ , DragtS , IsingH , KlaassenR , et al. Preventive psychotherapy. Schizophrenia Research2014;153:S42‐3. [CSzG: Ref29601] RietdijkJ , DragtS , KlaassenR , IsingH , NiemanD , WunderinkL , et al. A single blind randomised controlled trial of cognitive behavioural therapy in a help‐seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE‐NL) trial. Trials2010;11:30. [CSzG: Ref20654] Van DerGaagM . The effects of CBT in personswith ultra high risk: the Dutch EDIE trial. European Archives of Psychiatry and Clinical Neuroscience2011;261:S18. [CSzG: Ref23756] Van DerGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first‐episode of psychosis. Early Intervention in Psychiatry2012;6:12. [CSzG: Ref24985] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomised controlled clinical trial. Schizophrenia Bulletin2012;38(6):1180‐8. [CSzG: Ref24935] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. The effects of cognitive behavioural therapy for subjects at ultra‐high risk for developing psychosis. Schizophrenia Bulletin2013;39:S356. [CSzG: Ref28121] Van derGaagM . The prevention of psychosis in at risk mental state. www.controlled‐trials.com2008. [CSzG: Ref17488] Van derGaagM , NiemanD , Van denBergD . CBT for those at risk of a first episode psychosis: Evidence‐based psychotherapy for people with an 'at risk mental state'. 1st Edition. Hove, UK: Routledge, 2013. Van derGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first episode of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29692] ">EDIE‐NL</a><a href="./references#CD012236-bbs2-0007" title="FrenchP , ShryaneN , BentallRP , LewisSW , MorrisonAP . Effects of cognitive therapy on the longitudinal development of psychotic experiences in people at high risk of developing psychosis. British Journal of Psychiatry. Supplements2007;191(Suppl 51):s82‐7. [CSzG: Ref16121] LewisS . EDIE ‐ Early detection and intervention for psychosis. National Research Register2001; Vol. 3. [CSzG: Ref13023] LewisS . EDIE ‐ early detection and intervention for psychosis (in primary care). National Research Register2002; Vol. 1. [CszG: Ref9342] MorrisonA . Early detection and intervention for psychosis in primary care. National Research Register2003. [CSzG: Ref15485] MorrisonA . Findings from a randomised controlled trial and clinical service delivering cognitive therapy to people at ultra‐high risk of developing psychosis. Schizophrenia Research2004;70(1):43‐4. [CSzG: Ref11526] MorrisonA . Follow‐up of prodromal symptoms. National Research Register2004; Vol. 3. [CSzG: Ref13036] MorrisonA , BentallR , FrenchP , Kilcommons A, LewisSW . Very early intervention in prodromal psychosis: a randomised trial. Schizophrenia Research2002;53(3 Suppl 1):42. [CSzG: Ref8096] MorrisonA , FrenchP , WalfordL , LewisS , Kilcommons A, GreenJ , et al. A randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;67(1):7. [CSzG: Ref11324] MorrisonA , FrenchP , WatfordL , LewisS , Kilcommons A, GreenJ , et al. Randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;70(1):63. [CSzG: Ref11527] MorrisonAP . Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: results of a randomised controlled trial. Schizophrenia Research2006;86(Suppl 1):S59. [CSzG: Ref13388] MorrisonAP , BentallRP , FrenchP , Kilcommons A, GreenJ , WalfordL , et al. Cognitive therapy in ultra high risk individuals for psychosis: randomised controlled trial. Schizophrenia Research2003;60:326. [CSzG: Ref9726] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, KnightA , et al. Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high‐risk individuals. Study design and interim analysis of transition rate and psychological risk factors. British Journal of Psychiatry. Supplements2002;181(43):s78‐84. [CSzG: Ref8737] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, LewisS . Early detection and intervention for psychosis in primary care. 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002. [CSzG: Ref8932] MorrisonAP , FrenchP , ParkerS , RobertsM , StevensH , BentallRP , et al. Three‐year follow‐up of a randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophrenia Bulletin2007;33(3):682‐7. [CSzG: Ref15288] MorrisonAP , FrenchP , WalfordL , LewisSW , Kilcommons A, GreenJ , et al. Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: randomised controlled trial. British Journal of Psychiatry2004;185:291‐7. [CSzG: Ref11450] MorrisonT . Early detection and intervention for psychosis in primary care. National Research Register2001; Vol. 1. [CSzG: Ref13037] MorrisonT , BentallR , FrenchP , Kilcommons A, GreenJ , LewisS . Early detection and intervention for psychosis in primary care. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:44. [CSzG: Ref8932] RentonJ , MorrisonA . Effectiveness of cognitive therapy for psychosis and implications for early intervention. Schizophrenia Research2004;70(1):142. [CSzG: Ref11536] ">EDIE‐UK</a>; <a href="./references#CD012236-bbs2-0009" title="BechdolfA . Preventing progression to first‐episode psychosis in people in the early initial prodromal state. Early Intervention in Psychiatry2012;6:11. [CSzG: 24944] BechdolfA , BuhlerB , BerningJ , WagnerM , StammE , StreitM . Cognitive behavioural therapy in the early initial prodromal state of psychosis: first results. Schizophrenia Research2004;67(1):202. [CSzG: Ref11285] BechdolfA , KlosterkotterJ . Cognitive‐behavioural treatment (CBT) in the early initial prodromal state of psychosis: concept and practical approach. Schizophrenia Research2004;70(1):52. [CSzG: Ref11506] BechdolfA , RuhrmannS , JanssenB , BottlenderR , WagnerM , MaurerK , et al. Early recognition and intervention for people at risk of schizophrenia [Fruherkennung und intervention bei personen mit erhohtem psychoserisiko]. Psychoneuroendocrinology2004;30(11):606‐14. [CSzG: Ref11376] BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: Ref12511] BechdolfA , VeithV , BerningJ , StammE , DeckerP , JanssenB , et al. Cognitive behavioral therapy (CBT) in the early initial prodromal state of psychosis: first results of a randomised trial. Schizophrenia Research2004;70(1):62‐3. [CSzG: Ref11507] BechdolfA , WagnerM , RuhrmannS , HarriganS , PutzfeldV , PukropR , et al. Preventing progression to first‐episode psychosis in early initial prodromal states. British Journal of Psychiatry2012;200(1):22‐9. [CSzG: Ref24206] BechdolfA , WagnerM , RuhrmannS , HarriganS , VeithV , PukropR , et al. CBT for prevention of first episode psychosis in people in an putative early initial prodromal state. Early Intervention in Psychiatry2008;2(Suppl 1):A16. [CSzG: 19109] BechdolfA , WagnerM , VeithV , PukropR , BerningJ , StammE , et al. A randomised controlled trial of cognitive‐behavioral therapy in the early initial prodromal state of psychosis. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:22‐3. [CSzG: 20193] BechdolfA , WagnerM , VeithV , RuhrmannR , JanssenB , BottlenderR , et al. A randomised controlled multicenter trial of cognitive behaviour therapy in the early initial prodromal state of psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13369] BechdolfA , WagnerM , VeithV , RuhrmannS , PukropR , Brockhaus‐DumkeA , et al. Randomised controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Intervention in Psychiatry2007;1(1):71‐8. [CSzG: 16450] BechdolfA , WesselsH , WagnerM , KuhrK , BerningJ , PutzfeldV , et al. Predictors of treatment response to psychosocial interventions in people at risk. European Archives of Psychiatry and Clinical Neuroscience2015;1:S9. [CSzG: 33601] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] KommescherM , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. Early Intervention in Psychiatry2016;10(1):17‐27. [CSzG: 32187] NCT00204087 . Psychological intervention for persons at risk of psychosis in the early initial prodromal state. www.ClinicalTrials.gov/ct/show/2005. [CSzG: 14890] WesselsH , WagnerM , FrommannI , BerningJ , PutzfeldV , JanssenB , et al. Neuropsychological functioning as a predictor of treatment response to psychoeducational, cognitive behavioral therapy in people at clinical high risk of first episode psychosis. Psychiatrische Praxis2015;42(6):313‐9. [CSzG: 33130] ZarafonitisS , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Psychoeducation for persons at risk of psychosis. Psychotherapeut2012;57(4):326‐34. [CSzG: 24807] ">EIPS‐Germany</a>). </p> <p>i. Cognitive behavioural therapy (CBT)</p> <p>CBT sessions were manualised and time limited, ranging from 20 sessions (<a href="./references#CD012236-bbs2-0001" title="AddingtonJ , EpsteinI , LiuL , FrenchP , BoydellKM , ZipurskyRB . A randomised controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research2011;125(1):54‐61. [CSzG: Ref21945] AddingtonJ , ZipurskyR , EpsteinI . ADAPT (Access, Detection and Psychological Treatments). Schizophrenia Research2006;86(Suppl 1):S6. [CSzG: Ref13364] NCT00260273 . Access, detection and psychological treatments. www.ClinicalTrials.gov/ct/show/2005. [CSzG: Ref14638] ">ADAPT‐Canada</a>), to 30 sessions (<a href="./references#CD012236-bbs2-0009" title="BechdolfA . Preventing progression to first‐episode psychosis in people in the early initial prodromal state. Early Intervention in Psychiatry2012;6:11. [CSzG: 24944] BechdolfA , BuhlerB , BerningJ , WagnerM , StammE , StreitM . Cognitive behavioural therapy in the early initial prodromal state of psychosis: first results. Schizophrenia Research2004;67(1):202. [CSzG: Ref11285] BechdolfA , KlosterkotterJ . Cognitive‐behavioural treatment (CBT) in the early initial prodromal state of psychosis: concept and practical approach. Schizophrenia Research2004;70(1):52. [CSzG: Ref11506] BechdolfA , RuhrmannS , JanssenB , BottlenderR , WagnerM , MaurerK , et al. Early recognition and intervention for people at risk of schizophrenia [Fruherkennung und intervention bei personen mit erhohtem psychoserisiko]. Psychoneuroendocrinology2004;30(11):606‐14. [CSzG: Ref11376] BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: Ref12511] BechdolfA , VeithV , BerningJ , StammE , DeckerP , JanssenB , et al. Cognitive behavioral therapy (CBT) in the early initial prodromal state of psychosis: first results of a randomised trial. Schizophrenia Research2004;70(1):62‐3. [CSzG: Ref11507] BechdolfA , WagnerM , RuhrmannS , HarriganS , PutzfeldV , PukropR , et al. Preventing progression to first‐episode psychosis in early initial prodromal states. British Journal of Psychiatry2012;200(1):22‐9. [CSzG: Ref24206] BechdolfA , WagnerM , RuhrmannS , HarriganS , VeithV , PukropR , et al. CBT for prevention of first episode psychosis in people in an putative early initial prodromal state. Early Intervention in Psychiatry2008;2(Suppl 1):A16. [CSzG: 19109] BechdolfA , WagnerM , VeithV , PukropR , BerningJ , StammE , et al. A randomised controlled trial of cognitive‐behavioral therapy in the early initial prodromal state of psychosis. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:22‐3. [CSzG: 20193] BechdolfA , WagnerM , VeithV , RuhrmannR , JanssenB , BottlenderR , et al. A randomised controlled multicenter trial of cognitive behaviour therapy in the early initial prodromal state of psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13369] BechdolfA , WagnerM , VeithV , RuhrmannS , PukropR , Brockhaus‐DumkeA , et al. Randomised controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Intervention in Psychiatry2007;1(1):71‐8. [CSzG: 16450] BechdolfA , WesselsH , WagnerM , KuhrK , BerningJ , PutzfeldV , et al. Predictors of treatment response to psychosocial interventions in people at risk. European Archives of Psychiatry and Clinical Neuroscience2015;1:S9. [CSzG: 33601] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] KommescherM , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. Early Intervention in Psychiatry2016;10(1):17‐27. [CSzG: 32187] NCT00204087 . Psychological intervention for persons at risk of psychosis in the early initial prodromal state. www.ClinicalTrials.gov/ct/show/2005. [CSzG: 14890] WesselsH , WagnerM , FrommannI , BerningJ , PutzfeldV , JanssenB , et al. Neuropsychological functioning as a predictor of treatment response to psychoeducational, cognitive behavioral therapy in people at clinical high risk of first episode psychosis. Psychiatrische Praxis2015;42(6):313‐9. [CSzG: 33130] ZarafonitisS , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Psychoeducation for persons at risk of psychosis. Psychotherapeut2012;57(4):326‐34. [CSzG: 24807] ">EIPS‐Germany</a>). The sessions were individual therapy sessions. The CBT sessions focused on a combination of psychoeducation, symptom, stress and crisis management, as well as any anxiety, depression, family or occupational problems. </p> <p>ii. Supportive therapy</p> <p>Supportive therapy varied between studies. <a href="./references#CD012236-bbs2-0001" title="AddingtonJ , EpsteinI , LiuL , FrenchP , BoydellKM , ZipurskyRB . A randomised controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research2011;125(1):54‐61. [CSzG: Ref21945] AddingtonJ , ZipurskyR , EpsteinI . ADAPT (Access, Detection and Psychological Treatments). Schizophrenia Research2006;86(Suppl 1):S6. [CSzG: Ref13364] NCT00260273 . Access, detection and psychological treatments. www.ClinicalTrials.gov/ct/show/2005. [CSzG: Ref14638] ">ADAPT‐Canada</a> provided active supportive psychological therapy during the six‐month treatment period. <a href="./references#CD012236-bbs2-0009" title="BechdolfA . Preventing progression to first‐episode psychosis in people in the early initial prodromal state. Early Intervention in Psychiatry2012;6:11. [CSzG: 24944] BechdolfA , BuhlerB , BerningJ , WagnerM , StammE , StreitM . Cognitive behavioural therapy in the early initial prodromal state of psychosis: first results. Schizophrenia Research2004;67(1):202. [CSzG: Ref11285] BechdolfA , KlosterkotterJ . Cognitive‐behavioural treatment (CBT) in the early initial prodromal state of psychosis: concept and practical approach. Schizophrenia Research2004;70(1):52. [CSzG: Ref11506] BechdolfA , RuhrmannS , JanssenB , BottlenderR , WagnerM , MaurerK , et al. Early recognition and intervention for people at risk of schizophrenia [Fruherkennung und intervention bei personen mit erhohtem psychoserisiko]. Psychoneuroendocrinology2004;30(11):606‐14. [CSzG: Ref11376] BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: Ref12511] BechdolfA , VeithV , BerningJ , StammE , DeckerP , JanssenB , et al. Cognitive behavioral therapy (CBT) in the early initial prodromal state of psychosis: first results of a randomised trial. Schizophrenia Research2004;70(1):62‐3. [CSzG: Ref11507] BechdolfA , WagnerM , RuhrmannS , HarriganS , PutzfeldV , PukropR , et al. Preventing progression to first‐episode psychosis in early initial prodromal states. British Journal of Psychiatry2012;200(1):22‐9. [CSzG: Ref24206] BechdolfA , WagnerM , RuhrmannS , HarriganS , VeithV , PukropR , et al. CBT for prevention of first episode psychosis in people in an putative early initial prodromal state. Early Intervention in Psychiatry2008;2(Suppl 1):A16. [CSzG: 19109] BechdolfA , WagnerM , VeithV , PukropR , BerningJ , StammE , et al. A randomised controlled trial of cognitive‐behavioral therapy in the early initial prodromal state of psychosis. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:22‐3. [CSzG: 20193] BechdolfA , WagnerM , VeithV , RuhrmannR , JanssenB , BottlenderR , et al. A randomised controlled multicenter trial of cognitive behaviour therapy in the early initial prodromal state of psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13369] BechdolfA , WagnerM , VeithV , RuhrmannS , PukropR , Brockhaus‐DumkeA , et al. Randomised controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Intervention in Psychiatry2007;1(1):71‐8. [CSzG: 16450] BechdolfA , WesselsH , WagnerM , KuhrK , BerningJ , PutzfeldV , et al. Predictors of treatment response to psychosocial interventions in people at risk. European Archives of Psychiatry and Clinical Neuroscience2015;1:S9. [CSzG: 33601] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] KommescherM , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. Early Intervention in Psychiatry2016;10(1):17‐27. [CSzG: 32187] NCT00204087 . Psychological intervention for persons at risk of psychosis in the early initial prodromal state. www.ClinicalTrials.gov/ct/show/2005. [CSzG: 14890] WesselsH , WagnerM , FrommannI , BerningJ , PutzfeldV , JanssenB , et al. Neuropsychological functioning as a predictor of treatment response to psychoeducational, cognitive behavioral therapy in people at clinical high risk of first episode psychosis. Psychiatrische Praxis2015;42(6):313‐9. [CSzG: 33130] ZarafonitisS , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Psychoeducation for persons at risk of psychosis. Psychotherapeut2012;57(4):326‐34. [CSzG: 24807] ">EIPS‐Germany</a> also provided supportive counselling to control participants. </p> <p>The control group in <a href="./references#CD012236-bbs2-0005" title="ByrneRE , MorrisonAP . Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. Psychology and Psychotherapy2014;87(3):357‐71. [CSzG: Ref29312] FlachC , FrenchP , DunnG , FowlerD , GumleyAI , BirchwoodM , et al. Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE‐2 trial. British Journal of Psychiatry2015;207(2):123‐9. [CSzG: Ref33109] MorrisonA . Early detection and intervention evaluation for individuals at high risk of psychosis 2. http://www.controlled‐trials.com2008. [CSzG: Ref18285] MorrisonA . Early detection and intervention evaluation for people at risk of psychosis (edie‐2): A multisite randomised controlled trial of cognitive therapy for at‐risk mental states. Early Intervention in Psychiatry2012;6:11. [CSzG: Ref24968] MorrisonA , FrenchP , BentallR , LewisS , BirchwoodM , FowlerD , et al. Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. Early Intervention in Psychiatry2008;2(Suppl 1):A15. [CSzG: Ref19128] MorrisonAP . EDIE‐2: early detection and psychological intervention for individuals at high risk of psychosis (2). www.controlled‐trials.com2007. [CSzG: Ref15381] MorrisonAP , BirchwoodM , PyleM , FlachC , StewartSL , ByrneR , et al. Impact of cognitive therapy on internalised stigma in people with at‐risk mental states. British Journal of Psychiatry2013;203(2):140‐5. [CSzG: Ref28630] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ2012;344(7852):e2233. [CSzG: Ref24208] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at‐risk of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29554] MorrisonAP , PyleM , StewartSL , FrenchP , ByrneR , FlachC , et al. Internalised stigma in young people at high risk of developing psychosis: findings from a cognitive therapy trial. Schizophrenia Research2014;153:S42. [CSzG: Ref29555] MorrisonAP , StewartSL , FrenchP , BentallRP , BirchwoodM , ByrneR , et al. Early detection and intervention evaluation for people at high‐risk of psychosis‐2 (EDIE‐2): trial rationale, design and baseline characteristics. Early Intervention in Psychiatry2011;5(1):24‐32. [CSzG: Ref22695] MorrisonT . Early detection and psychological intervention for individuals at high risk of psychosis. EDIE‐2. Data on File2006. [CSzG: Ref13874] PelosiAJ . Rational policy making for early psychosis might yet become possible. BMJ2012;344(7856):e3137. [CSzG: Ref24326] PyleM , StewartSL , FrenchP , ByrneR , PattersonP , GumleyA , et al. Internalised stigma, emotional dysfunction and unusual experiences in young people at risk of psychosis. Early Intervention in Psychiatry2015;9(2):133‐40. [CSzG: Ref29813] ">EDIE‐2‐UK</a> had treatment as usual plus regular monitoring. This provided warm, empathic and non‐judgemental face‐to‐face contact, supportive listening and signposting to appropriate local services for unmet needs and crisis management when required. <a href="./references#CD012236-bbs2-0006" title="DragtS , Van derGaagM . Prevention of psychosis with a cognitive behavioural intervention in help‐seeking young people with an at risk mental state for developing psychosis. www.trialregister.nl/trialreg/index.asp2007. [CSzG: Ref19655] IsingHK , KraanTC , RietdijkJ , DragtS , KlaassenRM , BoonstraN , et al. Four‐year follow‐up of cognitive behavioral therapy in persons at ultra‐high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2016;42(5):1243‐52. [CSzG: Ref35214] IsingHK , LokkerbolJ , RietdijkJ , DragtS , KlaassenRM , KraanT , et al. Four‐year cost‐effectiveness of cognitive behavior therapy for preventing first‐episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2017;43(2):365‐74. [CSzG: Ref35824] IsingHK , SmitF , VelingW , RietdijkJ , DragtS , KlaassenRM , et al. Cost‐effectiveness of preventing first‐episode psychosis in ultra‐high‐risk subjects: multi‐centre randomised controlled trial. Psychological Medicine2015;45(7):1435‐46. [CSzG: Ref27798] KraanTC , IsingHK , FokkemaM , VelthorstE , Van denBergDP , KerkhovenM , et al. The effect of childhood adversity on 4‐year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE‐NL) Trial. Psychiatry Research2017;247:55‐62. [CSzG: Ref35559] NiemanDH , RuhrmannS , RietdijkJ , DragtS , IsingH , KlaassenR , et al. Preventive psychotherapy. Schizophrenia Research2014;153:S42‐3. [CSzG: Ref29601] RietdijkJ , DragtS , KlaassenR , IsingH , NiemanD , WunderinkL , et al. A single blind randomised controlled trial of cognitive behavioural therapy in a help‐seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE‐NL) trial. Trials2010;11:30. [CSzG: Ref20654] Van DerGaagM . The effects of CBT in personswith ultra high risk: the Dutch EDIE trial. European Archives of Psychiatry and Clinical Neuroscience2011;261:S18. [CSzG: Ref23756] Van DerGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first‐episode of psychosis. Early Intervention in Psychiatry2012;6:12. [CSzG: Ref24985] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomised controlled clinical trial. Schizophrenia Bulletin2012;38(6):1180‐8. [CSzG: Ref24935] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. The effects of cognitive behavioural therapy for subjects at ultra‐high risk for developing psychosis. Schizophrenia Bulletin2013;39:S356. [CSzG: Ref28121] Van derGaagM . The prevention of psychosis in at risk mental state. www.controlled‐trials.com2008. [CSzG: Ref17488] Van derGaagM , NiemanD , Van denBergD . CBT for those at risk of a first episode psychosis: Evidence‐based psychotherapy for people with an 'at risk mental state'. 1st Edition. Hove, UK: Routledge, 2013. Van derGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first episode of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29692] ">EDIE‐NL</a> provided the control group with treatment as usual for the mental problems that they were seeking help for (e.g. depression, attention deficit hyperactivity disorder (ADHD) or anxiety disorder). <a href="./references#CD012236-bbs2-0007" title="FrenchP , ShryaneN , BentallRP , LewisSW , MorrisonAP . Effects of cognitive therapy on the longitudinal development of psychotic experiences in people at high risk of developing psychosis. British Journal of Psychiatry. Supplements2007;191(Suppl 51):s82‐7. [CSzG: Ref16121] LewisS . EDIE ‐ Early detection and intervention for psychosis. National Research Register2001; Vol. 3. [CSzG: Ref13023] LewisS . EDIE ‐ early detection and intervention for psychosis (in primary care). National Research Register2002; Vol. 1. [CszG: Ref9342] MorrisonA . Early detection and intervention for psychosis in primary care. National Research Register2003. [CSzG: Ref15485] MorrisonA . Findings from a randomised controlled trial and clinical service delivering cognitive therapy to people at ultra‐high risk of developing psychosis. Schizophrenia Research2004;70(1):43‐4. [CSzG: Ref11526] MorrisonA . Follow‐up of prodromal symptoms. National Research Register2004; Vol. 3. [CSzG: Ref13036] MorrisonA , BentallR , FrenchP , Kilcommons A, LewisSW . Very early intervention in prodromal psychosis: a randomised trial. Schizophrenia Research2002;53(3 Suppl 1):42. [CSzG: Ref8096] MorrisonA , FrenchP , WalfordL , LewisS , Kilcommons A, GreenJ , et al. A randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;67(1):7. [CSzG: Ref11324] MorrisonA , FrenchP , WatfordL , LewisS , Kilcommons A, GreenJ , et al. Randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;70(1):63. [CSzG: Ref11527] MorrisonAP . Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: results of a randomised controlled trial. Schizophrenia Research2006;86(Suppl 1):S59. [CSzG: Ref13388] MorrisonAP , BentallRP , FrenchP , Kilcommons A, GreenJ , WalfordL , et al. Cognitive therapy in ultra high risk individuals for psychosis: randomised controlled trial. Schizophrenia Research2003;60:326. [CSzG: Ref9726] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, KnightA , et al. Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high‐risk individuals. Study design and interim analysis of transition rate and psychological risk factors. British Journal of Psychiatry. Supplements2002;181(43):s78‐84. [CSzG: Ref8737] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, LewisS . Early detection and intervention for psychosis in primary care. 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002. [CSzG: Ref8932] MorrisonAP , FrenchP , ParkerS , RobertsM , StevensH , BentallRP , et al. Three‐year follow‐up of a randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophrenia Bulletin2007;33(3):682‐7. [CSzG: Ref15288] MorrisonAP , FrenchP , WalfordL , LewisSW , Kilcommons A, GreenJ , et al. Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: randomised controlled trial. British Journal of Psychiatry2004;185:291‐7. [CSzG: Ref11450] MorrisonT . Early detection and intervention for psychosis in primary care. National Research Register2001; Vol. 1. [CSzG: Ref13037] MorrisonT , BentallR , FrenchP , Kilcommons A, GreenJ , LewisS . Early detection and intervention for psychosis in primary care. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:44. [CSzG: Ref8932] RentonJ , MorrisonA . Effectiveness of cognitive therapy for psychosis and implications for early intervention. Schizophrenia Research2004;70(1):142. [CSzG: Ref11536] ">EDIE‐UK</a> monitored the control group without any active psychological intervention. However participants were provided with elements of case management for resolving crises with social issues and mental health risk. </p> <p><i>b. CBT plus risperidone versus CBT plus placebo</i> </p> <p>One study is relevant to this comparison (<a href="./references#CD012236-bbs2-0020" title="McGorryP . Second generation intervention research in the pre‐psychotic phase of illness in schizophrenia and related psychoses. Australian New Zealand Clinical Trials Registry2000. [CSzG: 18439] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceyS , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: 12‐month outcome. Schizophrenia Research2012;136:S17‐8. [CSzG: 29547] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceySM , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: twelve‐month outcome. Journal of Clinical Psychiatry2013;74(4):349‐56. [CSzG: 28737] NelsonB , PhillipsLJ , YungAR , FranceySM , LeicesterS , BakerK , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and supportive therapy in young people with subthreshold symptoms at incipient risk of psychotic disorder: baseline characteristics of the sample. Schizophrenia Bulletin2007;33(2):450. [CSzG: 15212] PhillipsLJ , NelsonB , YuenHP , FranceySM , SimmonsM , StanfordC , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: study design and baseline characteristics. Australian and New Zealand Journal of Psychiatry2009;;43(9):818–29. YungA , AmmingerP , BergerG , ThompsomA , PhillipsL , NelsonB , et al. Randomised controlled trial of antipsychotic and cognitive therapy in young people at ultra‐high risk of psychosis. Early Intervention in Psychiatry2012;6:11. [CSzG: 24989] YungA , NelsonB , PhillipsL , FranceyS , LeicesterS , YuenH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and supportive therapy in young people at ultra high risk of psychotic disorder: 12 month outcome data. Early Intervention in Psychiatry2008;2(Suppl 1):A12. [CSzG: 19138] YungAR , PhillipsLJ , NelsonB , FranceySM , YuenHP , SimmonsMB , et al. Randomised controlled trial of interventions for young people at ultra high risk for psychosis: 6‐month analysis. Journal of Clinical Psychiatry2011;72(4):430‐40. [CSzG: 22929] ">Yung‐Australia</a>). </p> <p>i. Cognitive behavioural therapy (CBT)</p> <p>CBT sessions were manualised and time limited. These sessions were tailored to meet the individual’s needs, to help them to understand and cope with experienced symptoms, enhancing the control of them and reducing associated distress. </p> <p>ii. Risperidone</p> <p>The risperidone that was given with the CBT was at a low dose (0.5 mg/day to 2.0 mg/day).</p> <p><i>c. CBT (specific preventive intervention) plus needs‐based intervention versus needs‐based intervention</i> </p> <p><a href="./references#CD012236-bbs2-0015" title="McGorryP . Can the onset of schizophrenia be delayed or prevented?. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S26. [CSzG: 8351] McGorryP , AdlardS , YungA , McDonaldA , PhillipsL , HearnN . Detection and intervention in pre‐psychotic schizophrenia. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4836] McGorryP , YungA , FranceyS , PhillipsL , NelsonB . A blinded, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and befriending in young people at risk of psychotic disorder: baseline characteristics of the sample. Acta Neuropsychiatrica2006;18(6):261. [CSzG: 35157] McGorryPD , HearnN , GermanoD , BravinJ , PhillipsLJ , YungAR , et al. Prepsychotic intervention in schizophrenia: a stitch in time?. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington DC, USA. 1999. [CSzG: 3584] McGorryPD , PhillipsLJ , NelsonB , LeicesterS , BakerK , KrstevH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and befriending in young people with subthreshold symptoms at incipient risk of psychotic disorder: six month outcome data. Schizophrenia Bulletin2007;33(2):446. [CSzG: 15203] McGorryPD , PhillipsLJ , YungAR , FranceyS , GermanoD , BravinJ , et al. A randomised controlled trial of interventions in the pre psychotic phase of psychotic disorders. Schizophrenia Research2000;41(1):9. [CSzG: 5149] McGorryPD , YungAR , PhillipsL , AdlardS , HallgrenM , PattonG , et al. Pre‐psychotic intervention in schizophrenia: a stitch in time?. Schizophrenia Research1998;29(1‐2):160. [CSzG: 3585] McGorryPD , YungAR , PhillipsLJ , YuenHP , FranceyS , CosgraveEM , et al. Randomised controlled trial of interventions designed to reduce the risk of progression to first‐episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry2002;59(10):921‐8. [CSzG: 8576] PhilippsLJ , McGorryP , YungA , FranceyD , GermanoF , BravinJ , et al. The development of preventive interventions for early psychosis: early findings and directions for the future. 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001; Vol. 2, issue Suppl 1. [CSzG: 7614] PhillipsL , CottonS , YuenHP , MihalopoulosC , ShihS , KellyD , et al. Cost effectiveness of a preventive intervention for young people at ultra high risk of developing psychosis. Schizophrenia Bulletin2007;33(2):488‐9. [CSzG: 15227] PhillipsLJ , CottonS , MihalopoulosC , ShihS , YungAR , CarterR , et al. Cost implications of specific and non‐specific treatment for young persons at ultra high risk of developing a first episode of psychosis. Early Intervention in Psychiatry2009;3(1):28‐34. [CSzG: 18308] PhillipsLJ , LeicesterSB , O'DwyerLE , FranceySM , KoutsogiannisJ , Abdel‐BakiA , et al. The PACE clinic: identification and management of young people at &quot;ultra&quot; high risk of psychosis. Journal of Psychiatric Practice2002;8(5):255‐69. [CSzG: 18235] PhillipsLJ , McGorryPD , YuenHP , WardJ , DonovanK , KellyD , et al. Medium term follow‐up of a randomised controlled trial of interventions for young people at ultra high risk of psychosis. Schizophrenia Research2007;96(1‐3):25‐33. [CSzG: 15544] PhillipsLJ , YungAR , YuenHP , PantelisC , McGorryPD . Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. American Journal of Medical Genetics2002;114(8):929‐37. [CSzG: 18236] ">PACE‐Australia</a> randomised patients into two groups: needs‐based intervention (NBI) and specific preventive intervention (SPI). </p> <p>i. Specific preventive intervention</p> <p>SPI included manualised CBT and low doses of risperidone (mean dosage 1.3mg/day), along with all elements of NBI. </p> <p>ii. Needs‐based intervention</p> <p>NBI comprised supportive psychotherapy primarily focusing on pertinent issues such as social relationships and vocational and family issues. Both groups received case management from a PACE (Playfulness, Acceptance, Curiosity and Empathy) therapist. </p> </section> </section> <section id="CD012236-sec-0137"> <h6 class="title">5.3 Group C: differential effects</h6> <section id="CD012236-sec-0138"> <p><b>5.3.1 Cognitive behavioural therapy (CBT)</b></p> <p><i>a. CBT versus supportive therapy</i> </p> <p>One study is relevant to this comparison (<a href="./references#CD012236-bbs2-0020" title="McGorryP . Second generation intervention research in the pre‐psychotic phase of illness in schizophrenia and related psychoses. Australian New Zealand Clinical Trials Registry2000. [CSzG: 18439] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceyS , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: 12‐month outcome. Schizophrenia Research2012;136:S17‐8. [CSzG: 29547] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceySM , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: twelve‐month outcome. Journal of Clinical Psychiatry2013;74(4):349‐56. [CSzG: 28737] NelsonB , PhillipsLJ , YungAR , FranceySM , LeicesterS , BakerK , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and supportive therapy in young people with subthreshold symptoms at incipient risk of psychotic disorder: baseline characteristics of the sample. Schizophrenia Bulletin2007;33(2):450. [CSzG: 15212] PhillipsLJ , NelsonB , YuenHP , FranceySM , SimmonsM , StanfordC , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: study design and baseline characteristics. Australian and New Zealand Journal of Psychiatry2009;;43(9):818–29. YungA , AmmingerP , BergerG , ThompsomA , PhillipsL , NelsonB , et al. Randomised controlled trial of antipsychotic and cognitive therapy in young people at ultra‐high risk of psychosis. Early Intervention in Psychiatry2012;6:11. [CSzG: 24989] YungA , NelsonB , PhillipsL , FranceyS , LeicesterS , YuenH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and supportive therapy in young people at ultra high risk of psychotic disorder: 12 month outcome data. Early Intervention in Psychiatry2008;2(Suppl 1):A12. [CSzG: 19138] YungAR , PhillipsLJ , NelsonB , FranceySM , YuenHP , SimmonsMB , et al. Randomised controlled trial of interventions for young people at ultra high risk for psychosis: 6‐month analysis. Journal of Clinical Psychiatry2011;72(4):430‐40. [CSzG: 22929] ">Yung‐Australia</a>). </p> <p>i. Cognitive behavioural therapy (CBT)</p> <p>CBT sessions were manualised and time limited. These sessions were tailored to meet the individual’s needs, to help them to understand and cope with experienced symptoms, enhancing the control of them and reducing associated distress. </p> <p>ii. Supportive therapy</p> <p>This therapy was delivered by the same psychologists who delivered the CBT. The aim of this was to provide the participant with emotional and social support, as well as basic problem solving, stress management, and psychoeducation. </p> <p><i>b. CBT plus supportive intervention versus non‐directive reflective listening plus supportive intervention</i> </p> <p><a href="./references#CD012236-bbs2-0004" title="CrittendenK , FlemingJ , StartupM , CarrV , BakerA , SchallU , et al. Recruitment and engagement of youth in an ultra high risk treatment study. Early Intervention in Psychiatry2008;2(Suppl 1):A127. [CSzG: Ref19115] StainH , BucciS , HalperinS , EmsleyR , ShallU , LewinT , et al. DEPTh: randomised controlled trial of cognitive behavioral therapy for young people at ultra high risk for psychosis. Early Intervention in Psychiatry2014;8:15. [CSzG: Ref29673] StainHJ , BucciS , BakerA , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of CBT for young people at risk for psychosis: the Detection and Evaluation of Psychological Therapy (DEPTh) trial. European Archives of Psychiatry and Clinical Neuroscience2015;1:S8‐9. [CSzG: Ref33810] StainHJ , BucciS , BakerAL , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of cognitive behaviour therapy versus non‐directive reflective listening for young people at ultra high risk of developing psychosis: the detection and evaluation of psychological therapy (DEPTh) trial. Schizophrenia Research2016;176(2‐3):212‐9. [CSzG: Ref35298] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. Rural and urban youth at ultra high risk for psychosis: baseline characteristics from the DEPTh randomised controlled trial of cognitive behavior therapy. Schizophrenia Bulletin2011;37:322. [CSzG: Ref22815] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy for youth at ultra high risk for psychosis: baseline characteristics for rural and urban youth. Australian and New Zealand Journal of Psychiatry2010:25‐6. [CSzG: Ref21845] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy targeting ultra high risk for psychosis: baseline comparisons for rural and urban youth. Early Intervention in Psychiatry2010;4(Suppl 1):113. [CSzG: Ref23498] StainHJ , StartupM , CarrV , BakerA , SchallU . The DEPTh project: a multisite RCT for youths at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S51‐2. [CSzG: Ref13401] StartupM . The DEPTh project: detection, evaluation, and psychological therapy for health. Australian New Zealand Clinical Trials Registry2006. [CszG: Ref18442] ">DEPTh‐Australia</a> compared CBT with non‐directive reflective listening (NDRL). </p> <p>i. Cognitive behavioural therapy (CBT)</p> <p>CBT sessions were manualised and time limited. These sessions were tailored to meet the individual’s needs, to help them to understand and cope with experienced symptoms, enhancing the control of them and reducing associated distress. </p> <p>ii. Supportive therapy</p> <p>This therapy was delivered by the same psychologists who delivered the CBT. The aim of this was to provide the participant with emotional and social support, as well as basic problem solving, stress management, and psychoeducation. </p> <p>iii. Non‐directive reflective listening</p> <p>This is a form of person‐centred counselling in which participants could discuss topics that they chose, while the therapist offered empathic reflections and positive regard. All participants were offered casework (help with accommodation, education and employment) and non‐structured family intervention (brief education and support). </p> <p><i>c. CBT plus risperidone versus supportive therapy</i> </p> <p>One study is relevant to this comparison (<a href="./references#CD012236-bbs2-0020" title="McGorryP . Second generation intervention research in the pre‐psychotic phase of illness in schizophrenia and related psychoses. Australian New Zealand Clinical Trials Registry2000. [CSzG: 18439] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceyS , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: 12‐month outcome. Schizophrenia Research2012;136:S17‐8. [CSzG: 29547] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceySM , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: twelve‐month outcome. Journal of Clinical Psychiatry2013;74(4):349‐56. [CSzG: 28737] NelsonB , PhillipsLJ , YungAR , FranceySM , LeicesterS , BakerK , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and supportive therapy in young people with subthreshold symptoms at incipient risk of psychotic disorder: baseline characteristics of the sample. Schizophrenia Bulletin2007;33(2):450. [CSzG: 15212] PhillipsLJ , NelsonB , YuenHP , FranceySM , SimmonsM , StanfordC , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: study design and baseline characteristics. Australian and New Zealand Journal of Psychiatry2009;;43(9):818–29. YungA , AmmingerP , BergerG , ThompsomA , PhillipsL , NelsonB , et al. Randomised controlled trial of antipsychotic and cognitive therapy in young people at ultra‐high risk of psychosis. Early Intervention in Psychiatry2012;6:11. [CSzG: 24989] YungA , NelsonB , PhillipsL , FranceyS , LeicesterS , YuenH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and supportive therapy in young people at ultra high risk of psychotic disorder: 12 month outcome data. Early Intervention in Psychiatry2008;2(Suppl 1):A12. [CSzG: 19138] YungAR , PhillipsLJ , NelsonB , FranceySM , YuenHP , SimmonsMB , et al. Randomised controlled trial of interventions for young people at ultra high risk for psychosis: 6‐month analysis. Journal of Clinical Psychiatry2011;72(4):430‐40. [CSzG: 22929] ">Yung‐Australia</a>). </p> <p>i. Cognitive behavioural therapy (CBT)</p> <p>CBT sessions were manualised and time limited. These sessions were tailored to meet the individual’s needs, to help them to understand and cope with experienced symptoms, enhancing the control of them and reducing associated distress. </p> <p>ii. Supportive therapy</p> <p>This therapy was delivered by the same psychologists who delivered the CBT. The aim of this was to provide the participant with emotional and social support, as well as basic problem solving, stress management, and psychoeducation. </p> <p>iii. Risperidone</p> <p>The risperidone that was given with the CBT was at a low dose (0.5 mg/day to 2.0 mg/day).</p> </section> <section id="CD012236-sec-0139"> <p><b>5.3.2 Cognitive training versus active control</b></p> <p>Three included studies compared cognitive training with active control (<a href="./references#CD012236-bbs2-0003" title="ChoiJ , CorcoranC , DixonL , FiszdonJ , JavittD . Processing speed training and social functioning in young adults at clinical high risk for psychosis: a pilot study. Early Intervention in Psychiatry2014;8:109. [CSzG: Ref29417] ChoiJ , CorcoranC , DixonL , JavittDC . Processing speed training and social functioning in teenagers and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2015;41:S41. [CSzG: Ref29418] ChoiJ , CorcoranCM , FiszdonJM , StevensM , JavittDC , DeasyM , et al. Pupillometer‐based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis. Psychiatric Rehabilitation Journal2017;40(1):33‐42. [CSzG: Ref35317] ">Choi‐USA</a>; <a href="./references#CD012236-bbs2-0016" title="NCT01619319 . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. ClinicalTrials.gov/show/NCT016193192012. [CSzG: 24387] PiskulicD , BarbatoM , AddingtonJ . Cognitive remediation in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:89. [CSzG: 24973] PiskulicD , BarbatoM , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2012;136:S245‐6. [CSzG: 29632] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2014;153(Suppl. 1):S218. [CSzG: 28827] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation therapy on cognition in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2014;8:86. [CSzG: 29633] ">Piskulic‐Canada</a>; <a href="./references#CD012236-bbs2-0018" title="LoewyR , FisherM , MathalonDH , VinogradovS . Interim analyses of a randomised controlled trial of computerised cognitive training in clinical high risk for psychosis. Schizophrenia Bulletin2013;39:S238‐9. [CSzG: 28151] LoewyR , FisherM , SchlosserDA , BiagiantiB , StuartB , MathalonDH , et al. Intensive auditory cognitive training improves verbal memory in adolescents and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2016;42(Suppl 1):S118‐26. [CSzG: 35221] VinogradovS , LoewyR , FisherM , LeeA , NiendamT , RaglandJD , et al. Neuroplasticity‐based cognitive training in ultra‐high risk adolescents and recent onset patients with schizophrenia. Schizophrenia Research2012;136:S30. [CSzG: 29703] ">Vinogradov‐USA</a>). </p> <p><i>a. Cognitive training</i> </p> <p><a href="./references#CD012236-bbs2-0003" title="ChoiJ , CorcoranC , DixonL , FiszdonJ , JavittD . Processing speed training and social functioning in young adults at clinical high risk for psychosis: a pilot study. Early Intervention in Psychiatry2014;8:109. [CSzG: Ref29417] ChoiJ , CorcoranC , DixonL , JavittDC . Processing speed training and social functioning in teenagers and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2015;41:S41. [CSzG: Ref29418] ChoiJ , CorcoranCM , FiszdonJM , StevensM , JavittDC , DeasyM , et al. Pupillometer‐based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis. Psychiatric Rehabilitation Journal2017;40(1):33‐42. [CSzG: Ref35317] ">Choi‐USA</a> used processing speed training (PST) as the intervention. PST is delivered on tablets and it consists of exercises centred on pupillometric cognitive load, working memory theory, and motivational psychology. During each PST session, participants worked in groups of two or three on tablets for approximately 30 hours over the course of two months (about 3.5 to 4.0 hours per week). </p> <p>The participants in <a href="./references#CD012236-bbs2-0016" title="NCT01619319 . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. ClinicalTrials.gov/show/NCT016193192012. [CSzG: 24387] PiskulicD , BarbatoM , AddingtonJ . Cognitive remediation in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:89. [CSzG: 24973] PiskulicD , BarbatoM , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2012;136:S245‐6. [CSzG: 29632] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2014;153(Suppl. 1):S218. [CSzG: 28827] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation therapy on cognition in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2014;8:86. [CSzG: 29633] ">Piskulic‐Canada</a> took part in Posit Science Brain Fitness Training (PSBFT), a cognitive remediation therapy that involves auditory training exercises. This was delivered online, and activity was monitored via an online monitoring system. </p> <p>The participants in the intervention group of <a href="./references#CD012236-bbs2-0018" title="LoewyR , FisherM , MathalonDH , VinogradovS . Interim analyses of a randomised controlled trial of computerised cognitive training in clinical high risk for psychosis. Schizophrenia Bulletin2013;39:S238‐9. [CSzG: 28151] LoewyR , FisherM , SchlosserDA , BiagiantiB , StuartB , MathalonDH , et al. Intensive auditory cognitive training improves verbal memory in adolescents and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2016;42(Suppl 1):S118‐26. [CSzG: 35221] VinogradovS , LoewyR , FisherM , LeeA , NiendamT , RaglandJD , et al. Neuroplasticity‐based cognitive training in ultra‐high risk adolescents and recent onset patients with schizophrenia. Schizophrenia Research2012;136:S30. [CSzG: 29703] ">Vinogradov‐USA</a> were enrolled in an Auditory Training Program (AT). AT consisted of computer exercises for improving speed and accuracy of auditory information processing that were continuously adjusted at adequate difficulty level, with rewards (points and animations) for correct studies. During each session, the participant had four of six exercises (15 minutes per exercise). Compliance was monitored by electronic data upload. Participants were asked to complete 20 to 40 hours of training. </p> <p><i>b. Active control</i> </p> <p>The control group for <a href="./references#CD012236-bbs2-0003" title="ChoiJ , CorcoranC , DixonL , FiszdonJ , JavittD . Processing speed training and social functioning in young adults at clinical high risk for psychosis: a pilot study. Early Intervention in Psychiatry2014;8:109. [CSzG: Ref29417] ChoiJ , CorcoranC , DixonL , JavittDC . Processing speed training and social functioning in teenagers and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2015;41:S41. [CSzG: Ref29418] ChoiJ , CorcoranCM , FiszdonJM , StevensM , JavittDC , DeasyM , et al. Pupillometer‐based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis. Psychiatric Rehabilitation Journal2017;40(1):33‐42. [CSzG: Ref35317] ">Choi‐USA</a> participated in active control training (commercial tablet games) in the same dose and duration as the intervention participants. </p> <p>The control group for <a href="./references#CD012236-bbs2-0016" title="NCT01619319 . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. ClinicalTrials.gov/show/NCT016193192012. [CSzG: 24387] PiskulicD , BarbatoM , AddingtonJ . Cognitive remediation in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:89. [CSzG: 24973] PiskulicD , BarbatoM , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2012;136:S245‐6. [CSzG: 29632] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2014;153(Suppl. 1):S218. [CSzG: 28827] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation therapy on cognition in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2014;8:86. [CSzG: 29633] ">Piskulic‐Canada</a> played commercial games (CG). The activity for this was monitored online. </p> <p>The control group for <a href="./references#CD012236-bbs2-0018" title="LoewyR , FisherM , MathalonDH , VinogradovS . Interim analyses of a randomised controlled trial of computerised cognitive training in clinical high risk for psychosis. Schizophrenia Bulletin2013;39:S238‐9. [CSzG: 28151] LoewyR , FisherM , SchlosserDA , BiagiantiB , StuartB , MathalonDH , et al. Intensive auditory cognitive training improves verbal memory in adolescents and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2016;42(Suppl 1):S118‐26. [CSzG: 35221] VinogradovS , LoewyR , FisherM , LeeA , NiendamT , RaglandJD , et al. Neuroplasticity‐based cognitive training in ultra‐high risk adolescents and recent onset patients with schizophrenia. Schizophrenia Research2012;136:S30. [CSzG: 29703] ">Vinogradov‐USA</a> participated in a series of available games. During the study, participants received different types of treatment from therapists who were not involved in the study (psychoeducation, psychotherapy, pharmacotherapy if clinically indicated). </p> </section> <section id="CD012236-sec-0140"> <p><b>5.3.3 Family treatment versus enhanced treatment</b></p> <p>Two included studies are relevant (<a href="./references#CD012236-bbs2-0008" title="McFarlaneWR , CookWL , WoodberryKA . A randomised clinical trial of familyaided assertive community treatment for young persons at high risk for onset of an initial psychosis. Schizophrenia Bulletin2011;37:314. [CSzG: Ref22796] NCT01597141 . Psychosis: early detection, intervention and prevention. ClinicalTrials.gov/show/NCT015971412012. [CSzG: Ref24315] ">EDIP‐USA</a> and <a href="./references#CD012236-bbs2-0012" title="MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Family‐focused therapy for individuals at clinical high risk for psychosis: treatment fidelity within a multisite randomised trial. Early Intervention in Psychiatry2016;10(2):137‐43. [CSzG: 29018] MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Treatment fidelity and differentiation in a randomised controlled trial of family‐focused therapy for youth at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:95. [CSzG: 24965] MiklowitzDJ , O'BrienMP , SchlosserDA , AddingtonJ , CandanKA , MarshallC , et al. Family‐focused treatment for adolescents and young adults at high risk for psychosis: results of a randomised trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(8):848‐58. [CSzG: 29019] NCT01907282 . Prevention trial of family focused treatment in youth at risk for psychosis. Clinicaltrials.gov/show/NCT019072822010. [CSzG: 27965] O'BrienMP , MiklowitzDJ , CandanKA , MarshallC , DominguesI , WalshBC , et al. A randomised trial of family focused therapy with populations at clinical high risk for psychosis: effects on interactional behavior. Journal of Consulting and Clinical Psychology2013;82(1):90‐101. [CSzG: 28565] O'BrienMP , MiklowitzDJ , CannonTD . Decreases in perceived maternal criticism predict improvement in subthreshold psychotic symptoms in a randomised trial of family‐focused therapy for individuals at clinical high risk for psychosis. Journal of Family Psychology2015;29(6):945–951.. [CSzG: 32212] SchlosserDA , MiklowitzDJ , O'BrienMP , DeSilvaSD , ZinbergJL , CannonTD . A randomised trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Intervention in Psychiatry2012;6(3):283‐91. [CSzG: 24491] ">Miklowitz‐USA</a>). </p> <p><i>a. Family treatment</i> </p> <p><a href="./references#CD012236-bbs2-0008" title="McFarlaneWR , CookWL , WoodberryKA . A randomised clinical trial of familyaided assertive community treatment for young persons at high risk for onset of an initial psychosis. Schizophrenia Bulletin2011;37:314. [CSzG: Ref22796] NCT01597141 . Psychosis: early detection, intervention and prevention. ClinicalTrials.gov/show/NCT015971412012. [CSzG: Ref24315] ">EDIP‐USA</a> used family‐aided assertive community treatment (FACT) as the active intervention. FACT was a combination of multifamily psychoeducational group therapy, assertive community treatment, supported education/employment and psychotropic medication. </p> <p>The active intervention for <a href="./references#CD012236-bbs2-0012" title="MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Family‐focused therapy for individuals at clinical high risk for psychosis: treatment fidelity within a multisite randomised trial. Early Intervention in Psychiatry2016;10(2):137‐43. [CSzG: 29018] MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Treatment fidelity and differentiation in a randomised controlled trial of family‐focused therapy for youth at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:95. [CSzG: 24965] MiklowitzDJ , O'BrienMP , SchlosserDA , AddingtonJ , CandanKA , MarshallC , et al. Family‐focused treatment for adolescents and young adults at high risk for psychosis: results of a randomised trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(8):848‐58. [CSzG: 29019] NCT01907282 . Prevention trial of family focused treatment in youth at risk for psychosis. Clinicaltrials.gov/show/NCT019072822010. [CSzG: 27965] O'BrienMP , MiklowitzDJ , CandanKA , MarshallC , DominguesI , WalshBC , et al. A randomised trial of family focused therapy with populations at clinical high risk for psychosis: effects on interactional behavior. Journal of Consulting and Clinical Psychology2013;82(1):90‐101. [CSzG: 28565] O'BrienMP , MiklowitzDJ , CannonTD . Decreases in perceived maternal criticism predict improvement in subthreshold psychotic symptoms in a randomised trial of family‐focused therapy for individuals at clinical high risk for psychosis. Journal of Family Psychology2015;29(6):945–951.. [CSzG: 32212] SchlosserDA , MiklowitzDJ , O'BrienMP , DeSilvaSD , ZinbergJL , CannonTD . A randomised trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Intervention in Psychiatry2012;6(3):283‐91. [CSzG: 24491] ">Miklowitz‐USA</a> was family‐focused treatment (FFT). FFT was an 18‐session training consisting of psychoeducation, communication enhancement, and problem‐solving skills training over six months, focusing on skills for coping with symptoms and improving family communication and problem‐solving. </p> <p><i>b. Enhanced treatment</i> </p> <p>Control participants in <a href="./references#CD012236-bbs2-0008" title="McFarlaneWR , CookWL , WoodberryKA . A randomised clinical trial of familyaided assertive community treatment for young persons at high risk for onset of an initial psychosis. Schizophrenia Bulletin2011;37:314. [CSzG: Ref22796] NCT01597141 . Psychosis: early detection, intervention and prevention. ClinicalTrials.gov/show/NCT015971412012. [CSzG: Ref24315] ">EDIP‐USA</a> received enhanced standard treatment (EST). This comprised psychotropic drugs, individual case management, family education and crisis intervention. </p> <p>Control participants in <a href="./references#CD012236-bbs2-0012" title="MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Family‐focused therapy for individuals at clinical high risk for psychosis: treatment fidelity within a multisite randomised trial. Early Intervention in Psychiatry2016;10(2):137‐43. [CSzG: 29018] MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Treatment fidelity and differentiation in a randomised controlled trial of family‐focused therapy for youth at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:95. [CSzG: 24965] MiklowitzDJ , O'BrienMP , SchlosserDA , AddingtonJ , CandanKA , MarshallC , et al. Family‐focused treatment for adolescents and young adults at high risk for psychosis: results of a randomised trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(8):848‐58. [CSzG: 29019] NCT01907282 . Prevention trial of family focused treatment in youth at risk for psychosis. Clinicaltrials.gov/show/NCT019072822010. [CSzG: 27965] O'BrienMP , MiklowitzDJ , CandanKA , MarshallC , DominguesI , WalshBC , et al. A randomised trial of family focused therapy with populations at clinical high risk for psychosis: effects on interactional behavior. Journal of Consulting and Clinical Psychology2013;82(1):90‐101. [CSzG: 28565] O'BrienMP , MiklowitzDJ , CannonTD . Decreases in perceived maternal criticism predict improvement in subthreshold psychotic symptoms in a randomised trial of family‐focused therapy for individuals at clinical high risk for psychosis. Journal of Family Psychology2015;29(6):945–951.. [CSzG: 32212] SchlosserDA , MiklowitzDJ , O'BrienMP , DeSilvaSD , ZinbergJL , CannonTD . A randomised trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Intervention in Psychiatry2012;6(3):283‐91. [CSzG: 24491] ">Miklowitz‐USA</a> had three sessions of psychoeducational treatment for assisting participants and their families in coping with early signs of psychosis. Additional medication was allowed for both participant groups (antipsychotics, antidepressants, mood stabilisers, anxiolytics, psychostimulants). </p> </section> <section id="CD012236-sec-0141"> <p><b>5.3.4 Integrated treatment versus standard treatment</b></p> <p>There is one included study in this comparison (<a href="./references#CD012236-bbs2-0014" title="NordentoftM , JeppesenP , PetersenL , ThorupA , OhlenschlaegerJ , ChristensenT , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. European Psychiatry2007;22:S129‐S. [CSzG: 20471] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the OPUS trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;83(1):29‐40. [CSzG: 13197] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;86(Suppl 1):S44. [CSzG: 13393] ">Nordentoft‐Denmark</a>). </p> <p><i>a. Integrated treatment</i> </p> <p>This consisted of Assertive Community Treatment, social skills training (individual or group) and group psychoeducation for patients and their family members. </p> <p><i>b. Standard treatment</i> </p> <p>Standard treatment was treatment as usual within standard mental health services in Copenhagen and Aarhus. Participants were usually offered treatment at a community mental health centre, and were in contact with a physician, community mental health nurse and in some cases a social worker. Visits usually took place once a month. In a small proportion of cases, the standard treatment included psychosocial interventions such as training in social skills or daily living activities, or supportive contacts with the family. </p> <p>For description of adherence to treatment, see additional <a href="#CD012236-tbl-0014">Table 1</a>. </p> <div class="table" id="CD012236-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adherence table</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0001" title="AddingtonJ , EpsteinI , LiuL , FrenchP , BoydellKM , ZipurskyRB . A randomised controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research2011;125(1):54‐61. [CSzG: Ref21945] AddingtonJ , ZipurskyR , EpsteinI . ADAPT (Access, Detection and Psychological Treatments). Schizophrenia Research2006;86(Suppl 1):S6. [CSzG: Ref13364] NCT00260273 . Access, detection and psychological treatments. www.ClinicalTrials.gov/ct/show/2005. [CSzG: Ref14638] ">ADAPT‐Canada</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall the mean number of sessions was 12 (SD = 6.2, range 1–26). 31% (N = 16) received &lt; 7 sessions. Those who left before the 6‐month follow‐up had significantly fewer sessions (5 vs 13.4; T = 7.1, P &lt; 0.0001). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0002" title="AmmingerG . Ethyl eicosapentanoic acid for prodromal psychosis. Stanley Foundation Research Programs2009. [CSzG: Ref17423] AmmingerG , SchaferM , PapageorgiouK , CottonS , HarriganS , MackinnonA , et al. Indicated prevention with long‐chain omega‐3 fatty acids in adolescents at ultra‐high‐risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2008;2(Suppl 1):A29. [CSzG: Ref19107] AmmingerGP , ChanenAM , OhmannS , KlierCM , MossahebN , BechdolfA , et al. Omega‐3 fatty acid supplementation in adolescents with borderline personality disorder and ultra‐high risk criteria for psychosis: a post hoc subgroup analysis of a double‐blind, randomised controlled trial. Canadian Journal of Psychiatry2013;58(7):402‐8. [CSzG: Ref28534] AmmingerGP , HarrisMS , McGorryPD , HenryLP . Omega‐3 fatty acids for indicated prevention: treatment results and pathomechanisms. European Archives of Psychiatry and Clinical Neuroscience2013;263(Suppl. 1):S44‐5. [CSzG: Ref28434] AmmingerGP , LeicesterS , YungAR , YuenHP , McGorryPD . Age predicts transition to psychosis in an ultra‐high risk sample. Proceedings of the 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:61. AmmingerGP , McGorryPD . Update on omega‐3 polyunsaturated fatty acids in early ‐stage psychotic disorders. Neuropsychopharmacology2012;37(1):309‐10. [CSzG: Ref23726] AmmingerGP , MechelliA , RiceS , KimSW , KlierCM , McNamaraRK , et al. Predictors of treatment response in young people at ultra‐high risk for psychosis who received long‐chain omega‐3 fatty acids. Translational Psychiatry2015;5:e495. [CSzG: Ref29299] AmmingerGP , SchaferMR . Indicated prevention with omega‐3 fatty acids in adolescents at ultra‐high risk for psychosis ‐ rationale, methods, and 3‐months outcome. Schizophrenia Research2006;86(Suppl 1):S97‐8. [CSzG: Ref13367] AmmingerGP , SchaferMR . Is it feasible to conduct a RCT in ultra‐high risk individuals at a child and adolescent psychiatric service?. Schizophrenia Research2006;86(Suppl 1):S98. [CSzG: Ref13368] AmmingerGP , SchaferMR , KlierCM , PapageorgiouK , SlavikJ , HolzerI , et al. Indicated prevention with long‐chain omega‐3 fatty acids in young people at ultra‐high risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2010;4(Suppl 1):7. [CSzG: Ref23467] AmmingerGP , SchaferMR , SchlogelhoferM , KlierCM , McGorryPD . Longer‐term outcome in the prevention of psychotic disorders by the Vienna omega‐3 study. Nature Communications2015;6:7934. [CSzG: Ref33023] AmmingerGP , SchlogelhoferM , KlierC , McGorryP , SchaferM . Longer‐term follow‐up in the Vienna omega‐3 psychosis prevention trial. Early Intervention in Psychiatry2014;8:41. [CSzG: Ref29378] AmmingerGP , SchäferMR , PapageorgiouK , KlierCM , CottonSM , HarriganSM , et al. Long‐chain omega‐3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo‐controlled trial. Archives of General Psychiatry2010;67(2):146‐54. [CSzG: Ref20680; DOI: 10.1001/archgenpsychiatry.2009.192.] AmmingerP , MossahebN , SchlgelhoferM , SchaferM . Fatty acid metabolism and the onset of psychotic disorder. European Psychiatry2011;26(Suppl 1):2089. [CSzG: Ref22967] Anonymous . Fish oil may help ward off psychosis. Journal of Psychosocial Nursing and Mental Health Services2010;48(5):55. [CSzG: Ref20739] BergerG , AmmingerP , McGorryP . Stage dependant effect of omega‐3 fatty acids in emerging psychosis. European Psychiatry2011;26(Suppl 1):1347. [CSzG: Ref22966] BergerGE , ProffittTM , McConchieM , YuenH , WoodSJ , AmmingerGP , et al. Ethyl‐eicosapentaenoic acid in first‐episode psychosis: a randomised, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(12):1867‐75. [CSzG: Ref15561; ISSN: 1555‐2101] EhrlichA . Evidence‐based medicine. Omega‐3 supplementation delays transition to psychotic disorder in ultra‐high‐risk adolescents and young adults. Clinical Advisor for Nurse Practitioners2010;13(5):79‐80. [CSzG: Ref21562] FöckingM , DickerP , LopezLM , CannonM , SchäferMR , McGorryPD , et al. Differential expression of the inflammation marker IL12p40 in the at‐risk mental state for psychosis: a predictor of transition to psychotic disorder?. BMC Psychiatry2016;16(1):326. [DOI: 10.1186/s12888‐016‐1039‐7] KlierC , HollmannM , SchlögelhoferM , MossahebN , FriedrichM , AmmingerPG . Indicated prevention with omega‐3 fatty acids (EPA/DHA) in adolescents with &quot;at‐risk‐mental‐state“ for psychosis. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. [CSzG: Ref12438] LavoieS , BenningerF , FeuchtM , KlierCM , SchaeferMR , AmmingerGP . Correlates of EEG resting states with erythrocyte membrane omega‐3 fatty acid levels and psychopathological symptoms in individuals at ultra‐high risk for psychosis. Early Intervention in Psychiatry2014;8:137. [CSzG: Ref29516] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultra‐high risk individuals who transitioned to psychosis. Schizophrenia Research2012;138(2‐3):206‐11. [CSzG: Ref24256] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultrahigh risk individuals who transitioned to psychosis. Early Intervention in Psychiatry2012;6:38. [CSzG: Ref24960] MossahebN , PapageorgiouK , SchaferMR , BeckerJ , SchloegelhoferM , AmmingerGP . Changes in triglyceride levels in ultra‐high risk for psychosis individuals treated with omega‐3 fatty acids. Early Intervention in Psychiatry2018; Vol. 12, issue 1:30‐36. [DOI: 10.1111/eip.12275] MossahebN , SchaferMR , SchlogelhoferM , KlierCM , CottonSM , McGorryPD , et al. Effect of omega‐3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?. Schizophrenia Research2013;148(1‐3):163‐7. [CSzG: Ref28649] NCT00396643 . Indicated prevention with omega‐3 fatty acids in adolescents with ‘at‐risk‐mental‐state’ for psychosis: a randomised, double blind, placebo‐controlled treatment trial. www.ClinicalTrials.gov/ct/show/2006. [CSzG: Ref14873] PapageorgiouK , SchaferMR , SchlogelhoferM , MossahebN , AmmingerGP . Indicated prevention with omega‐3 fatty acids in young people with 'at‐risk‐mental‐state' for psychosis: design of a 5‐year follow‐up. European Archives of Psychiatry and Clinical Neuroscience2011;261:S55. [CSzG: Ref23749] SchaferMR , KlierCM , PapageorgiouK , FriedrichMH , AmmingerGP . Early detection of psychotic disorders. Neuropsychiatrie2007;21(1):37‐44. [CSzG: Ref15290] SmesnyS , MilleitB , HiplerUC , MilleitC , SchaferMR , KlierCM , et al. Omega‐3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra‐high risk for psychosis. Molecular Psychiatry2013;19(3):317‐24. [CSzG: Ref28243] SmesnyS , MilleitB , SchaeferMR , HesseJ , SchlögelhoferM , LangbeinK , et al. Effects of omega‐3 PUFA on immune markers in adolescent individuals at ultra‐high risk for psychosis ‐ results of the randomised controlled Vienna omega‐3 study. Schizophrenia Research2017;S0920‐9964(17):30039‐7. [DOI: 10.1016/j.schres.2017.01.026] ">Amminger‐Austria</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean rate for adherence with study medication, based on pill count and self‐report, was 81.4% (SD, 17.7%) in the omega‐3 group and 75.4% (SD, 17.8%) in the placebo group (P = 0.13). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0003" title="ChoiJ , CorcoranC , DixonL , FiszdonJ , JavittD . Processing speed training and social functioning in young adults at clinical high risk for psychosis: a pilot study. Early Intervention in Psychiatry2014;8:109. [CSzG: Ref29417] ChoiJ , CorcoranC , DixonL , JavittDC . Processing speed training and social functioning in teenagers and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2015;41:S41. [CSzG: Ref29418] ChoiJ , CorcoranCM , FiszdonJM , StevensM , JavittDC , DeasyM , et al. Pupillometer‐based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis. Psychiatric Rehabilitation Journal2017;40(1):33‐42. [CSzG: Ref35317] ">Choi‐USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference in the dosage of training between groups as participants in PST completed 30.32 (SD = 0.92) h versus 30.11 (SD = 0.84) h for ACG (T = 0.94, P = 0.353). As expected, given the structured nature of the programmes at both sites (participants were coming in for a regimen of treatments, usually 2 days/week), treatment intensity between groups was also not significantly different (PST, 3.37 h/week, SD 1.03; ACG, 3.52 h/week, SD 0.94; T 0.60, p. 558). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0004" title="CrittendenK , FlemingJ , StartupM , CarrV , BakerA , SchallU , et al. Recruitment and engagement of youth in an ultra high risk treatment study. Early Intervention in Psychiatry2008;2(Suppl 1):A127. [CSzG: Ref19115] StainH , BucciS , HalperinS , EmsleyR , ShallU , LewinT , et al. DEPTh: randomised controlled trial of cognitive behavioral therapy for young people at ultra high risk for psychosis. Early Intervention in Psychiatry2014;8:15. [CSzG: Ref29673] StainHJ , BucciS , BakerA , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of CBT for young people at risk for psychosis: the Detection and Evaluation of Psychological Therapy (DEPTh) trial. European Archives of Psychiatry and Clinical Neuroscience2015;1:S8‐9. [CSzG: Ref33810] StainHJ , BucciS , BakerAL , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of cognitive behaviour therapy versus non‐directive reflective listening for young people at ultra high risk of developing psychosis: the detection and evaluation of psychological therapy (DEPTh) trial. Schizophrenia Research2016;176(2‐3):212‐9. [CSzG: Ref35298] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. Rural and urban youth at ultra high risk for psychosis: baseline characteristics from the DEPTh randomised controlled trial of cognitive behavior therapy. Schizophrenia Bulletin2011;37:322. [CSzG: Ref22815] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy for youth at ultra high risk for psychosis: baseline characteristics for rural and urban youth. Australian and New Zealand Journal of Psychiatry2010:25‐6. [CSzG: Ref21845] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy targeting ultra high risk for psychosis: baseline comparisons for rural and urban youth. Early Intervention in Psychiatry2010;4(Suppl 1):113. [CSzG: Ref23498] StainHJ , StartupM , CarrV , BakerA , SchallU . The DEPTh project: a multisite RCT for youths at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S51‐2. [CSzG: Ref13401] StartupM . The DEPTh project: detection, evaluation, and psychological therapy for health. Australian New Zealand Clinical Trials Registry2006. [CszG: Ref18442] ">DEPTh‐Australia</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean number of sessions completed was 9.2 for CBT (3% had no sessions, 17% had 1–5, 47% had 6–11, 30% had 12–26), and 10.1 for NDRL (4% had no sessions, 26% had 1–5, 37% had 6–11, 33% had 12–26). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0005" title="ByrneRE , MorrisonAP . Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. Psychology and Psychotherapy2014;87(3):357‐71. [CSzG: Ref29312] FlachC , FrenchP , DunnG , FowlerD , GumleyAI , BirchwoodM , et al. Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE‐2 trial. British Journal of Psychiatry2015;207(2):123‐9. [CSzG: Ref33109] MorrisonA . Early detection and intervention evaluation for individuals at high risk of psychosis 2. http://www.controlled‐trials.com2008. [CSzG: Ref18285] MorrisonA . Early detection and intervention evaluation for people at risk of psychosis (edie‐2): A multisite randomised controlled trial of cognitive therapy for at‐risk mental states. Early Intervention in Psychiatry2012;6:11. [CSzG: Ref24968] MorrisonA , FrenchP , BentallR , LewisS , BirchwoodM , FowlerD , et al. Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. Early Intervention in Psychiatry2008;2(Suppl 1):A15. [CSzG: Ref19128] MorrisonAP . EDIE‐2: early detection and psychological intervention for individuals at high risk of psychosis (2). www.controlled‐trials.com2007. [CSzG: Ref15381] MorrisonAP , BirchwoodM , PyleM , FlachC , StewartSL , ByrneR , et al. Impact of cognitive therapy on internalised stigma in people with at‐risk mental states. British Journal of Psychiatry2013;203(2):140‐5. [CSzG: Ref28630] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ2012;344(7852):e2233. [CSzG: Ref24208] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at‐risk of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29554] MorrisonAP , PyleM , StewartSL , FrenchP , ByrneR , FlachC , et al. Internalised stigma in young people at high risk of developing psychosis: findings from a cognitive therapy trial. Schizophrenia Research2014;153:S42. [CSzG: Ref29555] MorrisonAP , StewartSL , FrenchP , BentallRP , BirchwoodM , ByrneR , et al. Early detection and intervention evaluation for people at high‐risk of psychosis‐2 (EDIE‐2): trial rationale, design and baseline characteristics. Early Intervention in Psychiatry2011;5(1):24‐32. [CSzG: Ref22695] MorrisonT . Early detection and psychological intervention for individuals at high risk of psychosis. EDIE‐2. Data on File2006. [CSzG: Ref13874] PelosiAJ . Rational policy making for early psychosis might yet become possible. BMJ2012;344(7856):e3137. [CSzG: Ref24326] PyleM , StewartSL , FrenchP , ByrneR , PattersonP , GumleyA , et al. Internalised stigma, emotional dysfunction and unusual experiences in young people at risk of psychosis. Early Intervention in Psychiatry2015;9(2):133‐40. [CSzG: Ref29813] ">EDIE‐2‐UK</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Those allocated to cognitive therapy received a mean of 9.11 (SD 6.69; range 0‐26) sessions, each lasting on average 1 h. Adherence to cognitive therapy was reasonably good, with only 9 of 144 (6.25%) participants not attending any sessions and 108 (75%) receiving at least ≥ 4 sessions. Fidelity to the therapy model was assessed using competency and adherence scales in relation to audio recordings of 80 therapy sessions. 90% of rated sessions scored over the threshold for competency and 93.3% met the criteria for therapy that adhered to the manual. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0006" title="DragtS , Van derGaagM . Prevention of psychosis with a cognitive behavioural intervention in help‐seeking young people with an at risk mental state for developing psychosis. www.trialregister.nl/trialreg/index.asp2007. [CSzG: Ref19655] IsingHK , KraanTC , RietdijkJ , DragtS , KlaassenRM , BoonstraN , et al. Four‐year follow‐up of cognitive behavioral therapy in persons at ultra‐high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2016;42(5):1243‐52. [CSzG: Ref35214] IsingHK , LokkerbolJ , RietdijkJ , DragtS , KlaassenRM , KraanT , et al. Four‐year cost‐effectiveness of cognitive behavior therapy for preventing first‐episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2017;43(2):365‐74. [CSzG: Ref35824] IsingHK , SmitF , VelingW , RietdijkJ , DragtS , KlaassenRM , et al. Cost‐effectiveness of preventing first‐episode psychosis in ultra‐high‐risk subjects: multi‐centre randomised controlled trial. Psychological Medicine2015;45(7):1435‐46. [CSzG: Ref27798] KraanTC , IsingHK , FokkemaM , VelthorstE , Van denBergDP , KerkhovenM , et al. The effect of childhood adversity on 4‐year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE‐NL) Trial. Psychiatry Research2017;247:55‐62. [CSzG: Ref35559] NiemanDH , RuhrmannS , RietdijkJ , DragtS , IsingH , KlaassenR , et al. Preventive psychotherapy. Schizophrenia Research2014;153:S42‐3. [CSzG: Ref29601] RietdijkJ , DragtS , KlaassenR , IsingH , NiemanD , WunderinkL , et al. A single blind randomised controlled trial of cognitive behavioural therapy in a help‐seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE‐NL) trial. Trials2010;11:30. [CSzG: Ref20654] Van DerGaagM . The effects of CBT in personswith ultra high risk: the Dutch EDIE trial. European Archives of Psychiatry and Clinical Neuroscience2011;261:S18. [CSzG: Ref23756] Van DerGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first‐episode of psychosis. Early Intervention in Psychiatry2012;6:12. [CSzG: Ref24985] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomised controlled clinical trial. Schizophrenia Bulletin2012;38(6):1180‐8. [CSzG: Ref24935] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. The effects of cognitive behavioural therapy for subjects at ultra‐high risk for developing psychosis. Schizophrenia Bulletin2013;39:S356. [CSzG: Ref28121] Van derGaagM . The prevention of psychosis in at risk mental state. www.controlled‐trials.com2008. [CSzG: Ref17488] Van derGaagM , NiemanD , Van denBergD . CBT for those at risk of a first episode psychosis: Evidence‐based psychotherapy for people with an 'at risk mental state'. 1st Edition. Hove, UK: Routledge, 2013. Van derGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first episode of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29692] ">EDIE‐NL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0007" title="FrenchP , ShryaneN , BentallRP , LewisSW , MorrisonAP . Effects of cognitive therapy on the longitudinal development of psychotic experiences in people at high risk of developing psychosis. British Journal of Psychiatry. Supplements2007;191(Suppl 51):s82‐7. [CSzG: Ref16121] LewisS . EDIE ‐ Early detection and intervention for psychosis. National Research Register2001; Vol. 3. [CSzG: Ref13023] LewisS . EDIE ‐ early detection and intervention for psychosis (in primary care). National Research Register2002; Vol. 1. [CszG: Ref9342] MorrisonA . Early detection and intervention for psychosis in primary care. National Research Register2003. [CSzG: Ref15485] MorrisonA . Findings from a randomised controlled trial and clinical service delivering cognitive therapy to people at ultra‐high risk of developing psychosis. Schizophrenia Research2004;70(1):43‐4. [CSzG: Ref11526] MorrisonA . Follow‐up of prodromal symptoms. National Research Register2004; Vol. 3. [CSzG: Ref13036] MorrisonA , BentallR , FrenchP , Kilcommons A, LewisSW . Very early intervention in prodromal psychosis: a randomised trial. Schizophrenia Research2002;53(3 Suppl 1):42. [CSzG: Ref8096] MorrisonA , FrenchP , WalfordL , LewisS , Kilcommons A, GreenJ , et al. A randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;67(1):7. [CSzG: Ref11324] MorrisonA , FrenchP , WatfordL , LewisS , Kilcommons A, GreenJ , et al. Randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;70(1):63. [CSzG: Ref11527] MorrisonAP . Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: results of a randomised controlled trial. Schizophrenia Research2006;86(Suppl 1):S59. [CSzG: Ref13388] MorrisonAP , BentallRP , FrenchP , Kilcommons A, GreenJ , WalfordL , et al. Cognitive therapy in ultra high risk individuals for psychosis: randomised controlled trial. Schizophrenia Research2003;60:326. [CSzG: Ref9726] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, KnightA , et al. Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high‐risk individuals. Study design and interim analysis of transition rate and psychological risk factors. British Journal of Psychiatry. Supplements2002;181(43):s78‐84. [CSzG: Ref8737] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, LewisS . Early detection and intervention for psychosis in primary care. 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002. [CSzG: Ref8932] MorrisonAP , FrenchP , ParkerS , RobertsM , StevensH , BentallRP , et al. Three‐year follow‐up of a randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophrenia Bulletin2007;33(3):682‐7. [CSzG: Ref15288] MorrisonAP , FrenchP , WalfordL , LewisSW , Kilcommons A, GreenJ , et al. Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: randomised controlled trial. British Journal of Psychiatry2004;185:291‐7. [CSzG: Ref11450] MorrisonT . Early detection and intervention for psychosis in primary care. National Research Register2001; Vol. 1. [CSzG: Ref13037] MorrisonT , BentallR , FrenchP , Kilcommons A, GreenJ , LewisS . Early detection and intervention for psychosis in primary care. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:44. [CSzG: Ref8932] RentonJ , MorrisonA . Effectiveness of cognitive therapy for psychosis and implications for early intervention. Schizophrenia Research2004;70(1):142. [CSzG: Ref11536] ">EDIE‐UK</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0008" title="McFarlaneWR , CookWL , WoodberryKA . A randomised clinical trial of familyaided assertive community treatment for young persons at high risk for onset of an initial psychosis. Schizophrenia Bulletin2011;37:314. [CSzG: Ref22796] NCT01597141 . Psychosis: early detection, intervention and prevention. ClinicalTrials.gov/show/NCT015971412012. [CSzG: Ref24315] ">EDIP‐USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0009" title="BechdolfA . Preventing progression to first‐episode psychosis in people in the early initial prodromal state. Early Intervention in Psychiatry2012;6:11. [CSzG: 24944] BechdolfA , BuhlerB , BerningJ , WagnerM , StammE , StreitM . Cognitive behavioural therapy in the early initial prodromal state of psychosis: first results. Schizophrenia Research2004;67(1):202. [CSzG: Ref11285] BechdolfA , KlosterkotterJ . Cognitive‐behavioural treatment (CBT) in the early initial prodromal state of psychosis: concept and practical approach. Schizophrenia Research2004;70(1):52. [CSzG: Ref11506] BechdolfA , RuhrmannS , JanssenB , BottlenderR , WagnerM , MaurerK , et al. Early recognition and intervention for people at risk of schizophrenia [Fruherkennung und intervention bei personen mit erhohtem psychoserisiko]. Psychoneuroendocrinology2004;30(11):606‐14. [CSzG: Ref11376] BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: Ref12511] BechdolfA , VeithV , BerningJ , StammE , DeckerP , JanssenB , et al. Cognitive behavioral therapy (CBT) in the early initial prodromal state of psychosis: first results of a randomised trial. Schizophrenia Research2004;70(1):62‐3. [CSzG: Ref11507] BechdolfA , WagnerM , RuhrmannS , HarriganS , PutzfeldV , PukropR , et al. Preventing progression to first‐episode psychosis in early initial prodromal states. British Journal of Psychiatry2012;200(1):22‐9. [CSzG: Ref24206] BechdolfA , WagnerM , RuhrmannS , HarriganS , VeithV , PukropR , et al. CBT for prevention of first episode psychosis in people in an putative early initial prodromal state. Early Intervention in Psychiatry2008;2(Suppl 1):A16. [CSzG: 19109] BechdolfA , WagnerM , VeithV , PukropR , BerningJ , StammE , et al. A randomised controlled trial of cognitive‐behavioral therapy in the early initial prodromal state of psychosis. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:22‐3. [CSzG: 20193] BechdolfA , WagnerM , VeithV , RuhrmannR , JanssenB , BottlenderR , et al. A randomised controlled multicenter trial of cognitive behaviour therapy in the early initial prodromal state of psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13369] BechdolfA , WagnerM , VeithV , RuhrmannS , PukropR , Brockhaus‐DumkeA , et al. Randomised controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Intervention in Psychiatry2007;1(1):71‐8. [CSzG: 16450] BechdolfA , WesselsH , WagnerM , KuhrK , BerningJ , PutzfeldV , et al. Predictors of treatment response to psychosocial interventions in people at risk. European Archives of Psychiatry and Clinical Neuroscience2015;1:S9. [CSzG: 33601] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] KommescherM , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. Early Intervention in Psychiatry2016;10(1):17‐27. [CSzG: 32187] NCT00204087 . Psychological intervention for persons at risk of psychosis in the early initial prodromal state. www.ClinicalTrials.gov/ct/show/2005. [CSzG: 14890] WesselsH , WagnerM , FrommannI , BerningJ , PutzfeldV , JanssenB , et al. Neuropsychological functioning as a predictor of treatment response to psychoeducational, cognitive behavioral therapy in people at clinical high risk of first episode psychosis. Psychiatrische Praxis2015;42(6):313‐9. [CSzG: 33130] ZarafonitisS , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Psychoeducation for persons at risk of psychosis. Psychotherapeut2012;57(4):326‐34. [CSzG: 24807] ">EIPS‐Germany</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After randomisation, 2 participants from the IPI group and 1 from the SC group failed to attend any treatment sessions. In the IPI group 22 (33.8%) of participants received &lt; 50% of treatment (&lt; 20 sessions) and in the SC group 20 (31.7%) participants received &lt; 50% of treatment (&lt; 13 sessions), but there were no statistical differences between the number of these participants (Chi<sup>2</sup> = 0.003, P = 0.956). Mean number of sessions for the SC group was 15.8 ± 6.8 and for the IPI group 23.7 ± 13.1, therefore participants from the SC group received significantly less treatment (P &lt; 0.001). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0010" title="KantrowitzJT , WoodsSW , PetkovaE , CornblattB , CorcoranCM , ChenH , et al. D‐serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double‐blind, placebo‐controlled, randomised parallel group mechanistic proof‐of‐concept trial. Lancet Psychiatry2015;2(5):403‐12. [CSzG: 29487] NCT00826202 . D‐serine for the schizophrenia prodrome. www.ClinicalTrials.gov/ct/show/2009. [CSzG: 17391] ">Kantrowitz‐USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0011" title="BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: 12511] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] RuhrmannS , BechdolfA , KuhnKU , WagnerM , Schultze‐LutterF Janssen B , et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry. Supplements2007;51:s88‐95. [CSzG: 16127] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Acute symptomatic treatment effects in persons clinically at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13397] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Intervention in the late initial prodromal state (LIPS) of psychosis. Schizophrenia Research2006;86(Suppl 1):S96. [CSzG: 13398] ">LIPS‐Germany</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0012" title="MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Family‐focused therapy for individuals at clinical high risk for psychosis: treatment fidelity within a multisite randomised trial. Early Intervention in Psychiatry2016;10(2):137‐43. [CSzG: 29018] MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Treatment fidelity and differentiation in a randomised controlled trial of family‐focused therapy for youth at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:95. [CSzG: 24965] MiklowitzDJ , O'BrienMP , SchlosserDA , AddingtonJ , CandanKA , MarshallC , et al. Family‐focused treatment for adolescents and young adults at high risk for psychosis: results of a randomised trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(8):848‐58. [CSzG: 29019] NCT01907282 . Prevention trial of family focused treatment in youth at risk for psychosis. Clinicaltrials.gov/show/NCT019072822010. [CSzG: 27965] O'BrienMP , MiklowitzDJ , CandanKA , MarshallC , DominguesI , WalshBC , et al. A randomised trial of family focused therapy with populations at clinical high risk for psychosis: effects on interactional behavior. Journal of Consulting and Clinical Psychology2013;82(1):90‐101. [CSzG: 28565] O'BrienMP , MiklowitzDJ , CannonTD . Decreases in perceived maternal criticism predict improvement in subthreshold psychotic symptoms in a randomised trial of family‐focused therapy for individuals at clinical high risk for psychosis. Journal of Family Psychology2015;29(6):945–951.. [CSzG: 32212] SchlosserDA , MiklowitzDJ , O'BrienMP , DeSilvaSD , ZinbergJL , CannonTD . A randomised trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Intervention in Psychiatry2012;6(3):283‐91. [CSzG: 24491] ">Miklowitz‐USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The average number of sessions in the FFT group was 11.0 ± 7.1 (range 0–19) sessions and 42 (63.6%) participants took part in at least 1 session of communication or problem‐solving skills training. Out of 66 participants in this group, 18 received &lt; 50% of sessions (9 sessions) and 37 &gt; 9 sessions. The rest dropped out before the first session. In the enhanced care group, average number of sessions was 2.4 ± 1.2 sessions (range 0–4) and 50 (79.4%) took part in most or all (2–3 sessions) of the psychoeducational training. Out of 63 participants in this group, 5 received &lt; 50% of sessions (1 session) and 48 received &gt; 50% of sessions (2‐3 sessions). Participants in both FFT and enhanced treatment groups were equally likely to obtain extra‐protocol individual or group therapy sessions (34.5% and 36.2%; 2(1) = 03, P = 0.86). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0013" title="ACTRN12608000475347 . A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder. Australian New Zealand Clinical Trials Registry2009. [CSzG: 18420] HKCTR‐1438 . The NEURAPRO‐E (North America, EURope, Australia PROdrome) Study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for symptomatic patients at ultra‐high risk for early progression to schizophrenia and other psychotic disorders. www.hkClinicaltrials.com/trial_details.aspx?trialID=d09bd177‐b9fd‐4162‐b04f‐3ebfed49baa32011. [CSzG: 29270] McGorryP , MarkulevC , NelsonB , YuenHP , SchaeferM , YungAR , et al. The NEURAPRO‐E study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Schizophrenia Bulletin2015;41:S322‐3. [CSzG: 29546] McGorryPD , NelsonB , MarkulevC , YuenHP , SchaferMR , MossahebN , et al. Effect of omega‐3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomised clinical trial. JAMA psychiatry2017;74(1):19‐27. [CSzG: 35590] NelsonB , AmmingerG , MarkulevC , YuenHP , LavoieS , SchaeferM , et al. NEURAPOR: a multi‐center RCT of omega‐3 polyunsaturated fatty acids versus placebo in young people at ultra‐high risk of psychotic disorders: medium‐term outcome. Schizophrenia Bulletin2017;43:S107. [CSzG: 36016] ">NEURAPRO‐AAE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were 66 adherent participants (43.1%) in the omega‐3 PUFA group and 62 in the placebo group (41.1%). Participants who had missing data for the capsule counts (N = 35 in omega‐3 fatty acids group and 48 in placebo group) were considered as non‐adherent. The overall median number of CBCM sessions attended was 8 (range, 1‐35), in omega‐3 fatty acids group 11.2 ± 6.4 and 10.3 ± 6.0 in placebo group. The transition rate was lower in the adherent participants, but without significant difference. There was no significant difference between groups in transition rates for those with a number of CBCM sessions ≤ median (P = 0.31), as well as for those &gt; median (P = 0.50). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0014" title="NordentoftM , JeppesenP , PetersenL , ThorupA , OhlenschlaegerJ , ChristensenT , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. European Psychiatry2007;22:S129‐S. [CSzG: 20471] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the OPUS trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;83(1):29‐40. [CSzG: 13197] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;86(Suppl 1):S44. [CSzG: 13393] ">Nordentoft‐Denmark</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0015" title="McGorryP . Can the onset of schizophrenia be delayed or prevented?. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S26. [CSzG: 8351] McGorryP , AdlardS , YungA , McDonaldA , PhillipsL , HearnN . Detection and intervention in pre‐psychotic schizophrenia. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4836] McGorryP , YungA , FranceyS , PhillipsL , NelsonB . A blinded, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and befriending in young people at risk of psychotic disorder: baseline characteristics of the sample. Acta Neuropsychiatrica2006;18(6):261. [CSzG: 35157] McGorryPD , HearnN , GermanoD , BravinJ , PhillipsLJ , YungAR , et al. Prepsychotic intervention in schizophrenia: a stitch in time?. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington DC, USA. 1999. [CSzG: 3584] McGorryPD , PhillipsLJ , NelsonB , LeicesterS , BakerK , KrstevH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and befriending in young people with subthreshold symptoms at incipient risk of psychotic disorder: six month outcome data. Schizophrenia Bulletin2007;33(2):446. [CSzG: 15203] McGorryPD , PhillipsLJ , YungAR , FranceyS , GermanoD , BravinJ , et al. A randomised controlled trial of interventions in the pre psychotic phase of psychotic disorders. Schizophrenia Research2000;41(1):9. [CSzG: 5149] McGorryPD , YungAR , PhillipsL , AdlardS , HallgrenM , PattonG , et al. Pre‐psychotic intervention in schizophrenia: a stitch in time?. Schizophrenia Research1998;29(1‐2):160. [CSzG: 3585] McGorryPD , YungAR , PhillipsLJ , YuenHP , FranceyS , CosgraveEM , et al. Randomised controlled trial of interventions designed to reduce the risk of progression to first‐episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry2002;59(10):921‐8. [CSzG: 8576] PhilippsLJ , McGorryP , YungA , FranceyD , GermanoF , BravinJ , et al. The development of preventive interventions for early psychosis: early findings and directions for the future. 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001; Vol. 2, issue Suppl 1. [CSzG: 7614] PhillipsL , CottonS , YuenHP , MihalopoulosC , ShihS , KellyD , et al. Cost effectiveness of a preventive intervention for young people at ultra high risk of developing psychosis. Schizophrenia Bulletin2007;33(2):488‐9. [CSzG: 15227] PhillipsLJ , CottonS , MihalopoulosC , ShihS , YungAR , CarterR , et al. Cost implications of specific and non‐specific treatment for young persons at ultra high risk of developing a first episode of psychosis. Early Intervention in Psychiatry2009;3(1):28‐34. [CSzG: 18308] PhillipsLJ , LeicesterSB , O'DwyerLE , FranceySM , KoutsogiannisJ , Abdel‐BakiA , et al. The PACE clinic: identification and management of young people at &quot;ultra&quot; high risk of psychosis. Journal of Psychiatric Practice2002;8(5):255‐69. [CSzG: 18235] PhillipsLJ , McGorryPD , YuenHP , WardJ , DonovanK , KellyD , et al. Medium term follow‐up of a randomised controlled trial of interventions for young people at ultra high risk of psychosis. Schizophrenia Research2007;96(1‐3):25‐33. [CSzG: 15544] PhillipsLJ , YungAR , YuenHP , PantelisC , McGorryPD . Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. American Journal of Medical Genetics2002;114(8):929‐37. [CSzG: 18236] ">PACE‐Australia</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Variable adherence to risperidone was reported; in the SPI group (N = 31), 13 participants were classified as nonadherent (&lt; 50% doses taken), 4 as partially adherent, and 14 as fully adherent (almost 100% doses taken). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0016" title="NCT01619319 . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. ClinicalTrials.gov/show/NCT016193192012. [CSzG: 24387] PiskulicD , BarbatoM , AddingtonJ . Cognitive remediation in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:89. [CSzG: 24973] PiskulicD , BarbatoM , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2012;136:S245‐6. [CSzG: 29632] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2014;153(Suppl. 1):S218. [CSzG: 28827] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation therapy on cognition in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2014;8:86. [CSzG: 29633] ">Piskulic‐Canada</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Half of all participants completed between 2 and 4 training sessions/week, the other half failed to reach the target, completing 42 sessions on any given week. On average, participants across both groups completed 20 training sessions (SD = 13.5 sessions) and 50% of all participants completed between 20 and 40 training sessions (N = 7 in Post Science Brain Fitness group and N = 9 in control treatment group) in 12 weeks. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0017" title='BlockJJ , McGlashonTH . Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790‐9. American Journal of Psychiatry2006; Vol. 163, issue 10:1838. [CSzG: 13960] BreierAF , ZipurskyRB , PerkinsDO , AddingtonJM , TohenMF , DavidSR , et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951] HawkinsKA , AddingtonJ , KeefeR , ChristensenB , WoodsS , ZipurskyR , et al. Neuropsychological functioning in the first episode prodrome and early psychosis. Schizophrenia Research2004;70(1):101. [CSzG: 11515] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , MillerTJ , et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research2004;67(1):205. [CSzG: Ref11301] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , ZipurskyRB , et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. [CSzG: 16470] HawkinsKA , KeefeRS , ChristensenBK , AddingtonJ , WoodsSW , CallahanJ , et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. Schizophrenia Research2008;105(1‐3):1‐9. [CSzG: 16983] HoffmanRE , WoodsS , PredaA , TohenM , BreierA , GlistJ , et al. Excessive top‐down perceptual processing and reduced real‐world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. Schizophrenia Research2006;86(Suppl 1):S46. [CSzG: 13377] HoffmanRE , WoodsSW , HawkinsKA , PittmanB , TohenM , PredaA , et al. Extracting spurious messages from noise and risk of schizophrenia‐spectrum disorders in prodromal population. British Journal of Psychiatry2007;191(2):355‐6. [CSzG: 16068] McGlashanT , ZipurskyR , PerkinsD , AddingtonJ . Olanzapine for treatment of the schizophrenia prodrome: 2‐year results of a randomised placebo‐controlled study. Schizophrenia Research2004;67(1):164. [CSzG: 11320] McGlashanTH . Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. [CSzG: 10191] McGlashanTH . Treatment intervention in the New Haven PRIME clinic prodromal sample. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4835] McGlashanTH , MillerTJ , WoodsSW . Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research2002;53(3 Suppl 1):15. [CSzG: 8093] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005] McGlashanTH , MillerTJ , ZipurskyRB , WoodsSW , PerkinsDO , HawkinsKA , et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9803] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerT , WoodsSW , et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry2006;163(5):790‐9. [CSzG: 12654] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerTJ , WoodsSW , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research2003;61(1):7‐18. [CSzG: 9828] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJ , WoodsSW , MillerTJ , et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research2003;60:295. [CSzG: 9722] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJM , WoodsSW , LindborgS , et al. Olanzapine versus pbo for the schizophrenic prodrome: one‐year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9804] McGlashlanTH , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTH , WoodsSW , et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:42. [CSzG: 8934] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , MillerT , WoodsS , et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. Schizophrenia Research2004;70(1):6. [CSzG: 11524] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , WoodsS , MillerT , et al. Olanzapine vs. placebo for prodromal schizophrenia. Schizophrenia Research2004;67(1):6. [CSzG: 11321] MillerTJ , ZipurskyRB , PerkinsD , AddingtonJ , WoodsSW , HawkinsKA , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research2003;61(1):19‐30. [CSzG: 9829] RosenJL , WoodsSW , MillerTJ , McGlashanTH . Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease2002;190:133‐41. [CSzG: 8274] TaylorHE , ParkerS , MansellW , MorrisonAP . Effects of appraisals of anomalous experience on distress in people at risk of psychosis. Behavioural and Cognitive Psychotherapy2012;41(1):24‐33. [CSzG: 24374] WoodsS , ZipurskyR , PerkinsD , AddingtonJ , MarquezE , BreierA , et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:43. [CSzG: 8933] WoodsSW . Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):497. [CSzG: 19829] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research. 2003. [CSzG: 9978] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research2003;60:306‐7. [CSzG: 9752] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):453‐64. [CSzG: 9994] WoodsSW , McGlashanTH . Sample size planning for prodromal intervention trials. Schizophrenia Research2002;53(3 Suppl 1):40. [CSzG: 8116] WoodsSW , ZipurskyRB , PerkinsDO , AddingtonJM , MillerTJ , BreierAF , et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053] '>PRIME‐USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0018" title="LoewyR , FisherM , MathalonDH , VinogradovS . Interim analyses of a randomised controlled trial of computerised cognitive training in clinical high risk for psychosis. Schizophrenia Bulletin2013;39:S238‐9. [CSzG: 28151] LoewyR , FisherM , SchlosserDA , BiagiantiB , StuartB , MathalonDH , et al. Intensive auditory cognitive training improves verbal memory in adolescents and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2016;42(Suppl 1):S118‐26. [CSzG: 35221] VinogradovS , LoewyR , FisherM , LeeA , NiendamT , RaglandJD , et al. Neuroplasticity‐based cognitive training in ultra‐high risk adolescents and recent onset patients with schizophrenia. Schizophrenia Research2012;136:S30. [CSzG: 29703] ">Vinogradov‐USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0019" title="NCT00291226 . Glycine vs Placebo for the Schizophrenia Prodrome. www.ClinicalTrials.gov/ct/show/2006. [CSzG: 14759] WoodsS , WalshB , HawkinsK , MillerT , SaksaJ , D'SouzaD , et al. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. Early Intervention in Psychiatry2012;6:29. [CSzG: 24987] WoodsSW , KantrowitzJT , JavittDC . NMDAR‐based treatments for patients at clinical high risk for psychosis. Biological Psychiatry2014;1:11S. [CSzG: 29041] WoodsSW , WalshBC , HawkinsKA , MillerTJ , SaksaJR , D'SouzaDC , et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. European Neuropsychopharmacology2013;23(8):931‐40. [CSzG: 28750] ">Woods‐1‐USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "Two placebo subjects missed one or more rating visits", no other data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0020" title="McGorryP . Second generation intervention research in the pre‐psychotic phase of illness in schizophrenia and related psychoses. Australian New Zealand Clinical Trials Registry2000. [CSzG: 18439] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceyS , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: 12‐month outcome. Schizophrenia Research2012;136:S17‐8. [CSzG: 29547] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceySM , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: twelve‐month outcome. Journal of Clinical Psychiatry2013;74(4):349‐56. [CSzG: 28737] NelsonB , PhillipsLJ , YungAR , FranceySM , LeicesterS , BakerK , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and supportive therapy in young people with subthreshold symptoms at incipient risk of psychotic disorder: baseline characteristics of the sample. Schizophrenia Bulletin2007;33(2):450. [CSzG: 15212] PhillipsLJ , NelsonB , YuenHP , FranceySM , SimmonsM , StanfordC , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: study design and baseline characteristics. Australian and New Zealand Journal of Psychiatry2009;;43(9):818–29. YungA , AmmingerP , BergerG , ThompsomA , PhillipsL , NelsonB , et al. Randomised controlled trial of antipsychotic and cognitive therapy in young people at ultra‐high risk of psychosis. Early Intervention in Psychiatry2012;6:11. [CSzG: 24989] YungA , NelsonB , PhillipsL , FranceyS , LeicesterS , YuenH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and supportive therapy in young people at ultra high risk of psychotic disorder: 12 month outcome data. Early Intervention in Psychiatry2008;2(Suppl 1):A12. [CSzG: 19138] YungAR , PhillipsLJ , NelsonB , FranceySM , YuenHP , SimmonsMB , et al. Randomised controlled trial of interventions for young people at ultra high risk for psychosis: 6‐month analysis. Journal of Clinical Psychiatry2011;72(4):430‐40. [CSzG: 22929] ">Yung‐Australia</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Poor therapy adherence (only 2 participants (4.7%) had full adherence to risperidone).</p> <p>Problems with therapy supervision (only 24 of 41 tapes from the cognitive therapy groups (58.5%) were classified as receiving cognitive therapy, 9 participants (22.0%) allocated to cognitive therapy were judged to be receiving supportive therapy, and, in a further 8 cases (19.5%), the nature of the psychological therapy was rated as not known). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>ACG:</b> active control group; <b>CBCM:</b> cognitive behavioural case management; <b>CBT:</b> cognitive behavioural therapy; <b>FFT:</b> family‐focused treatment <b>IPI:</b> integrated psychological intervention; <b>NDRL:</b> non‐directive reflective listening; <b>PST:</b> processing speed training; <b>SC:</b> supportive counselling; <b>SD:</b> standard deviation; <b>SPI:</b> specific preventive intervention </p> </td> </tr> </tbody> </table> </div> </section> </section> </section> <section id="CD012236-sec-0142"> <h5 class="title">6. Outcomes</h5> <section id="CD012236-sec-0143"> <h6 class="title">6.1 Non‐scale data</h6> <p>We were able to report dichotomous data on leaving the study early, transition to psychosis and adverse effects. </p> </section> <section id="CD012236-sec-0144"> <h6 class="title">6.2 Scale‐derived data</h6> <p>We have only shown details of the outcome scales that provided usable data below and we have given reasons for exclusions of data under 'Outcomes' in <a href="./references#CD012236-sec-0539" title="">Characteristics of included studies</a>. </p> <section id="CD012236-sec-0145"> <p><b>6.2.1 Global state</b></p> <p>a. Clinical Global Impression (CGI; <a href="./references#CD012236-bbs2-0132" title="GuyW (editor) . ECDEU Assessment Manual for Psychopharmacology. Rockville: US Department of Health, Education, and Welfare, 1976. ">Guy 1976</a>) </p> <p>The CGI is a brief observer‐rated scale consisting of Severity scale (CGI‐S) and Improvement scale (CGI‐I). Both CGI‐S and CGI‐I are seven‐point scales rating the severity or improvement of the patient's illness at the time of assessment. Higher scores represent higher severity and worsening of the illness (1: normal or very much improved; 7: among the most severely ill or very much worse since the initiation of treatment). Scores range from 2 to 14. <a href="./references#CD012236-bbs2-0017" title='BlockJJ , McGlashonTH . Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790‐9. American Journal of Psychiatry2006; Vol. 163, issue 10:1838. [CSzG: 13960] BreierAF , ZipurskyRB , PerkinsDO , AddingtonJM , TohenMF , DavidSR , et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951] HawkinsKA , AddingtonJ , KeefeR , ChristensenB , WoodsS , ZipurskyR , et al. Neuropsychological functioning in the first episode prodrome and early psychosis. Schizophrenia Research2004;70(1):101. [CSzG: 11515] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , MillerTJ , et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research2004;67(1):205. [CSzG: Ref11301] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , ZipurskyRB , et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. [CSzG: 16470] HawkinsKA , KeefeRS , ChristensenBK , AddingtonJ , WoodsSW , CallahanJ , et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. Schizophrenia Research2008;105(1‐3):1‐9. [CSzG: 16983] HoffmanRE , WoodsS , PredaA , TohenM , BreierA , GlistJ , et al. Excessive top‐down perceptual processing and reduced real‐world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. Schizophrenia Research2006;86(Suppl 1):S46. [CSzG: 13377] HoffmanRE , WoodsSW , HawkinsKA , PittmanB , TohenM , PredaA , et al. Extracting spurious messages from noise and risk of schizophrenia‐spectrum disorders in prodromal population. British Journal of Psychiatry2007;191(2):355‐6. [CSzG: 16068] McGlashanT , ZipurskyR , PerkinsD , AddingtonJ . Olanzapine for treatment of the schizophrenia prodrome: 2‐year results of a randomised placebo‐controlled study. Schizophrenia Research2004;67(1):164. [CSzG: 11320] McGlashanTH . Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. [CSzG: 10191] McGlashanTH . Treatment intervention in the New Haven PRIME clinic prodromal sample. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4835] McGlashanTH , MillerTJ , WoodsSW . Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research2002;53(3 Suppl 1):15. [CSzG: 8093] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005] McGlashanTH , MillerTJ , ZipurskyRB , WoodsSW , PerkinsDO , HawkinsKA , et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9803] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerT , WoodsSW , et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry2006;163(5):790‐9. [CSzG: 12654] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerTJ , WoodsSW , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research2003;61(1):7‐18. [CSzG: 9828] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJ , WoodsSW , MillerTJ , et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research2003;60:295. [CSzG: 9722] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJM , WoodsSW , LindborgS , et al. Olanzapine versus pbo for the schizophrenic prodrome: one‐year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9804] McGlashlanTH , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTH , WoodsSW , et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:42. [CSzG: 8934] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , MillerT , WoodsS , et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. Schizophrenia Research2004;70(1):6. [CSzG: 11524] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , WoodsS , MillerT , et al. Olanzapine vs. placebo for prodromal schizophrenia. Schizophrenia Research2004;67(1):6. [CSzG: 11321] MillerTJ , ZipurskyRB , PerkinsD , AddingtonJ , WoodsSW , HawkinsKA , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research2003;61(1):19‐30. [CSzG: 9829] RosenJL , WoodsSW , MillerTJ , McGlashanTH . Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease2002;190:133‐41. [CSzG: 8274] TaylorHE , ParkerS , MansellW , MorrisonAP . Effects of appraisals of anomalous experience on distress in people at risk of psychosis. Behavioural and Cognitive Psychotherapy2012;41(1):24‐33. [CSzG: 24374] WoodsS , ZipurskyR , PerkinsD , AddingtonJ , MarquezE , BreierA , et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:43. [CSzG: 8933] WoodsSW . Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):497. [CSzG: 19829] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research. 2003. [CSzG: 9978] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research2003;60:306‐7. [CSzG: 9752] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):453‐64. [CSzG: 9994] WoodsSW , McGlashanTH . Sample size planning for prodromal intervention trials. Schizophrenia Research2002;53(3 Suppl 1):40. [CSzG: 8116] WoodsSW , ZipurskyRB , PerkinsDO , AddingtonJM , MillerTJ , BreierAF , et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053] '>PRIME‐USA</a> reported data from this scale. </p> <p>b. Personal Beliefs about Illness Questionnaire (PBIQ; <a href="./references#CD012236-bbs2-0095" title="BirchwoodM , MasonR , MacMillanF , HealyJ . Depression, demoralisation and control over psychotic illness: a comparison of depressed and non‐depressed patients with a chronic psychosis. Psychological Medicine1993;23:387–95. [DOI: 10.1017/s0033291700028488] ">Birchwood 1993</a>) </p> <p>PBIQ is a 16‐item scale originally developed to assess five constructs related to people’s appraisals of their psychotic illness: control over illness, self as illness, illness as an impediment to the attainment of goals, humiliation and guilt, and need for social containment. Personal Beliefs about Illness Questionnaire ‐ Revised (PBIQ‐R; <a href="./references#CD012236-bbs2-0096" title="BirchwoodM , JacksonCh , BrunetK , HoldenJ , BartonK . Personal beliefs about illness questionnaire‐revised (PBIQ‐R): reliability and validation in a first episode sample. British Journal of Clinical Psychology2012;51:448–58. ">Birchwood 2012</a>), is a 29‐item scale, designed to measure five different categories of emotion/appraisal following a psychotic illness: shame (six items); loss (seven items); entrapment (six items); control over illness (five items), and social marginalisation/group fit (five items). The scale was designed to measure both stigma‐ and social rank‐based variables. <a href="./references#CD012236-bbs2-0006" title="DragtS , Van derGaagM . Prevention of psychosis with a cognitive behavioural intervention in help‐seeking young people with an at risk mental state for developing psychosis. www.trialregister.nl/trialreg/index.asp2007. [CSzG: Ref19655] IsingHK , KraanTC , RietdijkJ , DragtS , KlaassenRM , BoonstraN , et al. Four‐year follow‐up of cognitive behavioral therapy in persons at ultra‐high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2016;42(5):1243‐52. [CSzG: Ref35214] IsingHK , LokkerbolJ , RietdijkJ , DragtS , KlaassenRM , KraanT , et al. Four‐year cost‐effectiveness of cognitive behavior therapy for preventing first‐episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2017;43(2):365‐74. [CSzG: Ref35824] IsingHK , SmitF , VelingW , RietdijkJ , DragtS , KlaassenRM , et al. Cost‐effectiveness of preventing first‐episode psychosis in ultra‐high‐risk subjects: multi‐centre randomised controlled trial. Psychological Medicine2015;45(7):1435‐46. [CSzG: Ref27798] KraanTC , IsingHK , FokkemaM , VelthorstE , Van denBergDP , KerkhovenM , et al. The effect of childhood adversity on 4‐year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE‐NL) Trial. Psychiatry Research2017;247:55‐62. [CSzG: Ref35559] NiemanDH , RuhrmannS , RietdijkJ , DragtS , IsingH , KlaassenR , et al. Preventive psychotherapy. Schizophrenia Research2014;153:S42‐3. [CSzG: Ref29601] RietdijkJ , DragtS , KlaassenR , IsingH , NiemanD , WunderinkL , et al. A single blind randomised controlled trial of cognitive behavioural therapy in a help‐seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE‐NL) trial. Trials2010;11:30. [CSzG: Ref20654] Van DerGaagM . The effects of CBT in personswith ultra high risk: the Dutch EDIE trial. European Archives of Psychiatry and Clinical Neuroscience2011;261:S18. [CSzG: Ref23756] Van DerGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first‐episode of psychosis. Early Intervention in Psychiatry2012;6:12. [CSzG: Ref24985] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomised controlled clinical trial. Schizophrenia Bulletin2012;38(6):1180‐8. [CSzG: Ref24935] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. The effects of cognitive behavioural therapy for subjects at ultra‐high risk for developing psychosis. Schizophrenia Bulletin2013;39:S356. [CSzG: Ref28121] Van derGaagM . The prevention of psychosis in at risk mental state. www.controlled‐trials.com2008. [CSzG: Ref17488] Van derGaagM , NiemanD , Van denBergD . CBT for those at risk of a first episode psychosis: Evidence‐based psychotherapy for people with an 'at risk mental state'. 1st Edition. Hove, UK: Routledge, 2013. Van derGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first episode of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29692] ">EDIE‐NL</a> reported data from this scale. An adapted version of PBIQ, Personal Beliefs about Experiences Questionnaire (PBEQ; <a href="./references#CD012236-bbs2-0167" title="PyleM , StewartSL , FrenchP , ByrneR , PattersonP , GumleyA , et al. Internalised stigma, emotional dysfunction and unusual experiences in young people at risk of psychosis. Early Intervention in Psychiatry2015;9:133–40. [DOI: 10.1111/eip.12098] ">Pyle 2015</a>) is a 13‐item, self‐report questionnaire. Each item reflects social and cultural beliefs/stereotypes about psychosis. Participants rate the degree to which they endorse statements to be true about themselves on a four‐point scale. <a href="./references#CD012236-bbs2-0005" title="ByrneRE , MorrisonAP . Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. Psychology and Psychotherapy2014;87(3):357‐71. [CSzG: Ref29312] FlachC , FrenchP , DunnG , FowlerD , GumleyAI , BirchwoodM , et al. Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE‐2 trial. British Journal of Psychiatry2015;207(2):123‐9. [CSzG: Ref33109] MorrisonA . Early detection and intervention evaluation for individuals at high risk of psychosis 2. http://www.controlled‐trials.com2008. [CSzG: Ref18285] MorrisonA . Early detection and intervention evaluation for people at risk of psychosis (edie‐2): A multisite randomised controlled trial of cognitive therapy for at‐risk mental states. Early Intervention in Psychiatry2012;6:11. [CSzG: Ref24968] MorrisonA , FrenchP , BentallR , LewisS , BirchwoodM , FowlerD , et al. Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. Early Intervention in Psychiatry2008;2(Suppl 1):A15. [CSzG: Ref19128] MorrisonAP . EDIE‐2: early detection and psychological intervention for individuals at high risk of psychosis (2). www.controlled‐trials.com2007. [CSzG: Ref15381] MorrisonAP , BirchwoodM , PyleM , FlachC , StewartSL , ByrneR , et al. Impact of cognitive therapy on internalised stigma in people with at‐risk mental states. British Journal of Psychiatry2013;203(2):140‐5. [CSzG: Ref28630] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ2012;344(7852):e2233. [CSzG: Ref24208] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at‐risk of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29554] MorrisonAP , PyleM , StewartSL , FrenchP , ByrneR , FlachC , et al. Internalised stigma in young people at high risk of developing psychosis: findings from a cognitive therapy trial. Schizophrenia Research2014;153:S42. [CSzG: Ref29555] MorrisonAP , StewartSL , FrenchP , BentallRP , BirchwoodM , ByrneR , et al. Early detection and intervention evaluation for people at high‐risk of psychosis‐2 (EDIE‐2): trial rationale, design and baseline characteristics. Early Intervention in Psychiatry2011;5(1):24‐32. [CSzG: Ref22695] MorrisonT . Early detection and psychological intervention for individuals at high risk of psychosis. EDIE‐2. Data on File2006. [CSzG: Ref13874] PelosiAJ . Rational policy making for early psychosis might yet become possible. BMJ2012;344(7856):e3137. [CSzG: Ref24326] PyleM , StewartSL , FrenchP , ByrneR , PattersonP , GumleyA , et al. Internalised stigma, emotional dysfunction and unusual experiences in young people at risk of psychosis. Early Intervention in Psychiatry2015;9(2):133‐40. [CSzG: Ref29813] ">EDIE‐2‐UK</a> reported data from PBEQ (please see <a href="./appendices#CD012236-sec-0531">Appendix 1</a>). </p> </section> <section id="CD012236-sec-0146"> <p><b>6.2.2 Mental state</b></p> <p>a. Brief Psychopathological Rating Scale (BPRS; <a href="./references#CD012236-bbs2-0165" title="OverallJE , GorhamDR . The Brief Psychiatric Rating Scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) </p> <p>The BPRS is a scale used for assessment of positive symptoms, general psychopathology and affective symptoms. The original scale has 16 items, but a revised scale consisting of 18 items is commonly used. Each item is rated from 0 (not present) to 7 (extremely severe), with total scores ranging from 0 to 126 (higher scores meaning more severe symptoms). <a href="./references#CD012236-bbs2-0015" title="McGorryP . Can the onset of schizophrenia be delayed or prevented?. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S26. [CSzG: 8351] McGorryP , AdlardS , YungA , McDonaldA , PhillipsL , HearnN . Detection and intervention in pre‐psychotic schizophrenia. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4836] McGorryP , YungA , FranceyS , PhillipsL , NelsonB . A blinded, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and befriending in young people at risk of psychotic disorder: baseline characteristics of the sample. Acta Neuropsychiatrica2006;18(6):261. [CSzG: 35157] McGorryPD , HearnN , GermanoD , BravinJ , PhillipsLJ , YungAR , et al. Prepsychotic intervention in schizophrenia: a stitch in time?. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington DC, USA. 1999. [CSzG: 3584] McGorryPD , PhillipsLJ , NelsonB , LeicesterS , BakerK , KrstevH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and befriending in young people with subthreshold symptoms at incipient risk of psychotic disorder: six month outcome data. Schizophrenia Bulletin2007;33(2):446. [CSzG: 15203] McGorryPD , PhillipsLJ , YungAR , FranceyS , GermanoD , BravinJ , et al. A randomised controlled trial of interventions in the pre psychotic phase of psychotic disorders. Schizophrenia Research2000;41(1):9. [CSzG: 5149] McGorryPD , YungAR , PhillipsL , AdlardS , HallgrenM , PattonG , et al. Pre‐psychotic intervention in schizophrenia: a stitch in time?. Schizophrenia Research1998;29(1‐2):160. [CSzG: 3585] McGorryPD , YungAR , PhillipsLJ , YuenHP , FranceyS , CosgraveEM , et al. Randomised controlled trial of interventions designed to reduce the risk of progression to first‐episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry2002;59(10):921‐8. [CSzG: 8576] PhilippsLJ , McGorryP , YungA , FranceyD , GermanoF , BravinJ , et al. The development of preventive interventions for early psychosis: early findings and directions for the future. 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001; Vol. 2, issue Suppl 1. [CSzG: 7614] PhillipsL , CottonS , YuenHP , MihalopoulosC , ShihS , KellyD , et al. Cost effectiveness of a preventive intervention for young people at ultra high risk of developing psychosis. Schizophrenia Bulletin2007;33(2):488‐9. [CSzG: 15227] PhillipsLJ , CottonS , MihalopoulosC , ShihS , YungAR , CarterR , et al. Cost implications of specific and non‐specific treatment for young persons at ultra high risk of developing a first episode of psychosis. Early Intervention in Psychiatry2009;3(1):28‐34. [CSzG: 18308] PhillipsLJ , LeicesterSB , O'DwyerLE , FranceySM , KoutsogiannisJ , Abdel‐BakiA , et al. The PACE clinic: identification and management of young people at &quot;ultra&quot; high risk of psychosis. Journal of Psychiatric Practice2002;8(5):255‐69. [CSzG: 18235] PhillipsLJ , McGorryPD , YuenHP , WardJ , DonovanK , KellyD , et al. Medium term follow‐up of a randomised controlled trial of interventions for young people at ultra high risk of psychosis. Schizophrenia Research2007;96(1‐3):25‐33. [CSzG: 15544] PhillipsLJ , YungAR , YuenHP , PantelisC , McGorryPD . Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. American Journal of Medical Genetics2002;114(8):929‐37. [CSzG: 18236] ">PACE‐Australia</a> and <a href="./references#CD012236-bbs2-0020" title="McGorryP . Second generation intervention research in the pre‐psychotic phase of illness in schizophrenia and related psychoses. Australian New Zealand Clinical Trials Registry2000. [CSzG: 18439] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceyS , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: 12‐month outcome. Schizophrenia Research2012;136:S17‐8. [CSzG: 29547] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceySM , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: twelve‐month outcome. Journal of Clinical Psychiatry2013;74(4):349‐56. [CSzG: 28737] NelsonB , PhillipsLJ , YungAR , FranceySM , LeicesterS , BakerK , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and supportive therapy in young people with subthreshold symptoms at incipient risk of psychotic disorder: baseline characteristics of the sample. Schizophrenia Bulletin2007;33(2):450. [CSzG: 15212] PhillipsLJ , NelsonB , YuenHP , FranceySM , SimmonsM , StanfordC , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: study design and baseline characteristics. Australian and New Zealand Journal of Psychiatry2009;;43(9):818–29. YungA , AmmingerP , BergerG , ThompsomA , PhillipsL , NelsonB , et al. Randomised controlled trial of antipsychotic and cognitive therapy in young people at ultra‐high risk of psychosis. Early Intervention in Psychiatry2012;6:11. [CSzG: 24989] YungA , NelsonB , PhillipsL , FranceyS , LeicesterS , YuenH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and supportive therapy in young people at ultra high risk of psychotic disorder: 12 month outcome data. Early Intervention in Psychiatry2008;2(Suppl 1):A12. [CSzG: 19138] YungAR , PhillipsLJ , NelsonB , FranceySM , YuenHP , SimmonsMB , et al. Randomised controlled trial of interventions for young people at ultra high risk for psychosis: 6‐month analysis. Journal of Clinical Psychiatry2011;72(4):430‐40. [CSzG: 22929] ">Yung‐Australia</a> reported data from this scale, while <a href="./references#CD012236-bbs2-0013" title="ACTRN12608000475347 . A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder. Australian New Zealand Clinical Trials Registry2009. [CSzG: 18420] HKCTR‐1438 . The NEURAPRO‐E (North America, EURope, Australia PROdrome) Study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for symptomatic patients at ultra‐high risk for early progression to schizophrenia and other psychotic disorders. www.hkClinicaltrials.com/trial_details.aspx?trialID=d09bd177‐b9fd‐4162‐b04f‐3ebfed49baa32011. [CSzG: 29270] McGorryP , MarkulevC , NelsonB , YuenHP , SchaeferM , YungAR , et al. The NEURAPRO‐E study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Schizophrenia Bulletin2015;41:S322‐3. [CSzG: 29546] McGorryPD , NelsonB , MarkulevC , YuenHP , SchaferMR , MossahebN , et al. Effect of omega‐3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomised clinical trial. JAMA psychiatry2017;74(1):19‐27. [CSzG: 35590] NelsonB , AmmingerG , MarkulevC , YuenHP , LavoieS , SchaeferM , et al. NEURAPOR: a multi‐center RCT of omega‐3 polyunsaturated fatty acids versus placebo in young people at ultra‐high risk of psychotic disorders: medium‐term outcome. Schizophrenia Bulletin2017;43:S107. [CSzG: 36016] ">NEURAPRO‐AAE</a> reported data for psychotic subscale (please see <a href="./appendices#CD012236-sec-0531">Appendix 1</a>). </p> <p>b. Positive and Negative Symptom Scale (PANSS; <a href="./references#CD012236-bbs2-0149" title="KaySR , OplerLA . The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin1987;13(2):261‐76. [PUBMED: 3616518] ">Kay 1987</a>) </p> <p>The PANSS is used for evaluation of positive, negative and other symptom dimensions in schizophrenia. The scale consists of 30 items divided into three subscales: positive (PANSS P), negative (PANSS N) and general (PANSS G) symptoms. Each item is rated on a seven‐point scoring system, higher levels meaning more severity of symptoms. Scores range from 30 to 210. <a href="./references#CD012236-bbs2-0002" title="AmmingerG . Ethyl eicosapentanoic acid for prodromal psychosis. Stanley Foundation Research Programs2009. [CSzG: Ref17423] AmmingerG , SchaferM , PapageorgiouK , CottonS , HarriganS , MackinnonA , et al. Indicated prevention with long‐chain omega‐3 fatty acids in adolescents at ultra‐high‐risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2008;2(Suppl 1):A29. [CSzG: Ref19107] AmmingerGP , ChanenAM , OhmannS , KlierCM , MossahebN , BechdolfA , et al. Omega‐3 fatty acid supplementation in adolescents with borderline personality disorder and ultra‐high risk criteria for psychosis: a post hoc subgroup analysis of a double‐blind, randomised controlled trial. Canadian Journal of Psychiatry2013;58(7):402‐8. [CSzG: Ref28534] AmmingerGP , HarrisMS , McGorryPD , HenryLP . Omega‐3 fatty acids for indicated prevention: treatment results and pathomechanisms. European Archives of Psychiatry and Clinical Neuroscience2013;263(Suppl. 1):S44‐5. [CSzG: Ref28434] AmmingerGP , LeicesterS , YungAR , YuenHP , McGorryPD . Age predicts transition to psychosis in an ultra‐high risk sample. Proceedings of the 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:61. AmmingerGP , McGorryPD . Update on omega‐3 polyunsaturated fatty acids in early ‐stage psychotic disorders. Neuropsychopharmacology2012;37(1):309‐10. [CSzG: Ref23726] AmmingerGP , MechelliA , RiceS , KimSW , KlierCM , McNamaraRK , et al. Predictors of treatment response in young people at ultra‐high risk for psychosis who received long‐chain omega‐3 fatty acids. Translational Psychiatry2015;5:e495. [CSzG: Ref29299] AmmingerGP , SchaferMR . Indicated prevention with omega‐3 fatty acids in adolescents at ultra‐high risk for psychosis ‐ rationale, methods, and 3‐months outcome. Schizophrenia Research2006;86(Suppl 1):S97‐8. [CSzG: Ref13367] AmmingerGP , SchaferMR . Is it feasible to conduct a RCT in ultra‐high risk individuals at a child and adolescent psychiatric service?. Schizophrenia Research2006;86(Suppl 1):S98. [CSzG: Ref13368] AmmingerGP , SchaferMR , KlierCM , PapageorgiouK , SlavikJ , HolzerI , et al. Indicated prevention with long‐chain omega‐3 fatty acids in young people at ultra‐high risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2010;4(Suppl 1):7. [CSzG: Ref23467] AmmingerGP , SchaferMR , SchlogelhoferM , KlierCM , McGorryPD . Longer‐term outcome in the prevention of psychotic disorders by the Vienna omega‐3 study. Nature Communications2015;6:7934. [CSzG: Ref33023] AmmingerGP , SchlogelhoferM , KlierC , McGorryP , SchaferM . Longer‐term follow‐up in the Vienna omega‐3 psychosis prevention trial. Early Intervention in Psychiatry2014;8:41. [CSzG: Ref29378] AmmingerGP , SchäferMR , PapageorgiouK , KlierCM , CottonSM , HarriganSM , et al. Long‐chain omega‐3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo‐controlled trial. Archives of General Psychiatry2010;67(2):146‐54. [CSzG: Ref20680; DOI: 10.1001/archgenpsychiatry.2009.192.] AmmingerP , MossahebN , SchlgelhoferM , SchaferM . Fatty acid metabolism and the onset of psychotic disorder. European Psychiatry2011;26(Suppl 1):2089. [CSzG: Ref22967] Anonymous . Fish oil may help ward off psychosis. Journal of Psychosocial Nursing and Mental Health Services2010;48(5):55. [CSzG: Ref20739] BergerG , AmmingerP , McGorryP . Stage dependant effect of omega‐3 fatty acids in emerging psychosis. European Psychiatry2011;26(Suppl 1):1347. [CSzG: Ref22966] BergerGE , ProffittTM , McConchieM , YuenH , WoodSJ , AmmingerGP , et al. Ethyl‐eicosapentaenoic acid in first‐episode psychosis: a randomised, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(12):1867‐75. [CSzG: Ref15561; ISSN: 1555‐2101] EhrlichA . Evidence‐based medicine. Omega‐3 supplementation delays transition to psychotic disorder in ultra‐high‐risk adolescents and young adults. Clinical Advisor for Nurse Practitioners2010;13(5):79‐80. [CSzG: Ref21562] FöckingM , DickerP , LopezLM , CannonM , SchäferMR , McGorryPD , et al. Differential expression of the inflammation marker IL12p40 in the at‐risk mental state for psychosis: a predictor of transition to psychotic disorder?. BMC Psychiatry2016;16(1):326. [DOI: 10.1186/s12888‐016‐1039‐7] KlierC , HollmannM , SchlögelhoferM , MossahebN , FriedrichM , AmmingerPG . Indicated prevention with omega‐3 fatty acids (EPA/DHA) in adolescents with &quot;at‐risk‐mental‐state“ for psychosis. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. [CSzG: Ref12438] LavoieS , BenningerF , FeuchtM , KlierCM , SchaeferMR , AmmingerGP . Correlates of EEG resting states with erythrocyte membrane omega‐3 fatty acid levels and psychopathological symptoms in individuals at ultra‐high risk for psychosis. Early Intervention in Psychiatry2014;8:137. [CSzG: Ref29516] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultra‐high risk individuals who transitioned to psychosis. Schizophrenia Research2012;138(2‐3):206‐11. [CSzG: Ref24256] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultrahigh risk individuals who transitioned to psychosis. Early Intervention in Psychiatry2012;6:38. [CSzG: Ref24960] MossahebN , PapageorgiouK , SchaferMR , BeckerJ , SchloegelhoferM , AmmingerGP . Changes in triglyceride levels in ultra‐high risk for psychosis individuals treated with omega‐3 fatty acids. Early Intervention in Psychiatry2018; Vol. 12, issue 1:30‐36. [DOI: 10.1111/eip.12275] MossahebN , SchaferMR , SchlogelhoferM , KlierCM , CottonSM , McGorryPD , et al. Effect of omega‐3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?. Schizophrenia Research2013;148(1‐3):163‐7. [CSzG: Ref28649] NCT00396643 . Indicated prevention with omega‐3 fatty acids in adolescents with ‘at‐risk‐mental‐state’ for psychosis: a randomised, double blind, placebo‐controlled treatment trial. www.ClinicalTrials.gov/ct/show/2006. [CSzG: Ref14873] PapageorgiouK , SchaferMR , SchlogelhoferM , MossahebN , AmmingerGP . Indicated prevention with omega‐3 fatty acids in young people with 'at‐risk‐mental‐state' for psychosis: design of a 5‐year follow‐up. European Archives of Psychiatry and Clinical Neuroscience2011;261:S55. [CSzG: Ref23749] SchaferMR , KlierCM , PapageorgiouK , FriedrichMH , AmmingerGP . Early detection of psychotic disorders. Neuropsychiatrie2007;21(1):37‐44. [CSzG: Ref15290] SmesnyS , MilleitB , HiplerUC , MilleitC , SchaferMR , KlierCM , et al. Omega‐3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra‐high risk for psychosis. Molecular Psychiatry2013;19(3):317‐24. [CSzG: Ref28243] SmesnyS , MilleitB , SchaeferMR , HesseJ , SchlögelhoferM , LangbeinK , et al. Effects of omega‐3 PUFA on immune markers in adolescent individuals at ultra‐high risk for psychosis ‐ results of the randomised controlled Vienna omega‐3 study. Schizophrenia Research2017;S0920‐9964(17):30039‐7. [DOI: 10.1016/j.schres.2017.01.026] ">Amminger‐Austria</a>, <a href="./references#CD012236-bbs2-0009" title="BechdolfA . Preventing progression to first‐episode psychosis in people in the early initial prodromal state. Early Intervention in Psychiatry2012;6:11. [CSzG: 24944] BechdolfA , BuhlerB , BerningJ , WagnerM , StammE , StreitM . Cognitive behavioural therapy in the early initial prodromal state of psychosis: first results. Schizophrenia Research2004;67(1):202. [CSzG: Ref11285] BechdolfA , KlosterkotterJ . Cognitive‐behavioural treatment (CBT) in the early initial prodromal state of psychosis: concept and practical approach. Schizophrenia Research2004;70(1):52. [CSzG: Ref11506] BechdolfA , RuhrmannS , JanssenB , BottlenderR , WagnerM , MaurerK , et al. Early recognition and intervention for people at risk of schizophrenia [Fruherkennung und intervention bei personen mit erhohtem psychoserisiko]. Psychoneuroendocrinology2004;30(11):606‐14. [CSzG: Ref11376] BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: Ref12511] BechdolfA , VeithV , BerningJ , StammE , DeckerP , JanssenB , et al. Cognitive behavioral therapy (CBT) in the early initial prodromal state of psychosis: first results of a randomised trial. Schizophrenia Research2004;70(1):62‐3. [CSzG: Ref11507] BechdolfA , WagnerM , RuhrmannS , HarriganS , PutzfeldV , PukropR , et al. Preventing progression to first‐episode psychosis in early initial prodromal states. British Journal of Psychiatry2012;200(1):22‐9. [CSzG: Ref24206] BechdolfA , WagnerM , RuhrmannS , HarriganS , VeithV , PukropR , et al. CBT for prevention of first episode psychosis in people in an putative early initial prodromal state. Early Intervention in Psychiatry2008;2(Suppl 1):A16. [CSzG: 19109] BechdolfA , WagnerM , VeithV , PukropR , BerningJ , StammE , et al. A randomised controlled trial of cognitive‐behavioral therapy in the early initial prodromal state of psychosis. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:22‐3. [CSzG: 20193] BechdolfA , WagnerM , VeithV , RuhrmannR , JanssenB , BottlenderR , et al. A randomised controlled multicenter trial of cognitive behaviour therapy in the early initial prodromal state of psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13369] BechdolfA , WagnerM , VeithV , RuhrmannS , PukropR , Brockhaus‐DumkeA , et al. Randomised controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Intervention in Psychiatry2007;1(1):71‐8. [CSzG: 16450] BechdolfA , WesselsH , WagnerM , KuhrK , BerningJ , PutzfeldV , et al. Predictors of treatment response to psychosocial interventions in people at risk. European Archives of Psychiatry and Clinical Neuroscience2015;1:S9. [CSzG: 33601] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] KommescherM , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. Early Intervention in Psychiatry2016;10(1):17‐27. [CSzG: 32187] NCT00204087 . Psychological intervention for persons at risk of psychosis in the early initial prodromal state. www.ClinicalTrials.gov/ct/show/2005. [CSzG: 14890] WesselsH , WagnerM , FrommannI , BerningJ , PutzfeldV , JanssenB , et al. Neuropsychological functioning as a predictor of treatment response to psychoeducational, cognitive behavioral therapy in people at clinical high risk of first episode psychosis. Psychiatrische Praxis2015;42(6):313‐9. [CSzG: 33130] ZarafonitisS , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Psychoeducation for persons at risk of psychosis. Psychotherapeut2012;57(4):326‐34. [CSzG: 24807] ">EIPS‐Germany</a>, <a href="./references#CD012236-bbs2-0011" title="BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: 12511] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] RuhrmannS , BechdolfA , KuhnKU , WagnerM , Schultze‐LutterF Janssen B , et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry. Supplements2007;51:s88‐95. [CSzG: 16127] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Acute symptomatic treatment effects in persons clinically at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13397] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Intervention in the late initial prodromal state (LIPS) of psychosis. Schizophrenia Research2006;86(Suppl 1):S96. [CSzG: 13398] ">LIPS‐Germany</a> and <a href="./references#CD012236-bbs2-0017" title='BlockJJ , McGlashonTH . Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790‐9. American Journal of Psychiatry2006; Vol. 163, issue 10:1838. [CSzG: 13960] BreierAF , ZipurskyRB , PerkinsDO , AddingtonJM , TohenMF , DavidSR , et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951] HawkinsKA , AddingtonJ , KeefeR , ChristensenB , WoodsS , ZipurskyR , et al. Neuropsychological functioning in the first episode prodrome and early psychosis. Schizophrenia Research2004;70(1):101. [CSzG: 11515] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , MillerTJ , et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research2004;67(1):205. [CSzG: Ref11301] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , ZipurskyRB , et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. [CSzG: 16470] HawkinsKA , KeefeRS , ChristensenBK , AddingtonJ , WoodsSW , CallahanJ , et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. Schizophrenia Research2008;105(1‐3):1‐9. [CSzG: 16983] HoffmanRE , WoodsS , PredaA , TohenM , BreierA , GlistJ , et al. Excessive top‐down perceptual processing and reduced real‐world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. Schizophrenia Research2006;86(Suppl 1):S46. [CSzG: 13377] HoffmanRE , WoodsSW , HawkinsKA , PittmanB , TohenM , PredaA , et al. Extracting spurious messages from noise and risk of schizophrenia‐spectrum disorders in prodromal population. British Journal of Psychiatry2007;191(2):355‐6. [CSzG: 16068] McGlashanT , ZipurskyR , PerkinsD , AddingtonJ . Olanzapine for treatment of the schizophrenia prodrome: 2‐year results of a randomised placebo‐controlled study. Schizophrenia Research2004;67(1):164. [CSzG: 11320] McGlashanTH . Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. [CSzG: 10191] McGlashanTH . Treatment intervention in the New Haven PRIME clinic prodromal sample. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4835] McGlashanTH , MillerTJ , WoodsSW . Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research2002;53(3 Suppl 1):15. [CSzG: 8093] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005] McGlashanTH , MillerTJ , ZipurskyRB , WoodsSW , PerkinsDO , HawkinsKA , et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9803] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerT , WoodsSW , et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry2006;163(5):790‐9. [CSzG: 12654] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerTJ , WoodsSW , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research2003;61(1):7‐18. [CSzG: 9828] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJ , WoodsSW , MillerTJ , et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research2003;60:295. [CSzG: 9722] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJM , WoodsSW , LindborgS , et al. Olanzapine versus pbo for the schizophrenic prodrome: one‐year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9804] McGlashlanTH , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTH , WoodsSW , et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:42. [CSzG: 8934] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , MillerT , WoodsS , et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. Schizophrenia Research2004;70(1):6. [CSzG: 11524] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , WoodsS , MillerT , et al. Olanzapine vs. placebo for prodromal schizophrenia. Schizophrenia Research2004;67(1):6. [CSzG: 11321] MillerTJ , ZipurskyRB , PerkinsD , AddingtonJ , WoodsSW , HawkinsKA , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research2003;61(1):19‐30. [CSzG: 9829] RosenJL , WoodsSW , MillerTJ , McGlashanTH . Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease2002;190:133‐41. [CSzG: 8274] TaylorHE , ParkerS , MansellW , MorrisonAP . Effects of appraisals of anomalous experience on distress in people at risk of psychosis. Behavioural and Cognitive Psychotherapy2012;41(1):24‐33. [CSzG: 24374] WoodsS , ZipurskyR , PerkinsD , AddingtonJ , MarquezE , BreierA , et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:43. [CSzG: 8933] WoodsSW . Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):497. [CSzG: 19829] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research. 2003. [CSzG: 9978] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research2003;60:306‐7. [CSzG: 9752] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):453‐64. [CSzG: 9994] WoodsSW , McGlashanTH . Sample size planning for prodromal intervention trials. Schizophrenia Research2002;53(3 Suppl 1):40. [CSzG: 8116] WoodsSW , ZipurskyRB , PerkinsDO , AddingtonJM , MillerTJ , BreierAF , et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053] '>PRIME‐USA</a> reported data from the PANSS. </p> <p>c. Scale for the Assessment of Negative Symptoms (SANS; <a href="./references#CD012236-bbs2-0082" title="AndreasenNC . Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa, 1983. ">Andreasen 1983</a>) </p> <p>SANS is an observer‐rated, 26‐item scale for measuring the severity of negative symptoms of schizophrenia across five domains (alogia, affective blunting, avolition‐apathy, anhedonia‐asociality, attention impairment). Items are rated on a six‐point scale from 0 to 5, with higher scores indicating more severe symptoms. <a href="./references#CD012236-bbs2-0013" title="ACTRN12608000475347 . A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder. Australian New Zealand Clinical Trials Registry2009. [CSzG: 18420] HKCTR‐1438 . The NEURAPRO‐E (North America, EURope, Australia PROdrome) Study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for symptomatic patients at ultra‐high risk for early progression to schizophrenia and other psychotic disorders. www.hkClinicaltrials.com/trial_details.aspx?trialID=d09bd177‐b9fd‐4162‐b04f‐3ebfed49baa32011. [CSzG: 29270] McGorryP , MarkulevC , NelsonB , YuenHP , SchaeferM , YungAR , et al. The NEURAPRO‐E study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Schizophrenia Bulletin2015;41:S322‐3. [CSzG: 29546] McGorryPD , NelsonB , MarkulevC , YuenHP , SchaferMR , MossahebN , et al. Effect of omega‐3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomised clinical trial. JAMA psychiatry2017;74(1):19‐27. [CSzG: 35590] NelsonB , AmmingerG , MarkulevC , YuenHP , LavoieS , SchaeferM , et al. NEURAPOR: a multi‐center RCT of omega‐3 polyunsaturated fatty acids versus placebo in young people at ultra‐high risk of psychotic disorders: medium‐term outcome. Schizophrenia Bulletin2017;43:S107. [CSzG: 36016] ">NEURAPRO‐AAE</a>, <a href="./references#CD012236-bbs2-0014" title="NordentoftM , JeppesenP , PetersenL , ThorupA , OhlenschlaegerJ , ChristensenT , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. European Psychiatry2007;22:S129‐S. [CSzG: 20471] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the OPUS trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;83(1):29‐40. [CSzG: 13197] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;86(Suppl 1):S44. [CSzG: 13393] ">Nordentoft‐Denmark</a>, <a href="./references#CD012236-bbs2-0015" title="McGorryP . Can the onset of schizophrenia be delayed or prevented?. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S26. [CSzG: 8351] McGorryP , AdlardS , YungA , McDonaldA , PhillipsL , HearnN . Detection and intervention in pre‐psychotic schizophrenia. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4836] McGorryP , YungA , FranceyS , PhillipsL , NelsonB . A blinded, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and befriending in young people at risk of psychotic disorder: baseline characteristics of the sample. Acta Neuropsychiatrica2006;18(6):261. [CSzG: 35157] McGorryPD , HearnN , GermanoD , BravinJ , PhillipsLJ , YungAR , et al. Prepsychotic intervention in schizophrenia: a stitch in time?. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington DC, USA. 1999. [CSzG: 3584] McGorryPD , PhillipsLJ , NelsonB , LeicesterS , BakerK , KrstevH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and befriending in young people with subthreshold symptoms at incipient risk of psychotic disorder: six month outcome data. Schizophrenia Bulletin2007;33(2):446. [CSzG: 15203] McGorryPD , PhillipsLJ , YungAR , FranceyS , GermanoD , BravinJ , et al. A randomised controlled trial of interventions in the pre psychotic phase of psychotic disorders. Schizophrenia Research2000;41(1):9. [CSzG: 5149] McGorryPD , YungAR , PhillipsL , AdlardS , HallgrenM , PattonG , et al. Pre‐psychotic intervention in schizophrenia: a stitch in time?. Schizophrenia Research1998;29(1‐2):160. [CSzG: 3585] McGorryPD , YungAR , PhillipsLJ , YuenHP , FranceyS , CosgraveEM , et al. Randomised controlled trial of interventions designed to reduce the risk of progression to first‐episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry2002;59(10):921‐8. [CSzG: 8576] PhilippsLJ , McGorryP , YungA , FranceyD , GermanoF , BravinJ , et al. The development of preventive interventions for early psychosis: early findings and directions for the future. 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001; Vol. 2, issue Suppl 1. [CSzG: 7614] PhillipsL , CottonS , YuenHP , MihalopoulosC , ShihS , KellyD , et al. Cost effectiveness of a preventive intervention for young people at ultra high risk of developing psychosis. Schizophrenia Bulletin2007;33(2):488‐9. [CSzG: 15227] PhillipsLJ , CottonS , MihalopoulosC , ShihS , YungAR , CarterR , et al. Cost implications of specific and non‐specific treatment for young persons at ultra high risk of developing a first episode of psychosis. Early Intervention in Psychiatry2009;3(1):28‐34. [CSzG: 18308] PhillipsLJ , LeicesterSB , O'DwyerLE , FranceySM , KoutsogiannisJ , Abdel‐BakiA , et al. The PACE clinic: identification and management of young people at &quot;ultra&quot; high risk of psychosis. Journal of Psychiatric Practice2002;8(5):255‐69. [CSzG: 18235] PhillipsLJ , McGorryPD , YuenHP , WardJ , DonovanK , KellyD , et al. Medium term follow‐up of a randomised controlled trial of interventions for young people at ultra high risk of psychosis. Schizophrenia Research2007;96(1‐3):25‐33. [CSzG: 15544] PhillipsLJ , YungAR , YuenHP , PantelisC , McGorryPD . Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. American Journal of Medical Genetics2002;114(8):929‐37. [CSzG: 18236] ">PACE‐Australia</a> and <a href="./references#CD012236-bbs2-0020" title="McGorryP . Second generation intervention research in the pre‐psychotic phase of illness in schizophrenia and related psychoses. Australian New Zealand Clinical Trials Registry2000. [CSzG: 18439] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceyS , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: 12‐month outcome. Schizophrenia Research2012;136:S17‐8. [CSzG: 29547] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceySM , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: twelve‐month outcome. Journal of Clinical Psychiatry2013;74(4):349‐56. [CSzG: 28737] NelsonB , PhillipsLJ , YungAR , FranceySM , LeicesterS , BakerK , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and supportive therapy in young people with subthreshold symptoms at incipient risk of psychotic disorder: baseline characteristics of the sample. Schizophrenia Bulletin2007;33(2):450. [CSzG: 15212] PhillipsLJ , NelsonB , YuenHP , FranceySM , SimmonsM , StanfordC , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: study design and baseline characteristics. Australian and New Zealand Journal of Psychiatry2009;;43(9):818–29. YungA , AmmingerP , BergerG , ThompsomA , PhillipsL , NelsonB , et al. Randomised controlled trial of antipsychotic and cognitive therapy in young people at ultra‐high risk of psychosis. Early Intervention in Psychiatry2012;6:11. [CSzG: 24989] YungA , NelsonB , PhillipsL , FranceyS , LeicesterS , YuenH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and supportive therapy in young people at ultra high risk of psychotic disorder: 12 month outcome data. Early Intervention in Psychiatry2008;2(Suppl 1):A12. [CSzG: 19138] YungAR , PhillipsLJ , NelsonB , FranceySM , YuenHP , SimmonsMB , et al. Randomised controlled trial of interventions for young people at ultra high risk for psychosis: 6‐month analysis. Journal of Clinical Psychiatry2011;72(4):430‐40. [CSzG: 22929] ">Yung‐Australia</a> reported data from this scale (please see <a href="./appendices#CD012236-sec-0531">Appendix 1</a>). </p> <p>d. Comprehensive Assessment of At‐Risk Mental States (CAARMS; <a href="./references#CD012236-bbs2-0198" title="YungAR , YuenHP , McGorryPD , PhillipsLJ , KellyD , Dell’OlioM , et al. Mapping the onset of psychosis: the Comprehensive Assessment of At‐Risk Mental States. Australian &amp; New Zealand Journal of Psychiatry2005;39(11‐12):964‐71. ">Yung 2005</a>) </p> <p>This is a semi‐structured interview designed to identify people who meet criteria for at‐risk mental state. Rater assesses symptoms, frequency and distress under these categories: disorders of thought content; perceptual abnormalities; conceptual disorganisation; motor changes; concentration and attention; emotion and affect; subjectively impaired energy; and impaired tolerance to normal stress. <a href="./references#CD012236-bbs2-0004" title="CrittendenK , FlemingJ , StartupM , CarrV , BakerA , SchallU , et al. Recruitment and engagement of youth in an ultra high risk treatment study. Early Intervention in Psychiatry2008;2(Suppl 1):A127. [CSzG: Ref19115] StainH , BucciS , HalperinS , EmsleyR , ShallU , LewinT , et al. DEPTh: randomised controlled trial of cognitive behavioral therapy for young people at ultra high risk for psychosis. Early Intervention in Psychiatry2014;8:15. [CSzG: Ref29673] StainHJ , BucciS , BakerA , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of CBT for young people at risk for psychosis: the Detection and Evaluation of Psychological Therapy (DEPTh) trial. European Archives of Psychiatry and Clinical Neuroscience2015;1:S8‐9. [CSzG: Ref33810] StainHJ , BucciS , BakerAL , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of cognitive behaviour therapy versus non‐directive reflective listening for young people at ultra high risk of developing psychosis: the detection and evaluation of psychological therapy (DEPTh) trial. Schizophrenia Research2016;176(2‐3):212‐9. [CSzG: Ref35298] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. Rural and urban youth at ultra high risk for psychosis: baseline characteristics from the DEPTh randomised controlled trial of cognitive behavior therapy. Schizophrenia Bulletin2011;37:322. [CSzG: Ref22815] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy for youth at ultra high risk for psychosis: baseline characteristics for rural and urban youth. Australian and New Zealand Journal of Psychiatry2010:25‐6. [CSzG: Ref21845] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy targeting ultra high risk for psychosis: baseline comparisons for rural and urban youth. Early Intervention in Psychiatry2010;4(Suppl 1):113. [CSzG: Ref23498] StainHJ , StartupM , CarrV , BakerA , SchallU . The DEPTh project: a multisite RCT for youths at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S51‐2. [CSzG: Ref13401] StartupM . The DEPTh project: detection, evaluation, and psychological therapy for health. Australian New Zealand Clinical Trials Registry2006. [CszG: Ref18442] ">DEPTh‐Australia</a>, <a href="./references#CD012236-bbs2-0005" title="ByrneRE , MorrisonAP . Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. Psychology and Psychotherapy2014;87(3):357‐71. [CSzG: Ref29312] FlachC , FrenchP , DunnG , FowlerD , GumleyAI , BirchwoodM , et al. Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE‐2 trial. British Journal of Psychiatry2015;207(2):123‐9. [CSzG: Ref33109] MorrisonA . Early detection and intervention evaluation for individuals at high risk of psychosis 2. http://www.controlled‐trials.com2008. [CSzG: Ref18285] MorrisonA . Early detection and intervention evaluation for people at risk of psychosis (edie‐2): A multisite randomised controlled trial of cognitive therapy for at‐risk mental states. Early Intervention in Psychiatry2012;6:11. [CSzG: Ref24968] MorrisonA , FrenchP , BentallR , LewisS , BirchwoodM , FowlerD , et al. Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. Early Intervention in Psychiatry2008;2(Suppl 1):A15. [CSzG: Ref19128] MorrisonAP . EDIE‐2: early detection and psychological intervention for individuals at high risk of psychosis (2). www.controlled‐trials.com2007. [CSzG: Ref15381] MorrisonAP , BirchwoodM , PyleM , FlachC , StewartSL , ByrneR , et al. Impact of cognitive therapy on internalised stigma in people with at‐risk mental states. British Journal of Psychiatry2013;203(2):140‐5. [CSzG: Ref28630] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ2012;344(7852):e2233. [CSzG: Ref24208] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at‐risk of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29554] MorrisonAP , PyleM , StewartSL , FrenchP , ByrneR , FlachC , et al. Internalised stigma in young people at high risk of developing psychosis: findings from a cognitive therapy trial. Schizophrenia Research2014;153:S42. [CSzG: Ref29555] MorrisonAP , StewartSL , FrenchP , BentallRP , BirchwoodM , ByrneR , et al. Early detection and intervention evaluation for people at high‐risk of psychosis‐2 (EDIE‐2): trial rationale, design and baseline characteristics. Early Intervention in Psychiatry2011;5(1):24‐32. [CSzG: Ref22695] MorrisonT . Early detection and psychological intervention for individuals at high risk of psychosis. EDIE‐2. Data on File2006. [CSzG: Ref13874] PelosiAJ . Rational policy making for early psychosis might yet become possible. BMJ2012;344(7856):e3137. [CSzG: Ref24326] PyleM , StewartSL , FrenchP , ByrneR , PattersonP , GumleyA , et al. Internalised stigma, emotional dysfunction and unusual experiences in young people at risk of psychosis. Early Intervention in Psychiatry2015;9(2):133‐40. [CSzG: Ref29813] ">EDIE‐2‐UK</a> and <a href="./references#CD012236-bbs2-0006" title="DragtS , Van derGaagM . Prevention of psychosis with a cognitive behavioural intervention in help‐seeking young people with an at risk mental state for developing psychosis. www.trialregister.nl/trialreg/index.asp2007. [CSzG: Ref19655] IsingHK , KraanTC , RietdijkJ , DragtS , KlaassenRM , BoonstraN , et al. Four‐year follow‐up of cognitive behavioral therapy in persons at ultra‐high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2016;42(5):1243‐52. [CSzG: Ref35214] IsingHK , LokkerbolJ , RietdijkJ , DragtS , KlaassenRM , KraanT , et al. Four‐year cost‐effectiveness of cognitive behavior therapy for preventing first‐episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2017;43(2):365‐74. [CSzG: Ref35824] IsingHK , SmitF , VelingW , RietdijkJ , DragtS , KlaassenRM , et al. Cost‐effectiveness of preventing first‐episode psychosis in ultra‐high‐risk subjects: multi‐centre randomised controlled trial. Psychological Medicine2015;45(7):1435‐46. [CSzG: Ref27798] KraanTC , IsingHK , FokkemaM , VelthorstE , Van denBergDP , KerkhovenM , et al. The effect of childhood adversity on 4‐year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE‐NL) Trial. Psychiatry Research2017;247:55‐62. [CSzG: Ref35559] NiemanDH , RuhrmannS , RietdijkJ , DragtS , IsingH , KlaassenR , et al. Preventive psychotherapy. Schizophrenia Research2014;153:S42‐3. [CSzG: Ref29601] RietdijkJ , DragtS , KlaassenR , IsingH , NiemanD , WunderinkL , et al. A single blind randomised controlled trial of cognitive behavioural therapy in a help‐seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE‐NL) trial. Trials2010;11:30. [CSzG: Ref20654] Van DerGaagM . The effects of CBT in personswith ultra high risk: the Dutch EDIE trial. European Archives of Psychiatry and Clinical Neuroscience2011;261:S18. [CSzG: Ref23756] Van DerGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first‐episode of psychosis. Early Intervention in Psychiatry2012;6:12. [CSzG: Ref24985] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomised controlled clinical trial. Schizophrenia Bulletin2012;38(6):1180‐8. [CSzG: Ref24935] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. The effects of cognitive behavioural therapy for subjects at ultra‐high risk for developing psychosis. Schizophrenia Bulletin2013;39:S356. [CSzG: Ref28121] Van derGaagM . The prevention of psychosis in at risk mental state. www.controlled‐trials.com2008. [CSzG: Ref17488] Van derGaagM , NiemanD , Van denBergD . CBT for those at risk of a first episode psychosis: Evidence‐based psychotherapy for people with an 'at risk mental state'. 1st Edition. Hove, UK: Routledge, 2013. Van derGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first episode of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29692] ">EDIE‐NL</a> reported data for this scale (please see <a href="./appendices#CD012236-sec-0531">Appendix 1</a>). </p> <p>e. Scale of Psychotic Symptoms (SOPS; <a href="./references#CD012236-bbs2-0160" title="MillerTJ , McGlashanTH , WoodsSW , SteinK , DriesenN , CorcoranCM , et al. Symptom assessment in schizophrenic prodromal states. Psychiatric Quarterly1999;70:273‐87. ">Miller 1999</a>) </p> <p>The SOPS is a 19‐item scale designed according to the PANSS scale to measure the severity of prodromal symptoms. It consists of five positive symptom items (unusual thought content/delusional ideas, suspiciousness/persecutory ideas, grandiosity, perceptual abnormalities/hallucinations, disorganised communication), six negative symptom items (social anhedonia, avolition, expression of emotion, experience of emotions and self, ideational richness, occupational functioning), four disorganisational symptoms items (odd behavior and appearance, bizarre thinking, trouble with focus and attention, personal hygiene) and four general symptom items (sleep disturbance, dysphoric mood, motor disturbances, impaired tolerance to normal stress). Each item is rated on a seven‐point scale from 0 (never, absent) to 6 (severe/extreme ‐ and psychotic for the positive items), total scores ranging from 0 to 114. <a href="./references#CD012236-bbs2-0001" title="AddingtonJ , EpsteinI , LiuL , FrenchP , BoydellKM , ZipurskyRB . A randomised controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research2011;125(1):54‐61. [CSzG: Ref21945] AddingtonJ , ZipurskyR , EpsteinI . ADAPT (Access, Detection and Psychological Treatments). Schizophrenia Research2006;86(Suppl 1):S6. [CSzG: Ref13364] NCT00260273 . Access, detection and psychological treatments. www.ClinicalTrials.gov/ct/show/2005. [CSzG: Ref14638] ">ADAPT‐Canada</a>, <a href="./references#CD012236-bbs2-0017" title='BlockJJ , McGlashonTH . Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790‐9. American Journal of Psychiatry2006; Vol. 163, issue 10:1838. [CSzG: 13960] BreierAF , ZipurskyRB , PerkinsDO , AddingtonJM , TohenMF , DavidSR , et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951] HawkinsKA , AddingtonJ , KeefeR , ChristensenB , WoodsS , ZipurskyR , et al. Neuropsychological functioning in the first episode prodrome and early psychosis. Schizophrenia Research2004;70(1):101. [CSzG: 11515] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , MillerTJ , et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research2004;67(1):205. [CSzG: Ref11301] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , ZipurskyRB , et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. [CSzG: 16470] HawkinsKA , KeefeRS , ChristensenBK , AddingtonJ , WoodsSW , CallahanJ , et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. Schizophrenia Research2008;105(1‐3):1‐9. [CSzG: 16983] HoffmanRE , WoodsS , PredaA , TohenM , BreierA , GlistJ , et al. Excessive top‐down perceptual processing and reduced real‐world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. Schizophrenia Research2006;86(Suppl 1):S46. [CSzG: 13377] HoffmanRE , WoodsSW , HawkinsKA , PittmanB , TohenM , PredaA , et al. Extracting spurious messages from noise and risk of schizophrenia‐spectrum disorders in prodromal population. British Journal of Psychiatry2007;191(2):355‐6. [CSzG: 16068] McGlashanT , ZipurskyR , PerkinsD , AddingtonJ . Olanzapine for treatment of the schizophrenia prodrome: 2‐year results of a randomised placebo‐controlled study. Schizophrenia Research2004;67(1):164. [CSzG: 11320] McGlashanTH . Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. [CSzG: 10191] McGlashanTH . Treatment intervention in the New Haven PRIME clinic prodromal sample. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4835] McGlashanTH , MillerTJ , WoodsSW . Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research2002;53(3 Suppl 1):15. [CSzG: 8093] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005] McGlashanTH , MillerTJ , ZipurskyRB , WoodsSW , PerkinsDO , HawkinsKA , et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9803] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerT , WoodsSW , et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry2006;163(5):790‐9. [CSzG: 12654] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerTJ , WoodsSW , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research2003;61(1):7‐18. [CSzG: 9828] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJ , WoodsSW , MillerTJ , et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research2003;60:295. [CSzG: 9722] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJM , WoodsSW , LindborgS , et al. Olanzapine versus pbo for the schizophrenic prodrome: one‐year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9804] McGlashlanTH , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTH , WoodsSW , et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:42. [CSzG: 8934] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , MillerT , WoodsS , et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. Schizophrenia Research2004;70(1):6. [CSzG: 11524] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , WoodsS , MillerT , et al. Olanzapine vs. placebo for prodromal schizophrenia. Schizophrenia Research2004;67(1):6. [CSzG: 11321] MillerTJ , ZipurskyRB , PerkinsD , AddingtonJ , WoodsSW , HawkinsKA , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research2003;61(1):19‐30. [CSzG: 9829] RosenJL , WoodsSW , MillerTJ , McGlashanTH . Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease2002;190:133‐41. [CSzG: 8274] TaylorHE , ParkerS , MansellW , MorrisonAP . Effects of appraisals of anomalous experience on distress in people at risk of psychosis. Behavioural and Cognitive Psychotherapy2012;41(1):24‐33. [CSzG: 24374] WoodsS , ZipurskyR , PerkinsD , AddingtonJ , MarquezE , BreierA , et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:43. [CSzG: 8933] WoodsSW . Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):497. [CSzG: 19829] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research. 2003. [CSzG: 9978] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research2003;60:306‐7. [CSzG: 9752] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):453‐64. [CSzG: 9994] WoodsSW , McGlashanTH . Sample size planning for prodromal intervention trials. Schizophrenia Research2002;53(3 Suppl 1):40. [CSzG: 8116] WoodsSW , ZipurskyRB , PerkinsDO , AddingtonJM , MillerTJ , BreierAF , et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053] '>PRIME‐USA</a>, <a href="./references#CD012236-bbs2-0018" title="LoewyR , FisherM , MathalonDH , VinogradovS . Interim analyses of a randomised controlled trial of computerised cognitive training in clinical high risk for psychosis. Schizophrenia Bulletin2013;39:S238‐9. [CSzG: 28151] LoewyR , FisherM , SchlosserDA , BiagiantiB , StuartB , MathalonDH , et al. Intensive auditory cognitive training improves verbal memory in adolescents and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2016;42(Suppl 1):S118‐26. [CSzG: 35221] VinogradovS , LoewyR , FisherM , LeeA , NiendamT , RaglandJD , et al. Neuroplasticity‐based cognitive training in ultra‐high risk adolescents and recent onset patients with schizophrenia. Schizophrenia Research2012;136:S30. [CSzG: 29703] ">Vinogradov‐USA</a> and <a href="./references#CD012236-bbs2-0019" title="NCT00291226 . Glycine vs Placebo for the Schizophrenia Prodrome. www.ClinicalTrials.gov/ct/show/2006. [CSzG: 14759] WoodsS , WalshB , HawkinsK , MillerT , SaksaJ , D'SouzaD , et al. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. Early Intervention in Psychiatry2012;6:29. [CSzG: 24987] WoodsSW , KantrowitzJT , JavittDC . NMDAR‐based treatments for patients at clinical high risk for psychosis. Biological Psychiatry2014;1:11S. [CSzG: 29041] WoodsSW , WalshBC , HawkinsKA , MillerTJ , SaksaJR , D'SouzaDC , et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. European Neuropsychopharmacology2013;23(8):931‐40. [CSzG: 28750] ">Woods‐1‐USA</a> reported data from SOPS, while <a href="./references#CD012236-bbs2-0012" title="MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Family‐focused therapy for individuals at clinical high risk for psychosis: treatment fidelity within a multisite randomised trial. Early Intervention in Psychiatry2016;10(2):137‐43. [CSzG: 29018] MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Treatment fidelity and differentiation in a randomised controlled trial of family‐focused therapy for youth at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:95. [CSzG: 24965] MiklowitzDJ , O'BrienMP , SchlosserDA , AddingtonJ , CandanKA , MarshallC , et al. Family‐focused treatment for adolescents and young adults at high risk for psychosis: results of a randomised trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(8):848‐58. [CSzG: 29019] NCT01907282 . Prevention trial of family focused treatment in youth at risk for psychosis. Clinicaltrials.gov/show/NCT019072822010. [CSzG: 27965] O'BrienMP , MiklowitzDJ , CandanKA , MarshallC , DominguesI , WalshBC , et al. A randomised trial of family focused therapy with populations at clinical high risk for psychosis: effects on interactional behavior. Journal of Consulting and Clinical Psychology2013;82(1):90‐101. [CSzG: 28565] O'BrienMP , MiklowitzDJ , CannonTD . Decreases in perceived maternal criticism predict improvement in subthreshold psychotic symptoms in a randomised trial of family‐focused therapy for individuals at clinical high risk for psychosis. Journal of Family Psychology2015;29(6):945–951.. [CSzG: 32212] SchlosserDA , MiklowitzDJ , O'BrienMP , DeSilvaSD , ZinbergJL , CannonTD . A randomised trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Intervention in Psychiatry2012;6(3):283‐91. [CSzG: 24491] ">Miklowitz‐USA</a> reported data for SOPS positive symptoms. </p> <p>f. Hamilton Rating Scale for Anxiety (HRSA; <a href="./references#CD012236-bbs2-0134" title="HamiltonM . The assessment of anxiety states by rating. British Journal of Medical Psychology1959;32:50–5. ">Hamilton 1959</a>) </p> <p>Hamilton Rating Scale for Anxiety (HRSA) is one of the first rating scales developed to quantify the severity of anxiety symptoms. HAMA consists of 14 items, each defined by a series of symptoms. The 14 items consist of: anxious mood; tension; fears; insomnia; intellectual; depressed mood; somatic complaints (muscular); somatic complaints (sensory); cardiovascular symptoms; respiratory symptoms; gastrointestinal symptoms; genitourinary symptoms; autonomic symptoms and behaviour at Interview. Each item is rated on a five‐point scale, from 0 (not present) to 4 (severe). Total score range is between 0 an 56, with higher score indicating more severe symptoms. <a href="./references#CD012236-bbs2-0015" title="McGorryP . Can the onset of schizophrenia be delayed or prevented?. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S26. [CSzG: 8351] McGorryP , AdlardS , YungA , McDonaldA , PhillipsL , HearnN . Detection and intervention in pre‐psychotic schizophrenia. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4836] McGorryP , YungA , FranceyS , PhillipsL , NelsonB . A blinded, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and befriending in young people at risk of psychotic disorder: baseline characteristics of the sample. Acta Neuropsychiatrica2006;18(6):261. [CSzG: 35157] McGorryPD , HearnN , GermanoD , BravinJ , PhillipsLJ , YungAR , et al. Prepsychotic intervention in schizophrenia: a stitch in time?. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington DC, USA. 1999. [CSzG: 3584] McGorryPD , PhillipsLJ , NelsonB , LeicesterS , BakerK , KrstevH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and befriending in young people with subthreshold symptoms at incipient risk of psychotic disorder: six month outcome data. Schizophrenia Bulletin2007;33(2):446. [CSzG: 15203] McGorryPD , PhillipsLJ , YungAR , FranceyS , GermanoD , BravinJ , et al. A randomised controlled trial of interventions in the pre psychotic phase of psychotic disorders. Schizophrenia Research2000;41(1):9. [CSzG: 5149] McGorryPD , YungAR , PhillipsL , AdlardS , HallgrenM , PattonG , et al. Pre‐psychotic intervention in schizophrenia: a stitch in time?. Schizophrenia Research1998;29(1‐2):160. [CSzG: 3585] McGorryPD , YungAR , PhillipsLJ , YuenHP , FranceyS , CosgraveEM , et al. Randomised controlled trial of interventions designed to reduce the risk of progression to first‐episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry2002;59(10):921‐8. [CSzG: 8576] PhilippsLJ , McGorryP , YungA , FranceyD , GermanoF , BravinJ , et al. The development of preventive interventions for early psychosis: early findings and directions for the future. 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001; Vol. 2, issue Suppl 1. [CSzG: 7614] PhillipsL , CottonS , YuenHP , MihalopoulosC , ShihS , KellyD , et al. Cost effectiveness of a preventive intervention for young people at ultra high risk of developing psychosis. Schizophrenia Bulletin2007;33(2):488‐9. [CSzG: 15227] PhillipsLJ , CottonS , MihalopoulosC , ShihS , YungAR , CarterR , et al. Cost implications of specific and non‐specific treatment for young persons at ultra high risk of developing a first episode of psychosis. Early Intervention in Psychiatry2009;3(1):28‐34. [CSzG: 18308] PhillipsLJ , LeicesterSB , O'DwyerLE , FranceySM , KoutsogiannisJ , Abdel‐BakiA , et al. The PACE clinic: identification and management of young people at &quot;ultra&quot; high risk of psychosis. Journal of Psychiatric Practice2002;8(5):255‐69. [CSzG: 18235] PhillipsLJ , McGorryPD , YuenHP , WardJ , DonovanK , KellyD , et al. Medium term follow‐up of a randomised controlled trial of interventions for young people at ultra high risk of psychosis. Schizophrenia Research2007;96(1‐3):25‐33. [CSzG: 15544] PhillipsLJ , YungAR , YuenHP , PantelisC , McGorryPD . Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. American Journal of Medical Genetics2002;114(8):929‐37. [CSzG: 18236] ">PACE‐Australia</a> reported data from this scale. </p> <p>g. Hamilton Rating Scale for Depression (HRSD; <a href="./references#CD012236-bbs2-0135" title="Hamilton , M . A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry1960;23:56‐62. ">Hamilton 1960</a>) </p> <p>This is an observer‐rated scale, designed to rate the severity of depression by probing mood, feelings of guilt, suicide ideation, insomnia, interest, agitation or retardation, anxiety (psychic and somatic), weight loss, somatic symptoms and insight. It consists of 17 variables measured on either a three‐point or a five‐point rating scale. A score of 0 to 7 is considered to be normal, higher scores indicate depression (mild, moderate, severe, very severe). <a href="./references#CD012236-bbs2-0015" title="McGorryP . Can the onset of schizophrenia be delayed or prevented?. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S26. [CSzG: 8351] McGorryP , AdlardS , YungA , McDonaldA , PhillipsL , HearnN . Detection and intervention in pre‐psychotic schizophrenia. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4836] McGorryP , YungA , FranceyS , PhillipsL , NelsonB . A blinded, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and befriending in young people at risk of psychotic disorder: baseline characteristics of the sample. Acta Neuropsychiatrica2006;18(6):261. [CSzG: 35157] McGorryPD , HearnN , GermanoD , BravinJ , PhillipsLJ , YungAR , et al. Prepsychotic intervention in schizophrenia: a stitch in time?. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington DC, USA. 1999. [CSzG: 3584] McGorryPD , PhillipsLJ , NelsonB , LeicesterS , BakerK , KrstevH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and befriending in young people with subthreshold symptoms at incipient risk of psychotic disorder: six month outcome data. Schizophrenia Bulletin2007;33(2):446. [CSzG: 15203] McGorryPD , PhillipsLJ , YungAR , FranceyS , GermanoD , BravinJ , et al. A randomised controlled trial of interventions in the pre psychotic phase of psychotic disorders. Schizophrenia Research2000;41(1):9. [CSzG: 5149] McGorryPD , YungAR , PhillipsL , AdlardS , HallgrenM , PattonG , et al. Pre‐psychotic intervention in schizophrenia: a stitch in time?. Schizophrenia Research1998;29(1‐2):160. [CSzG: 3585] McGorryPD , YungAR , PhillipsLJ , YuenHP , FranceyS , CosgraveEM , et al. Randomised controlled trial of interventions designed to reduce the risk of progression to first‐episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry2002;59(10):921‐8. [CSzG: 8576] PhilippsLJ , McGorryP , YungA , FranceyD , GermanoF , BravinJ , et al. The development of preventive interventions for early psychosis: early findings and directions for the future. 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001; Vol. 2, issue Suppl 1. [CSzG: 7614] PhillipsL , CottonS , YuenHP , MihalopoulosC , ShihS , KellyD , et al. Cost effectiveness of a preventive intervention for young people at ultra high risk of developing psychosis. Schizophrenia Bulletin2007;33(2):488‐9. [CSzG: 15227] PhillipsLJ , CottonS , MihalopoulosC , ShihS , YungAR , CarterR , et al. Cost implications of specific and non‐specific treatment for young persons at ultra high risk of developing a first episode of psychosis. Early Intervention in Psychiatry2009;3(1):28‐34. [CSzG: 18308] PhillipsLJ , LeicesterSB , O'DwyerLE , FranceySM , KoutsogiannisJ , Abdel‐BakiA , et al. The PACE clinic: identification and management of young people at &quot;ultra&quot; high risk of psychosis. Journal of Psychiatric Practice2002;8(5):255‐69. [CSzG: 18235] PhillipsLJ , McGorryPD , YuenHP , WardJ , DonovanK , KellyD , et al. Medium term follow‐up of a randomised controlled trial of interventions for young people at ultra high risk of psychosis. Schizophrenia Research2007;96(1‐3):25‐33. [CSzG: 15544] PhillipsLJ , YungAR , YuenHP , PantelisC , McGorryPD . Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. American Journal of Medical Genetics2002;114(8):929‐37. [CSzG: 18236] ">PACE‐Australia</a> reported data from this scale. </p> <p>h. Calgary Depression Scale for Schizophrenia (CDSS; <a href="./references#CD012236-bbs2-0075" title="AddingtonD , AddingtonJ , Maticka‐TyndaleE . Specificity of the Calgary Depression Scale for schizophrenics. Schizophrenia Research1994;11:239‐44. ">Addington 1990</a>) </p> <p>The CDSS is a nine‐item scale (0 = absent; 1 = mild; 2 = moderate; 3 = severe) that was specifically developed for assessment of depression in people with schizophrenia, independent of the negative symptoms. It has been evaluated in both relapsed and remitted patients, and is provided as a semi‐structured interview. High scores indicate worse outcome. <a href="./references#CD012236-bbs2-0001" title="AddingtonJ , EpsteinI , LiuL , FrenchP , BoydellKM , ZipurskyRB . A randomised controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research2011;125(1):54‐61. [CSzG: Ref21945] AddingtonJ , ZipurskyR , EpsteinI . ADAPT (Access, Detection and Psychological Treatments). Schizophrenia Research2006;86(Suppl 1):S6. [CSzG: Ref13364] NCT00260273 . Access, detection and psychological treatments. www.ClinicalTrials.gov/ct/show/2005. [CSzG: Ref14638] ">ADAPT‐Canada</a> and <a href="./references#CD012236-bbs2-0006" title="DragtS , Van derGaagM . Prevention of psychosis with a cognitive behavioural intervention in help‐seeking young people with an at risk mental state for developing psychosis. www.trialregister.nl/trialreg/index.asp2007. [CSzG: Ref19655] IsingHK , KraanTC , RietdijkJ , DragtS , KlaassenRM , BoonstraN , et al. Four‐year follow‐up of cognitive behavioral therapy in persons at ultra‐high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2016;42(5):1243‐52. [CSzG: Ref35214] IsingHK , LokkerbolJ , RietdijkJ , DragtS , KlaassenRM , KraanT , et al. Four‐year cost‐effectiveness of cognitive behavior therapy for preventing first‐episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2017;43(2):365‐74. [CSzG: Ref35824] IsingHK , SmitF , VelingW , RietdijkJ , DragtS , KlaassenRM , et al. Cost‐effectiveness of preventing first‐episode psychosis in ultra‐high‐risk subjects: multi‐centre randomised controlled trial. Psychological Medicine2015;45(7):1435‐46. [CSzG: Ref27798] KraanTC , IsingHK , FokkemaM , VelthorstE , Van denBergDP , KerkhovenM , et al. The effect of childhood adversity on 4‐year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE‐NL) Trial. Psychiatry Research2017;247:55‐62. [CSzG: Ref35559] NiemanDH , RuhrmannS , RietdijkJ , DragtS , IsingH , KlaassenR , et al. Preventive psychotherapy. Schizophrenia Research2014;153:S42‐3. [CSzG: Ref29601] RietdijkJ , DragtS , KlaassenR , IsingH , NiemanD , WunderinkL , et al. A single blind randomised controlled trial of cognitive behavioural therapy in a help‐seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE‐NL) trial. Trials2010;11:30. [CSzG: Ref20654] Van DerGaagM . The effects of CBT in personswith ultra high risk: the Dutch EDIE trial. European Archives of Psychiatry and Clinical Neuroscience2011;261:S18. [CSzG: Ref23756] Van DerGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first‐episode of psychosis. Early Intervention in Psychiatry2012;6:12. [CSzG: Ref24985] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomised controlled clinical trial. Schizophrenia Bulletin2012;38(6):1180‐8. [CSzG: Ref24935] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. The effects of cognitive behavioural therapy for subjects at ultra‐high risk for developing psychosis. Schizophrenia Bulletin2013;39:S356. [CSzG: Ref28121] Van derGaagM . The prevention of psychosis in at risk mental state. www.controlled‐trials.com2008. [CSzG: Ref17488] Van derGaagM , NiemanD , Van denBergD . CBT for those at risk of a first episode psychosis: Evidence‐based psychotherapy for people with an 'at risk mental state'. 1st Edition. Hove, UK: Routledge, 2013. Van derGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first episode of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29692] ">EDIE‐NL</a> reported data from this scale. </p> <p>i. Montgomery Asberg Depression Rating Scale (MADRS; <a href="./references#CD012236-bbs2-0162" title="MontgomerySA , AsbergM . A new depression scale designed to be sensitive to change. British Journal of Psychiatry1979;134:382‐9. ">Montgomery 1979</a>) </p> <p>MADRS is a scale designed for assessment of depressive symptoms through 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts). Each item is rated on a seven‐point scale from 0 to 6. Higher scores indicate more severe symptoms. Total scores range from 0 to 60, results from 0 to 6 are considered as normal/symptom absent. <a href="./references#CD012236-bbs2-0002" title="AmmingerG . Ethyl eicosapentanoic acid for prodromal psychosis. Stanley Foundation Research Programs2009. [CSzG: Ref17423] AmmingerG , SchaferM , PapageorgiouK , CottonS , HarriganS , MackinnonA , et al. Indicated prevention with long‐chain omega‐3 fatty acids in adolescents at ultra‐high‐risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2008;2(Suppl 1):A29. [CSzG: Ref19107] AmmingerGP , ChanenAM , OhmannS , KlierCM , MossahebN , BechdolfA , et al. Omega‐3 fatty acid supplementation in adolescents with borderline personality disorder and ultra‐high risk criteria for psychosis: a post hoc subgroup analysis of a double‐blind, randomised controlled trial. Canadian Journal of Psychiatry2013;58(7):402‐8. [CSzG: Ref28534] AmmingerGP , HarrisMS , McGorryPD , HenryLP . Omega‐3 fatty acids for indicated prevention: treatment results and pathomechanisms. European Archives of Psychiatry and Clinical Neuroscience2013;263(Suppl. 1):S44‐5. [CSzG: Ref28434] AmmingerGP , LeicesterS , YungAR , YuenHP , McGorryPD . Age predicts transition to psychosis in an ultra‐high risk sample. Proceedings of the 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:61. AmmingerGP , McGorryPD . Update on omega‐3 polyunsaturated fatty acids in early ‐stage psychotic disorders. Neuropsychopharmacology2012;37(1):309‐10. [CSzG: Ref23726] AmmingerGP , MechelliA , RiceS , KimSW , KlierCM , McNamaraRK , et al. Predictors of treatment response in young people at ultra‐high risk for psychosis who received long‐chain omega‐3 fatty acids. Translational Psychiatry2015;5:e495. [CSzG: Ref29299] AmmingerGP , SchaferMR . Indicated prevention with omega‐3 fatty acids in adolescents at ultra‐high risk for psychosis ‐ rationale, methods, and 3‐months outcome. Schizophrenia Research2006;86(Suppl 1):S97‐8. [CSzG: Ref13367] AmmingerGP , SchaferMR . Is it feasible to conduct a RCT in ultra‐high risk individuals at a child and adolescent psychiatric service?. Schizophrenia Research2006;86(Suppl 1):S98. [CSzG: Ref13368] AmmingerGP , SchaferMR , KlierCM , PapageorgiouK , SlavikJ , HolzerI , et al. Indicated prevention with long‐chain omega‐3 fatty acids in young people at ultra‐high risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2010;4(Suppl 1):7. [CSzG: Ref23467] AmmingerGP , SchaferMR , SchlogelhoferM , KlierCM , McGorryPD . Longer‐term outcome in the prevention of psychotic disorders by the Vienna omega‐3 study. Nature Communications2015;6:7934. [CSzG: Ref33023] AmmingerGP , SchlogelhoferM , KlierC , McGorryP , SchaferM . Longer‐term follow‐up in the Vienna omega‐3 psychosis prevention trial. Early Intervention in Psychiatry2014;8:41. [CSzG: Ref29378] AmmingerGP , SchäferMR , PapageorgiouK , KlierCM , CottonSM , HarriganSM , et al. Long‐chain omega‐3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo‐controlled trial. Archives of General Psychiatry2010;67(2):146‐54. [CSzG: Ref20680; DOI: 10.1001/archgenpsychiatry.2009.192.] AmmingerP , MossahebN , SchlgelhoferM , SchaferM . Fatty acid metabolism and the onset of psychotic disorder. European Psychiatry2011;26(Suppl 1):2089. [CSzG: Ref22967] Anonymous . Fish oil may help ward off psychosis. Journal of Psychosocial Nursing and Mental Health Services2010;48(5):55. [CSzG: Ref20739] BergerG , AmmingerP , McGorryP . Stage dependant effect of omega‐3 fatty acids in emerging psychosis. European Psychiatry2011;26(Suppl 1):1347. [CSzG: Ref22966] BergerGE , ProffittTM , McConchieM , YuenH , WoodSJ , AmmingerGP , et al. Ethyl‐eicosapentaenoic acid in first‐episode psychosis: a randomised, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(12):1867‐75. [CSzG: Ref15561; ISSN: 1555‐2101] EhrlichA . Evidence‐based medicine. Omega‐3 supplementation delays transition to psychotic disorder in ultra‐high‐risk adolescents and young adults. Clinical Advisor for Nurse Practitioners2010;13(5):79‐80. [CSzG: Ref21562] FöckingM , DickerP , LopezLM , CannonM , SchäferMR , McGorryPD , et al. Differential expression of the inflammation marker IL12p40 in the at‐risk mental state for psychosis: a predictor of transition to psychotic disorder?. BMC Psychiatry2016;16(1):326. [DOI: 10.1186/s12888‐016‐1039‐7] KlierC , HollmannM , SchlögelhoferM , MossahebN , FriedrichM , AmmingerPG . Indicated prevention with omega‐3 fatty acids (EPA/DHA) in adolescents with &quot;at‐risk‐mental‐state“ for psychosis. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. [CSzG: Ref12438] LavoieS , BenningerF , FeuchtM , KlierCM , SchaeferMR , AmmingerGP . Correlates of EEG resting states with erythrocyte membrane omega‐3 fatty acid levels and psychopathological symptoms in individuals at ultra‐high risk for psychosis. Early Intervention in Psychiatry2014;8:137. [CSzG: Ref29516] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultra‐high risk individuals who transitioned to psychosis. Schizophrenia Research2012;138(2‐3):206‐11. [CSzG: Ref24256] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultrahigh risk individuals who transitioned to psychosis. Early Intervention in Psychiatry2012;6:38. [CSzG: Ref24960] MossahebN , PapageorgiouK , SchaferMR , BeckerJ , SchloegelhoferM , AmmingerGP . Changes in triglyceride levels in ultra‐high risk for psychosis individuals treated with omega‐3 fatty acids. Early Intervention in Psychiatry2018; Vol. 12, issue 1:30‐36. [DOI: 10.1111/eip.12275] MossahebN , SchaferMR , SchlogelhoferM , KlierCM , CottonSM , McGorryPD , et al. Effect of omega‐3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?. Schizophrenia Research2013;148(1‐3):163‐7. [CSzG: Ref28649] NCT00396643 . Indicated prevention with omega‐3 fatty acids in adolescents with ‘at‐risk‐mental‐state’ for psychosis: a randomised, double blind, placebo‐controlled treatment trial. www.ClinicalTrials.gov/ct/show/2006. [CSzG: Ref14873] PapageorgiouK , SchaferMR , SchlogelhoferM , MossahebN , AmmingerGP . Indicated prevention with omega‐3 fatty acids in young people with 'at‐risk‐mental‐state' for psychosis: design of a 5‐year follow‐up. European Archives of Psychiatry and Clinical Neuroscience2011;261:S55. [CSzG: Ref23749] SchaferMR , KlierCM , PapageorgiouK , FriedrichMH , AmmingerGP . Early detection of psychotic disorders. Neuropsychiatrie2007;21(1):37‐44. [CSzG: Ref15290] SmesnyS , MilleitB , HiplerUC , MilleitC , SchaferMR , KlierCM , et al. Omega‐3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra‐high risk for psychosis. Molecular Psychiatry2013;19(3):317‐24. [CSzG: Ref28243] SmesnyS , MilleitB , SchaeferMR , HesseJ , SchlögelhoferM , LangbeinK , et al. Effects of omega‐3 PUFA on immune markers in adolescent individuals at ultra‐high risk for psychosis ‐ results of the randomised controlled Vienna omega‐3 study. Schizophrenia Research2017;S0920‐9964(17):30039‐7. [DOI: 10.1016/j.schres.2017.01.026] ">Amminger‐Austria</a>, <a href="./references#CD012236-bbs2-0009" title="BechdolfA . Preventing progression to first‐episode psychosis in people in the early initial prodromal state. Early Intervention in Psychiatry2012;6:11. [CSzG: 24944] BechdolfA , BuhlerB , BerningJ , WagnerM , StammE , StreitM . Cognitive behavioural therapy in the early initial prodromal state of psychosis: first results. Schizophrenia Research2004;67(1):202. [CSzG: Ref11285] BechdolfA , KlosterkotterJ . Cognitive‐behavioural treatment (CBT) in the early initial prodromal state of psychosis: concept and practical approach. Schizophrenia Research2004;70(1):52. [CSzG: Ref11506] BechdolfA , RuhrmannS , JanssenB , BottlenderR , WagnerM , MaurerK , et al. Early recognition and intervention for people at risk of schizophrenia [Fruherkennung und intervention bei personen mit erhohtem psychoserisiko]. Psychoneuroendocrinology2004;30(11):606‐14. [CSzG: Ref11376] BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: Ref12511] BechdolfA , VeithV , BerningJ , StammE , DeckerP , JanssenB , et al. Cognitive behavioral therapy (CBT) in the early initial prodromal state of psychosis: first results of a randomised trial. Schizophrenia Research2004;70(1):62‐3. [CSzG: Ref11507] BechdolfA , WagnerM , RuhrmannS , HarriganS , PutzfeldV , PukropR , et al. Preventing progression to first‐episode psychosis in early initial prodromal states. British Journal of Psychiatry2012;200(1):22‐9. [CSzG: Ref24206] BechdolfA , WagnerM , RuhrmannS , HarriganS , VeithV , PukropR , et al. CBT for prevention of first episode psychosis in people in an putative early initial prodromal state. Early Intervention in Psychiatry2008;2(Suppl 1):A16. [CSzG: 19109] BechdolfA , WagnerM , VeithV , PukropR , BerningJ , StammE , et al. A randomised controlled trial of cognitive‐behavioral therapy in the early initial prodromal state of psychosis. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:22‐3. [CSzG: 20193] BechdolfA , WagnerM , VeithV , RuhrmannR , JanssenB , BottlenderR , et al. A randomised controlled multicenter trial of cognitive behaviour therapy in the early initial prodromal state of psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13369] BechdolfA , WagnerM , VeithV , RuhrmannS , PukropR , Brockhaus‐DumkeA , et al. Randomised controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Intervention in Psychiatry2007;1(1):71‐8. [CSzG: 16450] BechdolfA , WesselsH , WagnerM , KuhrK , BerningJ , PutzfeldV , et al. Predictors of treatment response to psychosocial interventions in people at risk. European Archives of Psychiatry and Clinical Neuroscience2015;1:S9. [CSzG: 33601] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] KommescherM , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. Early Intervention in Psychiatry2016;10(1):17‐27. [CSzG: 32187] NCT00204087 . Psychological intervention for persons at risk of psychosis in the early initial prodromal state. www.ClinicalTrials.gov/ct/show/2005. [CSzG: 14890] WesselsH , WagnerM , FrommannI , BerningJ , PutzfeldV , JanssenB , et al. Neuropsychological functioning as a predictor of treatment response to psychoeducational, cognitive behavioral therapy in people at clinical high risk of first episode psychosis. Psychiatrische Praxis2015;42(6):313‐9. [CSzG: 33130] ZarafonitisS , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Psychoeducation for persons at risk of psychosis. Psychotherapeut2012;57(4):326‐34. [CSzG: 24807] ">EIPS‐Germany</a>, <a href="./references#CD012236-bbs2-0011" title="BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: 12511] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] RuhrmannS , BechdolfA , KuhnKU , WagnerM , Schultze‐LutterF Janssen B , et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry. Supplements2007;51:s88‐95. [CSzG: 16127] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Acute symptomatic treatment effects in persons clinically at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13397] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Intervention in the late initial prodromal state (LIPS) of psychosis. Schizophrenia Research2006;86(Suppl 1):S96. [CSzG: 13398] ">LIPS‐Germany</a>, <a href="./references#CD012236-bbs2-0013" title="ACTRN12608000475347 . A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder. Australian New Zealand Clinical Trials Registry2009. [CSzG: 18420] HKCTR‐1438 . The NEURAPRO‐E (North America, EURope, Australia PROdrome) Study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for symptomatic patients at ultra‐high risk for early progression to schizophrenia and other psychotic disorders. www.hkClinicaltrials.com/trial_details.aspx?trialID=d09bd177‐b9fd‐4162‐b04f‐3ebfed49baa32011. [CSzG: 29270] McGorryP , MarkulevC , NelsonB , YuenHP , SchaeferM , YungAR , et al. The NEURAPRO‐E study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Schizophrenia Bulletin2015;41:S322‐3. [CSzG: 29546] McGorryPD , NelsonB , MarkulevC , YuenHP , SchaferMR , MossahebN , et al. Effect of omega‐3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomised clinical trial. JAMA psychiatry2017;74(1):19‐27. [CSzG: 35590] NelsonB , AmmingerG , MarkulevC , YuenHP , LavoieS , SchaeferM , et al. NEURAPOR: a multi‐center RCT of omega‐3 polyunsaturated fatty acids versus placebo in young people at ultra‐high risk of psychotic disorders: medium‐term outcome. Schizophrenia Bulletin2017;43:S107. [CSzG: 36016] ">NEURAPRO‐AAE</a>, <a href="./references#CD012236-bbs2-0017" title='BlockJJ , McGlashonTH . Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790‐9. American Journal of Psychiatry2006; Vol. 163, issue 10:1838. [CSzG: 13960] BreierAF , ZipurskyRB , PerkinsDO , AddingtonJM , TohenMF , DavidSR , et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951] HawkinsKA , AddingtonJ , KeefeR , ChristensenB , WoodsS , ZipurskyR , et al. Neuropsychological functioning in the first episode prodrome and early psychosis. Schizophrenia Research2004;70(1):101. [CSzG: 11515] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , MillerTJ , et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research2004;67(1):205. [CSzG: Ref11301] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , ZipurskyRB , et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. [CSzG: 16470] HawkinsKA , KeefeRS , ChristensenBK , AddingtonJ , WoodsSW , CallahanJ , et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. Schizophrenia Research2008;105(1‐3):1‐9. [CSzG: 16983] HoffmanRE , WoodsS , PredaA , TohenM , BreierA , GlistJ , et al. Excessive top‐down perceptual processing and reduced real‐world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. Schizophrenia Research2006;86(Suppl 1):S46. [CSzG: 13377] HoffmanRE , WoodsSW , HawkinsKA , PittmanB , TohenM , PredaA , et al. Extracting spurious messages from noise and risk of schizophrenia‐spectrum disorders in prodromal population. British Journal of Psychiatry2007;191(2):355‐6. [CSzG: 16068] McGlashanT , ZipurskyR , PerkinsD , AddingtonJ . Olanzapine for treatment of the schizophrenia prodrome: 2‐year results of a randomised placebo‐controlled study. Schizophrenia Research2004;67(1):164. [CSzG: 11320] McGlashanTH . Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. [CSzG: 10191] McGlashanTH . Treatment intervention in the New Haven PRIME clinic prodromal sample. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4835] McGlashanTH , MillerTJ , WoodsSW . Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research2002;53(3 Suppl 1):15. [CSzG: 8093] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005] McGlashanTH , MillerTJ , ZipurskyRB , WoodsSW , PerkinsDO , HawkinsKA , et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9803] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerT , WoodsSW , et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry2006;163(5):790‐9. [CSzG: 12654] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerTJ , WoodsSW , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research2003;61(1):7‐18. [CSzG: 9828] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJ , WoodsSW , MillerTJ , et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research2003;60:295. [CSzG: 9722] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJM , WoodsSW , LindborgS , et al. Olanzapine versus pbo for the schizophrenic prodrome: one‐year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9804] McGlashlanTH , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTH , WoodsSW , et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:42. [CSzG: 8934] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , MillerT , WoodsS , et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. Schizophrenia Research2004;70(1):6. [CSzG: 11524] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , WoodsS , MillerT , et al. Olanzapine vs. placebo for prodromal schizophrenia. Schizophrenia Research2004;67(1):6. [CSzG: 11321] MillerTJ , ZipurskyRB , PerkinsD , AddingtonJ , WoodsSW , HawkinsKA , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research2003;61(1):19‐30. [CSzG: 9829] RosenJL , WoodsSW , MillerTJ , McGlashanTH . Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease2002;190:133‐41. [CSzG: 8274] TaylorHE , ParkerS , MansellW , MorrisonAP . Effects of appraisals of anomalous experience on distress in people at risk of psychosis. Behavioural and Cognitive Psychotherapy2012;41(1):24‐33. [CSzG: 24374] WoodsS , ZipurskyR , PerkinsD , AddingtonJ , MarquezE , BreierA , et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:43. [CSzG: 8933] WoodsSW . Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):497. [CSzG: 19829] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research. 2003. [CSzG: 9978] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research2003;60:306‐7. [CSzG: 9752] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):453‐64. [CSzG: 9994] WoodsSW , McGlashanTH . Sample size planning for prodromal intervention trials. Schizophrenia Research2002;53(3 Suppl 1):40. [CSzG: 8116] WoodsSW , ZipurskyRB , PerkinsDO , AddingtonJM , MillerTJ , BreierAF , et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053] '>PRIME‐USA</a> and <a href="./references#CD012236-bbs2-0019" title="NCT00291226 . Glycine vs Placebo for the Schizophrenia Prodrome. www.ClinicalTrials.gov/ct/show/2006. [CSzG: 14759] WoodsS , WalshB , HawkinsK , MillerT , SaksaJ , D'SouzaD , et al. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. Early Intervention in Psychiatry2012;6:29. [CSzG: 24987] WoodsSW , KantrowitzJT , JavittDC . NMDAR‐based treatments for patients at clinical high risk for psychosis. Biological Psychiatry2014;1:11S. [CSzG: 29041] WoodsSW , WalshBC , HawkinsKA , MillerTJ , SaksaJR , D'SouzaDC , et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. European Neuropsychopharmacology2013;23(8):931‐40. [CSzG: 28750] ">Woods‐1‐USA</a> used this scale. </p> <p>j. Beck Depression Inventory (BDI; <a href="./references#CD012236-bbs2-0090" title="BeckAT , WardCH , MendelsonM , MockJ , ErbaughJ . An inventory for measuring depression. Archives of General Psychiatry1961;4:561–71. ">Beck 1961</a>) </p> <p>This is a 21‐item self‐rating scale for assessment of presence and severity of depressive symptoms over the last week. Each item comprises four statements (rated 0 to 4). The score ranges from 0 to 63, higher scores meaning more severe depression. <a href="./references#CD012236-bbs2-0003" title="ChoiJ , CorcoranC , DixonL , FiszdonJ , JavittD . Processing speed training and social functioning in young adults at clinical high risk for psychosis: a pilot study. Early Intervention in Psychiatry2014;8:109. [CSzG: Ref29417] ChoiJ , CorcoranC , DixonL , JavittDC . Processing speed training and social functioning in teenagers and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2015;41:S41. [CSzG: Ref29418] ChoiJ , CorcoranCM , FiszdonJM , StevensM , JavittDC , DeasyM , et al. Pupillometer‐based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis. Psychiatric Rehabilitation Journal2017;40(1):33‐42. [CSzG: Ref35317] ">Choi‐USA</a> used a revised version of BDI, BDI‐II (<a href="./references#CD012236-bbs2-0091" title="BeckAT , SteerRA , BrownGK . Beck Depression Inventory‐II. San Antonio: Psychological Corporation, 1996. ">Beck 1996</a>), while <a href="./references#CD012236-bbs2-0006" title="DragtS , Van derGaagM . Prevention of psychosis with a cognitive behavioural intervention in help‐seeking young people with an at risk mental state for developing psychosis. www.trialregister.nl/trialreg/index.asp2007. [CSzG: Ref19655] IsingHK , KraanTC , RietdijkJ , DragtS , KlaassenRM , BoonstraN , et al. Four‐year follow‐up of cognitive behavioral therapy in persons at ultra‐high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2016;42(5):1243‐52. [CSzG: Ref35214] IsingHK , LokkerbolJ , RietdijkJ , DragtS , KlaassenRM , KraanT , et al. Four‐year cost‐effectiveness of cognitive behavior therapy for preventing first‐episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2017;43(2):365‐74. [CSzG: Ref35824] IsingHK , SmitF , VelingW , RietdijkJ , DragtS , KlaassenRM , et al. Cost‐effectiveness of preventing first‐episode psychosis in ultra‐high‐risk subjects: multi‐centre randomised controlled trial. Psychological Medicine2015;45(7):1435‐46. [CSzG: Ref27798] KraanTC , IsingHK , FokkemaM , VelthorstE , Van denBergDP , KerkhovenM , et al. The effect of childhood adversity on 4‐year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE‐NL) Trial. Psychiatry Research2017;247:55‐62. [CSzG: Ref35559] NiemanDH , RuhrmannS , RietdijkJ , DragtS , IsingH , KlaassenR , et al. Preventive psychotherapy. Schizophrenia Research2014;153:S42‐3. [CSzG: Ref29601] RietdijkJ , DragtS , KlaassenR , IsingH , NiemanD , WunderinkL , et al. A single blind randomised controlled trial of cognitive behavioural therapy in a help‐seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE‐NL) trial. Trials2010;11:30. [CSzG: Ref20654] Van DerGaagM . The effects of CBT in personswith ultra high risk: the Dutch EDIE trial. European Archives of Psychiatry and Clinical Neuroscience2011;261:S18. [CSzG: Ref23756] Van DerGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first‐episode of psychosis. Early Intervention in Psychiatry2012;6:12. [CSzG: Ref24985] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomised controlled clinical trial. Schizophrenia Bulletin2012;38(6):1180‐8. [CSzG: Ref24935] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. The effects of cognitive behavioural therapy for subjects at ultra‐high risk for developing psychosis. Schizophrenia Bulletin2013;39:S356. [CSzG: Ref28121] Van derGaagM . The prevention of psychosis in at risk mental state. www.controlled‐trials.com2008. [CSzG: Ref17488] Van derGaagM , NiemanD , Van denBergD . CBT for those at risk of a first episode psychosis: Evidence‐based psychotherapy for people with an 'at risk mental state'. 1st Edition. Hove, UK: Routledge, 2013. Van derGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first episode of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29692] ">EDIE‐NL</a> used the Dutch translation of the Beck Depression Inventory second edition, BDI‐II‐NL (<a href="./references#CD012236-bbs2-0184" title="Van derDoesJW . The Dutch version of the Beck Depression Inventory‐ (BDI‐IINL). 2nd Edition. Lisse: Swets Test Publishers, 2002. ">Van der Does 2002</a>). A shorter version of BDI, BDI‐PC (<a href="./references#CD012236-bbs2-0190" title="WinterLB , SteerR , Jones‐HicksL , BeckAT . Screening for major depressive disorder in adolescent medical outpatients with the Beck Depression Inventory for Primary Care. Journal of Adolescent Health1999;24:389–94. ">Winter 1999</a>), is comprised of seven items that are related to depressive symptoms, each rated on a four‐point scale (0 to 3). The BDI‐PC is scored by adding the ratings for each item to produce a total score, with a range of 0 to 21. <a href="./references#CD012236-bbs2-0005" title="ByrneRE , MorrisonAP . Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. Psychology and Psychotherapy2014;87(3):357‐71. [CSzG: Ref29312] FlachC , FrenchP , DunnG , FowlerD , GumleyAI , BirchwoodM , et al. Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE‐2 trial. British Journal of Psychiatry2015;207(2):123‐9. [CSzG: Ref33109] MorrisonA . Early detection and intervention evaluation for individuals at high risk of psychosis 2. http://www.controlled‐trials.com2008. [CSzG: Ref18285] MorrisonA . Early detection and intervention evaluation for people at risk of psychosis (edie‐2): A multisite randomised controlled trial of cognitive therapy for at‐risk mental states. Early Intervention in Psychiatry2012;6:11. [CSzG: Ref24968] MorrisonA , FrenchP , BentallR , LewisS , BirchwoodM , FowlerD , et al. Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. Early Intervention in Psychiatry2008;2(Suppl 1):A15. [CSzG: Ref19128] MorrisonAP . EDIE‐2: early detection and psychological intervention for individuals at high risk of psychosis (2). www.controlled‐trials.com2007. [CSzG: Ref15381] MorrisonAP , BirchwoodM , PyleM , FlachC , StewartSL , ByrneR , et al. Impact of cognitive therapy on internalised stigma in people with at‐risk mental states. British Journal of Psychiatry2013;203(2):140‐5. [CSzG: Ref28630] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ2012;344(7852):e2233. [CSzG: Ref24208] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at‐risk of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29554] MorrisonAP , PyleM , StewartSL , FrenchP , ByrneR , FlachC , et al. Internalised stigma in young people at high risk of developing psychosis: findings from a cognitive therapy trial. Schizophrenia Research2014;153:S42. [CSzG: Ref29555] MorrisonAP , StewartSL , FrenchP , BentallRP , BirchwoodM , ByrneR , et al. Early detection and intervention evaluation for people at high‐risk of psychosis‐2 (EDIE‐2): trial rationale, design and baseline characteristics. Early Intervention in Psychiatry2011;5(1):24‐32. [CSzG: Ref22695] MorrisonT . Early detection and psychological intervention for individuals at high risk of psychosis. EDIE‐2. Data on File2006. [CSzG: Ref13874] PelosiAJ . Rational policy making for early psychosis might yet become possible. BMJ2012;344(7856):e3137. [CSzG: Ref24326] PyleM , StewartSL , FrenchP , ByrneR , PattersonP , GumleyA , et al. Internalised stigma, emotional dysfunction and unusual experiences in young people at risk of psychosis. Early Intervention in Psychiatry2015;9(2):133‐40. [CSzG: Ref29813] ">EDIE‐2‐UK</a> reported data from this scale. </p> <p>k. Young Mania Scale (YMS; <a href="./references#CD012236-bbs2-0195" title="YoungRC , BiggsJT , ZieglerVE , MeyerDA . A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry1978;133:429‐35. ">Young 1978</a>) </p> <p>YMS is an interviewer‐rated, 11‐item scale designed for assessment of symptoms of mania. Seven items are graded on a 0 to 4 scale, but four items are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behaviour). Higher scores indicate more severe manic symptoms. <a href="./references#CD012236-bbs2-0013" title="ACTRN12608000475347 . A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder. Australian New Zealand Clinical Trials Registry2009. [CSzG: 18420] HKCTR‐1438 . The NEURAPRO‐E (North America, EURope, Australia PROdrome) Study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for symptomatic patients at ultra‐high risk for early progression to schizophrenia and other psychotic disorders. www.hkClinicaltrials.com/trial_details.aspx?trialID=d09bd177‐b9fd‐4162‐b04f‐3ebfed49baa32011. [CSzG: 29270] McGorryP , MarkulevC , NelsonB , YuenHP , SchaeferM , YungAR , et al. The NEURAPRO‐E study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Schizophrenia Bulletin2015;41:S322‐3. [CSzG: 29546] McGorryPD , NelsonB , MarkulevC , YuenHP , SchaferMR , MossahebN , et al. Effect of omega‐3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomised clinical trial. JAMA psychiatry2017;74(1):19‐27. [CSzG: 35590] NelsonB , AmmingerG , MarkulevC , YuenHP , LavoieS , SchaeferM , et al. NEURAPOR: a multi‐center RCT of omega‐3 polyunsaturated fatty acids versus placebo in young people at ultra‐high risk of psychotic disorders: medium‐term outcome. Schizophrenia Bulletin2017;43:S107. [CSzG: 36016] ">NEURAPRO‐AAE</a>, <a href="./references#CD012236-bbs2-0015" title="McGorryP . Can the onset of schizophrenia be delayed or prevented?. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S26. [CSzG: 8351] McGorryP , AdlardS , YungA , McDonaldA , PhillipsL , HearnN . Detection and intervention in pre‐psychotic schizophrenia. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4836] McGorryP , YungA , FranceyS , PhillipsL , NelsonB . A blinded, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and befriending in young people at risk of psychotic disorder: baseline characteristics of the sample. Acta Neuropsychiatrica2006;18(6):261. [CSzG: 35157] McGorryPD , HearnN , GermanoD , BravinJ , PhillipsLJ , YungAR , et al. Prepsychotic intervention in schizophrenia: a stitch in time?. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington DC, USA. 1999. [CSzG: 3584] McGorryPD , PhillipsLJ , NelsonB , LeicesterS , BakerK , KrstevH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and befriending in young people with subthreshold symptoms at incipient risk of psychotic disorder: six month outcome data. Schizophrenia Bulletin2007;33(2):446. [CSzG: 15203] McGorryPD , PhillipsLJ , YungAR , FranceyS , GermanoD , BravinJ , et al. A randomised controlled trial of interventions in the pre psychotic phase of psychotic disorders. Schizophrenia Research2000;41(1):9. [CSzG: 5149] McGorryPD , YungAR , PhillipsL , AdlardS , HallgrenM , PattonG , et al. Pre‐psychotic intervention in schizophrenia: a stitch in time?. Schizophrenia Research1998;29(1‐2):160. [CSzG: 3585] McGorryPD , YungAR , PhillipsLJ , YuenHP , FranceyS , CosgraveEM , et al. Randomised controlled trial of interventions designed to reduce the risk of progression to first‐episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry2002;59(10):921‐8. [CSzG: 8576] PhilippsLJ , McGorryP , YungA , FranceyD , GermanoF , BravinJ , et al. The development of preventive interventions for early psychosis: early findings and directions for the future. 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001; Vol. 2, issue Suppl 1. [CSzG: 7614] PhillipsL , CottonS , YuenHP , MihalopoulosC , ShihS , KellyD , et al. Cost effectiveness of a preventive intervention for young people at ultra high risk of developing psychosis. Schizophrenia Bulletin2007;33(2):488‐9. [CSzG: 15227] PhillipsLJ , CottonS , MihalopoulosC , ShihS , YungAR , CarterR , et al. Cost implications of specific and non‐specific treatment for young persons at ultra high risk of developing a first episode of psychosis. Early Intervention in Psychiatry2009;3(1):28‐34. [CSzG: 18308] PhillipsLJ , LeicesterSB , O'DwyerLE , FranceySM , KoutsogiannisJ , Abdel‐BakiA , et al. The PACE clinic: identification and management of young people at &quot;ultra&quot; high risk of psychosis. Journal of Psychiatric Practice2002;8(5):255‐69. [CSzG: 18235] PhillipsLJ , McGorryPD , YuenHP , WardJ , DonovanK , KellyD , et al. Medium term follow‐up of a randomised controlled trial of interventions for young people at ultra high risk of psychosis. Schizophrenia Research2007;96(1‐3):25‐33. [CSzG: 15544] PhillipsLJ , YungAR , YuenHP , PantelisC , McGorryPD . Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. American Journal of Medical Genetics2002;114(8):929‐37. [CSzG: 18236] ">PACE‐Australia</a> and <a href="./references#CD012236-bbs2-0017" title='BlockJJ , McGlashonTH . Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790‐9. American Journal of Psychiatry2006; Vol. 163, issue 10:1838. [CSzG: 13960] BreierAF , ZipurskyRB , PerkinsDO , AddingtonJM , TohenMF , DavidSR , et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951] HawkinsKA , AddingtonJ , KeefeR , ChristensenB , WoodsS , ZipurskyR , et al. Neuropsychological functioning in the first episode prodrome and early psychosis. Schizophrenia Research2004;70(1):101. [CSzG: 11515] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , MillerTJ , et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research2004;67(1):205. [CSzG: Ref11301] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , ZipurskyRB , et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. [CSzG: 16470] HawkinsKA , KeefeRS , ChristensenBK , AddingtonJ , WoodsSW , CallahanJ , et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. Schizophrenia Research2008;105(1‐3):1‐9. [CSzG: 16983] HoffmanRE , WoodsS , PredaA , TohenM , BreierA , GlistJ , et al. Excessive top‐down perceptual processing and reduced real‐world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. Schizophrenia Research2006;86(Suppl 1):S46. [CSzG: 13377] HoffmanRE , WoodsSW , HawkinsKA , PittmanB , TohenM , PredaA , et al. Extracting spurious messages from noise and risk of schizophrenia‐spectrum disorders in prodromal population. British Journal of Psychiatry2007;191(2):355‐6. [CSzG: 16068] McGlashanT , ZipurskyR , PerkinsD , AddingtonJ . Olanzapine for treatment of the schizophrenia prodrome: 2‐year results of a randomised placebo‐controlled study. Schizophrenia Research2004;67(1):164. [CSzG: 11320] McGlashanTH . Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. [CSzG: 10191] McGlashanTH . Treatment intervention in the New Haven PRIME clinic prodromal sample. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4835] McGlashanTH , MillerTJ , WoodsSW . Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research2002;53(3 Suppl 1):15. [CSzG: 8093] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005] McGlashanTH , MillerTJ , ZipurskyRB , WoodsSW , PerkinsDO , HawkinsKA , et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9803] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerT , WoodsSW , et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry2006;163(5):790‐9. [CSzG: 12654] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerTJ , WoodsSW , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research2003;61(1):7‐18. [CSzG: 9828] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJ , WoodsSW , MillerTJ , et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research2003;60:295. [CSzG: 9722] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJM , WoodsSW , LindborgS , et al. Olanzapine versus pbo for the schizophrenic prodrome: one‐year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9804] McGlashlanTH , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTH , WoodsSW , et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:42. [CSzG: 8934] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , MillerT , WoodsS , et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. Schizophrenia Research2004;70(1):6. [CSzG: 11524] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , WoodsS , MillerT , et al. Olanzapine vs. placebo for prodromal schizophrenia. Schizophrenia Research2004;67(1):6. [CSzG: 11321] MillerTJ , ZipurskyRB , PerkinsD , AddingtonJ , WoodsSW , HawkinsKA , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research2003;61(1):19‐30. [CSzG: 9829] RosenJL , WoodsSW , MillerTJ , McGlashanTH . Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease2002;190:133‐41. [CSzG: 8274] TaylorHE , ParkerS , MansellW , MorrisonAP . Effects of appraisals of anomalous experience on distress in people at risk of psychosis. Behavioural and Cognitive Psychotherapy2012;41(1):24‐33. [CSzG: 24374] WoodsS , ZipurskyR , PerkinsD , AddingtonJ , MarquezE , BreierA , et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:43. [CSzG: 8933] WoodsSW . Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):497. [CSzG: 19829] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research. 2003. [CSzG: 9978] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research2003;60:306‐7. [CSzG: 9752] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):453‐64. [CSzG: 9994] WoodsSW , McGlashanTH . Sample size planning for prodromal intervention trials. Schizophrenia Research2002;53(3 Suppl 1):40. [CSzG: 8116] WoodsSW , ZipurskyRB , PerkinsDO , AddingtonJM , MillerTJ , BreierAF , et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053] '>PRIME‐USA</a> reported data from this scale. </p> <p>l. Social Interaction and Anxiety Scale (SIAS; <a href="./references#CD012236-bbs2-0157" title="MattickRP , ClarkeJC . Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behaviour Research and Therapy1998;36:455–70. ">Mattick 1998</a>) </p> <p>The SIAS is a 20‐item questionnaire designed to measure levels of fear in social interaction situations. Each item is rated on a five‐point Likert scale (0 to 5). Total scores range from 0 to 80, higher scores reflecting more severe social anxiety. <a href="./references#CD012236-bbs2-0001" title="AddingtonJ , EpsteinI , LiuL , FrenchP , BoydellKM , ZipurskyRB . A randomised controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research2011;125(1):54‐61. [CSzG: Ref21945] AddingtonJ , ZipurskyR , EpsteinI . ADAPT (Access, Detection and Psychological Treatments). Schizophrenia Research2006;86(Suppl 1):S6. [CSzG: Ref13364] NCT00260273 . Access, detection and psychological treatments. www.ClinicalTrials.gov/ct/show/2005. [CSzG: Ref14638] ">ADAPT‐Canada</a>, <a href="./references#CD012236-bbs2-0005" title="ByrneRE , MorrisonAP . Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. Psychology and Psychotherapy2014;87(3):357‐71. [CSzG: Ref29312] FlachC , FrenchP , DunnG , FowlerD , GumleyAI , BirchwoodM , et al. Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE‐2 trial. British Journal of Psychiatry2015;207(2):123‐9. [CSzG: Ref33109] MorrisonA . Early detection and intervention evaluation for individuals at high risk of psychosis 2. http://www.controlled‐trials.com2008. [CSzG: Ref18285] MorrisonA . Early detection and intervention evaluation for people at risk of psychosis (edie‐2): A multisite randomised controlled trial of cognitive therapy for at‐risk mental states. Early Intervention in Psychiatry2012;6:11. [CSzG: Ref24968] MorrisonA , FrenchP , BentallR , LewisS , BirchwoodM , FowlerD , et al. Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. Early Intervention in Psychiatry2008;2(Suppl 1):A15. [CSzG: Ref19128] MorrisonAP . EDIE‐2: early detection and psychological intervention for individuals at high risk of psychosis (2). www.controlled‐trials.com2007. [CSzG: Ref15381] MorrisonAP , BirchwoodM , PyleM , FlachC , StewartSL , ByrneR , et al. Impact of cognitive therapy on internalised stigma in people with at‐risk mental states. British Journal of Psychiatry2013;203(2):140‐5. [CSzG: Ref28630] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ2012;344(7852):e2233. [CSzG: Ref24208] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at‐risk of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29554] MorrisonAP , PyleM , StewartSL , FrenchP , ByrneR , FlachC , et al. Internalised stigma in young people at high risk of developing psychosis: findings from a cognitive therapy trial. Schizophrenia Research2014;153:S42. [CSzG: Ref29555] MorrisonAP , StewartSL , FrenchP , BentallRP , BirchwoodM , ByrneR , et al. Early detection and intervention evaluation for people at high‐risk of psychosis‐2 (EDIE‐2): trial rationale, design and baseline characteristics. Early Intervention in Psychiatry2011;5(1):24‐32. [CSzG: Ref22695] MorrisonT . Early detection and psychological intervention for individuals at high risk of psychosis. EDIE‐2. Data on File2006. [CSzG: Ref13874] PelosiAJ . Rational policy making for early psychosis might yet become possible. BMJ2012;344(7856):e3137. [CSzG: Ref24326] PyleM , StewartSL , FrenchP , ByrneR , PattersonP , GumleyA , et al. Internalised stigma, emotional dysfunction and unusual experiences in young people at risk of psychosis. Early Intervention in Psychiatry2015;9(2):133‐40. [CSzG: Ref29813] ">EDIE‐2‐UK</a> and <a href="./references#CD012236-bbs2-0006" title="DragtS , Van derGaagM . Prevention of psychosis with a cognitive behavioural intervention in help‐seeking young people with an at risk mental state for developing psychosis. www.trialregister.nl/trialreg/index.asp2007. [CSzG: Ref19655] IsingHK , KraanTC , RietdijkJ , DragtS , KlaassenRM , BoonstraN , et al. Four‐year follow‐up of cognitive behavioral therapy in persons at ultra‐high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2016;42(5):1243‐52. [CSzG: Ref35214] IsingHK , LokkerbolJ , RietdijkJ , DragtS , KlaassenRM , KraanT , et al. Four‐year cost‐effectiveness of cognitive behavior therapy for preventing first‐episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2017;43(2):365‐74. [CSzG: Ref35824] IsingHK , SmitF , VelingW , RietdijkJ , DragtS , KlaassenRM , et al. Cost‐effectiveness of preventing first‐episode psychosis in ultra‐high‐risk subjects: multi‐centre randomised controlled trial. Psychological Medicine2015;45(7):1435‐46. [CSzG: Ref27798] KraanTC , IsingHK , FokkemaM , VelthorstE , Van denBergDP , KerkhovenM , et al. The effect of childhood adversity on 4‐year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE‐NL) Trial. Psychiatry Research2017;247:55‐62. [CSzG: Ref35559] NiemanDH , RuhrmannS , RietdijkJ , DragtS , IsingH , KlaassenR , et al. Preventive psychotherapy. Schizophrenia Research2014;153:S42‐3. [CSzG: Ref29601] RietdijkJ , DragtS , KlaassenR , IsingH , NiemanD , WunderinkL , et al. A single blind randomised controlled trial of cognitive behavioural therapy in a help‐seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE‐NL) trial. Trials2010;11:30. [CSzG: Ref20654] Van DerGaagM . The effects of CBT in personswith ultra high risk: the Dutch EDIE trial. European Archives of Psychiatry and Clinical Neuroscience2011;261:S18. [CSzG: Ref23756] Van DerGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first‐episode of psychosis. Early Intervention in Psychiatry2012;6:12. [CSzG: Ref24985] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomised controlled clinical trial. Schizophrenia Bulletin2012;38(6):1180‐8. [CSzG: Ref24935] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. The effects of cognitive behavioural therapy for subjects at ultra‐high risk for developing psychosis. Schizophrenia Bulletin2013;39:S356. [CSzG: Ref28121] Van derGaagM . The prevention of psychosis in at risk mental state. www.controlled‐trials.com2008. [CSzG: Ref17488] Van derGaagM , NiemanD , Van denBergD . CBT for those at risk of a first episode psychosis: Evidence‐based psychotherapy for people with an 'at risk mental state'. 1st Edition. Hove, UK: Routledge, 2013. Van derGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first episode of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29692] ">EDIE‐NL</a> reported data from this scale. </p> <p>m. The Social Phobia Scale (SPS; <a href="./references#CD012236-bbs2-0157" title="MattickRP , ClarkeJC . Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behaviour Research and Therapy1998;36:455–70. ">Mattick 1998</a>) </p> <p>The SPS is a 20‐item questionnaire for assessment of fear of being observed or scrutinised by others during routine activities, e.g. eating, writing, speaking in public. Each item is rated from 0 to 4 (all items are negatively worded), total scores ranging from 0 to 80. <a href="./references#CD012236-bbs2-0001" title="AddingtonJ , EpsteinI , LiuL , FrenchP , BoydellKM , ZipurskyRB . A randomised controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research2011;125(1):54‐61. [CSzG: Ref21945] AddingtonJ , ZipurskyR , EpsteinI . ADAPT (Access, Detection and Psychological Treatments). Schizophrenia Research2006;86(Suppl 1):S6. [CSzG: Ref13364] NCT00260273 . Access, detection and psychological treatments. www.ClinicalTrials.gov/ct/show/2005. [CSzG: Ref14638] ">ADAPT‐Canada</a> reported data from this scale. </p> <p>n. The Social Anxiety Scale for Adolescents (SAS‐A; <a href="./references#CD012236-bbs2-0150" title="LaGrecaAM , StoneWL . Social anxiety scale for children revised: factor structure and concurrent validity. Journal of Clinical Child Psychology1993;22:17–27. [DOI: 10.1207/s15374424jccp2201_2] ">La Greca 1993</a>) </p> <p>SAS‐A is a clinician‐rated scale for assessing social function specific to the fear of negative evaluation by peers, social avoidance, and social response to new situations. It contains 18 items rated on a five‐point scale ranging from 1 (not at all) to 5 (all the time), with total scores from 18 to 90 (higher scores indicating more anxiety and poorer relations). <a href="./references#CD012236-bbs2-0003" title="ChoiJ , CorcoranC , DixonL , FiszdonJ , JavittD . Processing speed training and social functioning in young adults at clinical high risk for psychosis: a pilot study. Early Intervention in Psychiatry2014;8:109. [CSzG: Ref29417] ChoiJ , CorcoranC , DixonL , JavittDC . Processing speed training and social functioning in teenagers and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2015;41:S41. [CSzG: Ref29418] ChoiJ , CorcoranCM , FiszdonJM , StevensM , JavittDC , DeasyM , et al. Pupillometer‐based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis. Psychiatric Rehabilitation Journal2017;40(1):33‐42. [CSzG: Ref35317] ">Choi‐USA</a> reported data from this scale. </p> <p>o. The Brief Symptom Inventory (BSI; <a href="./references#CD012236-bbs2-0111" title="DerogatisL . Brief Symptom Inventory. Baltimore: Research, CP, 1995. ">Derogatis 1995</a>) </p> <p>The BSI is a psychological self‐report symptom scale consisting of 53 items divided into nine primary symptom dimensions: somatisation, obsessive‐compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation and psychoticism. Each item of the BSI is rated on a five‐point scale of distress (0 to 4), ranging from 'not‐at‐all' to 'extremely'. <a href="./references#CD012236-bbs2-0004" title="CrittendenK , FlemingJ , StartupM , CarrV , BakerA , SchallU , et al. Recruitment and engagement of youth in an ultra high risk treatment study. Early Intervention in Psychiatry2008;2(Suppl 1):A127. [CSzG: Ref19115] StainH , BucciS , HalperinS , EmsleyR , ShallU , LewinT , et al. DEPTh: randomised controlled trial of cognitive behavioral therapy for young people at ultra high risk for psychosis. Early Intervention in Psychiatry2014;8:15. [CSzG: Ref29673] StainHJ , BucciS , BakerA , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of CBT for young people at risk for psychosis: the Detection and Evaluation of Psychological Therapy (DEPTh) trial. European Archives of Psychiatry and Clinical Neuroscience2015;1:S8‐9. [CSzG: Ref33810] StainHJ , BucciS , BakerAL , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of cognitive behaviour therapy versus non‐directive reflective listening for young people at ultra high risk of developing psychosis: the detection and evaluation of psychological therapy (DEPTh) trial. Schizophrenia Research2016;176(2‐3):212‐9. [CSzG: Ref35298] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. Rural and urban youth at ultra high risk for psychosis: baseline characteristics from the DEPTh randomised controlled trial of cognitive behavior therapy. Schizophrenia Bulletin2011;37:322. [CSzG: Ref22815] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy for youth at ultra high risk for psychosis: baseline characteristics for rural and urban youth. Australian and New Zealand Journal of Psychiatry2010:25‐6. [CSzG: Ref21845] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy targeting ultra high risk for psychosis: baseline comparisons for rural and urban youth. Early Intervention in Psychiatry2010;4(Suppl 1):113. [CSzG: Ref23498] StainHJ , StartupM , CarrV , BakerA , SchallU . The DEPTh project: a multisite RCT for youths at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S51‐2. [CSzG: Ref13401] StartupM . The DEPTh project: detection, evaluation, and psychological therapy for health. Australian New Zealand Clinical Trials Registry2006. [CszG: Ref18442] ">DEPTh‐Australia</a> reported data from this scale (please see <a href="./appendices#CD012236-sec-0531">Appendix 1</a>). </p> <p>p. The Scale for the Assessment of Positive Symptoms (SAPS; <a href="./references#CD012236-bbs2-0083" title="AndreasenNC . Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa, 1984. ">Andreasen 1984</a>) </p> <p>The SAPS is a rating scale developed for the assessment of positive symptoms in schizophrenia. It consists of four domains: hallucinations; delusion;, bizarre behaviour; and positive formal thought disorder. Within each domain, symptoms are rated from 0 (absent) to 5 (severe). <a href="./references#CD012236-bbs2-0014" title="NordentoftM , JeppesenP , PetersenL , ThorupA , OhlenschlaegerJ , ChristensenT , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. European Psychiatry2007;22:S129‐S. [CSzG: 20471] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the OPUS trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;83(1):29‐40. [CSzG: 13197] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;86(Suppl 1):S44. [CSzG: 13393] ">Nordentoft‐Denmark</a> reported data from this scale (please see <a href="./appendices#CD012236-sec-0531">Appendix 1</a>). </p> <p>q. The Early Recognition Inventory (ERIraos; <a href="./references#CD012236-bbs2-0158" title="MaurerK , HorrmannF , SchmidtG , TrendlerG , HäfnerH . The early recognition inventory ERIraos: a two‐step procedure for detection of ‘‘at‐risk mental states’’. Schizophrenia Research2004;70 (suppl):s76. ">Maurer 2004</a>) </p> <p>The ERIraos is a comprehensive early‐recognition inventory developed on an empirical basis as an extension of the Retrospective Assessment of the Onset and course of Schizophrenia and Other Psychoses (IRAOS; <a href="./references#CD012236-bbs2-0144" title="HäfnerH , Riecher‐RösslerA , HambrechtM , MaurerK , MeissnerS , SchmidtkeA , et al. IRAOS: an instrument for the assessment of onset and early course of schizophrenia. Schizophrenia Research1992;6:209–23. ">Häfner 1992</a>). The psychopathological section comprises a symptom list with 110 items structured in 12 sections. Each item score ranges from 0 to 3. <a href="./references#CD012236-bbs2-0011" title="BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: 12511] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] RuhrmannS , BechdolfA , KuhnKU , WagnerM , Schultze‐LutterF Janssen B , et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry. Supplements2007;51:s88‐95. [CSzG: 16127] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Acute symptomatic treatment effects in persons clinically at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13397] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Intervention in the late initial prodromal state (LIPS) of psychosis. Schizophrenia Research2006;86(Suppl 1):S96. [CSzG: 13398] ">LIPS‐Germany</a> used the ERIraos. Basic and Positive Psychotic Spectrum Symptoms score (ERI–BAPPSS score) used to assess treatment effects, was formed of the 16 items related to full‐blown psychotic symptoms (including disorganised thinking and behaviour), six items assessing attenuated positive symptoms and 10 items assessing a set of basic symptoms. Data were reported for two ERI–BAPPSS subscores, ERI–PPS score (the attenuated and full‐blown psychotic positive symptoms) and ERI–BS (the basic symptoms) (please see <a href="./appendices#CD012236-sec-0531">Appendix 1</a>). </p> <p>r. Cognitive tests</p> <p><a href="./references#CD012236-bbs2-0019" title="NCT00291226 . Glycine vs Placebo for the Schizophrenia Prodrome. www.ClinicalTrials.gov/ct/show/2006. [CSzG: 14759] WoodsS , WalshB , HawkinsK , MillerT , SaksaJ , D'SouzaD , et al. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. Early Intervention in Psychiatry2012;6:29. [CSzG: 24987] WoodsSW , KantrowitzJT , JavittDC . NMDAR‐based treatments for patients at clinical high risk for psychosis. Biological Psychiatry2014;1:11S. [CSzG: 29041] WoodsSW , WalshBC , HawkinsKA , MillerTJ , SaksaJR , D'SouzaDC , et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. European Neuropsychopharmacology2013;23(8):931‐40. [CSzG: 28750] ">Woods‐1‐USA</a> used various tests for neuropsychological assessment of processing speed, verbal memory, executive functioning, semantic (category) fluency, phonemic fluency, attention and working memory. Data were reported for the following tests: Trails B (<a href="./references#CD012236-bbs2-0168" title="ReitanRM , WolfsonD . The Halstead‐Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Tuscon: Neuropsychology Press, 1985. ">Reitan 1985</a>), Stroop Color Word Test (<a href="./references#CD012236-bbs2-0128" title="GoldenC . Stroop Color and Word Test: Manual for Clinical and Experimental Uses. Chicago: Stoelting, 1978. ">Golden 1978</a>), Auditory Verbal Learning Task (AVLT; <a href="./references#CD012236-bbs2-0170" title="ReyRA . L'examen clinique en psychologique, Vol. Paris: Presses Universitaires de France, 1964. ">Rey 1964</a>),Wisconsin Card Sort Test (WCS; <a href="./references#CD012236-bbs2-0136" title="HeatonRK , CheluneGJ , TalleyJL , KayGG , CurtisG . Wisconsin Card Sorting Test, Manual. Odessa: Psychological Assessment Resources, 1993. ">Heaton 1993</a>), semantic (category) fluency (<a href="./references#CD012236-bbs2-0179" title="SpreenO , StraussE . A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. 2nd Edition. New York: Oxford, 1998. ">Spreen 1998</a>), Controlled Oral Word Association (FAS) Test of phonemic fluency (<a href="./references#CD012236-bbs2-0178" title="SpreenO , BentonAL . Neurosensory Center Comprehensive Examination for Aphasia (NCCEA). Victoria: University of Victoria Neuropsychology Laboratory, 1969. ">Spreen 1969</a>), Letter‐number sequencing (<a href="./references#CD012236-bbs2-0127" title="GoldJM , CarpenterC , RandolphC , GoldbergTE , WeinbergerDR . Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Archives of General Psychiatry1997;54:159‐65. ">Gold 1997</a>) and Trails A (<a href="./references#CD012236-bbs2-0168" title="ReitanRM , WolfsonD . The Halstead‐Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Tuscon: Neuropsychology Press, 1985. ">Reitan 1985</a>). </p> <p><a href="./references#CD012236-bbs2-0016" title="NCT01619319 . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. ClinicalTrials.gov/show/NCT016193192012. [CSzG: 24387] PiskulicD , BarbatoM , AddingtonJ . Cognitive remediation in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:89. [CSzG: 24973] PiskulicD , BarbatoM , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2012;136:S245‐6. [CSzG: 29632] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2014;153(Suppl. 1):S218. [CSzG: 28827] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation therapy on cognition in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2014;8:86. [CSzG: 29633] ">Piskulic‐Canada</a> used modified battery of MATRICS measures (<a href="./references#CD012236-bbs2-0164" title="NuechterleinKH , GreenMF , KernRS , BaadeLE , BarchDM , CohenJD . The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. American Journal of Psychiatry2008;165:203–13. ">Neuchterlein 2008</a>), consisting of nine subtests for measuring neurocognitive functioning in the following domains: processing speed; attention/vigilance; working memory; verbal learning; visual learning; and reasoning and problem solving. </p> <p><a href="./references#CD012236-bbs2-0003" title="ChoiJ , CorcoranC , DixonL , FiszdonJ , JavittD . Processing speed training and social functioning in young adults at clinical high risk for psychosis: a pilot study. Early Intervention in Psychiatry2014;8:109. [CSzG: Ref29417] ChoiJ , CorcoranC , DixonL , JavittDC . Processing speed training and social functioning in teenagers and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2015;41:S41. [CSzG: Ref29418] ChoiJ , CorcoranCM , FiszdonJM , StevensM , JavittDC , DeasyM , et al. Pupillometer‐based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis. Psychiatric Rehabilitation Journal2017;40(1):33‐42. [CSzG: Ref35317] ">Choi‐USA</a> used neurocognitive tests for assessment of processing speed (Wechsler Adult Intelligence Scale‐Third Edition (WAIS‐III) Digit Symbol‐Coding subtest (<a href="./references#CD012236-bbs2-0186" title="WechslerD . Wechsler abbreviated scale of intelligence (WASI‐III) manual. San Antonio: Psychological Corporation, 1999. ">Wechsler 1999</a>), and The Minnesota Clerical Test (MCT; <a href="./references#CD012236-bbs2-0085" title="AndrewDM , PatersonDG , LongstaffHP . Minnesota Clerical Test Manual. 2nd Edition. San Antonio: Harcourt Assessment Company, Psychological Corporation, 1979. ">Andrew 1979</a>). </p> </section> <section id="CD012236-sec-0147"> <p><b>6.2.3 Functioning</b></p> <p>a. Global Assessment of Functioning (GAF; <a href="./references#CD012236-bbs2-0087" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth edition. 4th Edition. Washington: American Psychiatric Association, 1994. ">APA 1994</a>) </p> <p>This is an observer‐rated scale for measuring social, occupational and psychological functioning (impairment). Scores range from 100 (extremely high functioning) to 1 (inadequate information). <a href="./references#CD012236-bbs2-0001" title="AddingtonJ , EpsteinI , LiuL , FrenchP , BoydellKM , ZipurskyRB . A randomised controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research2011;125(1):54‐61. [CSzG: Ref21945] AddingtonJ , ZipurskyR , EpsteinI . ADAPT (Access, Detection and Psychological Treatments). Schizophrenia Research2006;86(Suppl 1):S6. [CSzG: Ref13364] NCT00260273 . Access, detection and psychological treatments. www.ClinicalTrials.gov/ct/show/2005. [CSzG: Ref14638] ">ADAPT‐Canada</a>, <a href="./references#CD012236-bbs2-0002" title="AmmingerG . Ethyl eicosapentanoic acid for prodromal psychosis. Stanley Foundation Research Programs2009. [CSzG: Ref17423] AmmingerG , SchaferM , PapageorgiouK , CottonS , HarriganS , MackinnonA , et al. Indicated prevention with long‐chain omega‐3 fatty acids in adolescents at ultra‐high‐risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2008;2(Suppl 1):A29. [CSzG: Ref19107] AmmingerGP , ChanenAM , OhmannS , KlierCM , MossahebN , BechdolfA , et al. Omega‐3 fatty acid supplementation in adolescents with borderline personality disorder and ultra‐high risk criteria for psychosis: a post hoc subgroup analysis of a double‐blind, randomised controlled trial. Canadian Journal of Psychiatry2013;58(7):402‐8. [CSzG: Ref28534] AmmingerGP , HarrisMS , McGorryPD , HenryLP . Omega‐3 fatty acids for indicated prevention: treatment results and pathomechanisms. European Archives of Psychiatry and Clinical Neuroscience2013;263(Suppl. 1):S44‐5. [CSzG: Ref28434] AmmingerGP , LeicesterS , YungAR , YuenHP , McGorryPD . Age predicts transition to psychosis in an ultra‐high risk sample. Proceedings of the 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:61. AmmingerGP , McGorryPD . Update on omega‐3 polyunsaturated fatty acids in early ‐stage psychotic disorders. Neuropsychopharmacology2012;37(1):309‐10. [CSzG: Ref23726] AmmingerGP , MechelliA , RiceS , KimSW , KlierCM , McNamaraRK , et al. Predictors of treatment response in young people at ultra‐high risk for psychosis who received long‐chain omega‐3 fatty acids. Translational Psychiatry2015;5:e495. [CSzG: Ref29299] AmmingerGP , SchaferMR . Indicated prevention with omega‐3 fatty acids in adolescents at ultra‐high risk for psychosis ‐ rationale, methods, and 3‐months outcome. Schizophrenia Research2006;86(Suppl 1):S97‐8. [CSzG: Ref13367] AmmingerGP , SchaferMR . Is it feasible to conduct a RCT in ultra‐high risk individuals at a child and adolescent psychiatric service?. Schizophrenia Research2006;86(Suppl 1):S98. [CSzG: Ref13368] AmmingerGP , SchaferMR , KlierCM , PapageorgiouK , SlavikJ , HolzerI , et al. Indicated prevention with long‐chain omega‐3 fatty acids in young people at ultra‐high risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2010;4(Suppl 1):7. [CSzG: Ref23467] AmmingerGP , SchaferMR , SchlogelhoferM , KlierCM , McGorryPD . Longer‐term outcome in the prevention of psychotic disorders by the Vienna omega‐3 study. Nature Communications2015;6:7934. [CSzG: Ref33023] AmmingerGP , SchlogelhoferM , KlierC , McGorryP , SchaferM . Longer‐term follow‐up in the Vienna omega‐3 psychosis prevention trial. Early Intervention in Psychiatry2014;8:41. [CSzG: Ref29378] AmmingerGP , SchäferMR , PapageorgiouK , KlierCM , CottonSM , HarriganSM , et al. Long‐chain omega‐3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo‐controlled trial. Archives of General Psychiatry2010;67(2):146‐54. [CSzG: Ref20680; DOI: 10.1001/archgenpsychiatry.2009.192.] AmmingerP , MossahebN , SchlgelhoferM , SchaferM . Fatty acid metabolism and the onset of psychotic disorder. European Psychiatry2011;26(Suppl 1):2089. [CSzG: Ref22967] Anonymous . Fish oil may help ward off psychosis. Journal of Psychosocial Nursing and Mental Health Services2010;48(5):55. [CSzG: Ref20739] BergerG , AmmingerP , McGorryP . Stage dependant effect of omega‐3 fatty acids in emerging psychosis. European Psychiatry2011;26(Suppl 1):1347. [CSzG: Ref22966] BergerGE , ProffittTM , McConchieM , YuenH , WoodSJ , AmmingerGP , et al. Ethyl‐eicosapentaenoic acid in first‐episode psychosis: a randomised, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(12):1867‐75. [CSzG: Ref15561; ISSN: 1555‐2101] EhrlichA . Evidence‐based medicine. Omega‐3 supplementation delays transition to psychotic disorder in ultra‐high‐risk adolescents and young adults. Clinical Advisor for Nurse Practitioners2010;13(5):79‐80. [CSzG: Ref21562] FöckingM , DickerP , LopezLM , CannonM , SchäferMR , McGorryPD , et al. Differential expression of the inflammation marker IL12p40 in the at‐risk mental state for psychosis: a predictor of transition to psychotic disorder?. BMC Psychiatry2016;16(1):326. [DOI: 10.1186/s12888‐016‐1039‐7] KlierC , HollmannM , SchlögelhoferM , MossahebN , FriedrichM , AmmingerPG . Indicated prevention with omega‐3 fatty acids (EPA/DHA) in adolescents with &quot;at‐risk‐mental‐state“ for psychosis. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. [CSzG: Ref12438] LavoieS , BenningerF , FeuchtM , KlierCM , SchaeferMR , AmmingerGP . Correlates of EEG resting states with erythrocyte membrane omega‐3 fatty acid levels and psychopathological symptoms in individuals at ultra‐high risk for psychosis. Early Intervention in Psychiatry2014;8:137. [CSzG: Ref29516] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultra‐high risk individuals who transitioned to psychosis. Schizophrenia Research2012;138(2‐3):206‐11. [CSzG: Ref24256] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultrahigh risk individuals who transitioned to psychosis. Early Intervention in Psychiatry2012;6:38. [CSzG: Ref24960] MossahebN , PapageorgiouK , SchaferMR , BeckerJ , SchloegelhoferM , AmmingerGP . Changes in triglyceride levels in ultra‐high risk for psychosis individuals treated with omega‐3 fatty acids. Early Intervention in Psychiatry2018; Vol. 12, issue 1:30‐36. [DOI: 10.1111/eip.12275] MossahebN , SchaferMR , SchlogelhoferM , KlierCM , CottonSM , McGorryPD , et al. Effect of omega‐3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?. Schizophrenia Research2013;148(1‐3):163‐7. [CSzG: Ref28649] NCT00396643 . Indicated prevention with omega‐3 fatty acids in adolescents with ‘at‐risk‐mental‐state’ for psychosis: a randomised, double blind, placebo‐controlled treatment trial. www.ClinicalTrials.gov/ct/show/2006. [CSzG: Ref14873] PapageorgiouK , SchaferMR , SchlogelhoferM , MossahebN , AmmingerGP . Indicated prevention with omega‐3 fatty acids in young people with 'at‐risk‐mental‐state' for psychosis: design of a 5‐year follow‐up. European Archives of Psychiatry and Clinical Neuroscience2011;261:S55. [CSzG: Ref23749] SchaferMR , KlierCM , PapageorgiouK , FriedrichMH , AmmingerGP . Early detection of psychotic disorders. Neuropsychiatrie2007;21(1):37‐44. [CSzG: Ref15290] SmesnyS , MilleitB , HiplerUC , MilleitC , SchaferMR , KlierCM , et al. Omega‐3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra‐high risk for psychosis. Molecular Psychiatry2013;19(3):317‐24. [CSzG: Ref28243] SmesnyS , MilleitB , SchaeferMR , HesseJ , SchlögelhoferM , LangbeinK , et al. Effects of omega‐3 PUFA on immune markers in adolescent individuals at ultra‐high risk for psychosis ‐ results of the randomised controlled Vienna omega‐3 study. Schizophrenia Research2017;S0920‐9964(17):30039‐7. [DOI: 10.1016/j.schres.2017.01.026] ">Amminger‐Austria</a>, <a href="./references#CD012236-bbs2-0004" title="CrittendenK , FlemingJ , StartupM , CarrV , BakerA , SchallU , et al. Recruitment and engagement of youth in an ultra high risk treatment study. Early Intervention in Psychiatry2008;2(Suppl 1):A127. [CSzG: Ref19115] StainH , BucciS , HalperinS , EmsleyR , ShallU , LewinT , et al. DEPTh: randomised controlled trial of cognitive behavioral therapy for young people at ultra high risk for psychosis. Early Intervention in Psychiatry2014;8:15. [CSzG: Ref29673] StainHJ , BucciS , BakerA , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of CBT for young people at risk for psychosis: the Detection and Evaluation of Psychological Therapy (DEPTh) trial. European Archives of Psychiatry and Clinical Neuroscience2015;1:S8‐9. [CSzG: Ref33810] StainHJ , BucciS , BakerAL , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of cognitive behaviour therapy versus non‐directive reflective listening for young people at ultra high risk of developing psychosis: the detection and evaluation of psychological therapy (DEPTh) trial. Schizophrenia Research2016;176(2‐3):212‐9. [CSzG: Ref35298] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. Rural and urban youth at ultra high risk for psychosis: baseline characteristics from the DEPTh randomised controlled trial of cognitive behavior therapy. Schizophrenia Bulletin2011;37:322. [CSzG: Ref22815] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy for youth at ultra high risk for psychosis: baseline characteristics for rural and urban youth. Australian and New Zealand Journal of Psychiatry2010:25‐6. [CSzG: Ref21845] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy targeting ultra high risk for psychosis: baseline comparisons for rural and urban youth. Early Intervention in Psychiatry2010;4(Suppl 1):113. [CSzG: Ref23498] StainHJ , StartupM , CarrV , BakerA , SchallU . The DEPTh project: a multisite RCT for youths at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S51‐2. [CSzG: Ref13401] StartupM . The DEPTh project: detection, evaluation, and psychological therapy for health. Australian New Zealand Clinical Trials Registry2006. [CszG: Ref18442] ">DEPTh‐Australia</a>, <a href="./references#CD012236-bbs2-0005" title="ByrneRE , MorrisonAP . Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. Psychology and Psychotherapy2014;87(3):357‐71. [CSzG: Ref29312] FlachC , FrenchP , DunnG , FowlerD , GumleyAI , BirchwoodM , et al. Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE‐2 trial. British Journal of Psychiatry2015;207(2):123‐9. [CSzG: Ref33109] MorrisonA . Early detection and intervention evaluation for individuals at high risk of psychosis 2. http://www.controlled‐trials.com2008. [CSzG: Ref18285] MorrisonA . Early detection and intervention evaluation for people at risk of psychosis (edie‐2): A multisite randomised controlled trial of cognitive therapy for at‐risk mental states. Early Intervention in Psychiatry2012;6:11. [CSzG: Ref24968] MorrisonA , FrenchP , BentallR , LewisS , BirchwoodM , FowlerD , et al. Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. Early Intervention in Psychiatry2008;2(Suppl 1):A15. [CSzG: Ref19128] MorrisonAP . EDIE‐2: early detection and psychological intervention for individuals at high risk of psychosis (2). www.controlled‐trials.com2007. [CSzG: Ref15381] MorrisonAP , BirchwoodM , PyleM , FlachC , StewartSL , ByrneR , et al. Impact of cognitive therapy on internalised stigma in people with at‐risk mental states. British Journal of Psychiatry2013;203(2):140‐5. [CSzG: Ref28630] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ2012;344(7852):e2233. [CSzG: Ref24208] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at‐risk of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29554] MorrisonAP , PyleM , StewartSL , FrenchP , ByrneR , FlachC , et al. Internalised stigma in young people at high risk of developing psychosis: findings from a cognitive therapy trial. Schizophrenia Research2014;153:S42. [CSzG: Ref29555] MorrisonAP , StewartSL , FrenchP , BentallRP , BirchwoodM , ByrneR , et al. Early detection and intervention evaluation for people at high‐risk of psychosis‐2 (EDIE‐2): trial rationale, design and baseline characteristics. Early Intervention in Psychiatry2011;5(1):24‐32. [CSzG: Ref22695] MorrisonT . Early detection and psychological intervention for individuals at high risk of psychosis. EDIE‐2. Data on File2006. [CSzG: Ref13874] PelosiAJ . Rational policy making for early psychosis might yet become possible. BMJ2012;344(7856):e3137. [CSzG: Ref24326] PyleM , StewartSL , FrenchP , ByrneR , PattersonP , GumleyA , et al. Internalised stigma, emotional dysfunction and unusual experiences in young people at risk of psychosis. Early Intervention in Psychiatry2015;9(2):133‐40. [CSzG: Ref29813] ">EDIE‐2‐UK</a>, <a href="./references#CD012236-bbs2-0008" title="McFarlaneWR , CookWL , WoodberryKA . A randomised clinical trial of familyaided assertive community treatment for young persons at high risk for onset of an initial psychosis. Schizophrenia Bulletin2011;37:314. [CSzG: Ref22796] NCT01597141 . Psychosis: early detection, intervention and prevention. ClinicalTrials.gov/show/NCT015971412012. [CSzG: Ref24315] ">EDIP‐USA</a>, <a href="./references#CD012236-bbs2-0011" title="BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: 12511] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] RuhrmannS , BechdolfA , KuhnKU , WagnerM , Schultze‐LutterF Janssen B , et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry. Supplements2007;51:s88‐95. [CSzG: 16127] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Acute symptomatic treatment effects in persons clinically at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13397] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Intervention in the late initial prodromal state (LIPS) of psychosis. Schizophrenia Research2006;86(Suppl 1):S96. [CSzG: 13398] ">LIPS‐Germany</a>, <a href="./references#CD012236-bbs2-0012" title="MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Family‐focused therapy for individuals at clinical high risk for psychosis: treatment fidelity within a multisite randomised trial. Early Intervention in Psychiatry2016;10(2):137‐43. [CSzG: 29018] MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Treatment fidelity and differentiation in a randomised controlled trial of family‐focused therapy for youth at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:95. [CSzG: 24965] MiklowitzDJ , O'BrienMP , SchlosserDA , AddingtonJ , CandanKA , MarshallC , et al. Family‐focused treatment for adolescents and young adults at high risk for psychosis: results of a randomised trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(8):848‐58. [CSzG: 29019] NCT01907282 . Prevention trial of family focused treatment in youth at risk for psychosis. Clinicaltrials.gov/show/NCT019072822010. [CSzG: 27965] O'BrienMP , MiklowitzDJ , CandanKA , MarshallC , DominguesI , WalshBC , et al. A randomised trial of family focused therapy with populations at clinical high risk for psychosis: effects on interactional behavior. Journal of Consulting and Clinical Psychology2013;82(1):90‐101. [CSzG: 28565] O'BrienMP , MiklowitzDJ , CannonTD . Decreases in perceived maternal criticism predict improvement in subthreshold psychotic symptoms in a randomised trial of family‐focused therapy for individuals at clinical high risk for psychosis. Journal of Family Psychology2015;29(6):945–951.. [CSzG: 32212] SchlosserDA , MiklowitzDJ , O'BrienMP , DeSilvaSD , ZinbergJL , CannonTD . A randomised trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Intervention in Psychiatry2012;6(3):283‐91. [CSzG: 24491] ">Miklowitz‐USA</a>, <a href="./references#CD012236-bbs2-0015" title="McGorryP . Can the onset of schizophrenia be delayed or prevented?. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S26. [CSzG: 8351] McGorryP , AdlardS , YungA , McDonaldA , PhillipsL , HearnN . Detection and intervention in pre‐psychotic schizophrenia. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4836] McGorryP , YungA , FranceyS , PhillipsL , NelsonB . A blinded, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and befriending in young people at risk of psychotic disorder: baseline characteristics of the sample. Acta Neuropsychiatrica2006;18(6):261. [CSzG: 35157] McGorryPD , HearnN , GermanoD , BravinJ , PhillipsLJ , YungAR , et al. Prepsychotic intervention in schizophrenia: a stitch in time?. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington DC, USA. 1999. [CSzG: 3584] McGorryPD , PhillipsLJ , NelsonB , LeicesterS , BakerK , KrstevH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and befriending in young people with subthreshold symptoms at incipient risk of psychotic disorder: six month outcome data. Schizophrenia Bulletin2007;33(2):446. [CSzG: 15203] McGorryPD , PhillipsLJ , YungAR , FranceyS , GermanoD , BravinJ , et al. A randomised controlled trial of interventions in the pre psychotic phase of psychotic disorders. Schizophrenia Research2000;41(1):9. [CSzG: 5149] McGorryPD , YungAR , PhillipsL , AdlardS , HallgrenM , PattonG , et al. Pre‐psychotic intervention in schizophrenia: a stitch in time?. Schizophrenia Research1998;29(1‐2):160. [CSzG: 3585] McGorryPD , YungAR , PhillipsLJ , YuenHP , FranceyS , CosgraveEM , et al. Randomised controlled trial of interventions designed to reduce the risk of progression to first‐episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry2002;59(10):921‐8. [CSzG: 8576] PhilippsLJ , McGorryP , YungA , FranceyD , GermanoF , BravinJ , et al. The development of preventive interventions for early psychosis: early findings and directions for the future. 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001; Vol. 2, issue Suppl 1. [CSzG: 7614] PhillipsL , CottonS , YuenHP , MihalopoulosC , ShihS , KellyD , et al. Cost effectiveness of a preventive intervention for young people at ultra high risk of developing psychosis. Schizophrenia Bulletin2007;33(2):488‐9. [CSzG: 15227] PhillipsLJ , CottonS , MihalopoulosC , ShihS , YungAR , CarterR , et al. Cost implications of specific and non‐specific treatment for young persons at ultra high risk of developing a first episode of psychosis. Early Intervention in Psychiatry2009;3(1):28‐34. [CSzG: 18308] PhillipsLJ , LeicesterSB , O'DwyerLE , FranceySM , KoutsogiannisJ , Abdel‐BakiA , et al. The PACE clinic: identification and management of young people at &quot;ultra&quot; high risk of psychosis. Journal of Psychiatric Practice2002;8(5):255‐69. [CSzG: 18235] PhillipsLJ , McGorryPD , YuenHP , WardJ , DonovanK , KellyD , et al. Medium term follow‐up of a randomised controlled trial of interventions for young people at ultra high risk of psychosis. Schizophrenia Research2007;96(1‐3):25‐33. [CSzG: 15544] PhillipsLJ , YungAR , YuenHP , PantelisC , McGorryPD . Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. American Journal of Medical Genetics2002;114(8):929‐37. [CSzG: 18236] ">PACE‐Australia</a>, <a href="./references#CD012236-bbs2-0017" title='BlockJJ , McGlashonTH . Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790‐9. American Journal of Psychiatry2006; Vol. 163, issue 10:1838. [CSzG: 13960] BreierAF , ZipurskyRB , PerkinsDO , AddingtonJM , TohenMF , DavidSR , et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951] HawkinsKA , AddingtonJ , KeefeR , ChristensenB , WoodsS , ZipurskyR , et al. Neuropsychological functioning in the first episode prodrome and early psychosis. Schizophrenia Research2004;70(1):101. [CSzG: 11515] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , MillerTJ , et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research2004;67(1):205. [CSzG: Ref11301] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , ZipurskyRB , et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. [CSzG: 16470] HawkinsKA , KeefeRS , ChristensenBK , AddingtonJ , WoodsSW , CallahanJ , et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. Schizophrenia Research2008;105(1‐3):1‐9. [CSzG: 16983] HoffmanRE , WoodsS , PredaA , TohenM , BreierA , GlistJ , et al. Excessive top‐down perceptual processing and reduced real‐world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. Schizophrenia Research2006;86(Suppl 1):S46. [CSzG: 13377] HoffmanRE , WoodsSW , HawkinsKA , PittmanB , TohenM , PredaA , et al. Extracting spurious messages from noise and risk of schizophrenia‐spectrum disorders in prodromal population. British Journal of Psychiatry2007;191(2):355‐6. [CSzG: 16068] McGlashanT , ZipurskyR , PerkinsD , AddingtonJ . Olanzapine for treatment of the schizophrenia prodrome: 2‐year results of a randomised placebo‐controlled study. Schizophrenia Research2004;67(1):164. [CSzG: 11320] McGlashanTH . Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. [CSzG: 10191] McGlashanTH . Treatment intervention in the New Haven PRIME clinic prodromal sample. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4835] McGlashanTH , MillerTJ , WoodsSW . Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research2002;53(3 Suppl 1):15. [CSzG: 8093] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005] McGlashanTH , MillerTJ , ZipurskyRB , WoodsSW , PerkinsDO , HawkinsKA , et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9803] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerT , WoodsSW , et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry2006;163(5):790‐9. [CSzG: 12654] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerTJ , WoodsSW , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research2003;61(1):7‐18. [CSzG: 9828] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJ , WoodsSW , MillerTJ , et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research2003;60:295. [CSzG: 9722] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJM , WoodsSW , LindborgS , et al. Olanzapine versus pbo for the schizophrenic prodrome: one‐year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9804] McGlashlanTH , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTH , WoodsSW , et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:42. [CSzG: 8934] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , MillerT , WoodsS , et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. Schizophrenia Research2004;70(1):6. [CSzG: 11524] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , WoodsS , MillerT , et al. Olanzapine vs. placebo for prodromal schizophrenia. Schizophrenia Research2004;67(1):6. [CSzG: 11321] MillerTJ , ZipurskyRB , PerkinsD , AddingtonJ , WoodsSW , HawkinsKA , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research2003;61(1):19‐30. [CSzG: 9829] RosenJL , WoodsSW , MillerTJ , McGlashanTH . Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease2002;190:133‐41. [CSzG: 8274] TaylorHE , ParkerS , MansellW , MorrisonAP . Effects of appraisals of anomalous experience on distress in people at risk of psychosis. Behavioural and Cognitive Psychotherapy2012;41(1):24‐33. [CSzG: 24374] WoodsS , ZipurskyR , PerkinsD , AddingtonJ , MarquezE , BreierA , et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:43. [CSzG: 8933] WoodsSW . Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):497. [CSzG: 19829] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research. 2003. [CSzG: 9978] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research2003;60:306‐7. [CSzG: 9752] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):453‐64. [CSzG: 9994] WoodsSW , McGlashanTH . Sample size planning for prodromal intervention trials. Schizophrenia Research2002;53(3 Suppl 1):40. [CSzG: 8116] WoodsSW , ZipurskyRB , PerkinsDO , AddingtonJM , MillerTJ , BreierAF , et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053] '>PRIME‐USA</a> and <a href="./references#CD012236-bbs2-0020" title="McGorryP . Second generation intervention research in the pre‐psychotic phase of illness in schizophrenia and related psychoses. Australian New Zealand Clinical Trials Registry2000. [CSzG: 18439] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceyS , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: 12‐month outcome. Schizophrenia Research2012;136:S17‐8. [CSzG: 29547] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceySM , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: twelve‐month outcome. Journal of Clinical Psychiatry2013;74(4):349‐56. [CSzG: 28737] NelsonB , PhillipsLJ , YungAR , FranceySM , LeicesterS , BakerK , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and supportive therapy in young people with subthreshold symptoms at incipient risk of psychotic disorder: baseline characteristics of the sample. Schizophrenia Bulletin2007;33(2):450. [CSzG: 15212] PhillipsLJ , NelsonB , YuenHP , FranceySM , SimmonsM , StanfordC , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: study design and baseline characteristics. Australian and New Zealand Journal of Psychiatry2009;;43(9):818–29. YungA , AmmingerP , BergerG , ThompsomA , PhillipsL , NelsonB , et al. Randomised controlled trial of antipsychotic and cognitive therapy in young people at ultra‐high risk of psychosis. Early Intervention in Psychiatry2012;6:11. [CSzG: 24989] YungA , NelsonB , PhillipsL , FranceyS , LeicesterS , YuenH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and supportive therapy in young people at ultra high risk of psychotic disorder: 12 month outcome data. Early Intervention in Psychiatry2008;2(Suppl 1):A12. [CSzG: 19138] YungAR , PhillipsLJ , NelsonB , FranceySM , YuenHP , SimmonsMB , et al. Randomised controlled trial of interventions for young people at ultra high risk for psychosis: 6‐month analysis. Journal of Clinical Psychiatry2011;72(4):430‐40. [CSzG: 22929] ">Yung‐Australia</a> reported data from this scale. </p> <p>b. The Global Functioning: Social and Role scales (<a href="./references#CD012236-bbs2-0106" title="CornblattBA , AutherAM , NiendamT , SmithCH , ZinbergJ , BeardenCE , et al. Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophrenia Bulletin2007;33(3):688‐702. ">Cornblatt 2007b</a>) </p> <p>The Global Functioning: Social (GFS) and Global Functioning: Role (GFR) scales were designed to distinguish social from role functioning and to detect functional changes over time, taking account the age and the phase of illness. Each scale consists of 10 items, with scores ranging between 1 (severe dysfunction) and 10 (superior functioning). Also, both scales generate three scores: lowest level of functioning in the past month (i.e. current functioning), and lowest and highest level of functioning reported over the past year. <a href="./references#CD012236-bbs2-0012" title="MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Family‐focused therapy for individuals at clinical high risk for psychosis: treatment fidelity within a multisite randomised trial. Early Intervention in Psychiatry2016;10(2):137‐43. [CSzG: 29018] MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Treatment fidelity and differentiation in a randomised controlled trial of family‐focused therapy for youth at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:95. [CSzG: 24965] MiklowitzDJ , O'BrienMP , SchlosserDA , AddingtonJ , CandanKA , MarshallC , et al. Family‐focused treatment for adolescents and young adults at high risk for psychosis: results of a randomised trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(8):848‐58. [CSzG: 29019] NCT01907282 . Prevention trial of family focused treatment in youth at risk for psychosis. Clinicaltrials.gov/show/NCT019072822010. [CSzG: 27965] O'BrienMP , MiklowitzDJ , CandanKA , MarshallC , DominguesI , WalshBC , et al. A randomised trial of family focused therapy with populations at clinical high risk for psychosis: effects on interactional behavior. Journal of Consulting and Clinical Psychology2013;82(1):90‐101. [CSzG: 28565] O'BrienMP , MiklowitzDJ , CannonTD . Decreases in perceived maternal criticism predict improvement in subthreshold psychotic symptoms in a randomised trial of family‐focused therapy for individuals at clinical high risk for psychosis. Journal of Family Psychology2015;29(6):945–951.. [CSzG: 32212] SchlosserDA , MiklowitzDJ , O'BrienMP , DeSilvaSD , ZinbergJL , CannonTD . A randomised trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Intervention in Psychiatry2012;6(3):283‐91. [CSzG: 24491] ">Miklowitz‐USA</a>, <a href="./references#CD012236-bbs2-0013" title="ACTRN12608000475347 . A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder. Australian New Zealand Clinical Trials Registry2009. [CSzG: 18420] HKCTR‐1438 . The NEURAPRO‐E (North America, EURope, Australia PROdrome) Study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for symptomatic patients at ultra‐high risk for early progression to schizophrenia and other psychotic disorders. www.hkClinicaltrials.com/trial_details.aspx?trialID=d09bd177‐b9fd‐4162‐b04f‐3ebfed49baa32011. [CSzG: 29270] McGorryP , MarkulevC , NelsonB , YuenHP , SchaeferM , YungAR , et al. The NEURAPRO‐E study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Schizophrenia Bulletin2015;41:S322‐3. [CSzG: 29546] McGorryPD , NelsonB , MarkulevC , YuenHP , SchaferMR , MossahebN , et al. Effect of omega‐3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomised clinical trial. JAMA psychiatry2017;74(1):19‐27. [CSzG: 35590] NelsonB , AmmingerG , MarkulevC , YuenHP , LavoieS , SchaeferM , et al. NEURAPOR: a multi‐center RCT of omega‐3 polyunsaturated fatty acids versus placebo in young people at ultra‐high risk of psychotic disorders: medium‐term outcome. Schizophrenia Bulletin2017;43:S107. [CSzG: 36016] ">NEURAPRO‐AAE</a>, <a href="./references#CD012236-bbs2-0016" title="NCT01619319 . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. ClinicalTrials.gov/show/NCT016193192012. [CSzG: 24387] PiskulicD , BarbatoM , AddingtonJ . Cognitive remediation in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:89. [CSzG: 24973] PiskulicD , BarbatoM , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2012;136:S245‐6. [CSzG: 29632] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2014;153(Suppl. 1):S218. [CSzG: 28827] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation therapy on cognition in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2014;8:86. [CSzG: 29633] ">Piskulic‐Canada</a> and <a href="./references#CD012236-bbs2-0018" title="LoewyR , FisherM , MathalonDH , VinogradovS . Interim analyses of a randomised controlled trial of computerised cognitive training in clinical high risk for psychosis. Schizophrenia Bulletin2013;39:S238‐9. [CSzG: 28151] LoewyR , FisherM , SchlosserDA , BiagiantiB , StuartB , MathalonDH , et al. Intensive auditory cognitive training improves verbal memory in adolescents and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2016;42(Suppl 1):S118‐26. [CSzG: 35221] VinogradovS , LoewyR , FisherM , LeeA , NiendamT , RaglandJD , et al. Neuroplasticity‐based cognitive training in ultra‐high risk adolescents and recent onset patients with schizophrenia. Schizophrenia Research2012;136:S30. [CSzG: 29703] ">Vinogradov‐USA</a> reported data from these scales. </p> <p>c. Social Functioning Scale‐II (SAS‐II; <a href="./references#CD012236-bbs2-0173" title="SchoolerN , HogartyG , WeissmanMM . Social Adjustment Scale II (SAS II). In: HargreavesWA , AttkissonCC , SorensonJE editor(s). Resource Materials for Community Mental Health Program Evaluators, publication No. (ADM) 79‐328. US Department of Health, Education, and Welfare, 1979:290‐330. ">Schooler 1979</a>) </p> <p>The SAS‐II is an interviewer‐rated scale containing 52 questions for assessment of current functioning: work role; relationship with a "principal household member"; sexual adjustment; romantic involvement; parental role; extended family relationships; social leisure activities; and personal well‐being. Each item is rated from 1 to 5, with higher scores indicating worse functioning. <a href="./references#CD012236-bbs2-0009" title="BechdolfA . Preventing progression to first‐episode psychosis in people in the early initial prodromal state. Early Intervention in Psychiatry2012;6:11. [CSzG: 24944] BechdolfA , BuhlerB , BerningJ , WagnerM , StammE , StreitM . Cognitive behavioural therapy in the early initial prodromal state of psychosis: first results. Schizophrenia Research2004;67(1):202. [CSzG: Ref11285] BechdolfA , KlosterkotterJ . Cognitive‐behavioural treatment (CBT) in the early initial prodromal state of psychosis: concept and practical approach. Schizophrenia Research2004;70(1):52. [CSzG: Ref11506] BechdolfA , RuhrmannS , JanssenB , BottlenderR , WagnerM , MaurerK , et al. Early recognition and intervention for people at risk of schizophrenia [Fruherkennung und intervention bei personen mit erhohtem psychoserisiko]. Psychoneuroendocrinology2004;30(11):606‐14. [CSzG: Ref11376] BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: Ref12511] BechdolfA , VeithV , BerningJ , StammE , DeckerP , JanssenB , et al. Cognitive behavioral therapy (CBT) in the early initial prodromal state of psychosis: first results of a randomised trial. Schizophrenia Research2004;70(1):62‐3. [CSzG: Ref11507] BechdolfA , WagnerM , RuhrmannS , HarriganS , PutzfeldV , PukropR , et al. Preventing progression to first‐episode psychosis in early initial prodromal states. British Journal of Psychiatry2012;200(1):22‐9. [CSzG: Ref24206] BechdolfA , WagnerM , RuhrmannS , HarriganS , VeithV , PukropR , et al. CBT for prevention of first episode psychosis in people in an putative early initial prodromal state. Early Intervention in Psychiatry2008;2(Suppl 1):A16. [CSzG: 19109] BechdolfA , WagnerM , VeithV , PukropR , BerningJ , StammE , et al. A randomised controlled trial of cognitive‐behavioral therapy in the early initial prodromal state of psychosis. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:22‐3. [CSzG: 20193] BechdolfA , WagnerM , VeithV , RuhrmannR , JanssenB , BottlenderR , et al. A randomised controlled multicenter trial of cognitive behaviour therapy in the early initial prodromal state of psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13369] BechdolfA , WagnerM , VeithV , RuhrmannS , PukropR , Brockhaus‐DumkeA , et al. Randomised controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Intervention in Psychiatry2007;1(1):71‐8. [CSzG: 16450] BechdolfA , WesselsH , WagnerM , KuhrK , BerningJ , PutzfeldV , et al. Predictors of treatment response to psychosocial interventions in people at risk. European Archives of Psychiatry and Clinical Neuroscience2015;1:S9. [CSzG: 33601] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] KommescherM , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. Early Intervention in Psychiatry2016;10(1):17‐27. [CSzG: 32187] NCT00204087 . Psychological intervention for persons at risk of psychosis in the early initial prodromal state. www.ClinicalTrials.gov/ct/show/2005. [CSzG: 14890] WesselsH , WagnerM , FrommannI , BerningJ , PutzfeldV , JanssenB , et al. Neuropsychological functioning as a predictor of treatment response to psychoeducational, cognitive behavioral therapy in people at clinical high risk of first episode psychosis. Psychiatrische Praxis2015;42(6):313‐9. [CSzG: 33130] ZarafonitisS , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Psychoeducation for persons at risk of psychosis. Psychotherapeut2012;57(4):326‐34. [CSzG: 24807] ">EIPS‐Germany</a> reported data from this scale (for subscores, please see <a href="./appendices#CD012236-sec-0531">Appendix 1</a>). </p> <p>d. Social Functioning Scale‐Self report (SAS‐SR; <a href="./references#CD012236-bbs2-0187" title="WeissmanMM , BothwellS . Assessment of social adjustment by patient self report. Archives of General Psychiatry1976;33:1111–15. ">Weissman 1976</a>) </p> <p>SAS‐SR is self‐administered version of the Social Adjustment Scale (SAS; <a href="./references#CD012236-bbs2-0187" title="WeissmanMM , BothwellS . Assessment of social adjustment by patient self report. Archives of General Psychiatry1976;33:1111–15. ">Weissman 1976</a>), commonly used to assess social adjustment in children and adolescents. It contains 54 items that measure performance in occupational role, social and leisure activities, relationship with extended family, marital role, parental role, family unit, and economic independence. The form is scored on a five‐point scale, higher scores indicating greater impairment. <a href="./references#CD012236-bbs2-0003" title="ChoiJ , CorcoranC , DixonL , FiszdonJ , JavittD . Processing speed training and social functioning in young adults at clinical high risk for psychosis: a pilot study. Early Intervention in Psychiatry2014;8:109. [CSzG: Ref29417] ChoiJ , CorcoranC , DixonL , JavittDC . Processing speed training and social functioning in teenagers and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2015;41:S41. [CSzG: Ref29418] ChoiJ , CorcoranCM , FiszdonJM , StevensM , JavittDC , DeasyM , et al. Pupillometer‐based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis. Psychiatric Rehabilitation Journal2017;40(1):33‐42. [CSzG: Ref35317] ">Choi‐USA</a> reported data from this scale. </p> <p>e. Social and Occupational Functioning Assessment Scale (SOFAS; <a href="./references#CD012236-bbs2-0129" title="GoldmanHH , SkodolAE , LaveTR . Revising axis V for DSM‐ IV: a review of measures of social functioning. American Journal of Psychiatry1992;149(9):1148‐56. ">Goldman 1992</a>) </p> <p>The SOFAS is an instrument for assessment of social or occupational functioning, or both, independent of the overall severity of the illness. To be counted, impairment must be a direct consequence of mental and physical health problems. The rating scores range from 0 (inadequate information) to 100 (superior functioning). <a href="./references#CD012236-bbs2-0004" title="CrittendenK , FlemingJ , StartupM , CarrV , BakerA , SchallU , et al. Recruitment and engagement of youth in an ultra high risk treatment study. Early Intervention in Psychiatry2008;2(Suppl 1):A127. [CSzG: Ref19115] StainH , BucciS , HalperinS , EmsleyR , ShallU , LewinT , et al. DEPTh: randomised controlled trial of cognitive behavioral therapy for young people at ultra high risk for psychosis. Early Intervention in Psychiatry2014;8:15. [CSzG: Ref29673] StainHJ , BucciS , BakerA , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of CBT for young people at risk for psychosis: the Detection and Evaluation of Psychological Therapy (DEPTh) trial. European Archives of Psychiatry and Clinical Neuroscience2015;1:S8‐9. [CSzG: Ref33810] StainHJ , BucciS , BakerAL , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of cognitive behaviour therapy versus non‐directive reflective listening for young people at ultra high risk of developing psychosis: the detection and evaluation of psychological therapy (DEPTh) trial. Schizophrenia Research2016;176(2‐3):212‐9. [CSzG: Ref35298] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. Rural and urban youth at ultra high risk for psychosis: baseline characteristics from the DEPTh randomised controlled trial of cognitive behavior therapy. Schizophrenia Bulletin2011;37:322. [CSzG: Ref22815] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy for youth at ultra high risk for psychosis: baseline characteristics for rural and urban youth. Australian and New Zealand Journal of Psychiatry2010:25‐6. [CSzG: Ref21845] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy targeting ultra high risk for psychosis: baseline comparisons for rural and urban youth. Early Intervention in Psychiatry2010;4(Suppl 1):113. [CSzG: Ref23498] StainHJ , StartupM , CarrV , BakerA , SchallU . The DEPTh project: a multisite RCT for youths at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S51‐2. [CSzG: Ref13401] StartupM . The DEPTh project: detection, evaluation, and psychological therapy for health. Australian New Zealand Clinical Trials Registry2006. [CszG: Ref18442] ">DEPTh‐Australia</a>, <a href="./references#CD012236-bbs2-0006" title="DragtS , Van derGaagM . Prevention of psychosis with a cognitive behavioural intervention in help‐seeking young people with an at risk mental state for developing psychosis. www.trialregister.nl/trialreg/index.asp2007. [CSzG: Ref19655] IsingHK , KraanTC , RietdijkJ , DragtS , KlaassenRM , BoonstraN , et al. Four‐year follow‐up of cognitive behavioral therapy in persons at ultra‐high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2016;42(5):1243‐52. [CSzG: Ref35214] IsingHK , LokkerbolJ , RietdijkJ , DragtS , KlaassenRM , KraanT , et al. Four‐year cost‐effectiveness of cognitive behavior therapy for preventing first‐episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2017;43(2):365‐74. [CSzG: Ref35824] IsingHK , SmitF , VelingW , RietdijkJ , DragtS , KlaassenRM , et al. Cost‐effectiveness of preventing first‐episode psychosis in ultra‐high‐risk subjects: multi‐centre randomised controlled trial. Psychological Medicine2015;45(7):1435‐46. [CSzG: Ref27798] KraanTC , IsingHK , FokkemaM , VelthorstE , Van denBergDP , KerkhovenM , et al. The effect of childhood adversity on 4‐year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE‐NL) Trial. Psychiatry Research2017;247:55‐62. [CSzG: Ref35559] NiemanDH , RuhrmannS , RietdijkJ , DragtS , IsingH , KlaassenR , et al. Preventive psychotherapy. Schizophrenia Research2014;153:S42‐3. [CSzG: Ref29601] RietdijkJ , DragtS , KlaassenR , IsingH , NiemanD , WunderinkL , et al. A single blind randomised controlled trial of cognitive behavioural therapy in a help‐seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE‐NL) trial. Trials2010;11:30. [CSzG: Ref20654] Van DerGaagM . The effects of CBT in personswith ultra high risk: the Dutch EDIE trial. European Archives of Psychiatry and Clinical Neuroscience2011;261:S18. [CSzG: Ref23756] Van DerGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first‐episode of psychosis. Early Intervention in Psychiatry2012;6:12. [CSzG: Ref24985] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomised controlled clinical trial. Schizophrenia Bulletin2012;38(6):1180‐8. [CSzG: Ref24935] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. The effects of cognitive behavioural therapy for subjects at ultra‐high risk for developing psychosis. Schizophrenia Bulletin2013;39:S356. [CSzG: Ref28121] Van derGaagM . The prevention of psychosis in at risk mental state. www.controlled‐trials.com2008. [CSzG: Ref17488] Van derGaagM , NiemanD , Van denBergD . CBT for those at risk of a first episode psychosis: Evidence‐based psychotherapy for people with an 'at risk mental state'. 1st Edition. Hove, UK: Routledge, 2013. Van derGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first episode of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29692] ">EDIE‐NL</a> and <a href="./references#CD012236-bbs2-0013" title="ACTRN12608000475347 . A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder. Australian New Zealand Clinical Trials Registry2009. [CSzG: 18420] HKCTR‐1438 . The NEURAPRO‐E (North America, EURope, Australia PROdrome) Study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for symptomatic patients at ultra‐high risk for early progression to schizophrenia and other psychotic disorders. www.hkClinicaltrials.com/trial_details.aspx?trialID=d09bd177‐b9fd‐4162‐b04f‐3ebfed49baa32011. [CSzG: 29270] McGorryP , MarkulevC , NelsonB , YuenHP , SchaeferM , YungAR , et al. The NEURAPRO‐E study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Schizophrenia Bulletin2015;41:S322‐3. [CSzG: 29546] McGorryPD , NelsonB , MarkulevC , YuenHP , SchaferMR , MossahebN , et al. Effect of omega‐3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomised clinical trial. JAMA psychiatry2017;74(1):19‐27. [CSzG: 35590] NelsonB , AmmingerG , MarkulevC , YuenHP , LavoieS , SchaeferM , et al. NEURAPOR: a multi‐center RCT of omega‐3 polyunsaturated fatty acids versus placebo in young people at ultra‐high risk of psychotic disorders: medium‐term outcome. Schizophrenia Bulletin2017;43:S107. [CSzG: 36016] ">NEURAPRO‐AAE</a> reported data from this scale. </p> <p>f. The Social Functioning Scale (SFS; <a href="./references#CD012236-bbs2-0094" title="BirchwoodM , SmithJ , CochraneR , WettonS , CopestakeS . The Social Functioning Scale: the development and validation of a new scale adjustment for use in family intervention programmes with schizophrenic patients. British Journal of Psychiatry1990;157:853–9. ">Birchwood 1990</a>). </p> <p>Social Functioning Scale, SFS is a 79‐item questionnaire, developed for assessing functioning and performance in seven areas: social engagement/withdrawal (time spent alone, initiation of conversations, social avoidance); interpersonal communication (number of friends, heterosexual contact, quality of communication); recreational activities (engagement in a range of common social activities, e.g. sport); social activities (engagement in a range of common hobbies, interests, pastimes etc.); independence competence (ability to perform skills necessary for independent living); independence performance (performance of skills necessary for independent living); and occupational activity (engagement in productive employment or structured programme of daily activity). Total score ranges between 55 and 145 points, with higher scores indicating better functioning. <a href="./references#CD012236-bbs2-0001" title="AddingtonJ , EpsteinI , LiuL , FrenchP , BoydellKM , ZipurskyRB . A randomised controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research2011;125(1):54‐61. [CSzG: Ref21945] AddingtonJ , ZipurskyR , EpsteinI . ADAPT (Access, Detection and Psychological Treatments). Schizophrenia Research2006;86(Suppl 1):S6. [CSzG: Ref13364] NCT00260273 . Access, detection and psychological treatments. www.ClinicalTrials.gov/ct/show/2005. [CSzG: Ref14638] ">ADAPT‐Canada</a> reported data from this scale. </p> </section> <section id="CD012236-sec-0148"> <p><b>6.2.4 Adverse effects</b></p> <p>a. Simpson Angus Scale (SAS; <a href="./references#CD012236-bbs2-0176" title="SimpsonGM , AngusJW . A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica1970;212:11‐19. ">Simpson 1970</a>) </p> <p>The SAS is a 10‐item scale used to evaluate the presence and severity of extrapyramidal side effects. The items are gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella tap, tremor and salivation. The 10 items focus on rigidity rather than bradykinesia and do not assess subjective rigidity or slowness. Each item is rated on a five‐point scale, from 0 (complete absence of condition) to 4 (presence of condition in extreme), higher scores indicating higher levels of side effects. <a href="./references#CD012236-bbs2-0017" title='BlockJJ , McGlashonTH . Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790‐9. American Journal of Psychiatry2006; Vol. 163, issue 10:1838. [CSzG: 13960] BreierAF , ZipurskyRB , PerkinsDO , AddingtonJM , TohenMF , DavidSR , et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951] HawkinsKA , AddingtonJ , KeefeR , ChristensenB , WoodsS , ZipurskyR , et al. Neuropsychological functioning in the first episode prodrome and early psychosis. Schizophrenia Research2004;70(1):101. [CSzG: 11515] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , MillerTJ , et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research2004;67(1):205. [CSzG: Ref11301] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , ZipurskyRB , et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. [CSzG: 16470] HawkinsKA , KeefeRS , ChristensenBK , AddingtonJ , WoodsSW , CallahanJ , et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. Schizophrenia Research2008;105(1‐3):1‐9. [CSzG: 16983] HoffmanRE , WoodsS , PredaA , TohenM , BreierA , GlistJ , et al. Excessive top‐down perceptual processing and reduced real‐world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. Schizophrenia Research2006;86(Suppl 1):S46. [CSzG: 13377] HoffmanRE , WoodsSW , HawkinsKA , PittmanB , TohenM , PredaA , et al. Extracting spurious messages from noise and risk of schizophrenia‐spectrum disorders in prodromal population. British Journal of Psychiatry2007;191(2):355‐6. [CSzG: 16068] McGlashanT , ZipurskyR , PerkinsD , AddingtonJ . Olanzapine for treatment of the schizophrenia prodrome: 2‐year results of a randomised placebo‐controlled study. Schizophrenia Research2004;67(1):164. [CSzG: 11320] McGlashanTH . Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. [CSzG: 10191] McGlashanTH . Treatment intervention in the New Haven PRIME clinic prodromal sample. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4835] McGlashanTH , MillerTJ , WoodsSW . Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research2002;53(3 Suppl 1):15. [CSzG: 8093] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005] McGlashanTH , MillerTJ , ZipurskyRB , WoodsSW , PerkinsDO , HawkinsKA , et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9803] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerT , WoodsSW , et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry2006;163(5):790‐9. [CSzG: 12654] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerTJ , WoodsSW , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research2003;61(1):7‐18. [CSzG: 9828] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJ , WoodsSW , MillerTJ , et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research2003;60:295. [CSzG: 9722] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJM , WoodsSW , LindborgS , et al. Olanzapine versus pbo for the schizophrenic prodrome: one‐year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9804] McGlashlanTH , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTH , WoodsSW , et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:42. [CSzG: 8934] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , MillerT , WoodsS , et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. Schizophrenia Research2004;70(1):6. [CSzG: 11524] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , WoodsS , MillerT , et al. Olanzapine vs. placebo for prodromal schizophrenia. Schizophrenia Research2004;67(1):6. [CSzG: 11321] MillerTJ , ZipurskyRB , PerkinsD , AddingtonJ , WoodsSW , HawkinsKA , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research2003;61(1):19‐30. [CSzG: 9829] RosenJL , WoodsSW , MillerTJ , McGlashanTH . Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease2002;190:133‐41. [CSzG: 8274] TaylorHE , ParkerS , MansellW , MorrisonAP . Effects of appraisals of anomalous experience on distress in people at risk of psychosis. Behavioural and Cognitive Psychotherapy2012;41(1):24‐33. [CSzG: 24374] WoodsS , ZipurskyR , PerkinsD , AddingtonJ , MarquezE , BreierA , et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:43. [CSzG: 8933] WoodsSW . Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):497. [CSzG: 19829] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research. 2003. [CSzG: 9978] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research2003;60:306‐7. [CSzG: 9752] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):453‐64. [CSzG: 9994] WoodsSW , McGlashanTH . Sample size planning for prodromal intervention trials. Schizophrenia Research2002;53(3 Suppl 1):40. [CSzG: 8116] WoodsSW , ZipurskyRB , PerkinsDO , AddingtonJM , MillerTJ , BreierAF , et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053] '>PRIME‐USA</a> reported data from this scale. </p> <p>b. Barnes Akathisia Rating Scale (BAS; <a href="./references#CD012236-bbs2-0089" title="BarnesTR . A rating scale for drug‐induced akathisia. British Journal of Psychiatry1989;154:672–6. ">Barnes 1989</a>) </p> <p>BAS is a four‐item scale to assess the presence and severity of drug‐induced movement disorder akathisia. Items include restless movements, the subjective awareness of restlessness, distress associated with the condition, and the global severity. Three items are rated on a four‐point scale and one on a six‐point scale, higher scores meaning more severe‐level akathisia. <a href="./references#CD012236-bbs2-0017" title='BlockJJ , McGlashonTH . Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790‐9. American Journal of Psychiatry2006; Vol. 163, issue 10:1838. [CSzG: 13960] BreierAF , ZipurskyRB , PerkinsDO , AddingtonJM , TohenMF , DavidSR , et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951] HawkinsKA , AddingtonJ , KeefeR , ChristensenB , WoodsS , ZipurskyR , et al. Neuropsychological functioning in the first episode prodrome and early psychosis. Schizophrenia Research2004;70(1):101. [CSzG: 11515] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , MillerTJ , et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research2004;67(1):205. [CSzG: Ref11301] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , ZipurskyRB , et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. [CSzG: 16470] HawkinsKA , KeefeRS , ChristensenBK , AddingtonJ , WoodsSW , CallahanJ , et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. Schizophrenia Research2008;105(1‐3):1‐9. [CSzG: 16983] HoffmanRE , WoodsS , PredaA , TohenM , BreierA , GlistJ , et al. Excessive top‐down perceptual processing and reduced real‐world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. Schizophrenia Research2006;86(Suppl 1):S46. [CSzG: 13377] HoffmanRE , WoodsSW , HawkinsKA , PittmanB , TohenM , PredaA , et al. Extracting spurious messages from noise and risk of schizophrenia‐spectrum disorders in prodromal population. British Journal of Psychiatry2007;191(2):355‐6. [CSzG: 16068] McGlashanT , ZipurskyR , PerkinsD , AddingtonJ . Olanzapine for treatment of the schizophrenia prodrome: 2‐year results of a randomised placebo‐controlled study. Schizophrenia Research2004;67(1):164. [CSzG: 11320] McGlashanTH . Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. [CSzG: 10191] McGlashanTH . Treatment intervention in the New Haven PRIME clinic prodromal sample. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4835] McGlashanTH , MillerTJ , WoodsSW . Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research2002;53(3 Suppl 1):15. [CSzG: 8093] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005] McGlashanTH , MillerTJ , ZipurskyRB , WoodsSW , PerkinsDO , HawkinsKA , et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9803] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerT , WoodsSW , et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry2006;163(5):790‐9. [CSzG: 12654] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerTJ , WoodsSW , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research2003;61(1):7‐18. [CSzG: 9828] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJ , WoodsSW , MillerTJ , et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research2003;60:295. [CSzG: 9722] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJM , WoodsSW , LindborgS , et al. Olanzapine versus pbo for the schizophrenic prodrome: one‐year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9804] McGlashlanTH , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTH , WoodsSW , et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:42. [CSzG: 8934] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , MillerT , WoodsS , et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. Schizophrenia Research2004;70(1):6. [CSzG: 11524] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , WoodsS , MillerT , et al. Olanzapine vs. placebo for prodromal schizophrenia. Schizophrenia Research2004;67(1):6. [CSzG: 11321] MillerTJ , ZipurskyRB , PerkinsD , AddingtonJ , WoodsSW , HawkinsKA , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research2003;61(1):19‐30. [CSzG: 9829] RosenJL , WoodsSW , MillerTJ , McGlashanTH . Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease2002;190:133‐41. [CSzG: 8274] TaylorHE , ParkerS , MansellW , MorrisonAP . Effects of appraisals of anomalous experience on distress in people at risk of psychosis. Behavioural and Cognitive Psychotherapy2012;41(1):24‐33. [CSzG: 24374] WoodsS , ZipurskyR , PerkinsD , AddingtonJ , MarquezE , BreierA , et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:43. [CSzG: 8933] WoodsSW . Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):497. [CSzG: 19829] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research. 2003. [CSzG: 9978] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research2003;60:306‐7. [CSzG: 9752] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):453‐64. [CSzG: 9994] WoodsSW , McGlashanTH . Sample size planning for prodromal intervention trials. Schizophrenia Research2002;53(3 Suppl 1):40. [CSzG: 8116] WoodsSW , ZipurskyRB , PerkinsDO , AddingtonJM , MillerTJ , BreierAF , et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053] '>PRIME‐USA</a> reported data from this scale. </p> <p>c. Abnormal Involuntary Movement Scale (AIMS; <a href="./references#CD012236-bbs2-0133" title="GuyW . ECDEU Assessment Manual for Psychopharmacology (DOTES: Dosage Record and Treatment Emergent Symptom Scale). Rockville: National Institute of Mental Health, 1976. ">Guy 1976b</a>) </p> <p>AIMS is a scale designed to assess abnormal involuntary movements associated with antipsychotic drugs, such as tardive dyskinesia and chronic akathisia, as well as 'spontaneous' motor disturbance related to the illness itself. Scoring consists of rating movement severity in the anatomical areas (facial/oral, extremities, trunk). Each item is rated on a five‐point scale from 0 to 4, with higher scores indicating higher levels of abnormal movements. <a href="./references#CD012236-bbs2-0017" title='BlockJJ , McGlashonTH . Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790‐9. American Journal of Psychiatry2006; Vol. 163, issue 10:1838. [CSzG: 13960] BreierAF , ZipurskyRB , PerkinsDO , AddingtonJM , TohenMF , DavidSR , et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951] HawkinsKA , AddingtonJ , KeefeR , ChristensenB , WoodsS , ZipurskyR , et al. Neuropsychological functioning in the first episode prodrome and early psychosis. Schizophrenia Research2004;70(1):101. [CSzG: 11515] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , MillerTJ , et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research2004;67(1):205. [CSzG: Ref11301] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , ZipurskyRB , et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. [CSzG: 16470] HawkinsKA , KeefeRS , ChristensenBK , AddingtonJ , WoodsSW , CallahanJ , et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. Schizophrenia Research2008;105(1‐3):1‐9. [CSzG: 16983] HoffmanRE , WoodsS , PredaA , TohenM , BreierA , GlistJ , et al. Excessive top‐down perceptual processing and reduced real‐world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. Schizophrenia Research2006;86(Suppl 1):S46. [CSzG: 13377] HoffmanRE , WoodsSW , HawkinsKA , PittmanB , TohenM , PredaA , et al. Extracting spurious messages from noise and risk of schizophrenia‐spectrum disorders in prodromal population. British Journal of Psychiatry2007;191(2):355‐6. [CSzG: 16068] McGlashanT , ZipurskyR , PerkinsD , AddingtonJ . Olanzapine for treatment of the schizophrenia prodrome: 2‐year results of a randomised placebo‐controlled study. Schizophrenia Research2004;67(1):164. [CSzG: 11320] McGlashanTH . Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. [CSzG: 10191] McGlashanTH . Treatment intervention in the New Haven PRIME clinic prodromal sample. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4835] McGlashanTH , MillerTJ , WoodsSW . Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research2002;53(3 Suppl 1):15. [CSzG: 8093] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005] McGlashanTH , MillerTJ , ZipurskyRB , WoodsSW , PerkinsDO , HawkinsKA , et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9803] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerT , WoodsSW , et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry2006;163(5):790‐9. [CSzG: 12654] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerTJ , WoodsSW , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research2003;61(1):7‐18. [CSzG: 9828] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJ , WoodsSW , MillerTJ , et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research2003;60:295. [CSzG: 9722] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJM , WoodsSW , LindborgS , et al. Olanzapine versus pbo for the schizophrenic prodrome: one‐year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9804] McGlashlanTH , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTH , WoodsSW , et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:42. [CSzG: 8934] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , MillerT , WoodsS , et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. Schizophrenia Research2004;70(1):6. [CSzG: 11524] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , WoodsS , MillerT , et al. Olanzapine vs. placebo for prodromal schizophrenia. Schizophrenia Research2004;67(1):6. [CSzG: 11321] MillerTJ , ZipurskyRB , PerkinsD , AddingtonJ , WoodsSW , HawkinsKA , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research2003;61(1):19‐30. [CSzG: 9829] RosenJL , WoodsSW , MillerTJ , McGlashanTH . Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease2002;190:133‐41. [CSzG: 8274] TaylorHE , ParkerS , MansellW , MorrisonAP . Effects of appraisals of anomalous experience on distress in people at risk of psychosis. Behavioural and Cognitive Psychotherapy2012;41(1):24‐33. [CSzG: 24374] WoodsS , ZipurskyR , PerkinsD , AddingtonJ , MarquezE , BreierA , et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:43. [CSzG: 8933] WoodsSW . Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):497. [CSzG: 19829] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research. 2003. [CSzG: 9978] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research2003;60:306‐7. [CSzG: 9752] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):453‐64. [CSzG: 9994] WoodsSW , McGlashanTH . Sample size planning for prodromal intervention trials. Schizophrenia Research2002;53(3 Suppl 1):40. [CSzG: 8116] WoodsSW , ZipurskyRB , PerkinsDO , AddingtonJM , MillerTJ , BreierAF , et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053] '>PRIME‐USA</a> reported data from this scale. </p> <p>d. Extrapyramidal Symptom Rating Scale (ESRS; <a href="./references#CD012236-bbs2-0102" title="ChouinardG , Ross‐ChouinardA , AnnableL , JonesB . The extrapyramidal symptom rating scale. Canadian Journal of Neurological Sciences1980;7(3):233. ">Chouinard 1980</a>) </p> <p>The ESRS consists of four subscales (subjective examination questionnaire, examination of parkinsonism and akathisia, dystonia, dyskinesia) and four clinical global impression severity scales (tardive dyskinesia, parkinsonism, dystonia and akathisia). The subjective examination (subscale I of the ESRS) is rated on a four‐point scale (higher scores meaning more severe symptoms). Tremors, rigidity dystonic and dyskinetic movements are rated for each body part as separate terms on a seven‐point scale from 0 (absent) to 6 (most severe). <a href="./references#CD012236-bbs2-0011" title="BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: 12511] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] RuhrmannS , BechdolfA , KuhnKU , WagnerM , Schultze‐LutterF Janssen B , et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry. Supplements2007;51:s88‐95. [CSzG: 16127] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Acute symptomatic treatment effects in persons clinically at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13397] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Intervention in the late initial prodromal state (LIPS) of psychosis. Schizophrenia Research2006;86(Suppl 1):S96. [CSzG: 13398] ">LIPS‐Germany</a> reported data from this scale. </p> <p>e. Side Effect Rating Scale (UKU; <a href="./references#CD012236-bbs2-0155" title="LingjærdeO , AhlforsUG , BechP , DenckerSJ , ElgenK . The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients. Acta Psychatrica Scandinavica1987;76:Suppl 334. ">Lingjærde 1987</a>) </p> <p>UKU is an observer‐rated, semi‐structured interview for assessment of side effects divided into four categories: psychic, neurologic, autonomic and other. Each of the 48 items is rated on a four‐point scale, from 0 to 3, a higher score meaning more severe side effects. UKU takes into account global assessment of the interference by existing side effects with the patient's daily performance and the consequence of it, as well as possible interactions with administered drugs. <a href="./references#CD012236-bbs2-0002" title="AmmingerG . Ethyl eicosapentanoic acid for prodromal psychosis. Stanley Foundation Research Programs2009. [CSzG: Ref17423] AmmingerG , SchaferM , PapageorgiouK , CottonS , HarriganS , MackinnonA , et al. Indicated prevention with long‐chain omega‐3 fatty acids in adolescents at ultra‐high‐risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2008;2(Suppl 1):A29. [CSzG: Ref19107] AmmingerGP , ChanenAM , OhmannS , KlierCM , MossahebN , BechdolfA , et al. Omega‐3 fatty acid supplementation in adolescents with borderline personality disorder and ultra‐high risk criteria for psychosis: a post hoc subgroup analysis of a double‐blind, randomised controlled trial. Canadian Journal of Psychiatry2013;58(7):402‐8. [CSzG: Ref28534] AmmingerGP , HarrisMS , McGorryPD , HenryLP . Omega‐3 fatty acids for indicated prevention: treatment results and pathomechanisms. European Archives of Psychiatry and Clinical Neuroscience2013;263(Suppl. 1):S44‐5. [CSzG: Ref28434] AmmingerGP , LeicesterS , YungAR , YuenHP , McGorryPD . Age predicts transition to psychosis in an ultra‐high risk sample. Proceedings of the 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:61. AmmingerGP , McGorryPD . Update on omega‐3 polyunsaturated fatty acids in early ‐stage psychotic disorders. Neuropsychopharmacology2012;37(1):309‐10. [CSzG: Ref23726] AmmingerGP , MechelliA , RiceS , KimSW , KlierCM , McNamaraRK , et al. Predictors of treatment response in young people at ultra‐high risk for psychosis who received long‐chain omega‐3 fatty acids. Translational Psychiatry2015;5:e495. [CSzG: Ref29299] AmmingerGP , SchaferMR . Indicated prevention with omega‐3 fatty acids in adolescents at ultra‐high risk for psychosis ‐ rationale, methods, and 3‐months outcome. Schizophrenia Research2006;86(Suppl 1):S97‐8. [CSzG: Ref13367] AmmingerGP , SchaferMR . Is it feasible to conduct a RCT in ultra‐high risk individuals at a child and adolescent psychiatric service?. Schizophrenia Research2006;86(Suppl 1):S98. [CSzG: Ref13368] AmmingerGP , SchaferMR , KlierCM , PapageorgiouK , SlavikJ , HolzerI , et al. Indicated prevention with long‐chain omega‐3 fatty acids in young people at ultra‐high risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2010;4(Suppl 1):7. [CSzG: Ref23467] AmmingerGP , SchaferMR , SchlogelhoferM , KlierCM , McGorryPD . Longer‐term outcome in the prevention of psychotic disorders by the Vienna omega‐3 study. Nature Communications2015;6:7934. [CSzG: Ref33023] AmmingerGP , SchlogelhoferM , KlierC , McGorryP , SchaferM . Longer‐term follow‐up in the Vienna omega‐3 psychosis prevention trial. Early Intervention in Psychiatry2014;8:41. [CSzG: Ref29378] AmmingerGP , SchäferMR , PapageorgiouK , KlierCM , CottonSM , HarriganSM , et al. Long‐chain omega‐3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo‐controlled trial. Archives of General Psychiatry2010;67(2):146‐54. [CSzG: Ref20680; DOI: 10.1001/archgenpsychiatry.2009.192.] AmmingerP , MossahebN , SchlgelhoferM , SchaferM . Fatty acid metabolism and the onset of psychotic disorder. European Psychiatry2011;26(Suppl 1):2089. [CSzG: Ref22967] Anonymous . Fish oil may help ward off psychosis. Journal of Psychosocial Nursing and Mental Health Services2010;48(5):55. [CSzG: Ref20739] BergerG , AmmingerP , McGorryP . Stage dependant effect of omega‐3 fatty acids in emerging psychosis. European Psychiatry2011;26(Suppl 1):1347. [CSzG: Ref22966] BergerGE , ProffittTM , McConchieM , YuenH , WoodSJ , AmmingerGP , et al. Ethyl‐eicosapentaenoic acid in first‐episode psychosis: a randomised, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(12):1867‐75. [CSzG: Ref15561; ISSN: 1555‐2101] EhrlichA . Evidence‐based medicine. Omega‐3 supplementation delays transition to psychotic disorder in ultra‐high‐risk adolescents and young adults. Clinical Advisor for Nurse Practitioners2010;13(5):79‐80. [CSzG: Ref21562] FöckingM , DickerP , LopezLM , CannonM , SchäferMR , McGorryPD , et al. Differential expression of the inflammation marker IL12p40 in the at‐risk mental state for psychosis: a predictor of transition to psychotic disorder?. BMC Psychiatry2016;16(1):326. [DOI: 10.1186/s12888‐016‐1039‐7] KlierC , HollmannM , SchlögelhoferM , MossahebN , FriedrichM , AmmingerPG . Indicated prevention with omega‐3 fatty acids (EPA/DHA) in adolescents with &quot;at‐risk‐mental‐state“ for psychosis. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. [CSzG: Ref12438] LavoieS , BenningerF , FeuchtM , KlierCM , SchaeferMR , AmmingerGP . Correlates of EEG resting states with erythrocyte membrane omega‐3 fatty acid levels and psychopathological symptoms in individuals at ultra‐high risk for psychosis. Early Intervention in Psychiatry2014;8:137. [CSzG: Ref29516] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultra‐high risk individuals who transitioned to psychosis. Schizophrenia Research2012;138(2‐3):206‐11. [CSzG: Ref24256] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultrahigh risk individuals who transitioned to psychosis. Early Intervention in Psychiatry2012;6:38. [CSzG: Ref24960] MossahebN , PapageorgiouK , SchaferMR , BeckerJ , SchloegelhoferM , AmmingerGP . Changes in triglyceride levels in ultra‐high risk for psychosis individuals treated with omega‐3 fatty acids. Early Intervention in Psychiatry2018; Vol. 12, issue 1:30‐36. [DOI: 10.1111/eip.12275] MossahebN , SchaferMR , SchlogelhoferM , KlierCM , CottonSM , McGorryPD , et al. Effect of omega‐3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?. Schizophrenia Research2013;148(1‐3):163‐7. [CSzG: Ref28649] NCT00396643 . Indicated prevention with omega‐3 fatty acids in adolescents with ‘at‐risk‐mental‐state’ for psychosis: a randomised, double blind, placebo‐controlled treatment trial. www.ClinicalTrials.gov/ct/show/2006. [CSzG: Ref14873] PapageorgiouK , SchaferMR , SchlogelhoferM , MossahebN , AmmingerGP . Indicated prevention with omega‐3 fatty acids in young people with 'at‐risk‐mental‐state' for psychosis: design of a 5‐year follow‐up. European Archives of Psychiatry and Clinical Neuroscience2011;261:S55. [CSzG: Ref23749] SchaferMR , KlierCM , PapageorgiouK , FriedrichMH , AmmingerGP . Early detection of psychotic disorders. Neuropsychiatrie2007;21(1):37‐44. [CSzG: Ref15290] SmesnyS , MilleitB , HiplerUC , MilleitC , SchaferMR , KlierCM , et al. Omega‐3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra‐high risk for psychosis. Molecular Psychiatry2013;19(3):317‐24. [CSzG: Ref28243] SmesnyS , MilleitB , SchaeferMR , HesseJ , SchlögelhoferM , LangbeinK , et al. Effects of omega‐3 PUFA on immune markers in adolescent individuals at ultra‐high risk for psychosis ‐ results of the randomised controlled Vienna omega‐3 study. Schizophrenia Research2017;S0920‐9964(17):30039‐7. [DOI: 10.1016/j.schres.2017.01.026] ">Amminger‐Austria</a>, <a href="./references#CD012236-bbs2-0011" title="BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: 12511] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] RuhrmannS , BechdolfA , KuhnKU , WagnerM , Schultze‐LutterF Janssen B , et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry. Supplements2007;51:s88‐95. [CSzG: 16127] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Acute symptomatic treatment effects in persons clinically at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13397] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Intervention in the late initial prodromal state (LIPS) of psychosis. Schizophrenia Research2006;86(Suppl 1):S96. [CSzG: 13398] ">LIPS‐Germany</a> and <a href="./references#CD012236-bbs2-0020" title="McGorryP . Second generation intervention research in the pre‐psychotic phase of illness in schizophrenia and related psychoses. Australian New Zealand Clinical Trials Registry2000. [CSzG: 18439] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceyS , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: 12‐month outcome. Schizophrenia Research2012;136:S17‐8. [CSzG: 29547] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceySM , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: twelve‐month outcome. Journal of Clinical Psychiatry2013;74(4):349‐56. [CSzG: 28737] NelsonB , PhillipsLJ , YungAR , FranceySM , LeicesterS , BakerK , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and supportive therapy in young people with subthreshold symptoms at incipient risk of psychotic disorder: baseline characteristics of the sample. Schizophrenia Bulletin2007;33(2):450. [CSzG: 15212] PhillipsLJ , NelsonB , YuenHP , FranceySM , SimmonsM , StanfordC , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: study design and baseline characteristics. Australian and New Zealand Journal of Psychiatry2009;;43(9):818–29. YungA , AmmingerP , BergerG , ThompsomA , PhillipsL , NelsonB , et al. Randomised controlled trial of antipsychotic and cognitive therapy in young people at ultra‐high risk of psychosis. Early Intervention in Psychiatry2012;6:11. [CSzG: 24989] YungA , NelsonB , PhillipsL , FranceyS , LeicesterS , YuenH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and supportive therapy in young people at ultra high risk of psychotic disorder: 12 month outcome data. Early Intervention in Psychiatry2008;2(Suppl 1):A12. [CSzG: 19138] YungAR , PhillipsLJ , NelsonB , FranceySM , YuenHP , SimmonsMB , et al. Randomised controlled trial of interventions for young people at ultra high risk for psychosis: 6‐month analysis. Journal of Clinical Psychiatry2011;72(4):430‐40. [CSzG: 22929] ">Yung‐Australia</a> reported data from this scale. </p> <p>f. Systematic Assessment For Treatment Emergent Adverse Events (SAFTEE; <a href="./references#CD012236-bbs2-0154" title="LevineJ , SchoolerNR . SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacology Bulletin1986;22(2):343‐81. ">Levine 1986</a>) </p> <p>The SAFTEE is designed for assessment of safety and adverse effects. The SAFTEE has two forms, a General Inquiry (GI) and a Specific Inquiry (SI) form. GI is an open‐ended form about any physical or health problems and their impact on functioning. SI is a detailed and systematic inquiry including 78 adverse effects divided into 23 categories corresponding to organ systems or body parts. <a href="./references#CD012236-bbs2-0019" title="NCT00291226 . Glycine vs Placebo for the Schizophrenia Prodrome. www.ClinicalTrials.gov/ct/show/2006. [CSzG: 14759] WoodsS , WalshB , HawkinsK , MillerT , SaksaJ , D'SouzaD , et al. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. Early Intervention in Psychiatry2012;6:29. [CSzG: 24987] WoodsSW , KantrowitzJT , JavittDC . NMDAR‐based treatments for patients at clinical high risk for psychosis. Biological Psychiatry2014;1:11S. [CSzG: 29041] WoodsSW , WalshBC , HawkinsKA , MillerTJ , SaksaJR , D'SouzaDC , et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. European Neuropsychopharmacology2013;23(8):931‐40. [CSzG: 28750] ">Woods‐1‐USA</a> reported data using SAFTEE. </p> </section> <section id="CD012236-sec-0149"> <p><b>6.2.5. Quality of life</b></p> <p>a. Quality of Life Scale; (QLS; <a href="./references#CD012236-bbs2-0137" title="HeinrichsDW , HanlonTE , CarpenterWT . The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin1984;10(3):388. ">Heinrichs 1984</a>) </p> <p>QLS is a semi‐structured interview administered and rated by trained clinicians. The 21 items are rated on a seven‐point scale based on the interviewer's judgement of patient functioning. Higher scores indicate better quality of life. Scores range from 0 to 126. <a href="./references#CD012236-bbs2-0004" title="CrittendenK , FlemingJ , StartupM , CarrV , BakerA , SchallU , et al. Recruitment and engagement of youth in an ultra high risk treatment study. Early Intervention in Psychiatry2008;2(Suppl 1):A127. [CSzG: Ref19115] StainH , BucciS , HalperinS , EmsleyR , ShallU , LewinT , et al. DEPTh: randomised controlled trial of cognitive behavioral therapy for young people at ultra high risk for psychosis. Early Intervention in Psychiatry2014;8:15. [CSzG: Ref29673] StainHJ , BucciS , BakerA , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of CBT for young people at risk for psychosis: the Detection and Evaluation of Psychological Therapy (DEPTh) trial. European Archives of Psychiatry and Clinical Neuroscience2015;1:S8‐9. [CSzG: Ref33810] StainHJ , BucciS , BakerAL , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of cognitive behaviour therapy versus non‐directive reflective listening for young people at ultra high risk of developing psychosis: the detection and evaluation of psychological therapy (DEPTh) trial. Schizophrenia Research2016;176(2‐3):212‐9. [CSzG: Ref35298] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. Rural and urban youth at ultra high risk for psychosis: baseline characteristics from the DEPTh randomised controlled trial of cognitive behavior therapy. Schizophrenia Bulletin2011;37:322. [CSzG: Ref22815] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy for youth at ultra high risk for psychosis: baseline characteristics for rural and urban youth. Australian and New Zealand Journal of Psychiatry2010:25‐6. [CSzG: Ref21845] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy targeting ultra high risk for psychosis: baseline comparisons for rural and urban youth. Early Intervention in Psychiatry2010;4(Suppl 1):113. [CSzG: Ref23498] StainHJ , StartupM , CarrV , BakerA , SchallU . The DEPTh project: a multisite RCT for youths at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S51‐2. [CSzG: Ref13401] StartupM . The DEPTh project: detection, evaluation, and psychological therapy for health. Australian New Zealand Clinical Trials Registry2006. [CszG: Ref18442] ">DEPTh‐Australia</a>, <a href="./references#CD012236-bbs2-0015" title="McGorryP . Can the onset of schizophrenia be delayed or prevented?. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S26. [CSzG: 8351] McGorryP , AdlardS , YungA , McDonaldA , PhillipsL , HearnN . Detection and intervention in pre‐psychotic schizophrenia. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4836] McGorryP , YungA , FranceyS , PhillipsL , NelsonB . A blinded, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and befriending in young people at risk of psychotic disorder: baseline characteristics of the sample. Acta Neuropsychiatrica2006;18(6):261. [CSzG: 35157] McGorryPD , HearnN , GermanoD , BravinJ , PhillipsLJ , YungAR , et al. Prepsychotic intervention in schizophrenia: a stitch in time?. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington DC, USA. 1999. [CSzG: 3584] McGorryPD , PhillipsLJ , NelsonB , LeicesterS , BakerK , KrstevH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and befriending in young people with subthreshold symptoms at incipient risk of psychotic disorder: six month outcome data. Schizophrenia Bulletin2007;33(2):446. [CSzG: 15203] McGorryPD , PhillipsLJ , YungAR , FranceyS , GermanoD , BravinJ , et al. A randomised controlled trial of interventions in the pre psychotic phase of psychotic disorders. Schizophrenia Research2000;41(1):9. [CSzG: 5149] McGorryPD , YungAR , PhillipsL , AdlardS , HallgrenM , PattonG , et al. Pre‐psychotic intervention in schizophrenia: a stitch in time?. Schizophrenia Research1998;29(1‐2):160. [CSzG: 3585] McGorryPD , YungAR , PhillipsLJ , YuenHP , FranceyS , CosgraveEM , et al. Randomised controlled trial of interventions designed to reduce the risk of progression to first‐episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry2002;59(10):921‐8. [CSzG: 8576] PhilippsLJ , McGorryP , YungA , FranceyD , GermanoF , BravinJ , et al. The development of preventive interventions for early psychosis: early findings and directions for the future. 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001; Vol. 2, issue Suppl 1. [CSzG: 7614] PhillipsL , CottonS , YuenHP , MihalopoulosC , ShihS , KellyD , et al. Cost effectiveness of a preventive intervention for young people at ultra high risk of developing psychosis. Schizophrenia Bulletin2007;33(2):488‐9. [CSzG: 15227] PhillipsLJ , CottonS , MihalopoulosC , ShihS , YungAR , CarterR , et al. Cost implications of specific and non‐specific treatment for young persons at ultra high risk of developing a first episode of psychosis. Early Intervention in Psychiatry2009;3(1):28‐34. [CSzG: 18308] PhillipsLJ , LeicesterSB , O'DwyerLE , FranceySM , KoutsogiannisJ , Abdel‐BakiA , et al. The PACE clinic: identification and management of young people at &quot;ultra&quot; high risk of psychosis. Journal of Psychiatric Practice2002;8(5):255‐69. [CSzG: 18235] PhillipsLJ , McGorryPD , YuenHP , WardJ , DonovanK , KellyD , et al. Medium term follow‐up of a randomised controlled trial of interventions for young people at ultra high risk of psychosis. Schizophrenia Research2007;96(1‐3):25‐33. [CSzG: 15544] PhillipsLJ , YungAR , YuenHP , PantelisC , McGorryPD . Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. American Journal of Medical Genetics2002;114(8):929‐37. [CSzG: 18236] ">PACE‐Australia</a> and <a href="./references#CD012236-bbs2-0020" title="McGorryP . Second generation intervention research in the pre‐psychotic phase of illness in schizophrenia and related psychoses. Australian New Zealand Clinical Trials Registry2000. [CSzG: 18439] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceyS , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: 12‐month outcome. Schizophrenia Research2012;136:S17‐8. [CSzG: 29547] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceySM , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: twelve‐month outcome. Journal of Clinical Psychiatry2013;74(4):349‐56. [CSzG: 28737] NelsonB , PhillipsLJ , YungAR , FranceySM , LeicesterS , BakerK , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and supportive therapy in young people with subthreshold symptoms at incipient risk of psychotic disorder: baseline characteristics of the sample. Schizophrenia Bulletin2007;33(2):450. [CSzG: 15212] PhillipsLJ , NelsonB , YuenHP , FranceySM , SimmonsM , StanfordC , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: study design and baseline characteristics. Australian and New Zealand Journal of Psychiatry2009;;43(9):818–29. YungA , AmmingerP , BergerG , ThompsomA , PhillipsL , NelsonB , et al. Randomised controlled trial of antipsychotic and cognitive therapy in young people at ultra‐high risk of psychosis. Early Intervention in Psychiatry2012;6:11. [CSzG: 24989] YungA , NelsonB , PhillipsL , FranceyS , LeicesterS , YuenH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and supportive therapy in young people at ultra high risk of psychotic disorder: 12 month outcome data. Early Intervention in Psychiatry2008;2(Suppl 1):A12. [CSzG: 19138] YungAR , PhillipsLJ , NelsonB , FranceySM , YuenHP , SimmonsMB , et al. Randomised controlled trial of interventions for young people at ultra high risk for psychosis: 6‐month analysis. Journal of Clinical Psychiatry2011;72(4):430‐40. [CSzG: 22929] ">Yung‐Australia</a> reported data from this scale (please also see <a href="./appendices#CD012236-sec-0531">Appendix 1</a>). </p> <p>b. Manchester Short Assessment of Quality of Life; (MANSA; <a href="./references#CD012236-bbs2-0166" title="PriebeS , HuxleyP , KnightS , EvansS . Application and results of the Manchester Short Assessment of Quality of Life (MANSA). International Journal of Social Psychiatry1999;45:7–12. ">Priebe 1999</a>) </p> <p>MANSA is a brief instrument for assessing quality of life focusing on satisfaction with life as a whole and with life domains. This self‐report questionnaire contains 16 items, which are rated on a seven‐point scale, higher scores meaning better quality of life. Scores range from 16 to 112. <a href="./references#CD012236-bbs2-0006" title="DragtS , Van derGaagM . Prevention of psychosis with a cognitive behavioural intervention in help‐seeking young people with an at risk mental state for developing psychosis. www.trialregister.nl/trialreg/index.asp2007. [CSzG: Ref19655] IsingHK , KraanTC , RietdijkJ , DragtS , KlaassenRM , BoonstraN , et al. Four‐year follow‐up of cognitive behavioral therapy in persons at ultra‐high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2016;42(5):1243‐52. [CSzG: Ref35214] IsingHK , LokkerbolJ , RietdijkJ , DragtS , KlaassenRM , KraanT , et al. Four‐year cost‐effectiveness of cognitive behavior therapy for preventing first‐episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2017;43(2):365‐74. [CSzG: Ref35824] IsingHK , SmitF , VelingW , RietdijkJ , DragtS , KlaassenRM , et al. Cost‐effectiveness of preventing first‐episode psychosis in ultra‐high‐risk subjects: multi‐centre randomised controlled trial. Psychological Medicine2015;45(7):1435‐46. [CSzG: Ref27798] KraanTC , IsingHK , FokkemaM , VelthorstE , Van denBergDP , KerkhovenM , et al. The effect of childhood adversity on 4‐year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE‐NL) Trial. Psychiatry Research2017;247:55‐62. [CSzG: Ref35559] NiemanDH , RuhrmannS , RietdijkJ , DragtS , IsingH , KlaassenR , et al. Preventive psychotherapy. Schizophrenia Research2014;153:S42‐3. [CSzG: Ref29601] RietdijkJ , DragtS , KlaassenR , IsingH , NiemanD , WunderinkL , et al. A single blind randomised controlled trial of cognitive behavioural therapy in a help‐seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE‐NL) trial. Trials2010;11:30. [CSzG: Ref20654] Van DerGaagM . The effects of CBT in personswith ultra high risk: the Dutch EDIE trial. European Archives of Psychiatry and Clinical Neuroscience2011;261:S18. [CSzG: Ref23756] Van DerGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first‐episode of psychosis. Early Intervention in Psychiatry2012;6:12. [CSzG: Ref24985] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomised controlled clinical trial. Schizophrenia Bulletin2012;38(6):1180‐8. [CSzG: Ref24935] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. The effects of cognitive behavioural therapy for subjects at ultra‐high risk for developing psychosis. Schizophrenia Bulletin2013;39:S356. [CSzG: Ref28121] Van derGaagM . The prevention of psychosis in at risk mental state. www.controlled‐trials.com2008. [CSzG: Ref17488] Van derGaagM , NiemanD , Van denBergD . CBT for those at risk of a first episode psychosis: Evidence‐based psychotherapy for people with an 'at risk mental state'. 1st Edition. Hove, UK: Routledge, 2013. Van derGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first episode of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29692] ">EDIE‐NL</a> reported data from this questionnaire. </p> </section> </section> <section id="CD012236-sec-0150"> <h6 class="title">6.3 Redundant data</h6> <p>Some studies reported data only as P values or statements of significant or non‐significant differences, and we could not extract other continuous data because the number of participants was missing or they had not reported standard deviations. </p> <p><b>6.4. Missing data</b> </p> <p>Ten of the included studies had missing outcomes that they had planned in the registered protocol or indicated in the methods section of the manuscript. These were: <a href="./references#CD012236-bbs2-0001" title="AddingtonJ , EpsteinI , LiuL , FrenchP , BoydellKM , ZipurskyRB . A randomised controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research2011;125(1):54‐61. [CSzG: Ref21945] AddingtonJ , ZipurskyR , EpsteinI . ADAPT (Access, Detection and Psychological Treatments). Schizophrenia Research2006;86(Suppl 1):S6. [CSzG: Ref13364] NCT00260273 . Access, detection and psychological treatments. www.ClinicalTrials.gov/ct/show/2005. [CSzG: Ref14638] ">ADAPT‐Canada</a> (part of the mental state and physical questionnaires/scales, cost‐effectiveness report); <a href="./references#CD012236-bbs2-0003" title="ChoiJ , CorcoranC , DixonL , FiszdonJ , JavittD . Processing speed training and social functioning in young adults at clinical high risk for psychosis: a pilot study. Early Intervention in Psychiatry2014;8:109. [CSzG: Ref29417] ChoiJ , CorcoranC , DixonL , JavittDC . Processing speed training and social functioning in teenagers and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2015;41:S41. [CSzG: Ref29418] ChoiJ , CorcoranCM , FiszdonJM , StevensM , JavittDC , DeasyM , et al. Pupillometer‐based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis. Psychiatric Rehabilitation Journal2017;40(1):33‐42. [CSzG: Ref35317] ">Choi‐USA</a> (2 specific cognitive tests); <a href="./references#CD012236-bbs2-0005" title="ByrneRE , MorrisonAP . Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. Psychology and Psychotherapy2014;87(3):357‐71. [CSzG: Ref29312] FlachC , FrenchP , DunnG , FowlerD , GumleyAI , BirchwoodM , et al. Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE‐2 trial. British Journal of Psychiatry2015;207(2):123‐9. [CSzG: Ref33109] MorrisonA . Early detection and intervention evaluation for individuals at high risk of psychosis 2. http://www.controlled‐trials.com2008. [CSzG: Ref18285] MorrisonA . Early detection and intervention evaluation for people at risk of psychosis (edie‐2): A multisite randomised controlled trial of cognitive therapy for at‐risk mental states. Early Intervention in Psychiatry2012;6:11. [CSzG: Ref24968] MorrisonA , FrenchP , BentallR , LewisS , BirchwoodM , FowlerD , et al. Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. Early Intervention in Psychiatry2008;2(Suppl 1):A15. [CSzG: Ref19128] MorrisonAP . EDIE‐2: early detection and psychological intervention for individuals at high risk of psychosis (2). www.controlled‐trials.com2007. [CSzG: Ref15381] MorrisonAP , BirchwoodM , PyleM , FlachC , StewartSL , ByrneR , et al. Impact of cognitive therapy on internalised stigma in people with at‐risk mental states. British Journal of Psychiatry2013;203(2):140‐5. [CSzG: Ref28630] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ2012;344(7852):e2233. [CSzG: Ref24208] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at‐risk of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29554] MorrisonAP , PyleM , StewartSL , FrenchP , ByrneR , FlachC , et al. Internalised stigma in young people at high risk of developing psychosis: findings from a cognitive therapy trial. Schizophrenia Research2014;153:S42. [CSzG: Ref29555] MorrisonAP , StewartSL , FrenchP , BentallRP , BirchwoodM , ByrneR , et al. Early detection and intervention evaluation for people at high‐risk of psychosis‐2 (EDIE‐2): trial rationale, design and baseline characteristics. Early Intervention in Psychiatry2011;5(1):24‐32. [CSzG: Ref22695] MorrisonT . Early detection and psychological intervention for individuals at high risk of psychosis. EDIE‐2. Data on File2006. [CSzG: Ref13874] PelosiAJ . Rational policy making for early psychosis might yet become possible. BMJ2012;344(7856):e3137. [CSzG: Ref24326] PyleM , StewartSL , FrenchP , ByrneR , PattersonP , GumleyA , et al. Internalised stigma, emotional dysfunction and unusual experiences in young people at risk of psychosis. Early Intervention in Psychiatry2015;9(2):133‐40. [CSzG: Ref29813] ">EDIE‐2‐UK</a> (part of the mental state questionnaires/scales, cost‐effectiveness report); <a href="./references#CD012236-bbs2-0006" title="DragtS , Van derGaagM . Prevention of psychosis with a cognitive behavioural intervention in help‐seeking young people with an at risk mental state for developing psychosis. www.trialregister.nl/trialreg/index.asp2007. [CSzG: Ref19655] IsingHK , KraanTC , RietdijkJ , DragtS , KlaassenRM , BoonstraN , et al. Four‐year follow‐up of cognitive behavioral therapy in persons at ultra‐high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2016;42(5):1243‐52. [CSzG: Ref35214] IsingHK , LokkerbolJ , RietdijkJ , DragtS , KlaassenRM , KraanT , et al. Four‐year cost‐effectiveness of cognitive behavior therapy for preventing first‐episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2017;43(2):365‐74. [CSzG: Ref35824] IsingHK , SmitF , VelingW , RietdijkJ , DragtS , KlaassenRM , et al. Cost‐effectiveness of preventing first‐episode psychosis in ultra‐high‐risk subjects: multi‐centre randomised controlled trial. Psychological Medicine2015;45(7):1435‐46. [CSzG: Ref27798] KraanTC , IsingHK , FokkemaM , VelthorstE , Van denBergDP , KerkhovenM , et al. The effect of childhood adversity on 4‐year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE‐NL) Trial. Psychiatry Research2017;247:55‐62. [CSzG: Ref35559] NiemanDH , RuhrmannS , RietdijkJ , DragtS , IsingH , KlaassenR , et al. Preventive psychotherapy. Schizophrenia Research2014;153:S42‐3. [CSzG: Ref29601] RietdijkJ , DragtS , KlaassenR , IsingH , NiemanD , WunderinkL , et al. A single blind randomised controlled trial of cognitive behavioural therapy in a help‐seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE‐NL) trial. Trials2010;11:30. [CSzG: Ref20654] Van DerGaagM . The effects of CBT in personswith ultra high risk: the Dutch EDIE trial. European Archives of Psychiatry and Clinical Neuroscience2011;261:S18. [CSzG: Ref23756] Van DerGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first‐episode of psychosis. Early Intervention in Psychiatry2012;6:12. [CSzG: Ref24985] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomised controlled clinical trial. Schizophrenia Bulletin2012;38(6):1180‐8. [CSzG: Ref24935] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. The effects of cognitive behavioural therapy for subjects at ultra‐high risk for developing psychosis. Schizophrenia Bulletin2013;39:S356. [CSzG: Ref28121] Van derGaagM . The prevention of psychosis in at risk mental state. www.controlled‐trials.com2008. [CSzG: Ref17488] Van derGaagM , NiemanD , Van denBergD . CBT for those at risk of a first episode psychosis: Evidence‐based psychotherapy for people with an 'at risk mental state'. 1st Edition. Hove, UK: Routledge, 2013. Van derGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first episode of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29692] ">EDIE‐NL</a> (a questionnaire for quality of life and cognitive test for verbal fluency); <a href="./references#CD012236-bbs2-0008" title="McFarlaneWR , CookWL , WoodberryKA . A randomised clinical trial of familyaided assertive community treatment for young persons at high risk for onset of an initial psychosis. Schizophrenia Bulletin2011;37:314. [CSzG: Ref22796] NCT01597141 . Psychosis: early detection, intervention and prevention. ClinicalTrials.gov/show/NCT015971412012. [CSzG: Ref24315] ">EDIP‐USA</a> (transition to psychosis after 60 months); <a href="./references#CD012236-bbs2-0011" title="BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: 12511] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] RuhrmannS , BechdolfA , KuhnKU , WagnerM , Schultze‐LutterF Janssen B , et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry. Supplements2007;51:s88‐95. [CSzG: 16127] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Acute symptomatic treatment effects in persons clinically at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13397] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Intervention in the late initial prodromal state (LIPS) of psychosis. Schizophrenia Research2006;86(Suppl 1):S96. [CSzG: 13398] ">LIPS‐Germany</a> (part of the mental state/functioning/adverse events questionnaire/scales); <a href="./references#CD012236-bbs2-0012" title="MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Family‐focused therapy for individuals at clinical high risk for psychosis: treatment fidelity within a multisite randomised trial. Early Intervention in Psychiatry2016;10(2):137‐43. [CSzG: 29018] MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Treatment fidelity and differentiation in a randomised controlled trial of family‐focused therapy for youth at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:95. [CSzG: 24965] MiklowitzDJ , O'BrienMP , SchlosserDA , AddingtonJ , CandanKA , MarshallC , et al. Family‐focused treatment for adolescents and young adults at high risk for psychosis: results of a randomised trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(8):848‐58. [CSzG: 29019] NCT01907282 . Prevention trial of family focused treatment in youth at risk for psychosis. Clinicaltrials.gov/show/NCT019072822010. [CSzG: 27965] O'BrienMP , MiklowitzDJ , CandanKA , MarshallC , DominguesI , WalshBC , et al. A randomised trial of family focused therapy with populations at clinical high risk for psychosis: effects on interactional behavior. Journal of Consulting and Clinical Psychology2013;82(1):90‐101. [CSzG: 28565] O'BrienMP , MiklowitzDJ , CannonTD . Decreases in perceived maternal criticism predict improvement in subthreshold psychotic symptoms in a randomised trial of family‐focused therapy for individuals at clinical high risk for psychosis. Journal of Family Psychology2015;29(6):945–951.. [CSzG: 32212] SchlosserDA , MiklowitzDJ , O'BrienMP , DeSilvaSD , ZinbergJL , CannonTD . A randomised trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Intervention in Psychiatry2012;6(3):283‐91. [CSzG: 24491] ">Miklowitz‐USA</a> (mental scale score after one year); <a href="./references#CD012236-bbs2-0014" title="NordentoftM , JeppesenP , PetersenL , ThorupA , OhlenschlaegerJ , ChristensenT , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. European Psychiatry2007;22:S129‐S. [CSzG: 20471] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the OPUS trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;83(1):29‐40. [CSzG: 13197] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;86(Suppl 1):S44. [CSzG: 13393] ">Nordentoft‐Denmark</a> (treatment satisfaction/compliance/adherence and suicidal behaviour); <a href="./references#CD012236-bbs2-0017" title='BlockJJ , McGlashonTH . Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790‐9. American Journal of Psychiatry2006; Vol. 163, issue 10:1838. [CSzG: 13960] BreierAF , ZipurskyRB , PerkinsDO , AddingtonJM , TohenMF , DavidSR , et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951] HawkinsKA , AddingtonJ , KeefeR , ChristensenB , WoodsS , ZipurskyR , et al. Neuropsychological functioning in the first episode prodrome and early psychosis. Schizophrenia Research2004;70(1):101. [CSzG: 11515] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , MillerTJ , et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research2004;67(1):205. [CSzG: Ref11301] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , ZipurskyRB , et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. [CSzG: 16470] HawkinsKA , KeefeRS , ChristensenBK , AddingtonJ , WoodsSW , CallahanJ , et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. Schizophrenia Research2008;105(1‐3):1‐9. [CSzG: 16983] HoffmanRE , WoodsS , PredaA , TohenM , BreierA , GlistJ , et al. Excessive top‐down perceptual processing and reduced real‐world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. Schizophrenia Research2006;86(Suppl 1):S46. [CSzG: 13377] HoffmanRE , WoodsSW , HawkinsKA , PittmanB , TohenM , PredaA , et al. Extracting spurious messages from noise and risk of schizophrenia‐spectrum disorders in prodromal population. British Journal of Psychiatry2007;191(2):355‐6. [CSzG: 16068] McGlashanT , ZipurskyR , PerkinsD , AddingtonJ . Olanzapine for treatment of the schizophrenia prodrome: 2‐year results of a randomised placebo‐controlled study. Schizophrenia Research2004;67(1):164. [CSzG: 11320] McGlashanTH . Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. [CSzG: 10191] McGlashanTH . Treatment intervention in the New Haven PRIME clinic prodromal sample. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4835] McGlashanTH , MillerTJ , WoodsSW . Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research2002;53(3 Suppl 1):15. [CSzG: 8093] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005] McGlashanTH , MillerTJ , ZipurskyRB , WoodsSW , PerkinsDO , HawkinsKA , et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9803] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerT , WoodsSW , et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry2006;163(5):790‐9. [CSzG: 12654] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerTJ , WoodsSW , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research2003;61(1):7‐18. [CSzG: 9828] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJ , WoodsSW , MillerTJ , et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research2003;60:295. [CSzG: 9722] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJM , WoodsSW , LindborgS , et al. Olanzapine versus pbo for the schizophrenic prodrome: one‐year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9804] McGlashlanTH , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTH , WoodsSW , et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:42. [CSzG: 8934] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , MillerT , WoodsS , et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. Schizophrenia Research2004;70(1):6. [CSzG: 11524] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , WoodsS , MillerT , et al. Olanzapine vs. placebo for prodromal schizophrenia. Schizophrenia Research2004;67(1):6. [CSzG: 11321] MillerTJ , ZipurskyRB , PerkinsD , AddingtonJ , WoodsSW , HawkinsKA , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research2003;61(1):19‐30. [CSzG: 9829] RosenJL , WoodsSW , MillerTJ , McGlashanTH . Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease2002;190:133‐41. [CSzG: 8274] TaylorHE , ParkerS , MansellW , MorrisonAP . Effects of appraisals of anomalous experience on distress in people at risk of psychosis. Behavioural and Cognitive Psychotherapy2012;41(1):24‐33. [CSzG: 24374] WoodsS , ZipurskyR , PerkinsD , AddingtonJ , MarquezE , BreierA , et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:43. [CSzG: 8933] WoodsSW . Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):497. [CSzG: 19829] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research. 2003. [CSzG: 9978] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research2003;60:306‐7. [CSzG: 9752] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):453‐64. [CSzG: 9994] WoodsSW , McGlashanTH . Sample size planning for prodromal intervention trials. Schizophrenia Research2002;53(3 Suppl 1):40. [CSzG: 8116] WoodsSW , ZipurskyRB , PerkinsDO , AddingtonJM , MillerTJ , BreierAF , et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053] '>PRIME‐USA</a> (quality of life questionnaire); and <a href="./references#CD012236-bbs2-0019" title="NCT00291226 . Glycine vs Placebo for the Schizophrenia Prodrome. www.ClinicalTrials.gov/ct/show/2006. [CSzG: 14759] WoodsS , WalshB , HawkinsK , MillerT , SaksaJ , D'SouzaD , et al. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. Early Intervention in Psychiatry2012;6:29. [CSzG: 24987] WoodsSW , KantrowitzJT , JavittDC . NMDAR‐based treatments for patients at clinical high risk for psychosis. Biological Psychiatry2014;1:11S. [CSzG: 29041] WoodsSW , WalshBC , HawkinsKA , MillerTJ , SaksaJR , D'SouzaDC , et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. European Neuropsychopharmacology2013;23(8):931‐40. [CSzG: 28750] ">Woods‐1‐USA</a> (multiple outcomes reported for only one participant). We did not find missing outcomes for other studies. </p> </section> </section> </section> <section id="CD012236-sec-0151"> <h4 class="title">Excluded studies</h4> <p>There are currently 29 excluded studies. We have summarized the reasons for excluding the studies in the following table: </p> <p> <div class="table" id="CD012236-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Totals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reasons</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Totals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not UHR sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0022" title="BerryK , GreggL , LobbanF , BarrowcloughC . Therapeutic alliance in psychological therapy for people with recent onset psychosis who use cannabis. Comprehensive Psychiatry2016;67:73‐80. ">Berry‐USA</a>, <a href="./references#CD012236-bbs2-0023" title="BiagiantiB , RoachBJ , FisherM , LoewyR , FordJM , VinogradovS , et al. Trait aspects of auditory mismatch negativity predict response to auditory training in individuals with early illness schizophrenia. Neuropsychiatric Electrophysiology2017;3:2. ">Biagianti‐USA</a>, <a href="./references#CD012236-bbs2-0024" title="ACTRN12612000963820 . An evaluation of the effectiveness of an internet‐based treatment program for psychotic like experiences. www.anzctr.org.au/ACTRN12612000963820.aspx2012. ">Capra‐Australia</a>, <a href="./references#CD012236-bbs2-0025" title="StoneWS , HsiX , GiulianoAJ , SeidmanLJ , TsuangMT . Validation of a liability syndrome for schizophrenia ('schizotaxia') and effects of low dose risperidone on neurocognitive, clinical and social functioning: results from the Changsha study. European Psychiatry2011;26(Suppl 1):1508. StoneWS , HsiX , GiulianoAJ , TanL , ZhuS , LiL , et al. Are neurocognitive, clinical and social dysfunctions in schizotaxia reversible pharmacologically? Results from the Changsha study. Asian Journal of Psychiatry2012;5(1):73‐82. ">CHANGSHA‐USA</a>, <a href="./references#CD012236-bbs2-0026" title="ChienWT , YipAL , LiuJY , McMasterTW . The effectiveness of manual‐guided, problem‐solving‐based self‐learning programme for family caregivers of people with recent‐onset psychosis: a randomised controlled trial with 6‐month follow‐up. International Journal of Nursing Studies2016;59:141‐55. ">Chien‐Hong Kong</a>, <a href="./references#CD012236-bbs2-0027" title="CordesJ , KahlK , JannerM , MullerH , WagnerM , MaierW , et al. Prevalence of the metabolic syndrome in men and women at risk of psychosis. European Archives of Psychiatry and Clinical Neuroscience2011;261:S33. NCT00169702 . The effect of a weight management program to prevent weight gain and metabolic abnormalities during treatment with the atypical neuroleptic olanzapine: a randomised study. www.ClinicalTrials.gov/ct/show/2005. ">Cordes‐Germany</a>, <a href="./references#CD012236-bbs2-0031" title="HolzerL , UrbenS , PassiniCM , JaugeyL , HerzogMH , HalfonO , et al. A randomised controlled trial of the effectiveness of computer‐assisted cognitive remediation (CACR) in adolescents with psychosis or at high risk of psychosis. Behavioural and Cognitive Psychotherapy2014;42(4):421‐34. HolzerL , UrbenS , PihetS , JaugeyL . A randomised controlled trial of the effectiveness of a computer‐assisted cognitive remediation (CACR) program in adolescents with psychosis or at high risk of psychosis: short‐term and long‐term outcomes. Neuropsychiatrie de L'Enfance et de L'Adolescence2012;60(5 Suppl):S71. JaugeyL , UrbenS , PihetS , HalfonO , HolzerL . Short‐and long‐term outcomes of a randomised controlled trial of a computer‐assisted cognitive remediation (CACR) program in adolescents with psychosis or at high risk of psychosis. Biological Psychiatry2012;8(Suppl 1):84S. TorrisiR , HolzerL , PihetS , SuterS , AeberhardA , PellandaV , et al. Computer‐assisted cognitive remediation program for adolescents at high risk of psychosis or with psychotic disorders: preliminary results. 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. UrbenS , PihetS , JaugeyL , HalfonO , HolzerL . A randomised controlled trial of the effectiveness of a computer‐assisted cognitive remediation (CACR) program in adolescents with psychosis or at high risk of psychosis: short term and long term outcomes. Early Intervention in Psychiatry2012;6:41. UrbenS , PihetS , JaugeyL , HalfonO , HolzerL . Computer‐assisted cognitive remediation in adolescents with psychosis or at risk for psychosis: a 6‐month follow‐up. Acta Neuropsychiatrica2012;24(6):328‐35. ">Holzer‐Switzerland</a>, <a href="./references#CD012236-bbs2-0033" title='KorenD , RadinS , LibasY . "Attenuated psychosis syndrome" versus "endangered realitytesting syndrome": a community‐based experimental vignette study of their effect on stigma, hope and help‐seeking. Early Intervention in Psychiatry2014;8:136. '>Koren‐Israel</a>, <a href="./references#CD012236-bbs2-0034" title="ISRCTN70185866 . LEGS cluster randomised trial: liaison with education and general practices to detect and refine referrals of people with at‐risk‐mental‐states (ARMS). isrctn.org/ISRCTN701858662010. JonesP . LEGS cluster randomised trial: liaison with education and general practices to detect and refine referrals of people with at‐risk‐mental‐states (ARMS). National Institute for Health Research2009. PerezJ , JinH , RussoDA , StochlJ , PainterM , ShelleyG , et al. Clinical effectiveness and cost‐effectiveness of tailored intensive liaison between primary and secondary care to identify individuals at risk of a first psychotic illness (the LEGs study): a cluster‐randomised controlled trial. Lancet Psychiatry2015;2(1):984‐93. PerezJ , RussoD , JinH , StochlJ , PainterM , GraffyJ , et al. Liaison with primary care to detect individuals at clinical high risk for psychosis: the LEGS CRCT. Schizophrenia Bulletin2015;41:S130. PerezJ , RussoDA , StochlJ , ByfordS , ZimbronJ , GraffyJP , et al. Comparison of high and low intensity contact between secondary and primary care to detect people at ultra‐high risk for psychosis: study protocol for a theory‐based, cluster randomised controlled trial. Trials2013;14:222. ">LEGS‐USA</a>, <a href="./references#CD012236-bbs2-0035" title="PowerP , CraigT , McguireP , IacoponiE , GaretyP , RussellM . A randomised controlled trial of an early detection team in first episode psychosis: the LEO CAT trial. Schizophrenia Research2004;67(1):36. PowerP , IacoponiE , RussellM , FisherH , McguireP , GaretyP , et al. A randomised controlled trial of an early detection team in first‐episode psychosis: provisional findings of the LEO CAT study. Schizophrenia Research2004;70(1):131. PowerP , MonteiroE , PobeeI , BurnsideA , PughC , ReynoldsN , et al. 18 months outcome of first episode psychosis patients attending the LEO service in south London. Early Intervention in Psychiatry2008;2(Suppl 1):A6. ">LEO CAT‐UK</a>, <a href="./references#CD012236-bbs2-0036" title="CraigT , GaretyP , PowerP , RahamanN , ColbertS , Fornells‐AmbrojoM . Lambeth early onset service: a randomised controlled trial. Schizophrenia Research2004;70(1):145‐6. CraigTK . Brixton early psychosis project. National Research Register2000. CraigTK , GaretyP , PowerP , RahamanN , ColbertS , Fornells‐AmbrojoM , et al. The Lambeth Early Onset (LEO) Team: randomised controlled trial of the effectiveness of specialised care for early psychosis. BMJ2004;329(7474):1067‐70. GaretyPA , CraigTK , DunnG , Fornells‐AmbrojoM , ColbertS , RahamanN , et al. Specialised care for early psychosis: symptoms, social functioning and patient satisfaction: randomised controlled trial. British Journal of Psychiatry2006;188(1):37‐45. GaretyPA , CraigTK , DunnG , Fornells‐AmbrojoM , ColbertS , RahamanN , et al. Specialised care for early psychosis: symptoms, social functioning and patient satisfaction: randomised controlled trial: corrigenda. British Journal of Psychiatry2006;188(3):295. PowerP , CraigT , GaretyP , RahamanN , ColbertS , Fornells‐AmbrojoM . Lambeth early onset (LEO) trial: a randomised controlled trial of assertive community follow‐up in early psychosis: initial 6 month data. Unknown Source. 1994. PowerP , IacoponiE , ReynoldsN , FisherH , RussellM , GaretyP , et al. The Lambeth Early Onset Crisis Assessment Team Study: general practitioner education and access to an early detection team in first‐episode psychosis. British Journal of Psychiatry. Supplements2007;51:s133‐9. PowerP , McGuireP , IacoponiE , GaretyP , MorrisE , ValmaggiaL , et al. Lambeth early onset (LEO) and outreach &amp; support in South London (OASIS) service. Early Intervention in Psychiatry2007;1(1):97‐103. TempierR , BalbuenaL , LepnurmM , CraigTK . Perceived emotional support in remission: results from an 18‐month follow‐up of patients with early episode psychosis. Social Psychiatry and Psychiatric Epidemiology2013;48(12):1897‐904. ">LEO‐UK</a>, <a href="./references#CD012236-bbs2-0037" title="DRKS00011151 . Enhancing recovery in early schizophrenia a multi‐center, two‐arm, double‐blind, randomised clinical trial investigating cannabidiol vs. placebo as an add‐on to an individualised antipsychotic treatment using either amisulpride or quetiapine. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS000111512016. [http://www.drks.de/DRKS00011151] ">Leweke‐Germany</a>, <a href="./references#CD012236-bbs2-0041" title="AlbertN , JensenH , MelauM , HjorthojC , NordentoftM . How long should a specialised assertive early intervention program last?. Early Intervention in Psychiatry2014;8:10. BertelsenM , JeppesenP , PetersenL , ThorupA , OhlenschlaegerJ , LeQuachP , et al. Course of illness in a sample of 265 patients with first‐episode psychosis ‐ five‐year follow‐up of the Danish OPUS trial. Schizophrenia Research2009;107(2‐3):173‐8. BertelsenM , JeppesenP , PetersenL , ThorupA , OhlenschlaegerJ , leQuachP , et al. First episode of psychosis intensive early intervention programme versus standard treatment ‐ secondary publication. Ugeskrift for Laeger2009;171(41):2992‐5. BertelsenM , JeppesenP , PetersenL , ThorupA , OhlenschlaegerJ , leQuachP , et al. Five‐year follow‐up of a randomised multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial. Archives of General Psychiatry2008;65(7):762‐71. BertelsenM , JeppesenP , PetersenL , ThorupA , OhlenschlaegerJ , leQuachP , et al. Suicidal behaviour and mortality in first‐episode psychosis: the OPUS trial. British Journal of Psychiatry. Supplements2007;191(Suppl 51):s140‐6. EllersgaardD , MorsO , ThorupA , JorgensenP , JeppesenP , NordentoftM . A prospective study of the course of delusional themes in first episode non‐affective psychosis. Early Intervention in Psychiatry2012;6:67. EllersgaardD , MorsO , ThorupA , JorgensenP , JeppesenP , NordentoftM . Prospective study of the course of delusional themes in first‐episode non‐affective psychosis. Early Intervention in Psychiatry2014;8(4):340‐7. HastrupLH , KronborgC , BertelsenM , JeppesenP , JorgensenP , PetersenL , et al. Cost‐effectiveness of early intervention in first‐episode psychosis: economic evaluation of a randomised controlled trial (the opus study). British Journal of Psychiatry2013;202(1):35‐41. HastrupLH , KronborgC , NordentoftM , SimonsenE . Cost‐effectiveness of a randomised multicenter trial in first‐episode psychosis (OPUS) in Denmark. Journal of Mental Health Policy and Economics2011;14:S10. JeppesenP , AbelMB , KrarupG , JorgensenP , NordentoftM . Family burden and expressed emotion in first episode psychosis. The OPUS‐trial. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:59. JeppesenP , HemmingsenR , JírgensenP , ReisbyN , AbelM‐B , NordentoftM . OPUS project: impact of mental disorder on caregivers. 11th World Congress of Psychiatry; 1999 Aug 6‐11; Hamburg, Germany1999;2:157. JeppesenP , HemmingsenR , ReisbyN , JørgensenP , NordentoftM , AbelM‐B . The impact of mental disorder on caregivers. 11th World Congress of Psychiatry; 1999 Aug 6‐11; Hamburg, Germany1999;2:187. JeppesenP , NordentoftM , AbelM , HemmingsenRP , Joergensen , KassowP . OPUS‐project: a RCT of integrated psychiatric treatment for recent onset psychotic patients. Schizophrenia Research2001;49(1‐2):262. JeppesenP , PetersenL , ThorupA , AbelM‐B , OehlenschlaegerJ , ChristensenTO , et al. Integrated treatment of first‐episode psychosis: effect of treatment on family burden: OPUS trial. British Journal of Psychiatry2005;48(Suppl):s85‐90. JeppesenP , PetersenL , ThorupA , AbelM‐B , OhlenschlaegerJ , ChristensenTO , et al. The association between pre‐morbid adjustment, duration of untreated psychosis and outcome in first‐episode psychosis. Psychological Medicine2008;38(8):1157‐66. JørgensenP , JeppesenP , AbelMB , KassowP , KrarupG , HemmingsenR , et al. Early intervention in schizophrenia. Nordic Journal of Psychiatry2002;56(2):8. JørgensenP , NordentoftM , AbelMB , GouliaevG , JeppesenP , KassowP . Early detection and assertive community treatment of young psychotics: the OPUS study rationale and design of the trial. Social Psychiatry and Psychiatric Epidemiology2000;35(7):283‐7. NordentoftM , BertelsenM , JeppesenP , ThorupA , PetersenL , OhlenschlaegerJ , et al. OPUS trial: a randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. Nordic Journal of Psychiatry2007;61(6):488. NordentoftM , BertelsenM , ThorupA , JeppesenP , PetersenL . The OPUS‐trial; a randomised multi‐centre trial of integrated versus standard treatment for patients with a first episode of psychotic illness‐five‐years follow‐up. 12th International Congress on Schizophrenia Research; 2009 Mar 28‐Apr 1; San Diego, CA. San Diego, CA, USA: Oxford Univ Press, 2009:370. NordentoftM , JeppesenP , AbelM , KassowP , PetersenL , ThorupA , et al. OPUS study: suicidal behaviour, suicidal ideation and hopelessness among patients with first‐episode psychosis. One‐year follow‐up of a randomised controlled trial. British Journal of Psychiatry. Supplements2002;181(Suppl 43):S98‐106. NordentoftM , JeppesenP , AbelM , PetersenL , ThorupA , ChristensenT , et al. Opus‐project: a randomised controlled trial of integrated psychiatric treatment in first‐episode psychosis ‐ clinical outcome improved. Proceedings of the 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:56. NordentoftM , JeppesenP , AbelMB , HemmingsenR , ReisbyN . Can duration of untreated psychosis be shortened and does optimal treatment program improve outcome? A randomised controlled study. Nordisk Psykiatrisk Tidsskrift1998;52(41):76. NordentoftM , JeppesenP , JorgensenP , AbelM , KassowP , ReisbyN , et al. OPUS‐project: a randomised controlled trial of first episode psychotic patients: better compliance. Schizophrenia Research2000;41(1):B145. NordentoftM , JeppesenP , JørgensenP , AbelMB , KassowP , ReisbyN , et al. OPUS ‐ project: a randomised controlled trial of first episode psychotic patients better compliance. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. NordentoftM , JeppesenP , KassowP , AbelM , PetersenL , ThorupA , et al. OPUS‐project: a randomised controlled trial of integrated psychiatric treatment in first‐episode psychosis‐clinical outcome improved. Schizophrenia Research2002;53(3 Suppl 1):51. NordentoftM , JeppesenP , KassowP , et al. OPUS project: a randomised controlled trial of integrated psychiatric treatment in first episode psychosis ‐ clinical outcome improved. Schizophrenia Research2002;53(Suppl. 1):51. NordentoftM , JeppesenP , PetersenL , ThorupA , AbelM , OhlenschlaegerJK , et al. OPUS project: a randomised controlled trial of integrated psychiatric treatment in first episode psychosis. Schizophrenia Research2003;60:297. NordentoftM , JeppesenP , PetersenL , ThorupA , JorgensenP . Duration of untreated psychosis predicts psychotic symptoms but not negative symptoms. Schizophrenia Bulletin2005;31:234. NordentoftM , JeppesenP , PetersenL , ThorupA , OhlenschlaegerJ , ChristensenT , et al. The OPUS trial: a randomised multi‐centre trial of integrated versus standard treatment for 547 first‐episode psychotic patients. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. NordentoftM , JeppesenP , PetersenL , Thorupa , KrarupG , AbelM , et al. The Danish OPUS‐trial: a randomised controlled trial of integrated treatment among 547 first‐episode psychotic patients. One and two years follow‐up. Schizophrenia Research2004;67(1):35‐6. NordentoftM , JeppesenP , VentegodtAT , JoergensenP , AbelM , PetersenL , et al. OPUS‐project: a randomised controlled trial of first episode psychotic patients: patient satisfaction, depression and suicidal behaviour. Schizophrenia Research2001;49(1‐2):265. NordentoftM , JorgensenP , JeppesenP , KassowP , AbelMB , ResibyN , et al. OPUS‐project: differences in clinical and social outcome of a randomised controlled trial of integrated care of first‐episode psychotic patients. Schizophrenia Research1999;36(1‐3):330. NordentoftM , MelauM , IversenT , PetersenL , JeppesenP , ThorupA , et al. From research to practice: How OPUS treatment was accepted and implemented throughout Denmark. Early Intervention in Psychiatry2015;9(2):156‐62. NordentoftM , MelauM , JeppesenP , PetersenL , ThorupA , OhlenschlagerJ , et al. The OPUS‐trial; a randomised single‐blinded trial of integrated versus standard treatment for patients with a first episode of psychotic illness ‐ results of five‐years follow‐up and presentation of a new trial. Schizophrenia Research2010;117(2‐3):116. NordentoftM , OhlenschlaegerJ , ThorupA , PetersenL , JeppesenP , BertelsenM . Deinstitutionalization revisited: a 5‐year follow‐up of a randomised clinical trial of hospital‐based rehabilitation versus specialised assertive intervention (OPUS) versus standard treatment for patients with first‐episode schizophrenia spectrum disorders. Psychological Medicine2010;40(10):1619‐26. NordentoftM , PetersenL , JeppesenP , ThorupAA , AbelMB , OhlenschlaegerJ , et al. OPUS: a randomised, multicenter clinical trial of integrated treatment compared with standard treatment before the first episode psychosis ‐ secondary publication. Ugeskrift for Laeger2006;168(4):381‐4. NordentoftM , ReisbyN , JeppesenP , AbelM‐B , KassowP , JírgensenP . OPUS‐project: differences in treatment outcome of a randomised controlled trial of integrated psychiatric treatment of first‐episode psychotic patients. 11th World Congress of Psychiatry; 1999 Aug 6‐11; Hamburg, Germany. 1999; Vol. 2:165. NordentoftM , SecherG , BertelsenM , ThorupA , AustinS , AlbertN , et al. Opus: concept and recent findings. European Archives of Psychiatry and Clinical Neuroscience2011;261:S37‐S8. NordentoftM , SecherG , HjorthojCR , AustinS , ThorupA , JeppesenP , et al. Ten‐year follow‐up of the OPUS specialised early intervention trial for patients with a first episode of psychosis. Schizophrenia Bulletin2015;41:S149. NordentoftM , ThorupA , PetersenL , JeppesenP , KrarupG , ChristensenT , et al. The OPUS trial: a randomised multi‐centre trial of integrated versus standard treatment for 547 first‐episode psychotic patients. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:8. PetersenL , JeppesenP , ThorupA , AbelMB , OhlenschlaegerJ , ChristensenTO , et al. A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. BMJ2005;331(7517):602‐8. PetersenL , JeppesenP , ThorupA , OhlenschlaegerJ , ChristensenT , KrarupG , et al. Substance abuse in first‐episode schizophrenia‐spectrum disorders. Schizophrenia Research2006;86(Suppl 1):S44. PetersenL , NordentoftM , JeppesenP , OhlenschaegerJ , ThorupA , ChristensenTO , et al. Improving 1‐year outcome in first‐episode psychosis: OPUS trial. British Journal of Psychiatry2005;48(Suppl):s98‐103. PetersenL , NordentoftM , ThorupA , OehlenschlaegerJ , JeppesenP , ChristensenT , et al. The OPUS trial: a randomised multi‐centre trial of integrated versus standard treatment for 547 first‐episode psychotic patients. Schizophrenia Bulletin2005;31:531. SecherRG , AustinSF , Ole MorsNP , NordentoftM . The OPUS‐trial: Intensive, early, psycho‐social intervention versus treatment as usual for first‐episode psychosis patients. Results from the 10‐year follow‐up. European Archives of Psychiatry and Clinical Neuroscience2011;261:S59. SecherRG , HjorthojCR , AustinSF , ThorupA , JeppesenP , MorsO , et al. Ten‐Year Follow‐up of the OPUS Specialised Early Intervention Trial for Patients With a First Episode of Psychosis. Schizophrenia Bulletin2015;41(3):617‐26. SecherRG , HjorthojCR , AustinSF , ThorupA , JeppesenP , MorsO , et al. Ten‐year follow‐up of the OPUS specialised early intervention trial for patients with a first episode of psychosis. Schizophrenia Bulletin2015;41(3):617‐26. StevensH , AgerboE , DeanK , MortensenPB , NordentoftM . Reduction of crime in first‐onset psychosis: a secondary analysis of the OPUS randomised trial. Journal of Clinical Psychiatry2013;74(5):e439‐44. ThorupA . Gender differences in first‐episode psychosis at five‐year followup ‐ results from the Danish OPUS study gender differences have been found. Early Intervention in Psychiatry2010;4(Suppl 1):53. ThorupA , AlbertN , BertelsenM , PetersenL , JeppesenP , LeQuackP , et al. Gender differences in first‐episode psychosis at 5‐year follow‐up ‐ two different courses of disease? Results from the OPUS study at 5‐year follow‐up. European Psychiatry2013;29(1):44‐51. ThorupA , NordentoftM , PetersenL , OehlensschlaegerJ , AbelM , JeppesenP , et al. The Danish OPUS‐project: psychopathology and gender differences in first episode psychotic patients. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:59. ThorupA , PetersenL , JeppesenP , NordentoftM . The quality of life among first‐episode psychotic patients in the OPUS trial. Schizophrenia Research2010;116(1):27‐34. ThorupA , PetersenL , JeppesenP , OhlenschlaegerJ , ChristensenT , KrarupG , et al. Integrated treatment ameliorates negative symptoms in first episode psychosis ‐ results from the Danish OPUS trial. Schizophrenia Research2005;79(1):95‐105. ØhlenschlægerJ , ThorupA , PetersenL , JeppesenP , AbelM , NordentoftM . Coercion in first episode psychosis. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:89‐90. ">OPUS‐Denmark</a>, <a href="./references#CD012236-bbs2-0043" title="BrunetteMF . Facilitators and barriers to implementation of coordinated specialty care in U.S. community mental health clinic. Schizophrenia Bulletin2015;41:S304. CadenheadK , AddingtonJ , BeardenC , CannonT , CornblattB , MathalonD , et al. Metabolic abnormalities prior to the onset of psychosis: another risk factor for psychosis?. Neuropsychopharmacology2015;40:S565. CorrellCU , RobinsonDG , SchoolerNR , BrunetteMF , MueserKT , RosenheckRA , et al. Cardiometabolic risk in patients with first‐episode schizophrenia spectrum disorders: baseline results from the RAISE‐ETP study. JAMA Psychiatry2014;71(12):1350‐63. GlynnSM , GingerichS , MueserKT , CatherC , PennD . The role of family intervention in coordinated specialty care for first episode psychosis. Schizophrenia Bulletin2015;41:S173. KaneJ , SchoolerN , RobinsonD , AddingtonJ , KaneJM . The NIMH RAISE ETP (Early Treatment Program): initial results. Early Intervention in Psychiatry2014;8:1. KaneJM . RAISE‐ETP: NAVIGATE vs usual care ‐ two year outcomes. Schizophrenia Bulletin2015;41:S317. KaneJM . The RAISE ETP study: initial results. Early Intervention in Psychiatry2014;8:2. KaneJM , RobinsonDG , SchoolerNR , MueserKT , PennDL , RosenheckRA , et al. Comprehensive versus usual community care for first‐episode psychosis: 2‐year outcomes from the NIMH RAISE early treatment program. American Journal of Psychiatry2016;173:362‐72. MueserKT . Description and implementation of the RAISE‐ETP study psychosocial treatment model: the NAVIGATE program. Schizophrenia Bulletin2015;41:S325‐6. MueserKT , PennDL , AddingtonJ , BrunetteMF , GingerichS , GlynnSM , et al. The NAVIGATE Program for first‐episode psychosis: rationale, overview, and description of psychosocial components. Psychiatric Services2015;66(7):680‐90. RobinsonDG , SchoolerNR , JohnM , CorrellCU , MarcyP , AddingtonJ , et al. Prescription practices in the treatment of first‐episode schizophrenia spectrum disorders: data from the national RAISE‐ETP study. American Journal of Psychiatry2015;172(3):237‐48. SchoolerN . RAISE‐ETP study design, site selection and implementation model. Early Intervention in Psychiatry2014;8:1. SchoolerNR . The RAISE‐ETP study design, research and implementation model. Schizophrenia Bulletin2015;41:S332‐3. ">RAISE‐ETP‐USA</a>, <a href="./references#CD012236-bbs2-0044" title="RamsayI , FryerS , BoosA , RoachBJ , FisherM , LoewyR , et al. Targeted cognitive training is neuroprotective against thalamic volume loss in early schizophrenia. Schizophrenia Bulletin2017;43:S49. ">Ramsay‐USA</a>, <a href="./references#CD012236-bbs2-0046" title="SchmechtigA , DourishC , CraigK , DawsonGR , WilliamsS , DeakinW , et al. Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by high schizotypy. Pharmacopsychiatry2011;21:A99. SchmechtigA , LeesJ , DawsonG , DourishC , CraigK , DeakinB , et al. Effects of high schizotypy on control of eye movements: Modulation by antipsychotic drugs and nicotine. Neuropsychopharmacology2010;35:S389. SchmechtigA , LeesJ , DawsonG , DourishC , CraigK , DeakinB , et al. Effects of high schizotypy on control of eye movements: modulation by antipsychotic drugs and nicotine. 49th Annual Meeting of the American College of Neuropsychopharmacology; 2010 Dec 5‐9; Miami, Florida. 2010. SchmechtigA , LeesJ , DawsonGR , DourishCT , CraigKJ , DeakinJF , et al. Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy. Pharmacopsychiatry. 2011:306. ">Schmechtig‐USA</a>, <a href="./references#CD012236-bbs2-0047" title="UherR , CumbyJ , MacKenzieLE , Morash‐ConwayJ , GloverJM , AylottA , et al. A familial risk enriched cohort as a platform for testing early interventions to prevent severe mental illness. BMC Psychiatry2014;14:344. UherR , CumbyJ , McKenzieL , MorashJ , BagnellA , PropperL , et al. Families overcoming risks and building opportunities for wellbeing (FORBOW): a high‐risk cohort multiple randomised controlled trial. Early Intervention in Psychiatry2014;8:6. ">Uher‐Canada</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terminated early</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0030" title="NCT00276263 . Sarcosine (n‐methylglycine) trial for individuals at risk for developing schizophrenia and related disorders. www.ClinicalTrials.gov/ct/show/2006. ">Heresco‐Levy‐Israel</a>, <a href="./references#CD012236-bbs2-0039" title="McGorryP , AmmingerP . A comparison study of quetiapine medication and psychological therapy versus placebo tablets and psychological therapy in patients who are deemed at risk of developing a psychotic disorder. Australian New Zealand Clinical Trials Registry2010. ">NEURAPRO‐Q‐Australia</a>, <a href="./references#CD012236-bbs2-0042" title="NCT02582528 . Cognitive remediation in youth at risk of serious mental Illness. ClinicalTrials.gov/show/NCT025825282015. ">Piskulic‐2‐Canada</a>, <a href="./references#CD012236-bbs2-0045" title="CornblattB . Risperidone vs sertraline for prodromal schizophrenia. Stanley Foundation Research Programs2009. NCT00169988 . Sertraline alone vs in combination with risperidone in the treatment of attenuated positive and negative symptoms. www.ClinicalTrials.gov/ct/show/2005. ">RAP‐USA</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Different outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0040" title="O'NeillA , WilsonR , Appiah‐KusiE , BossongM , McGuireP , BhattacharyyaS . Effects of cannabidiol on mediotemporal and dorsostriatal activity during encoding and recall, in the at‐risk mental state for psychosis. Schizophrenia Bulletin2017;43:S187. ">O'Neill‐UK</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Not randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0021" title="BergerG . Lithium in patients at ultra high risk of developing a first psychotic episode. Stanley Foundation Research Programs2006. BergerGE , WoodSJ , RossM , HamerCA , WellardRM , PellG , et al. Neuroprotective effects of low‐dose lithium in individuals at ultra‐high risk for psychosis. A longitudinal MRI/MRS study. Current Pharmaceutical Design2012;18:570‐5. ">Berger‐Australia</a>, <a href="./references#CD012236-bbs2-0028" title="Anonymous . Re: McFarlane, W. R., et al: clinical and functional outcomes after 2 years in the early detection and intervention for the prevention of psychosis multisite effectiveness trial. Schizophr Bull. 2015 Jan;41(1):30‐43. Schizophrenia Bulletin2015;41(2):532. McFarlaneWR , LevinB , TravisL , LucasFL , LynchS , VerdiM , et al. Clinical and functional outcomes after 2 years in the early detection and intervention for the prevention of psychosis multisite effectiveness trial. Schizophrenia Bulletin2015;41(1):30‐43. NCT00531518 . Early detection and intervention for the prevention of psychosis, a multisite study. www.ClinicalTrials.gov/ct/show/2007. ">EDIPP‐USA</a>, <a href="./references#CD012236-bbs2-0029" title="ChongS . Translational and clinical research programme in psychosis. Early Intervention in Psychiatry2008;2(Suppl 1):A130. ">EPIP‐Singapoure</a>, <a href="./references#CD012236-bbs2-0032" title="KeriS , KelemenO , JankaZ . Therapy of mental states at high risk for psychosis: preliminary results from Hungary [A psychosis szempontjából nagy kockázatú mentális állapotok és kezelésük: első hazai eredmények]. Orvosi Hetilap2006;147(5):201‐4. ">Keri‐Hungary</a>, <a href="./references#CD012236-bbs2-0038" title="LewisL , UnkeferEP , O'NealSK , CrithCJ , FultzJ . Cognitive rehabilitation with patients having persistent, severe psychiatric disabilities. Psychiatric Rehabilitation Journal2003;26(4):325‐31. ">Lewis‐USA</a>, <a href="./references#CD012236-bbs2-0049" title="NCT00268749 . Glycine treatment of prodromal symptoms. www.ClinicalTrials.gov/ct/show/2005. WoodsS . A 12‐week open label trial of glycine treatment of prodromal symptoms of schizophrenia in 25 patients. Glycine is an amino acid that stimulates the NMDA receptor. Some theories of schizophrenia posit that NMDA receptors may be hypoactive. Stanley Foundation Research Programs2002. ">Woods‐2‐USA</a>, <a href="./references#CD012236-bbs2-0048" title="VadhanNP , CorcoranCM , BediGI , LiebermanJG , HaneyM . Marijuana smokers at clinical high‐risk for schizophrenia exhibit an enhanced subjective, behavioral and physiological response to smoked marijuana. Comprehensive Psychiatry2013;54(8):e37. ">Vadhan‐USA</a> </p> </td> </tr> </tbody> </table> </div> </p> <p>Reasons for exclusion of each study are described in <a href="./references#CD012236-sec-0540" title="">Characteristics of excluded studies</a> tables. </p> <section id="CD012236-sec-0152"> <h5 class="title">Awaiting classification</h5> <p>Seven studies are awaiting assessment (see descriptions in <a href="./references#CD012236-sec-0541" title="">Characteristics of studies awaiting classification</a> table). For three of them published data are not usable for analysis and the other four require further clarification. Ultimately, we will exclude studies where data are unobtainable. </p> </section> <section id="CD012236-sec-0153"> <h5 class="title">Ongoing studies</h5> <p>We are awaiting data from 17 studies (see descriptions in <a href="./references#CD012236-sec-0542" title="">Characteristics of ongoing studies</a> table). This is an active area for research. </p> </section> </section> </section> <section id="CD012236-sec-0154"> <h3 class="title">Risk of bias in included studies</h3> <p>Overview of risk of bias in included studies is illustrated in <a href="#CD012236-fig-0001">Figure 1</a> and across different domains of risk of bias in <a href="#CD012236-fig-0002">Figure 2</a>. </p> <section id="CD012236-sec-0155"> <h4 class="title">Allocation</h4> <p>The authors of all 20 included studies described them as randomised. Eight studies adequately described the process of generating a random sequence using a computer or web‐based resources (<a href="./references#CD012236-bbs2-0002" title="AmmingerG . Ethyl eicosapentanoic acid for prodromal psychosis. Stanley Foundation Research Programs2009. [CSzG: Ref17423] AmmingerG , SchaferM , PapageorgiouK , CottonS , HarriganS , MackinnonA , et al. Indicated prevention with long‐chain omega‐3 fatty acids in adolescents at ultra‐high‐risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2008;2(Suppl 1):A29. [CSzG: Ref19107] AmmingerGP , ChanenAM , OhmannS , KlierCM , MossahebN , BechdolfA , et al. Omega‐3 fatty acid supplementation in adolescents with borderline personality disorder and ultra‐high risk criteria for psychosis: a post hoc subgroup analysis of a double‐blind, randomised controlled trial. Canadian Journal of Psychiatry2013;58(7):402‐8. [CSzG: Ref28534] AmmingerGP , HarrisMS , McGorryPD , HenryLP . Omega‐3 fatty acids for indicated prevention: treatment results and pathomechanisms. European Archives of Psychiatry and Clinical Neuroscience2013;263(Suppl. 1):S44‐5. [CSzG: Ref28434] AmmingerGP , LeicesterS , YungAR , YuenHP , McGorryPD . Age predicts transition to psychosis in an ultra‐high risk sample. Proceedings of the 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:61. AmmingerGP , McGorryPD . Update on omega‐3 polyunsaturated fatty acids in early ‐stage psychotic disorders. Neuropsychopharmacology2012;37(1):309‐10. [CSzG: Ref23726] AmmingerGP , MechelliA , RiceS , KimSW , KlierCM , McNamaraRK , et al. Predictors of treatment response in young people at ultra‐high risk for psychosis who received long‐chain omega‐3 fatty acids. Translational Psychiatry2015;5:e495. [CSzG: Ref29299] AmmingerGP , SchaferMR . Indicated prevention with omega‐3 fatty acids in adolescents at ultra‐high risk for psychosis ‐ rationale, methods, and 3‐months outcome. Schizophrenia Research2006;86(Suppl 1):S97‐8. [CSzG: Ref13367] AmmingerGP , SchaferMR . Is it feasible to conduct a RCT in ultra‐high risk individuals at a child and adolescent psychiatric service?. Schizophrenia Research2006;86(Suppl 1):S98. [CSzG: Ref13368] AmmingerGP , SchaferMR , KlierCM , PapageorgiouK , SlavikJ , HolzerI , et al. Indicated prevention with long‐chain omega‐3 fatty acids in young people at ultra‐high risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2010;4(Suppl 1):7. [CSzG: Ref23467] AmmingerGP , SchaferMR , SchlogelhoferM , KlierCM , McGorryPD . Longer‐term outcome in the prevention of psychotic disorders by the Vienna omega‐3 study. Nature Communications2015;6:7934. [CSzG: Ref33023] AmmingerGP , SchlogelhoferM , KlierC , McGorryP , SchaferM . Longer‐term follow‐up in the Vienna omega‐3 psychosis prevention trial. Early Intervention in Psychiatry2014;8:41. [CSzG: Ref29378] AmmingerGP , SchäferMR , PapageorgiouK , KlierCM , CottonSM , HarriganSM , et al. Long‐chain omega‐3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo‐controlled trial. Archives of General Psychiatry2010;67(2):146‐54. [CSzG: Ref20680; DOI: 10.1001/archgenpsychiatry.2009.192.] AmmingerP , MossahebN , SchlgelhoferM , SchaferM . Fatty acid metabolism and the onset of psychotic disorder. European Psychiatry2011;26(Suppl 1):2089. [CSzG: Ref22967] Anonymous . Fish oil may help ward off psychosis. Journal of Psychosocial Nursing and Mental Health Services2010;48(5):55. [CSzG: Ref20739] BergerG , AmmingerP , McGorryP . Stage dependant effect of omega‐3 fatty acids in emerging psychosis. European Psychiatry2011;26(Suppl 1):1347. [CSzG: Ref22966] BergerGE , ProffittTM , McConchieM , YuenH , WoodSJ , AmmingerGP , et al. Ethyl‐eicosapentaenoic acid in first‐episode psychosis: a randomised, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(12):1867‐75. [CSzG: Ref15561; ISSN: 1555‐2101] EhrlichA . Evidence‐based medicine. Omega‐3 supplementation delays transition to psychotic disorder in ultra‐high‐risk adolescents and young adults. Clinical Advisor for Nurse Practitioners2010;13(5):79‐80. [CSzG: Ref21562] FöckingM , DickerP , LopezLM , CannonM , SchäferMR , McGorryPD , et al. Differential expression of the inflammation marker IL12p40 in the at‐risk mental state for psychosis: a predictor of transition to psychotic disorder?. BMC Psychiatry2016;16(1):326. [DOI: 10.1186/s12888‐016‐1039‐7] KlierC , HollmannM , SchlögelhoferM , MossahebN , FriedrichM , AmmingerPG . Indicated prevention with omega‐3 fatty acids (EPA/DHA) in adolescents with &quot;at‐risk‐mental‐state“ for psychosis. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. [CSzG: Ref12438] LavoieS , BenningerF , FeuchtM , KlierCM , SchaeferMR , AmmingerGP . Correlates of EEG resting states with erythrocyte membrane omega‐3 fatty acid levels and psychopathological symptoms in individuals at ultra‐high risk for psychosis. Early Intervention in Psychiatry2014;8:137. [CSzG: Ref29516] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultra‐high risk individuals who transitioned to psychosis. Schizophrenia Research2012;138(2‐3):206‐11. [CSzG: Ref24256] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultrahigh risk individuals who transitioned to psychosis. Early Intervention in Psychiatry2012;6:38. [CSzG: Ref24960] MossahebN , PapageorgiouK , SchaferMR , BeckerJ , SchloegelhoferM , AmmingerGP . Changes in triglyceride levels in ultra‐high risk for psychosis individuals treated with omega‐3 fatty acids. Early Intervention in Psychiatry2018; Vol. 12, issue 1:30‐36. [DOI: 10.1111/eip.12275] MossahebN , SchaferMR , SchlogelhoferM , KlierCM , CottonSM , McGorryPD , et al. Effect of omega‐3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?. Schizophrenia Research2013;148(1‐3):163‐7. [CSzG: Ref28649] NCT00396643 . Indicated prevention with omega‐3 fatty acids in adolescents with ‘at‐risk‐mental‐state’ for psychosis: a randomised, double blind, placebo‐controlled treatment trial. www.ClinicalTrials.gov/ct/show/2006. [CSzG: Ref14873] PapageorgiouK , SchaferMR , SchlogelhoferM , MossahebN , AmmingerGP . Indicated prevention with omega‐3 fatty acids in young people with 'at‐risk‐mental‐state' for psychosis: design of a 5‐year follow‐up. European Archives of Psychiatry and Clinical Neuroscience2011;261:S55. [CSzG: Ref23749] SchaferMR , KlierCM , PapageorgiouK , FriedrichMH , AmmingerGP . Early detection of psychotic disorders. Neuropsychiatrie2007;21(1):37‐44. [CSzG: Ref15290] SmesnyS , MilleitB , HiplerUC , MilleitC , SchaferMR , KlierCM , et al. Omega‐3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra‐high risk for psychosis. Molecular Psychiatry2013;19(3):317‐24. [CSzG: Ref28243] SmesnyS , MilleitB , SchaeferMR , HesseJ , SchlögelhoferM , LangbeinK , et al. Effects of omega‐3 PUFA on immune markers in adolescent individuals at ultra‐high risk for psychosis ‐ results of the randomised controlled Vienna omega‐3 study. Schizophrenia Research2017;S0920‐9964(17):30039‐7. [DOI: 10.1016/j.schres.2017.01.026] ">Amminger‐Austria</a>; <a href="./references#CD012236-bbs2-0004" title="CrittendenK , FlemingJ , StartupM , CarrV , BakerA , SchallU , et al. Recruitment and engagement of youth in an ultra high risk treatment study. Early Intervention in Psychiatry2008;2(Suppl 1):A127. [CSzG: Ref19115] StainH , BucciS , HalperinS , EmsleyR , ShallU , LewinT , et al. DEPTh: randomised controlled trial of cognitive behavioral therapy for young people at ultra high risk for psychosis. Early Intervention in Psychiatry2014;8:15. [CSzG: Ref29673] StainHJ , BucciS , BakerA , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of CBT for young people at risk for psychosis: the Detection and Evaluation of Psychological Therapy (DEPTh) trial. European Archives of Psychiatry and Clinical Neuroscience2015;1:S8‐9. [CSzG: Ref33810] StainHJ , BucciS , BakerAL , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of cognitive behaviour therapy versus non‐directive reflective listening for young people at ultra high risk of developing psychosis: the detection and evaluation of psychological therapy (DEPTh) trial. Schizophrenia Research2016;176(2‐3):212‐9. [CSzG: Ref35298] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. Rural and urban youth at ultra high risk for psychosis: baseline characteristics from the DEPTh randomised controlled trial of cognitive behavior therapy. Schizophrenia Bulletin2011;37:322. [CSzG: Ref22815] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy for youth at ultra high risk for psychosis: baseline characteristics for rural and urban youth. Australian and New Zealand Journal of Psychiatry2010:25‐6. [CSzG: Ref21845] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy targeting ultra high risk for psychosis: baseline comparisons for rural and urban youth. Early Intervention in Psychiatry2010;4(Suppl 1):113. [CSzG: Ref23498] StainHJ , StartupM , CarrV , BakerA , SchallU . The DEPTh project: a multisite RCT for youths at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S51‐2. [CSzG: Ref13401] StartupM . The DEPTh project: detection, evaluation, and psychological therapy for health. Australian New Zealand Clinical Trials Registry2006. [CszG: Ref18442] ">DEPTh‐Australia</a>; <a href="./references#CD012236-bbs2-0005" title="ByrneRE , MorrisonAP . Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. Psychology and Psychotherapy2014;87(3):357‐71. [CSzG: Ref29312] FlachC , FrenchP , DunnG , FowlerD , GumleyAI , BirchwoodM , et al. Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE‐2 trial. British Journal of Psychiatry2015;207(2):123‐9. [CSzG: Ref33109] MorrisonA . Early detection and intervention evaluation for individuals at high risk of psychosis 2. http://www.controlled‐trials.com2008. [CSzG: Ref18285] MorrisonA . Early detection and intervention evaluation for people at risk of psychosis (edie‐2): A multisite randomised controlled trial of cognitive therapy for at‐risk mental states. Early Intervention in Psychiatry2012;6:11. [CSzG: Ref24968] MorrisonA , FrenchP , BentallR , LewisS , BirchwoodM , FowlerD , et al. Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. Early Intervention in Psychiatry2008;2(Suppl 1):A15. [CSzG: Ref19128] MorrisonAP . EDIE‐2: early detection and psychological intervention for individuals at high risk of psychosis (2). www.controlled‐trials.com2007. [CSzG: Ref15381] MorrisonAP , BirchwoodM , PyleM , FlachC , StewartSL , ByrneR , et al. Impact of cognitive therapy on internalised stigma in people with at‐risk mental states. British Journal of Psychiatry2013;203(2):140‐5. [CSzG: Ref28630] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ2012;344(7852):e2233. [CSzG: Ref24208] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at‐risk of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29554] MorrisonAP , PyleM , StewartSL , FrenchP , ByrneR , FlachC , et al. Internalised stigma in young people at high risk of developing psychosis: findings from a cognitive therapy trial. Schizophrenia Research2014;153:S42. [CSzG: Ref29555] MorrisonAP , StewartSL , FrenchP , BentallRP , BirchwoodM , ByrneR , et al. Early detection and intervention evaluation for people at high‐risk of psychosis‐2 (EDIE‐2): trial rationale, design and baseline characteristics. Early Intervention in Psychiatry2011;5(1):24‐32. [CSzG: Ref22695] MorrisonT . Early detection and psychological intervention for individuals at high risk of psychosis. EDIE‐2. Data on File2006. [CSzG: Ref13874] PelosiAJ . Rational policy making for early psychosis might yet become possible. BMJ2012;344(7856):e3137. [CSzG: Ref24326] PyleM , StewartSL , FrenchP , ByrneR , PattersonP , GumleyA , et al. Internalised stigma, emotional dysfunction and unusual experiences in young people at risk of psychosis. Early Intervention in Psychiatry2015;9(2):133‐40. [CSzG: Ref29813] ">EDIE‐2‐UK</a>; <a href="./references#CD012236-bbs2-0006" title="DragtS , Van derGaagM . Prevention of psychosis with a cognitive behavioural intervention in help‐seeking young people with an at risk mental state for developing psychosis. www.trialregister.nl/trialreg/index.asp2007. [CSzG: Ref19655] IsingHK , KraanTC , RietdijkJ , DragtS , KlaassenRM , BoonstraN , et al. Four‐year follow‐up of cognitive behavioral therapy in persons at ultra‐high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2016;42(5):1243‐52. [CSzG: Ref35214] IsingHK , LokkerbolJ , RietdijkJ , DragtS , KlaassenRM , KraanT , et al. Four‐year cost‐effectiveness of cognitive behavior therapy for preventing first‐episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2017;43(2):365‐74. [CSzG: Ref35824] IsingHK , SmitF , VelingW , RietdijkJ , DragtS , KlaassenRM , et al. Cost‐effectiveness of preventing first‐episode psychosis in ultra‐high‐risk subjects: multi‐centre randomised controlled trial. Psychological Medicine2015;45(7):1435‐46. [CSzG: Ref27798] KraanTC , IsingHK , FokkemaM , VelthorstE , Van denBergDP , KerkhovenM , et al. The effect of childhood adversity on 4‐year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE‐NL) Trial. Psychiatry Research2017;247:55‐62. [CSzG: Ref35559] NiemanDH , RuhrmannS , RietdijkJ , DragtS , IsingH , KlaassenR , et al. Preventive psychotherapy. Schizophrenia Research2014;153:S42‐3. [CSzG: Ref29601] RietdijkJ , DragtS , KlaassenR , IsingH , NiemanD , WunderinkL , et al. A single blind randomised controlled trial of cognitive behavioural therapy in a help‐seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE‐NL) trial. Trials2010;11:30. [CSzG: Ref20654] Van DerGaagM . The effects of CBT in personswith ultra high risk: the Dutch EDIE trial. European Archives of Psychiatry and Clinical Neuroscience2011;261:S18. [CSzG: Ref23756] Van DerGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first‐episode of psychosis. Early Intervention in Psychiatry2012;6:12. [CSzG: Ref24985] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomised controlled clinical trial. Schizophrenia Bulletin2012;38(6):1180‐8. [CSzG: Ref24935] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. The effects of cognitive behavioural therapy for subjects at ultra‐high risk for developing psychosis. Schizophrenia Bulletin2013;39:S356. [CSzG: Ref28121] Van derGaagM . The prevention of psychosis in at risk mental state. www.controlled‐trials.com2008. [CSzG: Ref17488] Van derGaagM , NiemanD , Van denBergD . CBT for those at risk of a first episode psychosis: Evidence‐based psychotherapy for people with an 'at risk mental state'. 1st Edition. Hove, UK: Routledge, 2013. Van derGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first episode of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29692] ">EDIE‐NL</a>; <a href="./references#CD012236-bbs2-0009" title="BechdolfA . Preventing progression to first‐episode psychosis in people in the early initial prodromal state. Early Intervention in Psychiatry2012;6:11. [CSzG: 24944] BechdolfA , BuhlerB , BerningJ , WagnerM , StammE , StreitM . Cognitive behavioural therapy in the early initial prodromal state of psychosis: first results. Schizophrenia Research2004;67(1):202. [CSzG: Ref11285] BechdolfA , KlosterkotterJ . Cognitive‐behavioural treatment (CBT) in the early initial prodromal state of psychosis: concept and practical approach. Schizophrenia Research2004;70(1):52. [CSzG: Ref11506] BechdolfA , RuhrmannS , JanssenB , BottlenderR , WagnerM , MaurerK , et al. Early recognition and intervention for people at risk of schizophrenia [Fruherkennung und intervention bei personen mit erhohtem psychoserisiko]. Psychoneuroendocrinology2004;30(11):606‐14. [CSzG: Ref11376] BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: Ref12511] BechdolfA , VeithV , BerningJ , StammE , DeckerP , JanssenB , et al. Cognitive behavioral therapy (CBT) in the early initial prodromal state of psychosis: first results of a randomised trial. Schizophrenia Research2004;70(1):62‐3. [CSzG: Ref11507] BechdolfA , WagnerM , RuhrmannS , HarriganS , PutzfeldV , PukropR , et al. Preventing progression to first‐episode psychosis in early initial prodromal states. British Journal of Psychiatry2012;200(1):22‐9. [CSzG: Ref24206] BechdolfA , WagnerM , RuhrmannS , HarriganS , VeithV , PukropR , et al. CBT for prevention of first episode psychosis in people in an putative early initial prodromal state. Early Intervention in Psychiatry2008;2(Suppl 1):A16. [CSzG: 19109] BechdolfA , WagnerM , VeithV , PukropR , BerningJ , StammE , et al. A randomised controlled trial of cognitive‐behavioral therapy in the early initial prodromal state of psychosis. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:22‐3. [CSzG: 20193] BechdolfA , WagnerM , VeithV , RuhrmannR , JanssenB , BottlenderR , et al. A randomised controlled multicenter trial of cognitive behaviour therapy in the early initial prodromal state of psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13369] BechdolfA , WagnerM , VeithV , RuhrmannS , PukropR , Brockhaus‐DumkeA , et al. Randomised controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Intervention in Psychiatry2007;1(1):71‐8. [CSzG: 16450] BechdolfA , WesselsH , WagnerM , KuhrK , BerningJ , PutzfeldV , et al. Predictors of treatment response to psychosocial interventions in people at risk. European Archives of Psychiatry and Clinical Neuroscience2015;1:S9. [CSzG: 33601] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] KommescherM , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. Early Intervention in Psychiatry2016;10(1):17‐27. [CSzG: 32187] NCT00204087 . Psychological intervention for persons at risk of psychosis in the early initial prodromal state. www.ClinicalTrials.gov/ct/show/2005. [CSzG: 14890] WesselsH , WagnerM , FrommannI , BerningJ , PutzfeldV , JanssenB , et al. Neuropsychological functioning as a predictor of treatment response to psychoeducational, cognitive behavioral therapy in people at clinical high risk of first episode psychosis. Psychiatrische Praxis2015;42(6):313‐9. [CSzG: 33130] ZarafonitisS , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Psychoeducation for persons at risk of psychosis. Psychotherapeut2012;57(4):326‐34. [CSzG: 24807] ">EIPS‐Germany</a>; <a href="./references#CD012236-bbs2-0013" title="ACTRN12608000475347 . A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder. Australian New Zealand Clinical Trials Registry2009. [CSzG: 18420] HKCTR‐1438 . The NEURAPRO‐E (North America, EURope, Australia PROdrome) Study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for symptomatic patients at ultra‐high risk for early progression to schizophrenia and other psychotic disorders. www.hkClinicaltrials.com/trial_details.aspx?trialID=d09bd177‐b9fd‐4162‐b04f‐3ebfed49baa32011. [CSzG: 29270] McGorryP , MarkulevC , NelsonB , YuenHP , SchaeferM , YungAR , et al. The NEURAPRO‐E study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Schizophrenia Bulletin2015;41:S322‐3. [CSzG: 29546] McGorryPD , NelsonB , MarkulevC , YuenHP , SchaferMR , MossahebN , et al. Effect of omega‐3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomised clinical trial. JAMA psychiatry2017;74(1):19‐27. [CSzG: 35590] NelsonB , AmmingerG , MarkulevC , YuenHP , LavoieS , SchaeferM , et al. NEURAPOR: a multi‐center RCT of omega‐3 polyunsaturated fatty acids versus placebo in young people at ultra‐high risk of psychotic disorders: medium‐term outcome. Schizophrenia Bulletin2017;43:S107. [CSzG: 36016] ">NEURAPRO‐AAE</a>; <a href="./references#CD012236-bbs2-0014" title="NordentoftM , JeppesenP , PetersenL , ThorupA , OhlenschlaegerJ , ChristensenT , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. European Psychiatry2007;22:S129‐S. [CSzG: 20471] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the OPUS trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;83(1):29‐40. [CSzG: 13197] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;86(Suppl 1):S44. [CSzG: 13393] ">Nordentoft‐Denmark</a>), or minimisation (<a href="./references#CD012236-bbs2-0001" title="AddingtonJ , EpsteinI , LiuL , FrenchP , BoydellKM , ZipurskyRB . A randomised controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research2011;125(1):54‐61. [CSzG: Ref21945] AddingtonJ , ZipurskyR , EpsteinI . ADAPT (Access, Detection and Psychological Treatments). Schizophrenia Research2006;86(Suppl 1):S6. [CSzG: Ref13364] NCT00260273 . Access, detection and psychological treatments. www.ClinicalTrials.gov/ct/show/2005. [CSzG: Ref14638] ">ADAPT‐Canada</a>), so we judged it at low risk of bias. In other studies method for generating random sequence was not described, so we judged them at unclear risk of bias. </p> <p>Allocation concealment was adequately described in only one study (<a href="./references#CD012236-bbs2-0010" title="KantrowitzJT , WoodsSW , PetkovaE , CornblattB , CorcoranCM , ChenH , et al. D‐serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double‐blind, placebo‐controlled, randomised parallel group mechanistic proof‐of‐concept trial. Lancet Psychiatry2015;2(5):403‐12. [CSzG: 29487] NCT00826202 . D‐serine for the schizophrenia prodrome. www.ClinicalTrials.gov/ct/show/2009. [CSzG: 17391] ">Kantrowitz‐USA</a>), so we judged it at low risk of bias. In the remaining studies allocation concealment was either not described or only briefly commented on and we were unable to determine in these instances if concealment was adequate, so we judged them at unclear risk of bias. </p> </section> <section id="CD012236-sec-0156"> <h4 class="title">Blinding</h4> <p>Eight studies used the double‐blind design, blinding both participants and clinicians (<a href="./references#CD012236-bbs2-0002" title="AmmingerG . Ethyl eicosapentanoic acid for prodromal psychosis. Stanley Foundation Research Programs2009. [CSzG: Ref17423] AmmingerG , SchaferM , PapageorgiouK , CottonS , HarriganS , MackinnonA , et al. Indicated prevention with long‐chain omega‐3 fatty acids in adolescents at ultra‐high‐risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2008;2(Suppl 1):A29. [CSzG: Ref19107] AmmingerGP , ChanenAM , OhmannS , KlierCM , MossahebN , BechdolfA , et al. Omega‐3 fatty acid supplementation in adolescents with borderline personality disorder and ultra‐high risk criteria for psychosis: a post hoc subgroup analysis of a double‐blind, randomised controlled trial. Canadian Journal of Psychiatry2013;58(7):402‐8. [CSzG: Ref28534] AmmingerGP , HarrisMS , McGorryPD , HenryLP . Omega‐3 fatty acids for indicated prevention: treatment results and pathomechanisms. European Archives of Psychiatry and Clinical Neuroscience2013;263(Suppl. 1):S44‐5. [CSzG: Ref28434] AmmingerGP , LeicesterS , YungAR , YuenHP , McGorryPD . Age predicts transition to psychosis in an ultra‐high risk sample. Proceedings of the 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:61. AmmingerGP , McGorryPD . Update on omega‐3 polyunsaturated fatty acids in early ‐stage psychotic disorders. Neuropsychopharmacology2012;37(1):309‐10. [CSzG: Ref23726] AmmingerGP , MechelliA , RiceS , KimSW , KlierCM , McNamaraRK , et al. Predictors of treatment response in young people at ultra‐high risk for psychosis who received long‐chain omega‐3 fatty acids. Translational Psychiatry2015;5:e495. [CSzG: Ref29299] AmmingerGP , SchaferMR . Indicated prevention with omega‐3 fatty acids in adolescents at ultra‐high risk for psychosis ‐ rationale, methods, and 3‐months outcome. Schizophrenia Research2006;86(Suppl 1):S97‐8. [CSzG: Ref13367] AmmingerGP , SchaferMR . Is it feasible to conduct a RCT in ultra‐high risk individuals at a child and adolescent psychiatric service?. Schizophrenia Research2006;86(Suppl 1):S98. [CSzG: Ref13368] AmmingerGP , SchaferMR , KlierCM , PapageorgiouK , SlavikJ , HolzerI , et al. Indicated prevention with long‐chain omega‐3 fatty acids in young people at ultra‐high risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2010;4(Suppl 1):7. [CSzG: Ref23467] AmmingerGP , SchaferMR , SchlogelhoferM , KlierCM , McGorryPD . Longer‐term outcome in the prevention of psychotic disorders by the Vienna omega‐3 study. Nature Communications2015;6:7934. [CSzG: Ref33023] AmmingerGP , SchlogelhoferM , KlierC , McGorryP , SchaferM . Longer‐term follow‐up in the Vienna omega‐3 psychosis prevention trial. Early Intervention in Psychiatry2014;8:41. [CSzG: Ref29378] AmmingerGP , SchäferMR , PapageorgiouK , KlierCM , CottonSM , HarriganSM , et al. Long‐chain omega‐3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo‐controlled trial. Archives of General Psychiatry2010;67(2):146‐54. [CSzG: Ref20680; DOI: 10.1001/archgenpsychiatry.2009.192.] AmmingerP , MossahebN , SchlgelhoferM , SchaferM . Fatty acid metabolism and the onset of psychotic disorder. European Psychiatry2011;26(Suppl 1):2089. [CSzG: Ref22967] Anonymous . Fish oil may help ward off psychosis. Journal of Psychosocial Nursing and Mental Health Services2010;48(5):55. [CSzG: Ref20739] BergerG , AmmingerP , McGorryP . Stage dependant effect of omega‐3 fatty acids in emerging psychosis. European Psychiatry2011;26(Suppl 1):1347. [CSzG: Ref22966] BergerGE , ProffittTM , McConchieM , YuenH , WoodSJ , AmmingerGP , et al. Ethyl‐eicosapentaenoic acid in first‐episode psychosis: a randomised, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(12):1867‐75. [CSzG: Ref15561; ISSN: 1555‐2101] EhrlichA . Evidence‐based medicine. Omega‐3 supplementation delays transition to psychotic disorder in ultra‐high‐risk adolescents and young adults. Clinical Advisor for Nurse Practitioners2010;13(5):79‐80. [CSzG: Ref21562] FöckingM , DickerP , LopezLM , CannonM , SchäferMR , McGorryPD , et al. Differential expression of the inflammation marker IL12p40 in the at‐risk mental state for psychosis: a predictor of transition to psychotic disorder?. BMC Psychiatry2016;16(1):326. [DOI: 10.1186/s12888‐016‐1039‐7] KlierC , HollmannM , SchlögelhoferM , MossahebN , FriedrichM , AmmingerPG . Indicated prevention with omega‐3 fatty acids (EPA/DHA) in adolescents with &quot;at‐risk‐mental‐state“ for psychosis. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. [CSzG: Ref12438] LavoieS , BenningerF , FeuchtM , KlierCM , SchaeferMR , AmmingerGP . Correlates of EEG resting states with erythrocyte membrane omega‐3 fatty acid levels and psychopathological symptoms in individuals at ultra‐high risk for psychosis. Early Intervention in Psychiatry2014;8:137. [CSzG: Ref29516] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultra‐high risk individuals who transitioned to psychosis. Schizophrenia Research2012;138(2‐3):206‐11. [CSzG: Ref24256] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultrahigh risk individuals who transitioned to psychosis. Early Intervention in Psychiatry2012;6:38. [CSzG: Ref24960] MossahebN , PapageorgiouK , SchaferMR , BeckerJ , SchloegelhoferM , AmmingerGP . Changes in triglyceride levels in ultra‐high risk for psychosis individuals treated with omega‐3 fatty acids. Early Intervention in Psychiatry2018; Vol. 12, issue 1:30‐36. [DOI: 10.1111/eip.12275] MossahebN , SchaferMR , SchlogelhoferM , KlierCM , CottonSM , McGorryPD , et al. Effect of omega‐3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?. Schizophrenia Research2013;148(1‐3):163‐7. [CSzG: Ref28649] NCT00396643 . Indicated prevention with omega‐3 fatty acids in adolescents with ‘at‐risk‐mental‐state’ for psychosis: a randomised, double blind, placebo‐controlled treatment trial. www.ClinicalTrials.gov/ct/show/2006. [CSzG: Ref14873] PapageorgiouK , SchaferMR , SchlogelhoferM , MossahebN , AmmingerGP . Indicated prevention with omega‐3 fatty acids in young people with 'at‐risk‐mental‐state' for psychosis: design of a 5‐year follow‐up. European Archives of Psychiatry and Clinical Neuroscience2011;261:S55. [CSzG: Ref23749] SchaferMR , KlierCM , PapageorgiouK , FriedrichMH , AmmingerGP . Early detection of psychotic disorders. Neuropsychiatrie2007;21(1):37‐44. [CSzG: Ref15290] SmesnyS , MilleitB , HiplerUC , MilleitC , SchaferMR , KlierCM , et al. Omega‐3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra‐high risk for psychosis. Molecular Psychiatry2013;19(3):317‐24. [CSzG: Ref28243] SmesnyS , MilleitB , SchaeferMR , HesseJ , SchlögelhoferM , LangbeinK , et al. Effects of omega‐3 PUFA on immune markers in adolescent individuals at ultra‐high risk for psychosis ‐ results of the randomised controlled Vienna omega‐3 study. Schizophrenia Research2017;S0920‐9964(17):30039‐7. [DOI: 10.1016/j.schres.2017.01.026] ">Amminger‐Austria</a>; <a href="./references#CD012236-bbs2-0003" title="ChoiJ , CorcoranC , DixonL , FiszdonJ , JavittD . Processing speed training and social functioning in young adults at clinical high risk for psychosis: a pilot study. Early Intervention in Psychiatry2014;8:109. [CSzG: Ref29417] ChoiJ , CorcoranC , DixonL , JavittDC . Processing speed training and social functioning in teenagers and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2015;41:S41. [CSzG: Ref29418] ChoiJ , CorcoranCM , FiszdonJM , StevensM , JavittDC , DeasyM , et al. Pupillometer‐based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis. Psychiatric Rehabilitation Journal2017;40(1):33‐42. [CSzG: Ref35317] ">Choi‐USA</a>; <a href="./references#CD012236-bbs2-0010" title="KantrowitzJT , WoodsSW , PetkovaE , CornblattB , CorcoranCM , ChenH , et al. D‐serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double‐blind, placebo‐controlled, randomised parallel group mechanistic proof‐of‐concept trial. Lancet Psychiatry2015;2(5):403‐12. [CSzG: 29487] NCT00826202 . D‐serine for the schizophrenia prodrome. www.ClinicalTrials.gov/ct/show/2009. [CSzG: 17391] ">Kantrowitz‐USA</a>; <a href="./references#CD012236-bbs2-0013" title="ACTRN12608000475347 . A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder. Australian New Zealand Clinical Trials Registry2009. [CSzG: 18420] HKCTR‐1438 . The NEURAPRO‐E (North America, EURope, Australia PROdrome) Study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for symptomatic patients at ultra‐high risk for early progression to schizophrenia and other psychotic disorders. www.hkClinicaltrials.com/trial_details.aspx?trialID=d09bd177‐b9fd‐4162‐b04f‐3ebfed49baa32011. [CSzG: 29270] McGorryP , MarkulevC , NelsonB , YuenHP , SchaeferM , YungAR , et al. The NEURAPRO‐E study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Schizophrenia Bulletin2015;41:S322‐3. [CSzG: 29546] McGorryPD , NelsonB , MarkulevC , YuenHP , SchaferMR , MossahebN , et al. Effect of omega‐3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomised clinical trial. JAMA psychiatry2017;74(1):19‐27. [CSzG: 35590] NelsonB , AmmingerG , MarkulevC , YuenHP , LavoieS , SchaeferM , et al. NEURAPOR: a multi‐center RCT of omega‐3 polyunsaturated fatty acids versus placebo in young people at ultra‐high risk of psychotic disorders: medium‐term outcome. Schizophrenia Bulletin2017;43:S107. [CSzG: 36016] ">NEURAPRO‐AAE</a>; <a href="./references#CD012236-bbs2-0017" title='BlockJJ , McGlashonTH . Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790‐9. American Journal of Psychiatry2006; Vol. 163, issue 10:1838. [CSzG: 13960] BreierAF , ZipurskyRB , PerkinsDO , AddingtonJM , TohenMF , DavidSR , et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951] HawkinsKA , AddingtonJ , KeefeR , ChristensenB , WoodsS , ZipurskyR , et al. Neuropsychological functioning in the first episode prodrome and early psychosis. Schizophrenia Research2004;70(1):101. [CSzG: 11515] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , MillerTJ , et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research2004;67(1):205. [CSzG: Ref11301] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , ZipurskyRB , et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. [CSzG: 16470] HawkinsKA , KeefeRS , ChristensenBK , AddingtonJ , WoodsSW , CallahanJ , et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. Schizophrenia Research2008;105(1‐3):1‐9. [CSzG: 16983] HoffmanRE , WoodsS , PredaA , TohenM , BreierA , GlistJ , et al. Excessive top‐down perceptual processing and reduced real‐world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. Schizophrenia Research2006;86(Suppl 1):S46. [CSzG: 13377] HoffmanRE , WoodsSW , HawkinsKA , PittmanB , TohenM , PredaA , et al. Extracting spurious messages from noise and risk of schizophrenia‐spectrum disorders in prodromal population. British Journal of Psychiatry2007;191(2):355‐6. [CSzG: 16068] McGlashanT , ZipurskyR , PerkinsD , AddingtonJ . Olanzapine for treatment of the schizophrenia prodrome: 2‐year results of a randomised placebo‐controlled study. Schizophrenia Research2004;67(1):164. [CSzG: 11320] McGlashanTH . Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. [CSzG: 10191] McGlashanTH . Treatment intervention in the New Haven PRIME clinic prodromal sample. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4835] McGlashanTH , MillerTJ , WoodsSW . Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research2002;53(3 Suppl 1):15. [CSzG: 8093] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005] McGlashanTH , MillerTJ , ZipurskyRB , WoodsSW , PerkinsDO , HawkinsKA , et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9803] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerT , WoodsSW , et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry2006;163(5):790‐9. [CSzG: 12654] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerTJ , WoodsSW , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research2003;61(1):7‐18. [CSzG: 9828] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJ , WoodsSW , MillerTJ , et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research2003;60:295. [CSzG: 9722] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJM , WoodsSW , LindborgS , et al. Olanzapine versus pbo for the schizophrenic prodrome: one‐year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9804] McGlashlanTH , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTH , WoodsSW , et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:42. [CSzG: 8934] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , MillerT , WoodsS , et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. Schizophrenia Research2004;70(1):6. [CSzG: 11524] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , WoodsS , MillerT , et al. Olanzapine vs. placebo for prodromal schizophrenia. Schizophrenia Research2004;67(1):6. [CSzG: 11321] MillerTJ , ZipurskyRB , PerkinsD , AddingtonJ , WoodsSW , HawkinsKA , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research2003;61(1):19‐30. [CSzG: 9829] RosenJL , WoodsSW , MillerTJ , McGlashanTH . Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease2002;190:133‐41. [CSzG: 8274] TaylorHE , ParkerS , MansellW , MorrisonAP . Effects of appraisals of anomalous experience on distress in people at risk of psychosis. Behavioural and Cognitive Psychotherapy2012;41(1):24‐33. [CSzG: 24374] WoodsS , ZipurskyR , PerkinsD , AddingtonJ , MarquezE , BreierA , et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:43. [CSzG: 8933] WoodsSW . Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):497. [CSzG: 19829] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research. 2003. [CSzG: 9978] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research2003;60:306‐7. [CSzG: 9752] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):453‐64. [CSzG: 9994] WoodsSW , McGlashanTH . Sample size planning for prodromal intervention trials. Schizophrenia Research2002;53(3 Suppl 1):40. [CSzG: 8116] WoodsSW , ZipurskyRB , PerkinsDO , AddingtonJM , MillerTJ , BreierAF , et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053] '>PRIME‐USA</a>; <a href="./references#CD012236-bbs2-0018" title="LoewyR , FisherM , MathalonDH , VinogradovS . Interim analyses of a randomised controlled trial of computerised cognitive training in clinical high risk for psychosis. Schizophrenia Bulletin2013;39:S238‐9. [CSzG: 28151] LoewyR , FisherM , SchlosserDA , BiagiantiB , StuartB , MathalonDH , et al. Intensive auditory cognitive training improves verbal memory in adolescents and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2016;42(Suppl 1):S118‐26. [CSzG: 35221] VinogradovS , LoewyR , FisherM , LeeA , NiendamT , RaglandJD , et al. Neuroplasticity‐based cognitive training in ultra‐high risk adolescents and recent onset patients with schizophrenia. Schizophrenia Research2012;136:S30. [CSzG: 29703] ">Vinogradov‐USA</a>; <a href="./references#CD012236-bbs2-0019" title="NCT00291226 . Glycine vs Placebo for the Schizophrenia Prodrome. www.ClinicalTrials.gov/ct/show/2006. [CSzG: 14759] WoodsS , WalshB , HawkinsK , MillerT , SaksaJ , D'SouzaD , et al. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. Early Intervention in Psychiatry2012;6:29. [CSzG: 24987] WoodsSW , KantrowitzJT , JavittDC . NMDAR‐based treatments for patients at clinical high risk for psychosis. Biological Psychiatry2014;1:11S. [CSzG: 29041] WoodsSW , WalshBC , HawkinsKA , MillerTJ , SaksaJR , D'SouzaDC , et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. European Neuropsychopharmacology2013;23(8):931‐40. [CSzG: 28750] ">Woods‐1‐USA</a>; <a href="./references#CD012236-bbs2-0020" title="McGorryP . Second generation intervention research in the pre‐psychotic phase of illness in schizophrenia and related psychoses. Australian New Zealand Clinical Trials Registry2000. [CSzG: 18439] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceyS , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: 12‐month outcome. Schizophrenia Research2012;136:S17‐8. [CSzG: 29547] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceySM , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: twelve‐month outcome. Journal of Clinical Psychiatry2013;74(4):349‐56. [CSzG: 28737] NelsonB , PhillipsLJ , YungAR , FranceySM , LeicesterS , BakerK , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and supportive therapy in young people with subthreshold symptoms at incipient risk of psychotic disorder: baseline characteristics of the sample. Schizophrenia Bulletin2007;33(2):450. [CSzG: 15212] PhillipsLJ , NelsonB , YuenHP , FranceySM , SimmonsM , StanfordC , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: study design and baseline characteristics. Australian and New Zealand Journal of Psychiatry2009;;43(9):818–29. YungA , AmmingerP , BergerG , ThompsomA , PhillipsL , NelsonB , et al. Randomised controlled trial of antipsychotic and cognitive therapy in young people at ultra‐high risk of psychosis. Early Intervention in Psychiatry2012;6:11. [CSzG: 24989] YungA , NelsonB , PhillipsL , FranceyS , LeicesterS , YuenH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and supportive therapy in young people at ultra high risk of psychotic disorder: 12 month outcome data. Early Intervention in Psychiatry2008;2(Suppl 1):A12. [CSzG: 19138] YungAR , PhillipsLJ , NelsonB , FranceySM , YuenHP , SimmonsMB , et al. Randomised controlled trial of interventions for young people at ultra high risk for psychosis: 6‐month analysis. Journal of Clinical Psychiatry2011;72(4):430‐40. [CSzG: 22929] ">Yung‐Australia</a>), so we judged them at low risk of bias. </p> <p>Nine studies blinded clinicians, but not participants (<a href="./references#CD012236-bbs2-0001" title="AddingtonJ , EpsteinI , LiuL , FrenchP , BoydellKM , ZipurskyRB . A randomised controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research2011;125(1):54‐61. [CSzG: Ref21945] AddingtonJ , ZipurskyR , EpsteinI . ADAPT (Access, Detection and Psychological Treatments). Schizophrenia Research2006;86(Suppl 1):S6. [CSzG: Ref13364] NCT00260273 . Access, detection and psychological treatments. www.ClinicalTrials.gov/ct/show/2005. [CSzG: Ref14638] ">ADAPT‐Canada</a>; <a href="./references#CD012236-bbs2-0004" title="CrittendenK , FlemingJ , StartupM , CarrV , BakerA , SchallU , et al. Recruitment and engagement of youth in an ultra high risk treatment study. Early Intervention in Psychiatry2008;2(Suppl 1):A127. [CSzG: Ref19115] StainH , BucciS , HalperinS , EmsleyR , ShallU , LewinT , et al. DEPTh: randomised controlled trial of cognitive behavioral therapy for young people at ultra high risk for psychosis. Early Intervention in Psychiatry2014;8:15. [CSzG: Ref29673] StainHJ , BucciS , BakerA , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of CBT for young people at risk for psychosis: the Detection and Evaluation of Psychological Therapy (DEPTh) trial. European Archives of Psychiatry and Clinical Neuroscience2015;1:S8‐9. [CSzG: Ref33810] StainHJ , BucciS , BakerAL , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of cognitive behaviour therapy versus non‐directive reflective listening for young people at ultra high risk of developing psychosis: the detection and evaluation of psychological therapy (DEPTh) trial. Schizophrenia Research2016;176(2‐3):212‐9. [CSzG: Ref35298] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. Rural and urban youth at ultra high risk for psychosis: baseline characteristics from the DEPTh randomised controlled trial of cognitive behavior therapy. Schizophrenia Bulletin2011;37:322. [CSzG: Ref22815] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy for youth at ultra high risk for psychosis: baseline characteristics for rural and urban youth. Australian and New Zealand Journal of Psychiatry2010:25‐6. [CSzG: Ref21845] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy targeting ultra high risk for psychosis: baseline comparisons for rural and urban youth. Early Intervention in Psychiatry2010;4(Suppl 1):113. [CSzG: Ref23498] StainHJ , StartupM , CarrV , BakerA , SchallU . The DEPTh project: a multisite RCT for youths at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S51‐2. [CSzG: Ref13401] StartupM . The DEPTh project: detection, evaluation, and psychological therapy for health. Australian New Zealand Clinical Trials Registry2006. [CszG: Ref18442] ">DEPTh‐Australia</a>; <a href="./references#CD012236-bbs2-0005" title="ByrneRE , MorrisonAP . Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. Psychology and Psychotherapy2014;87(3):357‐71. [CSzG: Ref29312] FlachC , FrenchP , DunnG , FowlerD , GumleyAI , BirchwoodM , et al. Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE‐2 trial. British Journal of Psychiatry2015;207(2):123‐9. [CSzG: Ref33109] MorrisonA . Early detection and intervention evaluation for individuals at high risk of psychosis 2. http://www.controlled‐trials.com2008. [CSzG: Ref18285] MorrisonA . Early detection and intervention evaluation for people at risk of psychosis (edie‐2): A multisite randomised controlled trial of cognitive therapy for at‐risk mental states. Early Intervention in Psychiatry2012;6:11. [CSzG: Ref24968] MorrisonA , FrenchP , BentallR , LewisS , BirchwoodM , FowlerD , et al. Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. Early Intervention in Psychiatry2008;2(Suppl 1):A15. [CSzG: Ref19128] MorrisonAP . EDIE‐2: early detection and psychological intervention for individuals at high risk of psychosis (2). www.controlled‐trials.com2007. [CSzG: Ref15381] MorrisonAP , BirchwoodM , PyleM , FlachC , StewartSL , ByrneR , et al. Impact of cognitive therapy on internalised stigma in people with at‐risk mental states. British Journal of Psychiatry2013;203(2):140‐5. [CSzG: Ref28630] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ2012;344(7852):e2233. [CSzG: Ref24208] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at‐risk of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29554] MorrisonAP , PyleM , StewartSL , FrenchP , ByrneR , FlachC , et al. Internalised stigma in young people at high risk of developing psychosis: findings from a cognitive therapy trial. Schizophrenia Research2014;153:S42. [CSzG: Ref29555] MorrisonAP , StewartSL , FrenchP , BentallRP , BirchwoodM , ByrneR , et al. Early detection and intervention evaluation for people at high‐risk of psychosis‐2 (EDIE‐2): trial rationale, design and baseline characteristics. Early Intervention in Psychiatry2011;5(1):24‐32. [CSzG: Ref22695] MorrisonT . Early detection and psychological intervention for individuals at high risk of psychosis. EDIE‐2. Data on File2006. [CSzG: Ref13874] PelosiAJ . Rational policy making for early psychosis might yet become possible. BMJ2012;344(7856):e3137. [CSzG: Ref24326] PyleM , StewartSL , FrenchP , ByrneR , PattersonP , GumleyA , et al. Internalised stigma, emotional dysfunction and unusual experiences in young people at risk of psychosis. Early Intervention in Psychiatry2015;9(2):133‐40. [CSzG: Ref29813] ">EDIE‐2‐UK</a>; <a href="./references#CD012236-bbs2-0006" title="DragtS , Van derGaagM . Prevention of psychosis with a cognitive behavioural intervention in help‐seeking young people with an at risk mental state for developing psychosis. www.trialregister.nl/trialreg/index.asp2007. [CSzG: Ref19655] IsingHK , KraanTC , RietdijkJ , DragtS , KlaassenRM , BoonstraN , et al. Four‐year follow‐up of cognitive behavioral therapy in persons at ultra‐high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2016;42(5):1243‐52. [CSzG: Ref35214] IsingHK , LokkerbolJ , RietdijkJ , DragtS , KlaassenRM , KraanT , et al. Four‐year cost‐effectiveness of cognitive behavior therapy for preventing first‐episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2017;43(2):365‐74. [CSzG: Ref35824] IsingHK , SmitF , VelingW , RietdijkJ , DragtS , KlaassenRM , et al. Cost‐effectiveness of preventing first‐episode psychosis in ultra‐high‐risk subjects: multi‐centre randomised controlled trial. Psychological Medicine2015;45(7):1435‐46. [CSzG: Ref27798] KraanTC , IsingHK , FokkemaM , VelthorstE , Van denBergDP , KerkhovenM , et al. The effect of childhood adversity on 4‐year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE‐NL) Trial. Psychiatry Research2017;247:55‐62. [CSzG: Ref35559] NiemanDH , RuhrmannS , RietdijkJ , DragtS , IsingH , KlaassenR , et al. Preventive psychotherapy. Schizophrenia Research2014;153:S42‐3. [CSzG: Ref29601] RietdijkJ , DragtS , KlaassenR , IsingH , NiemanD , WunderinkL , et al. A single blind randomised controlled trial of cognitive behavioural therapy in a help‐seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE‐NL) trial. Trials2010;11:30. [CSzG: Ref20654] Van DerGaagM . The effects of CBT in personswith ultra high risk: the Dutch EDIE trial. European Archives of Psychiatry and Clinical Neuroscience2011;261:S18. [CSzG: Ref23756] Van DerGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first‐episode of psychosis. Early Intervention in Psychiatry2012;6:12. [CSzG: Ref24985] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomised controlled clinical trial. Schizophrenia Bulletin2012;38(6):1180‐8. [CSzG: Ref24935] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. The effects of cognitive behavioural therapy for subjects at ultra‐high risk for developing psychosis. Schizophrenia Bulletin2013;39:S356. [CSzG: Ref28121] Van derGaagM . The prevention of psychosis in at risk mental state. www.controlled‐trials.com2008. [CSzG: Ref17488] Van derGaagM , NiemanD , Van denBergD . CBT for those at risk of a first episode psychosis: Evidence‐based psychotherapy for people with an 'at risk mental state'. 1st Edition. Hove, UK: Routledge, 2013. Van derGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first episode of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29692] ">EDIE‐NL</a>; <a href="./references#CD012236-bbs2-0007" title="FrenchP , ShryaneN , BentallRP , LewisSW , MorrisonAP . Effects of cognitive therapy on the longitudinal development of psychotic experiences in people at high risk of developing psychosis. British Journal of Psychiatry. Supplements2007;191(Suppl 51):s82‐7. [CSzG: Ref16121] LewisS . EDIE ‐ Early detection and intervention for psychosis. National Research Register2001; Vol. 3. [CSzG: Ref13023] LewisS . EDIE ‐ early detection and intervention for psychosis (in primary care). National Research Register2002; Vol. 1. [CszG: Ref9342] MorrisonA . Early detection and intervention for psychosis in primary care. National Research Register2003. [CSzG: Ref15485] MorrisonA . Findings from a randomised controlled trial and clinical service delivering cognitive therapy to people at ultra‐high risk of developing psychosis. Schizophrenia Research2004;70(1):43‐4. [CSzG: Ref11526] MorrisonA . Follow‐up of prodromal symptoms. National Research Register2004; Vol. 3. [CSzG: Ref13036] MorrisonA , BentallR , FrenchP , Kilcommons A, LewisSW . Very early intervention in prodromal psychosis: a randomised trial. Schizophrenia Research2002;53(3 Suppl 1):42. [CSzG: Ref8096] MorrisonA , FrenchP , WalfordL , LewisS , Kilcommons A, GreenJ , et al. A randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;67(1):7. [CSzG: Ref11324] MorrisonA , FrenchP , WatfordL , LewisS , Kilcommons A, GreenJ , et al. Randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;70(1):63. [CSzG: Ref11527] MorrisonAP . Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: results of a randomised controlled trial. Schizophrenia Research2006;86(Suppl 1):S59. [CSzG: Ref13388] MorrisonAP , BentallRP , FrenchP , Kilcommons A, GreenJ , WalfordL , et al. Cognitive therapy in ultra high risk individuals for psychosis: randomised controlled trial. Schizophrenia Research2003;60:326. [CSzG: Ref9726] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, KnightA , et al. Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high‐risk individuals. Study design and interim analysis of transition rate and psychological risk factors. British Journal of Psychiatry. Supplements2002;181(43):s78‐84. [CSzG: Ref8737] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, LewisS . Early detection and intervention for psychosis in primary care. 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002. [CSzG: Ref8932] MorrisonAP , FrenchP , ParkerS , RobertsM , StevensH , BentallRP , et al. Three‐year follow‐up of a randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophrenia Bulletin2007;33(3):682‐7. [CSzG: Ref15288] MorrisonAP , FrenchP , WalfordL , LewisSW , Kilcommons A, GreenJ , et al. Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: randomised controlled trial. British Journal of Psychiatry2004;185:291‐7. [CSzG: Ref11450] MorrisonT . Early detection and intervention for psychosis in primary care. National Research Register2001; Vol. 1. [CSzG: Ref13037] MorrisonT , BentallR , FrenchP , Kilcommons A, GreenJ , LewisS . Early detection and intervention for psychosis in primary care. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:44. [CSzG: Ref8932] RentonJ , MorrisonA . Effectiveness of cognitive therapy for psychosis and implications for early intervention. Schizophrenia Research2004;70(1):142. [CSzG: Ref11536] ">EDIE‐UK</a> (intended to be blind, but it was difficult in practice) <a href="./references#CD012236-bbs2-0008" title="McFarlaneWR , CookWL , WoodberryKA . A randomised clinical trial of familyaided assertive community treatment for young persons at high risk for onset of an initial psychosis. Schizophrenia Bulletin2011;37:314. [CSzG: Ref22796] NCT01597141 . Psychosis: early detection, intervention and prevention. ClinicalTrials.gov/show/NCT015971412012. [CSzG: Ref24315] ">EDIP‐USA</a>; <a href="./references#CD012236-bbs2-0012" title="MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Family‐focused therapy for individuals at clinical high risk for psychosis: treatment fidelity within a multisite randomised trial. Early Intervention in Psychiatry2016;10(2):137‐43. [CSzG: 29018] MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Treatment fidelity and differentiation in a randomised controlled trial of family‐focused therapy for youth at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:95. [CSzG: 24965] MiklowitzDJ , O'BrienMP , SchlosserDA , AddingtonJ , CandanKA , MarshallC , et al. Family‐focused treatment for adolescents and young adults at high risk for psychosis: results of a randomised trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(8):848‐58. [CSzG: 29019] NCT01907282 . Prevention trial of family focused treatment in youth at risk for psychosis. Clinicaltrials.gov/show/NCT019072822010. [CSzG: 27965] O'BrienMP , MiklowitzDJ , CandanKA , MarshallC , DominguesI , WalshBC , et al. A randomised trial of family focused therapy with populations at clinical high risk for psychosis: effects on interactional behavior. Journal of Consulting and Clinical Psychology2013;82(1):90‐101. [CSzG: 28565] O'BrienMP , MiklowitzDJ , CannonTD . Decreases in perceived maternal criticism predict improvement in subthreshold psychotic symptoms in a randomised trial of family‐focused therapy for individuals at clinical high risk for psychosis. Journal of Family Psychology2015;29(6):945–951.. [CSzG: 32212] SchlosserDA , MiklowitzDJ , O'BrienMP , DeSilvaSD , ZinbergJL , CannonTD . A randomised trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Intervention in Psychiatry2012;6(3):283‐91. [CSzG: 24491] ">Miklowitz‐USA</a>; <a href="./references#CD012236-bbs2-0015" title="McGorryP . Can the onset of schizophrenia be delayed or prevented?. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S26. [CSzG: 8351] McGorryP , AdlardS , YungA , McDonaldA , PhillipsL , HearnN . Detection and intervention in pre‐psychotic schizophrenia. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4836] McGorryP , YungA , FranceyS , PhillipsL , NelsonB . A blinded, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and befriending in young people at risk of psychotic disorder: baseline characteristics of the sample. Acta Neuropsychiatrica2006;18(6):261. [CSzG: 35157] McGorryPD , HearnN , GermanoD , BravinJ , PhillipsLJ , YungAR , et al. Prepsychotic intervention in schizophrenia: a stitch in time?. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington DC, USA. 1999. [CSzG: 3584] McGorryPD , PhillipsLJ , NelsonB , LeicesterS , BakerK , KrstevH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and befriending in young people with subthreshold symptoms at incipient risk of psychotic disorder: six month outcome data. Schizophrenia Bulletin2007;33(2):446. [CSzG: 15203] McGorryPD , PhillipsLJ , YungAR , FranceyS , GermanoD , BravinJ , et al. A randomised controlled trial of interventions in the pre psychotic phase of psychotic disorders. Schizophrenia Research2000;41(1):9. [CSzG: 5149] McGorryPD , YungAR , PhillipsL , AdlardS , HallgrenM , PattonG , et al. Pre‐psychotic intervention in schizophrenia: a stitch in time?. Schizophrenia Research1998;29(1‐2):160. [CSzG: 3585] McGorryPD , YungAR , PhillipsLJ , YuenHP , FranceyS , CosgraveEM , et al. Randomised controlled trial of interventions designed to reduce the risk of progression to first‐episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry2002;59(10):921‐8. [CSzG: 8576] PhilippsLJ , McGorryP , YungA , FranceyD , GermanoF , BravinJ , et al. The development of preventive interventions for early psychosis: early findings and directions for the future. 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001; Vol. 2, issue Suppl 1. [CSzG: 7614] PhillipsL , CottonS , YuenHP , MihalopoulosC , ShihS , KellyD , et al. Cost effectiveness of a preventive intervention for young people at ultra high risk of developing psychosis. Schizophrenia Bulletin2007;33(2):488‐9. [CSzG: 15227] PhillipsLJ , CottonS , MihalopoulosC , ShihS , YungAR , CarterR , et al. Cost implications of specific and non‐specific treatment for young persons at ultra high risk of developing a first episode of psychosis. Early Intervention in Psychiatry2009;3(1):28‐34. [CSzG: 18308] PhillipsLJ , LeicesterSB , O'DwyerLE , FranceySM , KoutsogiannisJ , Abdel‐BakiA , et al. The PACE clinic: identification and management of young people at &quot;ultra&quot; high risk of psychosis. Journal of Psychiatric Practice2002;8(5):255‐69. [CSzG: 18235] PhillipsLJ , McGorryPD , YuenHP , WardJ , DonovanK , KellyD , et al. Medium term follow‐up of a randomised controlled trial of interventions for young people at ultra high risk of psychosis. Schizophrenia Research2007;96(1‐3):25‐33. [CSzG: 15544] PhillipsLJ , YungAR , YuenHP , PantelisC , McGorryPD . Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. American Journal of Medical Genetics2002;114(8):929‐37. [CSzG: 18236] ">PACE‐Australia</a>; <a href="./references#CD012236-bbs2-0016" title="NCT01619319 . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. ClinicalTrials.gov/show/NCT016193192012. [CSzG: 24387] PiskulicD , BarbatoM , AddingtonJ . Cognitive remediation in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:89. [CSzG: 24973] PiskulicD , BarbatoM , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2012;136:S245‐6. [CSzG: 29632] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2014;153(Suppl. 1):S218. [CSzG: 28827] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation therapy on cognition in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2014;8:86. [CSzG: 29633] ">Piskulic‐Canada</a>). Two studies did not blind either participants or clinicians (<a href="./references#CD012236-bbs2-0011" title="BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: 12511] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] RuhrmannS , BechdolfA , KuhnKU , WagnerM , Schultze‐LutterF Janssen B , et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry. Supplements2007;51:s88‐95. [CSzG: 16127] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Acute symptomatic treatment effects in persons clinically at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13397] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Intervention in the late initial prodromal state (LIPS) of psychosis. Schizophrenia Research2006;86(Suppl 1):S96. [CSzG: 13398] ">LIPS‐Germany</a>; <a href="./references#CD012236-bbs2-0014" title="NordentoftM , JeppesenP , PetersenL , ThorupA , OhlenschlaegerJ , ChristensenT , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. European Psychiatry2007;22:S129‐S. [CSzG: 20471] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the OPUS trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;83(1):29‐40. [CSzG: 13197] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;86(Suppl 1):S44. [CSzG: 13393] ">Nordentoft‐Denmark</a>). One study did not provide information about blinding of participants and personnel in the manuscript (<a href="./references#CD012236-bbs2-0009" title="BechdolfA . Preventing progression to first‐episode psychosis in people in the early initial prodromal state. Early Intervention in Psychiatry2012;6:11. [CSzG: 24944] BechdolfA , BuhlerB , BerningJ , WagnerM , StammE , StreitM . Cognitive behavioural therapy in the early initial prodromal state of psychosis: first results. Schizophrenia Research2004;67(1):202. [CSzG: Ref11285] BechdolfA , KlosterkotterJ . Cognitive‐behavioural treatment (CBT) in the early initial prodromal state of psychosis: concept and practical approach. Schizophrenia Research2004;70(1):52. [CSzG: Ref11506] BechdolfA , RuhrmannS , JanssenB , BottlenderR , WagnerM , MaurerK , et al. Early recognition and intervention for people at risk of schizophrenia [Fruherkennung und intervention bei personen mit erhohtem psychoserisiko]. Psychoneuroendocrinology2004;30(11):606‐14. [CSzG: Ref11376] BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: Ref12511] BechdolfA , VeithV , BerningJ , StammE , DeckerP , JanssenB , et al. Cognitive behavioral therapy (CBT) in the early initial prodromal state of psychosis: first results of a randomised trial. Schizophrenia Research2004;70(1):62‐3. [CSzG: Ref11507] BechdolfA , WagnerM , RuhrmannS , HarriganS , PutzfeldV , PukropR , et al. Preventing progression to first‐episode psychosis in early initial prodromal states. British Journal of Psychiatry2012;200(1):22‐9. [CSzG: Ref24206] BechdolfA , WagnerM , RuhrmannS , HarriganS , VeithV , PukropR , et al. CBT for prevention of first episode psychosis in people in an putative early initial prodromal state. Early Intervention in Psychiatry2008;2(Suppl 1):A16. [CSzG: 19109] BechdolfA , WagnerM , VeithV , PukropR , BerningJ , StammE , et al. A randomised controlled trial of cognitive‐behavioral therapy in the early initial prodromal state of psychosis. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:22‐3. [CSzG: 20193] BechdolfA , WagnerM , VeithV , RuhrmannR , JanssenB , BottlenderR , et al. A randomised controlled multicenter trial of cognitive behaviour therapy in the early initial prodromal state of psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13369] BechdolfA , WagnerM , VeithV , RuhrmannS , PukropR , Brockhaus‐DumkeA , et al. Randomised controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Intervention in Psychiatry2007;1(1):71‐8. [CSzG: 16450] BechdolfA , WesselsH , WagnerM , KuhrK , BerningJ , PutzfeldV , et al. Predictors of treatment response to psychosocial interventions in people at risk. European Archives of Psychiatry and Clinical Neuroscience2015;1:S9. [CSzG: 33601] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] KommescherM , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. Early Intervention in Psychiatry2016;10(1):17‐27. [CSzG: 32187] NCT00204087 . Psychological intervention for persons at risk of psychosis in the early initial prodromal state. www.ClinicalTrials.gov/ct/show/2005. [CSzG: 14890] WesselsH , WagnerM , FrommannI , BerningJ , PutzfeldV , JanssenB , et al. Neuropsychological functioning as a predictor of treatment response to psychoeducational, cognitive behavioral therapy in people at clinical high risk of first episode psychosis. Psychiatrische Praxis2015;42(6):313‐9. [CSzG: 33130] ZarafonitisS , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Psychoeducation for persons at risk of psychosis. Psychotherapeut2012;57(4):326‐34. [CSzG: 24807] ">EIPS‐Germany</a>), but in the study protocol published online it was indicated that there was no masking, that the study was open‐label. We judged all of these studies at high risk of bias. </p> <p>In eleven studies, raters or attending psychiatrists were blind to the outcome assessments (<a href="./references#CD012236-bbs2-0001" title="AddingtonJ , EpsteinI , LiuL , FrenchP , BoydellKM , ZipurskyRB . A randomised controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research2011;125(1):54‐61. [CSzG: Ref21945] AddingtonJ , ZipurskyR , EpsteinI . ADAPT (Access, Detection and Psychological Treatments). Schizophrenia Research2006;86(Suppl 1):S6. [CSzG: Ref13364] NCT00260273 . Access, detection and psychological treatments. www.ClinicalTrials.gov/ct/show/2005. [CSzG: Ref14638] ">ADAPT‐Canada</a>; <a href="./references#CD012236-bbs2-0002" title="AmmingerG . Ethyl eicosapentanoic acid for prodromal psychosis. Stanley Foundation Research Programs2009. [CSzG: Ref17423] AmmingerG , SchaferM , PapageorgiouK , CottonS , HarriganS , MackinnonA , et al. Indicated prevention with long‐chain omega‐3 fatty acids in adolescents at ultra‐high‐risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2008;2(Suppl 1):A29. [CSzG: Ref19107] AmmingerGP , ChanenAM , OhmannS , KlierCM , MossahebN , BechdolfA , et al. Omega‐3 fatty acid supplementation in adolescents with borderline personality disorder and ultra‐high risk criteria for psychosis: a post hoc subgroup analysis of a double‐blind, randomised controlled trial. Canadian Journal of Psychiatry2013;58(7):402‐8. [CSzG: Ref28534] AmmingerGP , HarrisMS , McGorryPD , HenryLP . Omega‐3 fatty acids for indicated prevention: treatment results and pathomechanisms. European Archives of Psychiatry and Clinical Neuroscience2013;263(Suppl. 1):S44‐5. [CSzG: Ref28434] AmmingerGP , LeicesterS , YungAR , YuenHP , McGorryPD . Age predicts transition to psychosis in an ultra‐high risk sample. Proceedings of the 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:61. AmmingerGP , McGorryPD . Update on omega‐3 polyunsaturated fatty acids in early ‐stage psychotic disorders. Neuropsychopharmacology2012;37(1):309‐10. [CSzG: Ref23726] AmmingerGP , MechelliA , RiceS , KimSW , KlierCM , McNamaraRK , et al. Predictors of treatment response in young people at ultra‐high risk for psychosis who received long‐chain omega‐3 fatty acids. Translational Psychiatry2015;5:e495. [CSzG: Ref29299] AmmingerGP , SchaferMR . Indicated prevention with omega‐3 fatty acids in adolescents at ultra‐high risk for psychosis ‐ rationale, methods, and 3‐months outcome. Schizophrenia Research2006;86(Suppl 1):S97‐8. [CSzG: Ref13367] AmmingerGP , SchaferMR . Is it feasible to conduct a RCT in ultra‐high risk individuals at a child and adolescent psychiatric service?. Schizophrenia Research2006;86(Suppl 1):S98. [CSzG: Ref13368] AmmingerGP , SchaferMR , KlierCM , PapageorgiouK , SlavikJ , HolzerI , et al. Indicated prevention with long‐chain omega‐3 fatty acids in young people at ultra‐high risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2010;4(Suppl 1):7. [CSzG: Ref23467] AmmingerGP , SchaferMR , SchlogelhoferM , KlierCM , McGorryPD . Longer‐term outcome in the prevention of psychotic disorders by the Vienna omega‐3 study. Nature Communications2015;6:7934. [CSzG: Ref33023] AmmingerGP , SchlogelhoferM , KlierC , McGorryP , SchaferM . Longer‐term follow‐up in the Vienna omega‐3 psychosis prevention trial. Early Intervention in Psychiatry2014;8:41. [CSzG: Ref29378] AmmingerGP , SchäferMR , PapageorgiouK , KlierCM , CottonSM , HarriganSM , et al. Long‐chain omega‐3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo‐controlled trial. Archives of General Psychiatry2010;67(2):146‐54. [CSzG: Ref20680; DOI: 10.1001/archgenpsychiatry.2009.192.] AmmingerP , MossahebN , SchlgelhoferM , SchaferM . Fatty acid metabolism and the onset of psychotic disorder. European Psychiatry2011;26(Suppl 1):2089. [CSzG: Ref22967] Anonymous . Fish oil may help ward off psychosis. Journal of Psychosocial Nursing and Mental Health Services2010;48(5):55. [CSzG: Ref20739] BergerG , AmmingerP , McGorryP . Stage dependant effect of omega‐3 fatty acids in emerging psychosis. European Psychiatry2011;26(Suppl 1):1347. [CSzG: Ref22966] BergerGE , ProffittTM , McConchieM , YuenH , WoodSJ , AmmingerGP , et al. Ethyl‐eicosapentaenoic acid in first‐episode psychosis: a randomised, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(12):1867‐75. [CSzG: Ref15561; ISSN: 1555‐2101] EhrlichA . Evidence‐based medicine. Omega‐3 supplementation delays transition to psychotic disorder in ultra‐high‐risk adolescents and young adults. Clinical Advisor for Nurse Practitioners2010;13(5):79‐80. [CSzG: Ref21562] FöckingM , DickerP , LopezLM , CannonM , SchäferMR , McGorryPD , et al. Differential expression of the inflammation marker IL12p40 in the at‐risk mental state for psychosis: a predictor of transition to psychotic disorder?. BMC Psychiatry2016;16(1):326. [DOI: 10.1186/s12888‐016‐1039‐7] KlierC , HollmannM , SchlögelhoferM , MossahebN , FriedrichM , AmmingerPG . Indicated prevention with omega‐3 fatty acids (EPA/DHA) in adolescents with &quot;at‐risk‐mental‐state“ for psychosis. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. [CSzG: Ref12438] LavoieS , BenningerF , FeuchtM , KlierCM , SchaeferMR , AmmingerGP . Correlates of EEG resting states with erythrocyte membrane omega‐3 fatty acid levels and psychopathological symptoms in individuals at ultra‐high risk for psychosis. Early Intervention in Psychiatry2014;8:137. [CSzG: Ref29516] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultra‐high risk individuals who transitioned to psychosis. Schizophrenia Research2012;138(2‐3):206‐11. [CSzG: Ref24256] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultrahigh risk individuals who transitioned to psychosis. Early Intervention in Psychiatry2012;6:38. [CSzG: Ref24960] MossahebN , PapageorgiouK , SchaferMR , BeckerJ , SchloegelhoferM , AmmingerGP . Changes in triglyceride levels in ultra‐high risk for psychosis individuals treated with omega‐3 fatty acids. Early Intervention in Psychiatry2018; Vol. 12, issue 1:30‐36. [DOI: 10.1111/eip.12275] MossahebN , SchaferMR , SchlogelhoferM , KlierCM , CottonSM , McGorryPD , et al. Effect of omega‐3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?. Schizophrenia Research2013;148(1‐3):163‐7. [CSzG: Ref28649] NCT00396643 . Indicated prevention with omega‐3 fatty acids in adolescents with ‘at‐risk‐mental‐state’ for psychosis: a randomised, double blind, placebo‐controlled treatment trial. www.ClinicalTrials.gov/ct/show/2006. [CSzG: Ref14873] PapageorgiouK , SchaferMR , SchlogelhoferM , MossahebN , AmmingerGP . Indicated prevention with omega‐3 fatty acids in young people with 'at‐risk‐mental‐state' for psychosis: design of a 5‐year follow‐up. European Archives of Psychiatry and Clinical Neuroscience2011;261:S55. [CSzG: Ref23749] SchaferMR , KlierCM , PapageorgiouK , FriedrichMH , AmmingerGP . Early detection of psychotic disorders. Neuropsychiatrie2007;21(1):37‐44. [CSzG: Ref15290] SmesnyS , MilleitB , HiplerUC , MilleitC , SchaferMR , KlierCM , et al. Omega‐3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra‐high risk for psychosis. Molecular Psychiatry2013;19(3):317‐24. [CSzG: Ref28243] SmesnyS , MilleitB , SchaeferMR , HesseJ , SchlögelhoferM , LangbeinK , et al. Effects of omega‐3 PUFA on immune markers in adolescent individuals at ultra‐high risk for psychosis ‐ results of the randomised controlled Vienna omega‐3 study. Schizophrenia Research2017;S0920‐9964(17):30039‐7. [DOI: 10.1016/j.schres.2017.01.026] ">Amminger‐Austria</a>; <a href="./references#CD012236-bbs2-0003" title="ChoiJ , CorcoranC , DixonL , FiszdonJ , JavittD . Processing speed training and social functioning in young adults at clinical high risk for psychosis: a pilot study. Early Intervention in Psychiatry2014;8:109. [CSzG: Ref29417] ChoiJ , CorcoranC , DixonL , JavittDC . Processing speed training and social functioning in teenagers and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2015;41:S41. [CSzG: Ref29418] ChoiJ , CorcoranCM , FiszdonJM , StevensM , JavittDC , DeasyM , et al. Pupillometer‐based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis. Psychiatric Rehabilitation Journal2017;40(1):33‐42. [CSzG: Ref35317] ">Choi‐USA</a>; <a href="./references#CD012236-bbs2-0004" title="CrittendenK , FlemingJ , StartupM , CarrV , BakerA , SchallU , et al. Recruitment and engagement of youth in an ultra high risk treatment study. Early Intervention in Psychiatry2008;2(Suppl 1):A127. [CSzG: Ref19115] StainH , BucciS , HalperinS , EmsleyR , ShallU , LewinT , et al. DEPTh: randomised controlled trial of cognitive behavioral therapy for young people at ultra high risk for psychosis. Early Intervention in Psychiatry2014;8:15. [CSzG: Ref29673] StainHJ , BucciS , BakerA , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of CBT for young people at risk for psychosis: the Detection and Evaluation of Psychological Therapy (DEPTh) trial. European Archives of Psychiatry and Clinical Neuroscience2015;1:S8‐9. [CSzG: Ref33810] StainHJ , BucciS , BakerAL , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of cognitive behaviour therapy versus non‐directive reflective listening for young people at ultra high risk of developing psychosis: the detection and evaluation of psychological therapy (DEPTh) trial. Schizophrenia Research2016;176(2‐3):212‐9. [CSzG: Ref35298] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. Rural and urban youth at ultra high risk for psychosis: baseline characteristics from the DEPTh randomised controlled trial of cognitive behavior therapy. Schizophrenia Bulletin2011;37:322. [CSzG: Ref22815] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy for youth at ultra high risk for psychosis: baseline characteristics for rural and urban youth. Australian and New Zealand Journal of Psychiatry2010:25‐6. [CSzG: Ref21845] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy targeting ultra high risk for psychosis: baseline comparisons for rural and urban youth. Early Intervention in Psychiatry2010;4(Suppl 1):113. [CSzG: Ref23498] StainHJ , StartupM , CarrV , BakerA , SchallU . The DEPTh project: a multisite RCT for youths at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S51‐2. [CSzG: Ref13401] StartupM . The DEPTh project: detection, evaluation, and psychological therapy for health. Australian New Zealand Clinical Trials Registry2006. [CszG: Ref18442] ">DEPTh‐Australia</a>; <a href="./references#CD012236-bbs2-0006" title="DragtS , Van derGaagM . Prevention of psychosis with a cognitive behavioural intervention in help‐seeking young people with an at risk mental state for developing psychosis. www.trialregister.nl/trialreg/index.asp2007. [CSzG: Ref19655] IsingHK , KraanTC , RietdijkJ , DragtS , KlaassenRM , BoonstraN , et al. Four‐year follow‐up of cognitive behavioral therapy in persons at ultra‐high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2016;42(5):1243‐52. [CSzG: Ref35214] IsingHK , LokkerbolJ , RietdijkJ , DragtS , KlaassenRM , KraanT , et al. Four‐year cost‐effectiveness of cognitive behavior therapy for preventing first‐episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2017;43(2):365‐74. [CSzG: Ref35824] IsingHK , SmitF , VelingW , RietdijkJ , DragtS , KlaassenRM , et al. Cost‐effectiveness of preventing first‐episode psychosis in ultra‐high‐risk subjects: multi‐centre randomised controlled trial. Psychological Medicine2015;45(7):1435‐46. [CSzG: Ref27798] KraanTC , IsingHK , FokkemaM , VelthorstE , Van denBergDP , KerkhovenM , et al. The effect of childhood adversity on 4‐year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE‐NL) Trial. Psychiatry Research2017;247:55‐62. [CSzG: Ref35559] NiemanDH , RuhrmannS , RietdijkJ , DragtS , IsingH , KlaassenR , et al. Preventive psychotherapy. Schizophrenia Research2014;153:S42‐3. [CSzG: Ref29601] RietdijkJ , DragtS , KlaassenR , IsingH , NiemanD , WunderinkL , et al. A single blind randomised controlled trial of cognitive behavioural therapy in a help‐seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE‐NL) trial. Trials2010;11:30. [CSzG: Ref20654] Van DerGaagM . The effects of CBT in personswith ultra high risk: the Dutch EDIE trial. European Archives of Psychiatry and Clinical Neuroscience2011;261:S18. [CSzG: Ref23756] Van DerGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first‐episode of psychosis. Early Intervention in Psychiatry2012;6:12. [CSzG: Ref24985] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomised controlled clinical trial. Schizophrenia Bulletin2012;38(6):1180‐8. [CSzG: Ref24935] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. The effects of cognitive behavioural therapy for subjects at ultra‐high risk for developing psychosis. Schizophrenia Bulletin2013;39:S356. [CSzG: Ref28121] Van derGaagM . The prevention of psychosis in at risk mental state. www.controlled‐trials.com2008. [CSzG: Ref17488] Van derGaagM , NiemanD , Van denBergD . CBT for those at risk of a first episode psychosis: Evidence‐based psychotherapy for people with an 'at risk mental state'. 1st Edition. Hove, UK: Routledge, 2013. Van derGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first episode of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29692] ">EDIE‐NL</a>; <a href="./references#CD012236-bbs2-0008" title="McFarlaneWR , CookWL , WoodberryKA . A randomised clinical trial of familyaided assertive community treatment for young persons at high risk for onset of an initial psychosis. Schizophrenia Bulletin2011;37:314. [CSzG: Ref22796] NCT01597141 . Psychosis: early detection, intervention and prevention. ClinicalTrials.gov/show/NCT015971412012. [CSzG: Ref24315] ">EDIP‐USA</a>; <a href="./references#CD012236-bbs2-0013" title="ACTRN12608000475347 . A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder. Australian New Zealand Clinical Trials Registry2009. [CSzG: 18420] HKCTR‐1438 . The NEURAPRO‐E (North America, EURope, Australia PROdrome) Study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for symptomatic patients at ultra‐high risk for early progression to schizophrenia and other psychotic disorders. www.hkClinicaltrials.com/trial_details.aspx?trialID=d09bd177‐b9fd‐4162‐b04f‐3ebfed49baa32011. [CSzG: 29270] McGorryP , MarkulevC , NelsonB , YuenHP , SchaeferM , YungAR , et al. The NEURAPRO‐E study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Schizophrenia Bulletin2015;41:S322‐3. [CSzG: 29546] McGorryPD , NelsonB , MarkulevC , YuenHP , SchaferMR , MossahebN , et al. Effect of omega‐3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomised clinical trial. JAMA psychiatry2017;74(1):19‐27. [CSzG: 35590] NelsonB , AmmingerG , MarkulevC , YuenHP , LavoieS , SchaeferM , et al. NEURAPOR: a multi‐center RCT of omega‐3 polyunsaturated fatty acids versus placebo in young people at ultra‐high risk of psychotic disorders: medium‐term outcome. Schizophrenia Bulletin2017;43:S107. [CSzG: 36016] ">NEURAPRO‐AAE</a>; <a href="./references#CD012236-bbs2-0016" title="NCT01619319 . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. ClinicalTrials.gov/show/NCT016193192012. [CSzG: 24387] PiskulicD , BarbatoM , AddingtonJ . Cognitive remediation in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:89. [CSzG: 24973] PiskulicD , BarbatoM , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2012;136:S245‐6. [CSzG: 29632] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2014;153(Suppl. 1):S218. [CSzG: 28827] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation therapy on cognition in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2014;8:86. [CSzG: 29633] ">Piskulic‐Canada</a>; <a href="./references#CD012236-bbs2-0017" title='BlockJJ , McGlashonTH . Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790‐9. American Journal of Psychiatry2006; Vol. 163, issue 10:1838. [CSzG: 13960] BreierAF , ZipurskyRB , PerkinsDO , AddingtonJM , TohenMF , DavidSR , et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951] HawkinsKA , AddingtonJ , KeefeR , ChristensenB , WoodsS , ZipurskyR , et al. Neuropsychological functioning in the first episode prodrome and early psychosis. Schizophrenia Research2004;70(1):101. [CSzG: 11515] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , MillerTJ , et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research2004;67(1):205. [CSzG: Ref11301] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , ZipurskyRB , et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. [CSzG: 16470] HawkinsKA , KeefeRS , ChristensenBK , AddingtonJ , WoodsSW , CallahanJ , et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. Schizophrenia Research2008;105(1‐3):1‐9. [CSzG: 16983] HoffmanRE , WoodsS , PredaA , TohenM , BreierA , GlistJ , et al. Excessive top‐down perceptual processing and reduced real‐world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. Schizophrenia Research2006;86(Suppl 1):S46. [CSzG: 13377] HoffmanRE , WoodsSW , HawkinsKA , PittmanB , TohenM , PredaA , et al. Extracting spurious messages from noise and risk of schizophrenia‐spectrum disorders in prodromal population. British Journal of Psychiatry2007;191(2):355‐6. [CSzG: 16068] McGlashanT , ZipurskyR , PerkinsD , AddingtonJ . Olanzapine for treatment of the schizophrenia prodrome: 2‐year results of a randomised placebo‐controlled study. Schizophrenia Research2004;67(1):164. [CSzG: 11320] McGlashanTH . Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. [CSzG: 10191] McGlashanTH . Treatment intervention in the New Haven PRIME clinic prodromal sample. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4835] McGlashanTH , MillerTJ , WoodsSW . Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research2002;53(3 Suppl 1):15. [CSzG: 8093] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005] McGlashanTH , MillerTJ , ZipurskyRB , WoodsSW , PerkinsDO , HawkinsKA , et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9803] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerT , WoodsSW , et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry2006;163(5):790‐9. [CSzG: 12654] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerTJ , WoodsSW , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research2003;61(1):7‐18. [CSzG: 9828] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJ , WoodsSW , MillerTJ , et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research2003;60:295. [CSzG: 9722] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJM , WoodsSW , LindborgS , et al. Olanzapine versus pbo for the schizophrenic prodrome: one‐year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9804] McGlashlanTH , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTH , WoodsSW , et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:42. [CSzG: 8934] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , MillerT , WoodsS , et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. Schizophrenia Research2004;70(1):6. [CSzG: 11524] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , WoodsS , MillerT , et al. Olanzapine vs. placebo for prodromal schizophrenia. Schizophrenia Research2004;67(1):6. [CSzG: 11321] MillerTJ , ZipurskyRB , PerkinsD , AddingtonJ , WoodsSW , HawkinsKA , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research2003;61(1):19‐30. [CSzG: 9829] RosenJL , WoodsSW , MillerTJ , McGlashanTH . Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease2002;190:133‐41. [CSzG: 8274] TaylorHE , ParkerS , MansellW , MorrisonAP . Effects of appraisals of anomalous experience on distress in people at risk of psychosis. Behavioural and Cognitive Psychotherapy2012;41(1):24‐33. [CSzG: 24374] WoodsS , ZipurskyR , PerkinsD , AddingtonJ , MarquezE , BreierA , et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:43. [CSzG: 8933] WoodsSW . Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):497. [CSzG: 19829] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research. 2003. [CSzG: 9978] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research2003;60:306‐7. [CSzG: 9752] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):453‐64. [CSzG: 9994] WoodsSW , McGlashanTH . Sample size planning for prodromal intervention trials. Schizophrenia Research2002;53(3 Suppl 1):40. [CSzG: 8116] WoodsSW , ZipurskyRB , PerkinsDO , AddingtonJM , MillerTJ , BreierAF , et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053] '>PRIME‐USA</a>; <a href="./references#CD012236-bbs2-0018" title="LoewyR , FisherM , MathalonDH , VinogradovS . Interim analyses of a randomised controlled trial of computerised cognitive training in clinical high risk for psychosis. Schizophrenia Bulletin2013;39:S238‐9. [CSzG: 28151] LoewyR , FisherM , SchlosserDA , BiagiantiB , StuartB , MathalonDH , et al. Intensive auditory cognitive training improves verbal memory in adolescents and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2016;42(Suppl 1):S118‐26. [CSzG: 35221] VinogradovS , LoewyR , FisherM , LeeA , NiendamT , RaglandJD , et al. Neuroplasticity‐based cognitive training in ultra‐high risk adolescents and recent onset patients with schizophrenia. Schizophrenia Research2012;136:S30. [CSzG: 29703] ">Vinogradov‐USA</a>; <a href="./references#CD012236-bbs2-0020" title="McGorryP . Second generation intervention research in the pre‐psychotic phase of illness in schizophrenia and related psychoses. Australian New Zealand Clinical Trials Registry2000. [CSzG: 18439] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceyS , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: 12‐month outcome. Schizophrenia Research2012;136:S17‐8. [CSzG: 29547] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceySM , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: twelve‐month outcome. Journal of Clinical Psychiatry2013;74(4):349‐56. [CSzG: 28737] NelsonB , PhillipsLJ , YungAR , FranceySM , LeicesterS , BakerK , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and supportive therapy in young people with subthreshold symptoms at incipient risk of psychotic disorder: baseline characteristics of the sample. Schizophrenia Bulletin2007;33(2):450. [CSzG: 15212] PhillipsLJ , NelsonB , YuenHP , FranceySM , SimmonsM , StanfordC , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: study design and baseline characteristics. Australian and New Zealand Journal of Psychiatry2009;;43(9):818–29. YungA , AmmingerP , BergerG , ThompsomA , PhillipsL , NelsonB , et al. Randomised controlled trial of antipsychotic and cognitive therapy in young people at ultra‐high risk of psychosis. Early Intervention in Psychiatry2012;6:11. [CSzG: 24989] YungA , NelsonB , PhillipsL , FranceyS , LeicesterS , YuenH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and supportive therapy in young people at ultra high risk of psychotic disorder: 12 month outcome data. Early Intervention in Psychiatry2008;2(Suppl 1):A12. [CSzG: 19138] YungAR , PhillipsLJ , NelsonB , FranceySM , YuenHP , SimmonsMB , et al. Randomised controlled trial of interventions for young people at ultra high risk for psychosis: 6‐month analysis. Journal of Clinical Psychiatry2011;72(4):430‐40. [CSzG: 22929] ">Yung‐Australia</a>), so we judged them at low risk of bias. </p> <p>In six studies assessors were not kept blind to outcome assessments (<a href="./references#CD012236-bbs2-0007" title="FrenchP , ShryaneN , BentallRP , LewisSW , MorrisonAP . Effects of cognitive therapy on the longitudinal development of psychotic experiences in people at high risk of developing psychosis. British Journal of Psychiatry. Supplements2007;191(Suppl 51):s82‐7. [CSzG: Ref16121] LewisS . EDIE ‐ Early detection and intervention for psychosis. National Research Register2001; Vol. 3. [CSzG: Ref13023] LewisS . EDIE ‐ early detection and intervention for psychosis (in primary care). National Research Register2002; Vol. 1. [CszG: Ref9342] MorrisonA . Early detection and intervention for psychosis in primary care. National Research Register2003. [CSzG: Ref15485] MorrisonA . Findings from a randomised controlled trial and clinical service delivering cognitive therapy to people at ultra‐high risk of developing psychosis. Schizophrenia Research2004;70(1):43‐4. [CSzG: Ref11526] MorrisonA . Follow‐up of prodromal symptoms. National Research Register2004; Vol. 3. [CSzG: Ref13036] MorrisonA , BentallR , FrenchP , Kilcommons A, LewisSW . Very early intervention in prodromal psychosis: a randomised trial. Schizophrenia Research2002;53(3 Suppl 1):42. [CSzG: Ref8096] MorrisonA , FrenchP , WalfordL , LewisS , Kilcommons A, GreenJ , et al. A randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;67(1):7. [CSzG: Ref11324] MorrisonA , FrenchP , WatfordL , LewisS , Kilcommons A, GreenJ , et al. Randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;70(1):63. [CSzG: Ref11527] MorrisonAP . Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: results of a randomised controlled trial. Schizophrenia Research2006;86(Suppl 1):S59. [CSzG: Ref13388] MorrisonAP , BentallRP , FrenchP , Kilcommons A, GreenJ , WalfordL , et al. Cognitive therapy in ultra high risk individuals for psychosis: randomised controlled trial. Schizophrenia Research2003;60:326. [CSzG: Ref9726] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, KnightA , et al. Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high‐risk individuals. Study design and interim analysis of transition rate and psychological risk factors. British Journal of Psychiatry. Supplements2002;181(43):s78‐84. [CSzG: Ref8737] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, LewisS . Early detection and intervention for psychosis in primary care. 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002. [CSzG: Ref8932] MorrisonAP , FrenchP , ParkerS , RobertsM , StevensH , BentallRP , et al. Three‐year follow‐up of a randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophrenia Bulletin2007;33(3):682‐7. [CSzG: Ref15288] MorrisonAP , FrenchP , WalfordL , LewisSW , Kilcommons A, GreenJ , et al. Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: randomised controlled trial. British Journal of Psychiatry2004;185:291‐7. [CSzG: Ref11450] MorrisonT . Early detection and intervention for psychosis in primary care. National Research Register2001; Vol. 1. [CSzG: Ref13037] MorrisonT , BentallR , FrenchP , Kilcommons A, GreenJ , LewisS . Early detection and intervention for psychosis in primary care. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:44. [CSzG: Ref8932] RentonJ , MorrisonA . Effectiveness of cognitive therapy for psychosis and implications for early intervention. Schizophrenia Research2004;70(1):142. [CSzG: Ref11536] ">EDIE‐UK</a> intended the raters to be blind, but it was difficult in practice; <a href="./references#CD012236-bbs2-0009" title="BechdolfA . Preventing progression to first‐episode psychosis in people in the early initial prodromal state. Early Intervention in Psychiatry2012;6:11. [CSzG: 24944] BechdolfA , BuhlerB , BerningJ , WagnerM , StammE , StreitM . Cognitive behavioural therapy in the early initial prodromal state of psychosis: first results. Schizophrenia Research2004;67(1):202. [CSzG: Ref11285] BechdolfA , KlosterkotterJ . Cognitive‐behavioural treatment (CBT) in the early initial prodromal state of psychosis: concept and practical approach. Schizophrenia Research2004;70(1):52. [CSzG: Ref11506] BechdolfA , RuhrmannS , JanssenB , BottlenderR , WagnerM , MaurerK , et al. Early recognition and intervention for people at risk of schizophrenia [Fruherkennung und intervention bei personen mit erhohtem psychoserisiko]. Psychoneuroendocrinology2004;30(11):606‐14. [CSzG: Ref11376] BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: Ref12511] BechdolfA , VeithV , BerningJ , StammE , DeckerP , JanssenB , et al. Cognitive behavioral therapy (CBT) in the early initial prodromal state of psychosis: first results of a randomised trial. Schizophrenia Research2004;70(1):62‐3. [CSzG: Ref11507] BechdolfA , WagnerM , RuhrmannS , HarriganS , PutzfeldV , PukropR , et al. Preventing progression to first‐episode psychosis in early initial prodromal states. British Journal of Psychiatry2012;200(1):22‐9. [CSzG: Ref24206] BechdolfA , WagnerM , RuhrmannS , HarriganS , VeithV , PukropR , et al. CBT for prevention of first episode psychosis in people in an putative early initial prodromal state. Early Intervention in Psychiatry2008;2(Suppl 1):A16. [CSzG: 19109] BechdolfA , WagnerM , VeithV , PukropR , BerningJ , StammE , et al. A randomised controlled trial of cognitive‐behavioral therapy in the early initial prodromal state of psychosis. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:22‐3. [CSzG: 20193] BechdolfA , WagnerM , VeithV , RuhrmannR , JanssenB , BottlenderR , et al. A randomised controlled multicenter trial of cognitive behaviour therapy in the early initial prodromal state of psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13369] BechdolfA , WagnerM , VeithV , RuhrmannS , PukropR , Brockhaus‐DumkeA , et al. Randomised controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Intervention in Psychiatry2007;1(1):71‐8. [CSzG: 16450] BechdolfA , WesselsH , WagnerM , KuhrK , BerningJ , PutzfeldV , et al. Predictors of treatment response to psychosocial interventions in people at risk. European Archives of Psychiatry and Clinical Neuroscience2015;1:S9. [CSzG: 33601] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] KommescherM , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. Early Intervention in Psychiatry2016;10(1):17‐27. [CSzG: 32187] NCT00204087 . Psychological intervention for persons at risk of psychosis in the early initial prodromal state. www.ClinicalTrials.gov/ct/show/2005. [CSzG: 14890] WesselsH , WagnerM , FrommannI , BerningJ , PutzfeldV , JanssenB , et al. Neuropsychological functioning as a predictor of treatment response to psychoeducational, cognitive behavioral therapy in people at clinical high risk of first episode psychosis. Psychiatrische Praxis2015;42(6):313‐9. [CSzG: 33130] ZarafonitisS , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Psychoeducation for persons at risk of psychosis. Psychotherapeut2012;57(4):326‐34. [CSzG: 24807] ">EIPS‐Germany</a>; <a href="./references#CD012236-bbs2-0011" title="BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: 12511] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] RuhrmannS , BechdolfA , KuhnKU , WagnerM , Schultze‐LutterF Janssen B , et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry. Supplements2007;51:s88‐95. [CSzG: 16127] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Acute symptomatic treatment effects in persons clinically at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13397] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Intervention in the late initial prodromal state (LIPS) of psychosis. Schizophrenia Research2006;86(Suppl 1):S96. [CSzG: 13398] ">LIPS‐Germany</a>; <a href="./references#CD012236-bbs2-0012" title="MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Family‐focused therapy for individuals at clinical high risk for psychosis: treatment fidelity within a multisite randomised trial. Early Intervention in Psychiatry2016;10(2):137‐43. [CSzG: 29018] MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Treatment fidelity and differentiation in a randomised controlled trial of family‐focused therapy for youth at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:95. [CSzG: 24965] MiklowitzDJ , O'BrienMP , SchlosserDA , AddingtonJ , CandanKA , MarshallC , et al. Family‐focused treatment for adolescents and young adults at high risk for psychosis: results of a randomised trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(8):848‐58. [CSzG: 29019] NCT01907282 . Prevention trial of family focused treatment in youth at risk for psychosis. Clinicaltrials.gov/show/NCT019072822010. [CSzG: 27965] O'BrienMP , MiklowitzDJ , CandanKA , MarshallC , DominguesI , WalshBC , et al. A randomised trial of family focused therapy with populations at clinical high risk for psychosis: effects on interactional behavior. Journal of Consulting and Clinical Psychology2013;82(1):90‐101. [CSzG: 28565] O'BrienMP , MiklowitzDJ , CannonTD . Decreases in perceived maternal criticism predict improvement in subthreshold psychotic symptoms in a randomised trial of family‐focused therapy for individuals at clinical high risk for psychosis. Journal of Family Psychology2015;29(6):945–951.. [CSzG: 32212] SchlosserDA , MiklowitzDJ , O'BrienMP , DeSilvaSD , ZinbergJL , CannonTD . A randomised trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Intervention in Psychiatry2012;6(3):283‐91. [CSzG: 24491] ">Miklowitz‐USA</a>; <a href="./references#CD012236-bbs2-0014" title="NordentoftM , JeppesenP , PetersenL , ThorupA , OhlenschlaegerJ , ChristensenT , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. European Psychiatry2007;22:S129‐S. [CSzG: 20471] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the OPUS trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;83(1):29‐40. [CSzG: 13197] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;86(Suppl 1):S44. [CSzG: 13393] ">Nordentoft‐Denmark</a>; <a href="./references#CD012236-bbs2-0015" title="McGorryP . Can the onset of schizophrenia be delayed or prevented?. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S26. [CSzG: 8351] McGorryP , AdlardS , YungA , McDonaldA , PhillipsL , HearnN . Detection and intervention in pre‐psychotic schizophrenia. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4836] McGorryP , YungA , FranceyS , PhillipsL , NelsonB . A blinded, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and befriending in young people at risk of psychotic disorder: baseline characteristics of the sample. Acta Neuropsychiatrica2006;18(6):261. [CSzG: 35157] McGorryPD , HearnN , GermanoD , BravinJ , PhillipsLJ , YungAR , et al. Prepsychotic intervention in schizophrenia: a stitch in time?. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington DC, USA. 1999. [CSzG: 3584] McGorryPD , PhillipsLJ , NelsonB , LeicesterS , BakerK , KrstevH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and befriending in young people with subthreshold symptoms at incipient risk of psychotic disorder: six month outcome data. Schizophrenia Bulletin2007;33(2):446. [CSzG: 15203] McGorryPD , PhillipsLJ , YungAR , FranceyS , GermanoD , BravinJ , et al. A randomised controlled trial of interventions in the pre psychotic phase of psychotic disorders. Schizophrenia Research2000;41(1):9. [CSzG: 5149] McGorryPD , YungAR , PhillipsL , AdlardS , HallgrenM , PattonG , et al. Pre‐psychotic intervention in schizophrenia: a stitch in time?. Schizophrenia Research1998;29(1‐2):160. [CSzG: 3585] McGorryPD , YungAR , PhillipsLJ , YuenHP , FranceyS , CosgraveEM , et al. Randomised controlled trial of interventions designed to reduce the risk of progression to first‐episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry2002;59(10):921‐8. [CSzG: 8576] PhilippsLJ , McGorryP , YungA , FranceyD , GermanoF , BravinJ , et al. The development of preventive interventions for early psychosis: early findings and directions for the future. 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001; Vol. 2, issue Suppl 1. [CSzG: 7614] PhillipsL , CottonS , YuenHP , MihalopoulosC , ShihS , KellyD , et al. Cost effectiveness of a preventive intervention for young people at ultra high risk of developing psychosis. Schizophrenia Bulletin2007;33(2):488‐9. [CSzG: 15227] PhillipsLJ , CottonS , MihalopoulosC , ShihS , YungAR , CarterR , et al. Cost implications of specific and non‐specific treatment for young persons at ultra high risk of developing a first episode of psychosis. Early Intervention in Psychiatry2009;3(1):28‐34. [CSzG: 18308] PhillipsLJ , LeicesterSB , O'DwyerLE , FranceySM , KoutsogiannisJ , Abdel‐BakiA , et al. The PACE clinic: identification and management of young people at &quot;ultra&quot; high risk of psychosis. Journal of Psychiatric Practice2002;8(5):255‐69. [CSzG: 18235] PhillipsLJ , McGorryPD , YuenHP , WardJ , DonovanK , KellyD , et al. Medium term follow‐up of a randomised controlled trial of interventions for young people at ultra high risk of psychosis. Schizophrenia Research2007;96(1‐3):25‐33. [CSzG: 15544] PhillipsLJ , YungAR , YuenHP , PantelisC , McGorryPD . Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. American Journal of Medical Genetics2002;114(8):929‐37. [CSzG: 18236] ">PACE‐Australia</a>), so we judged them at high risk of bias. </p> <p>In two studies the process regarding blinding of outcome assessors was unclear (<a href="./references#CD012236-bbs2-0010" title="KantrowitzJT , WoodsSW , PetkovaE , CornblattB , CorcoranCM , ChenH , et al. D‐serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double‐blind, placebo‐controlled, randomised parallel group mechanistic proof‐of‐concept trial. Lancet Psychiatry2015;2(5):403‐12. [CSzG: 29487] NCT00826202 . D‐serine for the schizophrenia prodrome. www.ClinicalTrials.gov/ct/show/2009. [CSzG: 17391] ">Kantrowitz‐USA</a>; <a href="./references#CD012236-bbs2-0019" title="NCT00291226 . Glycine vs Placebo for the Schizophrenia Prodrome. www.ClinicalTrials.gov/ct/show/2006. [CSzG: 14759] WoodsS , WalshB , HawkinsK , MillerT , SaksaJ , D'SouzaD , et al. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. Early Intervention in Psychiatry2012;6:29. [CSzG: 24987] WoodsSW , KantrowitzJT , JavittDC . NMDAR‐based treatments for patients at clinical high risk for psychosis. Biological Psychiatry2014;1:11S. [CSzG: 29041] WoodsSW , WalshBC , HawkinsKA , MillerTJ , SaksaJR , D'SouzaDC , et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. European Neuropsychopharmacology2013;23(8):931‐40. [CSzG: 28750] ">Woods‐1‐USA</a>) and in one study blinding breaks were reported in a minority of participants (<a href="./references#CD012236-bbs2-0005" title="ByrneRE , MorrisonAP . Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. Psychology and Psychotherapy2014;87(3):357‐71. [CSzG: Ref29312] FlachC , FrenchP , DunnG , FowlerD , GumleyAI , BirchwoodM , et al. Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE‐2 trial. British Journal of Psychiatry2015;207(2):123‐9. [CSzG: Ref33109] MorrisonA . Early detection and intervention evaluation for individuals at high risk of psychosis 2. http://www.controlled‐trials.com2008. [CSzG: Ref18285] MorrisonA . Early detection and intervention evaluation for people at risk of psychosis (edie‐2): A multisite randomised controlled trial of cognitive therapy for at‐risk mental states. Early Intervention in Psychiatry2012;6:11. [CSzG: Ref24968] MorrisonA , FrenchP , BentallR , LewisS , BirchwoodM , FowlerD , et al. Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. Early Intervention in Psychiatry2008;2(Suppl 1):A15. [CSzG: Ref19128] MorrisonAP . EDIE‐2: early detection and psychological intervention for individuals at high risk of psychosis (2). www.controlled‐trials.com2007. [CSzG: Ref15381] MorrisonAP , BirchwoodM , PyleM , FlachC , StewartSL , ByrneR , et al. Impact of cognitive therapy on internalised stigma in people with at‐risk mental states. British Journal of Psychiatry2013;203(2):140‐5. [CSzG: Ref28630] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ2012;344(7852):e2233. [CSzG: Ref24208] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at‐risk of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29554] MorrisonAP , PyleM , StewartSL , FrenchP , ByrneR , FlachC , et al. Internalised stigma in young people at high risk of developing psychosis: findings from a cognitive therapy trial. Schizophrenia Research2014;153:S42. [CSzG: Ref29555] MorrisonAP , StewartSL , FrenchP , BentallRP , BirchwoodM , ByrneR , et al. Early detection and intervention evaluation for people at high‐risk of psychosis‐2 (EDIE‐2): trial rationale, design and baseline characteristics. Early Intervention in Psychiatry2011;5(1):24‐32. [CSzG: Ref22695] MorrisonT . Early detection and psychological intervention for individuals at high risk of psychosis. EDIE‐2. Data on File2006. [CSzG: Ref13874] PelosiAJ . Rational policy making for early psychosis might yet become possible. BMJ2012;344(7856):e3137. [CSzG: Ref24326] PyleM , StewartSL , FrenchP , ByrneR , PattersonP , GumleyA , et al. Internalised stigma, emotional dysfunction and unusual experiences in young people at risk of psychosis. Early Intervention in Psychiatry2015;9(2):133‐40. [CSzG: Ref29813] ">EDIE‐2‐UK</a>), so we judged these three studies at unclear risk of bias. </p> </section> <section id="CD012236-sec-0157"> <h4 class="title">Incomplete outcome data</h4> <p>We judged six studies as having low risk of attrition bias because they had attrition under 30% and clearly reported reasons for attrition (<a href="./references#CD012236-bbs2-0002" title="AmmingerG . Ethyl eicosapentanoic acid for prodromal psychosis. Stanley Foundation Research Programs2009. [CSzG: Ref17423] AmmingerG , SchaferM , PapageorgiouK , CottonS , HarriganS , MackinnonA , et al. Indicated prevention with long‐chain omega‐3 fatty acids in adolescents at ultra‐high‐risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2008;2(Suppl 1):A29. [CSzG: Ref19107] AmmingerGP , ChanenAM , OhmannS , KlierCM , MossahebN , BechdolfA , et al. Omega‐3 fatty acid supplementation in adolescents with borderline personality disorder and ultra‐high risk criteria for psychosis: a post hoc subgroup analysis of a double‐blind, randomised controlled trial. Canadian Journal of Psychiatry2013;58(7):402‐8. [CSzG: Ref28534] AmmingerGP , HarrisMS , McGorryPD , HenryLP . Omega‐3 fatty acids for indicated prevention: treatment results and pathomechanisms. European Archives of Psychiatry and Clinical Neuroscience2013;263(Suppl. 1):S44‐5. [CSzG: Ref28434] AmmingerGP , LeicesterS , YungAR , YuenHP , McGorryPD . Age predicts transition to psychosis in an ultra‐high risk sample. Proceedings of the 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:61. AmmingerGP , McGorryPD . Update on omega‐3 polyunsaturated fatty acids in early ‐stage psychotic disorders. Neuropsychopharmacology2012;37(1):309‐10. [CSzG: Ref23726] AmmingerGP , MechelliA , RiceS , KimSW , KlierCM , McNamaraRK , et al. Predictors of treatment response in young people at ultra‐high risk for psychosis who received long‐chain omega‐3 fatty acids. Translational Psychiatry2015;5:e495. [CSzG: Ref29299] AmmingerGP , SchaferMR . Indicated prevention with omega‐3 fatty acids in adolescents at ultra‐high risk for psychosis ‐ rationale, methods, and 3‐months outcome. Schizophrenia Research2006;86(Suppl 1):S97‐8. [CSzG: Ref13367] AmmingerGP , SchaferMR . Is it feasible to conduct a RCT in ultra‐high risk individuals at a child and adolescent psychiatric service?. Schizophrenia Research2006;86(Suppl 1):S98. [CSzG: Ref13368] AmmingerGP , SchaferMR , KlierCM , PapageorgiouK , SlavikJ , HolzerI , et al. Indicated prevention with long‐chain omega‐3 fatty acids in young people at ultra‐high risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2010;4(Suppl 1):7. [CSzG: Ref23467] AmmingerGP , SchaferMR , SchlogelhoferM , KlierCM , McGorryPD . Longer‐term outcome in the prevention of psychotic disorders by the Vienna omega‐3 study. Nature Communications2015;6:7934. [CSzG: Ref33023] AmmingerGP , SchlogelhoferM , KlierC , McGorryP , SchaferM . Longer‐term follow‐up in the Vienna omega‐3 psychosis prevention trial. Early Intervention in Psychiatry2014;8:41. [CSzG: Ref29378] AmmingerGP , SchäferMR , PapageorgiouK , KlierCM , CottonSM , HarriganSM , et al. Long‐chain omega‐3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo‐controlled trial. Archives of General Psychiatry2010;67(2):146‐54. [CSzG: Ref20680; DOI: 10.1001/archgenpsychiatry.2009.192.] AmmingerP , MossahebN , SchlgelhoferM , SchaferM . Fatty acid metabolism and the onset of psychotic disorder. European Psychiatry2011;26(Suppl 1):2089. [CSzG: Ref22967] Anonymous . Fish oil may help ward off psychosis. Journal of Psychosocial Nursing and Mental Health Services2010;48(5):55. [CSzG: Ref20739] BergerG , AmmingerP , McGorryP . Stage dependant effect of omega‐3 fatty acids in emerging psychosis. European Psychiatry2011;26(Suppl 1):1347. [CSzG: Ref22966] BergerGE , ProffittTM , McConchieM , YuenH , WoodSJ , AmmingerGP , et al. Ethyl‐eicosapentaenoic acid in first‐episode psychosis: a randomised, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(12):1867‐75. [CSzG: Ref15561; ISSN: 1555‐2101] EhrlichA . Evidence‐based medicine. Omega‐3 supplementation delays transition to psychotic disorder in ultra‐high‐risk adolescents and young adults. Clinical Advisor for Nurse Practitioners2010;13(5):79‐80. [CSzG: Ref21562] FöckingM , DickerP , LopezLM , CannonM , SchäferMR , McGorryPD , et al. Differential expression of the inflammation marker IL12p40 in the at‐risk mental state for psychosis: a predictor of transition to psychotic disorder?. BMC Psychiatry2016;16(1):326. [DOI: 10.1186/s12888‐016‐1039‐7] KlierC , HollmannM , SchlögelhoferM , MossahebN , FriedrichM , AmmingerPG . Indicated prevention with omega‐3 fatty acids (EPA/DHA) in adolescents with &quot;at‐risk‐mental‐state“ for psychosis. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. [CSzG: Ref12438] LavoieS , BenningerF , FeuchtM , KlierCM , SchaeferMR , AmmingerGP . Correlates of EEG resting states with erythrocyte membrane omega‐3 fatty acid levels and psychopathological symptoms in individuals at ultra‐high risk for psychosis. Early Intervention in Psychiatry2014;8:137. [CSzG: Ref29516] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultra‐high risk individuals who transitioned to psychosis. Schizophrenia Research2012;138(2‐3):206‐11. [CSzG: Ref24256] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultrahigh risk individuals who transitioned to psychosis. Early Intervention in Psychiatry2012;6:38. [CSzG: Ref24960] MossahebN , PapageorgiouK , SchaferMR , BeckerJ , SchloegelhoferM , AmmingerGP . Changes in triglyceride levels in ultra‐high risk for psychosis individuals treated with omega‐3 fatty acids. Early Intervention in Psychiatry2018; Vol. 12, issue 1:30‐36. [DOI: 10.1111/eip.12275] MossahebN , SchaferMR , SchlogelhoferM , KlierCM , CottonSM , McGorryPD , et al. Effect of omega‐3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?. Schizophrenia Research2013;148(1‐3):163‐7. [CSzG: Ref28649] NCT00396643 . Indicated prevention with omega‐3 fatty acids in adolescents with ‘at‐risk‐mental‐state’ for psychosis: a randomised, double blind, placebo‐controlled treatment trial. www.ClinicalTrials.gov/ct/show/2006. [CSzG: Ref14873] PapageorgiouK , SchaferMR , SchlogelhoferM , MossahebN , AmmingerGP . Indicated prevention with omega‐3 fatty acids in young people with 'at‐risk‐mental‐state' for psychosis: design of a 5‐year follow‐up. European Archives of Psychiatry and Clinical Neuroscience2011;261:S55. [CSzG: Ref23749] SchaferMR , KlierCM , PapageorgiouK , FriedrichMH , AmmingerGP . Early detection of psychotic disorders. Neuropsychiatrie2007;21(1):37‐44. [CSzG: Ref15290] SmesnyS , MilleitB , HiplerUC , MilleitC , SchaferMR , KlierCM , et al. Omega‐3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra‐high risk for psychosis. Molecular Psychiatry2013;19(3):317‐24. [CSzG: Ref28243] SmesnyS , MilleitB , SchaeferMR , HesseJ , SchlögelhoferM , LangbeinK , et al. Effects of omega‐3 PUFA on immune markers in adolescent individuals at ultra‐high risk for psychosis ‐ results of the randomised controlled Vienna omega‐3 study. Schizophrenia Research2017;S0920‐9964(17):30039‐7. [DOI: 10.1016/j.schres.2017.01.026] ">Amminger‐Austria</a>; <a href="./references#CD012236-bbs2-0006" title="DragtS , Van derGaagM . Prevention of psychosis with a cognitive behavioural intervention in help‐seeking young people with an at risk mental state for developing psychosis. www.trialregister.nl/trialreg/index.asp2007. [CSzG: Ref19655] IsingHK , KraanTC , RietdijkJ , DragtS , KlaassenRM , BoonstraN , et al. Four‐year follow‐up of cognitive behavioral therapy in persons at ultra‐high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2016;42(5):1243‐52. [CSzG: Ref35214] IsingHK , LokkerbolJ , RietdijkJ , DragtS , KlaassenRM , KraanT , et al. Four‐year cost‐effectiveness of cognitive behavior therapy for preventing first‐episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2017;43(2):365‐74. [CSzG: Ref35824] IsingHK , SmitF , VelingW , RietdijkJ , DragtS , KlaassenRM , et al. Cost‐effectiveness of preventing first‐episode psychosis in ultra‐high‐risk subjects: multi‐centre randomised controlled trial. Psychological Medicine2015;45(7):1435‐46. [CSzG: Ref27798] KraanTC , IsingHK , FokkemaM , VelthorstE , Van denBergDP , KerkhovenM , et al. The effect of childhood adversity on 4‐year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE‐NL) Trial. Psychiatry Research2017;247:55‐62. [CSzG: Ref35559] NiemanDH , RuhrmannS , RietdijkJ , DragtS , IsingH , KlaassenR , et al. Preventive psychotherapy. Schizophrenia Research2014;153:S42‐3. [CSzG: Ref29601] RietdijkJ , DragtS , KlaassenR , IsingH , NiemanD , WunderinkL , et al. A single blind randomised controlled trial of cognitive behavioural therapy in a help‐seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE‐NL) trial. Trials2010;11:30. [CSzG: Ref20654] Van DerGaagM . The effects of CBT in personswith ultra high risk: the Dutch EDIE trial. European Archives of Psychiatry and Clinical Neuroscience2011;261:S18. [CSzG: Ref23756] Van DerGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first‐episode of psychosis. Early Intervention in Psychiatry2012;6:12. [CSzG: Ref24985] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomised controlled clinical trial. Schizophrenia Bulletin2012;38(6):1180‐8. [CSzG: Ref24935] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. The effects of cognitive behavioural therapy for subjects at ultra‐high risk for developing psychosis. Schizophrenia Bulletin2013;39:S356. [CSzG: Ref28121] Van derGaagM . The prevention of psychosis in at risk mental state. www.controlled‐trials.com2008. [CSzG: Ref17488] Van derGaagM , NiemanD , Van denBergD . CBT for those at risk of a first episode psychosis: Evidence‐based psychotherapy for people with an 'at risk mental state'. 1st Edition. Hove, UK: Routledge, 2013. Van derGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first episode of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29692] ">EDIE‐NL</a>; <a href="./references#CD012236-bbs2-0012" title="MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Family‐focused therapy for individuals at clinical high risk for psychosis: treatment fidelity within a multisite randomised trial. Early Intervention in Psychiatry2016;10(2):137‐43. [CSzG: 29018] MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Treatment fidelity and differentiation in a randomised controlled trial of family‐focused therapy for youth at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:95. [CSzG: 24965] MiklowitzDJ , O'BrienMP , SchlosserDA , AddingtonJ , CandanKA , MarshallC , et al. Family‐focused treatment for adolescents and young adults at high risk for psychosis: results of a randomised trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(8):848‐58. [CSzG: 29019] NCT01907282 . Prevention trial of family focused treatment in youth at risk for psychosis. Clinicaltrials.gov/show/NCT019072822010. [CSzG: 27965] O'BrienMP , MiklowitzDJ , CandanKA , MarshallC , DominguesI , WalshBC , et al. A randomised trial of family focused therapy with populations at clinical high risk for psychosis: effects on interactional behavior. Journal of Consulting and Clinical Psychology2013;82(1):90‐101. [CSzG: 28565] O'BrienMP , MiklowitzDJ , CannonTD . Decreases in perceived maternal criticism predict improvement in subthreshold psychotic symptoms in a randomised trial of family‐focused therapy for individuals at clinical high risk for psychosis. Journal of Family Psychology2015;29(6):945–951.. [CSzG: 32212] SchlosserDA , MiklowitzDJ , O'BrienMP , DeSilvaSD , ZinbergJL , CannonTD . A randomised trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Intervention in Psychiatry2012;6(3):283‐91. [CSzG: 24491] ">Miklowitz‐USA</a>; <a href="./references#CD012236-bbs2-0013" title="ACTRN12608000475347 . A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder. Australian New Zealand Clinical Trials Registry2009. [CSzG: 18420] HKCTR‐1438 . The NEURAPRO‐E (North America, EURope, Australia PROdrome) Study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for symptomatic patients at ultra‐high risk for early progression to schizophrenia and other psychotic disorders. www.hkClinicaltrials.com/trial_details.aspx?trialID=d09bd177‐b9fd‐4162‐b04f‐3ebfed49baa32011. [CSzG: 29270] McGorryP , MarkulevC , NelsonB , YuenHP , SchaeferM , YungAR , et al. The NEURAPRO‐E study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Schizophrenia Bulletin2015;41:S322‐3. [CSzG: 29546] McGorryPD , NelsonB , MarkulevC , YuenHP , SchaferMR , MossahebN , et al. Effect of omega‐3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomised clinical trial. JAMA psychiatry2017;74(1):19‐27. [CSzG: 35590] NelsonB , AmmingerG , MarkulevC , YuenHP , LavoieS , SchaeferM , et al. NEURAPOR: a multi‐center RCT of omega‐3 polyunsaturated fatty acids versus placebo in young people at ultra‐high risk of psychotic disorders: medium‐term outcome. Schizophrenia Bulletin2017;43:S107. [CSzG: 36016] ">NEURAPRO‐AAE</a>; <a href="./references#CD012236-bbs2-0015" title="McGorryP . Can the onset of schizophrenia be delayed or prevented?. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S26. [CSzG: 8351] McGorryP , AdlardS , YungA , McDonaldA , PhillipsL , HearnN . Detection and intervention in pre‐psychotic schizophrenia. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4836] McGorryP , YungA , FranceyS , PhillipsL , NelsonB . A blinded, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and befriending in young people at risk of psychotic disorder: baseline characteristics of the sample. Acta Neuropsychiatrica2006;18(6):261. [CSzG: 35157] McGorryPD , HearnN , GermanoD , BravinJ , PhillipsLJ , YungAR , et al. Prepsychotic intervention in schizophrenia: a stitch in time?. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington DC, USA. 1999. [CSzG: 3584] McGorryPD , PhillipsLJ , NelsonB , LeicesterS , BakerK , KrstevH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and befriending in young people with subthreshold symptoms at incipient risk of psychotic disorder: six month outcome data. Schizophrenia Bulletin2007;33(2):446. [CSzG: 15203] McGorryPD , PhillipsLJ , YungAR , FranceyS , GermanoD , BravinJ , et al. A randomised controlled trial of interventions in the pre psychotic phase of psychotic disorders. Schizophrenia Research2000;41(1):9. [CSzG: 5149] McGorryPD , YungAR , PhillipsL , AdlardS , HallgrenM , PattonG , et al. Pre‐psychotic intervention in schizophrenia: a stitch in time?. Schizophrenia Research1998;29(1‐2):160. [CSzG: 3585] McGorryPD , YungAR , PhillipsLJ , YuenHP , FranceyS , CosgraveEM , et al. Randomised controlled trial of interventions designed to reduce the risk of progression to first‐episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry2002;59(10):921‐8. [CSzG: 8576] PhilippsLJ , McGorryP , YungA , FranceyD , GermanoF , BravinJ , et al. The development of preventive interventions for early psychosis: early findings and directions for the future. 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001; Vol. 2, issue Suppl 1. [CSzG: 7614] PhillipsL , CottonS , YuenHP , MihalopoulosC , ShihS , KellyD , et al. Cost effectiveness of a preventive intervention for young people at ultra high risk of developing psychosis. Schizophrenia Bulletin2007;33(2):488‐9. [CSzG: 15227] PhillipsLJ , CottonS , MihalopoulosC , ShihS , YungAR , CarterR , et al. Cost implications of specific and non‐specific treatment for young persons at ultra high risk of developing a first episode of psychosis. Early Intervention in Psychiatry2009;3(1):28‐34. [CSzG: 18308] PhillipsLJ , LeicesterSB , O'DwyerLE , FranceySM , KoutsogiannisJ , Abdel‐BakiA , et al. The PACE clinic: identification and management of young people at &quot;ultra&quot; high risk of psychosis. Journal of Psychiatric Practice2002;8(5):255‐69. [CSzG: 18235] PhillipsLJ , McGorryPD , YuenHP , WardJ , DonovanK , KellyD , et al. Medium term follow‐up of a randomised controlled trial of interventions for young people at ultra high risk of psychosis. Schizophrenia Research2007;96(1‐3):25‐33. [CSzG: 15544] PhillipsLJ , YungAR , YuenHP , PantelisC , McGorryPD . Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. American Journal of Medical Genetics2002;114(8):929‐37. [CSzG: 18236] ">PACE‐Australia</a>; <a href="./references#CD012236-bbs2-0019" title="NCT00291226 . Glycine vs Placebo for the Schizophrenia Prodrome. www.ClinicalTrials.gov/ct/show/2006. [CSzG: 14759] WoodsS , WalshB , HawkinsK , MillerT , SaksaJ , D'SouzaD , et al. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. Early Intervention in Psychiatry2012;6:29. [CSzG: 24987] WoodsSW , KantrowitzJT , JavittDC . NMDAR‐based treatments for patients at clinical high risk for psychosis. Biological Psychiatry2014;1:11S. [CSzG: 29041] WoodsSW , WalshBC , HawkinsKA , MillerTJ , SaksaJR , D'SouzaDC , et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. European Neuropsychopharmacology2013;23(8):931‐40. [CSzG: 28750] ">Woods‐1‐USA</a>). We judged eight studies as having unclear risk of attrition bias; two studies had attrition under 30%, but reasons for attrition were unclear (<a href="./references#CD012236-bbs2-0003" title="ChoiJ , CorcoranC , DixonL , FiszdonJ , JavittD . Processing speed training and social functioning in young adults at clinical high risk for psychosis: a pilot study. Early Intervention in Psychiatry2014;8:109. [CSzG: Ref29417] ChoiJ , CorcoranC , DixonL , JavittDC . Processing speed training and social functioning in teenagers and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2015;41:S41. [CSzG: Ref29418] ChoiJ , CorcoranCM , FiszdonJM , StevensM , JavittDC , DeasyM , et al. Pupillometer‐based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis. Psychiatric Rehabilitation Journal2017;40(1):33‐42. [CSzG: Ref35317] ">Choi‐USA</a>; <a href="./references#CD012236-bbs2-0014" title="NordentoftM , JeppesenP , PetersenL , ThorupA , OhlenschlaegerJ , ChristensenT , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. European Psychiatry2007;22:S129‐S. [CSzG: 20471] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the OPUS trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;83(1):29‐40. [CSzG: 13197] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;86(Suppl 1):S44. [CSzG: 13393] ">Nordentoft‐Denmark</a>), and the other six studies had attrition between 30% and 50% (<a href="./references#CD012236-bbs2-0001" title="AddingtonJ , EpsteinI , LiuL , FrenchP , BoydellKM , ZipurskyRB . A randomised controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research2011;125(1):54‐61. [CSzG: Ref21945] AddingtonJ , ZipurskyR , EpsteinI . ADAPT (Access, Detection and Psychological Treatments). Schizophrenia Research2006;86(Suppl 1):S6. [CSzG: Ref13364] NCT00260273 . Access, detection and psychological treatments. www.ClinicalTrials.gov/ct/show/2005. [CSzG: Ref14638] ">ADAPT‐Canada</a>; <a href="./references#CD012236-bbs2-0008" title="McFarlaneWR , CookWL , WoodberryKA . A randomised clinical trial of familyaided assertive community treatment for young persons at high risk for onset of an initial psychosis. Schizophrenia Bulletin2011;37:314. [CSzG: Ref22796] NCT01597141 . Psychosis: early detection, intervention and prevention. ClinicalTrials.gov/show/NCT015971412012. [CSzG: Ref24315] ">EDIP‐USA</a>; <a href="./references#CD012236-bbs2-0009" title="BechdolfA . Preventing progression to first‐episode psychosis in people in the early initial prodromal state. Early Intervention in Psychiatry2012;6:11. [CSzG: 24944] BechdolfA , BuhlerB , BerningJ , WagnerM , StammE , StreitM . Cognitive behavioural therapy in the early initial prodromal state of psychosis: first results. Schizophrenia Research2004;67(1):202. [CSzG: Ref11285] BechdolfA , KlosterkotterJ . Cognitive‐behavioural treatment (CBT) in the early initial prodromal state of psychosis: concept and practical approach. Schizophrenia Research2004;70(1):52. [CSzG: Ref11506] BechdolfA , RuhrmannS , JanssenB , BottlenderR , WagnerM , MaurerK , et al. Early recognition and intervention for people at risk of schizophrenia [Fruherkennung und intervention bei personen mit erhohtem psychoserisiko]. Psychoneuroendocrinology2004;30(11):606‐14. [CSzG: Ref11376] BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: Ref12511] BechdolfA , VeithV , BerningJ , StammE , DeckerP , JanssenB , et al. Cognitive behavioral therapy (CBT) in the early initial prodromal state of psychosis: first results of a randomised trial. Schizophrenia Research2004;70(1):62‐3. [CSzG: Ref11507] BechdolfA , WagnerM , RuhrmannS , HarriganS , PutzfeldV , PukropR , et al. Preventing progression to first‐episode psychosis in early initial prodromal states. British Journal of Psychiatry2012;200(1):22‐9. [CSzG: Ref24206] BechdolfA , WagnerM , RuhrmannS , HarriganS , VeithV , PukropR , et al. CBT for prevention of first episode psychosis in people in an putative early initial prodromal state. Early Intervention in Psychiatry2008;2(Suppl 1):A16. [CSzG: 19109] BechdolfA , WagnerM , VeithV , PukropR , BerningJ , StammE , et al. A randomised controlled trial of cognitive‐behavioral therapy in the early initial prodromal state of psychosis. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:22‐3. [CSzG: 20193] BechdolfA , WagnerM , VeithV , RuhrmannR , JanssenB , BottlenderR , et al. A randomised controlled multicenter trial of cognitive behaviour therapy in the early initial prodromal state of psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13369] BechdolfA , WagnerM , VeithV , RuhrmannS , PukropR , Brockhaus‐DumkeA , et al. Randomised controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Intervention in Psychiatry2007;1(1):71‐8. [CSzG: 16450] BechdolfA , WesselsH , WagnerM , KuhrK , BerningJ , PutzfeldV , et al. Predictors of treatment response to psychosocial interventions in people at risk. European Archives of Psychiatry and Clinical Neuroscience2015;1:S9. [CSzG: 33601] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] KommescherM , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. Early Intervention in Psychiatry2016;10(1):17‐27. [CSzG: 32187] NCT00204087 . Psychological intervention for persons at risk of psychosis in the early initial prodromal state. www.ClinicalTrials.gov/ct/show/2005. [CSzG: 14890] WesselsH , WagnerM , FrommannI , BerningJ , PutzfeldV , JanssenB , et al. Neuropsychological functioning as a predictor of treatment response to psychoeducational, cognitive behavioral therapy in people at clinical high risk of first episode psychosis. Psychiatrische Praxis2015;42(6):313‐9. [CSzG: 33130] ZarafonitisS , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Psychoeducation for persons at risk of psychosis. Psychotherapeut2012;57(4):326‐34. [CSzG: 24807] ">EIPS‐Germany</a>; <a href="./references#CD012236-bbs2-0011" title="BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: 12511] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] RuhrmannS , BechdolfA , KuhnKU , WagnerM , Schultze‐LutterF Janssen B , et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry. Supplements2007;51:s88‐95. [CSzG: 16127] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Acute symptomatic treatment effects in persons clinically at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13397] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Intervention in the late initial prodromal state (LIPS) of psychosis. Schizophrenia Research2006;86(Suppl 1):S96. [CSzG: 13398] ">LIPS‐Germany</a>; <a href="./references#CD012236-bbs2-0018" title="LoewyR , FisherM , MathalonDH , VinogradovS . Interim analyses of a randomised controlled trial of computerised cognitive training in clinical high risk for psychosis. Schizophrenia Bulletin2013;39:S238‐9. [CSzG: 28151] LoewyR , FisherM , SchlosserDA , BiagiantiB , StuartB , MathalonDH , et al. Intensive auditory cognitive training improves verbal memory in adolescents and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2016;42(Suppl 1):S118‐26. [CSzG: 35221] VinogradovS , LoewyR , FisherM , LeeA , NiendamT , RaglandJD , et al. Neuroplasticity‐based cognitive training in ultra‐high risk adolescents and recent onset patients with schizophrenia. Schizophrenia Research2012;136:S30. [CSzG: 29703] ">Vinogradov‐USA</a>; <a href="./references#CD012236-bbs2-0020" title="McGorryP . Second generation intervention research in the pre‐psychotic phase of illness in schizophrenia and related psychoses. Australian New Zealand Clinical Trials Registry2000. [CSzG: 18439] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceyS , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: 12‐month outcome. Schizophrenia Research2012;136:S17‐8. [CSzG: 29547] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceySM , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: twelve‐month outcome. Journal of Clinical Psychiatry2013;74(4):349‐56. [CSzG: 28737] NelsonB , PhillipsLJ , YungAR , FranceySM , LeicesterS , BakerK , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and supportive therapy in young people with subthreshold symptoms at incipient risk of psychotic disorder: baseline characteristics of the sample. Schizophrenia Bulletin2007;33(2):450. [CSzG: 15212] PhillipsLJ , NelsonB , YuenHP , FranceySM , SimmonsM , StanfordC , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: study design and baseline characteristics. Australian and New Zealand Journal of Psychiatry2009;;43(9):818–29. YungA , AmmingerP , BergerG , ThompsomA , PhillipsL , NelsonB , et al. Randomised controlled trial of antipsychotic and cognitive therapy in young people at ultra‐high risk of psychosis. Early Intervention in Psychiatry2012;6:11. [CSzG: 24989] YungA , NelsonB , PhillipsL , FranceyS , LeicesterS , YuenH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and supportive therapy in young people at ultra high risk of psychotic disorder: 12 month outcome data. Early Intervention in Psychiatry2008;2(Suppl 1):A12. [CSzG: 19138] YungAR , PhillipsLJ , NelsonB , FranceySM , YuenHP , SimmonsMB , et al. Randomised controlled trial of interventions for young people at ultra high risk for psychosis: 6‐month analysis. Journal of Clinical Psychiatry2011;72(4):430‐40. [CSzG: 22929] ">Yung‐Australia</a>). We judged six studies with high risk of attrition bias because the attrition was above 50% (<a href="./references#CD012236-bbs2-0004" title="CrittendenK , FlemingJ , StartupM , CarrV , BakerA , SchallU , et al. Recruitment and engagement of youth in an ultra high risk treatment study. Early Intervention in Psychiatry2008;2(Suppl 1):A127. [CSzG: Ref19115] StainH , BucciS , HalperinS , EmsleyR , ShallU , LewinT , et al. DEPTh: randomised controlled trial of cognitive behavioral therapy for young people at ultra high risk for psychosis. Early Intervention in Psychiatry2014;8:15. [CSzG: Ref29673] StainHJ , BucciS , BakerA , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of CBT for young people at risk for psychosis: the Detection and Evaluation of Psychological Therapy (DEPTh) trial. European Archives of Psychiatry and Clinical Neuroscience2015;1:S8‐9. [CSzG: Ref33810] StainHJ , BucciS , BakerAL , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of cognitive behaviour therapy versus non‐directive reflective listening for young people at ultra high risk of developing psychosis: the detection and evaluation of psychological therapy (DEPTh) trial. Schizophrenia Research2016;176(2‐3):212‐9. [CSzG: Ref35298] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. Rural and urban youth at ultra high risk for psychosis: baseline characteristics from the DEPTh randomised controlled trial of cognitive behavior therapy. Schizophrenia Bulletin2011;37:322. [CSzG: Ref22815] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy for youth at ultra high risk for psychosis: baseline characteristics for rural and urban youth. Australian and New Zealand Journal of Psychiatry2010:25‐6. [CSzG: Ref21845] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy targeting ultra high risk for psychosis: baseline comparisons for rural and urban youth. Early Intervention in Psychiatry2010;4(Suppl 1):113. [CSzG: Ref23498] StainHJ , StartupM , CarrV , BakerA , SchallU . The DEPTh project: a multisite RCT for youths at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S51‐2. [CSzG: Ref13401] StartupM . The DEPTh project: detection, evaluation, and psychological therapy for health. Australian New Zealand Clinical Trials Registry2006. [CszG: Ref18442] ">DEPTh‐Australia</a>; <a href="./references#CD012236-bbs2-0005" title="ByrneRE , MorrisonAP . Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. Psychology and Psychotherapy2014;87(3):357‐71. [CSzG: Ref29312] FlachC , FrenchP , DunnG , FowlerD , GumleyAI , BirchwoodM , et al. Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE‐2 trial. British Journal of Psychiatry2015;207(2):123‐9. [CSzG: Ref33109] MorrisonA . Early detection and intervention evaluation for individuals at high risk of psychosis 2. http://www.controlled‐trials.com2008. [CSzG: Ref18285] MorrisonA . Early detection and intervention evaluation for people at risk of psychosis (edie‐2): A multisite randomised controlled trial of cognitive therapy for at‐risk mental states. Early Intervention in Psychiatry2012;6:11. [CSzG: Ref24968] MorrisonA , FrenchP , BentallR , LewisS , BirchwoodM , FowlerD , et al. Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. Early Intervention in Psychiatry2008;2(Suppl 1):A15. [CSzG: Ref19128] MorrisonAP . EDIE‐2: early detection and psychological intervention for individuals at high risk of psychosis (2). www.controlled‐trials.com2007. [CSzG: Ref15381] MorrisonAP , BirchwoodM , PyleM , FlachC , StewartSL , ByrneR , et al. Impact of cognitive therapy on internalised stigma in people with at‐risk mental states. British Journal of Psychiatry2013;203(2):140‐5. [CSzG: Ref28630] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ2012;344(7852):e2233. [CSzG: Ref24208] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at‐risk of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29554] MorrisonAP , PyleM , StewartSL , FrenchP , ByrneR , FlachC , et al. Internalised stigma in young people at high risk of developing psychosis: findings from a cognitive therapy trial. Schizophrenia Research2014;153:S42. [CSzG: Ref29555] MorrisonAP , StewartSL , FrenchP , BentallRP , BirchwoodM , ByrneR , et al. Early detection and intervention evaluation for people at high‐risk of psychosis‐2 (EDIE‐2): trial rationale, design and baseline characteristics. Early Intervention in Psychiatry2011;5(1):24‐32. [CSzG: Ref22695] MorrisonT . Early detection and psychological intervention for individuals at high risk of psychosis. EDIE‐2. Data on File2006. [CSzG: Ref13874] PelosiAJ . Rational policy making for early psychosis might yet become possible. BMJ2012;344(7856):e3137. [CSzG: Ref24326] PyleM , StewartSL , FrenchP , ByrneR , PattersonP , GumleyA , et al. Internalised stigma, emotional dysfunction and unusual experiences in young people at risk of psychosis. Early Intervention in Psychiatry2015;9(2):133‐40. [CSzG: Ref29813] ">EDIE‐2‐UK</a>; <a href="./references#CD012236-bbs2-0007" title="FrenchP , ShryaneN , BentallRP , LewisSW , MorrisonAP . Effects of cognitive therapy on the longitudinal development of psychotic experiences in people at high risk of developing psychosis. British Journal of Psychiatry. Supplements2007;191(Suppl 51):s82‐7. [CSzG: Ref16121] LewisS . EDIE ‐ Early detection and intervention for psychosis. National Research Register2001; Vol. 3. [CSzG: Ref13023] LewisS . EDIE ‐ early detection and intervention for psychosis (in primary care). National Research Register2002; Vol. 1. [CszG: Ref9342] MorrisonA . Early detection and intervention for psychosis in primary care. National Research Register2003. [CSzG: Ref15485] MorrisonA . Findings from a randomised controlled trial and clinical service delivering cognitive therapy to people at ultra‐high risk of developing psychosis. Schizophrenia Research2004;70(1):43‐4. [CSzG: Ref11526] MorrisonA . Follow‐up of prodromal symptoms. National Research Register2004; Vol. 3. [CSzG: Ref13036] MorrisonA , BentallR , FrenchP , Kilcommons A, LewisSW . Very early intervention in prodromal psychosis: a randomised trial. Schizophrenia Research2002;53(3 Suppl 1):42. [CSzG: Ref8096] MorrisonA , FrenchP , WalfordL , LewisS , Kilcommons A, GreenJ , et al. A randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;67(1):7. [CSzG: Ref11324] MorrisonA , FrenchP , WatfordL , LewisS , Kilcommons A, GreenJ , et al. Randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;70(1):63. [CSzG: Ref11527] MorrisonAP . Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: results of a randomised controlled trial. Schizophrenia Research2006;86(Suppl 1):S59. [CSzG: Ref13388] MorrisonAP , BentallRP , FrenchP , Kilcommons A, GreenJ , WalfordL , et al. Cognitive therapy in ultra high risk individuals for psychosis: randomised controlled trial. Schizophrenia Research2003;60:326. [CSzG: Ref9726] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, KnightA , et al. Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high‐risk individuals. Study design and interim analysis of transition rate and psychological risk factors. British Journal of Psychiatry. Supplements2002;181(43):s78‐84. [CSzG: Ref8737] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, LewisS . Early detection and intervention for psychosis in primary care. 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002. [CSzG: Ref8932] MorrisonAP , FrenchP , ParkerS , RobertsM , StevensH , BentallRP , et al. Three‐year follow‐up of a randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophrenia Bulletin2007;33(3):682‐7. [CSzG: Ref15288] MorrisonAP , FrenchP , WalfordL , LewisSW , Kilcommons A, GreenJ , et al. Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: randomised controlled trial. British Journal of Psychiatry2004;185:291‐7. [CSzG: Ref11450] MorrisonT . Early detection and intervention for psychosis in primary care. National Research Register2001; Vol. 1. [CSzG: Ref13037] MorrisonT , BentallR , FrenchP , Kilcommons A, GreenJ , LewisS . Early detection and intervention for psychosis in primary care. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:44. [CSzG: Ref8932] RentonJ , MorrisonA . Effectiveness of cognitive therapy for psychosis and implications for early intervention. Schizophrenia Research2004;70(1):142. [CSzG: Ref11536] ">EDIE‐UK</a>; <a href="./references#CD012236-bbs2-0010" title="KantrowitzJT , WoodsSW , PetkovaE , CornblattB , CorcoranCM , ChenH , et al. D‐serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double‐blind, placebo‐controlled, randomised parallel group mechanistic proof‐of‐concept trial. Lancet Psychiatry2015;2(5):403‐12. [CSzG: 29487] NCT00826202 . D‐serine for the schizophrenia prodrome. www.ClinicalTrials.gov/ct/show/2009. [CSzG: 17391] ">Kantrowitz‐USA</a>; <a href="./references#CD012236-bbs2-0016" title="NCT01619319 . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. ClinicalTrials.gov/show/NCT016193192012. [CSzG: 24387] PiskulicD , BarbatoM , AddingtonJ . Cognitive remediation in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:89. [CSzG: 24973] PiskulicD , BarbatoM , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2012;136:S245‐6. [CSzG: 29632] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2014;153(Suppl. 1):S218. [CSzG: 28827] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation therapy on cognition in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2014;8:86. [CSzG: 29633] ">Piskulic‐Canada</a>; <a href="./references#CD012236-bbs2-0017" title='BlockJJ , McGlashonTH . Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790‐9. American Journal of Psychiatry2006; Vol. 163, issue 10:1838. [CSzG: 13960] BreierAF , ZipurskyRB , PerkinsDO , AddingtonJM , TohenMF , DavidSR , et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951] HawkinsKA , AddingtonJ , KeefeR , ChristensenB , WoodsS , ZipurskyR , et al. Neuropsychological functioning in the first episode prodrome and early psychosis. Schizophrenia Research2004;70(1):101. [CSzG: 11515] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , MillerTJ , et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research2004;67(1):205. [CSzG: Ref11301] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , ZipurskyRB , et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. [CSzG: 16470] HawkinsKA , KeefeRS , ChristensenBK , AddingtonJ , WoodsSW , CallahanJ , et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. Schizophrenia Research2008;105(1‐3):1‐9. [CSzG: 16983] HoffmanRE , WoodsS , PredaA , TohenM , BreierA , GlistJ , et al. Excessive top‐down perceptual processing and reduced real‐world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. Schizophrenia Research2006;86(Suppl 1):S46. [CSzG: 13377] HoffmanRE , WoodsSW , HawkinsKA , PittmanB , TohenM , PredaA , et al. Extracting spurious messages from noise and risk of schizophrenia‐spectrum disorders in prodromal population. British Journal of Psychiatry2007;191(2):355‐6. [CSzG: 16068] McGlashanT , ZipurskyR , PerkinsD , AddingtonJ . Olanzapine for treatment of the schizophrenia prodrome: 2‐year results of a randomised placebo‐controlled study. Schizophrenia Research2004;67(1):164. [CSzG: 11320] McGlashanTH . Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. [CSzG: 10191] McGlashanTH . Treatment intervention in the New Haven PRIME clinic prodromal sample. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4835] McGlashanTH , MillerTJ , WoodsSW . Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research2002;53(3 Suppl 1):15. [CSzG: 8093] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005] McGlashanTH , MillerTJ , ZipurskyRB , WoodsSW , PerkinsDO , HawkinsKA , et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9803] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerT , WoodsSW , et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry2006;163(5):790‐9. [CSzG: 12654] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerTJ , WoodsSW , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research2003;61(1):7‐18. [CSzG: 9828] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJ , WoodsSW , MillerTJ , et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research2003;60:295. [CSzG: 9722] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJM , WoodsSW , LindborgS , et al. Olanzapine versus pbo for the schizophrenic prodrome: one‐year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9804] McGlashlanTH , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTH , WoodsSW , et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:42. [CSzG: 8934] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , MillerT , WoodsS , et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. Schizophrenia Research2004;70(1):6. [CSzG: 11524] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , WoodsS , MillerT , et al. Olanzapine vs. placebo for prodromal schizophrenia. Schizophrenia Research2004;67(1):6. [CSzG: 11321] MillerTJ , ZipurskyRB , PerkinsD , AddingtonJ , WoodsSW , HawkinsKA , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research2003;61(1):19‐30. [CSzG: 9829] RosenJL , WoodsSW , MillerTJ , McGlashanTH . Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease2002;190:133‐41. [CSzG: 8274] TaylorHE , ParkerS , MansellW , MorrisonAP . Effects of appraisals of anomalous experience on distress in people at risk of psychosis. Behavioural and Cognitive Psychotherapy2012;41(1):24‐33. [CSzG: 24374] WoodsS , ZipurskyR , PerkinsD , AddingtonJ , MarquezE , BreierA , et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:43. [CSzG: 8933] WoodsSW . Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):497. [CSzG: 19829] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research. 2003. [CSzG: 9978] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research2003;60:306‐7. [CSzG: 9752] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):453‐64. [CSzG: 9994] WoodsSW , McGlashanTH . Sample size planning for prodromal intervention trials. Schizophrenia Research2002;53(3 Suppl 1):40. [CSzG: 8116] WoodsSW , ZipurskyRB , PerkinsDO , AddingtonJM , MillerTJ , BreierAF , et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053] '>PRIME‐USA</a>). </p> </section> <section id="CD012236-sec-0158"> <h4 class="title">Selective reporting</h4> <p>We found selective reporting in 10 studies, as they did not report in their results all the outcomes that were planned in the registered protocol, or indicated in the methods section of the manuscript if the study protocol registration was not mentioned (<a href="./references#CD012236-bbs2-0001" title="AddingtonJ , EpsteinI , LiuL , FrenchP , BoydellKM , ZipurskyRB . A randomised controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research2011;125(1):54‐61. [CSzG: Ref21945] AddingtonJ , ZipurskyR , EpsteinI . ADAPT (Access, Detection and Psychological Treatments). Schizophrenia Research2006;86(Suppl 1):S6. [CSzG: Ref13364] NCT00260273 . Access, detection and psychological treatments. www.ClinicalTrials.gov/ct/show/2005. [CSzG: Ref14638] ">ADAPT‐Canada</a>; <a href="./references#CD012236-bbs2-0003" title="ChoiJ , CorcoranC , DixonL , FiszdonJ , JavittD . Processing speed training and social functioning in young adults at clinical high risk for psychosis: a pilot study. Early Intervention in Psychiatry2014;8:109. [CSzG: Ref29417] ChoiJ , CorcoranC , DixonL , JavittDC . Processing speed training and social functioning in teenagers and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2015;41:S41. [CSzG: Ref29418] ChoiJ , CorcoranCM , FiszdonJM , StevensM , JavittDC , DeasyM , et al. Pupillometer‐based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis. Psychiatric Rehabilitation Journal2017;40(1):33‐42. [CSzG: Ref35317] ">Choi‐USA</a>; <a href="./references#CD012236-bbs2-0005" title="ByrneRE , MorrisonAP . Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. Psychology and Psychotherapy2014;87(3):357‐71. [CSzG: Ref29312] FlachC , FrenchP , DunnG , FowlerD , GumleyAI , BirchwoodM , et al. Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE‐2 trial. British Journal of Psychiatry2015;207(2):123‐9. [CSzG: Ref33109] MorrisonA . Early detection and intervention evaluation for individuals at high risk of psychosis 2. http://www.controlled‐trials.com2008. [CSzG: Ref18285] MorrisonA . Early detection and intervention evaluation for people at risk of psychosis (edie‐2): A multisite randomised controlled trial of cognitive therapy for at‐risk mental states. Early Intervention in Psychiatry2012;6:11. [CSzG: Ref24968] MorrisonA , FrenchP , BentallR , LewisS , BirchwoodM , FowlerD , et al. Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. Early Intervention in Psychiatry2008;2(Suppl 1):A15. [CSzG: Ref19128] MorrisonAP . EDIE‐2: early detection and psychological intervention for individuals at high risk of psychosis (2). www.controlled‐trials.com2007. [CSzG: Ref15381] MorrisonAP , BirchwoodM , PyleM , FlachC , StewartSL , ByrneR , et al. Impact of cognitive therapy on internalised stigma in people with at‐risk mental states. British Journal of Psychiatry2013;203(2):140‐5. [CSzG: Ref28630] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ2012;344(7852):e2233. [CSzG: Ref24208] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at‐risk of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29554] MorrisonAP , PyleM , StewartSL , FrenchP , ByrneR , FlachC , et al. Internalised stigma in young people at high risk of developing psychosis: findings from a cognitive therapy trial. Schizophrenia Research2014;153:S42. [CSzG: Ref29555] MorrisonAP , StewartSL , FrenchP , BentallRP , BirchwoodM , ByrneR , et al. Early detection and intervention evaluation for people at high‐risk of psychosis‐2 (EDIE‐2): trial rationale, design and baseline characteristics. Early Intervention in Psychiatry2011;5(1):24‐32. [CSzG: Ref22695] MorrisonT . Early detection and psychological intervention for individuals at high risk of psychosis. EDIE‐2. Data on File2006. [CSzG: Ref13874] PelosiAJ . Rational policy making for early psychosis might yet become possible. BMJ2012;344(7856):e3137. [CSzG: Ref24326] PyleM , StewartSL , FrenchP , ByrneR , PattersonP , GumleyA , et al. Internalised stigma, emotional dysfunction and unusual experiences in young people at risk of psychosis. Early Intervention in Psychiatry2015;9(2):133‐40. [CSzG: Ref29813] ">EDIE‐2‐UK</a>; <a href="./references#CD012236-bbs2-0006" title="DragtS , Van derGaagM . Prevention of psychosis with a cognitive behavioural intervention in help‐seeking young people with an at risk mental state for developing psychosis. www.trialregister.nl/trialreg/index.asp2007. [CSzG: Ref19655] IsingHK , KraanTC , RietdijkJ , DragtS , KlaassenRM , BoonstraN , et al. Four‐year follow‐up of cognitive behavioral therapy in persons at ultra‐high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2016;42(5):1243‐52. [CSzG: Ref35214] IsingHK , LokkerbolJ , RietdijkJ , DragtS , KlaassenRM , KraanT , et al. Four‐year cost‐effectiveness of cognitive behavior therapy for preventing first‐episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2017;43(2):365‐74. [CSzG: Ref35824] IsingHK , SmitF , VelingW , RietdijkJ , DragtS , KlaassenRM , et al. Cost‐effectiveness of preventing first‐episode psychosis in ultra‐high‐risk subjects: multi‐centre randomised controlled trial. Psychological Medicine2015;45(7):1435‐46. [CSzG: Ref27798] KraanTC , IsingHK , FokkemaM , VelthorstE , Van denBergDP , KerkhovenM , et al. The effect of childhood adversity on 4‐year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE‐NL) Trial. Psychiatry Research2017;247:55‐62. [CSzG: Ref35559] NiemanDH , RuhrmannS , RietdijkJ , DragtS , IsingH , KlaassenR , et al. Preventive psychotherapy. Schizophrenia Research2014;153:S42‐3. [CSzG: Ref29601] RietdijkJ , DragtS , KlaassenR , IsingH , NiemanD , WunderinkL , et al. A single blind randomised controlled trial of cognitive behavioural therapy in a help‐seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE‐NL) trial. Trials2010;11:30. [CSzG: Ref20654] Van DerGaagM . The effects of CBT in personswith ultra high risk: the Dutch EDIE trial. European Archives of Psychiatry and Clinical Neuroscience2011;261:S18. [CSzG: Ref23756] Van DerGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first‐episode of psychosis. Early Intervention in Psychiatry2012;6:12. [CSzG: Ref24985] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomised controlled clinical trial. Schizophrenia Bulletin2012;38(6):1180‐8. [CSzG: Ref24935] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. The effects of cognitive behavioural therapy for subjects at ultra‐high risk for developing psychosis. Schizophrenia Bulletin2013;39:S356. [CSzG: Ref28121] Van derGaagM . The prevention of psychosis in at risk mental state. www.controlled‐trials.com2008. [CSzG: Ref17488] Van derGaagM , NiemanD , Van denBergD . CBT for those at risk of a first episode psychosis: Evidence‐based psychotherapy for people with an 'at risk mental state'. 1st Edition. Hove, UK: Routledge, 2013. Van derGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first episode of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29692] ">EDIE‐NL</a>; <a href="./references#CD012236-bbs2-0008" title="McFarlaneWR , CookWL , WoodberryKA . A randomised clinical trial of familyaided assertive community treatment for young persons at high risk for onset of an initial psychosis. Schizophrenia Bulletin2011;37:314. [CSzG: Ref22796] NCT01597141 . Psychosis: early detection, intervention and prevention. ClinicalTrials.gov/show/NCT015971412012. [CSzG: Ref24315] ">EDIP‐USA</a>; <a href="./references#CD012236-bbs2-0011" title="BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: 12511] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] RuhrmannS , BechdolfA , KuhnKU , WagnerM , Schultze‐LutterF Janssen B , et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry. Supplements2007;51:s88‐95. [CSzG: 16127] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Acute symptomatic treatment effects in persons clinically at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13397] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Intervention in the late initial prodromal state (LIPS) of psychosis. Schizophrenia Research2006;86(Suppl 1):S96. [CSzG: 13398] ">LIPS‐Germany</a>; <a href="./references#CD012236-bbs2-0012" title="MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Family‐focused therapy for individuals at clinical high risk for psychosis: treatment fidelity within a multisite randomised trial. Early Intervention in Psychiatry2016;10(2):137‐43. [CSzG: 29018] MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Treatment fidelity and differentiation in a randomised controlled trial of family‐focused therapy for youth at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:95. [CSzG: 24965] MiklowitzDJ , O'BrienMP , SchlosserDA , AddingtonJ , CandanKA , MarshallC , et al. Family‐focused treatment for adolescents and young adults at high risk for psychosis: results of a randomised trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(8):848‐58. [CSzG: 29019] NCT01907282 . Prevention trial of family focused treatment in youth at risk for psychosis. Clinicaltrials.gov/show/NCT019072822010. [CSzG: 27965] O'BrienMP , MiklowitzDJ , CandanKA , MarshallC , DominguesI , WalshBC , et al. A randomised trial of family focused therapy with populations at clinical high risk for psychosis: effects on interactional behavior. Journal of Consulting and Clinical Psychology2013;82(1):90‐101. [CSzG: 28565] O'BrienMP , MiklowitzDJ , CannonTD . Decreases in perceived maternal criticism predict improvement in subthreshold psychotic symptoms in a randomised trial of family‐focused therapy for individuals at clinical high risk for psychosis. Journal of Family Psychology2015;29(6):945–951.. [CSzG: 32212] SchlosserDA , MiklowitzDJ , O'BrienMP , DeSilvaSD , ZinbergJL , CannonTD . A randomised trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Intervention in Psychiatry2012;6(3):283‐91. [CSzG: 24491] ">Miklowitz‐USA</a>; <a href="./references#CD012236-bbs2-0014" title="NordentoftM , JeppesenP , PetersenL , ThorupA , OhlenschlaegerJ , ChristensenT , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. European Psychiatry2007;22:S129‐S. [CSzG: 20471] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the OPUS trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;83(1):29‐40. [CSzG: 13197] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;86(Suppl 1):S44. [CSzG: 13393] ">Nordentoft‐Denmark</a>; <a href="./references#CD012236-bbs2-0017" title='BlockJJ , McGlashonTH . Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790‐9. American Journal of Psychiatry2006; Vol. 163, issue 10:1838. [CSzG: 13960] BreierAF , ZipurskyRB , PerkinsDO , AddingtonJM , TohenMF , DavidSR , et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951] HawkinsKA , AddingtonJ , KeefeR , ChristensenB , WoodsS , ZipurskyR , et al. Neuropsychological functioning in the first episode prodrome and early psychosis. Schizophrenia Research2004;70(1):101. [CSzG: 11515] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , MillerTJ , et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research2004;67(1):205. [CSzG: Ref11301] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , ZipurskyRB , et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. [CSzG: 16470] HawkinsKA , KeefeRS , ChristensenBK , AddingtonJ , WoodsSW , CallahanJ , et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. Schizophrenia Research2008;105(1‐3):1‐9. [CSzG: 16983] HoffmanRE , WoodsS , PredaA , TohenM , BreierA , GlistJ , et al. Excessive top‐down perceptual processing and reduced real‐world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. Schizophrenia Research2006;86(Suppl 1):S46. [CSzG: 13377] HoffmanRE , WoodsSW , HawkinsKA , PittmanB , TohenM , PredaA , et al. Extracting spurious messages from noise and risk of schizophrenia‐spectrum disorders in prodromal population. British Journal of Psychiatry2007;191(2):355‐6. [CSzG: 16068] McGlashanT , ZipurskyR , PerkinsD , AddingtonJ . Olanzapine for treatment of the schizophrenia prodrome: 2‐year results of a randomised placebo‐controlled study. Schizophrenia Research2004;67(1):164. [CSzG: 11320] McGlashanTH . Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. [CSzG: 10191] McGlashanTH . Treatment intervention in the New Haven PRIME clinic prodromal sample. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4835] McGlashanTH , MillerTJ , WoodsSW . Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research2002;53(3 Suppl 1):15. [CSzG: 8093] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005] McGlashanTH , MillerTJ , ZipurskyRB , WoodsSW , PerkinsDO , HawkinsKA , et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9803] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerT , WoodsSW , et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry2006;163(5):790‐9. [CSzG: 12654] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerTJ , WoodsSW , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research2003;61(1):7‐18. [CSzG: 9828] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJ , WoodsSW , MillerTJ , et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research2003;60:295. [CSzG: 9722] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJM , WoodsSW , LindborgS , et al. Olanzapine versus pbo for the schizophrenic prodrome: one‐year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9804] McGlashlanTH , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTH , WoodsSW , et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:42. [CSzG: 8934] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , MillerT , WoodsS , et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. Schizophrenia Research2004;70(1):6. [CSzG: 11524] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , WoodsS , MillerT , et al. Olanzapine vs. placebo for prodromal schizophrenia. Schizophrenia Research2004;67(1):6. [CSzG: 11321] MillerTJ , ZipurskyRB , PerkinsD , AddingtonJ , WoodsSW , HawkinsKA , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research2003;61(1):19‐30. [CSzG: 9829] RosenJL , WoodsSW , MillerTJ , McGlashanTH . Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease2002;190:133‐41. [CSzG: 8274] TaylorHE , ParkerS , MansellW , MorrisonAP . Effects of appraisals of anomalous experience on distress in people at risk of psychosis. Behavioural and Cognitive Psychotherapy2012;41(1):24‐33. [CSzG: 24374] WoodsS , ZipurskyR , PerkinsD , AddingtonJ , MarquezE , BreierA , et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:43. [CSzG: 8933] WoodsSW . Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):497. [CSzG: 19829] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research. 2003. [CSzG: 9978] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research2003;60:306‐7. [CSzG: 9752] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):453‐64. [CSzG: 9994] WoodsSW , McGlashanTH . Sample size planning for prodromal intervention trials. Schizophrenia Research2002;53(3 Suppl 1):40. [CSzG: 8116] WoodsSW , ZipurskyRB , PerkinsDO , AddingtonJM , MillerTJ , BreierAF , et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053] '>PRIME‐USA</a>; <a href="./references#CD012236-bbs2-0019" title="NCT00291226 . Glycine vs Placebo for the Schizophrenia Prodrome. www.ClinicalTrials.gov/ct/show/2006. [CSzG: 14759] WoodsS , WalshB , HawkinsK , MillerT , SaksaJ , D'SouzaD , et al. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. Early Intervention in Psychiatry2012;6:29. [CSzG: 24987] WoodsSW , KantrowitzJT , JavittDC . NMDAR‐based treatments for patients at clinical high risk for psychosis. Biological Psychiatry2014;1:11S. [CSzG: 29041] WoodsSW , WalshBC , HawkinsKA , MillerTJ , SaksaJR , D'SouzaDC , et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. European Neuropsychopharmacology2013;23(8):931‐40. [CSzG: 28750] ">Woods‐1‐USA</a>); we judged them at unclear risk of bias. We did not identify overt under‐reporting of outcomes in the other included studies so we judged them at low risk of bias, although we did not have access to study protocols to check whether they had recorded other data but not reported them in the final papers. </p> </section> <section id="CD012236-sec-0159"> <h4 class="title">Other potential sources of bias</h4> <p>We did not find other potential sources of bias in the included studies.</p> </section> </section> <section id="CD012236-sec-0160"> <h3 class="title" id="CD012236-sec-0160">Effects of interventions</h3> <p>See: <a href="./full#CD012236-tbl-0001"><b>Summary of findings for the main comparison</b> Group A: amino acids compared to placebo for prodromal stage of psychosis</a>; <a href="./full#CD012236-tbl-0002"><b>Summary of findings 2</b> Group A: omega‐3 fatty acids compared to placebo for prodromal stage of psychosis</a>; <a href="./full#CD012236-tbl-0003"><b>Summary of findings 3</b> Group B antipsychotic drugs: amisulpiride + needs‐focused intervention compared to needs‐focused intervention for prodromal stage of psychosis</a>; <a href="./full#CD012236-tbl-0004"><b>Summary of findings 4</b> Group B antipsychotic drugs: olanzapine + supportive intervention compared to placebo + supportive intervention for prodromal stage of psychosis</a>; <a href="./full#CD012236-tbl-0005"><b>Summary of findings 5</b> Group B cognitive behavioural therapy: cognitive behavioural therapy + supportive therapy compared to supportive therapy for prodromal stage of psychosis</a>; <a href="./full#CD012236-tbl-0006"><b>Summary of findings 6</b> Group B cognitive behavioural therapy: cognitive behavioural therapy + risperidone compared to cognitive behavioural therapy + placebo for prodromal stage of psychosis</a>; <a href="./full#CD012236-tbl-0007"><b>Summary of findings 7</b> Group B cognitive behavioural therapy: cognitive behavioural therapy (specific preventive intervention) + needs‐based intervention + risperidone compared to needs‐based intervention for prodromal stage of psychosis</a>; <a href="./full#CD012236-tbl-0008"><b>Summary of findings 8</b> Group C cognitive behavioural therapy: cognitive behavioural therapy + placebo compared to supportive therapy + placebo for prodromal stage of psychosis</a>; <a href="./full#CD012236-tbl-0009"><b>Summary of findings 9</b> Group C cognitive behavioural therapy: cognitive behavioural therapy + supportive intervention compared to non‐directive reflective listening + supportive intervention for prodromal stage of psychosis</a>; <a href="./full#CD012236-tbl-0010"><b>Summary of findings 10</b> Group C cognitive behavioural therapy: cognitive behavioural therapy + risperidone compared to supportive therapy + placebo for prodromal stage of psychosis</a>; <a href="./full#CD012236-tbl-0011"><b>Summary of findings 11</b> Group C other: cognitive training compared to active control (tablet games) for prodromal stage of psychosis</a>; <a href="./full#CD012236-tbl-0012"><b>Summary of findings 12</b> Group C other: family treatment compared to enhanced care for prodromal stage of psychosis</a>; <a href="./full#CD012236-tbl-0013"><b>Summary of findings 13</b> Group C other: integrated treatment compared to standard treatment for prodromal stage of psychosis</a> </p> <p>For this review we generated 13 comparisons. In total there are 20 relevant randomised studies. As stated above in <a href="#CD012236-sec-0117">Description of studies</a>, we loosely categorised comparisons into three. Group A comparisons explored the absolute effects of the experimental intervention. Group B was a series of comparisons (further subdivided into antipsychotic and CBT) within which we could not be clear whether differential interactive effects were also ongoing in each intervention group. For example it is not clear, for Comparison 5, whether the supportive therapy's effect is changed by being accompanied by the CBT. The combination may be interactive making this comparison more like those in Group C rather than Group A. Group C comparisons explore differential effects between clearly distinct treatments. Again we have subdivided these again into CBT treatments and several others. </p> <section id="CD012236-sec-0161"> <h4 class="title">Group A: absolute effects</h4> <section id="CD012236-sec-0162"> <h5 class="title">1. Comparison: amino acids versus placebo</h5> <p>This comparison has 10 outcomes.</p> <section id="CD012236-sec-0163"> <h6 class="title">1.1 Prodromal symptoms: transition to psychosis, end point data</h6> <p>We identified two studies relevant to this outcome, the data from which we divided into two subgroups, with a total of 52 participants. There was no clear difference between amino acids and placebo (RR 0.48, 95% CI 0.08 to 2.98; <a href="./references#CD012236-fig-0004" title="">Analysis 1.1</a>). </p> <section id="CD012236-sec-0164"> <p><b>1.1.1 Short‐term (16 weeks, D‐serine)</b></p> <p>We found one study to be relevant to this subgroup (44 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.60, 95% CI 0.06 to 6.14; <a href="./references#CD012236-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD012236-sec-0165"> <p><b>1.1.2 Short‐term (24 weeks, glycine)</b></p> <p>We found one study to be relevant to this subgroup (8 participants). There was no clear difference between amino acids and placebo within this subgroup (RR 0.33, 95% CI 0.02 to 6.37; <a href="./references#CD012236-fig-0004" title="">Analysis 1.1</a>). </p> </section> </section> <section id="CD012236-sec-0166"> <h6 class="title">1.2 Mental state 1 specific: psychosis risk symptoms, average total score, short‐term (at 8 weeks), SOPS (higher score = worse) </h6> <p>We identified one study relevant to this outcome and categorised data into five subgroups.</p> <section id="CD012236-sec-0167"> <p><b>1.2.1 Total score</b></p> <p>There is a single study in this subgroup (8 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD −10.00, 95% CI −22.38 to 2.38; <a href="./references#CD012236-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD012236-sec-0168"> <p><b>1.2.2 Positive score</b></p> <p>There is a single study in this subgroup (8 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD −2.50, 95% CI −7.86 to 2.86; <a href="./references#CD012236-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD012236-sec-0169"> <p><b>1.2.3 Negative score</b></p> <p>There is a single study in this subgroup (8 participants). There was no clear difference between amino acids and placebo within this subgroup (MD −1.80, 95% CI −4.88 to 1.28; <a href="./references#CD012236-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD012236-sec-0170"> <p><b>1.2.4 Disorganisation score</b></p> <p>There is a single study in this subgroup (8 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD 1.00, 95% CI −1.57 to 3.57; <a href="./references#CD012236-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD012236-sec-0171"> <p><b>1.2.5 General score</b></p> <p>We found one study relevant to this subgroup (8 participants). For this outcome, within this subgroup, we did find evidence that amino acids were clearly superior compared with placebo (MD −6.80, 95% CI −9.47 to −4.13; <a href="./references#CD012236-fig-0005" title="">Analysis 1.2</a>). </p> </section> </section> <section id="CD012236-sec-0172"> <h6 class="title">1.3 Mental state 2, specific: depression, average total score, short‐term (at 8 weeks), MADRS (higher score = worse) skewed data </h6> <p>These continuous data, from a single study, had such large standard deviations as to suggest that analysis within <a href="./references#CD012236-bbs2-0169" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a> would be inadvisable (please see <a href="./references#CD012236-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD012236-sec-0173"> <h6 class="title">1.4 Mental state 3.a, specific: cognitive symptoms, average total score, short‐term (at 12 weeks), various tests (higher score = better) </h6> <p>For this outcome we found a single study and categorised data into five subgroups.</p> <section id="CD012236-sec-0174"> <p><b>1.4.1 Immediate verbal memory (AVLT immediate studies sum)</b></p> <p>There is a single study in this subgroup (5 participants). There was no clear difference between amino acids and placebo within this subgroup (MD 6.50, 95% CI −2.15 to 15.15; <a href="./references#CD012236-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD012236-sec-0175"> <p><b>1.4.2 Delayed verbal memory (AVLT delay trial)</b></p> <p>We found one study to be relevant to this subgroup (5 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD 0.50, 95% CI −1.17 to 2.17; <a href="./references#CD012236-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD012236-sec-0176"> <p><b>1.4.3 Executive functioning (semantic fluency test)</b></p> <p>We found one study to be relevant to this subgroup (4 participants). There was no clear difference between amino acids and placebo within this subgroup (MD −0.50, 95% CI −10.53 to 9.53; <a href="./references#CD012236-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD012236-sec-0177"> <p><b>1.4.4 Executive functioning (phonemic fluency test)</b></p> <p>We found one study to be relevant to this subgroup (4 participants). There was no clear difference between amino acids and placebo within this subgroup (MD −3.00, 95% CI −20.38 to 14.38; <a href="./references#CD012236-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD012236-sec-0178"> <p><b>1.4.5 Attention and working memory (letter‐number sequencing)</b></p> <p>There is a single study in this subgroup (5 participants). For this outcome, within this subgroup, we found evidence that amino acids were clearly superior in their effects compared with placebo (MD 4.50, 95% CI 2.04 to 6.96; <a href="./references#CD012236-fig-0007" title="">Analysis 1.4</a>). </p> </section> </section> <section id="CD012236-sec-0179"> <h6 class="title">1.5 Mental state 3.b, specific: cognitive symptoms, average total score, short‐term (at 12 weeks), various tests (higher score = worse) </h6> <p>For this outcome we found a single study, the data from which we divided into six subgroups. </p> <section id="CD012236-sec-0180"> <p><b>1.5.1 Processing speed (Trails A)</b></p> <p>There is a single study in this subgroup (4 participants). There was no clear difference between amino acids and placebo within this subgroup (MD 8.80, 95% CI −8.57 to 26.17; <a href="./references#CD012236-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD012236-sec-0181"> <p><b>1.5.2 Attention and working memory (Trails B)</b></p> <p>There is a single study in this subgroup (4 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD −2.80, 95% CI −48.7 to 43.10; <a href="./references#CD012236-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD012236-sec-0182"> <p><b>1.5.3 Processing speed (Stroop Words)</b></p> <p>There is a single study in this subgroup (4 participants). There was no clear difference between amino acids and placebo within this subgroup (MD −11.50, 95% CI −27.49 to 4.49; <a href="./references#CD012236-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD012236-sec-0183"> <p><b>1.5.4 Processing speed (Stroop Colors)</b></p> <p>There is a single study in this subgroup (4 participants). There was no clear difference between amino acids and placebo within this subgroup (MD −6.60, 95% CI −17.45 to 4.25; <a href="./references#CD012236-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD012236-sec-0184"> <p><b>1.5.5 Processing speed (Stroop Color‐Words)</b></p> <p>There is a single study in this subgroup (4 participants). We found evidence of a clear difference between amino acids and placebo within this subgroup, in favour of amino acids (MD −6.00, 95% CI −9.50 to −2.50; <a href="./references#CD012236-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD012236-sec-0185"> <p><b>1.5.6 Executive functioning (WCS perseverative errors)</b></p> <p>There is a single study in this subgroup (5 participants). For this outcome, within this subgroup, we found evidence that amino acids were clearly inferior in effect compared with placebo (MD 9.70, 95% CI 4.16 to 15.24; <a href="./references#CD012236-fig-0008" title="">Analysis 1.5</a>). </p> </section> </section> <section id="CD012236-sec-0186"> <h6 class="title">1.6 Adverse effects 1, specific: treatment‐emergent adverse effects, short‐term (by 8 weeks) </h6> <p>We identified one study relevant to this outcome and categorised data into eight subgroups.</p> <section id="CD012236-sec-0187"> <p><b>1.6.1 Psychological: irritability</b></p> <p>There is a single study in this subgroup (8 participants). There was no clear difference between amino acids and placebo within this subgroup (RR 0.33, 95% CI 0.02 to 6.37; <a href="./references#CD012236-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD012236-sec-0188"> <p><b>1.6.2 Psychological: mentation impaired</b></p> <p>There is a single study in this subgroup (8 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.33, 95% CI 0.02 to 6.37; <a href="./references#CD012236-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD012236-sec-0189"> <p><b>1.6.3 Psychological: hallucinations</b></p> <p>We found one study to be relevant to this subgroup (8 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.33, 95% CI 0.02 to 6.37; <a href="./references#CD012236-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD012236-sec-0190"> <p><b>1.6.4 Arousal: sedation</b></p> <p>We found one study to be relevant to this subgroup (8 participants). There was no clear difference between amino acids and placebo within this subgroup (RR 0.20, 95% CI 0.01 to 3.20; <a href="./references#CD012236-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD012236-sec-0191"> <p><b>1.6.5 Arousal: disturbed sleep</b></p> <p>There is a single study in this subgroup (8 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.20, 95% CI 0.01 to 3.20; <a href="./references#CD012236-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD012236-sec-0192"> <p><b>1.6.6 Arousal: malaise</b></p> <p>We found one study to be relevant to this subgroup (8 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.33, 95% CI 0.02 to 6.37; <a href="./references#CD012236-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD012236-sec-0193"> <p><b>1.6.7 Sexual: orgasm dysfunction</b></p> <p>There is a single study in this subgroup (8 participants). There was no clear difference between amino acids and placebo within this subgroup (RR 3.00, 95% CI 0.16 to 57.36; <a href="./references#CD012236-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD012236-sec-0194"> <p><b>1.6.8 Gastrointestinal: stomach discomfort</b></p> <p>We found one study to be relevant to this subgroup (8 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.33, 95% CI 0.02 to 6.37; <a href="./references#CD012236-fig-0009" title="">Analysis 1.6</a>). </p> </section> </section> <section id="CD012236-sec-0195"> <h6 class="title">1.7 Adverse effects 2, specific: cardiovascular, average total score, short‐term (by 8 weeks), blood pressure and pulse rate (higher score = worse) </h6> <p>We identified one study relevant to this outcome and categorised data into three subgroups.</p> <section id="CD012236-sec-0196"> <p><b>1.7.1 Systolic blood pressure</b></p> <p>We found one study to be relevant to this subgroup (8 participants). There was no clear difference between amino acids and placebo within this subgroup (MD 6.00, 95% CI −8.70 to 20.70; <a href="./references#CD012236-fig-0010" title="">Analysis 1.7</a>). </p> </section> <section id="CD012236-sec-0197"> <p><b>1.7.2 Diastolic blood pressure</b></p> <p>We found one study to be relevant to this subgroup (8 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD 2.00, 95% CI −12.03 to 16.03; <a href="./references#CD012236-fig-0010" title="">Analysis 1.7</a>). </p> </section> <section id="CD012236-sec-0198"> <p><b>1.7.3 Pulse</b></p> <p>We found one study to be relevant to this subgroup (8 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD −20.0, 95% CI −41.76 to 1.76; <a href="./references#CD012236-fig-0010" title="">Analysis 1.7</a>). </p> </section> </section> <section id="CD012236-sec-0199"> <h6 class="title">1.8 Adverse effects 3, specific: weight, average total score, short‐term (by 8 weeks), weight gain (higher score = worse) </h6> <p>For this outcome we found a single study (8 participants). We found evidence of a clear difference between amino acids and placebo, in favour of amino acids (MD −0.67, 95% CI −2.13 to −0.79; <a href="./references#CD012236-fig-0011" title="">Analysis 1.8</a>). </p> </section> <section id="CD012236-sec-0200"> <h6 class="title">1.9 Adverse effects 4, specific: suicidal thoughts, short‐term (by 16 weeks)</h6> <p>For this outcome we found a single study (44 participants). There was no clear difference between amino acids and placebo (RR 3.57, 95% CI 0.15 to 83.14; <a href="./references#CD012236-fig-0012" title="">Analysis 1.9</a>). </p> </section> <section id="CD012236-sec-0201"> <h6 class="title">1.10 Satisfaction with treatment: leaving the study early, end point data</h6> <p>For this outcome we found two relevant studies and categorised data into two subgroups (total 52 participants). There was no clear difference between amino acids and placebo (RR 0.96, 95% CI 0.55 to 1.69; <a href="./references#CD012236-fig-0013" title="">Analysis 1.10</a>). </p> <section id="CD012236-sec-0202"> <p><b>1.10.1 Short‐term (16 weeks, D‐serine)</b></p> <p>There is a single study in this subgroup (44 participants). There was no clear difference between amino acids and placebo within this subgroup (RR 0.92, 95% CI 0.52 to 1.64; <a href="./references#CD012236-fig-0013" title="">Analysis 1.10</a>). </p> </section> <section id="CD012236-sec-0203"> <p><b>1.10.2 Short‐term (24 weeks, glycine)</b></p> <p>There is a single study in this subgroup (8 participants). There was no clear difference between amino acids and placebo within this subgroup (RR 3.0, 95% CI 0.16 to 57.36; <a href="./references#CD012236-fig-0013" title="">Analysis 1.10</a>). </p> </section> </section> </section> <section id="CD012236-sec-0204"> <h5 class="title">2. Comparison: omega‐3 fatty acids versus placebo</h5> <p>In this comparison, there were 13 outcomes.</p> <section id="CD012236-sec-0205"> <h6 class="title">2.1 Prodromal symptoms: transition to psychosis</h6> <p>We identified two studies relevant to this outcome, the data from which we divided into two subgroups. </p> <section id="CD012236-sec-0206"> <p><b>2.1.1 Medium‐term (at 12 months)</b></p> <p>We found two studies to be relevant to this subgroup (385 participants). There was no clear difference between omega‐3 fatty acids and placebo within this subgroup (RR 0.50, 95% CI 0.08 to 3.08). For this outcome heterogeneity is high (Chi² = 5.36; df = 1.0; P = 0.02; I² = 81%; <a href="./references#CD012236-fig-0014" title="">Analysis 2.1</a>). </p> </section> <section id="CD012236-sec-0207"> <p><b>2.1.2 Long‐term (at 7 years)</b></p> <p>There is a single study in this subgroup (81 participants). We found evidence of a clear difference between omega‐3 fatty acids and placebo within this subgroup, in favour of omega‐3 fatty acids (RR 0.24, 95% CI 0.09 to 0.67; <a href="./references#CD012236-fig-0014" title="">Analysis 2.1</a>). </p> </section> </section> <section id="CD012236-sec-0208"> <h6 class="title">2.2 Global state: antipsychotic prescription, long‐term (at 7 years' follow‐up)</h6> <p>For this outcome we found a single study (69 participants). We found evidence of a clear difference between omega‐3 fatty acids and placebo, in favour of omega‐3 fatty acids (RR 0.54, 95% CI 0.30 to 0.99; <a href="./references#CD012236-fig-0015" title="">Analysis 2.2</a>). </p> </section> <section id="CD012236-sec-0209"> <h6 class="title">2.3 Mental state 1.a, specific: psychotic symptoms, average total score, PANSS (higher score = worse) </h6> <p>We identified one study relevant to this outcome and categorised data into eight subgroups.</p> <section id="CD012236-sec-0210"> <p><b>2.3.1 General: medium‐term (at 12 months)</b></p> <p>We found one study to be relevant to this subgroup (81 participants). For this outcome, within this subgroup, we did not find evidence that omega‐3 fatty acids were clearly different in effect compared with placebo (MD −3.90, 95% CI −8.06 to 0.26; <a href="./references#CD012236-fig-0016" title="">Analysis 2.3</a>). </p> </section> <section id="CD012236-sec-0211"> <p><b>2.3.2 General: long‐term (up to 7 years)</b></p> <p>There is a single study in this subgroup (81 participants). We did not find evidence of a clear difference between omega‐3 fatty acids and placebo within this subgroup (MD −4.70, 95% CI −9.69 to 0.29; <a href="./references#CD012236-fig-0016" title="">Analysis 2.3</a>). </p> </section> <section id="CD012236-sec-0212"> <p><b>2.3.3 Negative: medium‐term (at 12 months)</b></p> <p>There is a single study in this subgroup (81 participants). We found evidence of a clear difference between omega‐3 fatty acids and placebo within this subgroup in favour of omega‐3 fatty acids (MD −2.60, 95% CI −5.09 to −0.11; <a href="./references#CD012236-fig-0016" title="">Analysis 2.3</a>). </p> </section> <section id="CD012236-sec-0213"> <p><b>2.3.4 Negative: long‐term (up to 7 years)</b></p> <p>We found one study to be relevant to this subgroup (81 participants). For this outcome, within this subgroup, we found evidence that omega‐3 fatty acids were clearly superior in effect compared with placebo (MD −3.10, 95% CI −6.15 to −0.05; <a href="./references#CD012236-fig-0016" title="">Analysis 2.3</a>). </p> </section> <section id="CD012236-sec-0214"> <p><b>2.3.5 Positive: medium‐term (at 12 months)</b></p> <p>There is a single study in this subgroup (81 participants). For this outcome, within this subgroup, we found evidence that omega‐3 fatty acids were clearly superior in effect compared with placebo (MD −2.10, 95% CI −4.32 to 0.12; <a href="./references#CD012236-fig-0016" title="">Analysis 2.3</a>). </p> </section> <section id="CD012236-sec-0215"> <p><b>2.3.6 Positive: long‐term (up to 7 years)</b></p> <p>We found one study to be relevant to this subgroup (81 participants). We found evidence of a clear difference between omega‐3 fatty acids and placebo within this subgroup, in favour of omega‐3 fatty acids (MD −3.50, 95% CI −5.99 to −1.01; <a href="./references#CD012236-fig-0016" title="">Analysis 2.3</a>). </p> </section> <section id="CD012236-sec-0216"> <p><b>2.3.7 Total: medium‐term (at 12 months)</b></p> <p>We found one study to be relevant to this subgroup (81 participants). We found evidence of a clear difference between omega‐3 fatty acids and placebo within this subgroup, in favour of omega‐3 fatty acids (MD −8.60, 95% CI −16.36 to −0.84; <a href="./references#CD012236-fig-0016" title="">Analysis 2.3</a>). </p> </section> <section id="CD012236-sec-0217"> <p><b>2.3.8 Total: long‐term (up to 7 years)</b></p> <p>There is a single study in this subgroup (81 participants). We found evidence of a clear difference between omega‐3 fatty acids and placebo within this subgroup, in favour of omega‐3 fatty acids (MD −11.40, 95% CI −20.55 to −2.25; <a href="./references#CD012236-fig-0016" title="">Analysis 2.3</a>). </p> </section> </section> <section id="CD012236-sec-0218"> <h6 class="title">2.4 Mental state 1.b, specific: negative symptoms, average total score, medium‐term (at 12 months), SANS (higher score = worse) </h6> <p>We identified one study relevant to this outcome (225 participants). We did not find evidence of a clear difference between omega‐3 fatty acids and placebo in this comparison (MD 0.50, 95% CI −2.56 to 3.56; <a href="./references#CD012236-fig-0017" title="">Analysis 2.4</a>). </p> </section> <section id="CD012236-sec-0219"> <h6 class="title">2.5 Mental state 2, specific: depression, average total score, medium‐term (at 12 months), MADRS (higher score = worse), skewed data </h6> <p>For this outcome we found a single study (225 participants). We did not find evidence of a clear difference between omega‐3 fatty acids and placebo in this comparison (MD −0.3, 95% CI −2.78 to 2.18; <a href="./references#CD012236-fig-0018" title="">Analysis 2.5</a>). </p> </section> <section id="CD012236-sec-0220"> <h6 class="title">2.6 Mental state 3, specific: mania, average total score, medium‐term (at 12 months), YMS (higher score = worse) </h6> <p>We identified one study relevant to this outcome (225 participants). We did not find evidence of a clear difference between omega‐3 fatty acids and placebo in this comparison (MD 0.4, 95% CI −0.35 to 1.15; <a href="./references#CD012236-fig-0019" title="">Analysis 2.6</a>). </p> </section> <section id="CD012236-sec-0221"> <h6 class="title">2.7 Mental state 4, specific: average total scores, various scales (higher score = worse), skewed data </h6> <p>These continuous data (1 RCT) had such large standard deviations as to suggest that analysis within <a href="./references#CD012236-bbs2-0169" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a> would be inadvisable. Therefore, we have presented them in <a href="./references#CD012236-fig-0020" title="">Analysis 2.7</a>). </p> </section> <section id="CD012236-sec-0222"> <h6 class="title">2.8 Functioning 1, global: average total score GAF (higher score = better)</h6> <p>For this outcome we found a single study and categorised data into two subgroups.</p> <section id="CD012236-sec-0223"> <p><b>2.8.1 Medium‐term (at 12 months)</b></p> <p>There is a single study in this subgroup (81 participants). We found evidence of a clear difference between omega‐3 fatty acids and placebo within this subgroup, in favour of omega‐3 fatty acids (MD 11.5, 95% CI 5.12 to 17.88; <a href="./references#CD012236-fig-0021" title="">Analysis 2.8</a>). </p> </section> <section id="CD012236-sec-0224"> <p><b>2.8.2 Long‐term (at up to 7 years)</b></p> <p>We found one study to be relevant to this subgroup (81 participants). We found evidence of a clear difference between omega‐3 fatty acids and placebo, in favour of omega‐3 fatty acids (MD 9.50, 95% CI 2.02 to 16.98; <a href="./references#CD012236-fig-0021" title="">Analysis 2.8</a>). </p> </section> </section> <section id="CD012236-sec-0225"> <h6 class="title">2.9 Functioning 2, specific: role functioning, average total score, medium‐term (at 12 months), GFR (higher score = better) </h6> <p>We identified one study relevant to this outcome (225 participants). We found no clear difference between omega‐3 fatty acids and placebo (MD 0.00, 95% CI −0.49 to 0.49; <a href="./references#CD012236-fig-0022" title="">Analysis 2.9</a>). </p> </section> <section id="CD012236-sec-0226"> <h6 class="title">2.10 Functioning 3.a, specific: social functioning, average total score, medium‐term (at 12 months), GFS (higher score = better) </h6> <p>We identified one study relevant to this outcome (225 participants). For this outcome, we did not find evidence that omega‐3 fatty acids were clearly different in effect compared with placebo (MD −0.20, 95% CI −0.59 to 0.19; <a href="./references#CD012236-fig-0023" title="">Analysis 2.10</a>). </p> </section> <section id="CD012236-sec-0227"> <h6 class="title">2.11 Functioning 3.b, specific: social functioning, average total score, medium‐term (at 12 months), SOFAS, (higher score = better) </h6> <p>For this outcome we found a single study (225 participants). There was no clear difference between omega‐3 fatty acids and placebo (MD 0.10, 95% CI −4.60 to 4.80; <a href="./references#CD012236-fig-0024" title="">Analysis 2.11</a>). </p> </section> <section id="CD012236-sec-0228"> <h6 class="title">2.12 Adverse effects, specific: medium‐term (by 12 months), UKU checklist</h6> <p>We identified two studies relevant to this outcome and categorised data into 23 subgroups.</p> <section id="CD012236-sec-0229"> <p><b>2.12.1 Arousal: concentration difficulties</b></p> <p>We found one study to be relevant to this subgroup (81 participants). For this subgroup, we did not find evidence of a clear difference between omega‐3 fatty acids and placebo (RR 0.20, 95% CI 0.02 to 1.60; <a href="./references#CD012236-fig-0025" title="">Analysis 2.12</a>). </p> </section> <section id="CD012236-sec-0230"> <p><b>2.12.2 Arousal: increased fatigability</b></p> <p>We found one study to be relevant to this subgroup (81 participants). There was no clear difference between omega‐3 fatty acids and placebo within this subgroup (RR 1.46, 95% CI 0.26 to 8.3; <a href="./references#CD012236-fig-0025" title="">Analysis 2.12</a>). </p> </section> <section id="CD012236-sec-0231"> <p><b>2.12.3 Arousal: sleep: reduced duration of sleep</b></p> <p>We found one study to be relevant to this subgroup (81 participants). For this subgroup, we did not find evidence of a clear difference between omega‐3 fatty acids and placebo (RR 0.98, 95% CI 0.21 to 4.55; <a href="./references#CD012236-fig-0025" title="">Analysis 2.12</a>). </p> </section> <section id="CD012236-sec-0232"> <p><b>2.12.4 Arousal: sleep‐related: unspecified</b></p> <p>There is a single study in this subgroup (304 participants). For this subgroup, we did not find evidence of a clear difference between omega‐3 fatty acids and placebo (RR 0.83, 95% CI 0.49 to 1.42; <a href="./references#CD012236-fig-0025" title="">Analysis 2.12</a>). </p> </section> <section id="CD012236-sec-0233"> <p><b>2.12.5 Autonomic nervous system: orthostatic dizziness</b></p> <p>We found one study to be relevant to this subgroup (81 participants). For this subgroup, we did not find evidence of a clear difference between omega‐3 fatty acids and placebo (RR 0.20, 95% CI 0.01 to 3.94; <a href="./references#CD012236-fig-0025" title="">Analysis 2.12</a>). </p> </section> <section id="CD012236-sec-0234"> <p><b>2.12.6 Autonomic nervous system: sweating increase</b></p> <p>There is a single study in this subgroup (81 participants). For this subgroup, we did not find evidence of a clear difference between omega‐3 fatty acids and placebo (RR 0.20, 95% CI 0.01 to 3.94; <a href="./references#CD012236-fig-0025" title="">Analysis 2.12</a>). </p> </section> <section id="CD012236-sec-0235"> <p><b>2.12.7 Autonomic nervous system: unspecified</b></p> <p>We found one study to be relevant to this subgroup (304 participants). There was no clear difference between omega‐3 fatty acids and placebo within this subgroup (RR 1.56, 95% CI 0.79 to 3.11; <a href="./references#CD012236-fig-0025" title="">Analysis 2.12</a>). </p> </section> <section id="CD012236-sec-0236"> <p><b>2.12.8 Gastrointestinal: diarrhoea</b></p> <p>We found one study to be relevant to this subgroup (81 participants). For this subgroup, we did not find evidence of a clear difference between omega‐3 fatty acids and placebo (RR 0.24, 95% CI 0.03 to 2.09; <a href="./references#CD012236-fig-0025" title="">Analysis 2.12</a>). </p> </section> <section id="CD012236-sec-0237"> <p><b>2.12.9 Gastrointestinal: nausea/vomiting</b></p> <p>There is a single study in this subgroup (81 participants). For this subgroup, we did not find evidence of a clear difference between omega‐3 fatty acids and placebo (RR 0.98, 95% CI 0.21 to 4.55; <a href="./references#CD012236-fig-0025" title="">Analysis 2.12</a>). </p> </section> <section id="CD012236-sec-0238"> <p><b>2.12.10 Gastrointestinal: unspecified</b></p> <p>We found one study to be relevant to this subgroup (304 participants). For this subgroup, we did not find evidence of a clear difference between omega‐3 fatty acids and placebo (RR 1.28, 95% CI 0.91 to 1.79; <a href="./references#CD012236-fig-0025" title="">Analysis 2.12</a>). </p> </section> <section id="CD012236-sec-0239"> <p><b>2.12.11 Haematological: increased bleeding</b></p> <p>There is a single study in this subgroup (304 participants). For this subgroup, we did not find evidence of a clear difference between omega‐3 fatty acids and placebo (RR 0.33, 95% CI 0.01 to 8.01; <a href="./references#CD012236-fig-0025" title="">Analysis 2.12</a>). </p> </section> <section id="CD012236-sec-0240"> <p><b>2.12.12 Hormonal: unspecified</b></p> <p>There is a single study in this subgroup (304 participants). There was no clear difference between omega‐3 fatty acids and placebo within this subgroup (RR 0.61, 95% CI 0.26 to 1.42; <a href="./references#CD012236-fig-0025" title="">Analysis 2.12</a>). </p> </section> <section id="CD012236-sec-0241"> <p><b>2.12.13 Neurological: extrapyramidal</b></p> <p>There is a single study in this subgroup (304 participants). There was no clear difference between omega‐3 fatty acids and placebo within this subgroup (RR 2.57, 95% CI 0.94 to 7.02; <a href="./references#CD012236-fig-0025" title="">Analysis 2.12</a>). </p> </section> <section id="CD012236-sec-0242"> <p><b>2.12.14 Neurological: failing memory</b></p> <p>We found one study to be relevant to this subgroup (81 participants). For this subgroup, we did not find evidence of a clear difference between omega‐3 fatty acids and placebo (RR 0.20, 95% CI 0.01 to 3.94; <a href="./references#CD012236-fig-0025" title="">Analysis 2.12</a>). </p> </section> <section id="CD012236-sec-0243"> <p><b>2.12.15 Neurological: tension headache</b></p> <p>There is a single study in this subgroup (81 participants). There was no clear difference between omega‐3 fatty acids and placebo within this subgroup (RR 0.24, 95% CI 0.03 to 2.09; <a href="./references#CD012236-fig-0025" title="">Analysis 2.12</a>). </p> </section> <section id="CD012236-sec-0244"> <p><b>2.12.16 Neurological: unspecified</b></p> <p>There is a single study in this subgroup (304 participants). There was no clear difference between omega‐3 fatty acids and placebo within this subgroup (RR 1.85, 95% CI 0.81 to 4.24; <a href="./references#CD012236-fig-0025" title="">Analysis 2.12</a>). </p> </section> <section id="CD012236-sec-0245"> <p><b>2.12.17 Psychological: depression</b></p> <p>We found one study to be relevant to this subgroup (81 participants). For this subgroup, we did not find evidence of a clear difference between omega‐3 fatty acids and placebo (RR 0.39, 95% CI 0.08 to 1.90; <a href="./references#CD012236-fig-0025" title="">Analysis 2.12</a>). </p> </section> <section id="CD012236-sec-0246"> <p><b>2.12.18 Psychological: emotional indifference</b></p> <p>We found one study to be relevant to this subgroup (81 participants). For this subgroup, we did not find evidence of a clear difference between omega‐3 fatty acids and placebo (RR 0.49, 95% CI 0.09 to 2.52; <a href="./references#CD012236-fig-0025" title="">Analysis 2.12</a>). </p> </section> <section id="CD012236-sec-0247"> <p><b>2.12.19 Psychological: tension/inner unrest</b></p> <p>There is a single study in this subgroup (81 participants). There was no clear difference between omega‐3 fatty acids and placebo within this subgroup (RR 0.78, 95% CI 0.23 to 2.70; <a href="./references#CD012236-fig-0025" title="">Analysis 2.12</a>). </p> </section> <section id="CD012236-sec-0248"> <p><b>2.12.20 Psychological: unspecified</b></p> <p>We found one study to be relevant to this subgroup (304 participants). There was no clear difference between omega‐3 fatty acids and placebo within this subgroup (RR 1.32, 95% CI 0.70 to 2.47; <a href="./references#CD012236-fig-0025" title="">Analysis 2.12</a>). </p> </section> <section id="CD012236-sec-0249"> <p><b>2.12.21 Sexual: unspecified</b></p> <p>There is a single study in this subgroup (304 participants). There was no clear difference between omega‐3 fatty acids and placebo within this subgroup (RR 6.91, 95% CI 0.86 to 55.48; <a href="./references#CD012236-fig-0025" title="">Analysis 2.12</a>). </p> </section> <section id="CD012236-sec-0250"> <p><b>2.12.22 Skin: unspecified</b></p> <p>There is a single study in this subgroup (304 participants). There was no clear difference between omega‐3 fatty acids and placebo within this subgroup (RR 0.70, 95% CI 0.23 to 2.17; <a href="./references#CD012236-fig-0025" title="">Analysis 2.12</a>). </p> </section> <section id="CD012236-sec-0251"> <p><b>2.12.23 Other: unspecified</b></p> <p>We found one study to be relevant to this subgroup (304 participants). There was no clear difference between omega‐3 fatty acids and placebo within this subgroup (RR 1.12, 95% CI 0.66 to 1.90; <a href="./references#CD012236-fig-0025" title="">Analysis 2.12</a>). </p> </section> </section> <section id="CD012236-sec-0252"> <h6 class="title">2.13 Satisfaction with treatment: leaving the study early</h6> <p>We identified two studies relevant to this outcome, the data from which we divided into two subgroups. </p> <section id="CD012236-sec-0253"> <p><b>2.13.1 Medium‐term (by 12 months, end point)</b></p> <p>There are two relevant studies in this subgroup (385 participants). There was no clear difference between omega‐3 fatty acids and placebo within this subgroup (RR 0.98, 95% CI 0.68 to 1.42; <a href="./references#CD012236-fig-0026" title="">Analysis 2.13</a>). </p> </section> <section id="CD012236-sec-0254"> <p><b>2.13.2 Long‐term (by 7 years, additional follow‐up)</b></p> <p>We found one study to be relevant to this subgroup (81 participants). For this subgroup, we did not find evidence of a clear difference between omega‐3 fatty acids and placebo (RR 1.46, 95% CI 0.45 to 4.80; <a href="./references#CD012236-fig-0026" title="">Analysis 2.13</a>). </p> </section> </section> </section> </section> <section id="CD012236-sec-0255"> <h4 class="title">Group B: comparisons where it is unclear how interaction has affected the interventions</h4> <section id="CD012236-sec-0256"> <h5 class="title">B.i. Antipsychotic drugs</h5> </section> <section id="CD012236-sec-0257"> <h5 class="title">3. Comparison: amisulpiride + needs‐focused intervention versus needs‐focused intervention</h5> <p>This comparison has seven outcomes.</p> <section id="CD012236-sec-0258"> <h6 class="title">3.1 Mental state, specific: average end point scores, short‐term (at 12 weeks), various scales (higher score = worse), skewed data </h6> <p>These continuous data, from a single study, had such large standard deviations as to suggest that analysis within <a href="./references#CD012236-bbs2-0169" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a> would be inadvisable (please see <a href="./references#CD012236-fig-0027" title="">Analysis 3.1</a>). </p> </section> <section id="CD012236-sec-0259"> <h6 class="title">3.2 Functioning, global: average end point score, short‐term (at 12 weeks), GAF (higher score = better) </h6> <p>For this outcome we found a single study (102 participants). We found evidence of a clear difference between amisulpiride + needs‐focused intervention (NFI) and NFI alone in this comparison, in favour of amisulpiride + NFI (MD 6.10, 95% CI 0.44 to 11.76; <a href="./references#CD012236-fig-0028" title="">Analysis 3.2</a>). </p> </section> <section id="CD012236-sec-0260"> <h6 class="title">3.3 Adverse effects 1.a, specific: akathisia, short‐term (at 12 weeks), ESRS</h6> <p>For this outcome we found a single study (104 participants). There was no clear difference between amisulpiride + NFI and NFI (RR 2.82, 95% CI 0.33 to 24.36; <a href="./references#CD012236-fig-0029" title="">Analysis 3.3</a>). </p> </section> <section id="CD012236-sec-0261"> <h6 class="title">3.4 Adverse effects 1.b, specific: akathisia, average end point score, short‐term (at 12 weeks), ESRS (higher score = worse), skewed data </h6> <p>These continuous data (1 RCT) were too skewed to report in a graph (please see <a href="./references#CD012236-fig-0030" title="">Analysis 3.4</a>). </p> </section> <section id="CD012236-sec-0262"> <h6 class="title">3.5 Adverse effects 2, specific: increased prolactin levels, short‐term (at 12 weeks)</h6> <p>For this outcome we found a single study (78 participants). We found evidence of a clear difference between amisulpiride + NFI and NFI, in favour of NFI (RR 3.97, 95% CI 2.02 to 7.80; <a href="./references#CD012236-fig-0031" title="">Analysis 3.5</a>). </p> </section> <section id="CD012236-sec-0263"> <h6 class="title">3.6 Adverse effects 3, specific: severity of at least moderate and a frequency of at least 5%, short‐term (at 12 weeks), UKU </h6> <p>For this outcome we found a single study, the data from which we divided into subgroups.</p> <section id="CD012236-sec-0264"> <p><b>3.6.1 Psychological: concentration difficulties</b></p> <p>There is a single study in this subgroup (101 participants). There was no clear difference between amisulpiride + NFI and NFI within this subgroup (RR 1.01, 95% CI 0.78 to 1.31; <a href="./references#CD012236-fig-0032" title="">Analysis 3.6</a>). </p> </section> <section id="CD012236-sec-0265"> <p><b>3.6.2 Psychological: asthenia/lassitude/increased fatigability</b></p> <p>There is a single study in this subgroup (101 participants). We found evidence of a clear difference between amisulpiride + NFI and NFI within this subgroup, in favour of NFI (RR 1.64, 95% CI 1.08 to 2.50; <a href="./references#CD012236-fig-0032" title="">Analysis 3.6</a>). </p> </section> <section id="CD012236-sec-0266"> <p><b>3.6.3 Psychological: failing memory</b></p> <p>We found one study to be relevant to this subgroup (101 participants). For this outcome, within this subgroup, we found evidence that amisulpiride + NFI was inferior compared to NFI (RR 2.19, 95% CI 1.17 to 4.10; <a href="./references#CD012236-fig-0032" title="">Analysis 3.6</a>). </p> </section> <section id="CD012236-sec-0267"> <p><b>3.6.4 Psychological: depression</b></p> <p>There is a single study in this subgroup (101 participants). There was no clear difference between amisulpiride + NFI and NFI within this subgroup (RR 1.10, 95% CI 0.82 to 1.48; <a href="./references#CD012236-fig-0032" title="">Analysis 3.6</a>). </p> </section> <section id="CD012236-sec-0268"> <p><b>3.6.5 Psychological: tension</b></p> <p>There is a single study in this subgroup (101 participants). There was no clear difference between amisulpiride + NFI and NFI within this subgroup (RR 1.17, 95% CI 0.85 to 1.61; <a href="./references#CD012236-fig-0032" title="">Analysis 3.6</a>). </p> </section> <section id="CD012236-sec-0269"> <p><b>3.6.6 Arousal: sleepiness/sedation</b></p> <p>There is a single study in this subgroup (101 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 1.48, 95% CI 0.49 to 4.47; <a href="./references#CD012236-fig-0032" title="">Analysis 3.6</a>). </p> </section> <section id="CD012236-sec-0270"> <p><b>3.6.7 Arousal: increased duration of sleep</b></p> <p>We found one study to be relevant to this subgroup (101 participants). We found evidence of a clear difference between amisulpiride + NFI and NFI within this subgroup, in favour of NFI (RR 3.28, 95% CI 1.37 to 7.85; <a href="./references#CD012236-fig-0032" title="">Analysis 3.6</a>). </p> </section> <section id="CD012236-sec-0271"> <p><b>3.6.8 Arousal: decreased duration of sleep</b></p> <p>We found one study to be relevant to this subgroup (101 participants). There was no clear difference between amisulpiride + NFI and NFI within this subgroup (RR 0.49, 95% CI 0.23 to 1.06; <a href="./references#CD012236-fig-0032" title="">Analysis 3.6</a>). </p> </section> <section id="CD012236-sec-0272"> <p><b>3.6.9 Arousal: increased dream activity</b></p> <p>We found one study to be relevant to this subgroup (101 participants). For this outcome, within this subgroup, we found evidence that amisulpiride + NFI was inferior to NFI (RR 21.82, 95% CI 1.35 to 353.77; <a href="./references#CD012236-fig-0032" title="">Analysis 3.6</a>). </p> </section> <section id="CD012236-sec-0273"> <p><b>3.6.10 Gastrointestinal: nausea/vomiting</b></p> <p>We found one study to be relevant to this subgroup (101 participants). There was no clear difference between amisulpiride + NFI and NFI within this subgroup (RR 9.92, 95% CI 0.58 to 169.0; <a href="./references#CD012236-fig-0032" title="">Analysis 3.6</a>). </p> </section> <section id="CD012236-sec-0274"> <p><b>3.6.11 Autonomic nervous system: orthostatic dizziness</b></p> <p>There is a single study in this subgroup (101 participants). There was no clear difference between amisulpiride + NFI and NFI within this subgroup (RR 5.95, 95% CI 0.33 to 107.62; <a href="./references#CD012236-fig-0032" title="">Analysis 3.6</a>). </p> </section> <section id="CD012236-sec-0275"> <p><b>3.6.12 Autonomic nervous system: increased tendency to sweating</b></p> <p>There is a single study in this subgroup (101 participants). For this outcome, within this subgroup, we found evidence that amisulpiride + NFI was inferior to NFI (RR 16.53, 95% CI 1.01 to 271.60). <a href="./references#CD012236-fig-0032" title="">Analysis 3.6</a>). </p> </section> <section id="CD012236-sec-0276"> <p><b>3.6.13 Cardiological: palpitation/tachycardia</b></p> <p>There is a single study in this subgroup (101 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.98, 95% CI 0.30 to 3.27; <a href="./references#CD012236-fig-0032" title="">Analysis 3.6</a>). </p> </section> <section id="CD012236-sec-0277"> <p><b>3.6.14 Neurological: headache</b></p> <p>We found one study to be relevant to this subgroup (101 participants). There was no clear difference between amisulpiride + NFI and NFI within this subgroup (RR 1.86, 95% CI 0.8 to 4.31; <a href="./references#CD012236-fig-0032" title="">Analysis 3.6</a>). </p> </section> <section id="CD012236-sec-0278"> <p><b>3.6.15 Endocrinological: polyuria/polydipsia</b></p> <p>We found one study to be relevant to this subgroup (101 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.98, 95% CI 0.30 to 3.27; <a href="./references#CD012236-fig-0032" title="">Analysis 3.6</a>). </p> </section> <section id="CD012236-sec-0279"> <p><b>3.6.16 Sexual: diminished sexual desire</b></p> <p>There is a single study in this subgroup (101 participants). We found evidence of a clear difference between amisulpiride + NFI and NFI within this subgroup, in favour of NFI (RR 3.44, 95% CI 1.28 to 9.28; <a href="./references#CD012236-fig-0032" title="">Analysis 3.6</a>). </p> </section> <section id="CD012236-sec-0280"> <p><b>3.6.17 Sexual: orgasmic dysfunction</b></p> <p>There is a single study in this subgroup (101 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 5.95, 95% CI 0.33 to 107.62; <a href="./references#CD012236-fig-0032" title="">Analysis 3.6</a>). </p> </section> </section> <section id="CD012236-sec-0281"> <h6 class="title">3.7 Adverse effects 4, specific: suicidal thoughts</h6> <p>For this important outcome we identified one small study (102 participants). We identified no clear difference between groups (RR 0.25, 95% CI 0.01 to 6.10; <a href="./references#CD012236-fig-0033" title="">Analysis 3.7</a>). </p> </section> <section id="CD012236-sec-0282"> <h6 class="title">3.8 Satisfaction with treatment: leaving the study early, end point data</h6> <p>For this outcome we found a single study (124 participants). We found evidence of a clear difference between amisulpiride + NFI and NFI (RR 0.59, 95% CI 0.38 to 0.94; <a href="./references#CD012236-fig-0034" title="">Analysis 3.8</a>). </p> </section> </section> <section id="CD012236-sec-0283"> <h5 class="title">4. Comparison: olanzapine + supportive intervention versus placebo + supportive intervention</h5> <p>This comparison has 12 outcomes.</p> <section id="CD012236-sec-0284"> <h6 class="title">4.1 Prodromal symptoms: transition to psychosis, end point data, medium‐term (by 12 months) </h6> <p>We identified one study relevant to this outcome (60 participants). We did not find evidence of a clear difference between the two treatments in this comparison (RR 0.58, 95% CI 0.28 to 1.18; <a href="./references#CD012236-fig-0035" title="">Analysis 4.1</a>). </p> </section> <section id="CD012236-sec-0285"> <h6 class="title">4.2 Global state, global: illness severity, average total score, medium‐term (at 12 months), CGI (higher score = worse) </h6> <p>We identified one study relevant to this outcome (59 participants). For this outcome, we did not find evidence that olanzapine + supportive intervention was different in its effects compared with placebo + supportive intervention (MD −0.23, 95% CI −0.82 to 0.36; <a href="./references#CD012236-fig-0036" title="">Analysis 4.2</a>). </p> </section> <section id="CD012236-sec-0286"> <h6 class="title">4.3 Mental state, specific: average total scores, medium‐term (at 12 months), various scales (higher score = worse), skewed data </h6> <p>These continuous data (1 RCT) were too skewed to report in a graph (please see <a href="./references#CD012236-fig-0037" title="">Analysis 4.3</a>). </p> </section> <section id="CD012236-sec-0287"> <h6 class="title">4.4 Functioning, global: average total score, medium‐term (at 12 months), GAF (higher score = better) </h6> <p>We identified one study relevant to this outcome (59 participants). There was no clear difference between olanzapine + supportive intervention and placebo + supportive intervention (MD 2.43, 95% CI −4.77 to 9.63; <a href="./references#CD012236-fig-0038" title="">Analysis 4.4</a>). </p> </section> <section id="CD012236-sec-0288"> <h6 class="title">4.5 Adverse effects 1, specific: average total score, short‐term (at 8 weeks), various scales (higher score = worse), skewed data </h6> <p>These continuous data, from a single study, had such large standard deviations as to suggest that analysis within <a href="./references#CD012236-bbs2-0169" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a> would be inadvisable (please see <a href="./references#CD012236-fig-0039" title="">Analysis 4.5</a>). </p> </section> <section id="CD012236-sec-0289"> <h6 class="title">4.6 Adverse effects 2.a, specific: cardiovascular, average total score, short‐term (at 8 weeks), blood pressure and pulse rate (higher score = worse) </h6> <p>We identified one study relevant to this outcome, the data from which we divided into six subgroups. </p> <section id="CD012236-sec-0290"> <p><b>4.6.1 Sitting systolic blood pressure</b></p> <p>There is a single study in this subgroup (59 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD 1.00, 95% CI −4.28 to 6.28; <a href="./references#CD012236-fig-0040" title="">Analysis 4.6</a>). </p> </section> <section id="CD012236-sec-0291"> <p><b>4.6.2 Sitting diastolic blood pressure</b></p> <p>We found one study to be relevant to this subgroup (59 participants). There was no clear difference between olanzapine + supportive intervention and placebo + supportive intervention within this subgroup (MD 2.30, 95% CI −7.43 to 2.83; <a href="./references#CD012236-fig-0040" title="">Analysis 4.6</a>). </p> </section> <section id="CD012236-sec-0292"> <p><b>4.6.3 Sitting pulse</b></p> <p>We found one study to be relevant to this subgroup (59 participants). There was no clear difference between olanzapine + supportive intervention and placebo + supportive intervention within this subgroup (MD 8.20, 95% CI −0.03 to 16.37; <a href="./references#CD012236-fig-0040" title="">Analysis 4.6</a>). </p> </section> <section id="CD012236-sec-0293"> <p><b>4.6.4 Standing systolic blood pressure</b></p> <p>We found one study to be relevant to this subgroup (59 participants). There was no clear difference between olanzapine + supportive intervention and placebo + supportive intervention within this subgroup (MD −1.80, 95% CI −6.96 to 3.36; <a href="./references#CD012236-fig-0040" title="">Analysis 4.6</a>). </p> </section> <section id="CD012236-sec-0294"> <p><b>4.6.5 Standing diastolic blood pressure</b></p> <p>There is a single study in this subgroup (59 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD −1.80, 95% CI −6.96 to 3.36; <a href="./references#CD012236-fig-0040" title="">Analysis 4.6</a>). </p> </section> <section id="CD012236-sec-0295"> <p><b>4.6.6 Standing pulse</b></p> <p>There is a single study in this subgroup (59 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD 7.90, 95% CI −0.74 to 16.54; <a href="./references#CD012236-fig-0040" title="">Analysis 4.6</a>). </p> </section> </section> <section id="CD012236-sec-0296"> <h6 class="title">4.7 Adverse effects 2.b, specific: cardiovascular, average total score, medium‐term (at 12 months), pulse rate (higher score = worse) </h6> <p>For this outcome we found a single study and categorised data into two subgroups.</p> <section id="CD012236-sec-0297"> <p><b>4.7.1 Sitting pulse</b></p> <p>There is a single study in this subgroup (58 participants). For this subgroup, we found evidence of a difference between the two treatments, in favour of placebo + supportive intervention (MD 9.27, 95% CI 1.49 to 17.05; <a href="./references#CD012236-fig-0041" title="">Analysis 4.7</a>). </p> </section> <section id="CD012236-sec-0298"> <p><b>4.7.2 Standing pulse</b></p> <p>We found one study to be relevant to this subgroup (57 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD 6.94, 95% CI −2.61 to 16.49; <a href="./references#CD012236-fig-0041" title="">Analysis 4.7</a>). </p> </section> </section> <section id="CD012236-sec-0299"> <h6 class="title">4.8 Adverse effects 3, specific: treatment‐emergent adverse effects, short‐term (at 8 weeks) </h6> <p>We identified one study relevant to this outcome and categorised data into eight subgroups.</p> <section id="CD012236-sec-0300"> <p><b>4.8.1 Arousal: somnolence</b></p> <p>We found one study to be relevant to this subgroup (60 participants). There was no clear difference between olanzapine + supportive intervention and placebo + supportive intervention within this subgroup (RR 2.25, 95% CI 0.90 to 5.59; <a href="./references#CD012236-fig-0042" title="">Analysis 4.8</a>). </p> </section> <section id="CD012236-sec-0301"> <p><b>4.8.2 Gastrointestinal: weight gain</b></p> <p>There is a single study in this subgroup (60 participants). For this outcome, within this subgroup, we found evidence that olanzapine + supportive intervention was clearly different in its effects compared with placebo + supportive intervention, in favour of the control group (RR 10.29, 95% CI 1.42 to 74.79; <a href="./references#CD012236-fig-0042" title="">Analysis 4.8</a>). </p> </section> <section id="CD012236-sec-0302"> <p><b>4.8.3 Gastrointestinal: increased appetite</b></p> <p>We found one study to be relevant to this subgroup (60 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 1.87, 95% CI 0.51 to 6.80; <a href="./references#CD012236-fig-0042" title="">Analysis 4.8</a>). </p> </section> <section id="CD012236-sec-0303"> <p><b>4.8.4 Psychological: anxiety</b></p> <p>There is a single study in this subgroup (60 participants). There was no clear difference between olanzapine + supportive intervention and placebo + supportive intervention within this subgroup (RR 4.68, 95% CI 0.58 to 37.68; <a href="./references#CD012236-fig-0042" title="">Analysis 4.8</a>). </p> </section> <section id="CD012236-sec-0304"> <p><b>4.8.5 Psychological: nervousness</b></p> <p>We found one study to be relevant to this subgroup (60 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 1.87, 95% CI 0.37 to 9.46; <a href="./references#CD012236-fig-0042" title="">Analysis 4.8</a>). </p> </section> <section id="CD012236-sec-0305"> <p><b>4.8.6 Psychological: asthenia</b></p> <p>We found one study to be relevant to this subgroup (60 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 3.74, 95% CI 0.44 to 31.55; <a href="./references#CD012236-fig-0042" title="">Analysis 4.8</a>). </p> </section> <section id="CD012236-sec-0306"> <p><b>4.8.7 Psychological: abnormal thoughts</b></p> <p>We found one study to be relevant to this subgroup (60 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 1.40, 95% CI 0.25 to 7.81; <a href="./references#CD012236-fig-0042" title="">Analysis 4.8</a>). </p> </section> <section id="CD012236-sec-0307"> <p><b>4.8.8 Muscoloskeletal: joint disorder</b></p> <p>There is a single study in this subgroup (60 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.94, 95% CI 0.20 to 4.27; <a href="./references#CD012236-fig-0042" title="">Analysis 4.8</a>). </p> </section> </section> <section id="CD012236-sec-0308"> <h6 class="title">4.9 Adverse effects 4.a, specific: weight, average total weight change, kg gained (higher scores = worse) </h6> <p>For this outcome we found a single study (59 participants) with both short‐ and medium‐term data. For this outcome, we found evidence that olanzapine + supportive intervention was clearly inferior in its effects compared with placebo + supportive intervention by 12 months (MD 8.49, 95% CI 4.90 to 12.08; <a href="./references#CD012236-fig-0043" title="">Analysis 4.9</a>). </p> </section> <section id="CD012236-sec-0309"> <h6 class="title">4.10 Adverse effects 4.b, specific: weight gain, medium‐term (at 12 months)</h6> <p>For this outcome we found a single study (60 participants). For this outcome, we found evidence that olanzapine + supportive intervention was clearly inferior in its effects compared with placebo + supportive intervention (RR 3.55, 95% CI 1.53 to 8.28; <a href="./references#CD012236-fig-0044" title="">Analysis 4.10</a>). </p> </section> <section id="CD012236-sec-0310"> <h6 class="title">4.11 Adverse effects 5, specific: fatigue, medium‐term (at 12 months)</h6> <p>We identified one study relevant to this outcome (60 participants). We found evidence of a clear difference between olanzapine + supportive intervention and placebo + supportive intervention, in favour of the control group (RR 8.42, 95% CI 1.14 to 62.4; <a href="./references#CD012236-fig-0045" title="">Analysis 4.11</a>). </p> </section> <section id="CD012236-sec-0311"> <h6 class="title">4.12 Satisfaction with treatment: leaving the study early, end point data, medium‐term (by 12 months) </h6> <p>For this outcome we found a single study involving 60 participants. We did not find evidence of a clear difference between the two treatments in this comparison (RR 1.59, 95% CI 0.88 to 2.88; <a href="./references#CD012236-fig-0046" title="">Analysis 4.12</a>). </p> </section> </section> <section id="CD012236-sec-0312"> <h5 class="title">B.ii. Cognitive behavioural therapy</h5> </section> <section id="CD012236-sec-0313"> <h5 class="title">5. Comparison: cognitive behavioural therapy + supportive therapy versus supportive therapy </h5> <p>This comparison has 11 outcomes.</p> <section id="CD012236-sec-0314"> <h6 class="title">5.1 Prodromal symptoms: transition to psychosis</h6> <p>We identified five studies relevant to this outcome and categorised data into four subgroups. </p> <section id="CD012236-sec-0315"> <p><b>5.1.1 Medium‐term (by 12 months)</b></p> <p>We found five studies to be relevant to this subgroup (728 participants). We found evidence of a clear difference between cognitive behavioural therapy (CBT) + supportive therapy and supportive therapy within this subgroup, favouring a combination of CBT and supportive therapy (RR 0.47, 95% CI 0.29 to 0.76; <a href="./references#CD012236-fig-0047" title="">Analysis 5.1</a>). </p> </section> <section id="CD012236-sec-0316"> <p><b>5.1.2 Long‐term (by 18 months)</b></p> <p>We found two studies to be relevant to this subgroup (252 participants). We found evidence of a clear difference between CBT + supportive therapy and supportive therapy within this subgroup, favouring a combination of CBT and supportive therapy (RR 0.45, 95% CI 0.23 to 0.89; <a href="./references#CD012236-fig-0047" title="">Analysis 5.1</a>). </p> </section> <section id="CD012236-sec-0317"> <p><b>5.1.3 Long‐term (by 24 months)</b></p> <p>We found one study to be relevant to this subgroup (128 participants). For this outcome, within this subgroup, we found evidence that CBT + supportive therapy was superior in its effects compared with supportive therapy (RR 0.32, 95% CI 0.11 to 0.92; <a href="./references#CD012236-fig-0047" title="">Analysis 5.1</a>). </p> </section> <section id="CD012236-sec-0318"> <p><b>5.1.4 Long‐term (by 4 years: additional follow‐up)</b></p> <p>There is a single study in this subgroup (201 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.58, 95% CI 0.31 to 1.12; <a href="./references#CD012236-fig-0047" title="">Analysis 5.1</a>). </p> </section> </section> <section id="CD012236-sec-0319"> <h6 class="title">5.2 Global state, specific: personal beliefs, average scores, long‐term (at 18 months), PBIQ‐R (higher score = worse) </h6> <p>For this outcome we found a single study, the data from which we divided into five subgroups. </p> <section id="CD012236-sec-0320"> <p><b>5.2.1 Control</b></p> <p>There is a single study in this subgroup (140 participants). We did not find a clear difference between CBT + supportive therapy and supportive therapy within this subgroup (MD −0.70, 95% CI −1.79 to 0.39; <a href="./references#CD012236-fig-0048" title="">Analysis 5.2</a>). </p> </section> <section id="CD012236-sec-0321"> <p><b>5.2.2 Entrapment</b></p> <p>We found one study to be relevant to this subgroup (140 participants). For this outcome, within this subgroup, we did not find evidence that CBT + supportive therapy was clearly different in its effects compared with supportive therapy (MD −0.50, 95% CI −1.91 to 0.91; <a href="./references#CD012236-fig-0048" title="">Analysis 5.2</a>). </p> </section> <section id="CD012236-sec-0322"> <p><b>5.2.3 Loss</b></p> <p>There is a single study in this subgroup (140 participants). For this outcome, within this subgroup, we did not find evidence that CBT + supportive therapy was clearly different in its effects compared with supportive therapy (MD −0.90, 95% CI −2.37 to 0.57; <a href="./references#CD012236-fig-0048" title="">Analysis 5.2</a>). </p> </section> <section id="CD012236-sec-0323"> <p><b>5.2.4 Participation</b></p> <p>We found one study to be relevant to this subgroup (140 participants). For this outcome, within this subgroup, we did not find evidence that CBT + supportive therapy was clearly different in its effects compared with supportive therapy (MD −0.40, 95% CI −1.48 to 0.68; <a href="./references#CD012236-fig-0048" title="">Analysis 5.2</a>). </p> </section> <section id="CD012236-sec-0324"> <p><b>5.2.5 Shame</b></p> <p>We found one study to be relevant to this subgroup (140 participants). We did not find evidence of a clear difference between CBT + supportive therapy and supportive therapy within this subgroup (MD −0.40, 95% CI −1.68 to 0.88; <a href="./references#CD012236-fig-0048" title="">Analysis 5.2</a>). </p> </section> </section> <section id="CD012236-sec-0325"> <h6 class="title">5.3 Mental state 1, specific: social anxiety, average total score, long‐term (at 18 months), SAS (higher score = worse) </h6> <p>For this outcome we found a single study (28 participants). There was no clear difference between CBT + supportive therapy and supportive therapy (MD −3.60, 95% CI −12.34 to 5.14; <a href="./references#CD012236-fig-0049" title="">Analysis 5.3</a>). </p> </section> <section id="CD012236-sec-0326"> <h6 class="title">5.4 Mental state 2, specific: average scores, various scales (higher score = worse), skewed data </h6> <p>These continuous data, from four studies, had such large standard deviations as to suggest that analysis within <a href="./references#CD012236-bbs2-0169" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a> would be inadvisable (see <a href="./references#CD012236-fig-0050" title="">Analysis 5.4</a>). </p> </section> <section id="CD012236-sec-0327"> <h6 class="title">5.5 Functioning 1, global: average total score, GAF (higher score = better)</h6> <p>For this outcome we found three relevant studies and categorised data into two subgroups.</p> <section id="CD012236-sec-0328"> <p><b>5.5.1 Medium‐term (at 12 months)</b></p> <p>We found two studies to be relevant to this subgroup (294 participants). There was no clear difference between CBT + supportive therapy and supportive therapy within this subgroup (MD 5.97, 95% CI −1.33 to 13.27). For this outcome heterogeneity is high (Chi² = 5.54; df = 1.0; P = 0.02; I² = 82%; <a href="./references#CD012236-fig-0051" title="">Analysis 5.5</a>). </p> </section> <section id="CD012236-sec-0329"> <p><b>5.5.2 Long‐term (at 18 months)</b></p> <p>There is a single study in this subgroup (28 participants). There was no clear difference between CBT + supportive therapy and supportive therapy within this subgroup (MD −3.20, 95% CI −14.05 to 7.65; <a href="./references#CD012236-fig-0051" title="">Analysis 5.5</a>). </p> </section> </section> <section id="CD012236-sec-0330"> <h6 class="title">5.6 Functioning 2.a, specific: social functioning, average total score, medium‐term (at 12 months), SAS II (higher score = worse) </h6> <p>There is a single study in this outcome (67 participants). We did not find evidence of a clear difference between CBT + supportive therapy and supportive therapy within this outcome (MD 0.40, 95% CI −0.07 to 0.87; <a href="./references#CD012236-fig-0052" title="">Analysis 5.6</a>). The results were imprecise as the confidence interval includes both no effect and appreciable benefit. </p> </section> <section id="CD012236-sec-0331"> <h6 class="title">5.7 Functioning 2.b.i, specific: social functioning, average total score, long‐term (at 18 months), SFS (higher score = better) </h6> <p>We identified one study relevant to this outcome (28 participants). There was no clear difference between CBT + supportive therapy and supportive therapy (MD 9.10, 95% CI −5.65 to 23.85; <a href="./references#CD012236-fig-0053" title="">Analysis 5.7</a>). </p> </section> <section id="CD012236-sec-0332"> <h6 class="title">5.8 Functioning 2.b.ii, specific: social functioning, average total score, medium‐term (at 18 months), SOFAS (higher score = better) </h6> <p>For this outcome we found a single study (140 participants). There was no clear difference between CBT + supportive therapy and supportive therapy (MD 2.00, 95% CI −2.39 to 6.39; <a href="./references#CD012236-fig-0054" title="">Analysis 5.8</a>). </p> </section> <section id="CD012236-sec-0333"> <h6 class="title">5.9 Quality of life: average total score, long‐term (at 18 months), MANSA (higher score = better) </h6> <p>For this outcome we found a single study (140 participants). There was no clear difference between CBT + supportive therapy and supportive therapy (MD 1.50, 95% CI −2.93 to 5.93; <a href="./references#CD012236-fig-0055" title="">Analysis 5.9</a>). </p> </section> <section id="CD012236-sec-0334"> <h6 class="title">5.10 Cost: cumulative (USD) skewed data</h6> <p>These continuous data, from a single study, had such large standard deviations as to suggest that analysis within <a href="./references#CD012236-bbs2-0169" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a> would be inadvisable (see <a href="./references#CD012236-fig-0056" title="">Analysis 5.10</a>). </p> </section> <section id="CD012236-sec-0335"> <h6 class="title">5.11 Satisfaction with treatment: leaving the study early, end point data</h6> <p>For this outcome we found five relevant studies, the data from which we divided into two subgroups. </p> <section id="CD012236-sec-0336"> <p><b>5.11.1 By between 1 year to 2 years</b></p> <p>We found four studies to be relevant to this subgroup (668 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.98, 95% CI 0.87 to 1.10; <a href="./references#CD012236-fig-0057" title="">Analysis 5.11</a>). </p> </section> <section id="CD012236-sec-0337"> <p><b>5.11.2 By between 2 years to 4 years (additional follow‐up)</b></p> <p>We found two studies to be relevant to this subgroup (261 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.96, 95% CI 0.74 to 1.24; <a href="./references#CD012236-fig-0057" title="">Analysis 5.11</a>). </p> </section> </section> </section> <section id="CD012236-sec-0338"> <h5 class="title">6. Comparison: cognitive behavioural therapy + risperidone versus cognitive behavioural therapy + placebo </h5> <p>This comparison has seven outcomes.</p> <section id="CD012236-sec-0339"> <h6 class="title">6.1 Prodromal symptoms: transition to psychosis, end point data</h6> <p>We identified one study relevant to this outcome (87 participants). We did not find evidence of a clear difference between the two treatments in this comparison (RR 1.02, 95% CI 0.39 to 2.67; <a href="./references#CD012236-fig-0058" title="">Analysis 6.1</a>). </p> </section> <section id="CD012236-sec-0340"> <h6 class="title">6.2 Mental state, specific: average end point scores, medium‐term (at 12 months), various scales (higher score = worse), skewed data </h6> <p>These continuous data, from a single study, were too skewed to report in a graph (please see <a href="./references#CD012236-fig-0059" title="">Analysis 6.2</a>). </p> </section> <section id="CD012236-sec-0341"> <h6 class="title">6.3 Functioning, global: average end point score, medium‐term (at 12 months), GAF (higher score = better) </h6> <p>We identified one study relevant to this outcome (52 participants). There was no clear difference between CBT + risperidone and CBT + placebo (MD −2.00, 95% CI −6.55 to 2.55; <a href="./references#CD012236-fig-0060" title="">Analysis 6.3</a>). </p> </section> <section id="CD012236-sec-0342"> <h6 class="title">6.4 Adverse effects 1, specific: doctors' assessment of adverse effects, medium‐term (at 12 months), UKU </h6> <p>We identified one study relevant to this outcome (65 participants). We did not find evidence of a clear difference between the two treatments in this comparison (RR 1.03, 95% CI 0.55 to 1.91; <a href="./references#CD012236-fig-0061" title="">Analysis 6.4</a>). </p> </section> <section id="CD012236-sec-0343"> <h6 class="title">6.5 Adverse effects 2, specific: adverse effects reported by participants, medium‐term (at 12 months), UKU </h6> <p>For this outcome we found a single study, with a total of 65 participants. There was no clear difference between CBT + risperidone and CBT + placebo (RR 2.01, 95% CI 0.9 to 4.53; <a href="./references#CD012236-fig-0062" title="">Analysis 6.5</a>). </p> </section> <section id="CD012236-sec-0344"> <h6 class="title">6.6 Quality of life: average end point score, medium‐term (at 12 months), QLS (higher score = better) </h6> <p>We identified one study relevant to this outcome (51 participants). We did not find evidence of a clear difference between the two treatments in this comparison (MD 5.70, 95% CI −7.86 to 19.26; <a href="./references#CD012236-fig-0063" title="">Analysis 6.6</a>). </p> </section> <section id="CD012236-sec-0345"> <h6 class="title">6.7 Satisfaction with treatment: leaving the study early, end point data</h6> <p>We identified one study relevant to this outcome (87 participants). There was no clear difference between CBT + risperidone and CBT + placebo (RR 1.09, 95% CI 0.62 to 1.92; <a href="./references#CD012236-fig-0064" title="">Analysis 6.7</a>). </p> </section> </section> <section id="CD012236-sec-0346"> <h5 class="title">7. Comparison: cognitive behavioural therapy (specific preventive intervention) + needs‐based intervention + risperidone versus needs‐based intervention </h5> <p>This comparison has six outcomes.</p> <section id="CD012236-sec-0347"> <h6 class="title">7.1 Prodromal symptoms: transition to psychosis, end point data</h6> <p>We identified one study relevant to this outcome, the data from which we divided into two subgroups. </p> <section id="CD012236-sec-0348"> <p><b>7.1.1 Medium‐term (at 12 months)</b></p> <p>There is a single study in this subgroup (59 participants). There was no clear difference between CBT (specific preventive intervention (SPI)) + needs‐based intervention (NBI) + risperidone and NBI within this subgroup (RR 0.54, 95% CI 0.23 to 1.30; <a href="./references#CD012236-fig-0065" title="">Analysis 7.1</a>). </p> </section> <section id="CD012236-sec-0349"> <p><b>7.1.2 Long‐term (up to 4 years)</b></p> <p>We found one study to be relevant to this subgroup (59 participants). There was no clear difference between CBT (SPI) + NBI + risperidone and NBI within this subgroup (RR 0.75, 95% CI 0.39 to 1.46; <a href="./references#CD012236-fig-0065" title="">Analysis 7.1</a>). </p> </section> </section> <section id="CD012236-sec-0350"> <h6 class="title">7.2 Mental state, specific: average end point scores, various scales (high score = worse), skewed data </h6> <p>These continuous data, from a single study, had such large standard deviations as to suggest that analysis within <a href="./references#CD012236-bbs2-0169" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a> would be inadvisable (please see <a href="./references#CD012236-fig-0066" title="">Analysis 7.2</a>). </p> </section> <section id="CD012236-sec-0351"> <h6 class="title">7.3 Functioning, global: average end point score, GAF (higher score = better)</h6> <p>We identified one study relevant to this outcome and categorised data into two subgroups.</p> <section id="CD012236-sec-0352"> <p><b>7.3.1 Medium‐term (at 12 months)</b></p> <p>We found one study to be relevant to this subgroup (40 participants). There was no clear difference between CBT (SPI) + NBI + risperidone and NBI within this subgroup (MD −0.62, 95% CI −5.81 to 4.57; <a href="./references#CD012236-fig-0067" title="">Analysis 7.3</a>). </p> </section> <section id="CD012236-sec-0353"> <p><b>7.3.2 Long‐term (up to 4 years)</b></p> <p>We found one study to be relevant to this subgroup (40 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD −2.40, 95% CI −12.32 to 7.52; <a href="./references#CD012236-fig-0067" title="">Analysis 7.3</a>). </p> </section> </section> <section id="CD012236-sec-0354"> <h6 class="title">7.4 Quality of life: average end point score, QLS (higher score = better)</h6> <p>For this outcome we found a single study, the data from which we divided into three subgroups. </p> <section id="CD012236-sec-0355"> <p><b>7.4.1 immediately post‐treatment</b></p> <p>We found one study to be relevant to this subgroup (40 participants). There was no clear difference between CBT (SPI) + NBI + risperidone and NBI within this subgroup (MD 2.83, 95% CI −13.07 to 18.73; <a href="./references#CD012236-fig-0068" title="">Analysis 7.4</a>). </p> </section> <section id="CD012236-sec-0356"> <p><b>7.4.2 Medium‐term (at 12 months)</b></p> <p>We found one study to be relevant to this subgroup (40 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD −2.12, 95% CI −15.43 to 11.19; <a href="./references#CD012236-fig-0068" title="">Analysis 7.4</a>). </p> </section> <section id="CD012236-sec-0357"> <p><b>7.4.3 Long‐term (up to 4 years)</b></p> <p>There is a single study in this subgroup (40 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD −2.03, 95% CI −16.90 to 12.84; <a href="./references#CD012236-fig-0068" title="">Analysis 7.4</a>). </p> </section> </section> <section id="CD012236-sec-0358"> <h6 class="title">7.5 Cost: average cost of treatment (AUD), skewed data</h6> <p>These continuous data (1 RCT) had such large standard deviations as to suggest that analysis within <a href="./references#CD012236-bbs2-0169" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a> would be inadvisable (please see <a href="./references#CD012236-fig-0069" title="">Analysis 7.5</a>). </p> </section> <section id="CD012236-sec-0359"> <h6 class="title">7.6 Satisfaction with treatment: leaving the study early</h6> <p>For this outcome we found a single study and categorised data into two subgroups (59 participants). At medium‐term follow‐up (12 months) there were no dropouts in either group. At long‐term follow‐up (up to 4 years), we did not find evidence of a clear difference between the two treatments in this comparison (RR 0.57, 95% CI 0.26 to 1.28; <a href="./references#CD012236-fig-0070" title="">Analysis 7.6</a>). </p> </section> </section> </section> <section id="CD012236-sec-0360"> <h4 class="title">Group C: differential effects</h4> <section id="CD012236-sec-0361"> <h5 class="title">C.i Cognitive behavioural therapy</h5> </section> <section id="CD012236-sec-0362"> <h5 class="title">8. Comparison: cognitive behavioural therapy + placebo versus supportive therapy + placebo </h5> <p>There are seven outcomes in this comparison.</p> <section id="CD012236-sec-0363"> <h6 class="title">8.1 Prodromal symptoms: transition to psychosis, end point data</h6> <p>We found a single study relevant to this outcome (72 participants). There was no clear difference between CBT + placebo and supportive therapy + placebo (RR 0.74, 95% CI 0.28 to 1.98; <a href="./references#CD012236-fig-0071" title="">Analysis 8.1</a>). </p> </section> <section id="CD012236-sec-0364"> <h6 class="title">8.2 Mental state, specific: average end point scores, medium‐term (at 12 months), various scales (higher score = worse), skewed data </h6> <p>These continuous data, from a single study, had such large standard deviations as to suggest that data were very skewed and analysis within <a href="./references#CD012236-bbs2-0169" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a> would be inadvisable (<a href="./references#CD012236-fig-0072" title="">Analysis 8.2</a>). </p> </section> <section id="CD012236-sec-0365"> <h6 class="title">8.3 Functioning, global: average end point scores, medium‐term (at 12 months), GAF (higher score = better) </h6> <p>We identified one study relevant to this outcome (45 participants). We did not find evidence of a clear difference between the two treatments (MD 2.20, 95% CI −4.59 to 8.99; <a href="./references#CD012236-fig-0073" title="">Analysis 8.3</a>). </p> </section> <section id="CD012236-sec-0366"> <h6 class="title">8.4 Adverse effects 1, specific: doctors' assessment of adverse effects, medium‐term (at 12 months), UKU </h6> <p>We identified one study relevant to this outcome (51 participants). We did not find evidence of a clear difference between the two treatments in this comparison (RR 1.39, 95% CI 0.61 to 3.18; <a href="./references#CD012236-fig-0074" title="">Analysis 8.4</a>). </p> </section> <section id="CD012236-sec-0367"> <h6 class="title">8.5 Adverse effects 2, specific: adverse effects reported by participants, medium‐term (at 12 months), UKU </h6> <p>We identified one study relevant to this outcome (51 participants). There was no clear difference between CBT + placebo and supportive therapy + placebo (RR 0.91, 95% CI 0.32 to 2.60; <a href="./references#CD012236-fig-0075" title="">Analysis 8.5</a>). </p> </section> <section id="CD012236-sec-0368"> <h6 class="title">8.6 Quality of life: average end point scores, medium‐term (at 12 months), QLS (higher score = better) </h6> <p>We identified one study relevant to this outcome (44 participants). There was no clear difference between CBT + placebo and supportive therapy + placebo (MD −3.30, 95% CI, −18.76 to 12.16; <a href="./references#CD012236-fig-0076" title="">Analysis 8.6</a>). </p> </section> <section id="CD012236-sec-0369"> <h6 class="title">8.7 Satisfaction with treatment: leaving the study early, end point data</h6> <p>For this outcome we found a single study involving 72 participants. We did not find evidence of a clear difference between the two treatments in this comparison (RR 1.06, 95% CI 0.54 to 2.09; <a href="./references#CD012236-fig-0077" title="">Analysis 8.7</a>). </p> </section> </section> <section id="CD012236-sec-0370"> <h5 class="title">9. Comparison: cognitive behavioural therapy + supportive intervention versus non‐directive reflective listening + supportive intervention </h5> <p>Studies reported data on four outcomes.</p> <section id="CD012236-sec-0371"> <h6 class="title">9.1 Prodromal symptoms: transition to psychosis, end point data</h6> <p>We found a single study reporting this outcome (57 participants). We did not find evidence of a clear difference between the two treatments in this comparison (RR 6.32, 95% CI 0.34 to 117.09; <a href="./references#CD012236-fig-0078" title="">Analysis 9.1</a>). </p> </section> <section id="CD012236-sec-0372"> <h6 class="title">9.2 Functioning 1, global: average total score, short‐term (at 6 months), GAF (higher score = better) </h6> <p>We identified one study relevant to this outcome (34 participants). There was no clear difference between CBT + supportive intervention and non‐directive reflective listening (NDRL) + supportive intervention (MD −4.48, 95% CI −12.81 to 3.85; <a href="./references#CD012236-fig-0079" title="">Analysis 9.2</a>). </p> </section> <section id="CD012236-sec-0373"> <h6 class="title">9.3 Functioning 2, specific: social functioning, average total score, short‐term (at 6 months), SOFAS (higher score = better) </h6> <p>For this outcome we found a single study (34 participants). We did not find evidence of a clear difference between the two treatments in this comparison (MD −6.47, 95% CI −15.30 to 2.36; <a href="./references#CD012236-fig-0080" title="">Analysis 9.3</a>). </p> </section> <section id="CD012236-sec-0374"> <h6 class="title">9.4 Satisfaction with treatment: leaving the study early, end point data</h6> <p>One study was relevant (57 participants). We did not find evidence of a clear difference between the two treatments in this comparison (RR 1.35, 95% CI 0.81 to 2.25; <a href="./references#CD012236-fig-0081" title="">Analysis 9.4</a>). </p> </section> </section> <section id="CD012236-sec-0375"> <h5 class="title">10. Comparison: cognitive behavioural therapy + risperidone versus supportive therapy + placebo </h5> <p>In this comparison, there were seven outcomes.</p> <section id="CD012236-sec-0376"> <h6 class="title">10.1 Prodromal symptoms: transition to psychosis, end point data</h6> <p>We identified one study relevant to this outcome (71 participants). There was no clear difference between CBT + risperidone and supportive therapy + placebo (RR 0.76, 95% CI 0.28 to 2.03; <a href="./references#CD012236-fig-0082" title="">Analysis 10.1</a>). </p> </section> <section id="CD012236-sec-0377"> <h6 class="title">10.2 Mental state, specific: average end point scores, medium‐term (at 12 months), various scales (higher score = worse), skewed data </h6> <p>These continuous data, from a single study, were too skewed to report in a graph (please see <a href="./references#CD012236-fig-0083" title="">Analysis 10.2</a>). </p> </section> <section id="CD012236-sec-0378"> <h6 class="title">10.3 Functioning, global: average end point score, medium‐term (at 12 months), GAF (higher score = better) </h6> <p>We identified one study relevant to this outcome (45 participants). There was no clear difference between CBT + risperidone and supportive therapy + placebo (MD 0.20, 95% CI −6.83 to 7.23; <a href="./references#CD012236-fig-0084" title="">Analysis 10.3</a>). </p> </section> <section id="CD012236-sec-0379"> <h6 class="title">10.4 Adverse effects 1, specific: doctors' assessment of adverse effects, medium‐term (at 12 months), UKU </h6> <p>For this outcome we found a single study (58 participants). There was no clear difference between CBT + risperidone and supportive therapy + placebo (RR 1.43, 95% CI 0.64 to 3.16; <a href="./references#CD012236-fig-0085" title="">Analysis 10.4</a>). </p> </section> <section id="CD012236-sec-0380"> <h6 class="title">10.5 Adverse effects 2, specific: adverse effects reported by participants, medium‐term (at 12 months), UKU </h6> <p>For this outcome we found a single study (58 participants). We did not find evidence of a clear difference between the two treatments in this comparison (RR 1.83, 95% CI 0.77 to 4.34; <a href="./references#CD012236-fig-0086" title="">Analysis 10.5</a>). </p> </section> <section id="CD012236-sec-0381"> <h6 class="title">10.6 Quality of life: average end point scores, medium‐term (at 12 months), QLS (higher score = better) </h6> <p>For this outcome we found a single study (43 participants). We did not find evidence of a clear difference between the two treatments in this comparison (MD 2.40, 95% CI −9.91 to 14.71; <a href="./references#CD012236-fig-0087" title="">Analysis 10.6</a>). </p> </section> <section id="CD012236-sec-0382"> <h6 class="title">10.7 Satisfaction with treatment: leaving the study early, end point data</h6> <p>We identified one study relevant to this outcome (71 participants). There was no clear difference between CBT + risperidone and supportive therapy + placebo (RR 1.16, 95% CI 0.60 to 2.25; <a href="./references#CD012236-fig-0088" title="">Analysis 10.7</a>). </p> </section> </section> <section id="CD012236-sec-0383"> <h5 class="title">C.ii Other</h5> </section> <section id="CD012236-sec-0384"> <h5 class="title">11. Comparison: cognitive training versus active control (tablet games)</h5> <p>This comparison has nine outcomes.</p> <section id="CD012236-sec-0385"> <h6 class="title">11.1 Mental state 1, specific: average total scores, various scales (higher score = worse), skewed data </h6> <p>These continuous data, from two studies, were too skewed to report in a graph (please see <a href="./references#CD012236-fig-0089" title="">Analysis 11.1</a>). </p> </section> <section id="CD012236-sec-0386"> <h6 class="title">11.2 Mental state 2, specific: depression, average end point score, short‐term (at 4 months), BDI‐II (higher score = worse) </h6> <p>For this outcome we found a single study (62 participants). There was no clear difference between cognitive training and active control (tablet games) (MD 0.99, 95% CI −1.72 to 3.7; <a href="./references#CD012236-fig-0090" title="">Analysis 11.2</a>). </p> </section> <section id="CD012236-sec-0387"> <h6 class="title">11.3 Mental state 3.a, specific: cognitive, average end point score short‐term (at 4 months) </h6> <p>For this outcome we found a single study, the data from which we divided into two subgroups. </p> <section id="CD012236-sec-0388"> <p><b>11.3.1 Processing speed (Minnesota Clerical Test, T score, higher score = better)</b></p> <p>We found one study to be relevant to this subgroup (62 participants). We found evidence of a clear difference between cognitive training and active control (tablet games) within this subgroup, in favour of cognitive training (MD 6.25, 95% CI 1.70 to 10.80; <a href="./references#CD012236-fig-0091" title="">Analysis 11.3</a>). </p> </section> <section id="CD012236-sec-0389"> <p><b>11.3.2 Processing speed (Digit Symbol Coding, higher score = better)</b></p> <p>There is a single study in this subgroup (62 participants). There was a clear difference between cognitive training and active control (tablet games) within this subgroup, in favour of cognitive training (MD 1.69, 95% CI 0.69 to 2.69; <a href="./references#CD012236-fig-0091" title="">Analysis 11.3</a>). </p> </section> </section> <section id="CD012236-sec-0390"> <h6 class="title">11.4 Mental state 3.b, specific: cognitive, average total score (presented as least square means estimated by the generalised linear mixed models), short‐term (at 3 months), MATRICS (higher score = better) </h6> <p>For this outcome we found a single study, the data from which we divided into six subgroups. </p> <section id="CD012236-sec-0391"> <p><b>11.4.1 Attention/vigilance</b></p> <p>There is a single study in this subgroup (25 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD −3.12, 95% CI −11.48 to 5.24; <a href="./references#CD012236-fig-0092" title="">Analysis 11.4</a>). </p> </section> <section id="CD012236-sec-0392"> <p><b>11.4.2 Speed of processing</b></p> <p>There is a single study in this subgroup (25 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD −2.58, 95% CI −9.72 to 4.56; <a href="./references#CD012236-fig-0092" title="">Analysis 11.4</a>). </p> </section> <section id="CD012236-sec-0393"> <p><b>11.4.3 Reasoning and problem solving</b></p> <p>There is a single study in this subgroup (25 participants). There was no clear difference between cognitive training and active control (tablet games) within this subgroup (MD −1.84, 95% CI −8.32 to 4.64; <a href="./references#CD012236-fig-0092" title="">Analysis 11.4</a>). </p> </section> <section id="CD012236-sec-0394"> <p><b>11.4.4 Verbal learning</b></p> <p>There is a single study in this subgroup (25 participants). There was no clear difference between cognitive training and active control (tablet games) within this subgroup (MD −0.19, 95% CI −7.00 to 6.62; <a href="./references#CD012236-fig-0092" title="">Analysis 11.4</a>). </p> </section> <section id="CD012236-sec-0395"> <p><b>11.4.5 Visual learning</b></p> <p>We found one study to be relevant to this subgroup (25 participants). There was no clear difference between cognitive training and active control (tablet games) within this subgroup (MD −4.39, 95% CI −11.10 to 2.32; <a href="./references#CD012236-fig-0092" title="">Analysis 11.4</a>). </p> </section> <section id="CD012236-sec-0396"> <p><b>11.4.6 Working memory</b></p> <p>There is a single study in this subgroup (25 participants). There was no clear difference between cognitive training and active control (tablet games) within this subgroup (MD 3.56, 95% CI −4.88 to 12.0; <a href="./references#CD012236-fig-0092" title="">Analysis 11.4</a>). </p> </section> </section> <section id="CD012236-sec-0397"> <h6 class="title">11.5 Functioning 1, global: average total score, long‐term (at 24 months), GAF (higher score = better) </h6> <p>For this outcome we found a single study (83 participants). We did not find evidence of a clear difference between the two treatments in this comparison (MD 0.36, 95% CI −5.34 to 6.06; <a href="./references#CD012236-fig-0093" title="">Analysis 11.5</a>). </p> </section> <section id="CD012236-sec-0398"> <h6 class="title">11.6 Functioning 2, specific: role functioning, GFR (higher score = better)</h6> <p>We identified two studies relevant to this outcome, the data from which we divided into two subgroups. </p> <section id="CD012236-sec-0399"> <p><b>11.6.1 Role functioning: average total score (presented as least square means estimated by the generalised linear mixed models), short‐term (at 3 months)</b></p> <p>We found one study to be relevant to this subgroup (25 participants). We found evidence of a clear difference between cognitive training and active control (tablet games) within this subgroup, in favour of active control (tablet games) (MD −1.27, 95% CI −1.84 to −0.70; <a href="./references#CD012236-fig-0094" title="">Analysis 11.6</a>). </p> </section> <section id="CD012236-sec-0400"> <p><b>11.6.2 Role functioning: average total score, long‐term (at 24 months)</b></p> <p>We found one study to be relevant to this subgroup (83 participants). For this outcome, within this subgroup, we did not find evidence that cognitive training was clearly different in its effects compared with active control (tablet games) (MD −0.23, 95% CI −1.37 to 0.91; <a href="./references#CD012236-fig-0094" title="">Analysis 11.6</a>). </p> </section> </section> <section id="CD012236-sec-0401"> <h6 class="title">11.7 Functioning 3.a, specific: social functioning, GFS (higher score = better)</h6> <p>For this outcome we found two relevant studies, the data from which we divided into two subgroups. </p> <section id="CD012236-sec-0402"> <p><b>11.7.1 Social functioning: average total score (presented as least square means estimated by the generalised linear mixed models), short−term (at 3 months)</b></p> <p>We found one study to be relevant to this subgroup (25 participants). For this outcome, within this subgroup, we did not find evidence that cognitive training was clearly different in its effects compared with active control (tablet games) (MD −0.68, 95% CI −2.12 to 0.76; <a href="./references#CD012236-fig-0095" title="">Analysis 11.7</a>). </p> </section> <section id="CD012236-sec-0403"> <p><b>11.7.2 Social functioning: average total score, long‐term (at 24 months)</b></p> <p>There is a single study in this subgroup, which included a total of 83 participants. For this subgroup, we did not find evidence of a clear difference between the two treatments (MD 0.26, 95% CI −0.52 to 1.04; <a href="./references#CD012236-fig-0095" title="">Analysis 11.7</a>). </p> </section> </section> <section id="CD012236-sec-0404"> <h6 class="title">11.8 Functioning 3.b, specific: social functioning, average end point score, short‐term (at 4 months), SAS‐SR (higher score = worse) </h6> <p>We identified one study relevant to this outcome (62 participants). For this outcome, we found evidence that cognitive training was clearly different in its effects compared with active control (tablet games), in favour of cognitive training (MD −0.64, 95% CI −0.94 to −0.34; <a href="./references#CD012236-fig-0096" title="">Analysis 11.8</a>). </p> </section> <section id="CD012236-sec-0405"> <h6 class="title">11.9 Satisfaction with treatment: leaving the study early, end point data</h6> <p>For this outcome we found three relevant studies and categorised data into three subgroup (177 participants). There was no clear difference between cognitive training and active control (tablet games) (RR 0.93, 95% CI 0.82 to 1.05; <a href="./references#CD012236-fig-0097" title="">Analysis 11.9</a>). </p> <section id="CD012236-sec-0406"> <p><b>11.9.1 Short‐term (by 2 months, PST)</b></p> <p>There is a single study in this subgroup (62 participants). There was no clear difference between cognitive training and active control (tablet games) within this subgroup (RR 0.93, 95% CI 0.81 to 1.06; <a href="./references#CD012236-fig-0097" title="">Analysis 11.9</a>). </p> </section> <section id="CD012236-sec-0407"> <p><b>11.9.2 Medium‐term (by 9 months, AT)</b></p> <p>We found one study to be relevant to this subgroup (32 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 1.22, 95% CI 0.64 to 2.32; <a href="./references#CD012236-fig-0097" title="">Analysis 11.9</a>). </p> </section> <section id="CD012236-sec-0408"> <p><b>11.9.3 Long‐term (by 24 months, AT)</b></p> <p>We found one study to be relevant to this subgroup, which included a total of 83 participants. For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.78, 95% CI 0.48 to 1.29; <a href="./references#CD012236-fig-0097" title="">Analysis 11.9</a>). </p> </section> </section> </section> <section id="CD012236-sec-0409"> <h5 class="title">12. Comparison: family treatment versus enhanced care</h5> <p>This comparison has seven outcomes.</p> <section id="CD012236-sec-0410"> <h6 class="title">12.1 Prodromal symptoms: transition to psychosis</h6> <p>We identified two studies relevant to this outcome and categorised data into two subgroups (229 participants). We did not find evidence of a clear difference between the two treatments in this comparison (RR 0.54, 95% CI 0.18 to 1.59). </p> <section id="CD012236-sec-0411"> <p><b>12.1.1 Short‐term (6 months, FFT)</b></p> <p>There is a single study in this subgroup (129 participants). There was no clear difference between family treatment and enhanced care within this subgroup (RR 0.19, 95% CI 0.02 to 1.59; <a href="./references#CD012236-fig-0098" title="">Analysis 12.1</a>). </p> </section> <section id="CD012236-sec-0412"> <p><b>12.1.2 Long‐term (24 months, FACT)</b></p> <p>We found one study to be relevant to this subgroup (100 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.71, 95% CI 0.35 to 1.45; <a href="./references#CD012236-fig-0098" title="">Analysis 12.1</a>). </p> </section> </section> <section id="CD012236-sec-0413"> <h6 class="title">12.2 Global state: antipsychotic prescription, short‐term (by 6 months)</h6> <p>For this outcome we found a single study (129 participants). There was no clear difference between family treatment and enhanced care (RR 1.18, 95% CI 0.69 to 2.02; <a href="./references#CD012236-fig-0099" title="">Analysis 12.2</a>). </p> </section> <section id="CD012236-sec-0414"> <h6 class="title">12.3 Mental state, specific: psychosis risk, positive symptoms, average total score, short‐term (at 6 months), SOPS positive (higher score = worse) </h6> <p>For this outcome we found a single study (102 participants). There was a clear difference between family treatment and enhanced care, in favour of family treatment (MD −2.01, 95% CI −3.87 to −0.15; <a href="./references#CD012236-fig-0100" title="">Analysis 12.3</a>). </p> </section> <section id="CD012236-sec-0415"> <h6 class="title">12.4 Functioning, global: average total score, long‐term (at 24 months), GAF (higher score = better) </h6> <p>For this outcome we found a single study (69 participants). We did not find evidence of a clear difference between the two treatments in this comparison (MD 5.15, 95% CI −1.90 to 12.20; <a href="./references#CD012236-fig-0101" title="">Analysis 12.4</a>). </p> </section> <section id="CD012236-sec-0416"> <h6 class="title">12.5 Adverse events 1.a, specific: suicide, events, long‐term (by 24 months)</h6> <p>We identified one study relevant to this outcome (100 participants). We did not find evidence of a clear difference between the two treatments in this comparison (RR 1.00, 95% CI 0.06 to 15.55; <a href="./references#CD012236-fig-0102" title="">Analysis 12.5</a>). </p> </section> <section id="CD012236-sec-0417"> <h6 class="title">12.6 Adverse events 1.b, specific: suicide, participants affected/at risk, long‐term (by 24 months) </h6> <p>We identified one study relevant to this outcome (100 participants). There was no clear difference between family treatment and enhanced care (RR 1.00, 95% CI 0.06 to 15.55; <a href="./references#CD012236-fig-0103" title="">Analysis 12.6</a>). </p> </section> <section id="CD012236-sec-0418"> <h6 class="title">12.7 Satisfaction with treatment: leaving the study early</h6> <p>We identified two studies relevant to this outcome and categorised data into two subgroups (229 participants). There was no clear difference between family treatment and enhanced care (RR 0.81, 95% CI 0.52 to 1.26; <a href="./references#CD012236-fig-0104" title="">Analysis 12.7</a>). </p> <section id="CD012236-sec-0419"> <p><b>12.7.1 Short‐term (6 months, FFT)</b></p> <p>There is a single study in this subgroup (129 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.66, 95% CI 0.33 to 1.30; <a href="./references#CD012236-fig-0104" title="">Analysis 12.7</a>). </p> </section> <section id="CD012236-sec-0420"> <p><b>12.7.2 Long‐term (24 months, FACT)</b></p> <p>We found one study to be relevant to this subgroup (100 participants). There was no clear difference between family treatment and enhanced care within this subgroup (RR 0.94, 95% CI 0.52 to 1.68; <a href="./references#CD012236-fig-0104" title="">Analysis 12.7</a>). </p> </section> </section> </section> <section id="CD012236-sec-0421"> <h5 class="title">13. Comparison: integrated treatment versus standard treatment</h5> <p>There were three outcomes in this comparison.</p> <section id="CD012236-sec-0422"> <h6 class="title">13.1 Prodromal symptoms: transition to psychosis, end point data, long‐term (by 2 years) </h6> <p>For this outcome we found a single study (79 participants). We did not find evidence of a clear difference between the two treatments in this comparison (RR 0.57, 95% CI 0.28 to 1.15; <a href="./references#CD012236-fig-0105" title="">Analysis 13.1</a>). </p> </section> <section id="CD012236-sec-0423"> <h6 class="title">13.2 Mental state, specific: average total score, long‐term (at 2 years), various scales (higher score = worse), skewed data </h6> <p>These continuous data, from a single study, were too skewed to report in a graph (please see <a href="./references#CD012236-fig-0106" title="">Analysis 13.2</a>). </p> </section> <section id="CD012236-sec-0424"> <h6 class="title">13.3 Satisfaction with treatment: leaving the study early, end point data</h6> <p>We identified one study relevant to this outcome (79 participants). We did not find evidence of a clear difference between the two treatments in this comparison (RR 0.66, 95% CI 0.25 to 1.73; <a href="./references#CD012236-fig-0107" title="">Analysis 13.3</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012236-sec-0425" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012236-sec-0425">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012236-sec-0629">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012236-sec-0425"></div> <p>There is the impression that in this whole area there is a triumph of hope over adversity. There is the repeated hope invested in another ‐ often unique ‐ study question and then a study of fewer than 100 participants is completed. This results in the set of comparisons reported here, all of which are too under‐powered to really highlight clear differences. With more agreement, collaboration and co‐ordination across research teams in this area it might have been possible to find if, to take one example, cognitive therapy was truly more valuable than a simpler supportive approach. The diversity of underpowered testing in this area has left important questions still in doubt after well over a decade of highly‐expensive, and, no doubt, career‐enhancing, studies. </p> <p>To summarise the main findings we used outcomes chosen at review protocol stage for presentation in the 'Summary of findings' tables. No comparison reported data on all seven outcomes and we often had to use proxy measures. No comparison, however, reported explicitly on 'behaviour'. It is possible that this is thought to be covered by reporting 'global state' or 'mental state' but we still think it is reasonable to have included it in the original list. It is not difficult to report and is of great importance to carers. </p> <p> <div class="table" id="CD012236-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Pre‐defined 'Summary of findings' table outcome</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="15" rowspan="1" valign="top"> <p><b>Comparison number</b> </p> <p><b>(within clusters A‐C)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>A</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>B</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>C</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>9</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>11</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>12</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>13</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prodromal symptoms: transition to psychosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global state: clinically important change in global state</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state: clinically important change in mental state</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour: any change in behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects: at least one serious adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life: any change in quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Satisfaction with treatment: leaving the study early</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✔</p> </td> </tr> </tbody> </table> </div> </p> <section id="CD012236-sec-0426"> <h3 class="title" id="CD012236-sec-0426">Summary of main results</h3> <section id="CD012236-sec-0427"> <h4 class="title">Group A: absolute effects</h4> <p>Group A's interventions involved giving amino acids or omega‐3 and comparing these with placebo. Both comparisons involved low numbers of studies that were likely to be of very limited power. Data quality, at best, was low. There is no suggestion that amino acids have an effect. Adding omega‐3 did change both transition to psychosis and use of antipsychotic drugs in one small study but over a seven‐year follow‐up. </p> <section id="CD012236-sec-0428"> <h5 class="title">1. Amino acids compared to placebo for prodromal stage of psychosis</h5> <p>Please see <a href="./full#CD012236-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD012236-sec-0429"> <h6 class="title">1.1 Transition to psychosis, end point data</h6> <p>Very low‐quality evidence from two small studies (52 participants in total) failed to find a clear difference for this outcome. </p> </section> <section id="CD012236-sec-0430"> <h6 class="title">1.2 Psychosis risk symptoms, measured with SOPS total</h6> <p>Mental state was monitored using the SOPS, rating psychosis risk symptoms. No clear difference was apparent. This result is based on very low‐quality evidence from one small study with data for only eight participants. </p> </section> <section id="CD012236-sec-0431"> <h6 class="title">1.3 Adverse events: suicidal thoughts</h6> <p>Suicidal thoughts were rarely experienced (one person out of 20 in the experimental versus zero out of 24 in the placebo group) and it may have not been the best effect for us to highlight in our 'Summary of findings' table. However, in a broader range of general and specific adverse effects than are reported in the other comparisons within this review there was no real indication that the use of amino acids caused problems. Results are based on very low‐quality evidence from one small study with data for 44 participants. </p> </section> <section id="CD012236-sec-0432"> <h6 class="title">1.4 Satisfaction with treatment, measured as number of individuals leaving the study early </h6> <p>A little under half of the participants left early with no clear difference between groups (very low‐quality evidence, 2 RCTs, 52 participants). </p> </section> <section id="CD012236-sec-0433"> <h6 class="title">1.5 Missing outcomes</h6> <p>None of the studies reported usable data on global state, behaviour or quality of life. </p> </section> </section> <section id="CD012236-sec-0434"> <h5 class="title">2. Omega‐3 fatty acids compared to placebo for prodromal stage of psychosis</h5> <p>Please see <a href="./full#CD012236-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD012236-sec-0435"> <h6 class="title">2.1 Transition to psychosis</h6> <p>A lower number of participants in the intervention group treated with omega‐3 fatty acids transitioned to psychosis during long‐term follow‐up of seven years, compared to the placebo group (˜10% versus ˜33%, RR 0.24, 95%, 95% CI 0.09 to 0.67, low‐quality evidence, 1 RCT, 81 participants). If this outcome was an isolated positive finding there would be the strong suspicion that it was the result of the play of chance. However this is not necessarily the case with other outcomes also favouring the omega‐3 group (see below). All outcomes are low quality. All are from small studies undertaken by those probably who are prone to favour the omega‐3 group and biases can always creep in. However, these are rare positive findings, and have some limited consistency and may well be worthy of further investigation. </p> </section> <section id="CD012236-sec-0436"> <h6 class="title">2.2 Global state, measured with number of antipsychotic prescriptions</h6> <p>A significantly lower number of participants allocated to omega‐3 fatty acids had antipsychotic prescriptions during follow‐up of seven years, compared to those allocated to the placebo group (RR 0.54, 95% CI 0.30 to 0.99, low‐quality evidence, 1 RCT, 69 participants). </p> </section> <section id="CD012236-sec-0437"> <h6 class="title">2.3 Mental state, measured with PANSS total</h6> <p>Participants in the intervention group had significantly lower mean scores for psychotic symptoms (measured by PANSS total, scale from 30 to 210, MD 11.4 points lower, 95% CI 20.55 points lower to 2.25 lower, low‐quality evidence, 1 RCT, 81 participants). </p> </section> <section id="CD012236-sec-0438"> <h6 class="title">2.4 Adverse effects, neurological extrapyramidal symptoms measured with UKU Side Effect Rating Scale </h6> <p>Although more participants in the intervention group treated with omega‐3 fatty acids developed neurological extrapyramidal symptoms in follow‐up by 12 months compared to the placebo group, the results did not reach conventional levels of statistical significance (RR 2.57, 95% CI 0.94 to 7.02, low‐quality evidence, 1 RCT, 304 participants). </p> </section> <section id="CD012236-sec-0439"> <h6 class="title">2.5 Satisfaction with treatment, measured as number of individuals leaving the study early </h6> <p>About 25% of each group left the study early with no clear difference between groups (1 RCT, 81participants). </p> </section> <section id="CD012236-sec-0440"> <h6 class="title">2.6 Missing outcomes</h6> <p>No study reported usable data on behaviour or quality of life.</p> </section> </section> </section> <section id="CD012236-sec-0441"> <h4 class="title">Group B: comparisons where it is unclear how interaction has affected the interventions</h4> <section id="CD012236-sec-0442"> <h5 class="title">B.i Antipsychotic drugs</h5> <p>We were unclear if amisulpiride could interact with the needs‐focused intervention (NFI) or olanzapine with supportive therapy. In any event, data for the amisulpiride‐NFI comparison are so few and poor that no conclusion is warranted and those for the addition of olanzapine to supportive therapy are also limited in size and quality, so as to make firm conclusions impossible. There is no hint of an underlying effect. </p> </section> <section id="CD012236-sec-0443"> <h5 class="title">3. Amisulpiride + needs‐focused intervention compared to needs‐focused intervention for prodromal stage of psychosis </h5> <p>Please see <a href="./full#CD012236-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD012236-sec-0444"> <h6 class="title">3.1 Adverse events: suicidal thoughts</h6> <p>There was no difference between groups for a series of adverse events, including suicidal thoughts, and very few events in each group (very low‐quality evidence, 1 RCT, 102 participants). </p> </section> <section id="CD012236-sec-0445"> <h6 class="title">3.2 Satisfaction with treatment, measured as number of individuals leaving the study early </h6> <p>Fewer participants (around 30%) left the group assigned to also take amisulpiride, compared with those needs‐focused intervention (NFI only group (nearly 60% loss to follow‐up, RR 0.59, 95% CI 0.38 to 0.94, very low‐quality evidence, 1 RCT, 124 participants). Of course 'leaving early' is difficult to interpret and it is hard to be confident that this truly represents satisfaction. This could be a chance finding in many, but could also be a real expression of something. Most negatively it could be seen as a function of inertia facilitated by use of an antipsychotic ‐ but on the other hand it could represent a real expression of satisfaction mediated by some sort of improvement caused by use of the drug. </p> </section> <section id="CD012236-sec-0446"> <h6 class="title">3.3 Missing outcomes</h6> <p>There are particularly few usable data for this comparison. No study reported usable data on transition to psychosis, global state, mental state, behaviour or quality of life. </p> </section> </section> <section id="CD012236-sec-0447"> <h5 class="title">4. Olanzapine + supportive intervention compared to placebo + supportive intervention for prodromal stage of psychosis </h5> <p>Please see <a href="./full#CD012236-tbl-0004">summary of findings Table 4</a>. </p> <section id="CD012236-sec-0448"> <h6 class="title">4.1 Transition to psychosis</h6> <p>Although a lower number of participants in the intervention group treated with a combination of olanzapine and supportive intervention transitioned to psychosis during follow‐up of 12 months, compared to control group treated with a combination of placebo and supportive intervention (˜25% versus ˜40%), these results were imprecise and do not meet conventional levels of statistical significance (RR 0.58, 95% CI 0.28 to 1.18, 1 RCT, 60 participants; very low‐quality evidence). </p> </section> <section id="CD012236-sec-0449"> <h6 class="title">4.2 Global illness severity, measured by CGI</h6> <p>Nor was there a clear difference between groups for a continuous measure of global severity of illness (very low‐quality evidence, 1 RCT, 59 participants). </p> </section> <section id="CD012236-sec-0450"> <h6 class="title">4.3 Psychosis risk symptoms, measured with SOPS total</h6> <p>For mental state, again, there was no clear difference between groups when a specific scale was employed to identify 'psychosis risk symptoms'. This result is based on very low‐quality evidence from one small study with data for 59 participants. </p> </section> <section id="CD012236-sec-0451"> <h6 class="title">4.4 Adverse effects: average weight gain in kg</h6> <p>Unsurprisingly, for those who are familiar with use of and evidence around olanzapine, significantly ‐ statistically and clinically ‐ higher weight gain was observed in the intervention group. The average weight gain in the intervention group was approaching 5 kg (95% CI 2 kg to 7 kg higher). This is an important and well‐recognised adverse effect of this particular compound. In itself this could be enough to discourage use of olanzapine for this group of participants but as there are no clear effects ‐ or suggestion of effects ‐ in other outcomes, embarking on use of olanzapine in this group would seem very ill‐advised. </p> </section> <section id="CD012236-sec-0452"> <h6 class="title">4.5 Satisfaction with treatment, measured as number of individuals leaving the study early </h6> <p>There was no difference between the participants treated with a combination of olanzapine and supportive intervention and those treated with a combination of placebo and supportive intervention in terms of number of participants leaving the study early in a follow‐up by 12 months. Around half left the single study (60 participants). </p> </section> <section id="CD012236-sec-0453"> <h6 class="title">4.6 Missing outcomes</h6> <p>No study reported usable data on behaviour or quality of life.</p> </section> </section> <section id="CD012236-sec-0454"> <h5 class="title">B.ii Cognitive behavioural therapy</h5> <p>All findings within the CBT subgroup are equivocal except for outcome 5.1 (see below) where CBT added to supportive therapy did better for 'transition to psychosis' than supportive therapy alone (at 18 months). This is one finding out of many and is not of high quality. Several complex packages have been tested involving variations of treatments using a CBT ethos but all effects of these considerable complex and skilled efforts are unconvincing as to there being true benefit. </p> </section> <section id="CD012236-sec-0455"> <h5 class="title">5. Cognitive behavioural therapy + supportive therapy versus supportive therapy</h5> <p>Please see <a href="./full#CD012236-tbl-0005">summary of findings Table 5</a>. </p> <section id="CD012236-sec-0456"> <h6 class="title">5.1 Transition to psychosis</h6> <p>Around 8% of participants treated allocated to the combination of CBT and supportive therapy transitioned to psychosis during follow‐up by 18 months, compared with double that percentage in the supportive therapy alone group (RR 0.45, 95% CI 0.23 to 0.89; 2 RCTs, 252 participants; very low‐quality evidence). The finding chosen for the summary table was the medium‐term outcome but this finding is consistent ‐ and encouraging across all time periods (<a href="./references#CD012236-fig-0047" title="">Analysis 5.1</a>). Crudely calculated using the shorter‐term data, the number of participants needed to treat for around one year to avoid one transition in that time period is 13. It is difficult to know if this investment would be cost effective. The skilled therapists in these studies are not universal and biases in the studies would likely favour the CBT group. In addition, what data there are in <a href="./references#CD012236-fig-0047" title="">Analysis 5.1</a> suggests some diminution of effect across time. Transition may be postponed rather than avoided. If this is not the result of the play of chance, any effect for transition to psychosis is likely to be modest in everyday clinical life. </p> </section> <section id="CD012236-sec-0457"> <h6 class="title">5.2 Mental state, measured with SAS</h6> <p>Very low‐quality evidence from one study (28 participants) finds no clear difference between groups. </p> </section> <section id="CD012236-sec-0458"> <h6 class="title">5.3 Quality of life measured with MANSA</h6> <p>More evidence that we had to judge as being of very low quality (1 RCT, 140 participants) failed to highlight any differences between groups. </p> </section> <section id="CD012236-sec-0459"> <h6 class="title">5.4 Satisfaction with treatment, measured as number of individuals leaving the study early </h6> <p>This also applied to the outcome of satisfaction with care, with around half leaving their group of allocation early (<a href="./references#CD012236-fig-0057" title="">Analysis 5.11</a>). </p> </section> <section id="CD012236-sec-0460"> <h6 class="title">5.5 Missing outcomes</h6> <p>None of the studies reported usable data on global state, behaviour or adverse effects. Other, not dissimilar studies have, and more consistency in outcome reporting would have helped us compare across comparisons. </p> </section> </section> <section id="CD012236-sec-0461"> <h5 class="title">6. Cognitive behavioural therapy + risperidone versus cognitive behavioural therapy + placebo </h5> <p>Please see <a href="./full#CD012236-tbl-0006">summary of findings Table 6</a>. </p> <section id="CD012236-sec-0462"> <h6 class="title">6.1 Transition to psychosis, end point data</h6> <p>There is no evidence that adding risperidone to CBT does anything for any outcome including transition to psychosis (1 RCT, 87 participants; very low‐quality evidence). </p> </section> <section id="CD012236-sec-0463"> <h6 class="title">6.2 Mental state: psychopathology measured with BPRS</h6> <p>Imprecise, very low‐quality evidence found no difference between groups in terms of a mental state measure (1 RCT, 52 participants). </p> </section> <section id="CD012236-sec-0464"> <h6 class="title">6.3 Doctors' assessment of adverse effects measured with UKU Side Effect Rating Scale</h6> <p>Although there were more adverse effects in the risperidone group, the difference did not reach conventional levels of statistical significance (1 RCT, 65 participants; very low‐quality evidence). </p> </section> <section id="CD012236-sec-0465"> <h6 class="title">6.4 Quality of life measured with QLS</h6> <p>One small study (51 participants) reports evidence that we had to rate as being of very low‐quality evidence with no difference between groups. </p> </section> <section id="CD012236-sec-0466"> <h6 class="title">6.5 Satisfaction with treatment, measured as number of individuals leaving the study early </h6> <p>All continuous data for the single relevant study (<a href="./references#CD012236-bbs2-0020" title="McGorryP . Second generation intervention research in the pre‐psychotic phase of illness in schizophrenia and related psychoses. Australian New Zealand Clinical Trials Registry2000. [CSzG: 18439] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceyS , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: 12‐month outcome. Schizophrenia Research2012;136:S17‐8. [CSzG: 29547] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceySM , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: twelve‐month outcome. Journal of Clinical Psychiatry2013;74(4):349‐56. [CSzG: 28737] NelsonB , PhillipsLJ , YungAR , FranceySM , LeicesterS , BakerK , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and supportive therapy in young people with subthreshold symptoms at incipient risk of psychotic disorder: baseline characteristics of the sample. Schizophrenia Bulletin2007;33(2):450. [CSzG: 15212] PhillipsLJ , NelsonB , YuenHP , FranceySM , SimmonsM , StanfordC , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: study design and baseline characteristics. Australian and New Zealand Journal of Psychiatry2009;;43(9):818–29. YungA , AmmingerP , BergerG , ThompsomA , PhillipsL , NelsonB , et al. Randomised controlled trial of antipsychotic and cognitive therapy in young people at ultra‐high risk of psychosis. Early Intervention in Psychiatry2012;6:11. [CSzG: 24989] YungA , NelsonB , PhillipsL , FranceyS , LeicesterS , YuenH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and supportive therapy in young people at ultra high risk of psychotic disorder: 12 month outcome data. Early Intervention in Psychiatry2008;2(Suppl 1):A12. [CSzG: 19138] YungAR , PhillipsLJ , NelsonB , FranceySM , YuenHP , SimmonsMB , et al. Randomised controlled trial of interventions for young people at ultra high risk for psychosis: 6‐month analysis. Journal of Clinical Psychiatry2011;72(4):430‐40. [CSzG: 22929] ">Yung‐Australia</a>), were completer data and there is a danger that randomisation was compromised by this. Leaving the study early is, however, reported for everyone and there was no difference between groups, with around 30% of both groups leaving early (87 participants). Again, this is hard to interpret with no additional information but it is encouraging that the addition of risperidone did not clearly increase the considerable attrition. </p> </section> <section id="CD012236-sec-0467"> <h6 class="title">6.6 Missing outcomes</h6> <p>None of the studies reported usable data on global state or behaviour. It could be interpreted that outcomes already there covered these and further recording was unnecessary. We feel, however, that more explicit recording would not have complicated the study and would have been of interest to many. </p> </section> </section> <section id="CD012236-sec-0468"> <h5 class="title">7. Cognitive behavioural therapy (specific preventive intervention) + needs‐based intervention + risperidone compared to needs‐based intervention for prodromal stage of psychosis </h5> <p>Please see <a href="./full#CD012236-tbl-0007">summary of findings Table 7</a>. </p> <section id="CD012236-sec-0469"> <h6 class="title">7.1 Transition to psychosis</h6> <p>We found no clear difference between the two complex packages of care for this important outcome. This result is based on very low‐quality evidence from one small study (59 participants). </p> </section> <section id="CD012236-sec-0470"> <h6 class="title">7.2 Mental state: psychopathology measured with BPRS</h6> <p>The continuous mental state measure (BPRS) highlighted no difference between groups and, again, we had to grade these data as being of very low quality (1 RCT, 40 participants). </p> </section> <section id="CD012236-sec-0471"> <h6 class="title">7.3 Quality of life measured with QLS</h6> <p>Exactly the same applied to the QLS score.</p> </section> <section id="CD012236-sec-0472"> <h6 class="title">7.4 Satisfaction with treatment, measured as number of individuals leaving the study early </h6> <p>There was no difference between the intervention group, treated with a combination of SPI, CBT, NBI and risperidone and the control group in terms of number of participants leaving the study early in a follow‐up of up to four years. Overall there were impressively low numbers of participants lost to follow‐up with none at 12 months, rising to around 20% by four years. This result is based on evidence that we had to rate as being of very low quality (1 RCT, 59 participants). </p> </section> <section id="CD012236-sec-0473"> <h6 class="title">7.5 Missing outcomes</h6> <p>None of the studies reported usable data on global state, behaviour or adverse effects and several of the findings that had to be used were proxies for simpler and, we argue, more useful outcomes. </p> </section> </section> </section> <section id="CD012236-sec-0474"> <h4 class="title">Group C: differential effects</h4> <section id="CD012236-sec-0475"> <h5 class="title">C.i. Cognitive behavioural therapy</h5> <p>When CBT is directly compared with another treatment, for the broad prespecified 'Summary of findings' outcomes, much of the evidence was of very low quality and none showed a suggestion of clear differences between interventions. </p> </section> <section id="CD012236-sec-0476"> <h5 class="title">8. Cognitive behavioural therapy + placebo versus supportive therapy + placebo</h5> <p>Please see <a href="./full#CD012236-tbl-0008">summary of findings Table 8</a>. </p> <section id="CD012236-sec-0477"> <h6 class="title">8.1 Transition to psychosis, end point data</h6> <p>In a small study (72 participants) there was no clear difference between those allocated to CBT and those receiving a low grade, supportive therapy (RR 0.74, 95% CI 0.28 to 1.98). It is possible that this very low‐quality evidence hides a real effect but impossible to know at this point. </p> </section> <section id="CD012236-sec-0478"> <h6 class="title">8.2 Mental state: psychopathology measured with BPRS</h6> <p>The continuous proxy measure we had to use (BPRS) indicated that the CBT group was not better than the control group (45 participants; very low‐quality evidence). The finding that the CBT group was 2.2 points higher (worse) was compatible with also being 5 points lower to 9 points higher compared with the control group and we found no clear clinical explanation of these findings. </p> </section> <section id="CD012236-sec-0479"> <h6 class="title">8.3 Doctors' assessment of adverse effects measured with UKU</h6> <p>There was no clear difference in adverse effects between groups at 12 months (51 participants; very low‐quality evidence). It is good to see how the possibility of adverse effects of talking approaches is being considered in studies. </p> </section> <section id="CD012236-sec-0480"> <h6 class="title">8.4 Quality of life measured with QLS</h6> <p>There was no difference between the mean QLS score (a proxy for what was prestipulated in the review's protocol) at 12 months' follow‐up in the CBT and control group. The score for the intervention group was 3.3 points lower but 95% CI indicated that the result could be 19 points lower to 12 points higher compared to the control group on a scale from 0 to 126. That the finding is equivocal is helpful as we are unclear of the meaning of the range of figures and have found no explanation of these. In any event, this result is based on very low‐quality evidence from one small study with data for 44 participants. </p> </section> <section id="CD012236-sec-0481"> <h6 class="title">8.5 Satisfaction with treatment, measured as number of individuals leaving the study early </h6> <p>Approaching 30% of each group left the groups early. It is hard to know what this means. This level of attrition could be expected from the client group, or could reflect badly on either the intervention or study design (72 participants). </p> </section> <section id="CD012236-sec-0482"> <h6 class="title">8.6 Missing outcomes</h6> <p>None of the studies reported usable data on global state or behaviour. It could be that these outcomes are covered by what has been reported but it would be better to have been certain of the effects of these interventions on simple outcomes clearly falling into these categories. </p> </section> </section> <section id="CD012236-sec-0483"> <h5 class="title">9. Cognitive behavioural therapy + supportive intervention versus non‐directive reflective listening + supportive intervention </h5> <p>Please see <a href="./full#CD012236-tbl-0009">summary of findings Table 9</a>. </p> <section id="CD012236-sec-0484"> <h6 class="title">9.1 Transition to psychosis, end point data</h6> <p>In a group treated with a combination of CBT and supportive therapy, three participants transitioned to psychosis (out of 30), while in the control group none of the 27 analysed participants transitioned to psychosis. As the study was small, results were imprecise and we remain unclear if one or other intervention approach remains a risk. This result is based on very low‐quality evidence. </p> </section> <section id="CD012236-sec-0485"> <h6 class="title">9.2 Satisfaction with treatment, measured as number of individuals leaving the study early </h6> <p>There was no difference between groups in terms of number of participants leaving the study early (1 RCT, 57 participants) but over half left the CBT + supportive therapy group. </p> </section> <section id="CD012236-sec-0486"> <h6 class="title">9.3 Missing outcomes</h6> <p>None of the studies reported usable data on global or mental state, behaviour, adverse effects, or quality of life. Other, not dissimilar studies have, and more consistency in outcome reporting would have helped us compare across comparisons. </p> </section> </section> <section id="CD012236-sec-0487"> <h5 class="title">10. Cognitive behavioural therapy + risperidone compared to supportive therapy + placebo for prodromal stage of psychosis </h5> <p>Please see <a href="./full#CD012236-tbl-0010">summary of findings Table 10</a>. </p> <section id="CD012236-sec-0488"> <h6 class="title">10.1 Transition to psychosis, end point data</h6> <p>We found no clear difference between those allocated to a combination of CBT and risperidone compared to a combination of supportive therapy and placebo but data were of very low quality (1 RCT, 71 participants). </p> </section> <section id="CD012236-sec-0489"> <h6 class="title">10.2 Mental state: psychopathology measured with BPRS</h6> <p>Few, very low‐quality data (1 RCT, 45 participants) reported on a mental state outcome with no clear difference between groups. </p> </section> <section id="CD012236-sec-0490"> <h6 class="title">10.3 Doctors' assessment of adverse effects measured with UKU Side Effect Rating Scale</h6> <p>Although more adverse effects were apparent in the risperidone group, there was no clear, statistically significant or clinically important difference (very low‐quality, 1 RCT, 58 participants). </p> </section> <section id="CD012236-sec-0491"> <h6 class="title">10.4 Quality of life measured with QLS</h6> <p>The continuous score used to measure quality of life was also equivocal (very low‐quality evidence, 1 RCT, 43 participants). </p> </section> <section id="CD012236-sec-0492"> <h6 class="title">10.5 Satisfaction with treatment, measured as number of individuals leaving the study early </h6> <p>Finally, about 30% of participants left each group before study completion. There was no difference between groups (1 RCT, 71 participants; very low‐quality evidence). </p> </section> <section id="CD012236-sec-0493"> <h6 class="title">10.6 Missing outcomes</h6> <p>None of the studies reported usable data on global state or behaviour. As for many of the other comparisons, there are so few data for other outcomes ‐ all provided by one pioneering but single study (<a href="./references#CD012236-bbs2-0020" title="McGorryP . Second generation intervention research in the pre‐psychotic phase of illness in schizophrenia and related psychoses. Australian New Zealand Clinical Trials Registry2000. [CSzG: 18439] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceyS , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: 12‐month outcome. Schizophrenia Research2012;136:S17‐8. [CSzG: 29547] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceySM , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: twelve‐month outcome. Journal of Clinical Psychiatry2013;74(4):349‐56. [CSzG: 28737] NelsonB , PhillipsLJ , YungAR , FranceySM , LeicesterS , BakerK , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and supportive therapy in young people with subthreshold symptoms at incipient risk of psychotic disorder: baseline characteristics of the sample. Schizophrenia Bulletin2007;33(2):450. [CSzG: 15212] PhillipsLJ , NelsonB , YuenHP , FranceySM , SimmonsM , StanfordC , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: study design and baseline characteristics. Australian and New Zealand Journal of Psychiatry2009;;43(9):818–29. YungA , AmmingerP , BergerG , ThompsomA , PhillipsL , NelsonB , et al. Randomised controlled trial of antipsychotic and cognitive therapy in young people at ultra‐high risk of psychosis. Early Intervention in Psychiatry2012;6:11. [CSzG: 24989] YungA , NelsonB , PhillipsL , FranceyS , LeicesterS , YuenH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and supportive therapy in young people at ultra high risk of psychotic disorder: 12 month outcome data. Early Intervention in Psychiatry2008;2(Suppl 1):A12. [CSzG: 19138] YungAR , PhillipsLJ , NelsonB , FranceySM , YuenHP , SimmonsMB , et al. Randomised controlled trial of interventions for young people at ultra high risk for psychosis: 6‐month analysis. Journal of Clinical Psychiatry2011;72(4):430‐40. [CSzG: 22929] ">Yung‐Australia</a>), that we are left partially reassured that conducting evaluative studies in this area is possible but also thinking that clinicians, policy makers and above all those with prodromal signs of schizophrenia have been let down by the research fraternity and the latter's lack of co‐ordination and collaboration. </p> </section> </section> <section id="CD012236-sec-0494"> <h5 class="title">C.ii Other</h5> <p>Finally, in the last three comparisons, for the key outcomes of interest, there was no suggestion of any of the approaches having a clear effect. </p> </section> <section id="CD012236-sec-0495"> <h5 class="title">11. Cognitive training compared to active control (tablet games) for prodromal stage of psychosis </h5> <p>Please see <a href="./full#CD012236-tbl-0011">summary of findings Table 11</a>. </p> <section id="CD012236-sec-0496"> <h6 class="title">11.1 Psychosis risk symptoms, measured with SOPS total</h6> <p>The equivocal result is based on use of a proxy measure and we had to grade this evidence as being of very low quality (1 RCT, 62 participants). </p> </section> <section id="CD012236-sec-0497"> <h6 class="title">11.2 Satisfaction with treatment, measured as number of individuals leaving the study early </h6> <p>Overall, over half of all participants left the studies before completion (˜24 months). There was no difference between groups (3 RCTs, 177 participants). It is difficult to say if this is more to do with study design than the true acceptability of the approaches. </p> </section> <section id="CD012236-sec-0498"> <h6 class="title">11.3 Missing outcomes</h6> <p>There are particularly few usable data for this comparison. No studies reported on global state, mental state, behaviour, adverse effects or quality of life. </p> </section> </section> <section id="CD012236-sec-0499"> <h5 class="title">12. Family treatment compared to enhanced care for prodromal stage of psychosis</h5> <p>Please see <a href="./full#CD012236-tbl-0012">summary of findings Table 12</a>. </p> <section id="CD012236-sec-0500"> <h6 class="title">12.1 Transition to psychosis</h6> <p>There was no clear difference found between the packages of care for this important outcome. This result is based on very low‐quality evidence from one small study (100 participants). </p> </section> <section id="CD012236-sec-0501"> <h6 class="title">12.2 Global state, measured with number of antipsychotic prescriptions</h6> <p>We found no clear difference for this proxy measure of global state (very low‐quality evidence, 1 RCT, 129 participants). </p> </section> <section id="CD012236-sec-0502"> <h6 class="title">12.3 Psychosis risk, positive symptoms, measured with SOPS positive scale</h6> <p>In the group treated with family treatment, the mean SOPS positive score was 2.01 points lower than in the enhanced care control group (95% CI 3.87 points lower to 0.15 lower) on a scale from 0 to 30 at six months. Participants in the intervention group experienced improvement but we are unclear of the clinical meaning of these data and have not found them explained in the study (1 RCT, 102 participants; very low‐quality evidence). </p> </section> <section id="CD012236-sec-0503"> <h6 class="title">12.4 Adverse events: suicide</h6> <p>There was one suicide in each group of 50 participants by around two years ‐ indicating the vulnerability of this young cohort. </p> </section> <section id="CD012236-sec-0504"> <h6 class="title">12.5 Satisfaction with treatment, measured as number of individuals leaving the study early </h6> <p>Overall, 20% to 30% of participants in both groups left the studies early ‐ with no clear difference between treatments. It is unclear how valuable this outcome is for approximating satisfaction with treatment, so we have to grade the finding as being of very low quality. </p> </section> <section id="CD012236-sec-0505"> <h6 class="title">12.6 Missing outcomes</h6> <p>There are no usable data on mental state, behaviour or quality of life.</p> </section> </section> <section id="CD012236-sec-0506"> <h5 class="title">13. Integrated treatment compared to standard treatment for prodromal stage of psychosis</h5> <p>Please see <a href="./full#CD012236-tbl-0013">summary of findings Table 13</a>. </p> <section id="CD012236-sec-0507"> <h6 class="title">13.1 Transition to psychosis, end point data</h6> <p>We found ‐ again ‐ no clear difference between the treatment and control groups (RR 0.57, 95% CI 0.28 to 1.15, very low‐quality evidence) and ‐ again ‐ one small study with data (79 participants). </p> </section> <section id="CD012236-sec-0508"> <h6 class="title">13.2 Mental state: negative symptoms, measured with SANS</h6> <p>In this case, the SANS reported data did not highlight any difference between the groups but this result is based on very low‐quality evidence from one small study with data for only 57 participants. Although fine‐grain measures such as SANS may not require the numbers of more clinically interpretable binary outcomes to achieve adequate levels of power to have a likely chance of highlighting a difference between groups, studies with recruitment only in the 50s are really unlikely to be able to show anything with confidence. </p> </section> <section id="CD012236-sec-0509"> <h6 class="title">13.3 Satisfaction with treatment, measured as number of individuals leaving the study early </h6> <p>Around 10% left the treatment arm early. Approximately 30% were lost from the control arm. Such was the power of the study that this did not represent a clear difference between the group receiving integrated treatment and the standard treatment (1 RCT, 79 participants; very low‐quality evidence). </p> </section> <section id="CD012236-sec-0510"> <h6 class="title">13.4 Missing outcomes</h6> <p>There are few usable data for this comparison. No studies reported on global state, behaviour, adverse effects or quality of life. </p> </section> </section> </section> </section> <section id="CD012236-sec-0511"> <h3 class="title" id="CD012236-sec-0511">Overall completeness and applicability of evidence</h3> <section id="CD012236-sec-0512"> <h4 class="title">1. Completeness</h4> <p>All studies addressing the 13 comparisons had important outcomes missing. All of the data we do have is underpowered and of limited quality so just because we are able to report something does not all mean data are complete. While all comparisons had data about number of participants leaving the study early and the majority reported transition to psychosis and some mental state indicators, virtually none of the comparisons addressed behavioral outcomes, that is, any change in behaviour; only two reported outcomes regarding participants’ global state and four reported data for adverse effects. Only four comparisons had data on patient satisfaction and quality of life. </p> </section> <section id="CD012236-sec-0513"> <h4 class="title">2. Applicability</h4> <p>Although all studies included participants with clinical high risk for psychosis, criteria used to identify participants at risk were not uniform across the studies. However, this was foreseen and defined in the protocol for this review (<a href="./references#CD012236-bbs2-0199" title="BošnjakD , KekinI , HewJ , KuzmanMR . Early interventions for prodromal stage of psychosis. Cochrane Database of Systematic Reviews. John Wiley &amp; Sons, Ltd, 2016, issue 6. [DOI: 10.1002/14651858.CD012236] ">Bošnjak 2016</a>). Nevertheless, differences in tools that were used for recognition of individuals at risk may have contributed to some differences in populations studied. </p> <p>The main problem is that it was difficult to interpret the results. The majority of different included studies allowed additional types of interventions. For example, studies that compared different psychosocial approaches allowed the use of concomitant medications, such as antidepressants, anxiolytics or even antipsychotics that were not controlled for, but made part of the standard control treatment. Also, all studies that compared add‐on pharmacotherapy or the use of amino‐acids and omega‐3, also allowed psychosocial approaches as part of the control group. Comparisons that include different psychosocial approaches are very difficult, for at least several reasons: 1) comparison between different psychotherapies is not reliable if the compare different numbers and durations of sessions; 2) the definition of a standard control treatment may vary significantly from site to site due to the basic psychotherapy training of the psychiatrists in a respective country; 3) supportive therapy may incorporate elements from different psychotherapy approaches, and this may interfere with other approaches included in the 'intervention group' as well as intervention psychotherapy, as, for example, CBT also includes elements of supportive psychotherapy. </p> <p>Results for omega‐3 studies should be interpreted with caution as the results are based on the results from one study, and the follow‐up of seven years (6 years after the intervention was finished), without the estimation of other treatment methods on the studied outcomes that the participants received over the studied period. In summary, all studies analysed complex multimodal treatment, with different designs. Therefore, it is possible that different approaches are quite effective to a similar degree in the treatment of prodromes, rather than being ineffective. </p> </section> <section id="CD012236-sec-0514"> <h4 class="title">3. Potential harms of tested interventions</h4> <p>One study indicated significantly higher weight gain for the combination of olanzapine and supportive intervention compared to the control group, which received a combination of placebo and supportive intervention. There were no other clear differences in serious adverse events between interventions in either of the analysed studies. Therefore, none of the interventions analysed in the studies included in this systematic review were associated with significant harmful effects. </p> </section> </section> <section id="CD012236-sec-0515"> <h3 class="title" id="CD012236-sec-0515">Quality of the evidence</h3> <p>The majority of included studies were influenced by different domains of risk of bias at some level. Fifteen studies had one or more domains that we graded as high risk of bias, while all of them had one or more with an unclear risk of bias (<a href="#CD012236-fig-0001">Figure 1</a>; <a href="#CD012236-fig-0002">Figure 2</a>). GRADE assessment of evidence within the 'Summary of findings' tables indicated that key outcomes presented in these are based on very low‐ or low‐quality evidence. These limitations in study design, selective reporting and imprecision often can be avoided while conducting studies. Overall, this review included 20 studies with a total sample size of 2151 participants. One large study with a sample size of 1000 would have answered many of the questions that continue to linger with really poor levels of data. Although it is often difficult to achieve compliance in a vulnerable population like young people with prodromal symptoms of psychosis, it is needed for reliable results and adequate assessment of an intervention. Researchers should consider different options that could help to improve compliance (e.g. more frequent check‐ups), as well as to assure better reporting standards. Both compliance and higher reporting standards would help to improve study quality (see <a href="#CD012236-sec-0525">Implications for research</a>). </p> </section> <section id="CD012236-sec-0516"> <h3 class="title" id="CD012236-sec-0516">Potential biases in the review process</h3> <p>There are many ways in which bias could have been introduced into this review but we have made a great effort to use adequate methodological approaches and included co‐authors without conflicts of interest. </p> <section id="CD012236-sec-0517"> <h4 class="title">1. Study selection and data extraction</h4> <p>Searches predominantly used English terms and studies only undertaken and reported in the non‐English speaking world could have been missed. The Cochrane Schizophrenia Group's register of studies is compiled from multilingual searches in many different databases but indexing is in English ‐ so that English language searches should have identified the study if relevant. We think it unlikely that large important studies have been missed. </p> <p>To reduce the possibility of mistakes during study selections, two review authors independently screened all bibliographic records obtained by the search, and we used the same method for screening full texts, extracting data, assessing risk of bias and grading the quality of evidence. </p> <p>It is likely we have made mistakes in data extraction. This has been painstaking work and it is more than probable that some numbers are not fully accurate. We welcome any comments to help improve this review. We do not think that our mistakes are anything but random ‐ more the function of exhaustion rather than systematic bias. </p> </section> <section id="CD012236-sec-0518"> <h4 class="title">2. Review author conflict of interest</h4> <p>Authors of this review have no conflicts of interest to declare.</p> </section> </section> <section id="CD012236-sec-0519"> <h3 class="title" id="CD012236-sec-0519">Agreements and disagreements with other studies or reviews</h3> <p>A number of other reviews on this topic were published recently.</p> <p>The 2015 European Psychiatric Association (EPA) guidance formulated seven evidence‐based recommendations for early intervention in people at high risk of psychosis, but they emphasised that more studies are needed to investigate the specificity of treatment effects and potential age effects in order to tailor interventions to the individual's treatment needs and risk status (<a href="./references#CD012236-bbs2-0172" title="SchmidtSJ , Schultze‐LutterF , SchimmelmannBG , MaricNP , SalokangasRK , Riecher‐RösslerA , et al. EPA guidance on the early intervention in clinical high risk states of psychoses. European Psychiatry2015;30(3):388‐404. [DOI: 10.1016/j.eurpsy.2015.01.013] ">Schmidt 2015</a>). The 2017 Canadian treatment guidelines for people at clinical high risk of psychosis used a systematic search for evidence (<a href="./references#CD012236-bbs2-0076" title="AddingtonJ , AddingtonD , AbidiS , RaedlerT , RemingtonG . Canadian treatment guidelines for individuals at clinical high risk of psychosis. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie2017;62(9):656‐61. ">Addington 2017</a>). Their conclusion is that a staged approach with psychological treatments should be the first‐line treatment and that pharmacotherapy should be reserved for adults, people who did not respond to psychological interventions and those who had more severe symptoms. These guidelines include nine recommendations about diagnosis and treatment, with various strength of evidence (<a href="./references#CD012236-bbs2-0076" title="AddingtonJ , AddingtonD , AbidiS , RaedlerT , RemingtonG . Canadian treatment guidelines for individuals at clinical high risk of psychosis. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie2017;62(9):656‐61. ">Addington 2017</a>). </p> <p>Two network meta‐analyses were published in 2018 on this subject (<a href="./references#CD012236-bbs2-0107" title="DaviesC , RaduaJ , CiprianiA , StahlD , ProvenzaniU , McGuireP , et al. Efficacy and acceptability of interventions for attenuated positive psychotic symptoms in individuals at clinical high risk of psychosis: a network meta‐analysis. Frontiers in Psychiatry / Frontiers Research Foundation2018;9:187. ">Davies 2018a</a>; <a href="./references#CD012236-bbs2-0108" title="DaviesC , CiprianiA , IoannidisJP , RaduaJ , StahlD , ProvenzaniU , et al. Lack of evidence to favor specific preventive interventions in psychosis: a network meta‐analysis. World Psychiatry2018;17(2):196‐209. [DOI: 10.1002/wps.20526] ">Davies 2018b</a>). The first one (<a href="./references#CD012236-bbs2-0107" title="DaviesC , RaduaJ , CiprianiA , StahlD , ProvenzaniU , McGuireP , et al. Efficacy and acceptability of interventions for attenuated positive psychotic symptoms in individuals at clinical high risk of psychosis: a network meta‐analysis. Frontiers in Psychiatry / Frontiers Research Foundation2018;9:187. ">Davies 2018a</a>), analyzed efficacy and acceptability of interventions for attenuated positive psychotic symptoms in individuals at clinically high risk of psychosis, and looked only into follow‐up of six and 12 months. In our review, we looked into longer follow‐up times. The authors concluded that there was no robust evidence to favour any specific intervention for improving attenuated positive psychotic symptoms in individuals at clinical high risk of psychosis. The second network meta‐analysis (<a href="./references#CD012236-bbs2-0108" title="DaviesC , CiprianiA , IoannidisJP , RaduaJ , StahlD , ProvenzaniU , et al. Lack of evidence to favor specific preventive interventions in psychosis: a network meta‐analysis. World Psychiatry2018;17(2):196‐209. [DOI: 10.1002/wps.20526] ">Davies 2018b</a>), about preventive interventions in psychosis, also concluded that there was no evidence that any specific intervention is particularly effective over any other intervention in preventing transition to psychosis. Results of both of those network meta‐analyses are in line with our conclusion that there was no convincing, unbiased, high‐quality evidence to suggest that any type of intervention is of value for people at prodromal stage of psychosis in terms of preventing development of psychosis. Compared to these reviews, our review included longer follow‐up times and more studies. </p> <p>Devoe and colleagues used systematic review and network meta‐analysis to analyse efficacy and safety of negative symptom interventions in young people at risk of psychosis. They included both observational studies and those with experimental treatments. They found that no treatments significantly reduced negative symptoms and in the network meta‐analysis all confidence intervals overlapped the null line. Additionally, the authors warned that many relevant studies had small samples and the majority of studies was not designed to target negative symptoms (<a href="./references#CD012236-bbs2-0112" title="DevoeDJ , PetersonA , AddingtonJ . Negative symptom interventions in youth at risk of psychosis: a systematic review and network meta‐analysis. Schizophrenia Bulletin2018;44(4):807‐23. [DOI: 10.1093/schbul/sbx139; PUBMED: 29069511] ">Devoe 2018a</a>). A second systematic review and meta‐analysis from this group found that no treatment significantly improved social functioning in young people at risk of psychosis (<a href="./references#CD012236-bbs2-0113" title="DevoeDJ , FarrisMS , TownesP , AddingtonJ . Interventions and social functioning in youth at risk of psychosis: a systematic review and meta‐analysis. Early Intervention in Psychiatry2018;13(2):169‐180. [DOI: 10.1111/eip.12689] ">Devoe 2018b</a>). A third study from this group analysed attenuated psychotic symptom (APS) interventions in young people at risk of psychosis and found that, although participants treated with CBT demonstrated a slight trend in reducing APS by long‐term follow‐up compared to participants from control groups, no interventions were significantly more effective at reducing APS compared to all other interventions in network meta‐analysis ‐ again in line with the findings of this review (<a href="./references#CD012236-bbs2-0114" title="DevoeDJ , FarrisMS , TownesP , AddingtonJ . Attenuated psychotic symptom interventions in youth at risk of psychosis: a systematic review and meta‐analysis. Early Intervention in Psychiatry2018;13(1):3‐17. [DOI: 10.1111/eip.12677] ">Devoe 2018c</a>). We think networking of the data in this area has been ill‐advised. Nikolakopoulou found network analyses are not indicated when data are few, there are few common comparisons, there are no differences in the pair‐wise comparisons and networks are insufficiently connected (<a href="./references#CD012236-bbs2-0093" title="BergmanH , WalkerDM , NikolakopoulouA , Soares‐WeiserK , AdamsCE . Systematic review of interventions for treating or preventing antipsychotic‐induced tardive dyskinesia. Health Technology Assessment (Winchester, England)2017;21(43):1‐218. [PUBMED: 28812541] ">Bergman 2017</a>), and all these indicators would apply to our findings. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012236-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies" data-id="CD012236-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD012236-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD012236-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Group A: amino acids vs placebo, Outcome 1 Prodromal symptoms: transition to psychosis, endpoint data." data-id="CD012236-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Group A: amino acids vs placebo, Outcome 1 Prodromal symptoms: transition to psychosis, endpoint data. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Group A: amino acids vs placebo, Outcome 2 Mental state 1: specific, psychosis risk symptoms, average total score, short‐term (at 8 weeks), SOPS (higher score = worse)." data-id="CD012236-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Group A: amino acids vs placebo, Outcome 2 Mental state 1: specific, psychosis risk symptoms, average total score, short‐term (at 8 weeks), SOPS (higher score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0006"> <p> <div class="table" id="CD012236-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Note</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Woods‐1‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amino acids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Woods‐1‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Group A: amino acids vs placebo, Outcome 3 Mental state 2 specific: depression, average total score, short‐term (at 8 weeks), MADRS (higher score = worse), skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0006">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012236-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Group A: amino acids vs placebo, Outcome 4 Mental state 3a specific: cognitive symptoms, average total score, short‐term (at 12 weeks), various tests (higher score = better)." data-id="CD012236-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Group A: amino acids vs placebo, Outcome 4 Mental state 3a specific: cognitive symptoms, average total score, short‐term (at 12 weeks), various tests (higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Group A: amino acids vs placebo, Outcome 5 Mental state 3b specific: cognitive symptoms, average total score, short‐term (at 12 weeks), various tests (higher score = worse)." data-id="CD012236-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Group A: amino acids vs placebo, Outcome 5 Mental state 3b specific: cognitive symptoms, average total score, short‐term (at 12 weeks), various tests (higher score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Group A: amino acids vs placebo, Outcome 6 Adverse effects 1 specific: treatment‐emergent adverse effects, short‐term (by 8 weeks)." data-id="CD012236-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Group A: amino acids vs placebo, Outcome 6 Adverse effects 1 specific: treatment‐emergent adverse effects, short‐term (by 8 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Group A: amino acids vs placebo, Outcome 7 Adverse effects 2 specific: cardiovascular, average total score, short‐term (by 8 weeks), blood pressure and pulse rate (higher score = worse)." data-id="CD012236-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Group A: amino acids vs placebo, Outcome 7 Adverse effects 2 specific: cardiovascular, average total score, short‐term (by 8 weeks), blood pressure and pulse rate (higher score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Group A: amino acids vs placebo, Outcome 8 Adverse effects 3 specific: weight, average total change score, short‐term (by 8 weeks), kg gained (higher score = worse)." data-id="CD012236-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Group A: amino acids vs placebo, Outcome 8 Adverse effects 3 specific: weight, average total change score, short‐term (by 8 weeks), kg gained (higher score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Group A: amino acids vs placebo, Outcome 9 Adverse effects 4 specific: suicidal thoughts, short‐term (by 16 weeks)." data-id="CD012236-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Group A: amino acids vs placebo, Outcome 9 Adverse effects 4 specific: suicidal thoughts, short‐term (by 16 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Group A: amino acids vs placebo, Outcome 10 Satisfaction with treatment: leaving the study early ‐ end point data." data-id="CD012236-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Group A: amino acids vs placebo, Outcome 10 Satisfaction with treatment: leaving the study early ‐ end point data. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Group A: omega‐3 fatty acids vs placebo, Outcome 1 Prodromal symptoms: transition to psychosis." data-id="CD012236-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Group A: omega‐3 fatty acids vs placebo, Outcome 1 Prodromal symptoms: transition to psychosis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Group A: omega‐3 fatty acids vs placebo, Outcome 2 Global state: antipsychotic prescription, long‐term (at 7 years' follow‐up)." data-id="CD012236-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Group A: omega‐3 fatty acids vs placebo, Outcome 2 Global state: antipsychotic prescription, long‐term (at 7 years' follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Group A: omega‐3 fatty acids vs placebo, Outcome 3 Mental state 1a specific: psychotic symptoms, average total score, PANSS (higher score = worse)." data-id="CD012236-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Group A: omega‐3 fatty acids vs placebo, Outcome 3 Mental state 1a specific: psychotic symptoms, average total score, PANSS (higher score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Group A: omega‐3 fatty acids vs placebo, Outcome 4 Mental state 1b specific: negative symptoms, average total score, medium‐term (at 12 months), SANS (higher score = worse)." data-id="CD012236-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Group A: omega‐3 fatty acids vs placebo, Outcome 4 Mental state 1b specific: negative symptoms, average total score, medium‐term (at 12 months), SANS (higher score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Group A: omega‐3 fatty acids vs placebo, Outcome 5 Mental state 2 specific: depression, average total score, medium‐term (at 12 months), MADRS (higher score = worse), skewed data." data-id="CD012236-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Group A: omega‐3 fatty acids vs placebo, Outcome 5 Mental state 2 specific: depression, average total score, medium‐term (at 12 months), MADRS (higher score = worse), skewed data. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Group A: omega‐3 fatty acids vs placebo, Outcome 6 Mental state 3 specific: mania, average total score, medium‐term (at 12 months), YMS (higher score = worse)." data-id="CD012236-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Group A: omega‐3 fatty acids vs placebo, Outcome 6 Mental state 3 specific: mania, average total score, medium‐term (at 12 months), YMS (higher score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0020"> <p> <div class="table" id="CD012236-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Psychotic symptoms: positive (average total score), long‐term (by up to 7 years) PANSS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amminger‐Austria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omega‐3 fatty acids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amminger‐Austria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Psychotic symptoms: negative (average total score), medium‐term (at 12 months) PANSS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amminger‐Austria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omega‐3 fatty acids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amminger‐Austria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Psychotic symptoms: negative (average total score), long‐term (by up to 7 years) PANSS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amminger‐Austria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omega‐3 fatty acids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amminger‐Austria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Depression: average total score, medium‐term (at 12 months), MADRS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amminger‐Austria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omega‐3 fatty acids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amminger‐Austria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Depression: average total score, long‐term (by up to 7 years) MADRS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amminger‐Austria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omega‐3 fatty acids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amminger‐Austria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Group A: omega‐3 fatty acids vs placebo, Outcome 7 Mental state 4 specific: average total scores, various scales (higher score = worse), skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0020">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012236-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Group A: omega‐3 fatty acids vs placebo, Outcome 8 Functioning 1 global: average total score, GAF (higher score = better)." data-id="CD012236-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Group A: omega‐3 fatty acids vs placebo, Outcome 8 Functioning 1 global: average total score, GAF (higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Group A: omega‐3 fatty acids vs placebo, Outcome 9 Functioning 2 specific: role functioning, average total score, medium‐term (at 12 months), GFR (higher score = better)." data-id="CD012236-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Group A: omega‐3 fatty acids vs placebo, Outcome 9 Functioning 2 specific: role functioning, average total score, medium‐term (at 12 months), GFR (higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Group A: omega‐3 fatty acids vs placebo, Outcome 10 Functioning 3a specific: social functioning, average total score, medium‐term (at 12 months), GFS (higher score = better)." data-id="CD012236-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Group A: omega‐3 fatty acids vs placebo, Outcome 10 Functioning 3a specific: social functioning, average total score, medium‐term (at 12 months), GFS (higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Group A: omega‐3 fatty acids vs placebo, Outcome 11 Functioning 3b specific: social functioning, average total score, medium‐term (at 12 months), SOFAS (higher score = better)." data-id="CD012236-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Group A: omega‐3 fatty acids vs placebo, Outcome 11 Functioning 3b specific: social functioning, average total score, medium‐term (at 12 months), SOFAS (higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Group A: omega‐3 fatty acids vs placebo, Outcome 12 Adverse effects, specific: medium‐term (by 12 months), UKU checklist." data-id="CD012236-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Group A: omega‐3 fatty acids vs placebo, Outcome 12 Adverse effects, specific: medium‐term (by 12 months), UKU checklist. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Group A: omega‐3 fatty acids vs placebo, Outcome 13 Satisfaction with treatment: leaving the study early." data-id="CD012236-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Group A: omega‐3 fatty acids vs placebo, Outcome 13 Satisfaction with treatment: leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0027"> <p> <div class="table" id="CD012236-tblf-0007"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Note</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Psychotic symptoms: positive (endpoint score) PANSS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LIPS‐Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amisulpiride + Needs focused interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LIPS‐Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Needs focused interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Psychotic symptoms: negative (endpoint score) PANSS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LIPS‐Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amisulpiride + Needs focused interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LIPS‐Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Needs focused interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Psychotic symptoms: general (endpoint score) PANSS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LIPS‐Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amisulpiride + Needs focused interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LIPS‐Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Needs focused interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Depression (endpoint score) MADRS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LIPS‐Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amisulpiride + Needs focused interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LIPS‐Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Needs focused interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs‐focused intervention (NFI) vs NFI, Outcome 1 Mental state, specific: average endpoint scores, short‐term (at 12 weeks), various scales (higher score = worse), skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0027">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012236-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs‐focused intervention (NFI) vs NFI, Outcome 2 Functioning, global: average endpoint score, short‐term (at 12 weeks), GAF (higher score = better)." data-id="CD012236-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs‐focused intervention (NFI) vs NFI, Outcome 2 Functioning, global: average endpoint score, short‐term (at 12 weeks), GAF (higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs‐focused intervention (NFI) vs NFI, Outcome 3 Adverse effects 1a specific: akathisia, short‐term (at 12 weeks), ESRS." data-id="CD012236-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs‐focused intervention (NFI) vs NFI, Outcome 3 Adverse effects 1a specific: akathisia, short‐term (at 12 weeks), ESRS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0030"> <p> <div class="table" id="CD012236-tblf-0008"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Note</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LIPS‐Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amisulpiride + Needs focused interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LIPS‐Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Needs focused interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs‐focused intervention (NFI) vs NFI, Outcome 4 Adverse effects 1b specific: akathisia (average endpoint score), short‐term (at 12 weeks), ESRS (higher score = worse), skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0030">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012236-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs‐focused intervention (NFI) vs NFI, Outcome 5 Adverse effects 2 specific: increased prolactin levels, short‐term (at 12 weeks)." data-id="CD012236-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs‐focused intervention (NFI) vs NFI, Outcome 5 Adverse effects 2 specific: increased prolactin levels, short‐term (at 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs‐focused intervention (NFI) vs NFI, Outcome 6 Adverse effects 3 specific: severity of at least moderate and a frequency of at least 5%, short‐term (at 12 weeks), UKU." data-id="CD012236-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs‐focused intervention (NFI) vs NFI, Outcome 6 Adverse effects 3 specific: severity of at least moderate and a frequency of at least 5%, short‐term (at 12 weeks), UKU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs‐focused intervention (NFI) vs NFI, Outcome 7 Adverse effects 4 specific: suicidal thoughts." data-id="CD012236-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs‐focused intervention (NFI) vs NFI, Outcome 7 Adverse effects 4 specific: suicidal thoughts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs‐focused intervention (NFI) vs NFI, Outcome 8 Satisfaction with treatment: leaving the study early, end point data." data-id="CD012236-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs‐focused intervention (NFI) vs NFI, Outcome 8 Satisfaction with treatment: leaving the study early, end point data. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 1 Prodromal symptoms: transition to psychosis, endpoint data, medium‐term (by 12 months)." data-id="CD012236-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 1 Prodromal symptoms: transition to psychosis, endpoint data, medium‐term (by 12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 2 Global state, global: illness severity, average total score, medium‐term (at 12 months), CGI (higher score = worse)." data-id="CD012236-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 2 Global state, global: illness severity, average total score, medium‐term (at 12 months), CGI (higher score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0037"> <p> <div class="table" id="CD012236-tblf-0009"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Note</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Psychosis risk symptoms: total, average total change score, SOPS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Psychosis risk symptoms: positive, average total change score, SOPS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Psychosis risk symptoms: negative, average total change score, SOPS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Psychosis risk symptoms: disorganisation, average total change score, SOPS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Psychosis risk symptoms: general, average total change score, SOPS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Psychosis risk symptoms: total, average total change score, PANSS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Psychotic symptoms: positive, average total change score, PANSS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Psychotic symptoms: negative, average total change score, PANSS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Psychotic symptoms: general, average total change score, PANSS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Depression: average total change score, MADRS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Mania: average total change score, YMS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 3 Mental state specific: average total scores, medium‐term (at 12 months), various scales (higher score = worse), skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0037">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012236-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 4 Functioning, global: average total score, medium‐term (at 12 months), GAF (higher score = better)." data-id="CD012236-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 4 Functioning, global: average total score, medium‐term (at 12 months), GAF (higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0039"> <p> <div class="table" id="CD012236-tblf-0010"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Note</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Extrapyramidal symptoms: average total change score, Simpson‐Angus scale</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Akathisia: average total change score, Barnes akathisia scale</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Abnormal involuntary movements: average total change score, AIMS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIME‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + Supportive intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 5 Adverse effects 1 specific: average total score, short‐term (at 8 weeks), various scales (higher score = worse), skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0039">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012236-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 6 Adverse effects 2a specific: cardiovascular, average total change score, short‐term (at 8 weeks), blood pressure and pulse rate (higher score = worse)." data-id="CD012236-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 6 Adverse effects 2a specific: cardiovascular, average total change score, short‐term (at 8 weeks), blood pressure and pulse rate (higher score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 7 Adverse effects 2b specific: cardiovascular, average total score, medium‐term (at 12 months), pulse rate (higher score = worse)." data-id="CD012236-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 7 Adverse effects 2b specific: cardiovascular, average total score, medium‐term (at 12 months), pulse rate (higher score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 8 Adverse effects 3 specific: treatment‐emergent adverse effects, short‐term (at 8 weeks)." data-id="CD012236-fig-0042" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 8 Adverse effects 3 specific: treatment‐emergent adverse effects, short‐term (at 8 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 9 Adverse effects 4a specific: weight, average total weight change, kg gained (higher scores = worse)." data-id="CD012236-fig-0043" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 9 Adverse effects 4a specific: weight, average total weight change, kg gained (higher scores = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 10 Adverse effects 4b specific: weight gain, medium‐term (at 12 months)." data-id="CD012236-fig-0044" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 10 Adverse effects 4b specific: weight gain, medium‐term (at 12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-004-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-004-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 11 Adverse effects 5 specific: fatigue, medium‐term (at 12 months)." data-id="CD012236-fig-0045" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-004-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 11 Adverse effects 5 specific: fatigue, medium‐term (at 12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-004-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-004-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-004-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 12 Satisfaction with treatment: leaving the study early, endpoint data, medium‐term (by 12 months)." data-id="CD012236-fig-0046" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-004-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 12 Satisfaction with treatment: leaving the study early, endpoint data, medium‐term (by 12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-004-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 1 Prodromal symptoms: transition to psychosis." data-id="CD012236-fig-0047" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 1 Prodromal symptoms: transition to psychosis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 2 Global state specific: personal beliefs, average scores, long‐term (at 18 months), PBIQ‐ R (higher score = worse)." data-id="CD012236-fig-0048" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 2 Global state specific: personal beliefs, average scores, long‐term (at 18 months), PBIQ‐ R (higher score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 3 Mental state 1 specific: social anxiety, average total score, long‐term (at 18 months), SAS (higher score = worse)." data-id="CD012236-fig-0049" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 3 Mental state 1 specific: social anxiety, average total score, long‐term (at 18 months), SAS (higher score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0050"> <p> <div class="table" id="CD012236-tblf-0011"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Note</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Psychotic symptoms: total, average total score, medium‐term (at 12 months), PANSS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EIPS‐Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBT + Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EIPS‐Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Depression, average total score, medium‐term (at 12 months), BDI‐PC</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐2‐UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBT + Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐2‐UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Depression, average total score, medium‐term (at 12 months), MADRS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EIPS‐Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBT + Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EIPS‐Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Depression, average total score, long‐term (at 18 months), BDI‐II</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐NL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBT + Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐NL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Depression, average total score, long‐term (at 18 months), CDSS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADAPT‐Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBT + Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADAPT‐Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐NL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBT + Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐NL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Psychotic symptoms: positive, average total score, medium‐term (at 12 months), PANSS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EIPS‐Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBT + Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EIPS‐Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Psychotic symptoms: negative, average total score, medium‐term (at 12 months), PANSS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EIPS‐Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBT + Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EIPS‐Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Psychosis risk symptoms: positive, average total score, long‐term (at 18 months), SOPS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADAPT‐Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBT + Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADAPT‐Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Psychosis risk symptoms: negative, average total score, long‐term (at 18 months), SOPS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADAPT‐Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBT + Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADAPT‐Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Social interaction and anxiety: average total score, medium‐term (at 12 months), SIAS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐2‐UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBT + Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐2‐UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Social interaction and anxiety: average total score, long‐term (at 18 months), SIAS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADAPT‐Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBT + Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADAPT‐Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐NL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBT + Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐NL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 4 Mental state 2 specific: average scores, various scales, higher score = worse, skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0050">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012236-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 5 Functioning 1 global: average total score, GAF, (higher score = better)." data-id="CD012236-fig-0051" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 5 Functioning 1 global: average total score, GAF, (higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 6 Functioning 2.a specific: social functioning, average total score, medium‐term (at 12 months), SAS II (higher score = worse)." data-id="CD012236-fig-0052" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 6 Functioning 2.a specific: social functioning, average total score, medium‐term (at 12 months), SAS II (higher score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 7 Functioning 2.b.i. specific: social functioning, average total score, long‐term (at 18 months), SFS (higher score = better)." data-id="CD012236-fig-0053" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 7 Functioning 2.b.i. specific: social functioning, average total score, long‐term (at 18 months), SFS (higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 8 Functioning 2.b.ii. specific: social functioning, average total score, medium‐term (at 18 months), SOFAS (higher score = better)." data-id="CD012236-fig-0054" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 8 Functioning 2.b.ii. specific: social functioning, average total score, medium‐term (at 18 months), SOFAS (higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-005-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-005-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 9 Quality of life: average total score, long‐term (at 18 months), MANSA (higher score = better)." data-id="CD012236-fig-0055" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-005-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 9 Quality of life: average total score, long‐term (at 18 months), MANSA (higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-005-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0056"> <p> <div class="table" id="CD012236-tblf-0012"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Antipsychotic medication: 0‐18 months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐NL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBT + supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐NL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Antipsychotic medication: by 4 years</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐NL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBT + supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐NL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>111.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Productivity costs: 0‐18 months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐NL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBT + supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐27.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3936.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐NL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐843.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3947.99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Service use: 0‐18 months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐NL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBT + supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5829.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10093.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐NL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9505.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16187.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Service use: by 4 years</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐NL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBT + supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16506.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24362.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐NL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24452.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40552.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Travel: 0‐18 months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐NL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBT + supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>179.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>163.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐NL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>185.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>244.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Travel: by 4 years</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐NL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBT + supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>312.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>265.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐NL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>397.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>411.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Total: 0‐18 months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐NL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBT + supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8007.44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11225.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐NL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8851.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17179.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Total: by 4 years</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐NL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBT + supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19121.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24507.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EDIE‐NL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24898.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40936.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 10 Cost: cumulative, USD, skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0056">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012236-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-005-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-005-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 11 Satisfaction with treatment: leaving the study early, end point data." data-id="CD012236-fig-0057" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-005-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 11 Satisfaction with treatment: leaving the study early, end point data. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-005-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 1 Prodromal symptoms: transition to psychosis, end point data." data-id="CD012236-fig-0058" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 1 Prodromal symptoms: transition to psychosis, end point data. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0059"> <p> <div class="table" id="CD012236-tblf-0013"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Note</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Psychopathology: total, end point data, BPRS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yung‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone + CBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yung‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + CBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Negative symptoms: attention, end point data, SANS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yung‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone + CBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yung‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + CBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Negative symptoms: total, end point data, SANS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yung‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone + CBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yung‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + CBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 2 Mental state specific: average end point scores, medium‐term (at 12 months), various scales (higher score = worse), skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0059">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012236-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 3 Functioning global: average end point score, medium‐term (at 12 months), GAF (higher score = better)." data-id="CD012236-fig-0060" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 3 Functioning global: average end point score, medium‐term (at 12 months), GAF (higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 4 Adverse effects 1 specific: doctors' assessment of adverse effects, medium‐term (at 12 months), UKU." data-id="CD012236-fig-0061" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 4 Adverse effects 1 specific: doctors' assessment of adverse effects, medium‐term (at 12 months), UKU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 5 Adverse effects 2 specific: adverse effects reported by participants, medium‐term (at 12 months), UKU." data-id="CD012236-fig-0062" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 5 Adverse effects 2 specific: adverse effects reported by participants, medium‐term (at 12 months), UKU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 6 Quality of life: average end point score, medium‐term (at 12 months), QLS (higher score = better)." data-id="CD012236-fig-0063" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 6 Quality of life: average end point score, medium‐term (at 12 months), QLS (higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 7 Satisfaction with treatment: leaving the study early, end point data." data-id="CD012236-fig-0064" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 7 Satisfaction with treatment: leaving the study early, end point data. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Group B: cognitive behavioural therapy (CBT), CBT (specific preventive intervention (SPI) + needs‐based intervention (NBI) + risperidone vs NBI, Outcome 1 Prodromal symptoms: transition to psychosis, end point data." data-id="CD012236-fig-0065" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Group B: cognitive behavioural therapy (CBT), CBT (specific preventive intervention (SPI) + needs‐based intervention (NBI) + risperidone vs NBI, Outcome 1 Prodromal symptoms: transition to psychosis, end point data. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0066"> <p> <div class="table" id="CD012236-tblf-0014"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Anxiety: immediately post‐treatment, HRSA</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Specific treatment intervention (SPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Needs‐based intervention (NBI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Anxiety: medium‐term (at 12 months), HRSA</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Specific treatment intervention (SPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Needs‐based intervention (NBI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Anxiety: long‐term (at 4 years), HRSA</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Specific treatment intervention (SPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Needs‐based intervention (NBI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Depression: immediately post‐treatment, HRSD</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Specific treatment intervention (SPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Needs‐based intervention (NBI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Depression: medium‐term (at 12 months), HRSD</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Specific treatment intervention (SPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Needs‐based intervention (NBI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Depression: long‐term (at 4 years), HRSD</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Specific treatment intervention (SPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Needs‐based intervention (NBI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Mania: immediately post‐treatment, YMS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Specific treatment intervention (SPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Needs‐based intervention (NBI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Mania: medium‐term (at 12 months), YMS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Specific treatment intervention (SPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Needs‐based intervention (NBI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Mania: long‐term (at 4 years), YMS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Specific treatment intervention (SPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Needs‐based intervention (NBI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Negative symptoms: immediately post‐treatment, SANS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Specific treatment intervention (SPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Needs‐based intervention (NBI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Negative symptoms: medium‐term (at 12 months), SANS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Specific treatment intervention (SPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Needs‐based intervention (NBI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Negative symptoms: long‐term (at 4 years), SANS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Specific treatment intervention (SPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Needs‐based intervention (NBI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Psychopathology: total, immediately post‐treatment, BPRS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Specific treatment intervention (SPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Needs‐based intervention (NBI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Psychopathology: total, medium‐term (at 12 months), BPRS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Specific treatment intervention (SPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Needs‐based intervention (NBI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Psychopathology: total, long‐term (at 4 years), BPRS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Specific treatment intervention (SPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Needs‐based intervention (NBI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Group B: cognitive behavioural therapy (CBT), CBT (specific preventive intervention (SPI) + needs‐based intervention (NBI) + risperidone vs NBI, Outcome 2 Mental state specific: average end point scores, various scales (high score = worse), skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0066">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012236-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Group B: cognitive behavioural therapy (CBT), CBT (specific preventive intervention (SPI) + needs‐based intervention (NBI) + risperidone vs NBI, Outcome 3 Functioning global: average end point score, GAF (higher score = better)." data-id="CD012236-fig-0067" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Group B: cognitive behavioural therapy (CBT), CBT (specific preventive intervention (SPI) + needs‐based intervention (NBI) + risperidone vs NBI, Outcome 3 Functioning global: average end point score, GAF (higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Group B: cognitive behavioural therapy (CBT), CBT (specific preventive intervention (SPI) + needs‐based intervention (NBI) + risperidone vs NBI, Outcome 4 Quality of life: average end point score, QLS (higher score = better)." data-id="CD012236-fig-0068" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Group B: cognitive behavioural therapy (CBT), CBT (specific preventive intervention (SPI) + needs‐based intervention (NBI) + risperidone vs NBI, Outcome 4 Quality of life: average end point score, QLS (higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0069"> <p> <div class="table" id="CD012236-tblf-0015"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Inpatient costs: post‐treatment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>367.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1109.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1235.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3477.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Inpatient costs: medium‐term (at 12 months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>272.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>977.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>226.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>847.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Inpatient costs: long‐term (at 36 months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>757.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3078.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>866.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2353.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Outpatient costs: post‐treatment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2584.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2522.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1084.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>940.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Outpatient costs: medium‐term (at 12 months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1328.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1795.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1039.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1384.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Pharmacology costs: post‐treatment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>223.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>235.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Outpatient costs: long‐term (at 36 months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4101.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8334.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10423.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25277.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Pharmacology costs: medium‐term (at 12 months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Pharmacology costs: long‐term (at 36 months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>588.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1011.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>446.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>883.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Total costs: post‐treatment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3087.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2926.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2487.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3754.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Total costs: medium‐term (at 12 months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1800.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2234.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1428.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2330.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Total costs: long‐term (at 36 months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5667.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11432.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACE‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11613.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27120.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Group B: cognitive behavioural therapy (CBT), CBT (specific preventive intervention (SPI) + needs‐based intervention (NBI) + risperidone vs NBI, Outcome 5 Cost: average cost of treatment, AUD, skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0069">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012236-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-007-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-007-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Group B: cognitive behavioural therapy (CBT), CBT (specific preventive intervention (SPI) + needs‐based intervention (NBI) + risperidone vs NBI, Outcome 6 Satisfaction with treatment: leaving the study early." data-id="CD012236-fig-0070" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-007-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7 Group B: cognitive behavioural therapy (CBT), CBT (specific preventive intervention (SPI) + needs‐based intervention (NBI) + risperidone vs NBI, Outcome 6 Satisfaction with treatment: leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-007-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 1 Prodromal symptoms: transition to psychosis, end point data." data-id="CD012236-fig-0071" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 1 Prodromal symptoms: transition to psychosis, end point data. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0072"> <p> <div class="table" id="CD012236-tblf-0016"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Note</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Psychopathology: total, end point data, BPRS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yung‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + CBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yung‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Negative symptoms: attention, end‐point data, SANS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yung‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + CBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yung‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Negative symptoms: total, end point data, SANS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yung‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + CBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yung‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 2 Mental state specific: average end point scores, medium‐term (at 12 months), various scales (higher score = worse), skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0072">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012236-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 3 Functioning global: average end point scores, medium‐term (at 12 months), GAF (higher score = better)." data-id="CD012236-fig-0073" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 3 Functioning global: average end point scores, medium‐term (at 12 months), GAF (higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 4 Adverse effects 1 specific: doctors' assessment of adverse effects, medium‐term (at 12 months), UKU." data-id="CD012236-fig-0074" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 4 Adverse effects 1 specific: doctors' assessment of adverse effects, medium‐term (at 12 months), UKU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 5 Adverse effects 2 specific: adverse effects reported by participants, medium‐term (at 12 months), UKU." data-id="CD012236-fig-0075" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 5 Adverse effects 2 specific: adverse effects reported by participants, medium‐term (at 12 months), UKU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-008-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-008-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 6 Quality of life: average end point scores, medium‐term (at 12 months), QLS (higher score = better)." data-id="CD012236-fig-0076" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-008-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 6 Quality of life: average end point scores, medium‐term (at 12 months), QLS (higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-008-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-008-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-008-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 7 Satisfaction with treatment: leaving the study early, end point data." data-id="CD012236-fig-0077" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-008-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 7 Satisfaction with treatment: leaving the study early, end point data. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-008-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Group C: cognitive behavioural therapy (CBT), CBT + supportive intervention vs non‐directive reflective listening + supportive intervention, Outcome 1 Prodromal symptoms: transition to psychosis, end point data." data-id="CD012236-fig-0078" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Group C: cognitive behavioural therapy (CBT), CBT + supportive intervention vs non‐directive reflective listening + supportive intervention, Outcome 1 Prodromal symptoms: transition to psychosis, end point data. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Group C: cognitive behavioural therapy (CBT), CBT + supportive intervention vs non‐directive reflective listening + supportive intervention, Outcome 2 Functioning 1 global: average total score, short‐term (at 6 months), GAF (higher score = better)." data-id="CD012236-fig-0079" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Group C: cognitive behavioural therapy (CBT), CBT + supportive intervention vs non‐directive reflective listening + supportive intervention, Outcome 2 Functioning 1 global: average total score, short‐term (at 6 months), GAF (higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-009-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-009-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Group C: cognitive behavioural therapy (CBT), CBT + supportive intervention vs non‐directive reflective listening + supportive intervention, Outcome 3 Functioning 2 specific: social functioning, average total score, short‐term (at 6 months), SOFAS (higher score = better)." data-id="CD012236-fig-0080" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-009-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 Group C: cognitive behavioural therapy (CBT), CBT + supportive intervention vs non‐directive reflective listening + supportive intervention, Outcome 3 Functioning 2 specific: social functioning, average total score, short‐term (at 6 months), SOFAS (higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-009-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-009-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-009-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Group C: cognitive behavioural therapy (CBT), CBT + supportive intervention vs non‐directive reflective listening + supportive intervention, Outcome 4 Satisfaction with treatment: leaving the study early, end point data." data-id="CD012236-fig-0081" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-009-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9 Group C: cognitive behavioural therapy (CBT), CBT + supportive intervention vs non‐directive reflective listening + supportive intervention, Outcome 4 Satisfaction with treatment: leaving the study early, end point data. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-009-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 1 Prodromal symptoms: transition to psychosis, end point data." data-id="CD012236-fig-0082" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 1 Prodromal symptoms: transition to psychosis, end point data. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0083"> <p> <div class="table" id="CD012236-tblf-0017"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Note</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Psychopathology: total, end point data, BPRS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yung‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone + CBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yung‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Negative symptoms: attention, end point data, SANS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yung‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone + CBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yung‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Negative symptoms: total, end point data, SANS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yung‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone + CBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yung‐Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo + Supportive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 2 Mental state specific: average end point scores, medium‐term (at 12 months), various scales (higher score = worse), skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0083">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012236-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 3 Functioning global: average end point score, medium‐term (at 12 months), GAF (higher score = better)." data-id="CD012236-fig-0084" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 3 Functioning global: average end point score, medium‐term (at 12 months), GAF (higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-010-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-010-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 4 Adverse effects 1 specific: doctors' assessment of adverse effects, medium‐term (at 12 months), UKU." data-id="CD012236-fig-0085" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-010-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 4 Adverse effects 1 specific: doctors' assessment of adverse effects, medium‐term (at 12 months), UKU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-010-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-010-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-010-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 5 Adverse effects 2 specific: adverse effects reported by participants, medium‐term (at 12 months), UKU." data-id="CD012236-fig-0086" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-010-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 5 Adverse effects 2 specific: adverse effects reported by participants, medium‐term (at 12 months), UKU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-010-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-010-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-010-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 6 Quality of life: average end point scores, medium‐term (at 12 months), QLS (higher score = better)." data-id="CD012236-fig-0087" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-010-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.6</div> <div class="figure-caption"> <p>Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 6 Quality of life: average end point scores, medium‐term (at 12 months), QLS (higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-010-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-010-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-010-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 7 Satisfaction with treatment: leaving the study early, end point data." data-id="CD012236-fig-0088" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-010-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.7</div> <div class="figure-caption"> <p>Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 7 Satisfaction with treatment: leaving the study early, end point data. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-010-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0089"> <p> <div class="table" id="CD012236-tblf-0018"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Note</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Psychosis risk symptoms: total, average total score, long‐term (at 24 months), SOPS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vinogradov‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognitive training</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vinogradov‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tablet games</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Psychosis risk symptoms: negative, average total score, long‐term (at 24 months), SOPS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vinogradov‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognitive training</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vinogradov‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tablet games</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Psychosis risk symptoms: disorganised, average total score, long‐term (at 24 months), SOPS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vinogradov‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognitive training</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vinogradov‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tablet games</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Psychosis risk symptoms: general, average total score, long‐term (at 24 months), SOPS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vinogradov‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognitive training</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vinogradov‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tablet games</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Social anxiety: fear of negative evaluation, average end point score, short‐term (at 4 months), SAS‐A</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Choi‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognitive training</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Choi‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tablet games</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Social anxiety: avoidance/distress in new situations, average end point score, short‐term (at 4 months), SAS‐A</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Choi‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognitive training</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Choi‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tablet games</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Social anxiety: social avoidance and distress, average end point score, short‐term (at 4 months), SAS‐A</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Choi‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognitive training</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Choi‐USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tablet games</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 1 Mental state 1 specific: average total scores, various scales (higher score = worse), skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0089">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012236-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 2 Mental state 2 specific: depression, average end point score, short‐term (at 4 months), BDI‐II (higher score = worse)." data-id="CD012236-fig-0090" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 2 Mental state 2 specific: depression, average end point score, short‐term (at 4 months), BDI‐II (higher score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-011-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-011-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 3 Mental state 3.a specific: cognitive, average end point score, short‐term (at 4 months)." data-id="CD012236-fig-0091" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-011-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 3 Mental state 3.a specific: cognitive, average end point score, short‐term (at 4 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-011-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-011-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-011-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 4 Mental state 3.b specific: cognitive, average total score (presented as LSM = least square means estimated by the generalised linear mixed models), short‐term (at 3 months), MATRICS, higher score = better)." data-id="CD012236-fig-0092" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-011-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 4 Mental state 3.b specific: cognitive, average total score (presented as LSM = least square means estimated by the generalised linear mixed models), short‐term (at 3 months), MATRICS, higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-011-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-011-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-011-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 5 Functioning 1 global: average total score, long‐term (at 24 months), GAF (higher score = better)." data-id="CD012236-fig-0093" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-011-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 5 Functioning 1 global: average total score, long‐term (at 24 months), GAF (higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-011-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-011-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-011-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 6 Functioning 2 specific: role functioning, GFR (higher score = better)." data-id="CD012236-fig-0094" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-011-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.6</div> <div class="figure-caption"> <p>Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 6 Functioning 2 specific: role functioning, GFR (higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-011-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-011-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-011-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 7 Functioning 3.a specific: social functioning, GFS (higher score = better)." data-id="CD012236-fig-0095" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-011-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.7</div> <div class="figure-caption"> <p>Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 7 Functioning 3.a specific: social functioning, GFS (higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-011-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-011-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-011-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 8 Functioning 3.b specific: social functioning, average end point score, short‐term (at 4 months), SAS‐SR (higher score = worse)." data-id="CD012236-fig-0096" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-011-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.8</div> <div class="figure-caption"> <p>Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 8 Functioning 3.b specific: social functioning, average end point score, short‐term (at 4 months), SAS‐SR (higher score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-011-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-011-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-011-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 9 Satisfaction with treatment: leaving the study early, end point data." data-id="CD012236-fig-0097" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-011-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.9</div> <div class="figure-caption"> <p>Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 9 Satisfaction with treatment: leaving the study early, end point data. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-011-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 1 Prodromal symptoms: transition to psychosis." data-id="CD012236-fig-0098" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 1 Prodromal symptoms: transition to psychosis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-012-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-012-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 2 Global state: antipsychotic prescription, short‐term (by 6 months)." data-id="CD012236-fig-0099" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-012-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 2 Global state: antipsychotic prescription, short‐term (by 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-012-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-012-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-012-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 3 Mental state specific: psychosis risk positive symptoms, average total score, short‐term (at 6 months), SOPS positive (higher score = worse)." data-id="CD012236-fig-0100" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-012-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 3 Mental state specific: psychosis risk positive symptoms, average total score, short‐term (at 6 months), SOPS positive (higher score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-012-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-012-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-012-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 4 Functioning global: average total score, long‐term (at 24 months), GAF (higher score = better)." data-id="CD012236-fig-0101" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-012-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 4 Functioning global: average total score, long‐term (at 24 months), GAF (higher score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-012-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-012-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-012-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 5 Adverse events 1.a specific: suicide, long‐term (by 24 months), events." data-id="CD012236-fig-0102" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-012-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.5</div> <div class="figure-caption"> <p>Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 5 Adverse events 1.a specific: suicide, long‐term (by 24 months), events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-012-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-012-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-012-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 6 Adverse events 1.b specific: suicide, long‐term (by 24 months), participants affected/at risk." data-id="CD012236-fig-0103" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-012-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.6</div> <div class="figure-caption"> <p>Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 6 Adverse events 1.b specific: suicide, long‐term (by 24 months), participants affected/at risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-012-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-012-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-012-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 7 Satisfaction with treatment: leaving the study early." data-id="CD012236-fig-0104" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-012-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.7</div> <div class="figure-caption"> <p>Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 7 Satisfaction with treatment: leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-012-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-013-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-013-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Group C: other, integrated treatment vs standard treatment, Outcome 1 Prodromal symptoms: transition to psychosis, end point data, long‐term (by 2 years)." data-id="CD012236-fig-0105" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-013-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 Group C: other, integrated treatment vs standard treatment, Outcome 1 Prodromal symptoms: transition to psychosis, end point data, long‐term (by 2 years). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-013-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012236-fig-0106"> <p> <div class="table" id="CD012236-tblf-0019"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Note</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Negative symptoms: total average score, SANS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nordentoft‐Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Integrated treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nordentoft‐Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13 Group C: other, integrated treatment vs standard treatment, Outcome 2 Mental state specific: average total score, long‐term (at 2 years), various scales (higher score = worse), skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0106">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012236-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/urn:x-wiley:14651858:media:CD012236:CD012236-CMP-013-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_t/tCD012236-CMP-013-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Group C: other, integrated treatment vs standard treatment, Outcome 3 Satisfaction with treatment: leaving the study early, end point data." data-id="CD012236-fig-0107" src="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-013-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13 Group C: other, integrated treatment vs standard treatment, Outcome 3 Satisfaction with treatment: leaving the study early, end point data. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/media/CDSR/CD012236/image_n/nCD012236-CMP-013-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD012236-tbl-0015"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Suggested design for new study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised</p> <p>Blinding: double‐blind (participants and study team, treatment provider, investigator, outcomes assessor) </p> <p>Duration: &gt; 6 months of intervention period + &gt; 12 months' follow‐up period</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: ultra high risk sample</p> <p>N = 300*</p> <p>Sex: men and women</p> <p>Age: 14‐30 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stage 1</p> <p>1. Low‐dose antipsychotic + treatment as usual</p> <p>2. Treatment as usual: psychosocial programme available in the setting</p> <p>Stage 2</p> <p>Comparison of different components of the psychosocial programme (compared components should follow similar rules in the duration, frequency and number of sessions) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prodromal symptoms: transition to psychosis</p> <p>Global state: clinically important change in global state</p> <p>Mental state: clinically important change in mental state</p> <p>Functioning: clinically important change in functioning</p> <p>Adverse effects: at least one serious adverse event</p> <p>Quality of life: important change in quality of life</p> <p>Satisfaction with treatment: leaving the study early</p> <p>Economics: cost of care</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*Sample size suggested because at around 300 participants power to detect a difference in groups of 15% becomes realistic. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Suggested design for new study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012236-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Group A: amino acids compared to placebo for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Amino acids compared to placebo for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> amino acids<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with amino acids</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Prodromal symptoms: transition to psychosis</b> </p> <p>Endpoint data (events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.48<br/> (0.08 to 2.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>52<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>107 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>51 per 1000<br/> (9 to 319) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global state: clinically important change in global state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: psychosis risk symptoms</b> </p> <p>Average total score (SOPS total score; higher score = worse, scale from: 0‐114)</p> <p>Short‐term<br/> Follow‐up: 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychosis risk symptoms was 42.0 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 10 points lower<br/> (22.38 lower to 2.38 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for our predefined outcome of interest 'Clinically important change in mental state' were not reported by the studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: suicidal thoughts</b> </p> <p>Short‐term (events)<br/> Follow‐up: by 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.57<br/> (0.15 to 83.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>44<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life: clinically important change in quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>Endpoint data (events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/> (0.55 to 1.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>52<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>464 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>446 per 1000<br/> (255 to 785) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SOPS:</b> Scale of Psychotic Symptoms </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, high attrition, blinding of outcome assessors not described, unclear risk of selective reporting bias.<br/> <sup>2</sup>Imprecision: rated 'very serious'; evidence from two small studies.<br/> <sup>3</sup>Risk of bias: rated 'very serious'; 1 randomisation method not described, allocation concealment method not described, blinding of outcome assessors not described, unclear risk of selective reporting bias.<br/> <sup>4</sup>Imprecision: rated 'very serious'; evidence from one small study.<br/> <sup>5</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, high attrition. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Group A: amino acids compared to placebo for prodromal stage of psychosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012236-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Group A: omega‐3 fatty acids compared to placebo for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Omega‐3 fatty acids compared to placebo for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> omega‐3 fatty acids<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with omega‐3 fatty acids</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Prodromal symptoms: transition to psychosis</b> </p> <p>Long‐term (events)<br/> Follow‐up: 7 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.24<br/> (0.09 to 0.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>81<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>96 per 1000<br/> (36 to 268) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Global state: antipsychotic prescription</b> </p> <p>Long‐term (events)<br/> Follow‐up: 7 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.54<br/> (0.30 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>69<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>543 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>293 per 1000<br/> (163 to 537) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: psychotic symptoms</b> </p> <p>Average total score (PANSS, higher score = worse, scale from 30‐210)</p> <p>Long‐term (up to 7 years)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychotic symptoms was 57.4 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 11.40 points lower<br/> (20.55 lower to 2.25 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for our predefined outcome of interest 'Clinically important change in mental state' were not reported by the studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: neurological, extrapyramidal</b> </p> <p>UKU (events)</p> <p>Medium‐term<br/> Follow‐up: by 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.57<br/> (0.94 to 7.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>304<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000<br/> (31 to 232) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life: clinically important change in quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>Long‐term (events)<br/> Follow‐up: 7 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.46<br/> (0.45 to 4.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>81<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>146 per 1000<br/> (45 to 480) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>PANSS:</b> Positive and Negative Syndrome Scale; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>UKU:</b> Udvalg for Kliniske Undersøgelser Adverse Effects Scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Imprecision: rated 'very serious'; evidence from one small study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Group A: omega‐3 fatty acids compared to placebo for prodromal stage of psychosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012236-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Group B antipsychotic drugs: amisulpiride + needs‐focused intervention compared to needs‐focused intervention for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Amisulpiride + needs‐focused intervention compared to needs‐focused intervention for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> amisulpiride + needs‐focused intervention (NFI)<br/> <b>Comparison:</b> needs‐focused intervention (NFI) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with NFI</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with amisulpiride + NFI</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Prodromal symptoms: transition to psychosis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global state: clinically important change in global state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mental state: clinically important change in mental state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: suicidal thoughts</b> </p> <p>(events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.25<br/> (0.01 to 6.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>102<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/> (0 to 127) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life: clinically important change in quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>Endpoint data (events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.59<br/> (0.38 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>124<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>492 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>290 per 1000<br/> (187 to 462) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>NFI:</b> needs‐focused intervention; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, participants not blinded, outcome assessors not blinded, high attrition, unclear risk of selective reporting bias.<br/> <sup>2</sup>Imprecision: rated 'very serious'; evidence from one small study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Group B antipsychotic drugs: amisulpiride + needs‐focused intervention compared to needs‐focused intervention for prodromal stage of psychosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012236-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Group B antipsychotic drugs: olanzapine + supportive intervention compared to placebo + supportive intervention for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Olanzapine + supportive intervention compared to placebo + supportive intervention for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> olanzapine + supportive intervention<br/> <b>Comparison:</b> placebo + supportive intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo + supportive intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with olanzapine + supportive intervention</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Prodromal symptoms: transition to psychosis</b> </p> <p>Endpoint data, (events)</p> <p>Medium‐term<br/> Follow‐up: by 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.58<br/> (0.28 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>448 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>260 per 1000<br/> (126 to 529) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: global illness severity</b> </p> <p>Average total score, CGI (higher score = worse, scale from: 2‐14)</p> <p>Medium‐term<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean global state: global illness severity was 3.86 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.23 points lower<br/> (0.82 lower to 0.36 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: psychosis risk symptoms</b> </p> <p>SOPS total (higher score = worse, scale from: 0‐114)<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychosis risk symptoms was 36.56 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychosis risk symptoms was 33.8</p> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for this outcome were skewed, and therefore we did not present summary estimates</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: average weight gain change</b> </p> <p>kg gained (higher scores = worse)</p> <p>Medium‐term<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean adverse effects: average weight gain change was 0.32 kg</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 8.49 kg higher<br/> (4.90 higher to 12.08 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life: clinically important change in quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>Endpoint data (events)<br/> Medium‐term </p> <p>Follow‐up: by 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.59<br/> (0.88 to 2.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>345 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>548 per 1000<br/> (303 to 993) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CGI:</b> Clinical Global Impression‐Severity of Illness Scale; <b>CI:</b> Confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio; <b>SOPS:</b> Scale of Prodromal Symptoms </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, high attrition, unclear risk of selective reporting bias.<br/> <sup>2</sup>Imprecision: rated 'very serious'; evidence from one small study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Group B antipsychotic drugs: olanzapine + supportive intervention compared to placebo + supportive intervention for prodromal stage of psychosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012236-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Group B cognitive behavioural therapy: cognitive behavioural therapy + supportive therapy compared to supportive therapy for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cognitive behavioural therapy + supportive therapy compared to supportive therapy for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> cognitive behavioural therapy (CBT) + supportive therapy<br/> <b>Comparison:</b> supportive therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with supportive therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CBT + supportive therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Prodromal symptoms: transition to psychosis</b> </p> <p>Long‐term (events)<br/> Follow‐up: by 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.45<br/> (0.23 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>252<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>195 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88 per 1000<br/> (45 to 174) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global state: clinically important change in global state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state</b> </p> <p>PANSS total (higher score = worse, scale from: 30‐210)<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state was 39.1 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state was 39.4 points</p> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for this outcome were skewed, and therefore we did not present summary estimates</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects: at least one serious adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p>Average total score, MANSA (higher score = better, scale from: 16‐112)</p> <p>Long‐term<br/> Follow‐up: 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life was 55.5 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.50 points higher<br/> (2.93 lower to 5.93 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for clinically important change in quality of life not available.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>Endpoint data (events)</p> <p>Additional follow‐up: by between &gt; 2 years to 4 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/> (0.74 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>261<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>2,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>468 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>450 per 1000<br/> (347 to 581) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CBT:</b> cognitive behavioural therapy; <b>CI:</b> confidence interval; <b>MANSA:</b> Montgomery–Asberg Depression Rating Scale; <b>MD:</b> mean difference; <b>PANSS:</b> Positive and Negative Syndrome Scale; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SOPS:</b> Scale of Prodromal Symptoms </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated 'very serious'; allocation concealment not described, participants not blinded, high attrition, unclear risk of selective reporting bias.<br/> <sup>2</sup>Imprecision: rated 'very serious'; evidence from two small studies.<br/> <sup>3</sup>Risk of bias: rated 'very serious'; allocation concealment not described, participants not blinded, outcome assessors not blinded, high attrition.<br/> <sup>4</sup>Imprecision: rated 'very serious'; evidence from one small study.<br/> <sup>5</sup>Risk of bias: rated 'very serious; allocation concealment not described, participants not blinded, unclear risk of selective reporting bias.<br/> <sup>6</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, participants not blinded, outcome assessors not blinded, high attrition. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Group B cognitive behavioural therapy: cognitive behavioural therapy + supportive therapy compared to supportive therapy for prodromal stage of psychosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012236-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Group B cognitive behavioural therapy: cognitive behavioural therapy + risperidone compared to cognitive behavioural therapy + placebo for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cognitive behavioural therapy + risperidone compared to cognitive behavioural therapy + placebo for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> cognitive behavioural therapy (CBT) + risperidone<br/> <b>Comparison:</b> cognitive behavioural therapy (CBT) + placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CBT + placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CBT + risperidone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Prodromal symptoms: transition to psychosis</b> </p> <p>Endpoint data (events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.02<br/> (0.39 to 2.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>87<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>159 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>162 per 1000<br/> (62 to 425) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global state: clinically important change in global state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: psychopathology</b> </p> <p>Total endpoint data, BPRS (higher score = worse, scale from 0‐126)<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychopathology was 16.5 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychopathology was 14 points</p> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for this outcome were skewed, and therefore we did not present summary estimates</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: specific ‐ doctors' assessment of adverse effects</b> </p> <p>UKU (events)<br/> Medium‐term </p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (0.55 to 1.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>379 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>391 per 1000<br/> (209 to 724) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p>Average endpoint score, QLS (higher score = better, scale from: 0‐126)</p> <p>Medium‐term<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life was 0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 5.70 higher<br/> (7.86 lower to 19.26 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for clinically important change in quality of life were not available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>Endpoint data (events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.09<br/> (0.62 to 1.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>87<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>341 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>372 per 1000<br/> (211 to 655) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>BPRS:</b> Brief Psychiatric Rating Scale; <b>CBT:</b> cognitive behavioural therapy; <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>QLS:</b> Quality of Life Scale; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>UKU:</b> Udvalg for Kliniske Undersøgelser Adverse Effects Scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, high attrition.<br/> <sup>2</sup>Imprecision: rated 'very serious'; evidence from one small study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Group B cognitive behavioural therapy: cognitive behavioural therapy + risperidone compared to cognitive behavioural therapy + placebo for prodromal stage of psychosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012236-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Group B cognitive behavioural therapy: cognitive behavioural therapy (specific preventive intervention) + needs‐based intervention + risperidone compared to needs‐based intervention for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cognitive behavioural therapy (specific preventive intervention) + needs‐based intervention + risperidone compared to needs‐based intervention for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> cognitive behavioural therapy (specific preventive intervention) (CBT(SPI)) + needs‐based intervention (NBI) + risperidone<br/> <b>Comparison:</b> needs‐based intervention (NBI) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with NBI</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CBT(SPI) + NBI + risperidone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Prodromal symptoms: transition to psychosis</b> </p> <p>Endpoint data (events)</p> <p>Long‐term<br/> Follow‐up: up to 4 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.75<br/> (0.39 to 1.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>59<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>429 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>321 per 1000<br/> (167 to 626) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global state: clinically important change in global state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: psychopathology</b> </p> <p>Total endpoint data, BPRS (higher score = worse, scale from: 0‐126)<br/> Follow‐up: 4 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychopathology was 22.47</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychopathology was 26.33</p> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for this outcome were skewed, and therefore we did not present summary estimates</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects: at least one serious adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p>Average endpoint score, QLS (higher score = better, scale from: 0‐126)</p> <p>Long‐term<br/> Follow‐up: up to 4 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life was 80.53 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.03 points lower<br/> (16.90 lower to 12.84 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for clinically important change in quality of life were not available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>(events)</p> <p>Long‐term<br/> Follow‐up: up to 4 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.57<br/> (0.26 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>59<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>393 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>224 per 1000<br/> (102 to 503) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>BPRS:</b> Brief Psychiatric Rating Scale; <b>CBT(SPI):</b> cognitive behavioural therapy (specific preventive intervention); <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>QLS:</b> Quality of Life Scale; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment not described, participants not blinded, outcome assessors not blinded.<br/> <sup>2</sup>Imprecision: rated 'very serious'; evidence from one small study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Group B cognitive behavioural therapy: cognitive behavioural therapy (specific preventive intervention) + needs‐based intervention + risperidone compared to needs‐based intervention for prodromal stage of psychosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012236-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Group C cognitive behavioural therapy: cognitive behavioural therapy + placebo compared to supportive therapy + placebo for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cognitive behavioural therapy + placebo compared to supportive therapy + placebo for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> cognitive behavioural therapy (CBT) + placebo<br/> <b>Comparison:</b> supportive therapy + placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with supportive therapy + placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CBT + placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Prodromal symptoms: transition to psychosis</b> </p> <p>Endpoint data (events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.74<br/> (0.28 to 1.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>72<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>214 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>159 per 1000<br/> (60 to 424) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global state: clinically important change in global state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: psychopathology</b> </p> <p>Total endpoint data, BPRS (higher score = worse, scale from 0‐126)<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychopathology: was 15.3 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychopathology: was 16.5 points</p> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for this outcome were skewed, and therefore we did not present summary estimates</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported data we could use for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: specific ‐ doctors' assessment of adverse effects</b> </p> <p>UKU (events)</p> <p>Medium‐term<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.39<br/> (0.61 to 3.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>51<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>273 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>379 per 1000<br/> (166 to 867) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p>Average endpoint scores, QLS (higher score = better, scale from 0‐126)</p> <p>Medium‐term<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life was 84.4 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 3.30 points lower<br/> (18.76 lower to 12.16 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for clinically important change in quality of life were not available.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>Endpoint data (events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.06<br/> (0.54 to 2.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>72<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>321 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>341 per 1000<br/> (174 to 672) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>BPRS:</b> Brief Psychiatric Rating Scale; <b>CBT:</b> cognitive behavioural therapy; <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>QLS:</b> Quality of Life Scale; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>UKU:</b> Udvalg for Kliniske Undersøgelser Adverse Effects Scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated 'serious'; randomisation process unclear, method of allocation concealment unclear, large attrition of participants.<br/> <sup>2</sup>Imprecision: rated ' very serious'; evidence from one small study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Group C cognitive behavioural therapy: cognitive behavioural therapy + placebo compared to supportive therapy + placebo for prodromal stage of psychosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012236-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Group C cognitive behavioural therapy: cognitive behavioural therapy + supportive intervention compared to non‐directive reflective listening + supportive intervention for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cognitive behavioural therapy + supportive intervention compared to non‐directive reflective listening + supportive intervention for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> cognitive behavioural therapy (CBT) + supportive intervention<br/> <b>Comparison:</b> non‐directive reflective listening (NDRL) + supportive intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with NDRL + supportive intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CBT + supportive intervention</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Prodromal symptoms: transition to psychosis</b> </p> <p>Endpoint data (events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 6.32<br/> (0.34 to 117.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global state: clinically important change in global state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mental state: clinically important change in mental state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects: at least one serious adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life: clinically important change in quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>Endpoint data (events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.35<br/> (0.81 to 2.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>444 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>600 per 1000<br/> (360 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CBT:</b> cognitive behavioural therapy; <b>CI:</b> confidence interval; <b>NDRL:</b> non‐directive reflective listening; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated 'very serious'; allocation concealment method unclear; participants not blinded; high attrition.<br/> <sup>2</sup>Imprecision: rated 'very serious'; evidence from one small study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Group C cognitive behavioural therapy: cognitive behavioural therapy + supportive intervention compared to non‐directive reflective listening + supportive intervention for prodromal stage of psychosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012236-tbl-0010"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Group C cognitive behavioural therapy: cognitive behavioural therapy + risperidone compared to supportive therapy + placebo for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cognitive behavioural therapy + risperidone compared to supportive therapy + placebo for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> cognitive behavioural therapy (CBT) + risperidone<br/> <b>Comparison:</b> supportive therapy + placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with supportive therapy + placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CBT + risperidone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Prodromal symptoms: transition to psychosis</b> </p> <p>Endpoint data (events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.76<br/> (0.28 to 2.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>71<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>214 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>163 per 1000<br/> (60 to 435) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global state: clinically important change in global state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: psychopathology</b> </p> <p>Total endpoint data, BPRS (higher score = worse, scale from: 0‐126)<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychopathology was 15.3 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychopathology was 14 points</p> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for this outcome were skewed, and therefore we did not present summary estimates</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: doctors' assessment of adverse effects</b> </p> <p>UKU (events)</p> <p>Medium‐term<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.43<br/> (0.64 to 3.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>58<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>273 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>390 per 1000<br/> (175 to 862) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p>Average endpoint scores, QLS (higher score = better, scale from: 0‐126)</p> <p>Medium‐term<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life was 84.4 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.40 points higher<br/> (9.91 lower to 14.71 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for clinically important change in quality of life were not available.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>Endpoint data (events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.16<br/> (0.60 to 2.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>71<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>321 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>373 per 1000<br/> (193 to 723) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>BPRS:</b> Brief Psychiatric Rating Scale; <b>CI:</b> confidence interval; <b>QLS:</b> Quality of Life Scale; <b>RR:</b> risk ratio; <b>UKU:</b> Udvalg for Kliniske Undersøgelser Adverse Effects Scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, high attrition </p> <p><sup>2</sup> Imprecision: rated 'very serious'; evidence from one small study </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Group C cognitive behavioural therapy: cognitive behavioural therapy + risperidone compared to supportive therapy + placebo for prodromal stage of psychosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012236-tbl-0011"> <div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Group C other: cognitive training compared to active control (tablet games) for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cognitive training compared to active control (tablet games) for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> cognitive training<br/> <b>Comparison:</b> active control (tablet games) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with active control (tablet games)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with cognitive training</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Prodromal symptoms: transition to psychosis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global state: clinically important change in global state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: psychosis risk symptoms</b> </p> <p>SOPS total (higher score = worse, scale from: 0‐114)<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychosis risk symptoms was 25.49 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: psychosis risk symptoms was 33.9 points</p> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for this outcome were skewed, and therefore we did not present summary estimates</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects: at least one serious adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life: clinically important change in quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>Endpoint data (events)</p> <p>Long‐term<br/> Follow‐up: by 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.78<br/> (0.48 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>83<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>485 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>378 per 1000<br/> (233 to 625) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SOPS:</b> Scale of Prodromal Symptoms </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, high attrition.<br/> <sup>2</sup>Imprecision: rated 'very serious'; evidence from one small study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Group C other: cognitive training compared to active control (tablet games) for prodromal stage of psychosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012236-tbl-0012"> <div class="table-heading"><span class="table-label">Summary of findings 12.</span> <span class="table-title">Group C other: family treatment compared to enhanced care for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Family treatment compared to enhanced care for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> family treatment<br/> <b>Comparison:</b> enhanced care </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with enhanced care</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with family treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Prodromal symptoms: transition to psychosis</b> </p> <p>FACT</p> <p>Long‐term<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.71<br/> (0.35 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>199 per 1000<br/> (98 to 406) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Global state: antipsychotic prescriptions</b> </p> <p>(events)<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.18<br/> (0.69 to 2.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>129<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>270 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>318 per 1000<br/> (186 to 545) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: specific ‐ psychosis risk, positive symptoms</b> </p> <p>Average total score, SOPS positive (higher score = worse, scale from 0‐30)</p> <p>Short‐term<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: specific ‐ psychosis risk, positive symptoms was 9.84 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.01 points lower<br/> (3.87 lower to 0.15 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for our predefined outcome of interest 'Clinically important change in mental state' were not reported by the studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: suicide</b> </p> <p>(events)</p> <p>Long‐term (by 24 months)<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.00<br/> (0.06 to 15.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/> (1 to 311) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life: clinically important change in quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>FACT</p> <p>Long‐term<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/> (0.52 to 1.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>320 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>301 per 1000<br/> (166 to 538) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>FACT:</b> Family‐aided Assertive Community Treatment; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SOPS:</b> Scale for Prodromal Symptoms </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, participants not blinded, high attrition, unclear risk of selective reporting bias.<br/> <sup>2</sup>Imprecision: rated 'very serious'; evidence from one small study.<br/> <sup>3</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, participants not blinded, outcome assessors not blinded, unclear risk of selective reporting bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 12.</span> <span class="table-title">Group C other: family treatment compared to enhanced care for prodromal stage of psychosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012236-tbl-0013"> <div class="table-heading"><span class="table-label">Summary of findings 13.</span> <span class="table-title">Group C other: integrated treatment compared to standard treatment for prodromal stage of psychosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Integrated treatment compared to standard treatment for prodromal stage of psychosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people in the prodromal stage of psychosis<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> integrated treatment<br/> <b>Comparison:</b> standard treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with standard treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with integrated treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Prodromal symptoms: transition to psychosis</b> </p> <p>Endpoint data (events)</p> <p>Long‐term<br/> Follow‐up: by 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.57<br/> (0.28 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>79<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>378 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>216 per 1000<br/> (106 to 435) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global state: clinically important change in global state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state</b> </p> <p>SANS total (higher score = worse, scale from 0‐130)<br/> Follow‐up: 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state was 1.7 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state was 1.34 points</p> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for this outcome were skewed, and therefore we did not present summary estimates</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour: clinically important change in behaviour</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects: at least one serious adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life: clinically important change in quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Satisfaction with treatment: leaving the study early</b> </p> <p>Endpoint data (events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.66<br/> (0.25 to 1.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>79<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>216 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000<br/> (54 to 374) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio; <b>SANS:</b> Scale for Assessment of Negative Symptoms </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated 'very serious'; allocation concealment method not described, participants not blinded, outcome assessors not blinded, moderate attrition, unclear risk of selective reporting bias.<br/> <sup>2</sup>Imprecision: rated 'very serious'; evidence from one small study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 13.</span> <span class="table-title">Group C other: integrated treatment compared to standard treatment for prodromal stage of psychosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012236-tbl-0014"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adherence table</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0001" title="AddingtonJ , EpsteinI , LiuL , FrenchP , BoydellKM , ZipurskyRB . A randomised controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research2011;125(1):54‐61. [CSzG: Ref21945] AddingtonJ , ZipurskyR , EpsteinI . ADAPT (Access, Detection and Psychological Treatments). Schizophrenia Research2006;86(Suppl 1):S6. [CSzG: Ref13364] NCT00260273 . Access, detection and psychological treatments. www.ClinicalTrials.gov/ct/show/2005. [CSzG: Ref14638] ">ADAPT‐Canada</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall the mean number of sessions was 12 (SD = 6.2, range 1–26). 31% (N = 16) received &lt; 7 sessions. Those who left before the 6‐month follow‐up had significantly fewer sessions (5 vs 13.4; T = 7.1, P &lt; 0.0001). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0002" title="AmmingerG . Ethyl eicosapentanoic acid for prodromal psychosis. Stanley Foundation Research Programs2009. [CSzG: Ref17423] AmmingerG , SchaferM , PapageorgiouK , CottonS , HarriganS , MackinnonA , et al. Indicated prevention with long‐chain omega‐3 fatty acids in adolescents at ultra‐high‐risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2008;2(Suppl 1):A29. [CSzG: Ref19107] AmmingerGP , ChanenAM , OhmannS , KlierCM , MossahebN , BechdolfA , et al. Omega‐3 fatty acid supplementation in adolescents with borderline personality disorder and ultra‐high risk criteria for psychosis: a post hoc subgroup analysis of a double‐blind, randomised controlled trial. Canadian Journal of Psychiatry2013;58(7):402‐8. [CSzG: Ref28534] AmmingerGP , HarrisMS , McGorryPD , HenryLP . Omega‐3 fatty acids for indicated prevention: treatment results and pathomechanisms. European Archives of Psychiatry and Clinical Neuroscience2013;263(Suppl. 1):S44‐5. [CSzG: Ref28434] AmmingerGP , LeicesterS , YungAR , YuenHP , McGorryPD . Age predicts transition to psychosis in an ultra‐high risk sample. Proceedings of the 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:61. AmmingerGP , McGorryPD . Update on omega‐3 polyunsaturated fatty acids in early ‐stage psychotic disorders. Neuropsychopharmacology2012;37(1):309‐10. [CSzG: Ref23726] AmmingerGP , MechelliA , RiceS , KimSW , KlierCM , McNamaraRK , et al. Predictors of treatment response in young people at ultra‐high risk for psychosis who received long‐chain omega‐3 fatty acids. Translational Psychiatry2015;5:e495. [CSzG: Ref29299] AmmingerGP , SchaferMR . Indicated prevention with omega‐3 fatty acids in adolescents at ultra‐high risk for psychosis ‐ rationale, methods, and 3‐months outcome. Schizophrenia Research2006;86(Suppl 1):S97‐8. [CSzG: Ref13367] AmmingerGP , SchaferMR . Is it feasible to conduct a RCT in ultra‐high risk individuals at a child and adolescent psychiatric service?. Schizophrenia Research2006;86(Suppl 1):S98. [CSzG: Ref13368] AmmingerGP , SchaferMR , KlierCM , PapageorgiouK , SlavikJ , HolzerI , et al. Indicated prevention with long‐chain omega‐3 fatty acids in young people at ultra‐high risk for psychosis: a randomised, placebo‐controlled trial. Early Intervention in Psychiatry2010;4(Suppl 1):7. [CSzG: Ref23467] AmmingerGP , SchaferMR , SchlogelhoferM , KlierCM , McGorryPD . Longer‐term outcome in the prevention of psychotic disorders by the Vienna omega‐3 study. Nature Communications2015;6:7934. [CSzG: Ref33023] AmmingerGP , SchlogelhoferM , KlierC , McGorryP , SchaferM . Longer‐term follow‐up in the Vienna omega‐3 psychosis prevention trial. Early Intervention in Psychiatry2014;8:41. [CSzG: Ref29378] AmmingerGP , SchäferMR , PapageorgiouK , KlierCM , CottonSM , HarriganSM , et al. Long‐chain omega‐3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo‐controlled trial. Archives of General Psychiatry2010;67(2):146‐54. [CSzG: Ref20680; DOI: 10.1001/archgenpsychiatry.2009.192.] AmmingerP , MossahebN , SchlgelhoferM , SchaferM . Fatty acid metabolism and the onset of psychotic disorder. European Psychiatry2011;26(Suppl 1):2089. [CSzG: Ref22967] Anonymous . Fish oil may help ward off psychosis. Journal of Psychosocial Nursing and Mental Health Services2010;48(5):55. [CSzG: Ref20739] BergerG , AmmingerP , McGorryP . Stage dependant effect of omega‐3 fatty acids in emerging psychosis. European Psychiatry2011;26(Suppl 1):1347. [CSzG: Ref22966] BergerGE , ProffittTM , McConchieM , YuenH , WoodSJ , AmmingerGP , et al. Ethyl‐eicosapentaenoic acid in first‐episode psychosis: a randomised, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(12):1867‐75. [CSzG: Ref15561; ISSN: 1555‐2101] EhrlichA . Evidence‐based medicine. Omega‐3 supplementation delays transition to psychotic disorder in ultra‐high‐risk adolescents and young adults. Clinical Advisor for Nurse Practitioners2010;13(5):79‐80. [CSzG: Ref21562] FöckingM , DickerP , LopezLM , CannonM , SchäferMR , McGorryPD , et al. Differential expression of the inflammation marker IL12p40 in the at‐risk mental state for psychosis: a predictor of transition to psychotic disorder?. BMC Psychiatry2016;16(1):326. [DOI: 10.1186/s12888‐016‐1039‐7] KlierC , HollmannM , SchlögelhoferM , MossahebN , FriedrichM , AmmingerPG . Indicated prevention with omega‐3 fatty acids (EPA/DHA) in adolescents with &quot;at‐risk‐mental‐state“ for psychosis. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. [CSzG: Ref12438] LavoieS , BenningerF , FeuchtM , KlierCM , SchaeferMR , AmmingerGP . Correlates of EEG resting states with erythrocyte membrane omega‐3 fatty acid levels and psychopathological symptoms in individuals at ultra‐high risk for psychosis. Early Intervention in Psychiatry2014;8:137. [CSzG: Ref29516] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultra‐high risk individuals who transitioned to psychosis. Schizophrenia Research2012;138(2‐3):206‐11. [CSzG: Ref24256] LavoieS , SchaferMR , WhitfordTJ , BenningerF , FeuchtM , KlierCM , et al. Frontal delta power associated with negative symptoms in ultrahigh risk individuals who transitioned to psychosis. Early Intervention in Psychiatry2012;6:38. [CSzG: Ref24960] MossahebN , PapageorgiouK , SchaferMR , BeckerJ , SchloegelhoferM , AmmingerGP . Changes in triglyceride levels in ultra‐high risk for psychosis individuals treated with omega‐3 fatty acids. Early Intervention in Psychiatry2018; Vol. 12, issue 1:30‐36. [DOI: 10.1111/eip.12275] MossahebN , SchaferMR , SchlogelhoferM , KlierCM , CottonSM , McGorryPD , et al. Effect of omega‐3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?. Schizophrenia Research2013;148(1‐3):163‐7. [CSzG: Ref28649] NCT00396643 . Indicated prevention with omega‐3 fatty acids in adolescents with ‘at‐risk‐mental‐state’ for psychosis: a randomised, double blind, placebo‐controlled treatment trial. www.ClinicalTrials.gov/ct/show/2006. [CSzG: Ref14873] PapageorgiouK , SchaferMR , SchlogelhoferM , MossahebN , AmmingerGP . Indicated prevention with omega‐3 fatty acids in young people with 'at‐risk‐mental‐state' for psychosis: design of a 5‐year follow‐up. European Archives of Psychiatry and Clinical Neuroscience2011;261:S55. [CSzG: Ref23749] SchaferMR , KlierCM , PapageorgiouK , FriedrichMH , AmmingerGP . Early detection of psychotic disorders. Neuropsychiatrie2007;21(1):37‐44. [CSzG: Ref15290] SmesnyS , MilleitB , HiplerUC , MilleitC , SchaferMR , KlierCM , et al. Omega‐3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra‐high risk for psychosis. Molecular Psychiatry2013;19(3):317‐24. [CSzG: Ref28243] SmesnyS , MilleitB , SchaeferMR , HesseJ , SchlögelhoferM , LangbeinK , et al. Effects of omega‐3 PUFA on immune markers in adolescent individuals at ultra‐high risk for psychosis ‐ results of the randomised controlled Vienna omega‐3 study. Schizophrenia Research2017;S0920‐9964(17):30039‐7. [DOI: 10.1016/j.schres.2017.01.026] ">Amminger‐Austria</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean rate for adherence with study medication, based on pill count and self‐report, was 81.4% (SD, 17.7%) in the omega‐3 group and 75.4% (SD, 17.8%) in the placebo group (P = 0.13). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0003" title="ChoiJ , CorcoranC , DixonL , FiszdonJ , JavittD . Processing speed training and social functioning in young adults at clinical high risk for psychosis: a pilot study. Early Intervention in Psychiatry2014;8:109. [CSzG: Ref29417] ChoiJ , CorcoranC , DixonL , JavittDC . Processing speed training and social functioning in teenagers and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2015;41:S41. [CSzG: Ref29418] ChoiJ , CorcoranCM , FiszdonJM , StevensM , JavittDC , DeasyM , et al. Pupillometer‐based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis. Psychiatric Rehabilitation Journal2017;40(1):33‐42. [CSzG: Ref35317] ">Choi‐USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference in the dosage of training between groups as participants in PST completed 30.32 (SD = 0.92) h versus 30.11 (SD = 0.84) h for ACG (T = 0.94, P = 0.353). As expected, given the structured nature of the programmes at both sites (participants were coming in for a regimen of treatments, usually 2 days/week), treatment intensity between groups was also not significantly different (PST, 3.37 h/week, SD 1.03; ACG, 3.52 h/week, SD 0.94; T 0.60, p. 558). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0004" title="CrittendenK , FlemingJ , StartupM , CarrV , BakerA , SchallU , et al. Recruitment and engagement of youth in an ultra high risk treatment study. Early Intervention in Psychiatry2008;2(Suppl 1):A127. [CSzG: Ref19115] StainH , BucciS , HalperinS , EmsleyR , ShallU , LewinT , et al. DEPTh: randomised controlled trial of cognitive behavioral therapy for young people at ultra high risk for psychosis. Early Intervention in Psychiatry2014;8:15. [CSzG: Ref29673] StainHJ , BucciS , BakerA , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of CBT for young people at risk for psychosis: the Detection and Evaluation of Psychological Therapy (DEPTh) trial. European Archives of Psychiatry and Clinical Neuroscience2015;1:S8‐9. [CSzG: Ref33810] StainHJ , BucciS , BakerAL , CarrV , EmsleyR , HalpinS , et al. A randomised controlled trial of cognitive behaviour therapy versus non‐directive reflective listening for young people at ultra high risk of developing psychosis: the detection and evaluation of psychological therapy (DEPTh) trial. Schizophrenia Research2016;176(2‐3):212‐9. [CSzG: Ref35298] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. Rural and urban youth at ultra high risk for psychosis: baseline characteristics from the DEPTh randomised controlled trial of cognitive behavior therapy. Schizophrenia Bulletin2011;37:322. [CSzG: Ref22815] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy for youth at ultra high risk for psychosis: baseline characteristics for rural and urban youth. Australian and New Zealand Journal of Psychiatry2010:25‐6. [CSzG: Ref21845] StainHJ , CrittendenK , StartupM , CarrV , BakerA , SchallU , et al. The DEPTh randomised controlled trial of cognitive behaviour therapy targeting ultra high risk for psychosis: baseline comparisons for rural and urban youth. Early Intervention in Psychiatry2010;4(Suppl 1):113. [CSzG: Ref23498] StainHJ , StartupM , CarrV , BakerA , SchallU . The DEPTh project: a multisite RCT for youths at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S51‐2. [CSzG: Ref13401] StartupM . The DEPTh project: detection, evaluation, and psychological therapy for health. Australian New Zealand Clinical Trials Registry2006. [CszG: Ref18442] ">DEPTh‐Australia</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean number of sessions completed was 9.2 for CBT (3% had no sessions, 17% had 1–5, 47% had 6–11, 30% had 12–26), and 10.1 for NDRL (4% had no sessions, 26% had 1–5, 37% had 6–11, 33% had 12–26). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0005" title="ByrneRE , MorrisonAP . Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. Psychology and Psychotherapy2014;87(3):357‐71. [CSzG: Ref29312] FlachC , FrenchP , DunnG , FowlerD , GumleyAI , BirchwoodM , et al. Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE‐2 trial. British Journal of Psychiatry2015;207(2):123‐9. [CSzG: Ref33109] MorrisonA . Early detection and intervention evaluation for individuals at high risk of psychosis 2. http://www.controlled‐trials.com2008. [CSzG: Ref18285] MorrisonA . Early detection and intervention evaluation for people at risk of psychosis (edie‐2): A multisite randomised controlled trial of cognitive therapy for at‐risk mental states. Early Intervention in Psychiatry2012;6:11. [CSzG: Ref24968] MorrisonA , FrenchP , BentallR , LewisS , BirchwoodM , FowlerD , et al. Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. Early Intervention in Psychiatry2008;2(Suppl 1):A15. [CSzG: Ref19128] MorrisonAP . EDIE‐2: early detection and psychological intervention for individuals at high risk of psychosis (2). www.controlled‐trials.com2007. [CSzG: Ref15381] MorrisonAP , BirchwoodM , PyleM , FlachC , StewartSL , ByrneR , et al. Impact of cognitive therapy on internalised stigma in people with at‐risk mental states. British Journal of Psychiatry2013;203(2):140‐5. [CSzG: Ref28630] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ2012;344(7852):e2233. [CSzG: Ref24208] MorrisonAP , FrenchP , StewartSL , BirchwoodM , FowlerD , GumleyAI , et al. Early detection and intervention evaluation for people at‐risk of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29554] MorrisonAP , PyleM , StewartSL , FrenchP , ByrneR , FlachC , et al. Internalised stigma in young people at high risk of developing psychosis: findings from a cognitive therapy trial. Schizophrenia Research2014;153:S42. [CSzG: Ref29555] MorrisonAP , StewartSL , FrenchP , BentallRP , BirchwoodM , ByrneR , et al. Early detection and intervention evaluation for people at high‐risk of psychosis‐2 (EDIE‐2): trial rationale, design and baseline characteristics. Early Intervention in Psychiatry2011;5(1):24‐32. [CSzG: Ref22695] MorrisonT . Early detection and psychological intervention for individuals at high risk of psychosis. EDIE‐2. Data on File2006. [CSzG: Ref13874] PelosiAJ . Rational policy making for early psychosis might yet become possible. BMJ2012;344(7856):e3137. [CSzG: Ref24326] PyleM , StewartSL , FrenchP , ByrneR , PattersonP , GumleyA , et al. Internalised stigma, emotional dysfunction and unusual experiences in young people at risk of psychosis. Early Intervention in Psychiatry2015;9(2):133‐40. [CSzG: Ref29813] ">EDIE‐2‐UK</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Those allocated to cognitive therapy received a mean of 9.11 (SD 6.69; range 0‐26) sessions, each lasting on average 1 h. Adherence to cognitive therapy was reasonably good, with only 9 of 144 (6.25%) participants not attending any sessions and 108 (75%) receiving at least ≥ 4 sessions. Fidelity to the therapy model was assessed using competency and adherence scales in relation to audio recordings of 80 therapy sessions. 90% of rated sessions scored over the threshold for competency and 93.3% met the criteria for therapy that adhered to the manual. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0006" title="DragtS , Van derGaagM . Prevention of psychosis with a cognitive behavioural intervention in help‐seeking young people with an at risk mental state for developing psychosis. www.trialregister.nl/trialreg/index.asp2007. [CSzG: Ref19655] IsingHK , KraanTC , RietdijkJ , DragtS , KlaassenRM , BoonstraN , et al. Four‐year follow‐up of cognitive behavioral therapy in persons at ultra‐high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2016;42(5):1243‐52. [CSzG: Ref35214] IsingHK , LokkerbolJ , RietdijkJ , DragtS , KlaassenRM , KraanT , et al. Four‐year cost‐effectiveness of cognitive behavior therapy for preventing first‐episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE‐NL) trial. Schizophrenia Bulletin2017;43(2):365‐74. [CSzG: Ref35824] IsingHK , SmitF , VelingW , RietdijkJ , DragtS , KlaassenRM , et al. Cost‐effectiveness of preventing first‐episode psychosis in ultra‐high‐risk subjects: multi‐centre randomised controlled trial. Psychological Medicine2015;45(7):1435‐46. [CSzG: Ref27798] KraanTC , IsingHK , FokkemaM , VelthorstE , Van denBergDP , KerkhovenM , et al. The effect of childhood adversity on 4‐year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE‐NL) Trial. Psychiatry Research2017;247:55‐62. [CSzG: Ref35559] NiemanDH , RuhrmannS , RietdijkJ , DragtS , IsingH , KlaassenR , et al. Preventive psychotherapy. Schizophrenia Research2014;153:S42‐3. [CSzG: Ref29601] RietdijkJ , DragtS , KlaassenR , IsingH , NiemanD , WunderinkL , et al. A single blind randomised controlled trial of cognitive behavioural therapy in a help‐seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE‐NL) trial. Trials2010;11:30. [CSzG: Ref20654] Van DerGaagM . The effects of CBT in personswith ultra high risk: the Dutch EDIE trial. European Archives of Psychiatry and Clinical Neuroscience2011;261:S18. [CSzG: Ref23756] Van DerGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first‐episode of psychosis. Early Intervention in Psychiatry2012;6:12. [CSzG: Ref24985] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomised controlled clinical trial. Schizophrenia Bulletin2012;38(6):1180‐8. [CSzG: Ref24935] Van DerGaagM , NiemanDH , RietdijkJ , DragtS , IsingHK , KlaassenRMC , et al. The effects of cognitive behavioural therapy for subjects at ultra‐high risk for developing psychosis. Schizophrenia Bulletin2013;39:S356. [CSzG: Ref28121] Van derGaagM . The prevention of psychosis in at risk mental state. www.controlled‐trials.com2008. [CSzG: Ref17488] Van derGaagM , NiemanD , Van denBergD . CBT for those at risk of a first episode psychosis: Evidence‐based psychotherapy for people with an 'at risk mental state'. 1st Edition. Hove, UK: Routledge, 2013. Van derGaagM , NiemanD , WunderinkL , KlaassenR , RietdijkJ , DragtS , et al. The results of a specific CBT intervention in young help‐seeking patients with social decline and an ultra‐high risk for developing a first episode of psychosis. Schizophrenia Research2012;136:S17. [CSzG: Ref29692] ">EDIE‐NL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0007" title="FrenchP , ShryaneN , BentallRP , LewisSW , MorrisonAP . Effects of cognitive therapy on the longitudinal development of psychotic experiences in people at high risk of developing psychosis. British Journal of Psychiatry. Supplements2007;191(Suppl 51):s82‐7. [CSzG: Ref16121] LewisS . EDIE ‐ Early detection and intervention for psychosis. National Research Register2001; Vol. 3. [CSzG: Ref13023] LewisS . EDIE ‐ early detection and intervention for psychosis (in primary care). National Research Register2002; Vol. 1. [CszG: Ref9342] MorrisonA . Early detection and intervention for psychosis in primary care. National Research Register2003. [CSzG: Ref15485] MorrisonA . Findings from a randomised controlled trial and clinical service delivering cognitive therapy to people at ultra‐high risk of developing psychosis. Schizophrenia Research2004;70(1):43‐4. [CSzG: Ref11526] MorrisonA . Follow‐up of prodromal symptoms. National Research Register2004; Vol. 3. [CSzG: Ref13036] MorrisonA , BentallR , FrenchP , Kilcommons A, LewisSW . Very early intervention in prodromal psychosis: a randomised trial. Schizophrenia Research2002;53(3 Suppl 1):42. [CSzG: Ref8096] MorrisonA , FrenchP , WalfordL , LewisS , Kilcommons A, GreenJ , et al. A randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;67(1):7. [CSzG: Ref11324] MorrisonA , FrenchP , WatfordL , LewisS , Kilcommons A, GreenJ , et al. Randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra‐high risk. Schizophrenia Research2004;70(1):63. [CSzG: Ref11527] MorrisonAP . Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: results of a randomised controlled trial. Schizophrenia Research2006;86(Suppl 1):S59. [CSzG: Ref13388] MorrisonAP , BentallRP , FrenchP , Kilcommons A, GreenJ , WalfordL , et al. Cognitive therapy in ultra high risk individuals for psychosis: randomised controlled trial. Schizophrenia Research2003;60:326. [CSzG: Ref9726] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, KnightA , et al. Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high‐risk individuals. Study design and interim analysis of transition rate and psychological risk factors. British Journal of Psychiatry. Supplements2002;181(43):s78‐84. [CSzG: Ref8737] MorrisonAP , BentallRP , FrenchP , WalfordL , Kilcommons A, LewisS . Early detection and intervention for psychosis in primary care. 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002. [CSzG: Ref8932] MorrisonAP , FrenchP , ParkerS , RobertsM , StevensH , BentallRP , et al. Three‐year follow‐up of a randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophrenia Bulletin2007;33(3):682‐7. [CSzG: Ref15288] MorrisonAP , FrenchP , WalfordL , LewisSW , Kilcommons A, GreenJ , et al. Cognitive therapy for the prevention of psychosis in people at ultra‐high risk: randomised controlled trial. British Journal of Psychiatry2004;185:291‐7. [CSzG: Ref11450] MorrisonT . Early detection and intervention for psychosis in primary care. National Research Register2001; Vol. 1. [CSzG: Ref13037] MorrisonT , BentallR , FrenchP , Kilcommons A, GreenJ , LewisS . Early detection and intervention for psychosis in primary care. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:44. [CSzG: Ref8932] RentonJ , MorrisonA . Effectiveness of cognitive therapy for psychosis and implications for early intervention. Schizophrenia Research2004;70(1):142. [CSzG: Ref11536] ">EDIE‐UK</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0008" title="McFarlaneWR , CookWL , WoodberryKA . A randomised clinical trial of familyaided assertive community treatment for young persons at high risk for onset of an initial psychosis. Schizophrenia Bulletin2011;37:314. [CSzG: Ref22796] NCT01597141 . Psychosis: early detection, intervention and prevention. ClinicalTrials.gov/show/NCT015971412012. [CSzG: Ref24315] ">EDIP‐USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0009" title="BechdolfA . Preventing progression to first‐episode psychosis in people in the early initial prodromal state. Early Intervention in Psychiatry2012;6:11. [CSzG: 24944] BechdolfA , BuhlerB , BerningJ , WagnerM , StammE , StreitM . Cognitive behavioural therapy in the early initial prodromal state of psychosis: first results. Schizophrenia Research2004;67(1):202. [CSzG: Ref11285] BechdolfA , KlosterkotterJ . Cognitive‐behavioural treatment (CBT) in the early initial prodromal state of psychosis: concept and practical approach. Schizophrenia Research2004;70(1):52. [CSzG: Ref11506] BechdolfA , RuhrmannS , JanssenB , BottlenderR , WagnerM , MaurerK , et al. Early recognition and intervention for people at risk of schizophrenia [Fruherkennung und intervention bei personen mit erhohtem psychoserisiko]. Psychoneuroendocrinology2004;30(11):606‐14. [CSzG: Ref11376] BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: Ref12511] BechdolfA , VeithV , BerningJ , StammE , DeckerP , JanssenB , et al. Cognitive behavioral therapy (CBT) in the early initial prodromal state of psychosis: first results of a randomised trial. Schizophrenia Research2004;70(1):62‐3. [CSzG: Ref11507] BechdolfA , WagnerM , RuhrmannS , HarriganS , PutzfeldV , PukropR , et al. Preventing progression to first‐episode psychosis in early initial prodromal states. British Journal of Psychiatry2012;200(1):22‐9. [CSzG: Ref24206] BechdolfA , WagnerM , RuhrmannS , HarriganS , VeithV , PukropR , et al. CBT for prevention of first episode psychosis in people in an putative early initial prodromal state. Early Intervention in Psychiatry2008;2(Suppl 1):A16. [CSzG: 19109] BechdolfA , WagnerM , VeithV , PukropR , BerningJ , StammE , et al. A randomised controlled trial of cognitive‐behavioral therapy in the early initial prodromal state of psychosis. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:22‐3. [CSzG: 20193] BechdolfA , WagnerM , VeithV , RuhrmannR , JanssenB , BottlenderR , et al. A randomised controlled multicenter trial of cognitive behaviour therapy in the early initial prodromal state of psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13369] BechdolfA , WagnerM , VeithV , RuhrmannS , PukropR , Brockhaus‐DumkeA , et al. Randomised controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Intervention in Psychiatry2007;1(1):71‐8. [CSzG: 16450] BechdolfA , WesselsH , WagnerM , KuhrK , BerningJ , PutzfeldV , et al. Predictors of treatment response to psychosocial interventions in people at risk. European Archives of Psychiatry and Clinical Neuroscience2015;1:S9. [CSzG: 33601] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] KommescherM , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. Early Intervention in Psychiatry2016;10(1):17‐27. [CSzG: 32187] NCT00204087 . Psychological intervention for persons at risk of psychosis in the early initial prodromal state. www.ClinicalTrials.gov/ct/show/2005. [CSzG: 14890] WesselsH , WagnerM , FrommannI , BerningJ , PutzfeldV , JanssenB , et al. Neuropsychological functioning as a predictor of treatment response to psychoeducational, cognitive behavioral therapy in people at clinical high risk of first episode psychosis. Psychiatrische Praxis2015;42(6):313‐9. [CSzG: 33130] ZarafonitisS , WagnerM , PutzfeldV , BerningJ , JanssenB , DeckerP , et al. Psychoeducation for persons at risk of psychosis. Psychotherapeut2012;57(4):326‐34. [CSzG: 24807] ">EIPS‐Germany</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After randomisation, 2 participants from the IPI group and 1 from the SC group failed to attend any treatment sessions. In the IPI group 22 (33.8%) of participants received &lt; 50% of treatment (&lt; 20 sessions) and in the SC group 20 (31.7%) participants received &lt; 50% of treatment (&lt; 13 sessions), but there were no statistical differences between the number of these participants (Chi<sup>2</sup> = 0.003, P = 0.956). Mean number of sessions for the SC group was 15.8 ± 6.8 and for the IPI group 23.7 ± 13.1, therefore participants from the SC group received significantly less treatment (P &lt; 0.001). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0010" title="KantrowitzJT , WoodsSW , PetkovaE , CornblattB , CorcoranCM , ChenH , et al. D‐serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double‐blind, placebo‐controlled, randomised parallel group mechanistic proof‐of‐concept trial. Lancet Psychiatry2015;2(5):403‐12. [CSzG: 29487] NCT00826202 . D‐serine for the schizophrenia prodrome. www.ClinicalTrials.gov/ct/show/2009. [CSzG: 17391] ">Kantrowitz‐USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0011" title="BechdolfA , RuhrmannS , WagnerM , KuhnKU , JanssenB , BottlenderR , et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry. Supplements2005;187(Suppl 48):s45‐8. [CSzG: 12511] HafnerH , MaurerK , RuhrmannS , BechdolfA , KlosterkotterJ , WagnerM , et al. Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience2004;254(2):117‐28. [CSzG: 18539] RuhrmannS , BechdolfA , KuhnKU , WagnerM , Schultze‐LutterF Janssen B , et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry. Supplements2007;51:s88‐95. [CSzG: 16127] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Acute symptomatic treatment effects in persons clinically at risk for psychosis. Schizophrenia Research2006;86(Suppl 1):S8. [CSzG: 13397] RuhrmannS , HoppmannB , TheysohnS , PickerH , KuhnK‐U , Schultze‐LutterF , et al. Intervention in the late initial prodromal state (LIPS) of psychosis. Schizophrenia Research2006;86(Suppl 1):S96. [CSzG: 13398] ">LIPS‐Germany</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0012" title="MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Family‐focused therapy for individuals at clinical high risk for psychosis: treatment fidelity within a multisite randomised trial. Early Intervention in Psychiatry2016;10(2):137‐43. [CSzG: 29018] MarvinSE , MiklowitzDJ , O'BrienMP , CannonTD . Treatment fidelity and differentiation in a randomised controlled trial of family‐focused therapy for youth at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:95. [CSzG: 24965] MiklowitzDJ , O'BrienMP , SchlosserDA , AddingtonJ , CandanKA , MarshallC , et al. Family‐focused treatment for adolescents and young adults at high risk for psychosis: results of a randomised trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(8):848‐58. [CSzG: 29019] NCT01907282 . Prevention trial of family focused treatment in youth at risk for psychosis. Clinicaltrials.gov/show/NCT019072822010. [CSzG: 27965] O'BrienMP , MiklowitzDJ , CandanKA , MarshallC , DominguesI , WalshBC , et al. A randomised trial of family focused therapy with populations at clinical high risk for psychosis: effects on interactional behavior. Journal of Consulting and Clinical Psychology2013;82(1):90‐101. [CSzG: 28565] O'BrienMP , MiklowitzDJ , CannonTD . Decreases in perceived maternal criticism predict improvement in subthreshold psychotic symptoms in a randomised trial of family‐focused therapy for individuals at clinical high risk for psychosis. Journal of Family Psychology2015;29(6):945–951.. [CSzG: 32212] SchlosserDA , MiklowitzDJ , O'BrienMP , DeSilvaSD , ZinbergJL , CannonTD . A randomised trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Intervention in Psychiatry2012;6(3):283‐91. [CSzG: 24491] ">Miklowitz‐USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The average number of sessions in the FFT group was 11.0 ± 7.1 (range 0–19) sessions and 42 (63.6%) participants took part in at least 1 session of communication or problem‐solving skills training. Out of 66 participants in this group, 18 received &lt; 50% of sessions (9 sessions) and 37 &gt; 9 sessions. The rest dropped out before the first session. In the enhanced care group, average number of sessions was 2.4 ± 1.2 sessions (range 0–4) and 50 (79.4%) took part in most or all (2–3 sessions) of the psychoeducational training. Out of 63 participants in this group, 5 received &lt; 50% of sessions (1 session) and 48 received &gt; 50% of sessions (2‐3 sessions). Participants in both FFT and enhanced treatment groups were equally likely to obtain extra‐protocol individual or group therapy sessions (34.5% and 36.2%; 2(1) = 03, P = 0.86). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0013" title="ACTRN12608000475347 . A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder. Australian New Zealand Clinical Trials Registry2009. [CSzG: 18420] HKCTR‐1438 . The NEURAPRO‐E (North America, EURope, Australia PROdrome) Study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for symptomatic patients at ultra‐high risk for early progression to schizophrenia and other psychotic disorders. www.hkClinicaltrials.com/trial_details.aspx?trialID=d09bd177‐b9fd‐4162‐b04f‐3ebfed49baa32011. [CSzG: 29270] McGorryP , MarkulevC , NelsonB , YuenHP , SchaeferM , YungAR , et al. The NEURAPRO‐E study: a multicenter RCT of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Schizophrenia Bulletin2015;41:S322‐3. [CSzG: 29546] McGorryPD , NelsonB , MarkulevC , YuenHP , SchaferMR , MossahebN , et al. Effect of omega‐3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomised clinical trial. JAMA psychiatry2017;74(1):19‐27. [CSzG: 35590] NelsonB , AmmingerG , MarkulevC , YuenHP , LavoieS , SchaeferM , et al. NEURAPOR: a multi‐center RCT of omega‐3 polyunsaturated fatty acids versus placebo in young people at ultra‐high risk of psychotic disorders: medium‐term outcome. Schizophrenia Bulletin2017;43:S107. [CSzG: 36016] ">NEURAPRO‐AAE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were 66 adherent participants (43.1%) in the omega‐3 PUFA group and 62 in the placebo group (41.1%). Participants who had missing data for the capsule counts (N = 35 in omega‐3 fatty acids group and 48 in placebo group) were considered as non‐adherent. The overall median number of CBCM sessions attended was 8 (range, 1‐35), in omega‐3 fatty acids group 11.2 ± 6.4 and 10.3 ± 6.0 in placebo group. The transition rate was lower in the adherent participants, but without significant difference. There was no significant difference between groups in transition rates for those with a number of CBCM sessions ≤ median (P = 0.31), as well as for those &gt; median (P = 0.50). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0014" title="NordentoftM , JeppesenP , PetersenL , ThorupA , OhlenschlaegerJ , ChristensenT , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. European Psychiatry2007;22:S129‐S. [CSzG: 20471] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the OPUS trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;83(1):29‐40. [CSzG: 13197] NordentoftM , ThorupA , PetersenL , OhlenschlaegerJ , MelauM , ChristensenTO , et al. Transition rates from schizotypal disorder to psychotic disorder for first‐contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. Schizophrenia Research2006;86(Suppl 1):S44. [CSzG: 13393] ">Nordentoft‐Denmark</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0015" title="McGorryP . Can the onset of schizophrenia be delayed or prevented?. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S26. [CSzG: 8351] McGorryP , AdlardS , YungA , McDonaldA , PhillipsL , HearnN . Detection and intervention in pre‐psychotic schizophrenia. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4836] McGorryP , YungA , FranceyS , PhillipsL , NelsonB . A blinded, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and befriending in young people at risk of psychotic disorder: baseline characteristics of the sample. Acta Neuropsychiatrica2006;18(6):261. [CSzG: 35157] McGorryPD , HearnN , GermanoD , BravinJ , PhillipsLJ , YungAR , et al. Prepsychotic intervention in schizophrenia: a stitch in time?. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington DC, USA. 1999. [CSzG: 3584] McGorryPD , PhillipsLJ , NelsonB , LeicesterS , BakerK , KrstevH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and befriending in young people with subthreshold symptoms at incipient risk of psychotic disorder: six month outcome data. Schizophrenia Bulletin2007;33(2):446. [CSzG: 15203] McGorryPD , PhillipsLJ , YungAR , FranceyS , GermanoD , BravinJ , et al. A randomised controlled trial of interventions in the pre psychotic phase of psychotic disorders. Schizophrenia Research2000;41(1):9. [CSzG: 5149] McGorryPD , YungAR , PhillipsL , AdlardS , HallgrenM , PattonG , et al. Pre‐psychotic intervention in schizophrenia: a stitch in time?. Schizophrenia Research1998;29(1‐2):160. [CSzG: 3585] McGorryPD , YungAR , PhillipsLJ , YuenHP , FranceyS , CosgraveEM , et al. Randomised controlled trial of interventions designed to reduce the risk of progression to first‐episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry2002;59(10):921‐8. [CSzG: 8576] PhilippsLJ , McGorryP , YungA , FranceyD , GermanoF , BravinJ , et al. The development of preventive interventions for early psychosis: early findings and directions for the future. 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001; Vol. 2, issue Suppl 1. [CSzG: 7614] PhillipsL , CottonS , YuenHP , MihalopoulosC , ShihS , KellyD , et al. Cost effectiveness of a preventive intervention for young people at ultra high risk of developing psychosis. Schizophrenia Bulletin2007;33(2):488‐9. [CSzG: 15227] PhillipsLJ , CottonS , MihalopoulosC , ShihS , YungAR , CarterR , et al. Cost implications of specific and non‐specific treatment for young persons at ultra high risk of developing a first episode of psychosis. Early Intervention in Psychiatry2009;3(1):28‐34. [CSzG: 18308] PhillipsLJ , LeicesterSB , O'DwyerLE , FranceySM , KoutsogiannisJ , Abdel‐BakiA , et al. The PACE clinic: identification and management of young people at &quot;ultra&quot; high risk of psychosis. Journal of Psychiatric Practice2002;8(5):255‐69. [CSzG: 18235] PhillipsLJ , McGorryPD , YuenHP , WardJ , DonovanK , KellyD , et al. Medium term follow‐up of a randomised controlled trial of interventions for young people at ultra high risk of psychosis. Schizophrenia Research2007;96(1‐3):25‐33. [CSzG: 15544] PhillipsLJ , YungAR , YuenHP , PantelisC , McGorryPD . Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. American Journal of Medical Genetics2002;114(8):929‐37. [CSzG: 18236] ">PACE‐Australia</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Variable adherence to risperidone was reported; in the SPI group (N = 31), 13 participants were classified as nonadherent (&lt; 50% doses taken), 4 as partially adherent, and 14 as fully adherent (almost 100% doses taken). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0016" title="NCT01619319 . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. ClinicalTrials.gov/show/NCT016193192012. [CSzG: 24387] PiskulicD , BarbatoM , AddingtonJ . Cognitive remediation in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2012;6:89. [CSzG: 24973] PiskulicD , BarbatoM , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2012;136:S245‐6. [CSzG: 29632] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophrenia Research2014;153(Suppl. 1):S218. [CSzG: 28827] PiskulicD , BarbatoM , LiuL , AddingtonJ . Effects of cognitive remediation therapy on cognition in young people at clinical high risk of psychosis. Early Intervention in Psychiatry2014;8:86. [CSzG: 29633] ">Piskulic‐Canada</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Half of all participants completed between 2 and 4 training sessions/week, the other half failed to reach the target, completing 42 sessions on any given week. On average, participants across both groups completed 20 training sessions (SD = 13.5 sessions) and 50% of all participants completed between 20 and 40 training sessions (N = 7 in Post Science Brain Fitness group and N = 9 in control treatment group) in 12 weeks. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0017" title='BlockJJ , McGlashonTH . Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790‐9. American Journal of Psychiatry2006; Vol. 163, issue 10:1838. [CSzG: 13960] BreierAF , ZipurskyRB , PerkinsDO , AddingtonJM , TohenMF , DavidSR , et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951] HawkinsKA , AddingtonJ , KeefeR , ChristensenB , WoodsS , ZipurskyR , et al. Neuropsychological functioning in the first episode prodrome and early psychosis. Schizophrenia Research2004;70(1):101. [CSzG: 11515] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , MillerTJ , et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research2004;67(1):205. [CSzG: Ref11301] HawkinsKA , AddingtonJ , KeefeRS , ChristensenB , WoodsSW , ZipurskyRB , et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004. [CSzG: 16470] HawkinsKA , KeefeRS , ChristensenBK , AddingtonJ , WoodsSW , CallahanJ , et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. Schizophrenia Research2008;105(1‐3):1‐9. [CSzG: 16983] HoffmanRE , WoodsS , PredaA , TohenM , BreierA , GlistJ , et al. Excessive top‐down perceptual processing and reduced real‐world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. Schizophrenia Research2006;86(Suppl 1):S46. [CSzG: 13377] HoffmanRE , WoodsSW , HawkinsKA , PittmanB , TohenM , PredaA , et al. Extracting spurious messages from noise and risk of schizophrenia‐spectrum disorders in prodromal population. British Journal of Psychiatry2007;191(2):355‐6. [CSzG: 16068] McGlashanT , ZipurskyR , PerkinsD , AddingtonJ . Olanzapine for treatment of the schizophrenia prodrome: 2‐year results of a randomised placebo‐controlled study. Schizophrenia Research2004;67(1):164. [CSzG: 11320] McGlashanTH . Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 ‐ Apr 2; New York, New York, USA. 2000. [CSzG: 10191] McGlashanTH . Treatment intervention in the New Haven PRIME clinic prodromal sample. Current Opinion in Psychiatry1999;12(Suppl 1):S62. [CSzG: 4835] McGlashanTH , MillerTJ , WoodsSW . Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research2002;53(3 Suppl 1):15. [CSzG: 8093] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018] McGlashanTH , MillerTJ , WoodsSW , RosenJ , DavidsonL , PredaA , et al. Ethical issues in the pre‐onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005] McGlashanTH , MillerTJ , ZipurskyRB , WoodsSW , PerkinsDO , HawkinsKA , et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9803] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , VaglumP , FriisS , JohannessenJO , SimonsenE , LarsenTK , et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. Schizophrenia Bulletin2005;31:496. [CSzG: 11622] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerT , WoodsSW , et al. Randomised, double‐blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry2006;163(5):790‐9. [CSzG: 12654] McGlashanTH , ZipurskyRB , PerkinsD , AddingtonJ , MillerTJ , WoodsSW , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research2003;61(1):7‐18. [CSzG: 9828] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJ , WoodsSW , MillerTJ , et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research2003;60:295. [CSzG: 9722] McGlashanTH , ZipurskyRB , PerkinsDO , AddingtonJM , WoodsSW , LindborgS , et al. Olanzapine versus pbo for the schizophrenic prodrome: one‐year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. [CSzG: 9804] McGlashlanTH , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTH , WoodsSW , et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:42. [CSzG: 8934] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , MillerT , WoodsS , et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. Schizophrenia Research2004;70(1):6. [CSzG: 11524] McglashanT , ZipurskyR , PerkinsD , AddingtonJ , WoodsS , MillerT , et al. Olanzapine vs. placebo for prodromal schizophrenia. Schizophrenia Research2004;67(1):6. [CSzG: 11321] MillerTJ , ZipurskyRB , PerkinsD , AddingtonJ , WoodsSW , HawkinsKA , et al. The PRIME North America randomised double‐blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research2003;61(1):19‐30. [CSzG: 9829] RosenJL , WoodsSW , MillerTJ , McGlashanTH . Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease2002;190:133‐41. [CSzG: 8274] TaylorHE , ParkerS , MansellW , MorrisonAP . Effects of appraisals of anomalous experience on distress in people at risk of psychosis. Behavioural and Cognitive Psychotherapy2012;41(1):24‐33. [CSzG: 24374] WoodsS , ZipurskyR , PerkinsD , AddingtonJ , MarquezE , BreierA , et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25‐28; Copenhagen, Denmark. 2002:43. [CSzG: 8933] WoodsSW . Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):497. [CSzG: 19829] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research. 2003. [CSzG: 9978] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research2003;60:306‐7. [CSzG: 9752] WoodsSW , BreierA , ZipurskyRB , PerkinsDO , AddingtonJ , MillerTJ , et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry2003;54(4):453‐64. [CSzG: 9994] WoodsSW , McGlashanTH . Sample size planning for prodromal intervention trials. Schizophrenia Research2002;53(3 Suppl 1):40. [CSzG: 8116] WoodsSW , ZipurskyRB , PerkinsDO , AddingtonJM , MillerTJ , BreierAF , et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053] '>PRIME‐USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0018" title="LoewyR , FisherM , MathalonDH , VinogradovS . Interim analyses of a randomised controlled trial of computerised cognitive training in clinical high risk for psychosis. Schizophrenia Bulletin2013;39:S238‐9. [CSzG: 28151] LoewyR , FisherM , SchlosserDA , BiagiantiB , StuartB , MathalonDH , et al. Intensive auditory cognitive training improves verbal memory in adolescents and young adults at clinical high risk for psychosis. Schizophrenia Bulletin2016;42(Suppl 1):S118‐26. [CSzG: 35221] VinogradovS , LoewyR , FisherM , LeeA , NiendamT , RaglandJD , et al. Neuroplasticity‐based cognitive training in ultra‐high risk adolescents and recent onset patients with schizophrenia. Schizophrenia Research2012;136:S30. [CSzG: 29703] ">Vinogradov‐USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0019" title="NCT00291226 . Glycine vs Placebo for the Schizophrenia Prodrome. www.ClinicalTrials.gov/ct/show/2006. [CSzG: 14759] WoodsS , WalshB , HawkinsK , MillerT , SaksaJ , D'SouzaD , et al. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. Early Intervention in Psychiatry2012;6:29. [CSzG: 24987] WoodsSW , KantrowitzJT , JavittDC . NMDAR‐based treatments for patients at clinical high risk for psychosis. Biological Psychiatry2014;1:11S. [CSzG: 29041] WoodsSW , WalshBC , HawkinsKA , MillerTJ , SaksaJR , D'SouzaDC , et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. European Neuropsychopharmacology2013;23(8):931‐40. [CSzG: 28750] ">Woods‐1‐USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "Two placebo subjects missed one or more rating visits", no other data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012236-bbs2-0020" title="McGorryP . Second generation intervention research in the pre‐psychotic phase of illness in schizophrenia and related psychoses. Australian New Zealand Clinical Trials Registry2000. [CSzG: 18439] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceyS , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: 12‐month outcome. Schizophrenia Research2012;136:S17‐8. [CSzG: 29547] McGorryPD , NelsonB , PhillipsLJ , YuenHP , FranceySM , ThampiA , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: twelve‐month outcome. Journal of Clinical Psychiatry2013;74(4):349‐56. [CSzG: 28737] NelsonB , PhillipsLJ , YungAR , FranceySM , LeicesterS , BakerK , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, intensive psychological treatment and supportive therapy in young people with subthreshold symptoms at incipient risk of psychotic disorder: baseline characteristics of the sample. Schizophrenia Bulletin2007;33(2):450. [CSzG: 15212] PhillipsLJ , NelsonB , YuenHP , FranceySM , SimmonsM , StanfordC , et al. Randomised controlled trial of interventions for young people at ultra‐high risk of psychosis: study design and baseline characteristics. Australian and New Zealand Journal of Psychiatry2009;;43(9):818–29. YungA , AmmingerP , BergerG , ThompsomA , PhillipsL , NelsonB , et al. Randomised controlled trial of antipsychotic and cognitive therapy in young people at ultra‐high risk of psychosis. Early Intervention in Psychiatry2012;6:11. [CSzG: 24989] YungA , NelsonB , PhillipsL , FranceyS , LeicesterS , YuenH , et al. A double blind, placebo‐controlled randomised trial of low‐dose risperidone, cognitive‐behaviour therapy, and supportive therapy in young people at ultra high risk of psychotic disorder: 12 month outcome data. Early Intervention in Psychiatry2008;2(Suppl 1):A12. [CSzG: 19138] YungAR , PhillipsLJ , NelsonB , FranceySM , YuenHP , SimmonsMB , et al. Randomised controlled trial of interventions for young people at ultra high risk for psychosis: 6‐month analysis. Journal of Clinical Psychiatry2011;72(4):430‐40. [CSzG: 22929] ">Yung‐Australia</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Poor therapy adherence (only 2 participants (4.7%) had full adherence to risperidone).</p> <p>Problems with therapy supervision (only 24 of 41 tapes from the cognitive therapy groups (58.5%) were classified as receiving cognitive therapy, 9 participants (22.0%) allocated to cognitive therapy were judged to be receiving supportive therapy, and, in a further 8 cases (19.5%), the nature of the psychological therapy was rated as not known). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>ACG:</b> active control group; <b>CBCM:</b> cognitive behavioural case management; <b>CBT:</b> cognitive behavioural therapy; <b>FFT:</b> family‐focused treatment <b>IPI:</b> integrated psychological intervention; <b>NDRL:</b> non‐directive reflective listening; <b>PST:</b> processing speed training; <b>SC:</b> supportive counselling; <b>SD:</b> standard deviation; <b>SPI:</b> specific preventive intervention </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adherence table</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/full#CD012236-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012236-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Group A: amino acids vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prodromal symptoms: transition to psychosis, endpoint data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.08, 2.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mental state 1: specific, psychosis risk symptoms, average total score, short‐term (at 8 weeks), SOPS (higher score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.00 [‐22.38, 2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Positive score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.5 [‐7.86, 2.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Negative score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐4.88, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Disorganisation score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [‐1.57, 3.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 General score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.80 [‐9.47, ‐4.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state 2 specific: depression, average total score, short‐term (at 8 weeks), MADRS (higher score = worse), skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state 3a specific: cognitive symptoms, average total score, short‐term (at 12 weeks), various tests (higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Immediate verbal memory (AVLT immediate trials sum)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.5 [‐2.15, 15.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Delayed verbal memory (AVLT delay trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [‐1.17, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Executive functioning (semantic fluency test)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.5 [‐10.53, 9.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Executive functioning (phonemic fluency test)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐20.38, 14.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Attention and working memory (letter number sequencing)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.5 [2.04, 6.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state 3b specific: cognitive symptoms, average total score, short‐term (at 12 weeks), various tests (higher score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Processing speed (Trails A)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.8 [‐8.57, 26.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Attention and working memory (Trails B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.80 [‐48.70, 43.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Processing speed (Stroop words)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.5 [‐27.49, 4.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Processing speed (Stroop colors)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.60 [‐17.45, 4.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Processing speed (Stroop color‐words)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.0 [‐9.50, ‐2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Executive functioning (WCS perseverative errors)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.7 [4.16, 15.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse effects 1 specific: treatment‐emergent adverse effects, short‐term (by 8 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Psychological: irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 6.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Psychological: mentation impaired</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 6.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Psychological: hallucinations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 6.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Arousal: sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.2 [0.01, 3.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Arousal: disturbed sleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.2 [0.01, 3.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Arousal: malaise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 6.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7 Sexual: orgasm dysfunction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.16, 57.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8 Gastrointestinal: stomach discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 6.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse effects 2 specific: cardiovascular, average total score, short‐term (by 8 weeks), blood pressure and pulse rate (higher score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Systolic blood pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.0 [‐8.70, 20.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Diastolic blood pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [‐12.03, 16.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Pulse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐20.0 [‐41.76, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse effects 3 specific: weight, average total change score, short‐term (by 8 weeks), kg gained (higher score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.67 [‐2.13, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse effects 4 specific: suicidal thoughts, short‐term (by 16 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.57 [0.15, 83.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Satisfaction with treatment: leaving the study early ‐ end point data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.55, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Group A: amino acids vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012236-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Group A: omega‐3 fatty acids vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prodromal symptoms: transition to psychosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Medium‐term (at 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>385</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.08, 3.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Long‐term (at 7 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.09, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: antipsychotic prescription, long‐term (at 7 years' follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.30, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state 1a specific: psychotic symptoms, average total score, PANSS (higher score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 General: medium‐term (at 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.90 [‐8.06, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 General: long‐term (up to 7 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.70 [‐9.69, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Negative: medium‐term (at 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.60 [‐5.09, ‐0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Negative: long‐term (up to 7 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.10 [‐6.15, ‐0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Positive: medium‐term (at 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.10 [‐4.32, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Positive: long‐term (up to 7 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.50 [‐5.99, ‐1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Total: medium‐term (at 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.60 [‐16.36, ‐0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 Total: long‐term (up to 7 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.40 [‐20.55, ‐2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state 1b specific: negative symptoms, average total score, medium‐term (at 12 months), SANS (higher score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [‐2.56, 3.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state 2 specific: depression, average total score, medium‐term (at 12 months), MADRS (higher score = worse), skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐2.78, 2.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state 3 specific: mania, average total score, medium‐term (at 12 months), YMS (higher score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.35, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mental state 4 specific: average total scores, various scales (higher score = worse), skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Psychotic symptoms: positive (average total score), long‐term (by up to 7 years) PANSS </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Psychotic symptoms: negative (average total score), medium‐term (at 12 months) PANSS </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Psychotic symptoms: negative (average total score), long‐term (by up to 7 years) PANSS </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Depression: average total score, medium‐term (at 12 months), MADRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Depression: average total score, long‐term (by up to 7 years) MADRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Functioning 1 global: average total score, GAF (higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Medium‐term (at 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.5 [5.12, 17.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Long‐term (at up to 7 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.5 [2.02, 16.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Functioning 2 specific: role functioning, average total score, medium‐term (at 12 months), GFR (higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.49, 0.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Functioning 3a specific: social functioning, average total score, medium‐term (at 12 months), GFS (higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.59, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Functioning 3b specific: social functioning, average total score, medium‐term (at 12 months), SOFAS (higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐4.60, 4.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse effects, specific: medium‐term (by 12 months), UKU checklist <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Arousal: concentration difficulties</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.02, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Arousal: increased fatigability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.26, 8.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Arousal: sleep ‐ reduced duration of sleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.21, 4.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 Arousal: sleep‐related ‐ unspecified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.49, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 Autonomic nervous system: orthostatic dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 3.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.6 Autonomic nervous system: sweating increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 3.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.7 Autonomic nervous system: unspecified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.79, 3.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.8 Gastrointestinal: diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.03, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.9 Gastrointestinal: nausea/ vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.21, 4.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.10 Gastrointestinal: unspecified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.91, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.11 Haematological: increased bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.12 Hormonal: unspecified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.26, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.13 Neurological: extrapyramidal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [0.94, 7.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.14 Neurological: failing memory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 3.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.15 Neurological: tension headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.03, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.16 Neurological: unspecified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [0.81, 4.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.17 Psychological: depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.08, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.18 Psychological: emotional indifference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.09, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.19 Psychological: tension/inner unrest</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.23, 2.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.20 Psychological: unspecified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.70, 2.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.21 Sexual: unspecified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.91 [0.86, 55.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.22 Skin: unspecified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.23, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.23 Other: unspecified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.66, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Satisfaction with treatment: leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Medium‐term (by 12 months), endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>385</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.68, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Long‐term (by 7 years), additional follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.45, 4.80]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Group A: omega‐3 fatty acids vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012236-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Group B: antipsychotic drugs, amisulpiride + needs‐focused intervention (NFI) vs NFI</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mental state, specific: average endpoint scores, short‐term (at 12 weeks), various scales (higher score = worse), skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Psychotic symptoms: positive (endpoint score) PANSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Psychotic symptoms: negative (endpoint score) PANSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Psychotic symptoms: general (endpoint score) PANSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Depression (endpoint score) MADRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Functioning, global: average endpoint score, short‐term (at 12 weeks), GAF (higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.10 [0.44, 11.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse effects 1a specific: akathisia, short‐term (at 12 weeks), ESRS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.82 [0.33, 24.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse effects 1b specific: akathisia (average endpoint score), short‐term (at 12 weeks), ESRS (higher score = worse), skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects 2 specific: increased prolactin levels, short‐term (at 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.97 [2.02, 7.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse effects 3 specific: severity of at least moderate and a frequency of at least 5%, short‐term (at 12 weeks), UKU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Psychological: concentration difficulties</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.78, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Psychological: asthenia/lassitude/increased fatigability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [1.08, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Psychological: failing memory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.19 [1.17, 4.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Psychological: depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.82, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Psychological: tension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.85, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Arousal: sleepiness/sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.49, 4.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7 Arousal: increased duration of sleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.28 [1.37, 7.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8 Arousal: decreased duration of sleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.23, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.9 Arousal: increased dream activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>21.82 [1.35, 353.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.10 Gastrointestinal: nausea/vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.92 [0.58, 169.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.11 Autonomic nervous system: orthostatic dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.95 [0.33, 107.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.12 Autonomic nervous system: increased tendency to sweating</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.53 [1.01, 271.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.13 Cardiological: palpitation/tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.30, 3.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.14 Neurological: headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [0.80, 4.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.15 Endocrinological: polyuria/polydipsia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.30, 3.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.16 Sexual: diminished sexual desire</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.44 [1.28, 9.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.17 Sexual: orgasmic dysfunction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.95 [0.33, 107.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse effects 4 specific: suicidal thoughts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.01, 6.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Satisfaction with treatment: leaving the study early, end point data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.38, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Group B: antipsychotic drugs, amisulpiride + needs‐focused intervention (NFI) vs NFI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012236-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prodromal symptoms: transition to psychosis, endpoint data, medium‐term (by 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.28, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state, global: illness severity, average total score, medium‐term (at 12 months), CGI (higher score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.82, 0.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state specific: average total scores, medium‐term (at 12 months), various scales (higher score = worse), skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Psychosis risk symptoms: total, average total change score, SOPS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Psychosis risk symptoms: positive, average total change score, SOPS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Psychosis risk symptoms: negative, average total change score, SOPS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Psychosis risk symptoms: disorganisation, average total change score, SOPS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Psychosis risk symptoms: general, average total change score, SOPS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Psychosis risk symptoms: total, average total change score, PANSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Psychotic symptoms: positive, average total change score, PANSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 Psychotic symptoms: negative, average total change score, PANSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9 Psychotic symptoms: general, average total change score, PANSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10 Depression: average total change score, MADRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11 Mania: average total change score, YMS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Functioning, global: average total score, medium‐term (at 12 months), GAF (higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.43 [‐4.77, 9.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects 1 specific: average total score, short‐term (at 8 weeks), various scales (higher score = worse), skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Extrapyramidal symptoms: average total change score, Simpson‐Angus scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Akathisia: average total change score, Barnes akathisia scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Abnormal involuntary movements: average total change score, AIMS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse effects 2a specific: cardiovascular, average total change score, short‐term (at 8 weeks), blood pressure and pulse rate (higher score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Sitting systolic blood pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [‐4.28, 6.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Sitting diastolic blood pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.3 [‐7.43, 2.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Sittiing pulse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.2 [0.03, 16.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Standing systolic blood pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐8.18, 4.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Standing diastolic blood pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐6.96, 3.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Standing pulse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.9 [‐0.74, 16.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse effects 2b specific: cardiovascular, average total score, medium‐term (at 12 months), pulse rate (higher score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Sitting pulse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.27 [1.49, 17.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Standing pulse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.94 [‐2.61, 16.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse effects 3 specific: treatment‐emergent adverse effects, short‐term (at 8 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Arousal: somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [0.90, 5.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Gastrointestinal: weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.29 [1.42, 74.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Gastrointestinal: increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [0.51, 6.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Psychological: anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.68 [0.58, 37.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Psychological: nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [0.37, 9.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 Psychological: asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.74 [0.44, 31.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7 Psychological: abnormal thoughts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.25, 7.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.8 Muscoloskeletal: joint disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.20, 4.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse effects 4a specific: weight, average total weight change, kg gained (higher scores = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Short‐term (by 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.58 [2.02, 7.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Medium‐term (by 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.49 [4.90, 12.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse effects 4b specific: weight gain, medium‐term (at 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.55 [1.53, 8.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse effects 5 specific: fatigue, medium‐term (at 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.42 [1.14, 62.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Satisfaction with treatment: leaving the study early, endpoint data, medium‐term (by 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.88, 2.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012236-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prodromal symptoms: transition to psychosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Medium‐term (by 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>728</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.29, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Long‐term (by 18 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.23, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Long‐term (by 24 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.11, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Long‐term (by 4 years' additional follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.31, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state specific: personal beliefs, average scores, long‐term (at 18 months), PBIQ‐ R (higher score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐1.79, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Entrapment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.5 [‐1.91, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐2.37, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Participation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐1.48, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Shame</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐1.68, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state 1 specific: social anxiety, average total score, long‐term (at 18 months), SAS (higher score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.60 [‐12.34, 5.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state 2 specific: average scores, various scales, higher score = worse, skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Psychotic symptoms: total, average total score, medium‐term (at 12 months), PANSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Depression, average total score, medium‐term (at 12 months), BDI‐PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Depression, average total score, medium‐term (at 12 months), MADRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Depression, average total score, long‐term (at 18 months), BDI‐II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Depression, average total score, long‐term (at 18 months), CDSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Psychotic symptoms: positive, average total score, medium‐term (at 12 months), PANSS </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Psychotic symptoms: negative, average total score, medium‐term (at 12 months), PANSS </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 Psychosis risk symptoms: positive, average total score, long‐term (at 18 months), SOPS </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9 Psychosis risk symptoms: negative, average total score, long‐term (at 18 months), SOPS </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10 Social interaction and anxiety: average total score, medium‐term (at 12 months), SIAS </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11 Social interaction and anxiety: average total score, long‐term (at 18 months), SIAS </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Functioning 1 global: average total score, GAF, (higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Medium‐term (at 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.97 [‐1.33, 13.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 long‐term (at 18 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.20 [‐14.05, 7.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Functioning 2.a specific: social functioning, average total score, medium‐term (at 12 months), SAS II (higher score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.07, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Functioning 2.b.i. specific: social functioning, average total score, long‐term (at 18 months), SFS (higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.10 [‐5.65, 23.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Functioning 2.b.ii. specific: social functioning, average total score, medium‐term (at 18 months), SOFAS (higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [‐2.39, 6.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Quality of life: average total score, long‐term (at 18 months), MANSA (higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [‐2.93, 5.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Cost: cumulative, USD, skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Antipsychotic medication: 0‐18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Antipsychotic medication: by 4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Productivity costs: 0‐18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Service use: 0‐18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 Service use: by 4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6 Travel: 0‐18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.7 Travel: by 4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.8 Total: 0‐18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.9 Total: by 4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Satisfaction with treatment: leaving the study early, end point data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 By between &gt; 1 year to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.87, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 By between &gt; 2 years to 4 years (additional follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.74, 1.24]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012236-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prodromal symptoms: transition to psychosis, end point data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.39, 2.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mental state specific: average end point scores, medium‐term (at 12 months), various scales (higher score = worse), skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Psychopathology: total, end point data, BPRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Negative symptoms: attention, end point data, SANS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Negative symptoms: total, end point data, SANS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Functioning global: average end point score, medium‐term (at 12 months), GAF (higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.0 [‐6.55, 2.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse effects 1 specific: doctors' assessment of adverse effects, medium‐term (at 12 months), UKU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.55, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects 2 specific: adverse effects reported by participants, medium‐term (at 12 months), UKU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [0.90, 4.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Quality of life: average end point score, medium‐term (at 12 months), QLS (higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.70 [‐7.86, 19.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Satisfaction with treatment: leaving the study early, end point data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.62, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012236-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Group B: cognitive behavioural therapy (CBT), CBT (specific preventive intervention (SPI) + needs‐based intervention (NBI) + risperidone vs NBI</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prodromal symptoms: transition to psychosis, end point data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Medium‐term (at 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.23, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Long‐term (up to 4 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.39, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mental state specific: average end point scores, various scales (high score = worse), skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Anxiety: immediately post‐treatment, HRSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Anxiety: medium‐term (at 12 months), HRSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Anxiety: long‐term (at 4 years), HRSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Depression: immediately post‐treatment, HRSD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Depression: medium‐term (at 12 months), HRSD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Depression: long‐term (at 4 years), HRSD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 Mania: immediately post‐treatment, YMS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 Mania: medium‐term (at 12 months), YMS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9 Mania: long‐term (at 4 years), YMS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10 Negative symptoms: immediately post‐treatment, SANS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11 Negative symptoms: medium‐term (at 12 months), SANS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12 Negative symptoms: long‐term (at 4 years), SANS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13 Psychopathology: total, immediately post‐treatment, BPRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14 Psychopathology: total, medium‐term (at 12 months), BPRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15 Psychopathology: total, long‐term (at 4 years), BPRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Functioning global: average end point score, GAF (higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Medium‐term (at 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.62 [‐5.81, 4.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Long‐term (up to 4 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.40 [‐12.32, 7.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Quality of life: average end point score, QLS (higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Immediately post‐treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.83 [‐13.07, 18.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Medium‐term (at 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.12 [‐15.43, 11.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Long‐term (up to 4 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.03 [‐16.90, 12.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Cost: average cost of treatment, AUD, skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Inpatient costs: post‐treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Inpatient costs: medium‐term (at 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Inpatient costs: long‐term (at 36 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Outpatient costs: post‐treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Outpatient costs: medium‐term (at 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Pharmacology costs: post‐treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 Outpatient costs: long‐term (at 36 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8 Pharmacology costs: medium‐term (at 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9 Pharmacology costs: long‐term (at 36 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.10 Total costs: post‐treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.11 Total costs: medium‐term (at 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.12 Total costs: long‐term (at 36 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Satisfaction with treatment: leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Medium‐term (at 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Long‐term (up to 4 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.26, 1.28]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Group B: cognitive behavioural therapy (CBT), CBT (specific preventive intervention (SPI) + needs‐based intervention (NBI) + risperidone vs NBI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012236-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prodromal symptoms: transition to psychosis, end point data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.28, 1.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mental state specific: average end point scores, medium‐term (at 12 months), various scales (higher score = worse), skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Psychopathology: total, end point data, BPRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Negative symptoms: attention, end‐point data, SANS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Negative symptoms: total, end point data, SANS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Functioning global: average end point scores, medium‐term (at 12 months), GAF (higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [‐4.59, 8.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse effects 1 specific: doctors' assessment of adverse effects, medium‐term (at 12 months), UKU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.61, 3.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects 2 specific: adverse effects reported by participants, medium‐term (at 12 months), UKU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.32, 2.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Quality of life: average end point scores, medium‐term (at 12 months), QLS (higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.30 [‐18.76, 12.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Satisfaction with treatment: leaving the study early, end point data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.54, 2.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012236-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Group C: cognitive behavioural therapy (CBT), CBT + supportive intervention vs non‐directive reflective listening + supportive intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prodromal symptoms: transition to psychosis, end point data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.32 [0.34, 117.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Functioning 1 global: average total score, short‐term (at 6 months), GAF (higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.48 [‐12.81, 3.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Functioning 2 specific: social functioning, average total score, short‐term (at 6 months), SOFAS (higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.47 [‐15.30, 2.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Satisfaction with treatment: leaving the study early, end point data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.81, 2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Group C: cognitive behavioural therapy (CBT), CBT + supportive intervention vs non‐directive reflective listening + supportive intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012236-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prodromal symptoms: transition to psychosis, end point data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.28, 2.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mental state specific: average end point scores, medium‐term (at 12 months), various scales (higher score = worse), skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Psychopathology: total, end point data, BPRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Negative symptoms: attention, end point data, SANS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Negative symptoms: total, end point data, SANS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Functioning global: average end point score, medium‐term (at 12 months), GAF (higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐6.83, 7.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse effects 1 specific: doctors' assessment of adverse effects, medium‐term (at 12 months), UKU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.64, 3.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects 2 specific: adverse effects reported by participants, medium‐term (at 12 months), UKU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [0.77, 4.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Quality of life: average end point scores, medium‐term (at 12 months), QLS (higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.40 [‐9.91, 14.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Satisfaction with treatment: leaving the study early, end point data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.60, 2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012236-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Group C: other, cognitive training vs active control (tablet games)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mental state 1 specific: average total scores, various scales (higher score = worse), skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Psychosis risk symptoms: total, average total score, long‐term (at 24 months), SOPS </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Psychosis risk symptoms: negative, average total score, long‐term (at 24 months), SOPS </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Psychosis risk symptoms: disorganised, average total score, long‐term (at 24 months), SOPS </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Psychosis risk symptoms: general, average total score, long‐term (at 24 months), SOPS </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Social anxiety: fear of negative evaluation, average end point score, short‐term (at 4 months), SAS‐A </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Social anxiety: avoidance/distress in new situations, average end point score, short‐term (at 4 months), SAS‐A </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Social anxiety: social avoidance and distress, average end point score, short‐term (at 4 months), SAS‐A </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mental state 2 specific: depression, average end point score, short‐term (at 4 months), BDI‐II (higher score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [‐1.72, 3.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state 3.a specific: cognitive, average end point score, short‐term (at 4 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Processing speed (Minnesota Clerical Test, T score, higher score = better)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.25 [1.70, 10.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Processing speed (Digit Symbol Coding, higher score = better)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.69, 2.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state 3.b specific: cognitive, average total score (presented as LSM = least square means estimated by the generalised linear mixed models), short‐term (at 3 months), MATRICS, higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Attention/vigilance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.12 [‐11.48, 5.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Speed of processing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.58 [‐9.72, 4.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Reasoning and problem solving</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.84 [‐8.32, 4.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Verbal learning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐5.00, 6.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Visual learning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.39 [‐11.10, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Working memory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.56 [‐4.88, 12.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Functioning 1 global: average total score, long‐term (at 24 months), GAF (higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [‐5.34, 6.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Functioning 2 specific: role functioning, GFR (higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Role functioning: average total score (presented as LSM = least square means estimated by the generalised linear mixed models), short‐term (at 3 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.27 [‐1.84, ‐0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Role functioning: average total score, long‐term (at 24 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐1.37, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Functioning 3.a specific: social functioning, GFS (higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Social functioning: average total score (presented as LSM = least square means estimated by the generalised linear mixed models), short‐term (at 3 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.68 [‐2.12, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Social functioning: average total score, long‐term (at 24 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [‐0.52, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Functioning 3.b specific: social functioning, average end point score, short‐term (at 4 months), SAS‐SR (higher score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.64 [‐0.94, ‐0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Satisfaction with treatment: leaving the study early, end point data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.82, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Short‐term (by 2 months), PST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.81, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Medium‐term (by 9 months), AT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.64, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Long‐term (by 24 months), AT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.48, 1.29]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Group C: other, cognitive training vs active control (tablet games)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012236-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Group C: other, family treatment vs enhanced care</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prodromal symptoms: transition to psychosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.18, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Short‐term (6 months), FFT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.02, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Long‐term (24 months), FACT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.35, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: antipsychotic prescription, short‐term (by 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.69, 2.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state specific: psychosis risk positive symptoms, average total score, short‐term (at 6 months), SOPS positive (higher score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.01 [‐3.87, ‐0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Functioning global: average total score, long‐term (at 24 months), GAF (higher score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.15 [‐1.90, 12.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events 1.a specific: suicide, long‐term (by 24 months), events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.06, 15.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events 1.b specific: suicide, long‐term (by 24 months), participants affected/at risk <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.06, 15.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Satisfaction with treatment: leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.52, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Short‐term (6 months), FFT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.33, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Long‐term (24 months), FACT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.52, 1.68]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Group C: other, family treatment vs enhanced care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012236-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Group C: other, integrated treatment vs standard treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prodromal symptoms: transition to psychosis, end point data, long‐term (by 2 years) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.28, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mental state specific: average total score, long‐term (at 2 years), various scales (higher score = worse), skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Negative symptoms: total average score, SANS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Satisfaction with treatment: leaving the study early, end point data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.25, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Group C: other, integrated treatment vs standard treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012236.pub2/references#CD012236-tbl-0028">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012236.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012236-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012236-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012236-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD012236-note-0003">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD012236-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012236-note-0007">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD012236-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012236-note-0025">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012236\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012236\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012236\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012236\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012236\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012236\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012236\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012236\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012236\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012236\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012236\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012236\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012236\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012236\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012236\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012236\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012236\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012236\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012236.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012236.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012236.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012236.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012236.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725662370"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012236.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725662374"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012236.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e80ae3a54f466',t:'MTc0MDcyNTY2Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 